Antibody,Antibody binding type,PDB or other structure,Ab patient,Clonal lineage,Isolation paper(Pubmed ID),Neutralizing antibody feature,Germline paper(Pubmed ID),Germline software & DB,Heavy V (IGHV),Heavy D (IGHD),Heavy J (IGHJ),Heavy CDR3 length,Heavy CDR3 seq,HC SHM NA (%),HC SHM AA (%), Light V (IGKV or IGLV),Light J (IGKJ or IGLJ),Light CDR3 length,Light CDR3 seq,LC SHM NA (%),LC SHM AA (%), Light chain type,ADCC,Type,Species,Aliases,LANL comments,Mean panel IC50,SD panel IC50,# assays,CATNAP ID,Immuno ID,heavy_chain_aa,light_chain_aa,light_chain_na,heavy_chain_na,junction_aa_IMGT,v_identity
0.5gamma,gp120 V3 // V3 glycan (V3g),,KTS376 ,,Yoshimura2010(20504942) ,0.5Î³ epitope;Mutations coupling nAb resistance with ceniciviroc sensitivity,RamirezValdez2015(25486586) ,IMGT/V-QUEST,3-30*09 or 3-30*01,,,18.0,ARDLDQTIPDLTAPAFEV,,10.8,2-28*01 or 2D-28*01,,8.0,MQSLQTWT,,4.1,K,Yes,Natural monoclonal,human,"0.5 gamma, 0.5gamma, 1C10"," Ramirez-Valdez2015 SHM data are entered for AA, but it's unclear if the data are NT or AA.",31.1443,9.32793,48.0,498.0,2475.0,QVQLVESGGGVVQPGRSLRVSCVASGFMFSNYAMHWVRQTAGKGLEWVAIISNDGSDKYYADSVQGRFTVSRDNSQNTLFLQMSGLRPEDSGLYYCARDLDQTIPDLTAPAFEV,DIVMTQSPLSLAVTPGEPASISCRSSQSLLHSDGNNYLDWYLQKPGQSPQLLIYLTSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQSLQTWT,,,,
0PV-a.01,fusion peptide // near gp41-gp120 interface,6MQR(0PV-a.01 in complex with fusion peptide);6OSY(0PV-a.01 in complex with HIV-1 Env BG505 DS-SOSIP and antibodies VRC03 and PGT122),0PV ,,Kong2019(31348886) ,0PV-a.01 neutralization-associated sites;0PV-c.01 contacts,Kong2019(31348886) ,IgBlast IMGT/V-QUEST,,,,15.0,CARERVVAHNYYGLDLW,10.6,,,,9.0,CQQYEDFPLTF,10.2,,K,,Natural monoclonal,macaque,, ,57.1033,3.83337,417.0,820.0,4510.0,EVQLVESGPGVMKPSETLSLICAVSGDTISSPYYFWSWVRQPRGKGLEWIGGLYSNTMDVYYNPSLQSRVTISRDTSKNHFSLKVTSVTDTDTAVYYCARERVVAHNYYGLDLWGQGVAVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIKNSLSWYQQKLGKAPRRLMHHSSTLETGVPSRFSGSGYGTEFTLSINSLQPEDIAAYYCQQYEDFPLTFGGGTQVEIK,GACATTCAGATGACGCAGTCTCCATCCTCCCTCTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCGAGTCAGGACATTAAAAATTCTTTAAGTTGGTATCAACAGAAACTAGGGAAAGCCCCTAGGCGCCTAATGCATCATTCATCCACTTTGGAAACAGGGGTCCCATCAAGGTTTAGTGGAAGCGGATATGGGACAGAATTCACTCTCAGTATCAACAGTCTGCAGCCTGAAGATATTGCAGCATATTACTGTCAACAATATGAGGATTTCCCGCTCACTTTCGGCGGAGGGACGCAGGTGGAAATCAAA,GAGGTGCAGCTGGTGGAGTCGGGCCCAGGAGTGATGAAGCCTTCGGAGACCCTGTCCCTCATCTGCGCTGTCTCTGGTGACACCATCAGCAGTCCTTACTACTTCTGGAGCTGGGTCCGCCAGCCCCGAGGGAAGGGACTGGAGTGGATTGGGGGTCTCTATAGTAATACGATGGATGTCTACTACAATCCCTCCCTCCAGAGTCGAGTCACCATTTCAAGAGACACGTCCAAGAACCACTTCTCCCTAAAAGTGACCTCTGTGACCGACACGGACACGGCCGTATATTACTGTGCGAGAGAGAGAGTGGTGGCACATAATTACTACGGTTTGGATTTGTGGGGCCAAGGGGTCGCCGTCACCGTCTCCTCA,CARERVVAHNYYGLDLW,84.106
0PV-b.01,fusion peptide // near gp41-gp120 interface,6N16(0PV-b.01 in complex with HIV fusion peptide),0PV ,,Kong2019(31348886) ,0PV-b.01 neutralization-associated sites,Kong2019(31348886) ,IgBlast IMGT/V-QUEST,,,,14.0,CVREPVIAAAGTVDVW,7.3,,,,9.0,CEQTLQIPFTF,2.0,,K,,Natural monoclonal,macaque,, ,70.8693,2.5531,417.0,821.0,4511.0,QVQLQESGPGVVKPSETLSLTCGVSGGTISSSHFYWSWIRQPPGKGLEWIGGLYINDERINYNPSLESRVTISKDTSQNQFALKLTSVTAADTAVYYCVREPVIAAAGTVDVWGRGVLVTVSS,DIVMTQTPLSLSVTPGEPASISCRSSQSLLHSNGHTYVHWYLQKAGQSPQLLIYEVSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCEQTLQIPFTFGGGTKVEIK,GATATTGTGATGACCCAGACTCCACTCTCCCTCTCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGGCACACCTATGTGCATTGGTACTTGCAGAAGGCGGGCCAGTCTCCACAGCTCCTGATCTATGAGGTTTCCAACCGGGCCTCTGGAGTCCCTGACAGGTTCAGTGGCAGTGGGTCAGGCACTGATTTCACACTGAAAATCAGCCGGGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCGAGCAAACTCTACAAATTCCGTTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGAGTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGGTGTCTCTGGAGGCACCATCAGCAGTAGTCACTTCTACTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGGGTCTCTATATTAATGATGAGAGAATCAATTACAACCCCTCCCTCGAGAGTCGAGTCACCATTTCAAAAGACACGTCCCAGAATCAGTTCGCCCTAAAGTTGACGTCTGTGACCGCCGCGGACACGGCCGTGTATTATTGTGTGAGAGAACCGGTCATAGCAGCGGCTGGTACCGTGGATGTCTGGGGCCGGGGAGTTCTGGTCACCGTCTCCTCA,CVREPVIAAAGTVDVW,87.086
0PV-c.01,fusion peptide // near gp41-gp120 interface,6MQC(0PV-c.01 in complex with fusion peptide);6NF2(0PV-c.01 in complex with HIV-1 Env BG505 DS-SOSIP and antibodies VRC03 and PGT122),0PV ,,Kong2019(31348886) ,,Kong2019(31348886) ,IgBlast IMGT/V-QUEST,,,,17.0,TSRAKDYRGPSYSRIDVW,14.4,,,,9.0,CMQFVEFPLTF,4.3,,K,,Natural monoclonal,macaque,, ,59.855,2.84227,417.0,822.0,4512.0,QVQLVESGPGVVKPSETLSLTCVVSGGTPGRGFLYWSWVRQPPGKGLEWIGGTATNTDITDYNPSLKSRAAISKDTSRNQFLLNLKPLTAGDTAVYYCTSRAKDYRGPSYSRIDVWGPGVLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSQSLLDSDGNTCLDWFLQKPGQSPQLLIYDVSNRVSGVPDRFSGSGSDTDFTLKISRVEAEDVGVYYCMQFVEFPLTFGGGTKVEIR,GATATTGTGATGACCCAGACTCCGCTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCTTGGATAGTGACGGAAACACCTGTTTGGACTGGTTTCTGCAGAAGCCAGGCCAGTCTCCACAACTCCTGATCTATGACGTTTCCAACCGGGTCTCTGGAGTCCCTGACAGGTTCAGTGGCAGTGGGTCAGACACTGATTTCACACTGAAAATCAGCCGGGTGGAAGCTGAGGATGTTGGGGTCTATTATTGTATGCAATTTGTAGAGTTTCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAGA,CAGGTGCAGCTGGTGGAGTCGGGCCCAGGAGTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGTTGTCTCTGGTGGCACCCCCGGACGTGGCTTCCTCTACTGGAGTTGGGTCCGCCAGCCCCCCGGAAAGGGGCTGGAGTGGATTGGGGGCACCGCTACTAACACTGACATTACCGACTACAACCCCTCCCTCAAGAGTCGAGCCGCCATTTCAAAGGACACGTCCAGGAATCAGTTCTTACTAAACTTGAAGCCTTTGACCGCCGGTGACACGGCCGTATATTACTGTACGAGCCGCGCGAAAGACTATCGTGGTCCCTCGTACAGCCGGATCGATGTCTGGGGCCCGGGAGTCCTGGTCACCGTCTCCTCA,CTSRAKDYRGPSYSRIDVW,80.602
10-1074,gp120 V3 // V3 glycan (V3g),4FQ2(10-1074 Fab);5T3X(Natively Glycosylated BG505 SOSIP.664 in Complex with IOMA and 10-1074);5T3Z(Natively Glycosylated BG505 SOSIP.664 in Complex with IOMA and 10-1074);6OKP(SOSIP.664 in complex with SF12 and 10-1074);EMD-20100(B41 SOSIP.664 in complex with SF12 and 10-1074);EMD-20101(B41 SOSIP.664 trimer in complex with 2 Fab fragments of SF12 and 1 Fab fragment of 10-1074),Donor 17 ,PGT121,Mouquet2012a(23115339) ,10-1074 contacts;10-1074 contacts;10-1074 neutralization;10-1074 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Key sites for PGT121-like and 10-1074-like mAbs;mutations affecting 10-1074 binding;V3 Signature Analysis Summary,Klein2013(23540694) ,IgBlast,4-59,3-3,6,,,,,3-21,3 or 2,,,,,L,Yes,Natural monoclonal,human,10.1074, ,0.71153,60.8902,4396.0,17.0,2777.0,QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRESATYNPSLNSRVVISRDTSKNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHHHHHH,SYVRPLSVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,,,,
nan,,,,,,,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,3-3 or 16,6*03,24.0,ARRGQRIYGVVSFGEFFYYYSMDV,,,3-21*02,3*02,12.0,HMWDSRSGFSWS,,,,,,,,,,,,,,,,,,,
10-1074GM,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,1.70613,13.0582,26.0,362.0,3897.0,,,,,,
10-1074-IgG3C-,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,IgG3C hinge variant ,1.33043,48.2715,238.0,274.0,3539.0,,,,,,
10-1074V,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,,hypervariable loop characteristic correlations with bNAb sensitivity;V3 Signature Analysis Summary,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.44827,76.4079,600.0,243.0,3283.0,,,,,,
10-1121,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,3-3 or 3-10,6*03,24.0,ALHGKRIYGIVALGELFTYFYMDV,,,3-21*02,3*02,12.0,HIWDSRRPTNWV,,,L,,Natural monoclonal,human,, ,,,20.0,369.0,2803.0,QVQLQESGPGLVKPPETLSLTCSVSGASINDAYWSWIRQSPGKRPEWVGYVHHSGDTNYNPSLKRRVSFSLDTAKNEVSLKLVDLTAADSAIYFCARALHGKRIYGIVALGELFTYFYMDVWGKGTTVTVSS,SFVSVAPGQTARITCGEESLGSRSVIWYQQRPGQAPSLIMYNNHDRPSGIPERFSGSPGSTFGTTATLTITSVEAGDEADYYCHIWDSRRPTNWVFGEGTTLTVL,,,,
10-1130,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,3-10 or 3-3,6*03,24.0,ALHGKRIYGIVALGELFTYFYMDV,,,3-21*02,3*02,12.0,HIWDSRRPTNWV,,,L,,Natural monoclonal,human,, ,,,20.0,368.0,2804.0,QVQLQESGPGLVKPPETLSLTCSVSGASINDAYWSWIRQSPGKRPEWVGYVHHSGDTNYNPSLKRRVTFSLDTAKNEVSLKLVDLTAADSAVYFCARALHGKRIYGIVALGELFTYFYMDVWGKGTTVTVSS,SFVSVAPGQTARITCGEESLGSRSVIWYQQRPGQAPSLIIYNNNDRPSGIPERFSGSPGSTFGTTATLTITSVEAGDEADYYCHIWDSRRPTNWVFGEGTTLTVL,,,,
10-1146,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,10 or 3,6*03,24.0,AQQGKRIYGIVSFGEFFYYYYMDA,,,3-21*02,3*02,12.0,HYWDSRSPISWV,,,L,,Natural monoclonal,human,, ,,,20.0,370.0,2806.0,QVQLVESGPGLVTPSETLSLTCTVSNGSVSGRFWSWIRQSPGRGLEWIGYFSDTDRSEYSPSLRSRLTLSLDASRNQLSLKLKSVTAADSATYYCARAQQGKRIYGIVSFGEFFYYYYMDAWGKGTAVTVSS,SSLPLSLAPGATAKIPCGEKSRGSRAVQWYQQKPGQAPTLIIYNNQDRPAGVSERYSGNPDVAIGVTATLTISRVEAGDEAEYYCHYWDSRSPISWVFGGWTQLTVL,,,,
10-1341,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,3 or 16,6*03,24.0,ARRGQRIYGVVSFGEFFYYYSMDV,,,3-21*02,3*02,12.0,HMWDSRSGFSWS,,,L,,Natural monoclonal,human,, ,,,20.0,371.0,2813.0,QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRESATYNPSLNSRVVISRDTSTNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGRGTTVTVSS,SYVRPLSVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,,,,
10-1369,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,3-3 or 16,6*03,24.0,TKHGRRIYGVVAFGEWFTYFYMDV,,,3-21*02,3*02,12.0,HIYDARRPTNWV,,,L,,Natural monoclonal,human,, ,,,20.0,364.0,2815.0,QVQLQESGPGLVKPLETLSLTCNVSGAFIADHYWSWIRLPLGKGPEWIGYVHDSGDINYNPSLKNRVHLSLDKSTNQVSLKLMAVTAGDSALYYCATTKHGRRIYGVVAFGEWFTYFYMDVWGRGTTVTVSS,SSMSVSPGETAKITCGEKSIGSRAVQWYQKKPGQPPSLIIYNNQDRPSGVPERFSASPDIEFGTTATLTITNVEAGDEADYYCHIYDARRPTNWVFDRGTTLTVL,,,,
10-259,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,,6*03,24.0,TKHGRRIYGIVAFNEWFTYFYMDV,,,3-21*02,3*02,12.0,HIYDARGGTNWV,,,L,,Natural monoclonal,human,, ,,,20.0,365.0,2782.0,QVHLQESGPGLVKPSETLSLTCNVSGTLVRDNYWSWMRQPLGKQPEWIGYVHDSGDTNYNPSLKSRVHLSLDKSNNLVSLRLTAVTAADSATYYCATTKHGRRIYGIVAFNEWFTYFYMDVWGKGTTVTVSS,SSMSVSPGETAKISCGKESIGSRAVQWYQQKSGQPPSLIIYNNQDRPSGVPERFSATPDFGAGTTATLTITNVEADDEADYYCHIYDARGGTNWVFDRGATLTVL,,,,
10-303,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,3-3 or 9,6*03,24.0,TLHGRRIYGIVAFNEWFTYFYMDV,,,3-21*02,3*02,12.0,HIWDSRVPTKWV,,,L,,Natural monoclonal,human,, ,,,20.0,366.0,2785.0,QVQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSS,SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVL,,,,
10-410,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,3 or 3-10,6*03,24.0,ALHGKRIYGIVALGELFTYFYMDV,,,3-21*02,3*02,12.0,HIWDSRRPTNWV,,,L,,Natural monoclonal,human,, ,,,20.0,367.0,2787.0,QVQLQESGPGLVKPPETLSLTCSVSGASVNDAYWSWIRQSPGKRPEWVGYVHHSGDTNYNPSLKRRVTFSLDTAKNEVSLKLVALTAADSAVYFCARALHGKRIYGIVALGELFTYFYMDVWGKGTTVTVSS,SFVSVAPGQTARITCGEESLGSRSVIWYQQRPGQAPSLIIYNNNDRPSGIPERFSGSPGSTFGTTATLTITSVEAGDEADYYCHIWDSRRPTNWVFGEGTTLTVL,,,,
10-847,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,3-3 or 16,6*03,24.0,ARRGQRIYGVVSFGEFFYYYSMDV,,,3-21*02,3*02,12.0,HMWDSRSGFSWS,,,L,,Natural monoclonal,human,, ,,,20.0,372.0,2798.0,QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRASATYNPSLNSRVVISRDTSKNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGKGTTVTVSS,SYVRPLSVALGETASISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,,,,
10-996,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,10-996 signature predictions;Key sites for PGT121-like and 10-1074-like mAbs;V3 Signature Analysis Summary,Mouquet2012a(23115339) ,IgBlast IMGT/V-QUEST,4-59*01,3-3 or 10,6*03,24.0,TQQGKRIYGVVSFGEFFHYYYMDA,,,3-21*02,3*02,12.0,HKWDSRSPLSWV,,,L,,Natural monoclonal,human,, ,1.64005,44.6236,360.0,16.0,2800.0,QVQLQESGPGLVKPSETLSLTCSVSNGSVSGRFWSWIRQSPGRGLEWIGYFSDTEKSNYNPSLRSRLTLSVDASKNQLSLKLNSVTAADSATYYCARTQQGKRIYGVVSFGEFFHYYYMDAWGKGTAVTVSS,SSLPLSVAPGATAKIACGEKSFASRAVQWYQQKPGQAPVLIIYNNQDRPAGVSERFSGTPDVGFGSTATLTISRVEAGDEADYYCHKWDSRSPLSWVFGGGTQLTVL,,,,
10A3,gp120 V3 // V3 glycan (V3g),,uncoded_rabbit ,,Qin2015(26039641) ,10A3 epitope,,,,,,,,,,,,,,,,,,Natural monoclonal,rabbit,,rabbit antibody ,14.4323,20.4026,22.0,323.0,3863.0,,,,,,
10A37,gp120 V3 // V3 glycan (V3g),,uncoded_rabbit ,,Qin2015(26039641) ,10A37 epitope,,,,,,,,,,,,,,,,,,Natural monoclonal,rabbit,,rabbit antibody ,6.98787,20.2343,22.0,324.0,3864.0,,,,,,
10E8,gp41 MPER (membrane proximal external region),"4G6F(Fab 10E8 complexed with gp41 peptide);4U6G(10E8 Fab in complex with a hydrocarbon-stapled HIV-1 gp41 MPER peptide);5GHW(10E8 with long epitope bound);5IQ7(10E8-S74W Fab in complex with an HIV-1 gp41 peptide);5IQ9(10E8v4 Fab in complex with an HIV-1 gp41 peptide);5SY8(10E8 Fab light chain mutant1 and T117v2 HIV-1 MPER scaffold);5T29(10E8 Fab light chain mutant3, against the MPER region of the HIV-1 Env, in complex with the MPER epitope scaffold T117v2);5T5B(10E8 FAB LIGHT CHAIN MUTANT5 AND T117V2 HIV-1 MPER SCAFFOLD);5T6L(10E8 Fab in complex with the MPER epitope scaffold T117v2);5T80(10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidic acid);5T85(10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidylglycerol);5TFW(10E8 Fab light chain mutant2 against the MPER region of the HIV-1 Env, in complex with T117v2 epitope scaffold)",Donor N152 ,10E8,Huang2012a(23151583) ,10E8 contacts;10E8 contacts;10E8 residue prediction;10E8 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;mutations affecting 10E8 binding;Mutations affect neutralization by 10E8;Q563R affects binding and neutralization of MPER mAbs;Residues important for 10E8 binding;Signature Analysis Summary,Huang2012a(23151583) ,IMGT/V-QUEST,3-15*05,3-3*01,1*01,20.0,TGKYYDFWSGYPPGEEYFQD,21.0,,3-19*01,3*02,12.0,SSRDKSGSRLSV,14.0,,L,Yes,Natural monoclonal,human,, ,0.49996,6.42963,5646.0,12.0,2708.0,EVQLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLNSINFLYLEMNNLRMEDSGLYFCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTVSS,SYELTQETGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPILLFYGKNNRPSGVPDRFSGSASGNRASLTISGAQAEDDAEYYCSSRDKSGSRLSVFGGGTKLTVL,TCCTATGAGCTGACTCAGGAGACTGGTGTCTCTGTGGCCCTGGGACGGACAGTCACAATCACGTGCCGGGGAGACAGCCTCAGAAGTCATTATGCAAGTTGGTACCAAAAGAAGCCAGGACAGGCCCCTATACTTCTCTTCTATGGTAAAAATAATCGTCCTTCAGGGGTCCCAGACCGATTCTCTGGCTCCGCCTCAGGAAACAGAGCTTCCTTGACCATCTCTGGGGCTCAGGCGGAAGACGACGCGGAATATTATTGTAGTTCTCGGGACAAGAGTGGCAGCCGTCTGTCGGTCTTCGGCGGGGGGACCAAACTGACCGTCCTCA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCTGGAGGATCCCTTAGACTCTCATGTTCAGCCTCTGGTTTCGACTTCGATAACGCCTGGATGACTTGGGTCCGCCAGCCTCCAGGGAAGGGCCTCGAATGGGTTGGTCGTATTACGGGTCCAGGTGAAGGTTGGTCAGTGGACTATGCTGCACCCGTGGAAGGCAGATTTACCATCTCGAGACTCAATTCAATAAATTTCTTATATTTGGAGATGAACAATTTAAGAATGGAAGACTCAGGCCTTTACTTCTGTGCCCGCACGGGAAAATATTATGATTTTTGGAGTGGCTATCCGCCGGGAGAAGAATACTTCCAAGACTGGGGCCGGGGCACCCTGGTCACCGTCTCCTCA,CARTGKYYDFWSGYPPGEEYFQDW,78.451
10E8-0fH/0fL,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,3.87858,5.20716,21.0,121.0,3080.0,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMTWVRQAPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTTGKYYDFWSGYPPGEEYFQDWGQGTLVTVSS,SSELTQDPAVSVALGQTVRITCRGDSLRSHYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8-0fH/4fL,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,1.19809,5.99976,21.0,120.0,3079.0,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMTWVRQAPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTTGKYYDFWSGYPPGEEYFQDWGQGTLVTVSS,SYELTQDPAVSVALGQTVRITCRGDSLRSHYASWYQQKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNTASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8-10fH/10fL,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.9675,5.65735,21.0,116.0,3075.0,EVQLVESGGGLVKPGGSLRLSCAASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLDSINFLYLQMNSLKMEDTGVYYCARTGKYYDFWSGYPPGEEYFQDWGQGTLVTVSS,SYELTQDTGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNRASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8-10fH/16fL,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.56558,7.15275,21.0,115.0,3074.0,EVQLVESGGGLVKPGGSLRLSCAASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLDSINFLYLQMNSLKMEDTGVYYCARTGKYYDFWSGYPPGEEYFQDWGQGTLVTVSS,SYELTQETGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPILLFYGKNNRPSGVPDRFSGSASGNRASLTISGAQAEDDAEYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8-10fH/4fL,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,2.37887,6.84055,21.0,117.0,3076.0,EVQLVESGGGLVKPGGSLRLSCAASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLDSINFLYLQMNSLKMEDTGVYYCARTGKYYDFWSGYPPGEEYFQDWGQGTLVTVSS,SYELTQDPAVSVALGQTVRITCRGDSLRSHYASWYQQKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNTASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8-19fH/10fL,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.44926,8.98017,21.0,114.0,3073.0,EVQLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLNSINFLYLEMNNLRMEDSGLYFCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTVSS,SYELTQDTGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNRASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8-19fH/16fL,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.39459,7.48086,21.0,113.0,3072.0,EVQLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLNSINFLYLEMNNLRMEDSGLYFCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTVSS,SYELTQETGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPILLFYGKNNRPSGVPDRFSGSASGNRASLTISGAQAEDDAEYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8-2fH/0fL,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,7.97449,5.97822,21.0,122.0,3081.0,EVQLVESGGGLVKPGGSLRLSCAASGFDFDNAWMTWVRQAPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTTGKYYDFWSGYPPGEEYFQDWGQGTLVTVSS,SSELTQDPAVSVALGQTVRITCRGDSLRSHYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8-2fH/10fL,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.94299,6.20129,21.0,118.0,3077.0,EVQLVESGGGLVKPGGSLRLSCAASGFDFDNAWMTWVRQAPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTTGKYYDFWSGYPPGEEYFQDWGQGTLVTVSS,SYELTQDTGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNRASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8-2fH/4fL,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,5.13723,5.59785,21.0,119.0,3078.0,EVQLVESGGGLVKPGGSLRLSCAASGFDFDNAWMTWVRQAPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTTGKYYDFWSGYPPGEEYFQDWGQGTLVTVSS,SYELTQDPAVSVALGQTVRITCRGDSLRSHYASWYQQKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNTASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8-3R,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Rujas2018(29386285) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,10E8i, ,0.015334,5.19071,17.0,862.0,4658.0,EVQLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLNSINFLYLEMNNLRMEDSGLYFCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTVSS,SYELTQETGVSVALGRTVTITCRGDSLRRHYASWYQKKPGQAPILLFYGKRNRPSGVPDRFSGSARGNRASLTISGAQAEDDAEYYCSSRDKSGSRLSVFGGGTKLTVL,,,,
10E8 IgG mutant 1,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Irimia2017(28225819) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.25918,11.6142,108.0,448.0,4018.0,,,,,,
10E8 IgG mutant 2,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Irimia2017(28225819) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,2.70736,9.48824,108.0,449.0,4019.0,,,,,,
10E8 IgG mutant 3,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Irimia2017(28225819) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,52.1608,2.81275,108.0,450.0,4020.0,,,,,,
10E8 IgG mutant 5,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Irimia2017(28225819) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"10E8d, 10E8 mutant 5", ,33.6953,4.18346,110.0,452.0,4022.0,,,,,,
10E8/N6,gp120 CD4bs;gp41 MPER (membrane proximal external region),,Donor N152 Z258 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8fv-N6fv,bispecific ,0.049453,8.40368,108.0,427.0,3978.0,,,,,,
10E8/PGDM1400/PRO-140,gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region);non-HIV: host CCR5,,Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;humanized mouse,10E8Fab-PGDM1400fv-PRO140fv,trispecific ,0.012252,6.91922,105.0,425.0,3992.0,,,,,,
10E8/PGT121/PGDM1400.V1,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V1,trispecific ,0.52481,21.1939,28.0,428.0,3981.0,,,,,,
10E8/PGT121/PGDM1400.V2,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V2,trispecific ,1.53708,26.254,28.0,429.0,3982.0,,,,,,
10E8/PGT121/PGDM1400.V3,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V3,trispecific ,0.20382,20.0096,28.0,430.0,3984.0,,,,,,
10E8/PGT121/PGDM1400.V4,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V4,trispecific ,1.23307,32.5067,28.0,431.0,3983.0,,,,,,
10E8/PGT121/PGDM1400.V5,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V5,trispecific ,0.21034,19.1657,28.0,432.0,3985.0,,,,,,
10E8/PGT121/PGDM1400.V6,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V6,trispecific ,0.63234,24.5142,28.0,433.0,3986.0,,,,,,
10E8/PGT121/PGDM1400.V7,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V7,trispecific ,0.42434,17.4206,28.0,434.0,3987.0,,,,,,
10E8/PGT121/PGDM1400.V8,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V8,trispecific ,0.023348,12.7172,171.0,421.0,3988.0,,,,,,
10E8/PGT121/PGDM1400.V8.4DS,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V8.4DS,trispecific ,,,9.0,437.0,3991.0,,,,,,
10E8/PGT121/PGDM1400.V8Fc,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V8Fc,trispecific ,0.18638,13.9596,27.0,435.0,3989.0,,,,,,
10E8/PGT121/PGDM1400.V8LL,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor 84 Donor N152 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8Fab-PGT121fv-PGDM1400fv.V8LL,trispecific ,,,12.0,436.0,3990.0,,,,,,
10E8V1.1/P140,gp41 MPER (membrane proximal external region);non-HIV: host CCR5,,Donor N152 ,,Huang2016(27315479) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;humanized mouse,,bispecific ,0.0025529,7.94089,236.0,256.0,3471.0,,,,,,
10E8V2.0/iMab,gp41 MPER (membrane proximal external region);non-HIV: host CD4R,,Donor N152 ,,Huang2016(27315479) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;humanized mouse,"10E08-iMab, 10E8-iMAb, 10E8/iMAb",bispecific ,0.002227,5.6643,340.0,257.0,3472.0,,,,,,
10E8v4,gp41 MPER (membrane proximal external region),5IQ9(10E8v4 Fab in complex with an HIV-1 gp41 peptide);6X58(MPER-Fluc-Ec2 bound to 10E8v4 antibody);7MF7(Crystal structure of antibody 10E8v4-P100gA Fab);7MFB(10E8v4 Fab - light chain H31F variant),Donor N152 ,10E8,Kwon2016(27053554) ,,,,,,,,,,,,,,,,,L,Yes,Engineered monoclonal,human,, ,0.43791,6.17434,877.0,387.0,3508.0,EVRLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAESVKGRFTISRDNTKNTLYLEMNNVRTEDTGYYFCARTGKYYDFWSGYPPGEEYFQDWGQGTLVIVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,ASELTQDPAVSVALKQTVTITCRGDSLRSHYASWYQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNRASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,GCATCCGAACTGACTCAGGACCCTGCCGTCTCTGTGGCACTGAAGCAGACTGTGACTATTACTTGCCGAGGCGACTCACTGCGGAGCCACTACGCTTCCTGGTATCAGAAGAAACCCGGCCAGGCACCTGTGCTGCTGTTCTACGGAAAGAACAATAGGCCATCTGGCATCCCCGACCGCTTTTCTGGCAGTGCATCAGGGAACCGAGCCAGTCTGACCATTACCGGCGCCCAGGCTGAGGACGAAGCCGATTACTATTGCAGCTCCCGGGATAAGAGCGGCTCCAGACTGAGCGTGTTCGGAGGAGGAACTAAACTGACCGTCCTCAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCGAGTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA,GAGGTTAGACTGGTGGAGTCAGGAGGGGGGCTTGTGAAGCCCGGTGGGTCTCTCCGCCTGAGCTGTTCTGCCTCCGGCTTTGATTTCGATAACGCCTGGATGACCTGGGTCAGGCAGCCTCCAGGTAAGGGACTGGAGTGGGTGGGAAGAATCACAGGTCCAGGCGAGGGCTGGTCCGTGGACTACGCGGAATCTGTTAAAGGGCGGTTTACAATCTCAAGGGACAATACCAAGAATACCTTGTATTTGGAGATGAACAACGTGAGAACTGAAGACACCGGATATTACTTCTGTGCCAGAACAGGCAAATACTACGACTTCTGGTCCGGCTATCCCCCTGGCGAGGAATATTTTCAAGACTGGGGTCAGGGAACCCTTGTTATCGTGTCCTCCGCGTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,,
10E8v4-5R-100cF,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Kwon2018(29444432) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,10E8v4-5R+100cF 10E8v4-V5R-100cF 10E8v4-V5F-100cF, ,0.05102,5.58738,416.0,438.0,4002.0,,,,,,
10E8v4-DS,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Kwon2016(27053554) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,,,9.0,632.0,4263.0,EVRLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAESVKGRFTISRDNTKNTLYLEMNNVRTEDTGYYFCARTGKYYDFWSGCPPGEEYFQDWGQGTLVIVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,ASELTQDPAVSVALKQTVTITCRGDSLRCHYASWYQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNRASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,GCATCCGAACTGACTCAGGACCCTGCCGTCTCTGTGGCACTGAAGCAGACTGTGACTATTACTTGCCGAGGCGACTCACTGCGGTGCCACTACGCTTCCTGGTATCAGAAGAAACCCGGCCAGGCACCTGTGCTGCTGTTCTACGGAAAGAACAATAGGCCATCTGGCATCCCCGACCGCTTTTCTGGCAGTGCATCAGGGAACCGAGCCAGTCTGACCATTACCGGCGCCCAGGCTGAGGACGAAGCCGATTACTATTGCAGCTCCCGGGATAAGAGCGGCTCCAGACTGAGCGTGTTCGGAGGAGGAACTAAACTGACCGTCCTCAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCGAGTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA,GAGGTTAGACTGGTGGAGTCAGGAGGGGGGCTTGTGAAGCCCGGTGGGTCTCTCCGCCTGAGCTGTTCTGCCTCCGGCTTTGATTTCGATAACGCCTGGATGACCTGGGTCAGGCAGCCTCCAGGTAAGGGACTGGAGTGGGTGGGAAGAATCACAGGTCCAGGCGAGGGCTGGTCCGTGGACTACGCGGAATCTGTTAAAGGGCGGTTTACAATCTCAAGGGACAATACCAAGAATACCTTGTATTTGGAGATGAACAACGTGAGAACTGAAGACACCGGATATTACTTCTGTGCCAGAACAGGCAAATACTACGACTTCTGGTCCGGCTGCCCCCCTGGCGAGGAATATTTTCAAGACTGGGGTCAGGGAACCCTTGTTATCGTGTCCTCCGCGTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,,
10J4,gp41-gp41 interface,,Donor N152 ,35O22,Huang2014(25186731) ,,Huang2014(25186731) ,IMGT/V-QUEST,1-18*02,5-24*01,4*02 or 4*03,16.0,GLLRDGSSTWLPHL,,,2-14*02,1*01,10.0,CSYTHNSGCV,,,L,,Natural monoclonal,human,, ,,,8.0,160.0,3150.0,QGQLVQSGGELKKPGASVKISCKTSGYRFSFYHINWIRQLVGRGPEWMGWISPYNGGTNLAPELRGRLVLTTEREVVDTMTLSTGTAHMELRNLRSDDTGIYFCAKGLLRDGSSTWLPHLWGQGTLLTVSS,QSALTQPASVSGSLGQSVTISCTGPSSVCCSHKSISWYQWPPGRAPTLLIFEDSERSWGISDRFSGYKSYWSASLTISNLRPEDETTYYCCSYTHNSGCVFGTGTNVSVL,CAGTCTGCCCTGACTCAGCCTGCCTCCGTCTCTGGGTCTCTTGGTCAGTCGGTCACCATCTCCTGCACTGGACCCAGTAGTGTCTGTTGCAGTCATAAATCTATCTCCTGGTATCAGTGGCCCCCCGGCAGAGCCCCCACACTCCTCATTTTTGAAGACAGTGAGCGGTCCTGGGGAATCTCTGACCGCTTCTCTGGCTACAAGTCTTATTGGTCGGCCTCCCTGACAATCTCTAATCTCCGGCCTGAGGACGAGACCACTTATTATTGTTGTTCATATACTCACAACAGCGGCTGTGTCTTCGGCACTGGGACCAACGTCTCCGTCCTG,CAGGGTCAACTAGTCCAGTCTGGAGGTGAATTGAAGAAGCCTGGGGCCTCGGTGAAGATTTCCTGTAAGACCTCGGGTTATAGATTTAGTTTCTATCATATTAATTGGATTCGACAACTAGTAGGGCGCGGACCTGAGTGGATGGGCTGGATCAGCCCTTACAACGGAGGCACAAACCTCGCACCTGAGTTGCGAGGCAGACTCGTGCTAACCACAGAGAGAGAGGTCGTGGACACCATGACCCTGTCCACGGGCACAGCCCACATGGAACTAAGGAACCTAAGATCTGACGACACGGGCATCTACTTCTGTGCAAAGGGCCTCTTGCGCGACGGTTCGTCGACGTGGCTGCCTCATTTGTGGGGCCAGGGAACCCTGCTCACCGTCTCGTCA,CAKGLLRDGSSTWLPHLW,68.471
10M6,gp41-gp41 interface,,Donor N152 ,35O22,Huang2014(25186731) ,,Huang2014(25186731) ,IMGT/V-QUEST,1-18*02,5-24*01,4*02 or 4*03,16.0,GLLRDGSSTWLPHL,,,2-14*02,1*01,10.0,CSYTHNSGCV,,,L,,Natural monoclonal,human,, ,,,8.0,164.0,3154.0,QGQLVQSGGELKKPGASVKISCKTSGYRFSFYHINWIRQVIGRGPEWMGWISPYSGGTNLAPEFRGRLVLTTEREVVDTMTLSTGTAHMELRNLKSDDTGIYFCAKGLLRDGSSTWLPHLWGQGTLLTVSS,QSALTQPASVSGSLGQSVTISCTGPSSVCCSHKSISWYQWPPGRAPTLLIFEDSERSWGISDRFSGYKSYWSASLTISNLRPEDETTYFCCSYTHNSGCVFGTGTKVSVL,CAGTCTGCCCTGACTCAGCCTGCCTCCGTTTCTGGGTCTCTTGGTCAGTCGGTCACCATCTCCTGCACTGGACCCAGTAGTGTCTGTTGCAGTCATAAATCTATCTCCTGGTATCAGTGGCCCCCCGGCAGAGCCCCCACACTCCTCATTTTTGAAGACAGTGAGCGGTCCTGGGGAATCTCTGACCGCTTCTCTGGCTACAAGTCTTATTGGTCGGCCTCCCTGACAATCTCTAATCTCCGGCCTGAGGACGAGACCACTTACTTTTGTTGCTCATATACTCACAACAGCGGCTGTGTCTTCGGCACTGGGACCAAGGTCTCCGTCCTG,CAGGGTCAACTAGTCCAGTCTGGAGGTGAATTGAAGAAGCCTGGGGCCTCGGTGAAGATTTCCTGTAAGACCTCGGGTTATAGATTTAGTTTCTATCATATTAATTGGATTCGACAAGTAATAGGGCGCGGACCTGAGTGGATGGGCTGGATCAGCCCTTACAGCGGAGGCACAAACCTCGCACCTGAGTTCCGAGGCAGACTCGTGCTGACCACAGAGAGAGAGGTCGTGGACACCATGACCCTGTCCACGGGCACAGCCCACATGGAACTGAGGAACCTAAAATCTGACGACACGGGCATCTACTTCTGTGCAAAGGGCCTCTTGCGCGACGGTTCGTCGACGTGGCTGCCTCATTTGTGGGGCCAGGGAACCCTGCTCACCGTCTCGTCA,CAKGLLRDGSSTWLPHLW,69.108
11F1F,gp41 MPER (membrane proximal external region),,llama#9 ,,,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,,llama VHH ,28.2747,2.712,45.0,762.0,4475.0,,,,,,
12A12,gp120 CD4bs,,Patient 12 ,12A12,Scheid2011(21764753) ,12A12 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary,Klein2013(23540694) ,IgBlast,1-2,3-10 or 1-26 or 5-24,5,,,,,1-33,1,,,,,K,No,Natural monoclonal,human,12A12 d57, ,0.22938,10.2566,849.0,43.0,2581.0,SQHLVQSGTQVKKPGASVRISCQASGYSFTDYVLHWWRQAPGQGLEWMGWIKPVYGARNYARRFQGRINFDRDIYREIAFMDLSGLRSDDTALYFCARDGSGDDTSWHLDPWGQGTLVIVSAASTKGX,,,TCCCAGCATTTGGTGCAATCTGGGACTCAGGTGAAGAAGCCTGGGGCCTCAGTGAGGATCTCATGCCAGGCTTCTGGATACAGCTTCACCGACTACGTTCTCCACTGGTGGCGACAGGCCCCAGGCCAAGGGCTGGAGTGGATGGGGTGGATCAAGCCTGTCTACGGTGCCAGAAACTACGCGCGCAGGTTTCAGGGCAGGATAAACTTTGATCGGGACATCTACAGGGAGATAGCCTTCATGGACTTGAGTGGACTGAGATCTGACGACACGGCCCTATATTTTTGTGCGAGAGATGGGAGCGGGGACGACACCTCTTGGCACTTAGATCCCTGGGGCCAGGGAACGCTGGTCATTGTCTCCGCAGCGTCGACCAAGGGCC,CARDGSGDDTSWHLDPW,77.365
nan,,,,,,,Scheid2011(21764753) ,,1-2,1-26 or 3-10,4 or 5,13.0,DGSGDDTSWHLDP,,,1D-33,3,5.0,AVLEF,,,,,,,,,,,,,,,,,,,
12A21,gp120 CD4bs,4JPW(12a21 in complex with 93th057 gp120 mutant),Patient 12 ,12A12,Scheid2011(21764753) ,12A21 alanine scanning;12A21 contacts;Mutations allowing binding of germline Abs,Klein2013(23540694) ,IgBlast,1-2,6-19 or 3-10,5 or 4,,,,,1D-33,3,,,,,K,,Natural monoclonal,human,12A21 d57," 12A21 is a close clonal relative of 12A10 and 12A4, and the germline repertoir is as shown for 12A4 in Scheid2011.",0.42263,21.6335,323.0,93.0,2627.0,SQHLVQSGTQVKKPGASVRVSCQASGYTFTNYILHWWRQAPGQGLEWMGLIKPVFGAVNYARQFQGRIQLTRDIYREIAFLDLSGLRSDDTAVYYCARDESGDDLKWHLHPWGQGTQVIVSPASTKGP,DIQMTQSPSSLSASVGDRVTINCQAGQGIGSSLNWYQKKPGRAPKLLVHGASNLQRGVPSRFSGSGFHTTFTLTISSLQPDDVATYFCAVFQWFGPGTKVDIKRT,GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATAAACTGCCAGGCGGGTCAGGGCATTGGCTCCTCTTTAAATTGGTATCAAAAAAAACCAGGGAGAGCCCCTAAGCTCCTGGTCCACGGCGCTTCCAATCTTCAAAGAGGGGTCCCATCGAGGTTCAGTGGAAGTGGATTTCACACAACTTTCACTCTCACCATCAGCAGCCTGCAGCCTGACGATGTTGCGACATACTTCTGTGCGGTCTTTCAATGGTTCGGCCCTGGGACCAAAGTGGATATCAAACGTACG,TCCCAGCATTTGGTGCAATCTGGGACTCAGGTGAAGAAGCCTGGGGCCTCAGTGCGGGTCTCCTGCCAGGCTTCTGGATATACCTTCACCAATTACATTCTCCACTGGTGGCGACAGGCCCCTGGACAAGGGCTGGAGTGGATGGGATTGATCAAGCCTGTCTTTGGTGCCGTAAATTACGCGCGCCAGTTTCAGGGCAGGATTCAGTTGACTAGGGACATCTACAGGGAGATAGCCTTCCTGGACCTGAGTGGCCTCAGATCTGACGACACGGCCGTCTATTACTGTGCGCGAGATGAGAGCGGGGACGACCTCAAGTGGCACCTACATCCCTGGGGCCAGGGAACGCAGGTCATAGTTTCCCCAGCGTCGACCAAGGGCCC,,
nan,,,,,,,Scheid2011(21764753) ,,1-2,5-12 or 3-10,4 or 5,13.0,DESGDDLKWHLHP,,,1D-33,3,5.0,AVFQW,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Zhou2013a(23911655) ,IgBlast IMGT/V-QUEST,1-02*02,,,13.0,DESGDDLKWHLHP,,,1-33*01,1*01,5.0,AVFQW,,,,,,,,,,,,,,,,,,,
1357,gp120 V2 // V2 glycan(V2g) // V2 apex,,donor_uncoded_1 ,,Nyambi1998(9765494) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,1357-D, ,55.2765,3.29435,22.0,183.0,955.0,QVHLVQSGTEVKKPGASVTVSCKASGYSFTGYYLHWVRQAPGQGLEWMGWINPNSGGTYYAQNFQARVTMTRDTSISTVYMDLSRLRSDDTAVYYCVRRAVLTALPPRYYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISGNLNWYQQKPGKAPNLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYHCQQSHSTSWTFGQGTKVVIK,GACATCCAGATGACCCAGTCTCCGTCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCGGCAATTTAAATTGGTATCAGCAAAAACCAGGGAAAGCCCCTAACCTCCTGATCTATGGTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACCACTGTCAACAGAGTCACAGTACGTCCTGGACGTTCGGCCAAGGGACCAAGGTGGTAATCAAA,CAGGTGCACCTGGTGCAGTCTGGGACTGAGGTGAAGAAGCCTGGGGCCTCAGTGACGGTCTCCTGCAAGGCTTCTGGATACAGTTTCACCGGCTACTATTTGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAATAGTGGTGGCACATACTATGCTCAGAACTTTCAGGCCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGTCTACATGGACTTGAGCAGGCTCAGATCTGACGACACGGCCGTCTACTACTGTGTGCGGAGGGCGGTGTTGACTGCACTACCCCCTCGCTACTACTTTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CVRRAVLTALPPRYYFDFW,94.118
1361,gp120 V2 // V2 glycan(V2g) // V2 apex,,donor_uncoded_1 ,,Nyambi1998(9765494) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,58.917,3.3112,41.0,181.0,952.0,QVQLVQSGAEVKKPGSSVKVSCKASGGTFRSYAISWVRQAPGQGLEWMGGIIPIFGTADYAQKFQGKVTITADESTSTAYMELSSLTSEDTAMYYCARSRDHFFDTRVFQGWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYAGSRTFGQGTKVEIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAACATTATGCTGGCTCACGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGAAGTTATGCTATTAGTTGGGTGCGGCAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGGACAGCAGACTACGCACAGAAGTTCCAGGGCAAAGTCACGATTACCGCGGACGAGTCCACGAGCACAGCCTACATGGAGTTGAGCAGCCTAACATCTGAGGACACGGCCATGTATTACTGTGCGAGATCTCGGGATCATTTCTTTGATACTAGGGTCTTTCAAGGCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CARSRDHFFDTRVFQGW,95.578
1393A,gp120 V2 // V2 glycan(V2g) // V2 apex,,donor_uncoded_1 ,,Nyambi2000(10888650) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,63.231,3.07667,43.0,182.0,953.0,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGGIIPIFGTTDYAQKFQGRVTITADASTSTAYMELSSLRSDDTAVYYCARSRGHYFDTRVFEGWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRTFGQGTKVEIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCATGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAACTATGCTATCAGCTGGGTGCGGCAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAACAGACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGCATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGGTCTGATGACACGGCCGTGTATTACTGTGCGAGATCTCGGGGGCATTACTTTGATACTAGGGTCTTTGAAGGCTGGGGCCAGGGAACACTGGTCACCGTCTCCTCA,CARSRGHYFDTRVFEGW,97.619
13I10,gp41-gp41 interface,,Donor N152 ,35O22,Huang2014(25186731) ,,Huang2014(25186731) ,IMGT/V-QUEST,1-18*02,5-24*01,4*02 or 4*03,16.0,GLLRDGPSTWLPHL,,,2-14*02,1*01,10.0,CSYTHNSGCV,,,L,,Natural monoclonal,human,, ,,,8.0,162.0,3152.0,QGQLVQSGGELKKPGASVKISCKTSGYRFSFYHINWIRQVVGRGPEWMGWISPYNGGTNLAPEFRGRLVLTTEREVVDTMTMSTGTAHMELRNLKSDDTGLYFCAKGLLRDGPSTWLPHLWGQGTLLTVSS,QSALTQPASVSGSLGQSVTISCTGPSSVCCSHKSISWYQWPPGRAPTLLIFEDSERSWGISDRFSGYKSYWSASLTISNLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,CAGTCTGCCCTGACTCAGCCTGCCTCCGTTTCTGGGTCTCTTGGTCAGTCGGTCACCATCTCCTGCACTGGACCCAGTAGTGTCTGTTGCAGTCATAAATCTATCTCCTGGTATCAGTGGCCCCCCGGCAGAGCCCCCACACTCCTCATTTTTGAAGACAGTGAGCGGTCCTGGGGAATCTCTGACCGCTTCTCTGGCTACAAGTCTTATTGGTCGGCCTCCCTGACAATCTCTAATCTCCGGCCTGAGGACGAGACCACTTACTACTGTTGCTCATATACTCACAACAGCGGCTGTGTCTTCGGCACTGGGACCAAGGTCTCCGTCCTG,CAGGGTCAACTAGTCCAGTCTGGAGGTGAATTGAAGAAGCCTGGGGCCTCGGTGAAGATTTCCTGTAAGACTTCGGGTTATAGATTTAGTTTCTATCATATTAATTGGATTCGACAAGTAGTGGGGCGCGGACCTGAGTGGATGGGCTGGATCAGCCCTTACAACGGAGGCACAAACCTCGCACCTGAGTTCCGAGGCAGACTCGTGCTGACCACAGAGAGAGAGGTCGTGGACACCATGACCATGTCCACGGGCACAGCCCACATGGAACTAAGGAACCTAAAATCTGACGACACGGGCCTCTATTTCTGTGCAAAGGGCCTCTTGCGCGACGGTCCGTCGACGTGGCTTCCTCATTTGTGGGGCCAGGGAACCCTGCTCACCGTCTCGTCA,CAKGLLRDGPSTWLPHLW,69.745
15e,gp120 CD4bs,,N70 ,,Robinson1990c(1694449) ,,Gorny2009(18952295) ,,4-39*02,2-8,6,,,,,,,,,,,,Yes,Natural monoclonal,human,"15E, 1.5e, 1.5E, N70-1.5e", ,84.951,1.95986,111.0,53.0,627.0,QLQLQESGPGLVKPSETLSLTCTVSGGSISDFNYYWGWIRQPPGKGLEWIGSIYYSGSAYYKPSLKSRVTMSVDTSKNHFSLKLTSVTAADTAVYYCASQVYRPYFYSYYGMDVWGQGST,ELQLTQSPSSLSASVGVRVNLTCRASQSIDIYLNWYQQKPGNAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQREDFATYYCQQSSSTPQTFGPGTVVVIKR,GAACTGCAGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGTCAGAGTCAACCTCACTTGCCGGGCAAGTCAGAGCATTGACATCTATTTAAATTGGTATCAGCAGAAGCCAGGGAACGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTACAGAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGTCTGCAACGTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTCCAGTACCCCTCAGACGTTCGGCCCAGGGACCGTGGTGGTGATCAAACGT,CAACTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCGATTTTAATTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGACTTGAGTGGATTGGCAGTATCTATTATAGTGGGAGCGCCTACTATAAGCCGTCCCTCAAGAGTCGAGTCACCATGTCCGTCGACACGTCCAAGAATCACTTCTCCCTGAAGCTGACCTCTGTGACCGCCGCAGACACGGCTGTCTATTACTGTGCGAGTCAAGTCTATAGGCCATATTTCTACTCCTACTACGGTATGGACGTCTGGGGCCAAGGGAGCACG,CASQVYRPYFYSYYGMDVW,94.257
16G6,gp120 V3 // V3 glycan (V3g),,KTS376 ,,RamirezValdez2015(25486586) ,,RamirezValdez2015(25486586) ,IMGT/V-QUEST,5-51*01,,,7.0,ARGGGDI,,,3-19*01,,10.0,NSRDSSDHWV,,,L,Yes,Natural monoclonal,human,, ,60.3847,5.57495,48.0,529.0,3259.0,,,,,,
1-79,gp120 V3 // V3 glycan (V3g),,Patient 1 ,,Scheid2009(19287373) ,,Scheid2009(19287373) ,,5-51,3,3,16.0,SYYDFSIGDGNDAFDV,,,1-47,1,10.0,AAWDDSFDYV,,,K,,Natural monoclonal,human,, ,,,18.0,475.0,2199.0,EVQLVQSAAQVKKSGESLKISCQGPRDSFSSYWIAWVRQKPGKGLEWLGIIFFDDTDTRYNPSFQGHVTISVDKSITTSYVEWTSLQASDTATYFCARSYYDFSIGDGNDAFDVWGHGTMVTVSS,QSVLTQPPSASGTPGQSVSVSCSGGTSNIANNYVYWYQQLPGEAPRLLIYRSDQRPSGVPERFSGSKSGSSASLVIRGLRSEDEADYYCAAWDDSFDYVFGTGTTVTVL,CAGAGCGTGCTGACTCAGCCCCCCTCAGCGTCTGGGACCCCCGGGCAGAGTGTCTCCGTCTCTTGTTCTGGAGGCACTTCAAACATCGCAAACAATTATGTCTATTGGTATCAACAACTCCCAGGGGAGGCCCCCCGACTCCTCATCTATAGGAGTGATCAGCGGCCCTCAGGGGTCCCTGAGCGATTCTCTGGCTCCAAGTCTGGCTCCTCAGCCTCCCTGGTCATCAGGGGCCTCCGGTCCGAGGATGAGGCTGATTATTATTGTGCAGCCTGGGATGACAGTTTTGATTATGTCTTCGGAACTGGGACTACAGTCACCGTCCTC,GAGGTGCAGCTGGTGCAGTCTGCAGCACAAGTGAAAAAGTCTGGGGAGTCTCTGAAGATCTCTTGTCAGGGACCTCGGGACAGTTTCAGCAGTTATTGGATCGCCTGGGTGCGCCAGAAGCCCGGGAAAGGCCTGGAGTGGCTGGGTATCATATTTTTCGATGACACTGATACAAGATATAATCCGTCTTTCCAAGGGCACGTCACCATCTCAGTCGACAAGTCCATCACTACCTCCTACGTGGAGTGGACCAGCCTGCAGGCCTCGGACACCGCCACTTACTTCTGTGCGAGGTCCTATTATGATTTTTCCATTGGTGACGGCAATGATGCCTTTGATGTCTGGGGCCACGGGACAATGGTCACCGTCTCTTCA,CARSYYDFSIGDGNDAFDVW,83.959
179NC75,gp120 CD4bs,7LLK(Q23.17_DS-SOSIP in complex with 179NC75 Fab),EB179 ,,Freund2015(26516768) ,179NC75 binding-associated sites,Freund2015(26516768) ,IgBlast IMGT/V-QUEST,3-21,3-9,5,24.0,VHAWRYFDWVNRRSPVEKVLSIDL,,,3-1,2,10.0,QTWDSKNYVT,,,L,,Natural monoclonal,human,, ,12.6804,32.0116,240.0,226.0,3317.0,EMRLEESGGALVKPGGSLRLSCVASGFKLSEWSLMWVRQAPGKGLQWVSSISLNQDYISYAGSVRGRFDVFRDRTQTSLLLNMNKLKTEDTGVYFCARVHAWRYFDWVNRRSPVEKVLSIDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK,SVTSGATQPPSVSVSKGETARITCSGVELSSQYVSWYRQRPGQSPVLVMFHNNSRASRIPERFSASDSGDTATLTIAGAQDVDEAEYYCQTWDSKNYVTFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,,,,
17b,gp120 CD4i CoRbs (Cluster C),"1G9M(gp120 (HXB2) complexed with CD4 and 17b);1G9N(gp120 (YU2) complexed with CD4 and 17b);1GC1(gp120 core complexed with CD4 and 17b);1RZ8(antibody 17b);1RZJ(gp120 (HXB2) complexed with CD4 and 17b);1RZK(gp120 (YU2) complexed with CD4 and 17b);1YYL(CD4M33, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);1YYM(F23, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);2I5Y(CD4M47, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);2I60([Phe23]M47, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);2NXY(gp120 (S334A) complexed with CD4 and 17b);2NXZ(gp120 (T257S, S334A, S375W) complexed with CD4 and 17b);2NY0(gp120 (M95W, W96C, T257S, V275C, S334A, S375W, A433M) complexed with CD4 and 17b);2NY1(gp120 (I109C, T257S, S334A, S375W, Q428C) complexed with CD4 and 17b);2NY2(gp120 (T123C, T257S, S334A, S375W, G431C) complexed with CD4 and 17b);2NY3(gp120 (K231C, T257S, E267C, S334A, S375W) complexed with CD4 and 17b);2NY4(gp120 (K231C, T257S, E268C, S334A, S375W) complexed with CD4 and 17b);2NY5(gp120 (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) complexed with CD4 and 17b);2NY6(gp120 (M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, G431C) complexed with CD4 and 17b);4JM2(PGT 135 Fab in complex with gp120 core (JR-FL) bound to CD4 and 17b Fab);4RQS(gp120 core bound to CD4 and 17b Fab);5A7X(BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);5A8H(BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195)",N70 ,,,17b contacts;MPER membrane fusion mutations confer sensitivity;Mutation affects binding to 17b and 412d;Mutation affects neutralization;mutations affecting 17b binding;mutations affecting 17b binding;Mutations at the trimer apex that affect sensitivity,Klein2013(23540694) ,IgBlast,1-69,3-16 or 3-22,5,,,,,3-15,2,,,,,K,Yes,Natural monoclonal,human,"1.7b, 1.7B, sCD4-17b", ,72.4825,3.46118,834.0,52.0,658.0,EVQLVESGAEVKKPGSSVKVSCKASGDTFIRYSFTWVRQAPGQGLEWMGRIITILDVAHYAPHLQGRVTITADKSTSTVYLELRNLRSDDTAVYFCAGVYEGEADEGEYDNNGFLKHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP,DIVMTQSPATLSVSPGERATLSCRASESVSSDLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGAEFTLTISSLQSEDFAVYYCQQYNNWPPRYTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG,,,,
nan,,,,,,,Gorny2009(18952295) ,,1-69,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,
19b,gp120 V3 // V3 glycan (V3g),,N70 ,,Robinson1990c(1694449) ,,,,,,,,,,,,,,,,,K,No,Natural monoclonal,human,"1.9B, N70-1.9b, N701.9b", ,,,6.0,726.0,457.0,,,,,,
1B2530,gp120 CD4bs,4YFL(1B2530 in complex with HIV-1 clade AE 93TH057 gp120),Patient 1 ,,Scheid2011(21764753) ,1B2530 contacts;Signature Analysis Summary,Scheid2011(21764753) ,,1-46,6-13 or 6-19,4 or 5,16.0,AEAASDSHSRPIMFDH,,,1-47,3,11.0,ATYDSDGSIRL,,,L,,Natural monoclonal,human,," 1B2530 is a close clonal relative to INC127, and the germline repertoir is as shown for INC127 in Scheid2011.",12.3292,9.01227,318.0,97.0,2578.0,QVQLEQSGTAVRKPGASVTLSCQASGYNFVKYIIHWVRQKPGLGFEWVGMIDPYRGRPWSAHKFQGRLSLSRDTSMEILYMTLTSLKSDDTATYFCARAEAASDSHSRPIMFDHWGQGSLVTVSSASTKGPSVF,QSALTQPPSASGAPGQRVTISCSGGPSNVGGNYVYWYRQFPGTAPTLLILRDDQRPSGVPDRFSASKSGNSASLAISGLRPDDEGFYFCATYDSDGSIRLFGGGTALTVLSQPKAAPSVTLFPX,CAGTCTGCCCTGACTCAGCCACCCTCAGCGTCTGGGGCCCCCGGGCAGAGGGTCACCATCTCCTGTTCCGGAGGTCCCTCCAACGTCGGCGGCAATTATGTCTACTGGTATCGGCAGTTTCCAGGCACGGCCCCCACGCTCCTCATCCTTCGAGATGACCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCCGCGTCTAAGTCTGGCAATTCAGCCTCCCTGGCCATCAGTGGGCTCCGACCGGACGATGAGGGTTTTTATTTCTGTGCAACATATGATAGTGACGGAAGTATTCGACTGTTCGGCGGAGGAACCGCATTAACTGTCCTGAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCC,CAGGTGCAGCTGGAACAATCGGGGACTGCGGTGAGGAAGCCTGGGGCCTCGGTGACGCTTTCCTGCCAGGCGTCCGGTTACAACTTCGTCAAATACATCATTCACTGGGTGCGCCAGAAACCTGGACTCGGCTTTGAGTGGGTTGGCATGATCGACCCCTACCGTGGCCGGCCATGGTCCGCGCACAAATTTCAGGGTCGACTCTCCCTGAGTCGAGACACTTCCATGGAAATACTATATATGACCCTGACCAGCCTGAAATCTGACGACACGGCCACCTATTTCTGTGCGAGGGCTGAGGCAGCATCCGACAGTCATTCTCGACCCATCATGTTCGACCACTGGGGCCAGGGCTCCCTGGTCACCGTCTCCTCAGCGTCGACCAAGGGCCCATCGGTCTTC,CARAEAASDSHSRPIMFDHW,72.696
1B5,gp120 CD4i CoRbs (Cluster C),,llama#9 ,,Strokappe2012(22438910) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH 1B5,llama antibody ,22.1425,4.43342,32.0,230.0,3250.0,,,,,,
1C2-llama,gp120 V2-CD4bs,,,,Strokappe2012(22438910) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH 1C2,llama antibody ,13.908,6.2962,26.0,227.0,3247.0,,,,,,
1C2-rabbit,gp41-gp120 interface,6P65(HIV Env 16055 NFL TD 2CC+ in complex with antibody 1C2 fragment antigen binding);6PEH(Crystal structure of rabbit monoclonal anti-HIV antibody 1C2);EMD-20260(HIV Env 16055 NFL TD 2CC+ in complex with antibody 1C2 fragment antigen binding);EMD-20274(Negative stain reconstruction of HIV-1 Env 16055 NFL TD 2CC+ trimer in complex with rabbit antibody 1C2 fragment antigen binding),C3 ,,Dubrovskaya2019(31732167) ,1C2 contacts,,,,,,,,,,,,,,,,,,Natural monoclonal,rabbit,,rabbit antibody ,9.32833,4.41968,244.0,764.0,4471.0,QSLEESGGDLVKPGASLTLTCTASGFSFGWNDYMSWVRQAPGKGLEWIGCIYAGSTRSTYYANWAKGRLTISKTSSTAVTLQMTSLTAADTATYFCARGAVTYDGLGGAYLKHFNLWGPGTLVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLTNGVRTFPSVRQSSGLYSLSSVVSVTSSSQPVTCNVAHPATNTKVDKTVAPSTCSKHHHHHHHH,AIKMTQTPSSVSAAVGGTVTVNCRASEDIESYLAWYQQKPGQPPKLLIYDTSKLASGVPSRFKGSGSGTQFALTISGVQCDDAATYYCLYGYISSDRIDFGFGGGTELVVKGDPVAPSVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC,,,,
1D9,gp120 V3 // V3 glycan (V3g),,KTS376 ,,RamirezValdez2015(25486586) ,,RamirezValdez2015(25486586) ,IMGT/V-QUEST,3-30*09 or 3-30*01,,,16.0,AKDGADVDNLGPAFDY,,,2-28*01 or 2D-28*01,,8.0,MQPLQSWY,,,K,Yes,Natural monoclonal,human,, ,33.5155,9.68867,48.0,528.0,3257.0,,,,,,
1E1,gp120 V2-CD4bs,,,,Strokappe2012(22438910) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH 1E1,llama antibody ,70.1952,2.11803,26.0,229.0,3249.0,,,,,,
1E2,gp120 CD4i CoRbs (Cluster C),,llama#9 ,,Strokappe2012(22438910) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH 1E2,llama antibody ,67.1795,2.23987,26.0,233.0,3253.0,,,,,,
1F10,gp120 V3 // V3 glycan (V3g),,llama#9 ,,Strokappe2012(22438910) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH 1F10,llama antibody ,9.64739,7.96383,26.0,228.0,3248.0,,,,,,
1F7,gp120 CD4bs,,,,Buchacher1994(7520721) ,,Gach2013(23991039) ,,4-59*01,,,16.0,GRFDYFRGGHRLIFDS,,,1D-33*01,,9.0,QQFDSLPPT,,,K,,Natural monoclonal,human,human 1F7, ,36.7319,6.60166,122.0,165.0,949.0,QVQLQESGPGLVKPSETLSLTCSVSGGSLSNFYWSWIRQFPGKRLEWIAYINFNNEKSNQNPSLKGRLTVSGDPSKNHLSMRLTSVTAADTAVYFCAR,DIQMTQSPSSLSASVGDRVTFTCQADDDISNSLNWYQQKPNKAPKLLIYDASALETGVPSRFSGRGSGTDFTLTINSLQPDDVATYFCQQFDSLP,GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACGTTCACTTGCCAGGCGGATGATGACATTAGTAATTCTTTAAATTGGTATCAGCAAAAACCAAATAAAGCCCCTAAACTCCTTATCTACGATGCATCCGCTTTGGAAACAGGGGTCCCATCAAGGTTCAGTGGACGCGGGTCTGGGACAGATTTTACTTTAACCATCAACAGCCTGCAGCCTGACGATGTTGCAACCTATTTCTGTCAACAGTTTGATAGTCTCCCT,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTTGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCAGTGTCTCTGGTGGCTCCCTCAGTAATTTCTACTGGAGCTGGATCCGGCAGTTCCCCGGGAAGAGACTAGAGTGGATTGCATATATCAATTTCAACAATGAGAAGTCCAATCAGAACCCCTCCCTCAAGGGTCGACTCACCGTGTCAGGAGACCCGTCCAAGAACCATCTCTCTATGAGGCTCACCTCTGTGACCGCTGCAGATACGGCCGTATATTTCTGTGCGAGA,,
1H9,gp120 CD4i CoRbs (Cluster C),,llama#8 ,,Strokappe2012(22438910) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH 1H9,llama antibody ,25.1028,4.19244,26.0,231.0,3251.0,,,,,,
1NC9,gp120 CD4bs,,Patient 1 ,,Scheid2011(21764753) ,,Klein2013(23540694) ,IgBlast,1-46,2-8 or 5-12,4,,,,,1-47,3,,,,,L,,Natural monoclonal,human,, ,3.95204,24.6021,31.0,96.0,2900.0,QVRLVQSGAQLKKPGASVTVSCEASGYNFVNYIINWVRQTPGRSFEWVGMIDPRRGRPWSAQKFQGRLTLTRDIDSEKLYMHLSGLRGDDTAVYYCARQDSDFHDGHGHTLRGMFDSWGQGSLITVSSASTKGPSV,NFMLTQVLSVSGTPGQRVIISCSGTSSNVGGNLVSWYQHLPGAAPRLLIHRDDQRPSGVPDRFSGSKSGNSASLVISGLRSDDEADYFCAAYDSTFSLPVFGGGTRLTVLSQPKAAPSVTLYAPSSEEX,AATTTTATGCTGACTCAGGTCCTCTCAGTGTCTGGGACCCCCGGACAGAGAGTCATCATCTCCTGCTCTGGAACCAGCTCCAACGTCGGCGGTAACTTGGTTTCCTGGTATCAACACTTGCCAGGCGCGGCTCCCAGACTCCTCATCCATAGAGATGATCAACGGCCCTCTGGGGTCCCTGACCGCTTCTCCGGTTCCAAGTCTGGCAATTCAGCCTCCCTGGTCATCAGTGGGCTCCGGTCCGACGATGAGGCTGATTATTTCTGTGCCGCATATGATAGCACTTTCAGTCTTCCCGTCTTCGGCGGCGGGACCAGGTTGACCGTCTTAAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTACGCACCCTCGAGTGAGGAGA,CAGGTGCGATTAGTGCAATCTGGGGCACAGTTGAAGAAACCTGGGGCCTCAGTGACGGTCTCTTGCGAGGCGTCTGGATACAACTTCGTCAACTACATTATAAATTGGGTCCGACAGACACCTGGACGAAGTTTTGAGTGGGTGGGGATGATCGACCCTAGACGCGGCAGGCCATGGTCCGCGCAGAAGTTCCAGGGCAGACTCACTTTGACCCGGGACATCGACTCCGAGAAACTCTACATGCATTTGAGTGGCCTGAGAGGTGACGACACGGCCGTCTACTATTGCGCGAGGCAGGATTCAGACTTCCACGATGGACATGGCCACACTCTCCGCGGGATGTTTGACTCTTGGGGCCAGGGATCACTGATCACCGTCTCCTCAGCGTCGACCAAGGGCCCATCGGTC,CARQDSDFHDGHGHTLRGMFDSW,77.211
nan,,,,,,,Scheid2011(21764753) ,,1-46,5-12 or 2-8,4 or 5,19.0,QDSDFHDGHGHTLRGMFDS,,,1-47,3,11.0,AAYDSTFSLPV,,,,,,,,,,,,,,,,,,,
2158,gp120 V2 // V2 glycan(V2g) // V2 apex,4OAW(Fab structure of V2 mAb 2158),,,,Mutations at the trimer apex that affect sensitivity,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,64.9225,2.87065,43.0,186.0,1347.0,QVQLVQSGAEVKKPGSSVKVSCEASGVTSSSYTISWVRLAPGQGLEWMGRITPIFDITNYAQKFQGRVTLTADKSTGTTYMELSSLRSDDTAVYYCARDKSDVVVVTSIRPAYYYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQTISSWLAWYQQKSGTAPKLLIYKASSIVSGVPSRFSGSGSGTEFTLTITSLQPDDFATYYCQQYNSSPETFGQGTKVEIK,GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGACTATTAGCAGCTGGTTGGCCTGGTATCAGCAGAAGTCAGGGACAGCCCCTAAACTCCTGATCTATAAGGCGTCTAGTATAGTGAGTGGGGTGCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCACCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGTATAATAGTTCTCCAGAGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA,CAGGTCCAGCTGGTGCAATCTGGGGCTGAAGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGTGAGGCTTCTGGAGTCACGTCAAGCAGTTATACTATCAGCTGGGTGCGACTGGCCCCTGGACAAGGGCTAGAGTGGATGGGAAGGATCACCCCTATTTTTGATATAACAAACTACGCACAGAAGTTCCAGGGCAGAGTCACCCTGACCGCGGACAAATCCACGGGCACCACATACATGGAGCTGAGCAGCCTGAGATCTGACGACACGGCCGTCTATTATTGTGCGAGAGATAAATCTGATGTAGTAGTGGTGACCTCTATTCGTCCGGCCTACTACTACGGCATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCGTCA,CARDKSDVVVVTSIRPAYYYGMDVW,91.554
2191,gp120 V3 // V3 glycan (V3g),,,,Gorny2002(12186887) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,45.4818,5.17719,100.0,77.0,1092.0,,QSVLTQAPSSSGTPGQSVTISCSGSSSNMEINYVYWYRQFPGTAPQLLIYNDNQRPSGVPDRFSASKSGTSASLAIGGLRSEDEADYFCAVWHGDRGGPVFGGGTKLTVL,CAGTCTGTGTTGACTCAGGCACCCTCTTCGTCTGGGACCCCCGGGCAGAGCGTCACCATCTCTTGTTCTGGTAGCAGCTCCAACATGGAGATAAATTACGTCTACTGGTATCGGCAGTTCCCAGGAACGGCCCCCCAACTCCTCATCTACAATGATAATCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGCCTCCAAGTCTGGAACCTCAGCCTCCCTGGCCATCGGTGGCCTCCGGTCCGAGGATGAGGCTGACTATTTTTGTGCAGTCTGGCATGGCGACCGGGGTGGTCCGGTGTTCGGCGGCGGGACCAAGCTGACCGTCCTG,,,
2219,gp120 V3 // V3 glycan (V3g),2B0S(antibody 2219 in complex with three different V3 peptides);2B1A(Fab 2219 in complex with UG1033 peptide);2B1H(Fab 2219 in complex with UG29 peptide),,,Gorny2002(12186887) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,49.8952,4.25128,105.0,78.0,1089.0,QVQLVQSGAEVKKSGESLKISCQTSGYSFSDYWIGWVRQMPGKGLEWMGIFYPGDSDSRYSPSFEGQVTMSADRSTNTAHLQWSSLKPSDTALYYCARLGGDYEDSGADAFDFWGQGTLVSVSAASTKGPSV,QSVLTQPPSASGTPGQRISISCSGTSSNVENNYVYWYQHLPGTAPKLLIYRNDHRSSGIPDRFSASKSGTSASLAISGLRPEDEGDYYCAAWDDSRGGPDWVFGGGTKLTVLSQPKAAPSVTLFPP,CAGTCTGTGTTGACTCAGCCACCCTCCGCGTCTGGGACCCCCGGGCAGAGGATCAGCATCTCTTGTTCTGGAACCAGCTCTAACGTCGAAAATAATTACGTTTACTGGTATCAACACCTCCCAGGAACGGCCCCCAAACTCCTCATTTATAGGAATGATCACCGGTCCTCAGGAATTCCTGACCGATTTTCTGCCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGCCCGAGGATGAGGGTGATTATTACTGTGCAGCATGGGATGACAGCCGCGGTGGTCCGGATTGGGTCTTCGGCGGAGGCACCAAGTTGACCGTCCTCAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCACCC,CAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGTCGGGGGAGTCTCTGAAGATCTCCTGTCAGACTTCTGGATACAGTTTTTCTGACTATTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGCATCTTCTATCCTGGTGACTCTGACAGTAGATACAGTCCTTCGTTCGAAGGCCAGGTCACCATGTCAGCCGACAGGTCCACCAATACCGCCCACCTACAGTGGAGTAGCCTGAAGCCCTCGGACACCGCCCTATATTACTGTGCGCGATTGGGGGGGGACTACGAAGACTCCGGGGCAGACGCTTTTGATTTCTGGGGCCAGGGGACACTGGTCTCCGTCTCTGCAGCCTCCACCAAGGGCCCATCGGTC,CARLGGDYEDSGADAFDFW,89.116
2408b,gp120 CD4bs,,2408 ,,Chen2021(33453152) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,transgenic mouse,, ,50.8962,5.22233,416.0,851.0,4602.0,QVQLVQSGAEVKGPGAAVKVSCKASGYTFTAYFLHWLRQAPGQGLEWMGWIKPRWGAVNYAHKFQGRVTMTRDTSIDTAYLDLNRLTSDDTAVYYCAKSSFDSDAWYFDVWGAGTSVTVSS,EIVLTQSPGTLSLSPGERATLSCRTSHYVDSNNLAWYQQKPGQAPWLLIYGTSNRATGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQYEFFGQGTKVQVDIR,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGGGCCACCCTCTCCTGCAGGACCAGTCACTACGTTGACAGCAACAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCTGGCTCCTCATCTATGGTACATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTATATTACTGTCAACAGTATGAATTCTTCGGCCAAGGGACCAAGGTGCAGGTGGACATCAGA,CAGGTGCAGCTGGTGCAGTCTGGCGCTGAGGTGAAGGGGCCTGGGGCCGCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGCCTACTTTTTACACTGGCTACGACAGGCCCCTGGACAGGGACTTGAGTGGATGGGATGGATCAAACCTCGCTGGGGTGCCGTCAACTATGCACATAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCGACACTGCCTATTTGGACCTGAACAGGCTGACATCTGACGACACGGCCGTGTATTATTGTGCGAAGTCGTCGTTTGATTCCGACGCCTGGTATTTCGATGTCTGGGGCGCTGGGACCTCGGTCACCGTCTCCTCA,CAKSSFDSDAWYFDVW,89.726
2408c.3,gp120 CD4bs,,2408 ,,Chen2021(33453152) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,transgenic mouse,, ,48.9128,4.83593,416.0,853.0,4603.0,QVQLLQSGTEMKKPGASVRISCKTSGYDFTDYFIHWVRQAPGQGLEWMGWLNPTRGGVNYAHIFQGRVSMTRDTSTSTAYMELRGLKSDDTSVYFCARRGLHSDYDWDFSYWGQGTLVTVSA,EIVLTQSPDTLSLSPGERATLSCRASQSVGDLAWYQQKPAQSPRLLIYGTSNRAPGIPDRFSGSGSGSDFTLIISRLEPEDFAVYYCQQYEFFGQGTKVVVDSK,GAAATTGTATTGACGCAGTCTCCAGACACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGTAGGGCCAGTCAGAGTGTCGGCGACTTAGCCTGGTATCAGCAGAAGCCTGCCCAGTCTCCCAGGCTCCTCATCTATGGTACATCCAACAGGGCCCCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGTCAGACTTCACTCTCATCATCAGCAGACTGGAGCCTGAGGATTTTGCAGTGTATTACTGTCAGCAGTATGAATTCTTTGGTCAAGGGACCAAGGTGGTGGTGGACAGTAAA,CAGGTGCAGCTGCTACAGTCTGGGACTGAAATGAAGAAGCCTGGGGCCTCAGTGAGAATCTCCTGCAAGACTTCTGGATATGACTTCACCGACTACTTTATACACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAATGGATGGGATGGCTCAACCCTACCAGAGGTGGCGTGAACTACGCACACATCTTTCAGGGCAGGGTCTCCATGACCAGGGACACGTCCACCAGTACAGCCTACATGGAACTGCGCGGCCTGAAATCTGACGACACGTCCGTTTACTTCTGTGCGAGAAGGGGCCTCCACTCTGATTACGACTGGGACTTTTCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA,CARRGLHSDYDWDFSYW,87.075
2411a,gp120 CD4bs,7JKS(2411a in complex with HIV-1 gp120 core),2411 ,,Chen2021(33453152) ,2411a contacts,,,,,,,,,,,,,,,,,,Natural monoclonal,transgenic mouse,, ,12.3645,10.3959,416.0,852.0,4604.0,QVQLVQSGAEMKKPGASVRVSCEASGYTFTDYVLHWMRQAPGQGIEWLGWIKPRYGAVNYAHKFQGRVSMTRDTSIDTAYLELINLRSDDTAIYYCARSFDSDYEWWFTYWGQGTLVSVSA,EIVLTQSPGTLSLSPGERATLSCRASYFISRDYLAWYQQRPGQAPKLLIYGTTTRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYEFFGLGTKVEIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTTACTTTATTAGCCGCGACTATTTAGCCTGGTACCAACAGCGACCTGGCCAGGCTCCCAAACTCCTCATCTACGGTACAACAACCAGGGCCAGTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGTAGACTGGAGCCTGAAGATTTTGCTGTGTATTACTGTCAGCAGTATGAATTCTTCGGCCTAGGGACCAAGGTGGAAATCAAA,CAGGTGCAGTTGGTGCAGTCTGGGGCTGAGATGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCGAGGCTTCTGGATACACCTTCACCGACTACGTTCTTCACTGGATGCGACAGGCCCCTGGACAAGGGATTGAGTGGCTGGGATGGATCAAGCCTCGGTATGGTGCCGTAAATTACGCACATAAATTTCAGGGCCGGGTCTCCATGACCAGGGACACGTCCATCGACACAGCCTACCTGGAACTGATCAACCTGAGATCTGACGACACGGCCATTTATTACTGTGCGAGATCTTTTGACTCTGATTACGAGTGGTGGTTTACTTATTGGGGCCAGGGGACTCTGGTCTCTGTCTCTGCA,,
2413a,gp120 CD4bs,7JKT(2413a in complex with HIV-1 gp120 core),2413 ,,Chen2021(33453152) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,transgenic mouse,, ,32.2765,6.26601,416.0,854.0,4605.0,QVQLVQSGPEVRAPGASVTVSCKTSGYSFTDFFIHWVRQAPGQGLEWMGWLNPIFGAVNYAHKYQGRITLTRDTSMKTAYMQLTNLRSDDTAVFYCVRKRVYDEYDWDWAYWGQGTLVTVSA,EIVLTQSPGILSLSPGERATLSCRTSQDVGSNSLAWYQEKPGQAPRLLVYGASNRATGVPDRFSGGGSGTDFTLTISRLEPEDFAVYYCQQYEYFGRGTKVQVDIK,GAAATTGTGTTGACGCAGTCTCCAGGCATCCTATCGTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGACCAGTCAGGATGTTGGCAGCAACTCCTTAGCCTGGTACCAGGAGAAGCCTGGCCAGGCTCCCAGGCTCCTCGTCTATGGTGCATCCAACAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCGGTGGGTCTGGGACAGACTTCACTCTCACCATCAGTAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGAATACTTCGGCCGAGGGACCAAGGTGCAGGTGGACATCAAA,CAGGTGCAGTTGGTGCAATCTGGGCCTGAGGTGAGAGCGCCTGGGGCCTCAGTGACGGTCTCCTGTAAAACTTCTGGATATTCCTTCACCGACTTCTTTATTCACTGGGTGCGGCAGGCCCCTGGACAAGGCCTTGAGTGGATGGGATGGCTCAACCCTATCTTTGGTGCCGTCAATTATGCACATAAATACCAGGGCAGGATCACCTTGACCAGGGACACGTCCATGAAAACAGCCTACATGCAACTAACTAACCTGAGATCTGACGATACGGCCGTCTTTTATTGTGTGAGAAAAAGAGTCTATGATGAATATGATTGGGACTGGGCTTATTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA,CVRKRVYDEYDWDWAYW,83.673
2413b,gp120 CD4bs,,2413 ,,Chen2021(33453152) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,transgenic mouse,, ,21.259,5.66918,416.0,855.0,4606.0,QVQLVQSGAEMKLPGATVTVTCKASGYTFTGHLLHWLRQAPGQGLEWMGWINPLHGGLNYAKEFQGRITMTRDTSLNIAYLEMRGLTSDDSAIYYCARLPKDYDDLWYFDVWGAGTTVTVSS,GIVVTQSPATLSLSPGERATLSCRTSQSVGGTQLTWYQQKPGQAPRLLLYDTSTRATGIPDRFGGRGSGTDFTLTISRLEPEDFALYFCQHYEFFGQGTRVQVDIK,GGAATTGTGGTGACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAGAGAGCCACCCTCTCCTGCAGGACCAGTCAGAGTGTTGGCGGCACCCAATTAACCTGGTACCAACAAAAGCCTGGCCAGGCTCCCAGACTCCTCCTCTATGATACATCCACCAGGGCCACTGGCATCCCAGACAGATTCGGTGGCAGAGGGTCTGGGACAGACTTCACTCTCACCATCAGTAGACTGGAGCCTGAAGATTTTGCACTTTATTTCTGTCAACATTATGAATTCTTCGGCCAAGGGACCAGGGTGCAGGTGGACATCAAA,CAGGTGCAGCTGGTGCAGTCAGGGGCTGAAATGAAGCTGCCTGGGGCCACAGTGACGGTCACCTGTAAGGCGTCCGGATACACCTTCACCGGCCACCTTCTACACTGGTTGCGCCAGGCCCCTGGACAGGGACTTGAGTGGATGGGATGGATCAATCCTTTACATGGTGGCCTAAATTATGCAAAAGAATTTCAGGGCAGGATCACCATGACCAGGGACACGTCCCTCAATATAGCCTATTTGGAGATGAGAGGTCTGACATCTGACGACTCGGCCATTTATTACTGTGCGCGACTCCCCAAAGATTACGACGATCTCTGGTACTTCGATGTCTGGGGCGCTGGGACCACGGTCACCGTCTCCTCA,CARLPKDYDDLWYFDVW,83.333
2413c,gp120 CD4bs,,2413 ,,Chen2021(33453152) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,transgenic mouse,, ,31.8963,5.25383,416.0,856.0,4607.0,QVQLVQSGAEVKLPGASMTVSCKASGYTFTGHLLHWVRQAPGQGLEWLGWINPIHGAVNYAHSFQGRVTMTRDTSINTAYLEMTSLRSDDTAIYYCARLPSTYDDLWYFDVWGAGTEVTVSS,GIVLTQSPGTLSLSPGERATLSCRTSQSVGSHSLTWYQQKPGQAPRLLSYDGSSRATGIPDRFSGSGSGTDFVLTISRLEPEDFALYFCQHYEFFGQGTKVQVDIK,GGAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGACCAGTCAGAGTGTTGGCAGCCACTCCTTAACCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCAGTTATGATGGGTCCAGCAGGGCCACTGGCATTCCAGACAGATTTAGTGGCAGTGGGTCTGGGACAGACTTCGTTCTCACCATCAGCAGACTGGAGCCGGAAGATTTTGCCCTGTATTTCTGTCAACATTATGAATTCTTCGGCCAAGGGACCAAGGTTCAGGTGGACATCAAA,CAGGTGCAGCTGGTACAGTCTGGGGCTGAGGTGAAGCTGCCTGGGGCCTCAATGACCGTCTCCTGCAAGGCTTCTGGATATACCTTCACCGGCCACCTTCTACACTGGGTGCGACAGGCCCCTGGACAGGGTCTTGAGTGGTTGGGATGGATCAACCCTATCCATGGTGCCGTGAATTATGCACACAGTTTTCAGGGCAGAGTCACCATGACCAGGGACACGTCCATTAATACAGCCTACTTGGAGATGACCAGTCTGCGATCTGACGACACGGCCATCTATTACTGTGCGCGCCTCCCCTCTACTTACGACGATCTCTGGTATTTCGATGTCTGGGGCGCAGGGACCGAGGTCACCGTCTCCTCA,CARLPSTYDDLWYFDVW,87.285
246-D,gp41 cluster I,,,,Xu1991(1714520) ,,Gorny2009(18952295) ,,1-69*01,6-19,4,,,,,,,,,,,K,Yes,Natural monoclonal,human,"246, 246D, SZ-246.D", ,,,4.0,704.0,783.0,,,,,,
2557,gp120 V3 // V3 glycan (V3g),3MLR(Fab 2557 in complex with a NY5 V3 peptide);3MLS(FAb 2557 in complex with gp120 V3 mimotope);3MLT(Fab 2557 in complex with a UG1033 V3 peptide);3MLU(Fab 2557 in complex with a ZAM18 V3 peptide);3MLV(Fab 2557 in complex with an NOF V3 peptide),,,Gorny2004(14963135) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,5-51*01,,3*01,,TRLYLFEGAQSSNAFDL,14.2,,3-1*01,3*02,,QAWDASTGV,14.0,,L,,Natural monoclonal,human,, ,61.1682,3.59128,126.0,55.0,1315.0,EVQLVQSGGEVKQPGQSLKISCKSSGYNFLDSWIGWVRQIPGKGLEWIGIIYPDDSDAHYSPSFEGQVTMSVDKSISTAYLQWTTLQASDTGKYFCTRLYLFEGAQSSNAFDLWGQGTMILVSSASTK,SYDLTQPPSVSVSPGQTASISCSGDKLDDKYVSWYYQRPGQSPVLLMYQDFKRPSGIPERLSGSKSGKTATLTISGTQSLDEGDYYCQAWDASTGVSGGGTKLTVLFGDGTRLTVLGQPKAAPSVTLFPP,TCCTATGACTTGACTCAGCCACCCTCGGTGTCCGTGTCTCCAGGACAGACAGCCAGCATCAGCTGCTCTGGAGATAAATTGGATGACAAGTATGTTTCTTGGTATTATCAGAGGCCAGGCCAGTCCCCTGTTTTACTCATGTACCAAGATTTTAAGCGACCCTCAGGGATCCCTGAGCGACTCTCTGGCTCCAAATCTGGGAAAACCGCCACTCTGACCATCAGCGGGACCCAGTCTCTGGATGAAGGTGACTATTACTGTCAGGCATGGGACGCCTCTACGGGGGTGTCCGGCGGGGGGACCAAGCTGACCGTCCTCTTCGGCGACGGGACCAGACTGACCGTCCTGGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCC,GAGGTGCAGCTGGTGCAGTCTGGAGGAGAGGTGAAGCAGCCCGGGCAGTCTTTGAAGATATCGTGTAAGAGTTCTGGATACAACTTTCTCGACTCCTGGATTGGATGGGTGCGCCAGATCCCCGGGAAAGGCCTGGAGTGGATCGGAATCATTTATCCTGATGACTCGGATGCGCACTACAGCCCGTCATTCGAGGGCCAGGTCACCATGTCAGTCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGACCACACTGCAGGCCTCGGACACCGGCAAATACTTCTGTACGAGGTTGTATTTGTTTGAGGGTGCTCAGTCGAGTAACGCTTTTGATCTTTGGGGCCAAGGGACAATGATTTTAGTCTCTTCAGCCTCCACCAAG,CTRLYLFEGAQSSNAFDLW,85.666
2558,gp120 V3 // V3 glycan (V3g),3UJI(Fab 2558 in complex with MN peptide),,,Gorny2004(14963135) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,5-51*03,,4*02,,ARLGFEGDYSGSFFDY,7.3,,3-1*01,2*01 or 3*01,,QAWDSTLGVV,5.7,,L,,Natural monoclonal,human,, ,56.18,4.18878,121.0,54.0,1317.0,EVQLVQSAAEVKKPGEALKISCKGSGYSFSNYWIAWVRQMPGKGLEWMGIVYPDDSDSSYNSSFQGQITFSADKSISTAYLHWTSLQASDTAMYYCARLGFEGDYSGSFFDYWGQGTLLIVSSASTK,SYELTQPPSVSVSPGQTASITCSGDILGDKYVSWYQQKSGQSPLLVIYEDTKRPSGIPDRFSGSKSGNTATLTISGTQAMDEADYYCQAWDSTLGVVFGGGTKVTVLGQPKAAPSVTLFPP,TCCTATGAGCTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGACAGACAGCCAGCATCACCTGCTCTGGAGATATATTGGGGGATAAATATGTTTCCTGGTATCAGCAGAAGTCAGGCCAGTCCCCTCTACTGGTCATCTATGAGGACACCAAGCGGCCCTCAGGGATCCCTGACCGATTCTCTGGCTCCAAGTCTGGGAACACAGCCACTCTGACCATCAGCGGGACCCAGGCTATGGATGAGGCTGACTATTACTGTCAGGCATGGGACAGTACTTTGGGTGTGGTATTCGGCGGAGGGACCAAGGTGACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCC,GAGGTGCAGCTGGTGCAGTCTGCAGCAGAGGTGAAAAAGCCGGGGGAGGCCCTGAAGATCTCCTGTAAGGGTTCTGGCTACAGTTTTTCCAACTACTGGATCGCCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCGTCTATCCTGATGACTCTGACAGCAGCTACAACTCGTCCTTCCAAGGCCAGATCACCTTCTCAGCCGACAAGTCCATCAGTACCGCCTACCTGCACTGGACCAGCCTGCAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACTAGGGTTCGAAGGCGACTATAGTGGGAGCTTCTTTGACTACTGGGGCCAGGGAACCCTGCTCATCGTCTCCTCAGCCTCCACCAAG,CARLGFEGDYSGSFFDYW,92.881
25C4b,gp120 CD4i,,KTS376 ,,Tanaka2017(28938888) ,,Tanaka2017(28938888) ,,3-23,3-22,4,28.0,AKMPLWFAESLDYYDSSGSFWFSNYFDY,10.1,,3-20,4,9.0,QQYGRSPLT,6.0,,K,,Natural monoclonal,human,, Tanaka2017 %SHM shown for VH and VL only.,56.3613,3.97586,61.0,536.0,4144.0,,,,,,
2909,quaternary structure,3PIQ(2909 Fab),,,Gorny2005(15795308) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,,,12.0,199.0,1421.0,EVQLVESGGNVVQPGGSLRLSCTASGFSFDDSTMHWVRQAPGKGLQWVSLISWNGGRTYYADSVKGRFTISRDNSKNSLYLQMNSLKTEDTAFYFCAKDKGDSDYDYNLGYSYFYYMDGWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPK,SYVLTQPPSVSVAPGKTARITCGGNNIANKNVHWYQQKPGQAPVLVIYYDDDRPSGIPDRFSGSNSGNTATLTISRVEAGDEADYYCQVWDSNSDHVVFGGGTQLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPT,,,,
2D4,gp120 V2-CD4bs,,,,Strokappe2012(22438910) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH 2D4,llama antibody ,87.3381,1.38607,26.0,232.0,3252.0,,,,,,
2E7,gp41 MPER (membrane proximal external region),5HM1(Llama VHH 2E7 in complex with gp41),llama#9 ,,Strokappe2012(22438910) ,2E7 contacts,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH 2E7,llama antibody ,25.145,2.48845,26.0,234.0,3254.0,DVQLQESGGGLVQPGGSLRLSCAASGNIVSIDAAGWFRQAPGKQREPVATILTGGATNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCYAPMIYYGGRYSDYWGQGTQVTVS,,,,,
2F5,gp41 MPER (membrane proximal external region),1TJG(2F5 complexed with gp41 7mer epitope);1TJH(2F5 with a gp41 11mer epitope);1TJI(2F5 with a gp41 17mer epitope);1U8H(2F5 with gp41 Peptide ALDKWAS);1U8I(2F5 with gp41 Peptide ELDKWAN);1U8J(2F5 with gp41 Peptide ELDKWAG);1U8O(2F5 with gp41 Peptide ELDKHAS);1U8P(2F5 with gp41 Peptide ECDKWCS);1U8Q(2F5 with gp41 Peptide ELEKWAS);1U91(2F5 with gp41 Peptide Analog ENDKW-[Dap]-S (cyclic));1U92(2F5 with gp41 Peptide Analog E-[Dap]-DKWQS (cyclic));2F5A(Fab 2F5);2F5B(2F5 complexed with gp41 epitope);2P8L(2F5 with gp41 Peptide ELLELDKWASLWN);2P8M(2F5 with gp41 Peptide ELLELDKWASLWN in new crystal form);2P8P(2F5 with gp41 Peptide LELDKWASLW[N-Ac]);2PR4(2F5 Fab);2PW1(2F5 with gp41 Peptide ELDKWNSL);2PW2(2F5 with gp41 Peptide ELDKWKSL);3BQU(2F5 Fab-3H6 Fab Complex);3D0L(2F5 with gp41 FP-MPER Hyb3K construct);3D0V(2F5 with gp41 Peptide LLELDKWASLW);3DRO(2F5 with gp41 peptide ELLELDKWASLWN);3DRQ(2F5 with gp41 FP-MPER Hyb3K construct soaked in PEG/2-propanol);3DRT(2F5 with gp41 scrambledFP-MPER scrHyb3K construct);3EGS(2F5 with gp41 scrambledFP-MPER scrHyb3K construct soaked in ammonium sulfate);3IDG(2F5 with gp41 Peptide ALDKWD);3IDI(2F5 Fab fragment with gp41 Peptide ALDKWNQ);3IDJ(2F5 Fab fragment with gp41 Peptide analog ELD(Orn)WAS);3IDM(2F5 Fab fragment with gp41 Peptide analog ELD(Nrg)WAS);3IDN(2F5 Fab fragment with gp41 Peptide analog ELD(Paf)WAS);3LEV(2F5 with epitope scaffold ES2);3MOA(2F5 Fab fragment with 17 aa gp41 MPER-derived peptide);3MOB(2F5 Fab fragment with 11 aa gp41 MPER-derived peptide);3MOD(2F5 Fab fragment with 11 aa gp41 MPER-derived peptide),,,Buchacher1994(7520721) ,2F5 and 4E10 signature sites;2F5 contacts;2F5 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 2F5 binding;Mutation affects neutralization by 2F5 and 4E10;Mutation increases neutralization sensitivity;mutation increases sensitivity to MPER nAbs;Mutations at the trimer apex that affect sensitivity;Q563R affects binding and neutralization of MPER mAbs;Signature Analysis Summary,Zhang2019a(31772165) ,IMGT/V-QUEST,2-5*02,3-3*01,6*02,22.0,RRGPTTSSGVPIARGPVNAMDV,12.1,,1D-13*02,4*01,9.0,QQLHFYPHT,11.8,,K,Yes,Natural monoclonal,human,"c2F5, IAM 2F5, IAM2F5, IAM-41-2F5", ,15.6953,8.97083,3873.0,14.0,815.0,RITLKESGPPLVKPTQTLTLTCSFSGFSLSDFGVGVGWIRQPPGKALEWLAIIYSDDDKRYSPSLNTRLTITKDTSKNQVVLVMTRVSPVDTATYFCAH,ALQLTQSPSSLSASVGDRITITCRASQGVTSALAWYRQKPGSPPQLLIYDASSLESGVPSRFSGSGSGTEFTLTISTLRPEDFATYYCQQLHFYP,GCCCTCCAACTGACCCAGTCTCCGTCCTCCTTGTCTGCATCTGTTGGAGACAGAATCACCATCACTTGTCGGGCAAGTCAGGGCGTTACCAGTGCTTTAGCCTGGTATCGACAGAAGCCAGGAAGTCCTCCTCAACTCCTAATCTATGATGCCTCCTCTTTAGAAAGTGGGGTCCCATCGAGGTTCAGCGGCAGTGGTTCTGGGACGGAGTTCACTCTCACCATCAGCACCCTGCGGCCTGAAGATTTTGCAACTTATTACTGTCAACAATTACATTTTTACCCT,AGGATCACGTTAAAGGAATCGGGTCCTCCGCTGGTGAAACCCACACAGACTCTCACGCTGACCTGTTCCTTCTCTGGGTTCTCACTGTCCGATTTTGGAGTGGGTGTAGGCTGGATCCGTCAGCCCCCAGGAAAGGCCCTAGAGTGGCTTGCAATCATTTATTCGGATGATGATAAGCGCTACAGCCCATCGCTGAACACCAGACTCACCATCACCAAGGACACCTCCAAAAATCAAGTTGTCCTTGTCATGACTAGGGTGAGTCCTGTGGACACAGCCACGTATTTCTGTGCACAC,,
nan,,,,,,,Kunert1998(9737583) ,,2,,6,,,,,,,,,,,,,,,,,,,,,,,,,,,
2G12,"gp120 glycans;gp120 glycosylation sites in C2, C3, C4, and V4","1OM3(Fab 2G12);1OP3(Fab 2G12 bound to disaccharide mannose);1OP5(Fab 2G12 bound to oligosaccharide mannose);1ZLS(Fab 2G12 + Man4);1ZLU(Fab 2G12 + Man5);1ZLV(Fab 2G12 + Man7);1ZLW(Fab 2G12 + Man8);2OQJ(Fab 2G12 with 21-mer peptide ligand);3OAU(2G12 Recognizes Di-Mannose);3OAY(Mimic of the HIV glycan shield);3OAZ(Mimic of the HIV glycan shield);3OB0(Mimic of the HIV glycan shield);4RBP(2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomanose);6E5P(2G12 bound to HIV-1 Env BG505 DS-SOSIP, which was also bound to VRC03);EMD-8981(2G12 bound to HIV-1 Env BG505 DS-SOSIP which was also bound to VRC03)",,,Buchacher1994(7520721) ,"2G12 contacts;2G12 signature predictions;Mutation affects 2G12 binding;Mutation affects VRC01, PGT151, and 2G12 binding;Mutation increases neutralization sensitivity;mutations affecting 2G12 binding",Huber2010(20702640) ,IMGT/V-QUEST,3-21,6-25,3,,,,,1-5,1,,,,,K,Yes,Natural monoclonal,human,"c2G12, G12", Wu2011 %SHM calculated for heavy chain = VH and light chain = VL.,50.312,4.82269,2937.0,41.0,1370.0,EVQLVESGGGLVKAGGSLILSCGVSNFRISAHTMNWVRRVPGGGLEWVASISTSSTYRDYADAVKGRFTVSRDDLEDFVYLQMHKMRVEDTAIYYCAR,DIQMTQSPSTLSASVGDTITITCRASQSIETWLAWYQQKPGKAPKLLIYKASTLKTGVPSRFSGSGSGTEFTLTISGLQFDDFATYHCQHYAGYS,GACATCCAGATGACTCAGTCTCCTTCCACCCTGTCTGCATCTGTCGGAGACACAATCACCATCACTTGCCGGGCCAGTCAGAGTATTGAAACCTGGTTGGCCTGGTATCAGCAGAAGCCAGGGAAAGCCCCAAAACTCCTAATCTACAAGGCGTCTACTTTAAAAACTGGAGTCCCGTCAAGATTCAGCGGCAGTGGATCTGGAACAGAGTTCACTCTTACCATCAGTGGCCTGCAGTTCGATGACTTTGCAACTTATCACTGTCAGCACTATGCTGGTTATTCA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGGCGGGAGGATCCCTCATACTCTCCTGTGGAGTCTCTAATTTTAGAATCTCTGCCCATACCATGAATTGGGTCCGCCGGGTTCCAGGGGGGGGGCTGGAGTGGGTCGCTTCCATTAGTACGAGTTCCACTTATAGAGACTATGCAGACGCTGTGAAGGGCCGATTCACCGTTTCCAGAGACGACCTCGAAGACTTTGTGTATTTGCAAATGCACAAAATGAGAGTCGAAGACACGGCTATTTATTACTGCGCCAGA,,
nan,,,,,,,Wu2011(21835983) ,IgBlast,3-21*01 or 3-21*02 or 3-21*02 or 3-21*02,,,,,,30.6,1-5*03,,,,,17.7,,,,,,,,,,,,,,,,,
2H10,gp41 MPER (membrane proximal external region),4B50(HIV-1 gp41 MPER-specific llama VHH 2H10),,,LutjeHulsik2013(23505368) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,,Llama VHH ,100.0,1.0,33.0,761.0,4473.0,EVQLVESGGGLVQPGGSLRLSCAASGSISSVDVMSWYRQAPGKQRELVAFITDRGRTNYKVSVKGRFTISRDNSKNMVYLQMNSLKPEDTADYLCRAESRTSWSSPSPLDVWGRGTQVTVSS,,,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGAAGCATCAGTAGTGTCGATGTTATGAGTTGGTACCGCCAGGCTCCAGGAAAGCAGCGCGAGCTGGTCGCATTTATTACTGATCGTGGTCGCACAAACTATAAAGTGTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACTCCAAGAACATGGTGTATCTGCAAATGAACAGCCTGAAACCTGAGGACACGGCCGACTACCTTTGTAGAGCA,,
2N5,gp41-gp41 interface,,Donor N152 ,35O22,Huang2014(25186731) ,,Huang2014(25186731) ,IMGT/V-QUEST,1-18*02,5-24*01,4*02 or 4*03,16.0,GLLRDGSSTWLPYL,,,2-14*02,1*01,10.0,CSYTHNSGCV,,,L,,Natural monoclonal,human,, ,,,8.0,163.0,3153.0,QGQLVQSGAELKKPGASVKISCKTSGYKFSFFHINWIRQTAGRGPEWLGWISPYSGDKNYAPAFQDRVIMTTDKEVPVTSFTSTGTAYLEIRSLKPDDTGIYFCARGLLRDGSSTWLPYLWGQGTLLTVSS,QPVLTQPASVSGSLGQSVTISCTGPSSVCCSHKSISWYRWPPGRAPTLIIYEDNKRFSEISPRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFATGTKVSVL,CAGCCTGTGCTGACTCAGCCTGCCTCCGTATCTGGGTCTCTTGGACAGTCGGTCACCATCTCCTGCACTGGACCCAGTAGTGTTTGTTGCAGTCATAAATCTATCTCCTGGTATCGGTGGCCCCCAGGCAGAGCCCCCACACTCATCATTTATGAGGACAATAAAAGGTTCTCGGAAATCTCTCCCCGCTTCTCTGGCTACAAGTCGTATTGGTCGGCCTACTTGACAATCTCTGATCTCCGGCCTGAAGACGAGACCACTTATTATTGTTGCTCATACACTCACAATAGCGGCTGTGTCTTCGCGACTGGGACCAAGGTGTCCGTCTTG,CAGGGTCAACTAGTCCAGTCTGGAGCTGAGTTGAAGAAGCCTGGCGCCTCGGTAAAGATTTCCTGTAAGACTTCGGGTTATAAGTTTAGTTTCTTTCATATTAATTGGATTCGACAAACTGCAGGACGTGGACCTGAGTGGCTGGGATGGATCAGCCCTTACAGTGGTGACAAAAACTACGCACCTGCCTTTCAAGACAGAGTCATTATGACCACAGACAAAGAAGTCCCTGTGACCTCATTCACGTCCACGGGCACAGCCTATTTGGAAATAAGGAGCCTGAAACCTGACGACACGGGCATCTATTTTTGTGCGAGAGGCCTTCTGCGTGACGGTTCGTCGACATGGCTTCCTTATTTGTGGGGCCAGGGCACCCTACTCACCGTCTCGTCA,CARGLLRDGSSTWLPYLW,71.160
3019,gp120 V3 // V3 glycan (V3g),,,,Gorny2006(16809292) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,5-51*03,,3*01,,ARVEGDWGALDL,5.9,,3-1*01,2*01 or 3*01,,QAWDSSSAWGV,9.7,,L,,Natural monoclonal,human,, ,24.59,7.87061,21.0,56.0,1797.0,QVQLVQSGAEVKKPGDSLKISCKGSGYSFSTYWIAWVRQMPGKGLEWMGIVYPDDSDTTYSPSFQGQVTISADKSISIAYLQWGSLKASDTAIYYCARVEGDWGALDLWGRGTLVTVSSTSTKGPSVFPL,SADLTQTPSVSVSPGQTASITCSGDRLANKYASWYQQRPGQSPVLVIFQDNRRPSGIPERISGSHSGNTATLTISGTQVVDEAEYFCQAWDSSSAWGVFGGGTRLTVLGQPKAAPSVTLFPP,TCCGCTGACCTGACTCAGACACCCTCAGTGTCCGTGTCTCCAGGCCAGACAGCCAGCATCACCTGCTCTGGGGATAGATTGGCCAATAAATATGCTTCGTGGTATCAACAGAGGCCAGGCCAGTCCCCTGTCTTGGTCATCTTTCAAGATAACAGGCGGCCCTCAGGGATCCCTGAGCGAATCTCTGGCTCCCACTCTGGGAACACAGCCACTCTGACCATCAGCGGGACCCAGGTAGTGGATGAGGCTGAGTATTTCTGTCAGGCGTGGGACAGCAGCTCTGCGTGGGGGGTATTCGGCGGTGGGACCAGGTTGACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCC,CAGGTGCAGCTGGTGCAGTCTGGCGCAGAGGTGAAGAAGCCGGGGGACTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTAGTACCTACTGGATCGCCTGGGTGCGCCAGATGCCCGGCAAAGGCCTGGAGTGGATGGGGATCGTCTACCCTGATGACTCTGATACCACATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCATCGCCTACCTTCAGTGGGGCAGCCTGAAGGCCTCGGACACCGCCATCTATTACTGTGCGAGAGTTGAGGGTGACTGGGGCGCTCTTGATCTCTGGGGCCGAGGGACACTGGTCACCGTCTCTTCAACCTCCACCAAGGGCCCATCGGTCTTCCCCCTG,CARVEGDWGALDLW,94.218
3074,gp120 V3 // V3 glycan (V3g),3MLX(Fab 3074 in complex with an MN V3 peptide);3MLY(Fab 3074 in complex with a UR29 V3 peptide);3MLZ(Fab 3074 in complex with a VI191 V3 peptide),,,Gorny2006(16809292) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,4-59*01,,3*01,,ARDFGEYHYDGRGFQCEGFDL,5.9,,1-51*02,2*01 or 3*01,,ATWDGSLRTV,5.3,,L,,Natural monoclonal,human,V3-3074, ,53.4046,5.1668,544.0,65.0,1798.0,QVQLQESGPGLVKPSETLSLTCTVSGGSISGFHWSWIRQPPGKGLEYIGYIYYSGSTSYNPSLKSRVSMSVDTSRNQFSLELSSVTAADTAVYYCARDFGEYHYDGRGFQCEGFDLWGQGTLVTVSSASTKGPSVFPLAP,,,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACTTGCACTGTCTCTGGTGGCTCCATCAGTGGTTTCCACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTACATTGGCTATATCTATTACAGTGGGTCCACCAGCTACAACCCCTCCCTCAAGAGTCGAGTCAGTATGTCAGTAGACACGTCCCGGAACCAGTTCTCCCTGGAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTCTATTACTGTGCGAGAGATTTTGGGGAATATCACTATGATGGTCGTGGCTTCCAGTGTGAGGGTTTTGATCTCTGGGGCCAAGGGACACTGGTCACCGTCTCTTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC,CARDFGEYHYDGRGFQCEGFDLW,94.198
35O22,gp41-gp41 interface,"4TOY(35O22 Fab);4TVP(Env Trimer Ectodomain in Complex with Antibodies PGT122 and 35O22);5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5FYL(Clade A BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 and 35O22);5T3S(gp140 trimer MD39-10MUTA in complex with Fabs PGT124 and 35022);5U7M(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-378806 in Complex with Human Antibodies PGT122 and 35O22);5U7O(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-626529 in Complex with Human Antibodies PGT122 and 35O22);5UM8(trimer 16055 NFL TD CC (T569G) in complex with Fabs 35022 and PGT124);5UTF(DS-SOSIP.6mut BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, Y177W, N300M, N302M, T320L, I420M in Complex with Human Antibodies PGT122 and 35O22);5UTY(DS-SOSIP.mut4 BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, N300M, N302M, T320L in Complex with Human Antibodies PGT122 and 35O22);5V7J(BG505 SOSIP.664 Prefusion Env Trimer with Four Glycans removed in Complex with Neutralizing Antibodies 3H+109L and 35O22);5W6D(BG505-SOSIP.v4.1-GT1-N137A in complex with Fabs 35022 and 9H/109L);6CH7(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH8(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH9(A natively-glycosylated B41 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6NNF(BG505 SOSIP.664 Prefusion Env Trimer Bound to VRC01 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv);6OPA(bovine Fab NC-Cow1 in complex with BG505 SOSIP.664 and human Fabs 35022 and PGT128)",Donor N152 ,35O22,Huang2014(25186731) ,35O22 contacts;35O22 mutations affecting neutralization;Mutation affects neutralization by 35O22;mutations affecting 35O22 binding,Huang2014(25186731) ,IMGT/V-QUEST,1-18*02,5-24*01,4*03 or 4*02,16.0,GLLRDGSSTWLPYL,35.0,,2-14*02 or 2-23*03 or 2-23*02 or 2-23*01,1*01,10.0,CSYTHNSGCV,24.0,,L,,Natural monoclonal,human,35022, ,2.91957,51.8138,1056.0,157.0,3147.0,QGQLVQSGAELKKPGASVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVIMTTDTEVPVTSFTSTGAAYMEIRNLKFDDTGTYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSVLTQSASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLIIYEDNERAPGISPRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,CAGTCTGTGCTGACGCAGTCTGCCTCCGTGTCTGGGTCTCTTGGACAGTCGGTCACCATCTCCTGCACTGGACCCAATAGTGTTTGTTGCAGTCACAAATCTATCTCCTGGTATCAGTGGCCCCCAGGCAGAGCCCCCACACTCATCATTTATGAGGACAATGAAAGGGCCCCGGGAATCTCTCCTCGCTTCTCTGGCTACAAGTCGTATTGGTCGGCCTACTTGACAATCTCTGATCTCCGGCCTGAAGACGAGACCACTTACTACTGTTGCTCATACACTCACAATAGCGGCTGTGTCTTCGGGACTGGGACCAAGGTCTCCGTCTTG,CAGGGTCAACTAGTCCAGTCTGGAGCTGAATTGAAAAAGCCTGGCGCCTCGGTGAAGATTTCCTGTAAGACTTCGGGTTATAGGTTTAATTTCTATCATATTAATTGGATTCGACAAACTGCAGGACGTGGACCTGAGTGGATGGGATGGATCAGCCCTTACAGTGGTGACAAAAACCTCGCACCTGCCTTTCAAGACAGAGTCATTATGACGACAGACACAGAAGTCCCTGTGACCTCATTCACGTCCACGGGCGCAGCCTACATGGAAATAAGGAACCTGAAATTTGACGACACAGGCACCTATTTCTGTGCAAAAGGCCTCCTGCGTGACGGTTCGTCGACGTGGCTTCCTTATTTGTGGGGCCAGGGTACCCTACTCACCGTCTCGTCA,CAKGLLRDGSSTWLPYLW,69.906
3694,gp120 V3 // V3 glycan (V3g),,,,Gorny2009(18952295) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,5-51*03,,1*01,,VRLGHSDIGTSSGDVHN,18.1,,3-1*01,2*01 or 3*01,,QAWDTNTGVH,11.5,,L,,Natural monoclonal,human,, ,26.6133,6.82383,21.0,57.0,2067.0,EVQLVESGAEVKQPGNSLKISCKASGYTFTDFWIGWVRQTPGKALEWVGLVFPDDSTTTYSPGFRGHVTISADKSVTSAYLEWNNVRPSDTAMYYCVRLGHSDIGTSSGDVHNWGPGTLITVSSASTKGPSV,SAELTQPPSVSVSPGQTATIFCSGDLLRDKYASWYQQKAGQTPMLVIFEDVQRPSGIPERLSGSRSGTTATLTISGTQAMDEADYYCQAWDTNTGVHFGGGTKLTVLSQPKAAPSVTLFPP,TCCGCTGAGTTGACTCAGCCACCTTCAGTGTCCGTGTCCCCAGGACAGACAGCCACTATCTTCTGCTCTGGAGATCTTTTGAGAGATAAATATGCTTCTTGGTATCAGCAGAAGGCAGGCCAGACCCCTATGTTAGTCATCTTTGAAGATGTCCAGCGGCCCTCAGGGATCCCTGAGCGACTCTCTGGCTCCAGGTCTGGGACCACAGCCACTCTGACCATCAGCGGGACCCAGGCTATGGATGAGGCTGACTATTACTGTCAGGCGTGGGACACCAATACTGGAGTGCATTTCGGCGGAGGGACCAAGCTGACCGTCCTAAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCC,GAGGTGCAGCTGGTGGAGTCTGGAGCAGAAGTGAAACAGCCGGGGAACTCTCTGAAAATCTCTTGTAAGGCCTCTGGCTACACCTTTACTGACTTCTGGATCGGCTGGGTGCGCCAGACGCCCGGAAAAGCCCTGGAGTGGGTGGGACTCGTCTTTCCTGACGACTCTACCACCACATATAGTCCGGGCTTCCGAGGCCACGTCACCATCTCAGCCGACAAGTCCGTCACGTCCGCCTATTTAGAATGGAATAATGTGAGGCCCTCGGACACCGCCATGTATTATTGTGTGAGACTCGGTCACTCTGACATTGGAACTTCTTCAGGGGACGTCCACAACTGGGGCCCGGGCACCCTGATCACCGTCTCCTCCGCCTCCACCAAGGGCCCATCGGTC,CVRLGHSDIGTSSGDVHNW,82.034
3791,gp120 V3 // V3 glycan (V3g),,,,Gorny2009(18952295) ,MPER membrane fusion mutations confer sensitivity,Andrabi2013(23466102) ,IMGT/V-QUEST,1-18*01,,4*02,,VRVRDNEQGDYGQLDL,12.2,,1-1,4*01,,QQYESLPWA,4.3,,K,,Natural monoclonal,human,, ,40.5643,6.75034,23.0,68.0,2073.0,EVQLVESGPEVKRPGASVKVSCKASGYTFINYGINWVRQAPGQGLEWMGWSSTANDGTFYAQNLQGRVSMSTDKSTNTAHLELRSLTFDDTAVYYCVRVRDNEQGDYGQLDLWAQGTLVTVSSASTKGPSVF,,,GAGGTGCAGCTGGTGGAGTCTGGACCTGAGGTGAAGAGGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCCTCTGGTTACACGTTTATCAACTATGGTATCAACTGGGTGCGACAGGCCCCTGGACAAGGCCTTGAGTGGATGGGGTGGAGCAGCACTGCCAATGATGGCACATTCTATGCTCAGAATCTCCAGGGCAGAGTCTCCATGTCGACAGACAAATCCACGAACACAGCCCATCTGGAACTGAGGAGCCTGACATTTGACGACACGGCCGTTTATTACTGTGTGAGAGTAAGAGATAATGAACAGGGAGACTACGGCCAGTTAGACTTGTGGGCCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTC,,
3869,gp120 V3 // V3 glycan (V3g),,,,Gorny2009(18952295) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,1-f*01,,4*02,,ATSHCPGGSCSSSFDF,8.3,,3-1*01,2*01 or 3*01,,QVWDTTTTSYVI,8.6,,L,,Natural monoclonal,human,, ,62.4526,3.65919,130.0,63.0,2076.0,QVQLVQSGAEVKKPGAAVRISCKVSGYTFTDNYMYWVQQAPGKGLEWMGLIDPADGEARYAEKFQGRVSITADTSTDIVYMEVSGLTSDDTAVYYCATSHCPGGSCSSSFDFWGQGTLVTVSSASTKGPSVF,,,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCTGCAGTGAGAATCTCCTGCAAGGTTTCTGGATACACCTTCACCGACAACTACATGTACTGGGTACAACAGGCCCCTGGAAAAGGGCTTGAGTGGATGGGGCTTATTGATCCTGCAGATGGTGAAGCAAGATACGCAGAGAAGTTCCAGGGCAGAGTCTCCATAACCGCGGACACGTCTACAGACATAGTCTACATGGAAGTGAGCGGCCTCACATCTGACGACACGGCCGTCTATTACTGCGCAACTTCACATTGTCCTGGTGGGAGCTGCTCCTCTTCCTTTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTC,CATSHCPGGSCSSSFDFW,91.809
3881,gp120 V3 // V3 glycan (V3g),,,,Gorny2009(18952295) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,4-59*01,,3*02,,ARISVVVLPAVFPDI,11.2,,3-15*01,1*01,,QQYHDWLWT,5.4,,K,,Natural monoclonal,human,, ,56.9594,5.03908,21.0,67.0,2077.0,EVQLVESGPGLVKPSETLSLTCTVSGGSISNYYWGWIRQPPGKGLEWIGYIYYSGTTNYNPSLTTRLTISADTSNNRFSLKLTSLTAADTAVYYCARISVVVLPAVFPDIWGQGTMVIVSSASTKGPSVFPL,,,GAGGTGCAGCTGGTGGAGTCTGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGTTCCATCAGTAATTACTACTGGGGTTGGATTCGGCAGCCCCCCGGGAAGGGACTGGAATGGATTGGCTATATCTATTATAGTGGAACCACCAATTACAACCCCTCCCTCACGACTCGACTGACCATATCCGCGGACACGTCGAACAACCGCTTCTCCCTGAAGCTGACGTCTCTGACCGCTGCCGACACGGCCGTCTATTACTGTGCGCGGATTAGTGTTGTTGTCCTGCCAGCTGTTTTCCCTGATATCTGGGGCCAAGGGACGATGGTCATCGTCTCTTCTGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTG,CARISVVVLPAVFPDIW,88.889
3904,gp120 V3 // V3 glycan (V3g),,,,Gorny2009(18952295) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,3-30*03,,4*03,,AKAGEGVGVMDA,5.9,,1-39*01,3*01,,QQSYITIT,5.0,,K,,Natural monoclonal,human,, ,53.9037,4.7151,21.0,71.0,2070.0,QVQLVQSGGGVVQPGRSLRISCAASGFTFSNYGIYWVRQAPGKGLEWVAVISDDGSNKYYGDSVKGRFTISRDNSKNTVYVQMNSLRAEDTAVYYCAKAGEGVGVMDAWGQGTSVTVSSASTKGPSVFPL,,,CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGAATTTCCTGTGCAGCCTCTGGATTCACCTTCAGTAATTATGGCATCTACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCAGATGATGGAAGTAATAAGTACTATGGAGACTCCGTGAAGGGCCGATTCACTATCTCCAGAGACAATTCCAAGAACACGGTGTATGTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTCTATTATTGTGCGAAAGCGGGGGAAGGTGTCGGGGTTATGGACGCCTGGGGCCAAGGGACCTCGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTG,CAKAGEGVGVMDAW,94.237
3906,gp120 V3 // V3 glycan (V3g),,,,Gorny2009(18952295) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,5-51*01,,3*02,,ATMTITIGEEFANAFDI,7.3,,3-1*01,2*01 or 3*01,,QAWDRISAV,9.7,,L,,Natural monoclonal,human,, ,26.3043,7.41849,21.0,58.0,2064.0,EVQLVESGAEVKKPGESLKISCKASGYSFSDYWIGWVRQVPGKGLEWMGIIFPGDSDTTYSPSFQGQVTISVDTSINTAYLQWSSLRASDSAMYFCATMTITIGEEFANAFDIWGQGTMVTVSSASTKGPSV,SYELTQPPSVSVSPGQTATFTCSGDELGQKYICWYQKKAGQSPLLIIYEDKMRPSGIPERFAGSKSGNTATLTISGTQTVDEADYYCQAWDRISAVFGGGTKLTVLGQPKAAPSVTLFPP,TCCTATGAGCTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGACAGACAGCCACCTTCACCTGCTCTGGAGATGAATTGGGACAAAAATATATTTGCTGGTATCAGAAGAAGGCAGGCCAGTCCCCTCTCCTGATCATCTATGAAGATAAAATGCGGCCCTCAGGGATCCCTGAGCGATTCGCTGGCTCCAAGTCTGGGAACACAGCCACCCTGACCATCAGCGGGACCCAGACTGTCGATGAGGCTGATTATTACTGTCAGGCGTGGGACAGGATTTCTGCGGTATTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCC,GAGGTGCAGCTGGTGGAGTCTGGGGCAGAAGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGCCTCTGGATACAGCTTTAGTGACTACTGGATCGGCTGGGTGCGCCAGGTGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTTTCCTGGTGACTCTGATACCACATATAGTCCGTCCTTCCAAGGCCAGGTCACCATCTCAGTCGACACGTCCATCAACACCGCCTACCTGCAGTGGAGCAGCCTGCGGGCCTCGGACAGCGCCATGTATTTCTGTGCGACTATGACTATTACCATAGGTGAAGAGTTTGCCAATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGCCTCCACCAAGGGCCCATCGGTC,CATMTITIGEEFANAFDIW,92.808
3BC176,gp41-gp41 interface,5AWN(3BC176 Fab),Patient 3 ,,Klein2012(22826297) ,3BC176 and 3BC315 key sites;Signature Analysis Summary;Signature Analysis Summary,Klein2012(22826297) ,,1-2,5-12,2,19.0,SMRPVDHGIDYSGLFVFHF,,,2-23,3,10.0,CSYASYDRLI,,,L,,Natural monoclonal,human,, ,9.41136,12.6386,54.0,101.0,2825.0,QVQLMQSGAQLRDPGDSLKISCKASGYNFIDYHIHWVRLAPGRGLEWMGWIDPVGGITKYAGQFQGRLSLTRDTSTNTLFLELSRLTAGDTAVYFCARSMRPVDHGIDYSGLFVFHFWGRGSDVLVSS,QSVLTQPASVSASPGQSITVSCTGSRNDVGGYDFVSWYQRHPGGVPKLIIYEISKRPSGIPQRFSGSRSGNTASLTISGLQDDDEADYYCCSYASYDRLIFGGGTRVSVL,,,,
nan,,,,,,,Klein2013(23540694) ,IgBlast,1-2,5-12 or 3-16,3,,,,,2-23 or 3,,,,,,,,,,,,,,,,,,,,,,
3BC315,gp41-gp41 interface,5CCK(3BC315 Fab),Patient 3 ,,Klein2012(22826297) ,3BC176 and 3BC315 key sites,Klein2012(22826297) ,,1-2,5-12,3,19.0,PMRPVSHGIDYSGLFVFQF,,,2-23,3,10.0,CCSYANYDKL,,,L,,Natural monoclonal,human,, ,22.9459,5.64128,236.0,102.0,2824.0,QVQLVQSGAEMKDPGASVKVSCRASGYKFTDYYMHWVRQAPGQGLEWVGWVNTNGGFTKYGAKFQGRVTVTRDTSTNTVFLELSRLTFGDTAMYFCARPMRPVSHGIDYSGLFVFQFWGRGTMVTVSS,QSALTQPASVSASPGQSITISCSGTRSDVGGYDFVSWYQQHPGKVPKLIIYEVTKRPSGIPQRFSGSKSGNTASLTISGLQADDEADYYCCSYANYDKLILGGGTKLTVL,,,,
3BNC117,gp120 CD4bs,4JPV(3BNC117 complexed with gp120);4LSV(3BNC117 complexed with gp120 (C1086));5V8L(BG505 SOSIP.664 trimer in complex with 3BNC117 and PGT145);5V8M(BG505 SOSIP.664 trimer in complex with 3BNC117);7PC2(Env in complex with the IgA bNAb 7-269 and 3BNC117);EMD-13316(Env in complex with the IgA bNAb 7-269 and 3BNC117),Patient 3 ,3BNC117,Scheid2011(21764753) ,3BNC117 contacts;3BNC117 signature predictions;Altered glycosylation affects neutralization by CD4BS bnAbs;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 3BNC117 neutralization;mutations affecting 3BNC117 binding;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary;Sites selected during 3BNC117 immunotherapy,Klein2013(23540694) ,IgBlast,1-2,6-25 or 1-26,6 or 2,,,,,1-33,3,,,,,K,Yes,Natural monoclonal,human,3BNC117 dRU3, ,0.54326,21.3962,4736.0,15.0,2586.0,QVQLLQSGAAVTKPGASVRVSCEASGYNIRDYFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRHASWDFDTFSFYMDLKALRSDDTAVYFCARQRSDYWDFDVWGSGTQVTVSSASTKGP,,,CAGGTCCAATTGTTACAGTCTGGGGCAGCGGTGACGAAGCCCGGGGCCTCAGTGAGAGTCTCCTGCGAGGCTTCTGGATACAACATTCGTGACTACTTTATTCATTGGTGGCGACAGGCCCCAGGACAGGGCCTTCAGTGGGTGGGATGGATCAATCCTAAGACAGGTCAGCCAAACAATCCTCGTCAATTTCAGGGTAGAGTCAGTCTGACTCGACACGCGTCGTGGGACTTTGACACATTTTCCTTTTACATGGACCTGAAGGCACTAAGATCGGACGACACGGCCGTTTATTTCTGTGCGCGACAGCGCAGCGACTATTGGGATTTCGACGTCTGGGGCAGTGGAACCCAGGTCACTGTCTCGTCAGCGTCGACCAAGGGCCCA,CARQRSDYWDFDVW,72.876
nan,,,,,,,Scheid2011(21764753) ,,1-2,6-25 or 2-8,2 or 6,10.0,QRSDYWDFDV,,,1D-33,3,5.0,QVYEF,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Zhou2013a(23911655) ,IgBlast IMGT/V-QUEST,1-02*02,,,10.0,QRSDYWDFDV,,,1-33*01,3*01,5.0,QVYEF,,,,,,,,,,,,,,,,,,,
3BNC117/10-1074,gp120 CD4bs;gp120 V3 // V3 glycan (V3g),,Donor 17 Patient 3 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific ,0.3867,8.31339,254.0,268.0,3473.0,,,,,,
3BNC117/10-1074-IgG3C-,gp120 CD4bs;gp120 V3 // V3 glycan (V3g),,Donor 17 Patient 3 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific; IgG3C hinge variant ,0.14654,8.41105,240.0,269.0,3537.0,,,,,,
3BNC117_FR3-03,gp120 CD4bs,,Patient 3 ,3BNC117,Liu2019(30760721) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,3BNC117 FR3-03, ,0.50979,14.4176,416.0,797.0,4573.0,,,,,,
3BNC117-IgG3C-,gp120 CD4bs,,Patient 3 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,IgG3C hinge variant ,0.46648,15.5814,238.0,276.0,3538.0,,,,,,
3BNC117/PGT135-IgG3C-,gp120 CD4bs;gp120 V3 // V3 glycan (V3g),,Donor 39 Patient 3 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,3BNC117-PGT135,bispecific; IgG3C hinge variant ,0.069889,11.0323,327.0,278.0,3534.0,,,,,,
3BNC55,gp120 CD4bs,5I9Q(3BNC55 Fab in complex with 426c.TM4deltaV1-3 gp120),Patient 3 ,3BNC117,Scheid2011(21764753) ,3BNC55 signature predictions;Signature Analysis Summary,Scheid2011(21764753) ,,1-2,3-3 or 6-19 or 5-12,2 or 6,10.0,RHSDYCDFDI,,,1D-33,1 or 3,5.0,QVYEF,,,K,,Natural monoclonal,human,, ,4.68911,15.4342,367.0,42.0,2579.0,QVQLVQSGTAVKRPGASVRVSCQASGYTFTDYFIYWWRQAPGQGLEWLGWINPLTSQPSYPSRFQGRLTLTRDTFDEMLYMDLRGLRSDDTGIYFCARRHSDYCDFDIWGSGTQIIVSSASTKG,,,,,
3BNC60,gp120 CD4bs,3RPI(Fab 3BNC60);4GW4(3BNC60 Fab with P61A mutation);5FEC(3BNC60 Fab germline precursor in complex with 426c.TM4deltaV1-3 gp120),Patient 3 ,3BNC117,Scheid2011(21764753) ,3BNC60 contacts,Klein2013(23540694) ,IgBlast,1-2,3-3 or 6-25,2,,,,,1-33,3,,,,,K,,Natural monoclonal,human,," 3BNC60 is a close clonal relative of 3BNC23, 3BNC128, 3BNC64, 3BNC34, and the germline repertoir is as shown for 3BNC23 in Scheid2011.",0.23941,10.8391,81.0,94.0,2582.0,QVHLSQSGAAVTKPGASVRVSCEASGYKISDHFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRQASWDFDTYSFYMDLKAVRSDDTAIYFCARQRSDFWDFDVWGSGTQVTVSSASTKGPSX,DIQMTQSPSSLSARVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGVPARFSGRRWGQEYNLTINNLQPEDVATYFCQVYEFIVPGTRLDLKRTVAA,GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCACGTGTAGGCGATACCGTCACTATCACTTGCCAGGCAAACGGCTACTTAAATTGGTATCAACAGAGACGAGGGAAAGCCCCAAAACTCCTGATCTACGATGGGTCCAAATTGGAGAGAGGCGTCCCAGCAAGGTTCAGTGGAAGAAGATGGGGACAAGAATATAATCTGACCATCAACAATCTGCAGCCCGAAGACGTTGCAACATATTTTTGTCAAGTGTATGAGTTTATCGTCCCTGGGACCAGACTGGATTTAAAACGTACGGTGGCTGCA,CAGGTCCATTTGTCACAGTCTGGGGCAGCGGTGACGAAGCCCGGGGCCTCAGTGAGAGTCTCCTGCGAGGCTTCCGGATACAAGATTAGTGACCACTTTATTCATTGGTGGCGACAGGCCCCAGGACAGGGCCTTCAGTGGGTGGGGTGGATCAATCCTAAGACTGGTCAGCCAAACAATCCTCGTCAATTTCAGGGTAGAGTCAGTCTGACTCGACAGGCGTCGTGGGACTTTGACACATATTCCTTTTACATGGACCTCAAGGCAGTAAGATCGGACGACACGGCCATTTATTTCTGTGCGCGACAACGCAGCGACTTTTGGGATTTCGACGTCTGGGGCAGCGGCACGCAGGTCACTGTCTCGTCAGCGTCGACCAAGGGCCCATCGG,CARQRSDFWDFDVW,70.588
nan,,,,,,,Scheid2011(21764753) ,,1-2,6-25 or 3-3,2 or 6,10.0,QRSDFWDFDV,,,1D-33,3,5.0,QVYEF,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Zhou2013a(23911655) ,IgBlast IMGT/V-QUEST,,,,,,,,1-33*01,3*01,5.0,QVYEF,,,,,,,,,,,,,,,,,,,
3BNC62,gp120 CD4bs,,Patient 3 ,3BNC117,Scheid2011(21764753) ,,Scheid2011(21764753) ,,1-2,6-25 or 6-13 or 6-6,2 or 6,10.0,QRSDYWDFDV,,,1D-33,3,5.0,QVYEF,,,K,,Natural monoclonal,human,BNC62, ,0.83201,22.4684,30.0,95.0,2584.0,,,,,,
3E3,gp120 CD4bs,,llama#9 ,,McCoy2014a(25522326) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,3E3 VHH,llama antibody ,1.6937,13.0207,71.0,197.0,3221.0,EVQLVESGGGLVQPGGSLRLSCAASQFTLESYAIGWFRQAPGKDSEGVACISSSTYYADSVKGRFTISRDNAKNTVYLQMESLKPEDTAVYHCATSGAGSYCTLRAFGSWGQGTQVTVSS,,,,,
4022,gp120 V3 // V3 glycan (V3g),,,,Gorny2009(18952295) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,5-51*01,,5*02,,ARTGGPEGGGWFEP,11.8,,3-10*01,3*02,,YSTDSRGTYGV,7.9,,L,,Natural monoclonal,human,, ,29.5985,7.00816,21.0,59.0,2065.0,QVNLRESGAEVRRPGESLKISCKGSGYSFIDYWIVWVRQMPGKGLEWMGMIFPDDSDTRYGPSFQGQVTISADKSINTAYLHWSSLQASDTAVYYCARTGGPEGGGWFEPWGQGTRVTVSSASTKGPSVF,SYELTQPPSVSVSPGQTARITCSGDGLPDKYSYWYQQKSGQAPVLVIYEDIERPSGIPERFSGSKSGTMATLTISGAQVEDEADYYCYSTDSRGTYGVFGGGTKVTVLGQPKAAPSVTLFPP,TCCTATGAGCTGACACAGCCACCCTCGGTGTCGGTGTCCCCAGGACAAACGGCCAGGATCACCTGCTCTGGAGATGGTTTGCCAGACAAATATTCGTATTGGTACCAGCAGAAGTCAGGGCAGGCCCCTGTCTTGGTTATCTATGAGGACATCGAGCGGCCCTCCGGCATCCCTGAGAGATTCTCTGGCTCCAAGTCAGGGACAATGGCCACGTTGACTATCAGTGGGGCCCAGGTGGAGGACGAAGCTGACTACTACTGTTACTCAACAGACAGTCGTGGTACTTATGGGGTGTTCGGCGGAGGGACCAAGGTGACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCC,CAGGTCAACTTAAGGGAGTCTGGAGCAGAAGTGAGGAGGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTATCGATTACTGGATCGTCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATGATTTTTCCTGATGACTCTGATACGAGATATGGCCCGTCCTTCCAAGGCCAAGTCACCATCTCAGCCGACAAGTCCATCAACACCGCCTACCTTCACTGGAGCAGCCTGCAGGCCTCGGACACTGCCGTCTATTACTGTGCGCGAACCGGTGGACCCGAAGGGGGGGGCTGGTTCGAGCCCTGGGGCCAGGGAACCCGGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTC,CARTGGPEGGGWFEPW,88.095
4025,gp120 V3 // V3 glycan (V3g),3UJJ(Fab 4025 in complex with Con A),,,Gorny2009(18952295) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,5-51*01,,6*02,,AILGFWGANRGGGGMDV,3.8,,3-10*01,1*01,,YSTNSGGTFFV,4.7,,L,,Natural monoclonal,human,, ,38.9018,6.75202,21.0,62.0,2066.0,QVQLVQSGAEVKKPGESLKISCKASGYSFSSYWIAWVRQMPGKGLEWMGFIYPADSDTRYSPSFQGQGTISADKSISTAYLQWSSLKASDTAMYYCAILGFWGANRGGGGMDVWGQGTTVIVSSASTKGPSVFPLAPSSK,SYELTQPPSVSVSPGQTARITCSGDALPEKYAYWYQQKSGQAPVLIIYEDSKRPSGIPERFSGSRSGTMATLTISGAQVDDEADYYCYSTNSGGTFFVFGTGTKVTVLGQPKANPTVTLFPP,TCCTATGAGCTGACACAGCCACCCTCGGTATCAGTGTCCCCGGGGCAAACGGCCAGGATCACCTGCTCTGGAGATGCATTGCCAGAAAAATATGCCTATTGGTACCAGCAGAAGTCAGGCCAGGCCCCTGTGCTGATCATCTATGAAGACAGCAAACGACCCTCCGGGATCCCTGAGAGATTCTCTGGCTCCAGGTCAGGGACAATGGCCACTTTGACTATCAGTGGGGCCCAGGTGGACGATGAAGCAGACTACTACTGTTACTCAACAAACAGCGGTGGTACGTTTTTTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAGGTCAGCCCAAGGCCAACCCCACTGTCACTCTGTTCCCGCCC,CAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGCTTCTGGATACAGCTTTAGCAGCTACTGGATCGCCTGGGTGCGCCAGATGCCCGGGAAAGGACTGGAATGGATGGGATTCATCTATCCTGCTGACTCTGATACCAGATACAGCCCGTCCTTCCAGGGCCAGGGCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGATTTTAGGGTTTTGGGGTGCCAATAGGGGTGGCGGAGGAATGGACGTCTGGGGCCAAGGGACCACGGTCATCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAG,CAILGFWGANRGGGGMDVW,96.233
4121,gp120 V3 // V3 glycan (V3g),,,,Gorny2009(18952295) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,1-18*01,,4*02,,AISPLQLERLEDYFDY,5.2,,1-44*01,1*01,,AAWDDSLNGPFV,1.4,,L,,Natural monoclonal,human,, ,43.5332,4.23385,21.0,69.0,2074.0,EVQLVESGAEVKKPGASVKVSCKASGYTFTSFGISWVRQAPGQGLEWMGWISAYSGDSKYAQKLQGRVSMTTDTSTNTAYMQLRSLRSDDTAMYYCAISPLQLERLEDYFDYWGRGTLVTVSSASTKGPSVF,,,GAGGTGCAGCTGGTGGAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTTTGGTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGATGGATTAGCGCTTACAGTGGTGACTCAAAATATGCACAGAAACTTCAGGGCAGAGTCTCCATGACCACAGACACATCCACGAACACAGCCTACATGCAACTGAGGAGCCTGAGATCTGACGACACGGCCATGTATTATTGTGCGATTTCGCCGCTGCAACTGGAACGACTCGAGGACTACTTTGACTACTGGGGCCGGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTC,CAISPLQLERLEDYFDYW,93.836
412d,gp120 CCR5bs;gp120 CD4i,1RZG(Human anti-HIV-1 GP120 reactive antibody 412d),AC01 ,,,Mutation affects binding to 17b and 412d;Mutations at the trimer apex that affect sensitivity,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,"4.12D, 412D", ,,,6.0,750.0,1582.0,AEVKKPGSSVKVSCKASGGTFSNYAINWVRQAPGQGLEWMGGIIPIFNIAHYAQRFQGRVSITADESTSTAYMELSSLRSEDTAVFYCASPYPNDYNDYAPEEGMSWYFDLWGRGTLVTVSPASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK,SVGDRVTITCRASQSISNWLAWYQQKPGRAPKLLMYKASSLKSGVPSRFSGSGSGTEFTLTISSLQSDDFATYYCQQHDSSPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT,TCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCCAGTCAGAGTATTAGTAACTGGTTGGCCTGGTATCAGCAGAAACCAGGGAGGGCCCCTAAGCTCCTGATGTATAAGGCGTCTAGTTTAAAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGTCTGATGATTTTGCAACTTATTACTGCCAACAGCATGATAGTTCCCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTGACA,GCTGAGGTGAAGAAACCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAACTATGCTATCAACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCCATCTTTAATATAGCACACTACGCACAGAGATTCCAGGGCAGAGTCTCGATTACCGCGGACGAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTATTTTACTGTGCGAGCCCTTACCCGAATGACTACAATGACTACGCCCCAGAGGAGGGAATGAGCTGGTACTTCGATCTCTGGGGCCGGGGCACCCTGGTCACCGTCTCCCCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAG,CASPYPNDYNDYAPEEGMSWYFDLW,95.167
4139,gp120 V3 // V3 glycan (V3g),,,,Andrabi2013(23466102) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,1-8*01,,4*02,,ARLTVDCDDGGCYGDY,6.6,,2-14*01,2*01 or 3*01,,NSYRSDTLV,6.6,,L,,Natural monoclonal,human,, ,42.8949,5.76014,21.0,70.0,3025.0,,,,,,
4210,gp120 V3 // V3 glycan (V3g),,,,Andrabi2013(23466102) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,1-f*01,,3*02,,AIGKSVAGTSAYDI,5.6,,3-1*01,3*02,,QAWDSRAAV,4.3,,L,,Natural monoclonal,human,, ,27.2654,6.72866,21.0,64.0,3023.0,,,,,,
438-B11,gp120 V3 // V3 glycan (V3g),6UTK(438-B11 Fab in complex with an uncleaved prefusion optimized soluble BG505 trimer and Fab 35O22);6UUH(Crystal structure of broad and potent HIV-1 neutralizing antibody 438-B11);6UUM(438-B11 DSS mutant (Cys98A-Cys100aA));6V6W(438-B11 DSS mutant (Cys98A-100aA) in complex with an uncleaved prefusion optimized soluble BG505 trimer and Fab 35O22),CBJC438 ,438-B11,Kumar2020(32938661) ,438-B11 contacts,Kumar2020(32938661) ,IMGT/V-QUEST,1-69*01,3-3*01,3*01,21.0,WRGCGMCPYDTSSYYNDASDV,25.4,,3-20*01,3*01,9.0,QYYGGSFFT,12.7,,K,,Natural monoclonal,human,B11, ,4.05621,47.0693,272.0,679.0,4220.0,QVQLVQSGAEVRKPGSSVTISCKPVGGTFTNFAIHWVRQAPGQGLEWVGGRVPVVGIYKYGKKFHDRLRLYEDDPMKTVFLELRSLTSDDTGVYYCTRWRGCGMCPYDTSSYYNDASDVWGPGTKVIVSA,EIVLTQSPVTLSLSSGETGTLSCRASQNISSSWIAWYQQRRGQVPRLLISAASARAAGIPDRFTGRGSGTDFTLTITRLEPEDFGVYSCQYYGGSFFTFGPGTQVDVK,,,,
438-D5,gp120 V3 // V3 glycan (V3g),6UUL(Crystal structure of broad and potent HIV-1 neutralizing antibody 438-D5),CBJC438 ,438-B11,Kumar2020(32938661) ,,Kumar2020(32938661) ,IMGT/V-QUEST,1-69*01,3-3*01,3*01,21.0,WRGCGMCPYDTSSYYNDASDV,24.7,,3-20*01,3*01,9.0,QYYGGSFFT,13.5,,K,,Natural monoclonal,human,D5, ,1.12934,22.0589,14.0,680.0,4240.0,QVQLVQSGAEVKKPGSSVTISCKPVGGTFTNFAIHWVRQAPGQGLEWVGGRVPVVGIYKYGKKFHDRLRLYEDDPMKTVFLELRSLTSDDTGVYYCTRWRGCGMCPYDTSSYYNDASDVWGPGTKVIVSA,EIVLTQSPVTLSLSSGETGTLSCRASQNISSSWIAWYQQRRGQVPRLLISAASARAAGIPDRFTGRGSGTDFTLTITRLEPEDLGVYSCQYYGGSFFTFGPGTQVDVK,,,,
438-D6,gp120 V3 // V3 glycan (V3g),,CBJC438 ,,Kumar2020(32938661) ,,Kumar2020(32938661) ,IMGT/V-QUEST,3-48*02,1-20*01,4*02,8.0,,8.7,,2-11*01,3*02,10.0,,2.6,,L,,Natural monoclonal,human,D6, ,,,12.0,681.0,4264.0,,,,,,
438-F11,gp120 V3 // V3 glycan (V3g),,CBJC438 ,,Kumar2020(32938661) ,,Kumar2020(32938661) ,IMGT/V-QUEST,7-4-1*02,2-21*02,6*04,20.0,,10.1,,1-40*01,2*01,11.0,,7.8,,L,,Natural monoclonal,human,F11, ,,,12.0,682.0,4265.0,,,,,,
447-52D,gp120 V3 // V3 glycan (V3g),1Q1J(Fab 447-52D in complex with V3 peptide);3C2A(447-52D in complex with UG1033 peptide);3GHB(Fab 447-52D in complex with V3 peptide 92RW020);4M1D(Fab 447-52D with V3 cyclic peptide MN),,,Buchbinder1992(1466965) ,447-52D contacts;mutations affecting 447-52D binding;mutations affecting 447-52D binding;Mutations at the trimer apex that affect sensitivity,Klein2013(23540694) ,IgBlast,3-15,3-10 or 3-16,6,,,,,1-51,3,,,,,L,Yes,Natural monoclonal,human,"447, 447-52-D, 447/52-DII, 447d, 447-D, 447D, 447D-52", ,52.1248,6.55412,837.0,51.0,500.0,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVLWYQQFPGTAPKLLIYGNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYFCATWDSGLSADWVFGGGTKLTVLS,EVQLVESGGGLVKPGGSLRLTCVASGFTFSDVWLNWVRQAPGKGLEWVGRIKSRTDGGTTDYAASVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYSCTTDGFIMIRGVSEDYYYYYMDVWGKGTTVTVSS,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTCAGACTCACCTGTGTAGCCTCTGGTTTCACGTTCAGTGATGTCTGGCTGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCGGCCGTATTAAAAGCAGAACTGATGGTGGGACAACAGACTACGCTGCATCCGTGAAAGGCAGATTCACCATCTCAAGAGATGACTCAAAAAACACGCTATATCTGCAAATGAATAGCCTGAAAACCGAGGACACAGCCGTTTATTCCTGCACCACAGATGGTTTTATTATGATTCGGGGAGTCTCCGAGGACTACTACTACTACTACATGGACGTTTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGGAATAATTATGTATTGTGGTACCAGCAGTTCCCAGGAACAGCCCCCAAACTCCTCATTTATGGCAATAATAAGCGACCCTCAGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTTCTGCGCAACATGGGATAGCGGCCTGAGTGCTGATTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAAGT,CATWDSGLSADWVF,97.627
4487,gp120 V3 // V3 glycan (V3g),,,,Andrabi2013(23466102) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,5-51*03,,4*02,,ARLDGNAAAFDY,8.3,,1-51*02,2*01 or 3*01,,GTWDNNLRAG,5.6,,L,,Natural monoclonal,human,, ,34.0034,5.27528,21.0,60.0,3027.0,,,,,,
4490,gp120 V3 // V3 glycan (V3g),,,,Andrabi2013(23466102) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,5-51*01,,4*02,,ARVGYDSYGYSGSNFDE,4.5,,3-1*01,2*01 or 3*01,,QAWDTRTVV,5.0,,L,,Natural monoclonal,human,, ,39.1782,5.0526,21.0,61.0,3026.0,,,,,,
4508,gp120 V3 // V3 glycan (V3g),,,,Andrabi2013(23466102) ,,Andrabi2013(23466102) ,IMGT/V-QUEST,4-59*01,,4*02,,ARGPLLYFGAPRTHFDY,4.6,,4-1*01,3*01,,QQYYNTPPT,4.7,,K,,Natural monoclonal,human,, ,34.7707,7.50925,21.0,66.0,3024.0,,,,,,
45-46m2,gp120 CD4bs,4JKP(45-46m2 complexed with gp120),NIH45 ,VRC01,Diskin2013(23712429) ,45-46m2 signature predictions,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"m2, NIH45-46 G54W.HC_S28Y.LC", ,0.072729,38.6127,252.0,3.0,3161.0,,,,,,
45-46m25,gp120 CD4bs,,NIH45 ,VRC01,Diskin2013(23712429) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"m25, NIH45-46 G54W_W47I.HC_S28Y.LC", ,0.19645,24.9044,252.0,5.0,3167.0,,,,,,
45-46m28,gp120 CD4bs,,NIH45 ,VRC01,Diskin2013(23712429) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"m28, NIH45-46 G54W_W47T.HC_S28Y.LC, NIH45-46m28", ,0.13328,26.0761,252.0,6.0,3175.0,,,,,,
45-46m7,gp120 CD4bs,,NIH45 ,VRC01,Diskin2013(23712429) ,45-46m7 signature predictions,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"m7, NIH45-46 G54W_W47V.HC_S28Y.LC", ,0.1706,25.289,252.0,4.0,3162.0,,,,,,
48d,gp120 CD4i,1RZ7(Human anti-HIV-1 GP120-reactive antibody 48d);3JWD(gp120 with gp41-Interactive Region with Fab 48D);3JWO(gp120 with gp41-Interactive Region with Fab 48D);4DVR(YU2 gp120 core in complex with Fab 48d and NBD-557),,,,Mutations at the trimer apex that affect sensitivity,Gorny2009(18952295) ,,1-f*01,1-26,3,,,,,,,,,,,K,Yes,Natural monoclonal,human,"48D, 4.8d, 4.8D", ,83.8477,2.28492,452.0,377.0,659.0,EVQLVQSGAEVKKPGATVKISCKASGYTFSDFYMYWVRQAPGKGLEWMGLIDPEDADTMYAEKFRGRVTITADTSTDTGYLELSSLRSEDTAVYYCAADPWELNAFNVWGQGTLVSVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK,DIQMTQSPSSVSASVGDRVTITCRASQDISTWLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFSLTINSLQPEDFATYYCQQANSFFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFNRGE,GACATCCAGATGACCCAGTCTCCATCTTCTGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGATATTAGCACCTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATATATGCTGCATCCACTTTGCAAAGTGGTGTCCCGTCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCAGTCTCACTATCAACAGCCTGCAGCCTGAGGATTTTGCGACTTACTATTGTCAACAGGCTAACAGTTTCTTCACATTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAACTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTGACCAAGAGCTTCAACAGGGGCGAG,GAGGTCCAGCTGGTACAGTCCGGGGCTGAGGTGAAGAAGCCTGGGGCCACCGTGAAGATCTCCTGCAAGGCTTCTGGATACACCTTCAGCGACTTCTACATGTACTGGGTGCGACAGGCCCCTGGGAAAGGGCTTGAGTGGATGGGCCTTATTGATCCTGAAGATGCTGATACAATGTATGCAGAGAAGTTCCGGGGCAGAGTCACCATAACCGCAGACACGTCTACAGACACAGGCTATTTGGAACTGAGCAGCCTGAGATCTGAGGACACGGCCGTCTATTACTGTGCAGCAGATCCGTGGGAACTAAATGCATTTAATGTCTGGGGCCAAGGGACACTGGTCAGCGTCTCTTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAG,CAADPWELNAFNVW,91.892
49G2,gp120 CD4bs,,KTS376 ,,RamirezValdez2015(25486586) ,,RamirezValdez2015(25486586) ,IMGT/V-QUEST,1-18*01,,,22.0,ARRNYYDSGSYYIRDGDYSMDV,,,1-44*01,,11.0,ATWDDSLDGWV,,,L,Yes,Natural monoclonal,human,, ,45.4835,6.71738,48.0,531.0,3264.0,QVQLVQSAAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLQWMGWISAYNGNTKFAQEFKGRVTMTTDTSATTAYMELRSLRSDDTAVYYCARRNYYDSGSYYIRDGDYSMDV,QSVLTQPPSASGTPGQRVTISCSGSGSNIGSNTVNWYQQFPGTAPKLLIYNNNQRPSGVPDRFSGSKSGTSASLAISGLQSADEADYYCATWDDSLDGWV,,,,
4E10,gp41 MPER (membrane proximal external region),"1TZG(Fab 4E10 complexed with gp41 13mer epitope);2FX7(Fab 4E10 complexed with gp41 epitope);2FX8(Fab 4E10 complexed with gp41 Aib-induced peptide);2FX9(Fab 4e10 with 4e10 epitope on gp41);3H3P(Epitope-scaffold 4E10 Fv complex);4LLV(Unbound form of 4E10 Fv);4LRN(Ontogeny of recognition specificity and functionality for 4E10);4M62(Ontogeny of recognition specificity and functionality for 4E10);4M8Q(Ontogeny of recognition specificity and functionality for 4E10);4NGH(4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41 and a tethered phosphate moiety);4NHC(4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41);4OB5(Ontogeny of recognition specificity and functionality for 4E10);4ODX(4E10 germline encoded precursor no.7 in complex with epitope scaffold T117);4WY7(recombinant 4E10 expressed in Escherichia coli with epitope bound);4XAW(4E10 Fab in complex with its peptide epitope on HIV-1 gp41: Crystals cryoprotected with phosphatidic acid);4XBE(4E10 Fab in complex with its peptide epitope on HIV-1 gp41: crystals cryoprotected with sphingomyelin);4XBG(4E10 Fab in complex with phosphatidic acid: 2.73 A resolution);4XBP(4E10 Fab crystalized in the presence of Phosphatidylethanolamine);4XC1(4E10 Fab in complex with its peptide epitope on HIV-1 GP41: crystals cryoprotected with sn-Glycerol 3-phosphate);4XC3(4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with rac-glycerol 1-phosphate);4XCC(4E10 Fab crystalized in the presence of Phosphatidylcholine; I422 space group);4XCE(4E10 Fab crystalized in the presence of Phosphatidylcholine; C2 space group);4XCF(4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with phosphatidylcholine);4XCN(4E10 Fab in complex with phosphatidic acid; 2.9 A resolution);4XCY(4E10 Fab in complex with phosphatidylglycerol);5CIL(non-neutralizing version of 4E10 (WDWD) with epitope bound);5CIN(non-neutralizing version of 4E10 (DeltaLoop) with epitope bound);5CIP(Unbound 4E10);5X08(4E10, mutant Npro, with peptide bound)",,4E10,Buchacher1994(7520721) ,"2F5 and 4E10 signature sites;4E10 contacts;4E10 contacts;4E10 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 4E10 binding;Mutation affects neutralization;Mutation affects neutralization by 2F5 and 4E10;Mutation affects neutralization by PGZL1, H4K3, or 4E10;Mutation increases neutralization sensitivity;mutation increases sensitivity to MPER nAbs;Mutations at the trimer apex that affect sensitivity;Q563R affects binding and neutralization of MPER mAbs;Residues important for neutralization or binding by 4E10;Signature Analysis Summary",Zhang2019a(31772165) ,IMGT/V-QUEST,1-69*10,3-10*01,4*03,18.0,EGTTGWGWLGKPIGAFAH,6.8,,3-20*01,2*01,9.0,QQYGQSLST,4.7,,K,Yes,Natural monoclonal,human,," Morris2011 SHM data are entered for AA, but it's unclear if the data are NT or AA.",2.97937,5.21059,4311.0,13.0,846.0,GSQVQLVQSGAEVKRPGSSVTVSCKASGGSFSTYALSWVRQAPGRGLEWMGGVIPLLTITNYAPRFQGRITITADRSTSTAYLELNSLRPEDTAVYYCAREGTTGWGWLGKPIGAFAHWGQGTLVTVSS,EIVLTQSPGTQSLSPGERATLSCRASQSVGNNKLAWYQQRPGQAPRLLIYGASSRPSGVADRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGQSLSTFGQGTKVEVKLVPR,,,,
nan,,,,,,,Morris2011(21980336) ,SoDA,1-69*10,,1*01,18.0,REGTTGWGWLGKPIGAFA,,12.6,3-20*01,,9.0,QQYGQSLST,,7.0,,,,,,,,,,,,,,,,,
4E10-3R,gp41 MPER (membrane proximal external region),,,4E10,Rujas2018(29386285) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,,,6.0,863.0,4659.0,,,,,,
4E9C,gp120 CD4i,,KTS376 ,,Yoshimura2010(20504942) ,Mutations coupling nAb resistance with ceniciviroc sensitivity,Tanaka2017(28938888) ,,1-69,3-22,6,22.0,VGGRDNDYYDSSDISSYYAMDV,6.3,,3-15,2,11.0,QHYNNWPLLYT,5.4,,K,Yes,Natural monoclonal,human,,"Heavy chain sequences for 4E9C, 916B2, and 917B11 are based on CDRH3 data from RamirezValdez2015 Table 1 and Tanaka2017, which suggest that these 3 HC sequences were mislabeled in RamirezValdez2015 Supp Fig 1; the sequence for 4E9C was labeled as 917B11. Tanaka2017 %SHM shown for VH and VL only.",47.2906,4.86788,141.0,533.0,2477.0,QVQLVESGAEVKKPGSSVKVSCKASGGTLSNYAINWVRQAPGQGLEWMGGFIPMFGTPTYLQKLQGRLTIIADDSTSTAYMELSSLKSEDTALYYCVGGRDNDYYDSSDISSYYAMDV,SYVMTQSPATLSVSPGERATLSCRASQSVSRKLAWYQQKPGQAPRLLIYDASTRATGIPARFSGSGSGTEFTLTITSLQSEDFAVYYCQHYNNWPLLYT,,,,
nan,,,,,,,RamirezValdez2015(25486586) ,IMGT/V-QUEST,1-69*01 or 1-69D*01,,,22.0,,,,3-15*01,,11.0,QHYNNWPLLYT,,,,,,,,,,,,,,,,,,,
4O20,gp41-gp41 interface,,Donor N152 ,35O22,Huang2014(25186731) ,,Huang2014(25186731) ,IMGT/V-QUEST,1-18*02,5-24*01,4*02 or 4*03,16.0,GLLRDGSSTWLPYL,,,2-14*02,1*01,10.0,CSYTHNSGCV,,,L,,Natural monoclonal,human,, ,,,8.0,159.0,3149.0,QGQLVQSGAELKKPGGSVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVIMTTDKEVPVTAFTSTGTAYMEIRNLKFDDTGIYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSALTQPASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLIIYEDNEKAPGISHRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCTTGGACAGTCGGTCACCATCTCCTGCACTGGACCCAATAGTGTTTGTTGCAGTCACAAATCTATCTCCTGGTATCAGTGGCCCCCAGGCAGAGCCCCCACACTCATCATTTATGAGGACAATGAAAAGGCCCCGGGAATCTCTCATCGCTTCTCTGGCTACAAGTCGTATTGGTCGGCCTACTTGACAATCTCTGATCTCCGGCCTGAAGACGAGACCACTTACTATTGTTGCTCATACACTCACAATAGCGGCTGTGTCTTCGGGACTGGGACCAAGGTCTCCGTCTTG,CAGGGTCAACTAGTCCAGTCTGGAGCTGAGTTGAAAAAGCCTGGCGGCTCGGTGAAGATTTCCTGTAAGACTTCGGGTTATAGGTTTAATTTCTATCATATTAATTGGATTCGACAAACTGCAGGACGTGGACCTGAGTGGATGGGATGGATCAGCCCTTACAGTGGTGACAAAAACCTCGCACCTGCCTTTCAAGACAGAGTCATTATGACCACAGACAAAGAAGTCCCTGTGACCGCATTCACGTCCACGGGCACAGCCTACATGGAAATAAGGAATCTAAAATTTGACGACACAGGCATCTATTTTTGTGCGAAAGGCCTACTGCGCGACGGTTCGTCGACGTGGCTTCCTTATTTGTGGGGCCAGGGCACCCTGCTCACCGTCTCGTCA,CAKGLLRDGSSTWLPYLW,69.906
561_01_18,gp120 CD4bs,6UDJ(bNAb 1-18 in complex with BG505 SOSIP.664 and 10-1074);EMD-20739(bNAb 1-18 in complex with BG505 SOSIP.664 and 10-1074),IDC561 ,561_01_18,Schommers2020(32004464) ,561_01_18 contacts;561_01_18 escape mutations,Schommers2020(32004464) ,IgBlast,1-46*01,3-10*01,6*03,18.0,ARDPFGDRAPHYNYHMDV,,,3-20*01,3*01,9.0,QRYGGTPIT,,,K,,Natural monoclonal,human,1-18, ,0.087878,10.0157,439.0,472.0,4065.0,QGRLFQSGAEVKRPGASVRISCRADDDPYTDDDTFTKYWTHWIRQAPGQRPEWLGVISPHFARPIYSYKFRDRLTLTRDSSLTAVYLELKGLQPDDSGIYFCARDPFGDRAPHYNYHMDVWGGGTAVIVSS,EVVLTQSPAILSVSPGDRVILSCRASQGLDSSHLAWYRFKRGQIPTLVIFGTSNRARGTPDRFSGSGSGADFTLTISRVEPEDFATYYCQRYGGTPITFGGGTTLDKK,GAAGTTGTGTTGACACAGTCTCCAGCCATCCTCTCTGTGTCTCCGGGGGACAGAGTCATCCTCTCCTGTAGGGCCAGTCAGGGTCTTGATTCCAGCCACCTCGCCTGGTATCGGTTCAAACGTGGCCAGATTCCCACACTCGTCATCTTTGGTACTTCCAATAGGGCCAGAGGCACCCCAGACCGTTTCAGTGGCAGTGGGTCTGGGGCAGACTTCACCCTCACTATTAGCAGGGTGGAACCTGAAGATTTCGCTACTTATTACTGTCAGCGATATGGCGGCACGCCCATCACATTCGGCGGCGGGACCACATTGGACAAAAAA,CAGGGTCGTTTGTTTCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGGCCTCAGTGAGGATTTCTTGTCGGGCAGACGACGACCCCTACACCGACGACGACACCTTCACCAAATACTGGACACACTGGATTCGACAGGCCCCTGGACAGCGACCTGAGTGGCTGGGGGTCATCAGCCCTCACTTTGCTCGGCCCATTTACTCATATAAGTTCCGAGACAGACTCACGCTGACCAGGGACTCGTCCCTGACAGCCGTCTATTTGGAACTTAAAGGTCTGCAACCTGACGACTCGGGCATTTACTTCTGTGCGCGAGATCCGTTCGGGGACAGGGCCCCCCACTATAACTATCACATGGACGTCTGGGGCGGAGGGACCGCGGTCATCGTCTCCTCT,CARDPFGDRAPHYNYHMDVW,67.516
561_01_55,gp120 CD4bs,6UDK(bNAb 1-55 in complex with modified BG505 SOSIP-based immunogen RC1 and 10-1074);EMD-20740(bNAb 1-55 in complex with modified BG505 SOSIP-based immunogen RC1 and 10-1074),IDC561 ,561_01_18,Schommers2020(32004464) ,,Schommers2020(32004464) ,IgBlast,1-46*01,3-10*01,6*03,18.0,ARDPFGDMYPHYNYHMDV,,,3-20*01,3*01,9.0,QRYGGTPIT,,,K,,Natural monoclonal,human,1-55, ,0.15568,11.3586,256.0,474.0,4066.0,QRRLFQSGTEVKRPGASVKISCRADDDPYTDDDTFTKYYTHWIRQAPGQPPEWLGVISPHFARPIYSYKFRDRLTLTRDSSLTAVYFELRGLQPDDTGIYFCARDPFGDMYPHYNYHMDVWGGGTTVIVSA,EAVLTQSPAILSVSPGDRVILSCKASEGLSSSDLAWYRFKGGQIPTLVIFGASNRARGTPDRFSGSGSGTDFTLTINRVEPEDFATYYCQRYGGTPITFGGGTTLDKK,GAGGCTGTGTTGACACAGTCTCCAGCCATCCTCTCTGTGTCTCCGGGAGACAGAGTCATCCTCTCCTGTAAGGCCAGTGAGGGTCTTAGCTCCAGTGACCTGGCCTGGTATCGATTCAAAGGTGGCCAGATTCCCACTCTCGTCATCTTTGGTGCGTCCAATAGGGCCAGAGGCACCCCAGACCGTTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCACTATCAACAGGGTGGAACCTGAAGATTTCGCTACATATTACTGTCAACGATATGGCGGCACGCCCATCACATTCGGCGGCGGGACCACATTGGACAAAAAA,CAGCGTCGTTTGTTTCAGTCTGGGACTGAGGTGAAGAGGCCTGGGGCCTCAGTGAAGATTTCTTGTCGGGCAGACGACGACCCCTACACCGACGACGACACATTCACCAAATACTATACACACTGGATTCGACAGGCCCCTGGACAGCCACCTGAGTGGCTGGGGGTCATCAGCCCTCACTTTGCTCGGCCGATTTACTCATATAAGTTCCGAGACAGACTCACGCTGACCAGGGACTCGTCCCTGACAGCCGTCTATTTCGAACTTAGAGGTCTGCAACCTGACGACACGGGCATTTACTTCTGTGCGCGAGATCCCTTCGGGGACATGTACCCCCACTACAACTACCACATGGACGTCTGGGGCGGAGGGACCACAGTCATCGTCTCCGCA,CARDPFGDMYPHYNYHMDVW,67.516
561_02_12,gp120 CD4bs,,IDC561 ,,Schommers2020(32004464) ,,Schommers2020(32004464) ,IgBlast,1-46*01,3-16*01,6*04,20.0,ARDPFGETFRGHDQPYRMDV,,,3-20*01,4*01,10.0,QSYGSITPLV,,,K,,Natural monoclonal,human,2-12, ,0.23892,26.0208,432.0,473.0,4067.0,QLVQSGGGVRRPGASVKISCETPEDTFTKYWLHWLRQAPGQGLEWMGVVSPHGGRPMFAFEFRDRLTLTRDIHTTTHFMELRGLTSDDTAVYYCARDPFGETFRGHDQPYRMDVWGGGTTIVVSS,EPVLTQSPGTLSVSPGEGATLSCRARQGFSADHVAWFQKKPGRPPRLLIFEASRRASGTPERFSGSGSGPEYTLTITRVEAEDFAVYYCQSYGSITPLVFGGGTRVDVK,GAACCTGTCTTGACACAGTCTCCAGGCACCCTGTCTGTGTCTCCGGGGGAAGGAGCCACCCTCTCTTGCAGGGCCAGGCAGGGCTTCAGCGCCGATCACGTAGCCTGGTTTCAGAAAAAACCTGGCCGGCCTCCCAGACTCCTCATATTTGAGGCGTCTAGGAGGGCCAGTGGCACCCCAGAGCGGTTCAGTGGCAGTGGGTCTGGGCCCGAATACACTCTCACCATCACCCGTGTGGAAGCTGAAGATTTTGCGGTCTATTACTGCCAGTCATATGGCTCCATCACACCATTGGTTTTCGGCGGAGGGACCAGGGTGGACGTCAAA,CAATTAGTGCAGTCTGGCGGTGGGGTGAGGAGGCCTGGGGCCTCAGTGAAAATTTCCTGTGAGACACCAGAAGACACCTTCACTAAATACTGGCTTCACTGGCTGCGACAGGCCCCTGGGCAAGGACTTGAGTGGATGGGGGTTGTTAGCCCTCATGGTGGAAGGCCGATGTTCGCATTTGAGTTTCGGGACAGGCTCACTCTGACGAGGGACATTCACACGACAACACATTTTATGGAACTGAGAGGCCTAACCTCAGACGATACGGCCGTATATTATTGTGCCAGAGATCCCTTTGGGGAGACATTTCGCGGTCACGACCAGCCCTATCGGATGGACGTCTGGGGCGGAGGGACCACAATCGTCGTCTCCTCA,CARDPFGETFRGHDQPYRMDVW,73.448
5G2,gp120 V3 // V3 glycan (V3g),,KTS376 ,,RamirezValdez2015(25486586) ,,RamirezValdez2015(25486586) ,IMGT/V-QUEST,3-30*09 or 3-30*01,,,16.0,AKDGADENNLGPAFDY,,,2-28*01 or 2D-28*01,,8.0,MQSLHSWT,,,K,,Natural monoclonal,human,, ,48.3916,6.65393,48.0,526.0,3258.0,,,,,,
697-D,gp120 V2 // V2 glycan(V2g) // V2 apex,4D9L(Fab structure of V2 mAb 697),,,Gorny1994(7525987) ,Mutations at the trimer apex that affect sensitivity,,,,,,,,,,,,,,,,,,Natural monoclonal,human,"697-30D, 697D", ,72.5628,2.29489,47.0,184.0,325.0,QVQLVQSGAEVKKPGSSVKVSCKASGGNFNTYTISWVRQAPGQGLEWMGRIIPIFGIVNPAQKFPGRVTINVDKSTNTAYMELSSLRSEDTAVYYCATSGVGLHFGYFDYWGQGTQVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAHYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKVTVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCACATTATGATGTGCACTGGTACCAGCAGCTTCCAGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGTTATGTCTTCGGAACTGGGACCAAGGTCACCGTCCTA,CAGGTCCAGCTGGTGCAATCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCAACTTCAACACCTATACTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGAAGGATCATCCCTATATTTGGTATAGTAAATCCCGCACAGAAGTTCCCGGGCAGAGTCACGATTAATGTGGACAAATCCACGAACACAGCCTACATGGAGTTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTATTGTGCGACATCTGGGGTGGGACTACACTTCGGCTACTTTGACTACTGGGGCCAGGGAACCCAGGTCACCGTCTCCTCA,CATSGVGLHFGYFDYW,94.178
7-107,gp120 glycans,,pt7 ,7-269,Lorin2022(35230385) ,,Lorin2022(35230385) ,IgBlast,3-30,2-2,6,23.0,DDIVGDCSTGFCYWGYYYQGMDV,10.5,,3-15,2,10.0,QHYNSWPRAT,11.3,,K,Yes,Natural monoclonal,human,, ,13.7129,21.1528,48.0,604.0,4217.0,,,,,,
7-155,gp120 glycans,,pt7 ,,Lorin2022(35230385) ,,Lorin2022(35230385) ,IgBlast,1-69,2-21,6,12.0,GIWGGHYSPMDV,29.5,,1-5,2,9.0,QHYRENSYT,19.3,,K,No,Natural monoclonal,human,, ,24.5629,12.0493,48.0,605.0,4218.0,,,,,,
7-176,gp120 glycans,,pt7 ,,Lorin2022(35230385) ,,Lorin2022(35230385) ,IgBlast,1-69,4-11 or 3-10,6,13.0,HRDMGDYHHGMDV,25.9,,3-15,4,9.0,QHYESLPFT,17.6,,K,No,Natural monoclonal,human,, ,14.6654,16.8089,48.0,606.0,4219.0,,,,,,
717G2,gp120 V3 // V3 glycan (V3g),,KTS376 ,,RamirezValdez2015(25486586) ,,RamirezValdez2015(25486586) ,IMGT/V-QUEST,3-30*09 or 3-30*01,,,21.0,AREGPHVYDSSDPDPVLEMDF,,,2D-29*02,,8.0,MQSLHLWT,,,K,Yes,Natural monoclonal,human,, ,43.461,7.95622,48.0,527.0,3260.0,,,,,,
7-269,gp120 glycans,7PC2(Env in complex with the IgA bNAb 7-269 and 3BNC117);EMD-13316(Env in complex with the IgA bNAb 7-269 and 3BNC117),pt7 ,7-269,Lorin2022(35230385) ,7-269 contacts,Lorin2022(35230385) ,IgBlast,3-30,2-2,6,23.0,DDILGDCSTSHCYWGYYYQGMDV,9.1,,3-15,2,10.0,YHYNNWPRGS,9.5,,K,Yes,Natural monoclonal,human,, ,5.6157,37.8576,112.0,603.0,4216.0,,,,,,
7B9,gp41-gp41 interface,,Donor N152 ,35O22,Huang2014(25186731) ,,Huang2014(25186731) ,IMGT/V-QUEST,1-18*02,5-24*01,4*02 or 4*03,16.0,GLLRDGSSTWLPYL,,,2-14*02,1*01,10.0,CSYTHNSGCV,,,L,,Natural monoclonal,human,, ,,,8.0,158.0,3148.0,QGQLVQSGAELKKPGDSVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVIMTTDNEVPVTAFTSTGTAYMEIRNLRFDDTGIYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSALTQPASVSGSLGQSVTISCTGPNSACCSHKSISWHQWPPGRAPTLIIYEDNEKAPGISHRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCTTGGACAGTCGGTCACCATCTCCTGCACTGGACCCAATAGTGCTTGTTGCAGTCACAAATCTATCTCCTGGCATCAGTGGCCCCCAGGCAGAGCCCCCACACTCATCATTTATGAGGACAATGAAAAGGCCCCGGGAATCTCTCATCGCTTCTCTGGCTACAAGTCGTATTGGTCGGCCTACTTGACAATCTCTGATCTCCGGCCTGAAGACGAGACCACTTACTATTGTTGCTCATACACTCACAATAGCGGCTGTGTCTTCGGGACTGGGACCAAGGTCTCCGTCTTG,CAGGGTCAACTAGTCCAGTCTGGAGCTGAGTTGAAAAAGCCTGGCGACTCGGTGAAGATTTCCTGTAAGACTTCGGGTTATAGGTTTAATTTCTATCATATTAATTGGATTCGACAAACTGCAGGACGTGGACCTGAGTGGATGGGATGGATCAGCCCTTACAGTGGTGACAAAAACCTCGCACCTGCCTTTCAAGACAGAGTCATTATGACCACAGACAATGAAGTCCCTGTGACCGCATTCACGTCCACGGGCACAGCCTACATGGAAATAAGGAATCTGAGATTTGACGACACAGGCATCTATTTTTGTGCGAAAGGCCTACTGCGTGACGGTTCGTCGACGTGGCTTCCTTATTTGTGGGGCCAGGGTACCCTGCTCACCGTCTCGTCA,CAKGLLRDGSSTWLPYLW,70.533
7H6,gp41 MPER (membrane proximal external region),,Donor N152 ,10E8,Huang2012a(23151583) ,Q563R affects binding and neutralization of MPER mAbs,Huang2012a(23151583) ,IMGT/V-QUEST,3-15*05,3-3*01,1*01,22.0,TGKYYDFWSGYPPGEEYFQD,21.0,,3-19*01,3*02,12.0,SSRDKSGSRLSV,14.0,,L,,Natural monoclonal,human,, ,0.42023,8.13379,26.0,100.0,2709.0,EVQLVESGGGLVKPGGSLRLPCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLNSINFLYLEMNNLRMEDSGLYFCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTVSS,SYELTQETGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPKLLFYGKNNRPSGIPDRFSGSASGNRASLTISGAQAEDDAEYYCSSRDKSGSRLSVFGGGTKLTVL,TCCTATGAGCTGACACAGGAGACTGGTGTCTCTGTGGCCTTGGGACGGACAGTCACAATCACGTGCCGGGGAGACAGCCTCAGAAGTCATTATGCAAGTTGGTACCAAAAGAAGCCAGGACAGGCCCCTAAACTTCTCTTCTATGGTAAAAATAATCGTCCTTCAGGGATCCCAGACCGATTCTCTGGCTCCGCCTCAGGAAACAGAGCTTCCTTGACCATCTCTGGGGCTCAGGCGGAAGACGACGCGGAATATTATTGTAGTTCTCGAGACAAGAGTGGCAGCCGTCTGTCGGTCTTCGGCGGGGGGACCAAACTGACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCTGGAGGATCCCTTAGACTCCCATGTTCAGCCTCTGGTTTCGACTTCGATAACGCCTGGATGACTTGGGTCCGCCAGCCTCCAGGGAAGGGCCTCGAATGGGTTGGTCGTATTACGGGTCCAGGTGAAGGTTGGTCAGTGGACTATGCTGCACCCGTGGAAGGCAGATTTACCATCTCGAGACTCAATTCAATAAATTTCTTATATTTGGAGATGAACAATTTAAGAATGGAAGACTCAGGCCTTTACTTCTGTGCCCGCACGGGAAAATATTATGATTTTTGGAGTGGCTATCCGCCGGGAGAAGAATACTTCCAAGACTGGGGCCGGGGCACCCTGGTCACCGTCTCCTCA,CARTGKYYDFWSGYPPGEEYFQDW,78.114
7K3,gp41-gp41 interface,,Donor N152 ,35O22,Huang2014(25186731) ,,Huang2014(25186731) ,IMGT/V-QUEST,1-18*02,5-24*01,4*02 or 4*03,16.0,GLLRDGSSTWLPHL,,,2-14*02,1*01,10.0,CSYTHNSGCV,,,L,,Natural monoclonal,human,, ,,,8.0,161.0,3151.0,QGQLVQSGGELKKPGASVKISCKTSGYRFSFYHINWIRQVSGRGPEWMGWISPYSGDTNLAPDFRGRVVLTTDREVVDTMTMSTGTAHMELRNLKSDDTGLYFCAKGLLRDGSSTWLPHLWGQGTLLTVSS,QSALTQPASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLLIFEDSERSWGISDRFSGYKSYWSASLTISNLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,CAGTCTGCCCTGACTCAGCCTGCCTCCGTTTCTGGGTCTCTTGGTCAGTCGGTCACCATCTCCTGCACTGGACCCAATAGTGTCTGTTGCAGTCATAAATCTATCTCCTGGTATCAGTGGCCCCCCGGCAGAGCCCCCACACTCCTCATTTTTGAAGACAGTGAGCGGTCCTGGGGAATCTCTGACCGCTTCTCTGGCTACAAGTCTTATTGGTCGGCCTCCCTGACAATCTCTAATCTCCGGCCTGAGGACGAGACCACTTACTATTGTTGCTCATATACTCACAACAGCGGCTGTGTCTTCGGCACTGGGACCAAGGTCTCCGTCCTG,CAGGGTCAACTAGTCCAGTCTGGAGGTGAGTTGAAGAAGCCTGGGGCCTCGGTGAAGATTTCCTGTAAGACTTCGGGTTATAGATTTAGTTTCTATCATATTAATTGGATTCGACAAGTATCAGGGCGCGGACCTGAGTGGATGGGCTGGATCAGCCCTTACAGCGGAGACACAAACCTCGCACCTGACTTCCGAGGCAGAGTCGTTCTGACCACAGACAGAGAGGTCGTGGACACCATGACCATGTCCACGGGCACAGCCCACATGGAACTAAGGAACCTAAAATCTGACGACACGGGCCTCTATTTCTGTGCAAAGGGCCTCTTGCGCGACGGTTCGTCGACGTGGCTTCCTCATTTGTGGGGCCAGGGAACCCTGCTCACCGTCTCGTCA,CAKGLLRDGSSTWLPHLW,70.701
830A,gp120 V2 // V2 glycan(V2g) // V2 apex,4YWG(830A in complex with V1V2),,,Nyambi2000(10888650) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,74.8356,2.7642,41.0,185.0,954.0,QVQLQQWGPGLLKPSETLSLTCAVYGGSFGRYYWSWIRQSSGEGLEWLGQIDHTGSTTYNPSLKGRVTISIDSSTNQFSLKVTSVIAADTAVYYCARAPSGYPGVSLYQYYGLDVWGQGTTVTVSP,DTVMTQSPATLSVSPGERVTLSCRASQIINTNLAWYQKRPGQAPRLLIYAASARATGIPARFSGSGSGTEFTLTISGLQSEDSAVYYCQQYKHWPPYTFGRGTKLEIR,GACACAGTCATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGTCACACTCTCTTGCAGGGCCAGTCAGATTATTAACACCAATTTAGCCTGGTACCAGAAACGACCAGGCCAGGCTCCCAGGCTCCTCATCTATGCTGCATCCGCCAGGGCCACTGGTATCCCAGCCAGATTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCGGACTGCAGTCTGAAGATTCTGCAGTTTATTACTGTCAGCAATATAAGCACTGGCCTCCGTACACTTTTGGCCGGGGGACCAAGTTGGAGATCAGA,CAGGTGCAGCTGCAGCAGTGGGGCCCAGGACTGTTGAAGCCTTCGGAGACCCTGTCTCTCACGTGCGCTGTGTATGGTGGGTCATTTGGACGTTATTATTGGAGTTGGATCCGCCAGTCATCAGGAGAGGGACTGGAGTGGCTGGGGCAAATCGATCACACTGGTAGCACCACTTACAACCCGTCCCTCAAGGGTCGAGTCACCATATCAATAGACTCGTCCACGAACCAGTTCTCCCTGAAAGTGACCTCTGTGATCGCCGCGGACACGGCTGTCTATTACTGTGCGAGAGCCCCAAGTGGATATCCTGGCGTAAGTCTCTACCAATATTATGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCCCA,CARAPSGYPGVSLYQYYGLDVW,87.329
8ANC131,gp120 CD4bs,4RWY(8ANC131 in complex with HIV-1 clade B YU2 gp120),Patient 8 ,8ANC131,Scheid2011(21764753) ,8ANC131 contacts;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 8ANC131 neutralization;Signature Analysis Summary,Klein2013(23540694) ,IgBlast,1-46,3-16,6,,,,,3-NL5,3,,,,,K,,Natural monoclonal,human,, ,4.59984,11.8678,919.0,72.0,2587.0,QGQLVQSGGGLKKPGTSVTISCLASEYTFNEFVIHWIRQAPGQGPLWLGLIKRSGRLMTAYNFQDRLSLRRDRSTGTVFMELRGLRPDDTAVYYCARDGLGEVAPDYRYGIDVWGQGSTVIVTSASTKGPSVFX,,,CAGGGGCAGTTGGTGCAGTCCGGGGGTGGACTGAAGAAACCTGGGACGTCAGTGACGATTTCCTGCCTGGCATCTGAATACACATTCAACGAATTCGTTATTCACTGGATTCGACAGGCCCCTGGACAGGGGCCTCTGTGGCTGGGTCTAATCAAACGTAGCGGTCGTTTGATGACTGCCTATAATTTTCAAGACAGACTCAGTCTGCGAAGAGACCGTTCGACGGGAACAGTCTTCATGGAGTTGCGGGGTCTCAGACCTGACGACACGGCCGTGTATTATTGTGCGAGGGATGGATTGGGGGAGGTAGCGCCGGACTATCGTTACGGCATTGACGTCTGGGGTCAGGGGTCCACGGTCATCGTCACCTCAGCGTCGACCAAGGGCCCATCGGTCTTCCC,CARDGLGEVAPDYRYGIDVW,73.649
nan,,,,,,,Scheid2011(21764753) ,,1-46,3-16,6,16.0,DGLGEVAPDYRYGIDV,,,3-11,2 or 3,9.0,QEYSSTPYN,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Zhou2015(26004070) ,IMGT/V-QUEST,1-46,,,16.0,,,,3-20,,9.0,,,,,,,,,,,,,,,,,,,,
8ANC134,gp120 CD4bs,4RX4(8ANC134 in complex with HIV-1 clade A Q842.d12 gp120),Patient 8 ,8ANC131,Scheid2011(21764753) ,8ANC134 contacts,Scheid2011(21764753) ,,1-46,D3-16,6,16.0,DGLGEVAPAYLYGIDA,,,3-11,2 or 3,9.0,QEYSSTPYN,,,K,,Natural monoclonal,human,," 8ANC134 is a close clonal relative of 8ANC26, and the repertoir is as shown for 8ANC26 in Scheid2011.",8.4335,15.9968,203.0,98.0,2588.0,QGQLVQSGGGVKKPGTSVTISCLASEYTFNEFVIHWIRQAPGQGPVWLGLIKRSGRLMTSYKFQDRLSLRRDRSTGTVFMELRGLRLDDTAVYYCARDGLGEVAPAYLYGIDAWGQGSTVIVTSASTKX,EIVLTQSPATLSLSPGERATLSCRASQGLNFVVWYQQKGGQAPRLLIHGPTDRAPGVPDRFSARGSGTEFSLVISSVEPDDFALYYCQEYSSTPYNFGPGTRVDRKRTVAAPSVFIFPPSDEQLK,GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTCTGTCTCCAGGGGAAAGAGCCACCCTTTCCTGCAGGGCCAGTCAGGGTTTGAATTTCGTAGTCTGGTATCAACAAAAGGGTGGGCAGGCTCCCAGACTTCTCATCCACGGACCTACTGATAGGGCCCCTGGCGTCCCAGACAGATTCAGTGCCCGGGGGTCCGGGACAGAGTTCTCTCTCGTCATTAGTTCGGTGGAGCCTGATGATTTCGCACTATATTACTGTCAAGAATATAGTTCGACACCATATAACTTTGGCCCCGGGACCAGAGTGGATCGCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAA,CAGGGGCAGTTGGTGCAGTCCGGGGGTGGAGTGAAGAAACCTGGGACGTCAGTGACGATTTCCTGCCTGGCATCTGAGTACACATTCAATGAATTCGTTATTCACTGGATTAGACAGGCCCCTGGACAGGGGCCTGTGTGGCTGGGTCTAATCAAACGTAGCGGTCGTTTGATGACTTCCTATAAATTCCAAGACAGACTCAGTCTGCGAAGAGACCGTTCGACGGGAACAGTGTTCATGGAGTTGCGGGGTCTCAGACTTGACGACACGGCCGTCTATTACTGTGCGAGGGATGGATTGGGGGAGGTAGCGCCGGCCTATCTTTACGGCATCGACGCCTGGGGTCAGGGGTCCACGGTCATCGTCACCTCAGCGTCGACCAAGGG,CARDGLGEVAPAYLYGIDAW,72.973
8ANC195,gp41-gp120 interface,"4P9H(8ANC195 Fab in complex with gp120 of 93TH057 HIV-1 and soluble CD4 D1D2);4P9M(8ANC195 Fab);5A7X(negative stain EM of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);5A8H(cryo-ET subtomogram averaging of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);5C7K(BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195);5CJX(8ANC195 Fab in complex with BG505 SOSIP.664 HIV-1 Env trimer);5JS9(gp140 trimer with an engineered 8-residue HR1 turn bound to 8ANC195 and PGT128);5JSA(gp140 trimer with an engineered 10-residue HR1 turn bound to 8ANC195 and PGT128);5VIY(BG505 SOSIP.664 in complex with antibodies BG1 and 8ANC195);5VJ6(BG505 SOSIP.664 in complex with PG9 and 8ANC195)",Patient 8 ,,Scheid2011(21764753) ,8ANC195 contacts;8ANC195 contacts;8ANC195 residue prediction;8ANC195 signature predictions;mutation affecting 8ANC195 binding;Mutation affects 8ANC195 neutralization;Signature Analysis Summary,Klein2013(23540694) ,IgBlast,1-69,3-3,5 or 4,,,,,1-5,5,,,,,K,No,Natural monoclonal,human,," 8ANC195 is a close clonal relative of 8ANC142, and the repertoir is shown for 8ANC142 in Scheid2011.",5.9534,12.3504,1426.0,44.0,2583.0,QIHLVQSGTEVKKPGSSVTVSCKAYGVNTFGLYAVNWVRQAPGQSLEYIGQIWRWKSSASHHFRGRVLISAVDLTGSSPPISSLEIKNLTSDDTAVYFCTTTSTYDKWSGLHHDGVMAFSSWGQGTLISVSAASTKGPSVF,,,CAGATACACCTCGTACAATCTGGGACCGAAGTCAAGAAGCCTGGGTCCTCGGTGACGGTCTCCTGCAAGGCCTATGGAGTCAACACTTTCGGTCTCTATGCCGTCAATTGGGTGCGACAGGCCCCAGGACAAAGTCTTGAGTACATAGGACAGATATGGCGGTGGAAATCCAGCGCTTCACATCATTTCCGGGGCCGAGTCCTCATTTCCGCGGTGGACCTCACGGGCTCCTCGCCGCCTATTTCTTCCTTGGAGATCAAGAACCTGACCTCTGACGACACGGCCGTCTATTTTTGCACGACAACCTCGACGTACGACAAGTGGAGTGGCCTTCATCACGACGGGGTCATGGCATTTTCCTCTTGGGGCCAGGGAACCCTCATCTCCGTCTCCGCGGCGTCGACCAAGGGCCCATCGGTCTTC,CTTTSTYDKWSGLHHDGVMAFSSW,68.730
nan,,,,,,,Scheid2011(21764753) ,,1-69,3-3,,20.0,TSTYDQWSGLHHDGVMAFSS,,,1-5,1 or 5,9.0,QQYDTYPGT,,,,,,,,,,,,,,,,,,,
8ANC195-IgG3C-,gp41-gp120 interface,,Patient 8 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,IgG3C hinge variant ,3.67154,15.0125,232.0,270.0,3540.0,,,,,,
8ANC195/PGT128-IgG3C-,gp120 V3 // V3 glycan (V3g);gp41-gp120 interface,,Donor 36 Patient 8 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific; IgG3C hinge variant ,0.16412,16.5915,232.0,272.0,3532.0,,,,,,
916B2,gp120 CD4i,,KTS376 ,,RamirezValdez2015(25486586) ,,Tanaka2017(28938888) ,,1-69,2-15,4,16.0,ARDSDLYCSGGSCFEI,8.7,,7-46,3,9.0,LLSYSGARV,5.9,,L,Yes,Natural monoclonal,human,,"Heavy chain sequences for 4E9C, 916B2, and 917B11 are based on CDRH3 data from RamirezValdez2015 Table 1 and Tanaka2017, which suggest that these 3 HC sequences were mislabeled in RamirezValdez2015 Supp Fig 1; the sequence for 916B2 was labeled as 4E9C. Tanaka2017 %SHM shown for VH and VL only.",48.6996,5.07102,142.0,534.0,3268.0,QVQLVQSGTEVKKPGSSVTVSCKASGDTFNNYAISWVRQAPGRGLEWMGGILTVFGITKHAQKFQDRVTITADESSTTAYMELSSLRSEDTALYYCARDSDLYCSGGSCFEI,SYVVTQEPSLTVSPGGTVTLTCDSSTGAVTSDHYPHWIQRKPGQAPRTLIFGTSDKHSWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCLLSYSGARV,,,,
nan,,,,,,,RamirezValdez2015(25486586) ,IMGT/V-QUEST,1-69D*01 or 1-69*01,,,16.0,,,,7-46*01,,9.0,LLSYSGARV,,,,,,,,,,,,,,,,,,,
917B11,gp120 CD4i,,KTS376 ,,RamirezValdez2015(25486586) ,,Tanaka2017(28938888) ,,1-69,3-10,6,28.0,AGRSLEGADYYEAGTPYNVYYYYYVMDD,5.2,,1-51,2 or 3,11.0,GTWDSSLSAVV,2.8,,L,Yes,Natural monoclonal,human,,"Heavy chain sequences for 4E9C, 916B2, and 917B11 are based on CDRH3 data from RamirezValdez2015 Table 1 and Tanaka2017, which suggest that these 3 HC sequences were mislabeled in RamirezValdez2015 Supp Fig 1; the sequence for 917B11 was labeled as 916B2. Tanaka2017 %SHM shown for VH and VL only.",56.6966,5.96678,48.0,535.0,3269.0,EVQLLQSGAEVKKPGSSVKVSCKASGVTVSAYAISWVRQAPGQGLEWVGGIIPMFATENHAQKFQGRVTITADESTSTAYMDLSSLRSEDTAVYYCAGRSLEGADYYEAGTPYKVYYYYYVMDD,SYVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVV,,,,
nan,,,,,,,RamirezValdez2015(25486586) ,IMGT/V-QUEST,1-69D*01 or 1-69*01,,,28.0,,,,1-51*01,,11.0,GTWDSSLSAVV,,,,,,,,,,,,,,,,,,,
A10,gp41-gp120 interface,,C3 ,,Dubrovskaya2019(31732167) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,rabbit,,rabbit antibody ,41.6656,9.33613,16.0,766.0,4479.0,,,,,,
A12,gp120 CD4bs,,llama#44 ,,Forsman2008(18842738) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH A12,llama antibody ,30.7894,9.19053,95.0,190.0,1860.0,SQHLVQSGTQVKKPGASVRISCQASGYSFTDYVLHWWRQAPGQGLEWMGWIKPVYGARNYARRFQGRINFDRDIYREIAFMDLSGLRSDDTALYFCARDGSGDDTSWHLDPWGQGTLVIVSAASTKGX,QFVLTQPPSMSGAPGQRVTISCTGTNSNIGVNYVQWYQQFPGTAPKLLIYENYKRPSGISDRFSGSQSGSSASLTITGLQSEDEADYYCQSYDISLGAHVFGSGTELX,CAGTTTGTGCTGACGCAGCCGCCCTCAATGTCTGGGGCGCCCGGGCAGAGGGTCACCATCTCCTGCACTGGGACCAACTCCAACATTGGAGTTAATTATGTGCAGTGGTATCAGCAGTTTCCAGGAACGGCCCCCAAACTCCTCATCTATGAAAATTATAAGCGACCCTCAGGGATTTCTGATCGATTCTCTGGCTCCCAGTCTGGTTCCTCAGCCTCCCTGACCATCACTGGACTCCAGTCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACATCAGCTTGGGTGCTCATGTGTTCGGCAGTGGCACCGAGTTGAC,TCCCAGCATTTGGTGCAATCTGGGACTCAGGTGAAGAAGCCTGGGGCCTCAGTGAGGATCTCATGCCAGGCTTCTGGATACAGCTTCACCGACTACGTTCTCCACTGGTGGCGACAGGCCCCAGGCCAAGGGCTGGAGTGGATGGGGTGGATCAAGCCTGTCTACGGTGCCAGAAACTACGCGCGCAGGTTTCAGGGCAGGATAAACTTTGATCGGGACATCTACAGGGAGATAGCCTTCATGGACTTGAGTGGACTGAGATCTGACGACACGGCCCTATATTTTTGTGCGAGAGATGGGAGCGGGGACGACACCTCTTGGCACTTAGATCCCTGGGGCCAGGGAACGCTGGTCATTGTCTCCGCAGCGTCGACCAAGGGCC,CARDGSGDDTSWHLDPW,77.365
A12V163-a.01,fusion peptide // near gp41-gp120 interface,"6MQS(A12V163-a.01 in complex with HIV fusion peptide);6N1V(A12V163-a.01 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122)",A12V163 ,A12V163-a,Kong2019(31348886) ,A12V163-a.01 neutralization-associated sites,Kong2019(31348886) ,IgBlast IMGT/V-QUEST,,,,14.0,CVREGVPTEATTGDHW,6.0,,,,11.0,CQSYDISLGAHVF,4.4,,L,,Natural monoclonal,macaque,, ,93.7334,1.43785,416.0,826.0,4516.0,QVQLQESGPGLVKPSETLSLTCGVSGGSISDAYYWSWIRQSPGKRLEWIGYIFGSNGGTRYNPSLRSRVSISIDTSKNQLSLKLTSVTAADTAVYYCVREGVPTEATTGDHWGQGVPVTVSS,QFVLTQPPSMSGAPGQRVTISCTGTNSNIGVNYVQWYQQFPGTAPKLLIYENYKRPSGISDRFSGSQSGSSASLTITGLQSEDEADYYCQSYDISLGAHVFGSGTELX,CAGTTTGTGCTGACGCAGCCGCCCTCAATGTCTGGGGCGCCCGGGCAGAGGGTCACCATCTCCTGCACTGGGACCAACTCCAACATTGGAGTTAATTATGTGCAGTGGTATCAGCAGTTTCCAGGAACGGCCCCCAAACTCCTCATCTATGAAAATTATAAGCGACCCTCAGGGATTTCTGATCGATTCTCTGGCTCCCAGTCTGGTTCCTCAGCCTCCCTGACCATCACTGGACTCCAGTCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACATCAGCTTGGGTGCTCATGTGTTCGGCAGTGGCACCGAGTTGAC,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGGTGTCTCTGGTGGCTCCATCAGCGATGCTTACTACTGGAGCTGGATCCGCCAGTCCCCAGGGAAGCGACTGGAGTGGATCGGGTACATCTTTGGTAGTAATGGGGGCACCAGGTACAATCCCTCCCTCAGGAGTCGAGTCTCCATTTCAATAGACACGTCCAAGAACCAGCTCTCCCTGAAGTTGACCTCTGTGACCGCCGCGGACACGGCCGTATATTACTGTGTGAGAGAAGGAGTGCCCACGGAAGCAACTACGGGGGACCACTGGGGCCAGGGAGTCCCGGTCACCGTCTCCTCA,CVREGVPTEATTGDHW,89.298
A12V163-a.02,fusion peptide // near gp41-gp120 interface,,A12V163 ,A12V163-a,Kong2019(31348886) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,, ,97.8483,1.17193,416.0,827.0,4517.0,QVQLQESGPGLVKPSETLSLTCAVTGGSISDAYYWSWIRQFPGKRLEWIGYIYGSTGGTRYNPPLKNRVSISIDTSKNQFSLKLRSVTAADTAVYYCVRDGVATIETTGDHWGQGVLVTVSS,QFVLAQPPSVSGAPGQRVTLSCTGSNSNIGVNYVQWYQQLPGTAPKLLIYENNKRPSGVSDRFSGSQSGTSASLTITGLQSEDEADYYCQCYDISLGAHVFGSGTELX,CAGTTTGTGCTGGCGCAGCCGCCCTCAGTGTCTGGGGCGCCCGGGCAGAGGGTCACCCTCTCCTGCACTGGGAGCAACTCCAACATTGGAGTTAATTATGTGCAGTGGTACCAGCAGCTTCCAGGAACGGCCCCCAAACTCCTCATCTATGAAAATAATAAGCGACCCTCAGGGGTTTCTGATCGATTCTCTGGCTCCCAGTCTGGTACCTCAGCCTCCCTGACCATCACTGGACTCCAGTCTGAGGATGAGGCTGATTATTACTGCCAGTGCTATGACATCAGCTTGGGTGCTCATGTATTCGGAAGTGGGACCGAATTGAC,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGCTGTCACTGGTGGCTCCATCAGCGATGCTTACTACTGGAGTTGGATCCGCCAGTTCCCAGGGAAGAGACTGGAGTGGATTGGTTACATCTATGGTTCCACTGGGGGAACCAGGTACAATCCCCCCCTCAAGAATCGAGTCTCCATTTCAATTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGGTCTGTGACGGCCGCGGACACGGCCGTTTATTACTGTGTTAGAGATGGGGTGGCTACGATAGAAACTACGGGGGACCACTGGGGCCAGGGAGTCCTGGTCACCGTCTCCTCA,CVRDGVATIETTGDHW,88.294
A12V163-b.01,fusion peptide // near gp41-gp120 interface,"6MPG(A12V163-b.01, elicited by vaccination of Rhesus macaques, in complex with stabilized HIV-1 Env BG505 DS-SOSIP, which was also bound to antibodies VRC03 and PGT122)",A12V163 ,,Kong2019(31348886) ,,Kong2019(31348886) ,IgBlast IMGT/V-QUEST,,,,11.0,CTKESAAAIGHYW,5.7,,,,9.0,CQQYYTTPLTF,3.0,,K,,Natural monoclonal,macaque,, ,99.399,1.06318,416.0,828.0,4518.0,EVQLVESGGGLAKPGGSLRLSCAASGFTFSDYYMDWVRQAPGKGLEWVSRISNSGITWYTDSVRGRFTIFRDNAKNTLYLQMNSLRAEDTAVYYCTKESAAAIGHYWGQGVLVTVSS,DIVMTQSPDSLAVSLGERVTLNCKSSQSLLASSNNKNYLAWYYQKPGQAPKLLIYWASTRESGVPNRFSGSGSGSDFTLTISGLQAEDVAVYYCQQYYTTPLTFGGGTKVEIK,GATATTGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGAGAGAGGGTCACCCTCAACTGCAAGTCCAGCCAGAGTCTTTTAGCCAGCTCCAACAATAAGAACTACTTAGCCTGGTACTACCAGAAACCAGGACAGGCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCCTAACCGATTCAGTGGCAGTGGATCTGGGTCAGATTTCACTCTCACCATCAGTGGCCTGCAGGCTGAAGATGTGGCAGTGTATTACTGTCAGCAGTATTATACCACGCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA,GAGGTGCAGCTAGTGGAGTCTGGGGGCGGCTTGGCAAAGCCTGGGGGGTCCCTGAGACTCTCCTGCGCAGCCTCCGGATTCACCTTCAGTGACTACTACATGGACTGGGTCCGCCAGGCTCCAGGGAAGGGACTGGAGTGGGTCTCACGTATTAGTAACAGTGGTATTACTTGGTACACAGACTCCGTGAGGGGCAGATTCACCATTTTCAGAGACAACGCCAAGAACACACTGTATCTTCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTCTATTATTGTACGAAAGAGTCAGCGGCAGCTATCGGGCACTACTGGGGCCAGGGAGTCCTGGTCACAGTCTCCTCA,CTKESAAAIGHYW,89.078
A14,gp120 CD4bs,,llama#1 ,,McCoy2014a(25522326) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,A14 VHH,llama antibody ,1.96465,20.132,61.0,196.0,3218.0,EVQLVESGGGLVQAGGSLRLSCAASGFSFNDYAIGWFRQTPGKEREGVSCLSSSGMAHYADSVKGRFTIAYDNAKNTVYLQMNSLKPEDTAVYHCATHPFRCGNWRTVMGSWGQGTQVTVSS,,,,,
A16,gp120 CD4bs,,F524 ,,Qiao2016(27387828) ,A16 contacts,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,57.3488,3.53445,140.0,260.0,3491.0,,,,,,
A32,gp120 CD4i C1 (Cluster A),3TNM(A32 Fab);4YBL(stabilized inner domain of clade A/E HIV-1 gp120 in complex with antibody A32);4YC2(stabilized inner domain of clade A/E HIV-1 gp120 in complex with antibody A32),,,,W69 is important for ADCC,,,,,,,,,,,,,,,,,Yes,Natural monoclonal,human,A-32, ,,,38.0,725.0,660.0,QVQLQESGPGLVKPSQTLSLSCTVSGGSSSSGAHYWSWIRQYPGKGLEWIGYIHYSGNTYYNPSLKSRITISQHTSENQFSLKLNSVTVADTAVYYCARGTRLRTLRNAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPK,VLTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQHHPGKAPKLIISEVNNRPSGVPDRFSGSKSGNTASLTVSGLQAEDEAEYYCSSYTDIHNFVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAP,,,,
Ab1271,gp120 V3 // V3 glycan (V3g),,,,Escolano2021(34818054) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,1271,macaque antibody ,31.5585,3.35509,21.0,798.0,4410.0,QVQLVESGPGLVKPSETLSLTCAVSGDSISSTWWNWIRQPPGKGLEWIGRISGDGGNTDYSPSLKSRVTISTDTSKNQLSLRLTSVAAADTAVYFCAAPDCSGPDCSPGFDYWGPGVLVTVSS,QPVLTQPPSVSGAPGQRVTISCTGSSSDIGRFYVQWYQQLPGTAPKLLIYENTKRPSGISDRFSGSQSGPSASLTITGLQSEDEADYYCQSYDSSMSAHVLFGGGTRLTVL,,,,
Ab1289,gp120 V3 // V3 glycan (V3g),,,,Escolano2021(34818054) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,1289,macaque antibody ,48.8637,2.52122,21.0,799.0,4411.0,QVQLVQSGAEVKRAGESLRISCKTSGYIFSDSWIDWVRQMPGRGLEWMGSIYPGDSETRYNPSFQGHVTISADKSISTIYLQWSSLKASDTATYYCSKARYEDEYGYYYSDYGYWGQGVLVTVSS,QSVLTQPHSVSGAPGQSVTISCSGSSSNIETNYVYWYQQLSGRAPKLLIYNNDQRPSGVPDRFSGSTSGTSASLAISGLQSEDEADYYCSAWDNGLSGPVFGGGTRLTVL,,,,
Ab1303,gp120 CD4bs,7RYU(Anti-HIV neutralizing antibody Ab1303 Fab isolated from sequentially immunized mcaques);7TFN(Cryo-EM structure of CD4bs antibody Ab1303 in complex with HIV-1 Env trimer BG505 SOSIP.664),,,Escolano2021(34818054) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,1303,macaque antibody ,44.3951,3.40851,21.0,800.0,4417.0,QVQLQESGPGLVKPSETLSLTCAVSGGSISGNYWSWIRQSPGKGLEWIGHINDYSGRTDYNPSLKSRVTISTDTSTNQFFLTLSSVSAADTAVYYCARRDTDFWRGIYVFEFWGQGVLVTVSS,QSVLTQSPSASASLGASVKLTCTLSSGLRSYTIAWYQRQRGQAPRFLLRLDSVGSHTKVDGIPDRFSGSSSGTERYLTISNLQSEDEADYFCQTWTTGIYIFGGGTRLSVL,,,,
Ab1368,gp120 V3 // V3 glycan (V3g),,,,Escolano2021(34818054) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,1368,macaque antibody ,83.4315,1.32121,21.0,801.0,4412.0,EVQLVESGPAVVKPSETLSLTCAVSGGSISGNYWSWIRQAPGKGLEWIGSIYGSSGSTYNNPSLKTRVTISKDTSKNQISLKLSSVTAADTAVYYCARCIVAAGTFYFDYWGQGVLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNYVSWYQQHPGTAPKLMIYAVSKRPSGVSDRFSGSESGNTASLTISGLQAEDEADYYCCSYAGSYTWVFGGGTRLTVL,,,,
Ab1415,gp120 V3 // V3 glycan (V3g),,,,Escolano2021(34818054) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,1415,macaque antibody ,33.5022,5.1997,21.0,802.0,4413.0,EVQLVQSGAEVKRPGESLMISCKTSGYSFTDTWISWVRQTPGKGLEWIGSIYPGDSDTRYNPSFQGHVTISADKSISTTYLQWSDLKAPDTATYYCTIPDADNFNSPYFDYWGQGVLVTVSS,QLVLTQPPSVSGAPGQRVTFSCTGSSSNIGPYFVQWYQQYPGTAPKVLIYENNKRPSGVSDRFSGSLSDTSASLTITGLQAEDEADYYCQSYDSTLNAHVFGSGTKLTVL,,,,
Ab1456,gp120 V3 // V3 glycan (V3g),,,,Escolano2021(34818054) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,1456,macaque antibody ,36.61,7.64892,21.0,803.0,4414.0,EVQLVQSGAEVKRPGDSLKISCKTSGDVFTSTWITWVRQMPGKDLEWMASIYLDDSDTQYNPSFQGHVTISADKSINTIYLQLSSLKVSDTATYYCAKWGVDCSDSGCSSAFDSWGQGVLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGGTSNIGNYYVQWYQQLPGTAPKLLIYENNKRPSGISDRFSGSQSGTSGSLTITGLQSEDEADYFCQSYDDSLSAHVFGSGTKVTIL,,,,
Ab1457,gp120 V3 // V3 glycan (V3g),,,,Escolano2021(34818054) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,1457,macaque antibody ,41.0283,7.18878,21.0,804.0,4415.0,QVQLVESGPGLVKPSETLSLTCAVSGDSINNYWWNWIRQPPGEGLEWIGRIYGDDGTTTYNPSLQSRVTFSTDTSKNQFSLRLTSVTAADTAVYYCASPFCSTTSCHPSFDYWGQGVLVTVSS,NFMLTQPPSVSGAPGQRVTISCTGSNSNMGDYYVQWYQQPPGTAPKLLIYENTKRPSGVSDRFSSSLSGSSASLTITGLQSEDEADYYCQSFDNSPSAHVLFGGGTRLTVL,,,,
Ab1461,gp120 V3 // V3 glycan (V3g),,,,Escolano2021(34818054) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,1461,macaque antibody ,39.0173,6.32325,21.0,805.0,4416.0,QVQLVESGGEVKRPGESLRISCETSEYTFTNNWITWVRQVPGKGLEWMGNIFPDDSDTIYSPAFQGHVTFSADKSITTIYLQWRSLRASDTATYYCGRIDGDNGSFDDWGQGVLVTVSS,QSVLTQPPSVSGAPGQTVTISCTGSSSNIGNYFVSWYQHLPGAPPKVLIYQYNKRPSGVSDRFSGSKSDTSASLTITGLQTEDEADYYCLSYDSSLSGWLFGGGTRLTVL,,,,
Ab1485,gp120 V3 // V3 glycan (V3g),7KDE(BG505 SOSIP.664 with macaque mAb Ab1485 and human mAb 8ANC195),CE8J ,,Wang2020(33084569) ,Ab1485 contacts,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,,macaque antibody ,4.39027,63.7904,42.0,686.0,4252.0,QVQLQESGPGLVKPSETLSLTCTVSGYNIRSNNWWSWVRQPPGKGLEWIGGVYANSEITNYNSSLKSRVSISQDAWRNKFSLKLKSVTDADTAVYYCVRGPNHWEYFDSGNNEYFEFWGQGALVTVSSX,QSVLTQPPSVSGAPGQRVTISCTGTSSNIENYHAFWYQQFSGMAPKLLIRDNDKRPSGVSDRFSGSKSGASASLTITGLQTDDEADYYCQSYDSGLRSYIFASGTRLTVLX,CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGGGGCCCCAGGCCAGAGGGTCACCATCTCCTGCACTGGGACCAGTTCCAACATTGAAAATTATCATGCATTCTGGTACCAGCAATTCTCAGGAATGGCCCCCAAACTCCTCATCCGTGACAATGATAAGCGACCTTCAGGGGTTTCTGACCGATTCTCTGGCTCCAAGTCTGGTGCCTCAGCCTCCCTGACCATCACTGGGCTCCAGACTGACGATGAGGCTGATTATTACTGCCAGTCTTATGACAGCGGCCTGAGAAGTTACATCTTCGCTTCTGGGACCCGGCTCACCGTCCTAG,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTTATAACATCAGAAGTAATAATTGGTGGAGTTGGGTCCGCCAGCCCCCAGGGAAAGGGCTGGAGTGGATTGGGGGTGTCTACGCTAATAGTGAGATCACCAACTACAACTCCTCCCTCAAAAGTCGAGTCAGCATCTCACAAGACGCGTGGAGAAATAAATTCTCCTTGAAGCTGAAGTCTGTGACCGACGCGGACACGGCCGTGTATTACTGTGTGAGAGGACCCAATCATTGGGAATATTTTGATAGTGGTAACAATGAATATTTCGAATTCTGGGGCCAGGGCGCCCTGGTCACCGTCTCCTCAG,CVRGPNHWEYFDSGNNEYFEFW,86.242
Ab1573,gp120 CD4bs,7RYV(Anti-HIV neutralizing antibody Ab1573 Fab isolated from sequentially immunized macaques),,,Escolano2021(34818054) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,macaque,1573,macaque antibody ,65.278,2.58613,21.0,806.0,4418.0,QVQLVQSGAEVKKPGASVKVSCKASGFTFGRYSFTWVRQAPGQGLEWVGVIVPLVGVTNSAKKFQGRVTITADTSTNTVYMDLSSLRSEDTAVYYCARVGDRFGSGYAMDVWGRGALVTVSS,QSALTQPPSVSGAPGERVTISCSGSGSNFEYSFVYWYQQVPGMAPKLLIYDNYKRPSGVSDRFSGSRSGTSASLTITGLQTEDESDYYCQSYDSSLTYWVFGGGTRLTVL,,,,
ACS101,gp120 CD4bs,7U04(antibody ACS101);7Z3A(AMC009 SOSIPv5.2 in complex with Fabs ACS101 and ACS124),H18877 ,,vanSchooten2022a(35922441) ,ACS101 contacts,vanSchooten2022a(35922441) ,IMGT/V-QUEST,1-02*02,1-26*01,5*02,19.0,ARGGRGYDEPWGAYTWLDP,48.0,27.0,2-23*02,2*01,8.0,YSYDDMII,31.0,18.0,L,,Natural monoclonal,human,, ,25.9514,7.44959,283.0,752.0,4468.0,EVQLLESGAEVKKPGASVRVSCEASGYTFTKYFIHWVRQAPGHGLEWIGWINTLTSGVNYARNFQGRLTLTRDLSTETVYMDLRNLKSDDTAVYYCARGGRGYDEPWGAYTWLDPWGQGSLVTVSS,SYELTQPASVSGSPGQSITISCTGSSIGSYDLVSWYQQYPGKAPKVIIFEVSKRPSGVSHRFSGSKSGNTAALTISGLQVEDEAIYHCYSYDDMIIFGGGTRLTVL,TCCTATGAGCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGATCCAGCATTGGGAGTTATGACCTTGTCTCCTGGTACCAACAATACCCAGGCAAAGCCCCCAAAGTCATTATTTTTGAGGTCAGTAAGCGGCCCTCAGGGGTTTCTCATCGTTTCTCTGGCTCCAAGTCTGGCAACACGGCCGCCCTGACAATCTCTGGGCTCCAAGTTGAAGACGAGGCAATATATCACTGCTACTCATATGATGACATGATTATATTCGGCGGAGGGACCAGGCTGACCGTCCTA,GAGGTGCAGCTGTTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGAGTCTCCTGCGAGGCCTCTGGATACACCTTCACCAAATATTTTATCCACTGGGTGCGACAGGCCCCTGGACACGGACTTGAGTGGATAGGGTGGATCAACACTCTCACTAGTGGCGTCAACTACGCACGGAACTTTCAGGGCCGACTCACCTTGACCAGGGACCTGTCCACGGAAACAGTCTACATGGACCTGAGGAATCTAAAATCTGACGACACGGCCGTCTATTATTGTGCGAGAGGTGGGCGAGGCTACGACGAGCCCTGGGGAGCCTACACTTGGCTCGACCCCTGGGGCCAGGGATCCCTGGTCACCGTCTCCTCA,CARGGRGYDEPWGAYTWLDPW,83.729
ACS114,gp120 silent face,,H18877 ,,vanSchooten2022(36395347) ,ACS114 contacts;Mutation affects ACS114 neutralization,vanSchooten2022(36395347) ,IMGT/V-QUEST,4-34*08,,4*02 or 4*01,14.0,VRVGPGPHMAALDY,36.0,21.0,2-24*01,1*01,9.0,VQGTQFPWT,24.0,8.0,K,,Natural monoclonal,human,, ,49.4151,7.94023,243.0,753.0,4484.0,QVQLQQWGGGLLKPSQTLSLTCAVYRWTFNDHYWSWVRQSPGKGLEWIGEISWGGATNYNPSLKSRVTMSVDTSMSHVSLKMTSVTAADTGVYYCVRVGPGPHMAALDYWGHGSRVLVSSX,DIVMTQTPLSSPVTLGQPASISCGSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYKISNRISGLPDRFSGSGAETNFTLKISRVEAEDVGLYYCVQGTQFPWTSGQGTKVEIKX,GATATTGTGATGACCCAGACTCCGCTCTCCTCACCTGTCACTCTTGGACAGCCGGCCTCCATCTCCTGCGGCTCTAGTCAAAGTCTCGTTCACAGTGATGGAAACACGTATTTGAGTTGGCTGCAGCAGAGGCCAGGCCAGCCTCCAAGACTCCTAATTTACAAGATTTCTAATCGGATCTCTGGGCTCCCAGACAGATTCAGTGGCAGCGGGGCAGAGACAAATTTCACACTGAAGATCAGCAGGGTGGAAGCTGAAGATGTCGGACTTTATTACTGTGTCCAAGGTACACAATTTCCGTGGACCTCCGGCCAGGGGACCAAGGTGGAAATCAAAC,CAGGTGCAGCTACAGCAGTGGGGCGGAGGACTGCTGAAGCCTTCGCAGACCCTGTCCCTCACCTGCGCTGTCTATCGTTGGACCTTCAATGATCACTATTGGAGCTGGGTCCGCCAGTCTCCAGGGAAGGGCCTGGAGTGGATTGGAGAAATCAGTTGGGGTGGAGCAACCAACTACAACCCGTCTCTCAAGAGTCGAGTCACCATGTCAGTCGACACGTCCATGAGCCACGTCTCCCTGAAAATGACGTCTGTGACCGCCGCGGACACGGGTGTCTATTATTGTGTGAGAGTTGGGCCGGGGCCGCATATGGCAGCACTTGACTATTGGGGCCACGGAAGCCGGGTTCTCGTCTCGTCAG,,
ACS117,gp120 silent face,,H18877 ,,vanSchooten2022(36395347) ,,vanSchooten2022(36395347) ,IMGT/V-QUEST,4-34*01,,4*02,13.0,ARSWGPTGPAPNS,48.0,24.0,2-24*01,2*02,9.0,MQATHEPRT,23.0,11.0,K,,Natural monoclonal,human,, ,34.3591,8.08321,243.0,754.0,4487.0,QLQLQEWGARLLKPSETLSLTCAIYSESFTSYYWTWIRQSPEKGLEWIGEANHSGNDNYNPALRGRVTISIDIGNRRFSLKLNSVTAADTAVYYCARSWGPTGPAPNSWGQGALVTVSSX,DIVMTQTPLSSPVTVGQPASISCRSSQSLVHRNGNTFLSWFHLRPGQPPRPLIYQISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGFYYCMQATHFPRTFGQGTKLEIKX,GATATTGTGATGACCCAGACTCCACTCTCCTCGCCTGTCACAGTTGGACAGCCGGCCTCCATCTCCTGCAGGTCTAGCCAAAGTCTCGTACACCGTAATGGAAACACCTTCTTGAGTTGGTTTCATCTGAGGCCAGGCCAGCCTCCACGACCCCTAATTTATCAGATTTCTAATCGATTCTCTGGGGTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACAGATTTCACACTGAAAATTAGTCGGGTGGAAGCTGAGGATGTCGGTTTTTATTACTGCATGCAGGCTACACATTTTCCTCGCACTTTTGGCCAGGGGACCAAGCTGGAGATCAAAC,CAGCTGCAGCTGCAGGAGTGGGGCGCACGACTACTGAAGCCTTCGGAGACCCTCTCCCTCACGTGCGCTATCTACAGTGAGTCTTTCACGAGTTATTACTGGACCTGGATCCGCCAGTCCCCTGAGAAGGGGCTGGAGTGGATTGGGGAGGCCAATCATAGTGGAAATGACAACTACAACCCGGCCCTCAGGGGTCGAGTCACCATTTCAATAGACATAGGCAATAGACGCTTCTCCCTCAAGCTGAACTCTGTGACTGCCGCAGACACGGCTGTCTATTACTGCGCGAGATCGTGGGGGCCAACTGGTCCGGCCCCCAACTCCTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCAG,CARSWGPTGPAPNSW,83.505
ACS122,gp41-gp120 interface,7U5G(ACS122 Fab),H18877 ,,vanSchooten2022(36395347) ,ACS122 contacts,vanSchooten2022(36395347) ,IMGT/V-QUEST,4-59*03 or 4-59*11,,5*02,18.0,AREKSVVEPDNMVRWFDP,24.0,15.0,3-21*04,1*01,11.0,QVWDSSRDHCV,10.0,3.0,L,,Natural monoclonal,human,, ,85.7538,1.85158,243.0,755.0,4490.0,QVQLQESGPGLVKPSEALSLTCSVSGVAISRHYWNWIRQPPGKGLEWIGYIFFNGNTNYSPSLKSRVTISVDTSKNEFSLTLRSVTAADTAVYYCAREKSVVEPDNMVRWFDPWGQGTLVTVSSX,SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSKSGNTATLTISRVEAGDEADYYCQVWDSSRDHCVFGIGTKVTVLX,TCCTATGAGCTGACACAGCCACCCTCAGTGTCAGTGGCCCCTGGCAAGACGGCCAGGATTACCTGTGGGGGAAACAACATTGGAAGTAAAAGTGTCCACTGGTACCAACAGAAGCCAGGCCAGGCCCCTGTATTGGTCATCTATTATGATAGCGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAAGTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGGTGTGGGATAGTAGTCGTGATCATTGTGTCTTCGGAATTGGGACCAAGGTCACCGTCCTAG,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGGCCCTGTCCCTCACCTGCAGTGTCTCTGGTGTCGCCATCAGTCGTCACTACTGGAATTGGATCCGGCAGCCCCCCGGGAAGGGACTGGAATGGATTGGCTATATCTTTTTCAATGGCAATACCAACTACAGTCCCTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAAAACGAATTCTCCCTGACGCTGCGCTCTGTGACCGCTGCGGACACGGCCGTCTATTACTGTGCGCGAGAAAAGAGTGTAGTTGAACCAGATAATATGGTTCGATGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG,CAREKSVVEPDNMVRWFDPW,91.468
ACS125,gp41-gp120 interface,,H18877 ,,vanSchooten2022(36395347) ,,vanSchooten2022(36395347) ,IMGT/V-QUEST,4-59,,5*02,18.0,VQEKSIAEEDNMVRWFGP,30.0,15.0,3-21*04,1*01,11.0,QLWDSSLDQCV,18.0,7.0,L,,Natural monoclonal,human,, ,90.1082,1.53998,243.0,756.0,4493.0,QVQLQESGPGLVKPSDTLSLTCSVSGVPISRHYWNWIRQPPGKGLEWIGYIFFNGNANYNPSLKSRVTISVDMSKNQISLTLRSVTAADTAVYYCVQEKSIAEEDNMVRWFGPWGQGTLVTISSX,SYELTQPPSVSVAPGKTARITCGGSNLGSKSVHWYQQKPGQAPVNVIYYDSDRPSGIPERFSGSKSGNTATLTISRVEAGDEADYYCQLWDSSLDQCVFGIGTKVTVLX,TCCTATGAGCTGACTCAGCCACCCTCAGTATCAGTGGCCCCAGGAAAGACGGCCAGGATTACCTGTGGGGGAAGTAATCTTGGAAGTAAAAGTGTCCACTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGAACGTCATCTATTATGACAGTGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAAGTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGCGATGAGGCCGATTATTACTGTCAGCTGTGGGATAGTAGTCTTGATCAGTGTGTCTTCGGAATTGGGACCAAGGTCACCGTCCTAG,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGTCTGGTGAAGCCTTCGGACACCCTGTCCCTCACCTGCAGTGTCTCTGGTGTCCCCATCAGTCGTCACTACTGGAATTGGATCCGGCAGCCCCCCGGGAAGGGACTGGAATGGATTGGCTATATCTTTTTCAATGGCAATGCCAATTACAATCCCTCCCTCAAGAGTCGAGTTACCATATCAGTGGACATGTCCAAAAACCAGATCTCCCTGACGCTCCGCTCTGTGACCGCCGCGGACACGGCCGTCTATTACTGTGTGCAAGAAAAGAGTATAGCTGAAGAAGATAATATGGTTCGATGGTTCGGCCCCTGGGGCCAGGGAACCCTGGTCACCATCTCCTCAG,CVQEKSIAEEDNMVRWFGPW,88.737
ACS130,gp120 V3 // V3 glycan (V3g),,H18877 ,,vanSchooten2022(36395347) ,,vanSchooten2022(36395347) ,IMGT/V-QUEST,5-51*01,,4*02,12.0,ARLNGDYAQFDY,23.0,11.0,1-51*01,2*01 or 3*01,10.0,GTWDNSLNAL,21.0,12.0,L,,Natural monoclonal,human,, ,75.5775,2.44419,243.0,757.0,4495.0,QVQLVQSGAEVKKPGESLKISCKGFGYSFTDYWIGWVRQMPGKGLEWMGIIYPHDSDTRYSPSFEGQVTISVDKSTATAYLQRSSLKASDTGKYYCARLNGDYAQFDYWGQGTLVTVSSX,QSALTQPPSVSAAPGQQVTISCSVSSSNIANNYISWYQLVPGTAPKLLIYDNDKRPSGIPDRFTGSKSGTSATLAITGLQTGDEADYYCGTWDNSLNALFGGGTKLTVLX,CAGTCTGCCCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGCAGGTCACCATCTCCTGCTCTGTAAGTAGCTCCAACATTGCGAATAATTATATATCCTGGTATCAGTTAGTCCCAGGAACAGCCCCCAAACTCCTCATTTATGACAATGATAAGCGACCCTCAGGGATTCCTGACCGATTCACTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGAACATGGGATAACAGTCTAAATGCTTTATTCGGCGGAGGGACCAAGCTGACCGTCCTAC,CAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAATCTCTGAAGATCTCCTGTAAGGGTTTTGGATACAGCTTTACCGACTATTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTCATGACTCTGATACCAGATACAGCCCGTCTTTCGAGGGCCAGGTCACCATCTCAGTCGACAAGTCCACCGCCACCGCCTACCTGCAAAGAAGTAGCCTGAAGGCCTCGGACACTGGCAAATATTACTGTGCGAGACTTAACGGTGACTACGCTCAGTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG,CARLNGDYAQFDYW,92.203
ACS202,fusion peptide // near gp41-gp120 interface,6NC2(Env trimer in complex with fusion peptide targeting antibody ACS202 fragment antigen binding);6NCP(structure of HIV-1 broadly neutralizing antibody ACS202);EMD-0433(AMC011 v4.2 SOSIP Env trimer in complex with fusion peptide targeting antibody ACS202 fragment antigen binding);EMD-8299(AMC011 SOSIP trimer in complex with autologous antibody ACS202),D12950 ,,vanGils2016(27841852) ,ACS202 contacts;Mutation affects ACS202 neutralization or binding,vanGils2016(27841852) ,IMGT/V-QUEST,3-30*03,2-8*02,6*02,24.0,CARDRLGRPWNIGGRLVYYYYGMDVW,,,1-33*01,3*01,9.0,QEYENLQFT,,,K,,Natural monoclonal,human,, ,14.5742,20.5094,578.0,303.0,3545.0,EVQLVESGGGVVQPGGSLRLSCAASGFAFKDFGMHWVRQAPGKGLEWVAVIGGGHGQHQSYSESVKGRFAITRDNEKNKLYLHMDRLRTEDTAVYYCAKDRLGRPWNIGGRLVYYYYGMDVWGQGTTATVSS,DIRMTQAPVSLSASVGDRVTITCQASQDIKKSLNWYRQKPSKAPELLIHDASILQTGVPSAFTASGSGTHFSFVINKLQPEDVGTYFCQEYENLQFTFGPGTKVNIK,GACATCCGGATGACCCAGGCTCCAGTCTCCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAAGACATTAAAAAGTCTTTAAATTGGTATCGACAGAAACCAAGCAAAGCCCCTGAACTCCTGATCCACGATGCATCGATTTTGCAAACAGGCGTCCCGTCAGCCTTCACTGCGAGTGGATCTGGGACACATTTTTCTTTTGTCATCAACAAGCTACAGCCTGAAGATGTTGGCACATATTTTTGTCAAGAATATGAAAATCTTCAATTCACTTTCGGCCCTGGGACCAAAGTGAATATCAAA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTTAGACTCAGCTGTGCAGCCTCTGGATTCGCCTTCAAGGATTTTGGCATGCATTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCTGTTATAGGAGGTGGTCATGGACAGCATCAGTCTTATTCCGAGTCGGTGAAGGGCCGATTCGCCATCACCAGAGACAATGAAAAAAACAAACTGTATCTGCACATGGACAGACTGAGGACTGAGGACACGGCTGTCTATTACTGTGCGAAAGATCGATTAGGGAGACCTTGGAATATTGGCGGACGGCTGGTCTATTATTATTATGGAATGGACGTCTGGGGCCAAGGGACCACGGCCACCGTCTCCTCT,CAKDRLGRPWNIGGRLVYYYYGMDVW,83.612
AIIMS-P01,gp120 V3 // V3 glycan (V3g),,AIIMS_330 ,,Kumar2019(30429339) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,3.64015,27.933,127.0,453.0,4035.0,,,,,,
b12,gp120 CD4bs,1HZH(B12 unliganded);1N0X(B12 complexed with mimotope);2NY7(gp120 complexed with Fab b12);3RU8(Fab b12 with epitope scaffold);5VN8(B41 SOSIP.664 in complex with fragment antigen binding variable domain of b12),Donor b ,,Burton1991(1719545) ,"b12 contacts;b12 signature predictions;b12 signature sites;Mutation affects neutralization;Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;Mutation decreases binding to CD4BS mAbs;Mutation increases neutralization sensitivity;mutation increases sensitivity to MPER nAbs;Signature Analysis Summary",Wu2010(20616233) ,IMGT/V-QUEST JoinSolver,1-03*01,3-10*02,6*03,20.0,,13.0,,3-20*01,2*01,9.0,,13.0,,K,Yes,Natural monoclonal,human,"1b12, b4/12, Fab b12, Ib12, IgG1 b12, IgG1-b12, IgGB12, MAb IgG1b12", Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011: %SHM calculated for VH gene IGHV1-3*01 and VL gene IGKV3-20*01 by IMGT/V-QUEST on nt sequences.,29.5033,7.05754,4380.0,40.0,633.0,QVQLVESGPGLVKPSETLSLTCAVSGDSISSTWWNWIRQPPGKGLEWIGRISGDGGNTDYSPSLKSRVTISTDTSKNQLSLRLTSVAAADTAVYFCAAPDCSGPDCSPGFDYWGPGVLVTVSS,QPVLTQPPSVSGAPGQRVTISCTGSSSDIGRFYVQWYQQLPGTAPKLLIYENTKRPSGISDRFSGSQSGPSASLTITGLQSEDEADYYCQSYDSSMSAHVLFGGGTRLTVL,,CTCGAGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCTTGTCAGGCTTCTGGATACAGATTCAGTAACTTTGTTATTCATTGGGTGCGCCAGGCCCCCGGACAGAGGTTTGAGTGGATGGGATGGATCAATCCTTACAACGGAAACAAAGAATTTTCAGCGAAGTTCCAGGACAGAGTCACCTTTACCGCGGACACATCCGCGAACACAGCCTACATGGAGTTGAGGAGCCTCAGATCTGCAGACACGGCTGTTTATTATTGTGCGAGAGTGGGGCCATATAGTTGGGATGATTCTCCCCAGGACAATTATTATATGGACGTCTGGGGCAAAGGGACCACGGTCATCGTCTCCTCAGCCTCCACCAAGGG,CARVGPYSWDDSPQDNYYMDVW,87.413
nan,,,,,,,Zhang2013(24100711) ,IMGT/V-QUEST,1-03*01,2-21*01,6*03,20.0,,,,3-20,2,9.0,,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Barbas1993(8478936) ,,,,6,18.0,VGPYSWDDSPQDNYYMDV,,,,2,9.0,QVYGASSYT,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Wu2011(21835983) ,,,,,,,12.5,20.4,,,,,15.5,22.7,,,,,,,,,,,,,,,,,
b13,gp120 CD4bs,3IDX(gp120 core in complex with b13);3IDY(gp120 core in complex with b13),Donor b ,,Burton1991(1719545) ,Mutations at the trimer apex that affect sensitivity,Barbas1993(8478936) ,,,,4,19.0,DIGLKGEHYDILTAYGPDY,,,,4,9.0,QQHQNVPLT,,,K,,Natural monoclonal,human,, ,71.9753,3.28219,181.0,76.0,642.0,QVQLQESGPGLVKPSETLSLTCAVSGGSISGNYWSWIRQSPGKGLEWIGHINDYSGRTDYNPSLKSRVTISTDTSTNQFFLTLSSVSAADTAVYYCARRDTDFWRGIYVFEFWGQGVLVTVSS,QSVLTQSPSASASLGASVKLTCTLSSGLRSYTIAWYQRQRGQAPRFLLRLDSVGSHTKVDGIPDRFSGSSSGTERYLTISNLQSEDEADYFCQTWTTGIYIFGGGTRLSVL,,CTCGAGCAGTCTGGGGAAGCCGTGGTCCAGCCTGGGACGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGGAACTATGCCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTTGCACTTATAAAATATGATGGAAGAAATAAGTACTACGCAGATTCCGTGAAGGGCCGATTCAGCATTTCCAGAGACAATTCCAAGAACACGTTGTATCTGGAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTCTATTACTGTGCGAGAGATATTGGGTTAAAGGGCGAGCATTACGACATTTTGACTGCTTACGGCCCCGACTACTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCAGCCTCCACCAA,CARDIGLKGEHYDILTAYGPDYW,92.334
B21,gp120 CD4bs,,llama#3 ,,McCoy2014a(25522326) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,B21 VHH,llama antibody ,2.9596,17.6827,61.0,195.0,3220.0,EVQLVESGGGLVQAGGSLRLSCEASTSMFSIRAATWYRQAPGKQRELVANIDSEGTTGYSDSVKGRFTISRDNTKKTVYLQMNSLKPEDTAVYSCNAVVTYNMLVYDSWGQGTQVTVSS,,,,,
b6,gp120 CD4bs,,Donor b ,,Burton1991(1719545) ,MPER membrane fusion mutations confer sensitivity;Mutation decreases binding to CD4BS mAbs;Mutation increases neutralization sensitivity,Barbas1993(8478936) ,,,,3,22.0,QKPRYFDLLSGQYRRVAGAFDV,,,,2,9.0,QQYGTSPYT,,,K,Yes,Natural monoclonal,human,IgG1b6, ,,,87.0,476.0,641.0,LEESGGGLVKPGGSLRLSCVGSGFTFSSAWMAWVRQAPGRGLEWVGLIKSKADGETTDYATPVKGRFSISRNNLEDTVYLQMDSLRADDTAVYYCATQKPRYFDLLSGQYRRVAGAFDVWGHGTTVTVSP,ELTQSPGTLSLSPGERATLSCRAGQSISSNYLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTDFTLSISRLEPEDFAVYYCQQYGTSPYTFGQGTQLDIKRT,,,,
B9,gp120 CD4bs,,llama#1 ,,McCoy2014a(25522326) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,B9 VHH,llama antibody ,1.76635,20.2176,61.0,194.0,3219.0,QGQLVQSGAELKKPGDSVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVIMTTDNEVPVTAFTSTGTAYMEIRNLRFDDTGIYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSALTQPASVSGSLGQSVTISCTGPNSACCSHKSISWHQWPPGRAPTLIIYEDNEKAPGISHRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCTTGGACAGTCGGTCACCATCTCCTGCACTGGACCCAATAGTGCTTGTTGCAGTCACAAATCTATCTCCTGGCATCAGTGGCCCCCAGGCAGAGCCCCCACACTCATCATTTATGAGGACAATGAAAAGGCCCCGGGAATCTCTCATCGCTTCTCTGGCTACAAGTCGTATTGGTCGGCCTACTTGACAATCTCTGATCTCCGGCCTGAAGACGAGACCACTTACTATTGTTGCTCATACACTCACAATAGCGGCTGTGTCTTCGGGACTGGGACCAAGGTCTCCGTCTTG,CAGGGTCAACTAGTCCAGTCTGGAGCTGAGTTGAAAAAGCCTGGCGACTCGGTGAAGATTTCCTGTAAGACTTCGGGTTATAGGTTTAATTTCTATCATATTAATTGGATTCGACAAACTGCAGGACGTGGACCTGAGTGGATGGGATGGATCAGCCCTTACAGTGGTGACAAAAACCTCGCACCTGCCTTTCAAGACAGAGTCATTATGACCACAGACAATGAAGTCCCTGTGACCGCATTCACGTCCACGGGCACAGCCTACATGGAAATAAGGAATCTGAGATTTGACGACACAGGCATCTATTTTTGTGCGAAAGGCCTACTGCGTGACGGTTCGTCGACGTGGCTTCCTTATTTGTGGGGCCAGGGTACCCTGCTCACCGTCTCGTCA,CAKGLLRDGSSTWLPYLW,70.533
BE10,,,GX2016EU04 ,,Ju2018(30382080) ,,Ju2018(30382080) ,IMGT/V-QUEST,3-23*04,3-16*02,6*02,21.0,VKGLQASVHDWLWDGYRSPGA,19.44,,1-16*01,1*01,9.0,QQDKYYPWT,10.61,,K,,Natural monoclonal,human,, ,100.0,1.0,14.0,568.0,4178.0,,,,,,
BE7,,,GX2016EU04 ,,Ju2018(30382080) ,,Ju2018(30382080) ,IMGT/V-QUEST,1-69*11,3-22*01,3*01,17.0,ARAYYYDTTTGLGAMDV,16.32,,4-1*01,3*01,9.0,HQFHSSPIT,7.8,,K,,Natural monoclonal,human,, ,29.3592,17.219,14.0,566.0,4176.0,,,,,,
BF520.1,gp120 V3 // V3 glycan (V3g),6MN7(BG505.SOSIP.664 in complex with BF520.1 antigen binding fragment),BF520 ,BF520,Simonich2016(27345369) ,,Simonich2016(27345369) ,IMGT/V-QUEST,1-2,3-10,4,20.0,ARGPFPNYYGPGSYWGGLDF,6.6,11.2,3-15,3,11.0,QQYNNWPSPFT,5.0,11.6,K,,Natural monoclonal,human,, Simonich2016 %SHM calculated for VH and VL only.,17.1989,7.78369,76.0,373.0,3398.0,QVQLVQSGAEMKMPGASVKVSCKASGYTFTGNYIHWVRQAPGQGLEWMGWIAPHSGDTSYAQRFQGRVTMTGDTSLSTAYMELSRLRSDDTAVYYCARGPFPNYYGPGSYWGGLDFWGQGTLVSVSSX,EIVMTQSPATLSVSLGERATLSCRTSQNVAYNFAWYQQKPGQAPRLLIYEASSRATGTPARFSGSGFGTEFTLTISSMQSEDFAVYYCQQYNNWPSPFTFGPGTKVHIKX,GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCTAGGGGAAAGAGCCACCCTCTCCTGCAGGACCAGTCAGAATGTTGCCTACAACTTTGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGAAGCATCCAGCAGGGCCACTGGTACCCCAGCCAGGTTCAGTGGCAGTGGGTTTGGGACAGAGTTCACTCTCACCATCAGCAGCATGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTTCCCCATTCACTTTCGGCCCTGGGACCAAAGTGCATATCAAAC,CAGGTGCAGTTGGTACAGTCTGGGGCTGAGATGAAAATGCCTGGGGCCTCAGTAAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGGCAACTATATACATTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCGCCCCTCACAGTGGTGACACAAGCTATGCACAGAGGTTTCAGGGCAGGGTCACCATGACCGGGGACACGTCCCTCAGCACAGCCTACATGGAGCTCAGCAGGCTGAGATCTGACGACACGGCCGTCTATTACTGTGCGAGAGGGCCGTTCCCCAATTACTATGGTCCGGGAAGTTATTGGGGGGGTTTAGACTTCTGGGGCCAGGGAACCCTGGTCAGCGTCTCCTCAG,CARGPFPNYYGPGSYWGGLDFW,93.559
BF520.1-A52N(HC),gp120 V3 // V3 glycan (V3g),,BF520 ,BF520,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,20.9761,5.02805,13.0,745.0,4434.0,,,,,,
BF8,,,GX2016EU04 ,,Ju2018(30382080) ,,Ju2018(30382080) ,IMGT/V-QUEST,1-69*01,3-22*01,3*01,17.0,ARDLYYDTTTGLGAMDV,14.24,,4-1*01,3*01,9.0,QQYHSDPLT,10.64,,K,,Natural monoclonal,human,, ,31.9421,12.6671,14.0,563.0,4173.0,,,,,,
BG1,gp120 V1-V2,5VIY(BG505 SOSIP.664 in complex with antibodies BG1 and 8ANC195);5VVF(BG1 Fab),EB354 ,,Freund2017(28100831) ,,Freund2017(28100831) ,IMGT/V-QUEST,3-49,,,22.0,EQRNKDYRYGQEGFGYSYGMDV,27.2,,1-39,,,,19.9,,K,,Natural monoclonal,human,354BG1, Freund2017 %SHM calculated for VH and VL only.,16.3123,16.1097,242.0,306.0,3622.0,AEQLVESGGGLVPPGRSLRLSCSASGFYFPDYAMAWVRQAPGQGLQWVGFMRGWAYGGSAQFAAFAVGKFAISRDDGRNVVYLDVKNPTFEDTGVYFCAREQRNKDYRYGQEGFGYSYGMDVWGRGTTVVVSTASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKGLEVLFQHHHHHH,DIHMTQSPVSLSASVGDRVTITCRASHFIANYVNWYQQKPGKAPTLLIFESSTLQRGVPSRFSAYGDGTEFTLSINTLQPEDFASYICQQSHSPPVTFGAGTRVDQKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,,,,
BG18,gp120 V3 // V3 glycan (V3g),6CH7(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH8(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH9(A natively-glycosylated B41 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CHB(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and IOMA),EB354 ,BG18,Freund2017(28100831) ,BG18 contacts;BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7),Freund2017(28100831) ,IMGT/V-QUEST,4-4,,,21.0,NAIRIYGVVALGEWFHYGMDV,21.2,,3-25,,11.0,QSSDTSDSYKM,17.7,,L,,Natural monoclonal,human,354BG18, Freund2017 %SHM calculated for VH and VL only.,0.66662,95.1206,289.0,308.0,3623.0,QVQLRESGPGLVKPSETLSLSCTVSNDSRPSDHSWTWVRQSPGKALEWIGDIHYNGATTYNPSLRSRVRIELDQSIPRFSLKMTSMTAADTGMYYCARNAIRIYGVVALGEWFHYGMDVWGQGTAVTVSS,SSELTQPPSVSVSPGQTARITCSGAPLTSRFTYWYRQKPGQAPVLIISRSSQRSSGWSGRFSASWSGTTVTLTIRGVQADDEADYYCQSSDTSDSYKMFGGGTKLTVL,,,,
BG24,gp120 CD4bs,7UCE(BG24 Fab fragment);7UCF(BG505 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24);7UCG(DU422 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24);7UGM(BG24-iGL CDR3mat Fab);7UGN(BG24 inferred germline Fabs with germline CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1);7UGO(BG24 inferred germline Fabs with mature CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1);7UGP(BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan);7UGQ(BG24 Fabs with an inferred germline CDRL1 and 10-1074 Fabs in complex with HIV-1 Env 6405-SOSIP.664);EMD-26443(DU422 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24);EMD-26490(Cryo-EM structure of BG24 inferred germline Fabs with germline CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 - Class 1);EMD-26491(Cryo-EM structure of BG24 inferred germline Fabs with germline CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 - Class 2);EMD-26492(Cryo-EM structure of BG24 inferred germline Fabs with mature CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1);EMD-26493(Cryo-EM structure of BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan- Class 1);EMD-26494(Cryo-EM map of BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan- Class 2);EMD-26495(Cryo-EM map of BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan- Class 3);EMD-26496(Cryo-EM structure of BG24 Fabs with an inferred germline CDRL1 and 10-1074 Fabs in complex with HIV-1 Env 6405-SOSIP.664),391370 ,BG24,Barnes2022(35960796) ,BG24 contacts;Mutation abrogates BG24 OR VRC01 neutralization;Mutations associated with immunotherapy with BG24 or VRC01,Barnes2022(35960796) ,IgBlast IMGT/V-QUEST,1-02*02,,,16.0,ATQVKLDSSAGYPFDI,13.4,22.7,2-11*01,,5.0,SAFEY,8.0,19.5,L,,Natural monoclonal,human,, ,0.75835,12.2741,316.0,633.0,4243.0,QVQLVQSRAEVKKPGASVKVSCEASGYNFVDHYIHWVRQAPGQRPQWVGWMNPRGGGVNYSQRFQGRVTMTRDTSIDTAYMQLNRLTSGDTAVYYCATQVKLDSSAGYPFDIWGQGTMVTVSA,QSALTQPRSVSGSPGQSVNISCTGAYSGLGWYQQHPGRAPKLIIYEVNRRPSGVSDRFSGSKSGNTASLTISGLRTEDEADYFCSAFEYFGEGTKLTVL,CAGTCTGCCCTGACTCAGCCTCGCTCAGTGTCCGGGTCTCCTGGACAGTCAGTCAACATCTCCTGCACTGGAGCCTACAGTGGTCTTGGCTGGTACCAACAACACCCAGGCAGAGCCCCCAAACTCATAATTTATGAAGTCAATAGGCGGCCCTCAGGGGTCTCTGATCGCTTCTCTGGCTCCAAGTCTGGTAACACGGCCTCCCTGACCATCTCTGGGCTCCGGACTGAGGATGAGGCTGATTATTTCTGCTCCGCATTTGAATACTTCGGCGAAGGGACTAAACTGACCGTCCTA,CAGGTGCAGTTGGTGCAGTCTAGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCGAGGCTTCTGGATACAATTTCGTCGACCACTATATACATTGGGTGCGACAGGCCCCTGGACAAAGGCCTCAGTGGGTGGGGTGGATGAACCCTAGGGGAGGTGGCGTAAATTATTCACAGAGATTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCGACACAGCCTACATGCAACTGAACAGACTGACCTCTGGCGACACGGCCGTATACTATTGTGCGACTCAAGTGAAACTGGATTCCTCGGCAGGATATCCTTTTGATATTTGGGGCCAAGGAACAATGGTCACAGTGTCTGCA,CATQVKLDSSAGYPFDIW,86.644
BG24-CDR2-v1,gp120 CD4bs,,391370 ,BG24,Barnes2022(35960796) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,BG24-PG20-CDR2-v1, ,0.22486,10.727,254.0,638.0,4248.0,,,,,,
BG24-CDR2-v2,gp120 CD4bs,,391370 ,BG24,Barnes2022(35960796) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,BG24-PG20-CDR2-v2, ,0.23641,9.44785,254.0,639.0,4249.0,,,,,,
BG24-G54W,gp120 CD4bs,,391370 ,BG24,Barnes2022(35960796) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.31771,12.7243,254.0,637.0,4247.0,,,,,,
BG24-Y100DW,gp120 CD4bs,,391370 ,BG24,Barnes2022(35960796) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,3.0299,17.5689,252.0,640.0,4250.0,,,,,,
BG33,gp120 CD4bs,,391370 ,BG24,Barnes2022(35960796) ,,Barnes2022(35960796) ,IgBlast IMGT/V-QUEST,1-02*02,,,16.0,ASQVAVGDSTHYPFDV,14.7,26.8,2-11*01,,5.0,SAFEF,6.9,12.8,L,,Natural monoclonal,human,, ,8.17514,15.7693,30.0,635.0,4245.0,QAQLFQSRAEAKKPGASVRVSCEASGYNFIDHYVHWVRQAPGQGLEWVGWMKPYRGAVNYSWKFQGRVTMTRDLSVNTAYMELRRLQFDDTAVYYCASQVAVGDSTHYPFDVWGQGTMVTVSS,QSALTQPRSVSGSPGQSVTISCTGTNSGVGWYQQRPGKAPKLVIYDVDRRPSGVPDRFSGSKSGDTASLAISGLQPEDEADYYCSAFEFFGRGTKLTVL,CAGTCTGCCCTGACTCAGCCTCGCTCAGTGTCCGGGTCTCCTGGACAGTCAGTCACCATCTCCTGCACTGGAACCAACAGTGGTGTTGGTTGGTACCAACAACGCCCAGGCAAAGCCCCCAAACTCGTAATTTATGATGTCGATAGACGGCCCTCAGGGGTCCCTGATCGCTTCTCTGGCTCCAAGTCTGGCGACACGGCCTCCCTGGCCATCTCTGGGCTCCAGCCTGAGGATGAGGCTGATTATTATTGTTCCGCATTTGAATTCTTCGGCAGGGGGACCAAGCTGACCGTCCTA,CAGGCGCAGTTGTTCCAGTCTAGGGCTGAGGCGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCGAGGCTTCTGGATACAATTTCATCGACCACTATGTCCACTGGGTGCGACAGGCCCCCGGGCAAGGCCTTGAGTGGGTGGGGTGGATGAAGCCTTACAGAGGTGCCGTGAACTATTCATGGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACCTGTCCGTCAACACAGCCTACATGGAACTAAGGAGGCTGCAATTTGACGACACGGCCGTCTATTATTGTGCGAGTCAGGTGGCGGTGGGTGACTCCACACATTATCCCTTTGATGTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA,CASQVAVGDSTHYPFDVW,85.324
BG38,gp120 CD4bs,,391370 ,BG24,Barnes2022(35960796) ,,Barnes2022(35960796) ,IgBlast IMGT/V-QUEST,1-02*02,,,16.0,ATQVAVAASTGWAFDV,18.2,28.9,2-11*01,,5.0,SAFEY,10.7,17.2,L,,Natural monoclonal,human,, ,1.7106,24.7647,40.0,636.0,4246.0,RGQLVQSRAEVKKPGASVRVSCEASGYNFIDHYVHWVRQAPGQGLQWVGWMNPRGGGVNYSGRFRGRVTMTRVMSMDTDTAYMELKSLQGDDTAVYYCATQVAVAASTGWAFDVWGQGTMVTVSP,QSALTQPRSVSGSPGQSVTISCTGTNSGTAWFQKQPGKAPKLLIFDVSGRPSGVPDRFSGSKSGNTASLTISGLQPDDEADYYCSAFEYFGGGTKLTVL,CAGTCTGCCCTGACTCAGCCTCGCTCAGTGTCCGGGTCTCCTGGACAGTCAGTGACCATCTCGTGCACTGGAACCAACAGTGGTACTGCTTGGTTCCAAAAACAGCCAGGCAAAGCCCCCAAACTCCTAATATTCGATGTCAGTGGGCGGCCCTCAGGGGTCCCTGATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATTTCTGGGCTCCAGCCTGACGATGAGGCTGATTACTATTGTTCCGCATTTGAATACTTCGGCGGAGGGACCAAGTTGACCGTCCTG,CGGGGGCAATTGGTGCAGTCCAGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCGAGGCTTCTGGATACAATTTCATCGACCATTATGTCCACTGGGTGCGACAGGCCCCTGGACAAGGCCTTCAGTGGGTTGGATGGATGAACCCTCGCGGAGGTGGCGTGAATTACTCAGGGAGGTTTCGGGGCAGGGTCACCATGACCAGGGTGATGTCCATGGACACCGACACAGCCTACATGGAACTGAAGAGCCTACAAGGTGACGACACGGCCGTCTATTATTGTGCGACTCAAGTGGCGGTGGCTGCCTCAACAGGTTGGGCCTTTGATGTCTGGGGCCAAGGGACCATGGTCACCGTCTCTCCG,CATQVAVAASTGWAFDVW,80.537
BG5,gp120 CD4bs,,391370 ,BG24,Barnes2022(35960796) ,,Barnes2022(35960796) ,IgBlast IMGT/V-QUEST,1-02*02,,,16.0,ATRVKLPSSDDYGFDV,17.6,32.3,2-11*01,,5.0,SSYEF,7.1,13.5,L,,Natural monoclonal,human,, ,6.22045,30.5647,30.0,634.0,4244.0,QVLVQSRAEVKKPGASVRVSCEASGYNFIDHIIHWVRQVPGQRPEWMGWMKARGGAVNYARSFRGRITLTRQMSMDTDMAYMDLSRLRPDDTAVYYCATRVKLPSSDDYGFDVWGQGTLVKVSV,QSALTQPHSVSGSPGQSVTISCTGLSGYVDVVWYQQHPGKAPKLIIYDVNRRPSGVPDRFSGSKSGNTASLTISGLRAEDEADYFCSSYEFFGGGTRVTVL,CAGTCTGCCCTGACTCAGCCTCACTCAGTGTCCGGGTCTCCTGGACAGTCAGTCACCATCTCCTGCACTGGACTCAGCGGTTATGTTGATGTTGTTTGGTACCAACAGCACCCAGGCAAAGCCCCTAAACTCATCATTTATGATGTCAATAGGCGGCCCTCAGGGGTCCCTGATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCGGGCTGAAGATGAAGCTGATTATTTCTGCTCCTCATATGAATTCTTCGGCGGGGGGACCAGGGTGACCGTCCTA,CAGGTTCTGGTGCAATCTAGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGAGTCTCCTGCGAGGCTTCTGGATACAATTTTATCGACCACATTATACACTGGGTGCGACAGGTCCCTGGACAGAGGCCTGAGTGGATGGGATGGATGAAGGCTAGGGGAGGTGCCGTAAACTATGCACGAAGTTTTCGGGGCAGGATCACCTTGACCAGGCAAATGTCCATGGACACCGACATGGCCTACATGGACCTAAGCAGGCTGCGGCCCGACGACACGGCCGTGTATTATTGTGCGACCAGAGTGAAACTGCCTTCCTCAGACGACTATGGTTTTGATGTCTGGGGCCAAGGGACATTGGTCAAAGTCTCCGTA,CATRVKLPSSDDYGFDVW,79.661
BG8,gp120 V3 // V3 glycan (V3g),,EB354 ,BG18,Freund2017(28100831) ,,Freund2017(28100831) ,IMGT/V-QUEST,4-4,,,21.0,NVIRVFGFISLGEWFHYGMDV,25.4,,3-25,,11.0,QSSDTSDSYKM,20.5,,L,,Natural monoclonal,human,354BG8, Freund2017 %SHM calculated for VH and VL only.,1.84643,43.5005,234.0,307.0,3629.0,,,,,,
BiIA-DG,gp120 V3 // V3 glycan (V3g);non-HIV: host CD4R,,Donor 36 ,,Wu2018(29461979) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,"An engineered tandem bispecific bnAb composed from PGT128, iMab, and ImmunoAdhesin ",0.44461,16.383,40.0,375.0,3915.0,,,,,,
BiIA-SG,gp120 V3 // V3 glycan (V3g);non-HIV: host CD4R,,Donor 36 ,,Wu2018(29461979) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,"An engineered tandem bispecific bnAb composed from PGT128, iMab, and ImmunoAdhesin ",0.016005,9.66693,129.0,374.0,3907.0,,,,,,
Bi-NAb,gp120 CD4bs;gp120 V3 // V3 glycan (V3g),,Donor 17 NIH45 ,,Steinhardt2018(29491415) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,Bi-NAb dVRC01-5X-PGT121,bispecific involving VRC01 and PGT121 ,0.39295,7.9911,416.0,384.0,3921.0,,,,,,
BISC-1A,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g),,CAP256 Donor 17 ,,Davis-Gardner2020(31937648) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific composed of VRC26.25 scFv and 10-1074 ,0.022901,9.61404,30.0,767.0,4519.0,,,,,,
BISC-1B,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g),,CAP256 Donor 17 ,,Davis-Gardner2020(31937648) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific composed of VRC26.25 scFv and PGT121 ,0.024083,6.91222,30.0,768.0,4520.0,,,,,,
BISC-1C,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g),,CAP256 Donor 36 ,,Davis-Gardner2020(31937648) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific composed of VRC26.25 scFv and PGT128 ,0.012858,3.94184,30.0,769.0,4521.0,,,,,,
BISC-2A,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g),,Donor 17 Donor 84 ,,Davis-Gardner2020(31937648) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific composed of PGT145 scFv and 10-1074 ,,,18.0,770.0,4522.0,,,,,,
BISC-2B,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g),,Donor 17 Donor 84 ,,Davis-Gardner2020(31937648) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific composed of PGT145 scFv and PGT121 ,,,18.0,771.0,4523.0,,,,,,
BISC-2C,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g),,Donor 36 Donor 84 ,,Davis-Gardner2020(31937648) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific composed of PGT145 scFv and PGT128 ,,,18.0,772.0,4524.0,,,,,,
Bi-ScFv,gp120 CD4bs;gp120 V3 // V3 glycan (V3g),,Donor 17 NIH45 ,,Steinhardt2018(29491415) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,Bi-ScFv dVRC01-5X-PGT121,bispecific involving VRC01 and PGT121 ,0.14478,11.9134,416.0,385.0,3958.0,,,,,,
C8,gp120 CD4bs,,llama#44 ,,Forsman2008(18842738) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH C8,llama antibody ,52.7405,3.87312,89.0,192.0,1862.0,,,,,,
CAP228-16H,gp120 V2 // V2 glycan(V2g) // V2 apex,6FY1(CAP228-16H in complex with a scaffolded autologous V1V2);6FY2(CAP228-16H in complex with a heterologous CAP225 V1V2),CAP228 ,CAP228-16H,vanEeden2018(30540944) ,Contacts of IGHV5-51 V2 antibodies,vanEeden2018(30540944) ,IMGT/V-QUEST,5-51*03,10*01,3*02,16.0,ARHGRGVREVINAFDI,4.9,,3-21*01,2*01,11.0,QVWHSTSAVVF,8.3,,L,Yes,Natural monoclonal,human,, ,,,12.0,626.0,4026.0,EVQLVQSGAEVKKPGESLKISCKGSGYRFPSSWIGWVRQVPGKGLEWMGIIYPGDGETRYRASFQGQVTISADQSSNTAYLQWSSLKASDTAMYYCARHGRGVREVINAFDIWGQGTMVTVSS,SYELTQPPSVSVAPGTTATITCGGVDIGSTLVHWYQQRPGQAPLLVIYDDSDRPSGIPERFSGSNSGNMATLTISRVEAGDEADYYCQVWHSTSAVIFGGGTKLTVL,TCTTATGAGCTGACTCAGCCACCCTCAGTGTCAGTGGCCCCAGGAACGACGGCCACCATTACCTGTGGGGGAGTCGACATTGGAAGTACTCTTGTCCACTGGTACCAGCAGAGGCCAGGCCAGGCCCCTCTCCTGGTCATCTATGATGATTCCGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACATGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTATTGTCAGGTGTGGCATAGTACCAGTGCCGTGATATTCGGCGGAGGGACCAAGCTGACCGTCTTA,GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCGGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGATTTCCCAGCTCTTGGATCGGCTGGGTGCGCCAGGTGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACGGTGAAACCAGATACAGGGCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACCAGTCCAGCAACACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCAGACACCGCCATGTATTACTGTGCGAGACATGGGCGAGGGGTTCGGGAAGTTATTAATGCTTTTGATATTTGGGGCCAAGGGACTATGGTCACCGTCTCGTCA,CARHGRGVREVINAFDIW,95.270
CAP228-19F,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP228 ,CAP228-16H,vanEeden2018(30540944) ,,vanEeden2018(30540944) ,IMGT/V-QUEST,5-51*03,10*01,3*02,16.0,ARHGRGVREVINAFDI,4.9,,3-21*01,2*01,11.0,QVWHSTSAVVF,8.3,,L,Yes,Natural monoclonal,human,, ,,,12.0,627.0,4027.0,EVQLVQSGAEVKKPGESLKISCKGSGYRFPSSWIGWVRQVPGKGLEWMGIIYPGDGETRYRASFQGQVTISADQSTNTAYLQWSSLKASDTAMYYCARHGRGVREVINAFDIWGQGTMVTVSS,SYELTQPPSVSVAPGTTATITCGGVDIGSTLVHWYQQRPGQAPLLVIYDDSDRPSGIPERFSGSNSGNMATLTISRVEAGDEADYYCQVWHSTSAVIFGGGTKLTVL,TCTTATGAGCTGACTCAGCCACCCTCAGTGTCAGTGGCCCCAGGAACGACGGCCACCATTACCTGTGGGGGAGTCGACATTGGAAGTACTCTTGTCCACTGGTACCAGCAGAGGCCAGGCCAGGCCCCTCTCCTGGTCATCTATGATGATTCCGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACATGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTATTGTCAGGTGTGGCATAGTACCAGTGCCGTGATATTCGGCGGAGGGACCAAGCTGACCGTCTTA,GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCGGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGATTTCCCAGCTCTTGGATCGGCTGGGTGCGCCAGGTGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACGGTGAAACCAGATACAGGGCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACCAGTCCACCAACACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCAGACACCGCCATGTATTACTGTGCGAGACATGGGCGAGGGGTTCGGGAAGTTATTAATGCTTTTGATATTTGGGGCCAAGGGACTATGGTCACCGTCTCGTCA,CARHGRGVREVINAFDIW,95.270
CAP228-3D,gp120 V2 // V2 glycan(V2g) // V2 apex,6FY3(CAP228-3D bound to a heterologous V2 peptide),CAP228 ,,vanEeden2018(30540944) ,Contacts of IGHV5-51 V2 antibodies,vanEeden2018(30540944) ,IMGT/V-QUEST,5-51*03,3-22*01,2*01,19.0,ARLLNNYDSSGFLYWYLDL,3.9,,6-57*01,3*02,11.0,ADYYCQSYDMT,2.1,,L,Yes,Natural monoclonal,human,, ,,,14.0,628.0,4028.0,EVQLVQSGAEVKKPGESLKISCKGFGYSFSTYWIAWVRQMPGKGLEWMGMIYPGDSDTKYSPSLQGQVTISGDKSISTAYLQWSSLKASDTAMYYCARLLNNYDSSGFLYWYLDLWGRGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASDYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDMTNHNWVFGGGTKLTVL,AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCCGCAGTAGTGGCAGCATTGCCAGCGACTATGTGCAGTGGTACCAGCAGCGCCCGGGCAGTTCCCCCACCACTGTGATCTATGAGGATAACCAAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGACAGCTCCTCCAACTCTGCCTCCCTCACCATCTCTGGACTGAAGACTGAGGACGAGGCTGACTACTATTGTCAGTCTTATGATATGACCAATCATAATTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTA,GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAGAAGCCGGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTTTGGATACAGCTTTTCCACCTACTGGATCGCCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGCATGATCTATCCTGGTGACTCTGATACCAAATACAGCCCGTCCTTACAAGGCCAGGTCACCATCTCAGGCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTATTGTGCGAGACTTCTGAATAACTATGATAGTAGTGGCTTCCTCTACTGGTATCTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCA,CARLLNNYDSSGFLYWYLDLW,96.271
CAP248-2B,fusion peptide // near gp41-gp120 interface,5F89(Unliganded Fab from CAP248-2B);5MP6(Unliganded Fab from CAP248-2B),CAP248 ,,Wibmer2017(28076415) ,Mutation affects neutralization by CAP248-2B,Wibmer2017(28076415) ,IMGT/V-QUEST,4-31*05,6-13*01,3*02 or 3*01,15.0,EASTKITDDGGAFDF,13.54,,2-14*01,1*01,19.0,SSYTTKKTSFFGPATRAYV,9.72,,L,,Natural monoclonal,human,, ,44.1122,10.1748,19.0,570.0,3639.0,QVQLQQSGPGLVKPSQTLSLTCNVYGVAISNEDYYWTWIRQHPGKGLEWIGDIYYNSGTTHYNPSLKSRASVSVDLSRNQFTLKVTSVTTADAAVYYCAREASTKITDDGGAFDFWGRGTMVTVSS,QSALTQPASVSGSPGQSISISCTGTSSDIGGYKYVSWYQQHPGRAPKLIIYDVIKRPSGISDRFSGSKSANTASLTISGLQAGDEASYYCSSYTTKKTSFFGPATRAYVFGSGTQVTVL,,,,
CAP256.J3LS,gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex,8FIS(Bispecific CAP256V2LS-J3 Fab in complex with BG505 DS-SOSIP.664),CAP256 llama#8 ,,Zhang2023(36729903) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;llama,CAP256V2LS-J3,Bispecific involving VRC26.25 and llama antibody J3 ,0.017457,14.4059,616.0,760.0,4497.0,,,,,,
CAP256V2LS,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,,Zhang2022(36284200) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.11433,207.014,616.0,550.0,4153.0,,,,,,
CAP256V2LS-J3-3,gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 llama#8 ,,Zhang2023(36729903) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;llama,, ,0.012141,12.4808,416.0,763.0,4499.0,,,,,,
CAP257-RH1,gp120 CD4bs,5T33(CAP257-RH1 in complex with strain RHPA gp120 core with an oligomannose N276 glycan),CAP257 ,,Wibmer2016(27581986) ,CAP257-RH1 contacts;Mutation affects CAP257-RH1 neutralization,Wibmer2016(27581986) ,IMGT/V-QUEST,3-33*03,,6*03,11.0,AGGGKYDYLDV,8.68,,3-10*01,3*02,11.0,FSTDSSGQTWV,8.96,,L,,Natural monoclonal,human,, ,96.2519,1.70482,196.0,304.0,3544.0,QVQLVESGGGLFQPGRSLRLSCVASGFSFNEKAMHWVRQAPGKGLEWVAIIWYNSIHKNYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCANAGGGKYDYLDVWGRGTTVTVSS,SYELTQPPSVSVSPGQTARITCSGDTLSTKWSYWCQQKSGQAPVLVIYEGNKRFSGTPAKFSGFHSGTMATLTISGAQVDDEADYYCFSTDSSGQTWVFGGGTKLTVL,,,,
CD4-Ig,,,,,,,,,,,,,,,,,,,,,,,,,,, ,2.31306,7.65452,1061.0,22.0,,,,,,,
CH01,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CH0219 ,CH01,Bonsignori2011(21795340) ,CH01 signature sites;Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;L184F escapes V2-targeting bnAbs;Mutation affects neutralization by V1V2 glycan mAbs;Mutation affects PG9-like Ab sensitivity;PG9-like antibodies require N160 for neutralization;PG9-like contacts;V2 Signature Analysis Summary,Andrabi2015(26588781) ,IMGT/V-QUEST,3-20*01,3-10*01,2*01,26.0,,17.0,,3-20*01,1*01,9.0,,11.0,,K,,Natural monoclonal,human,, ,11.7528,10.6929,1029.0,84.0,2655.0,EVQLVESGANVVRPGGSLRLSCKASGFIFENFGFSWVRQAPGKGLQWVAGLNWNGGDTRYADSVKGRFRMSRDNSRNFVYLDMDKVGVDDTAFYYCARGTDYTIDDAGIHYQGSGTFWYFDLWGRGTLVSVSSX,EIVLAQSPGTLSLSPGERATLSCRASHNVHPKYFAWYQQKPGQSPRLLIYGGSTRAAGIPGKFSGSGSGTDFTLTISRVDPEDFAVYYCQQYGGSPYTFGQGTKVEIKX,GAAATTGTGTTGGCGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCACAATGTCCACCCCAAATATTTCGCCTGGTACCAGCAGAAGCCTGGCCAGTCTCCCCGACTCCTCATCTATGGTGGGTCCACCAGGGCCGCTGGCATTCCAGGCAAGTTCAGCGGCAGTGGGTCTGGGACCGACTTCACTCTCACCATCAGTCGAGTGGACCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATGGTGGCTCCCCGTACACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAC,GAGGTTCAGCTGGTGGAGTCTGGGGCAAATGTTGTACGGCCGGGGGGGTCCCTGAGACTCTCCTGTAAAGCGTCCGGATTCATCTTTGAAAATTTTGGTTTTAGTTGGGTCCGCCAGGCTCCAGGGAAGGGGCTTCAGTGGGTCGCTGGTCTTAATTGGAATGGTGGTGACACACGTTATGCAGACTCTGTGAAGGGCCGATTCAGAATGTCCAGAGACAACTCCAGGAATTTTGTGTATTTGGACATGGATAAAGTGGGAGTCGACGACACGGCCTTCTATTACTGTGCGAGAGGGACCGATTACACTATTGACGACGCGGGGATCCATTACCAAGGTTCGGGGACCTTCTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCAGTGTCTCTTCAG,CARGTDYTIDDAGIHYQGSGTFWYFDLW,84.068
nan,,,,,,,Bonsignori2011(21795340) ,SoDA,3-20,3-10,2,24.0,,,13.3,3-20,1,9.0,,,10.0,,,,,,,,,,,,,,,,,
nan,,,,,,,Doria-Rose2014(24590074) ,IMGT/V-QUEST,3-20*01,,,,,,,3-20*01,,,,,,,,,,,,,,,,,,,,,,
CH01_UA3,gp120 V2 // V2 glycan(V2g) // V2 apex,,CH0219 ,CH01,Liao2013b(23313589) ,,,,,,,,,,,,,,,,,K,,UCA or intermediate,human,CH01_RUA,Named CH01_RUA in Bibollet-Ruche2023 (referenced to the CH01_UA3 sequence from Liao2013b). ,,,6.0,746.0,4460.0,EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARGTDYTIDDQGIHYYGSGTYWYFDLWGRGTLVTVSS,,,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGTGTGGTACGGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGGCATGAGCTGGGTCCGCCAAGCTCCAGGGAAGGGGCTGGAGTGGGTCTCTGGTATTAATTGGAATGGTGGTAGCACAGGTTATGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCCGAGGACACGGCCTTGTATCACTGTGCGAGAGGGACCGATTACACTATTGACGACCAGGGGATCCATTACTATGGTTCGGGGACCTACTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCA,CARGTDYTIDDQGIHYYGSGTYWYFDLW,100.000
CH02,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CH0219 ,CH01,Bonsignori2011(21795340) ,Mutation affects PG9-like Ab sensitivity;PG9-like contacts,Bonsignori2011(21795340) ,SoDA,3-20,3-10,2,24.0,,,14.3,3-20,1,9.0,,,13.7,K,,Natural monoclonal,human,, ,12.23,16.0314,250.0,85.0,2656.0,EVQLVESGGSVVRPGGSLRLSCRASGFIFENYGLTWVRQVPGKGLHWVSGMNWNGGDTRYADSVRGRFSMSRDNSNNIAYLQMNNLRVEDTALYYCARGTDYTIDDQGRFYQGSGTFWYFDFWGRGTLVTVSSX,EIVLTQSPATLSVSPGERATLSCRASQNVHPRYFAWYQQKRGQSPRLLIHSGSTRAAGIADRFSGGGSGMHFTLTITRVEPEDFAVYFCQQYGGSPYTFGQGTRVELRX,GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCGGGGGAGAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAATGTCCACCCCAGATATTTCGCCTGGTATCAACAAAAACGTGGCCAGTCTCCCAGGCTCCTCATCCATAGTGGATCCACCAGGGCCGCTGGCATCGCAGACAGGTTCAGTGGCGGTGGGTCTGGAATGCACTTCACTCTCACCATCACCAGAGTGGAGCCTGAAGATTTTGCAGTCTATTTCTGTCAACAATACGGTGGTTCTCCCTACACGTTCGGCCAGGGGACCAGGGTGGAACTCAGAC,GAGGTTCAGCTGGTGGAGTCTGGGGGAAGTGTGGTGCGGCCGGGGGGGTCCCTGAGACTCTCCTGTAGAGCGTCCGGATTCATCTTTGAGAACTATGGCCTGACTTGGGTCCGCCAAGTTCCAGGGAAAGGGCTACATTGGGTCTCCGGGATGAATTGGAATGGTGGTGACACGCGTTATGCAGACTCTGTGAGGGGCCGATTTAGCATGTCCAGAGACAACAGCAACAACATCGCATATCTGCAAATGAATAATCTGAGAGTGGAGGACACGGCCTTGTATTACTGCGCGAGAGGGACCGATTACACGATAGACGACCAGGGAAGATTTTATCAAGGATCGGGGACCTTCTGGTACTTCGATTTTTGGGGCCGTGGCACACTGGTCACTGTCTCTTCAG,CARGTDYTIDDQGRFYQGSGTFWYFDFW,85.085
nan,,,,,,,Doria-Rose2014(24590074) ,IMGT/V-QUEST,3-20*01,,,,,,,3-20*01,,,,,,,,,,,,,,,,,,,,,,
CH03,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,5ESV(CH03 in Complex with Scaffolded Trimeric HIV-1 Env V1V2 Domain from Clade C Superinfecting Strain of Donor CAP256),CH0219 ,CH01,Bonsignori2011(21795340) ,Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;Mutation affects PG9-like Ab sensitivity;PG9-like contacts,Bonsignori2011(21795340) ,SoDA,3-20,3-10,2,24.0,,,12.0,3-20,1,9.0,,,10.6,K,,Natural monoclonal,human,, ,9.22651,20.6749,102.0,86.0,2657.0,EVQLVESGGGVVRPGGSLRLSCAASGFIFENYGLTWVRQVPGKGLHWVSGMNWNGGDTRYADSVRGRFSMSRDNSNNIAYLQMKNLRVDDTALYYCARGTDYTIDDQGIFYKGSGTFWYFDLWGRGTLVTVSSX,EIVLTQSPATLSLSPGERATLSCRASQSVHPKYFAWYQQKPGQSPRLLIYSGSTRAAGIADRFSGGGSGIHFTLTITRVEPEDFAVYFCQQYGGSPYTFGQGTKVELRX,GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCGGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTCCACCCCAAATATTTCGCCTGGTACCAGCAGAAACCTGGCCAGTCTCCCAGGCTCCTCATCTATAGTGGATCCACTAGGGCCGCTGGCATCGCAGACAGGTTCAGTGGCGGTGGGTCTGGAATACACTTCACTCTCACCATCACCAGAGTGGAGCCTGAAGATTTTGCAGTGTATTTCTGCCAACAATACGGTGGTTCCCCCTACACGTTCGGCCAGGGGACCAAGGTGGAACTCAGGC,GAGGTTCAGCTGGTGGAGTCTGGGGGAGGTGTGGTGCGGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGCGTCCGGATTCATTTTTGAGAACTACGGCTTGACTTGGGTCCGCCAAGTTCCAGGGAAAGGGCTGCATTGGGTCTCCGGTATGAATTGGAATGGTGGTGACACGCGTTATGCAGACTCTGTGAGGGGCCGATTCAGCATGTCCAGAGACAACAGCAATAATATCGCATATCTGCAAATGAAAAATCTGAGAGTCGACGACACGGCCTTGTATTACTGTGCGAGAGGGACCGATTACACGATAGACGACCAGGGAATTTTTTATAAAGGTTCGGGGACCTTCTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCTTCAG,CARGTDYTIDDQGIFYKGSGTFWYFDLW,86.441
nan,,,,,,,Doria-Rose2014(24590074) ,IMGT/V-QUEST,3-20*01,,,,,,,3-20*01,,,,,,,,,,,,,,,,,,,,,,
CH04,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,3TCL(Antibody CH04);5ESZ(CH04 in Complex with Scaffolded Trimeric HIV-1 Env V1V2 Domain from the Clade AE Strain A244),CH0219 ,CH01,Bonsignori2011(21795340) ,Mutation affects PG9-like Ab sensitivity;PG9-like contacts,Andrabi2015(26588781) ,IMGT/V-QUEST,3-20*01,3-10*01,2*01,26.0,,14.0,,3-20*01,1*01,9.0,,11.0,,K,,Natural monoclonal,human,, ,18.6072,12.7275,253.0,87.0,2654.0,EVQLVESGGGLIRPGGSLRLSCKGSGFIFENFGFGWVRQGPGKGLEWVSGTNWNGGDSRYGDSVKGRFTISRDNSNNFVYLQMNSLRPEDTAIYYCARGTDYTIDDQGIRYQGSGTFWYFDVWGRGTLVTVSSX,EIVLTQSPDTLSLSPGERATLSCRASQSVHSRYFAWYQHKPGQPPRLLIYGGSTRATGIPNRFSAGGSGTQFTLTVNRLEAEDFAVYYCQQYGRSPYTFGQGTKVEIRX,GAAATTGTGTTGACACAGTCTCCAGACACCCTGTCTTTGTCCCCAGGGGAGAGAGCCACCCTCTCATGCAGGGCCAGTCAGAGTGTTCACAGCAGATACTTTGCCTGGTACCAGCATAAACCTGGCCAGCCTCCCAGACTCCTCATCTATGGTGGGTCCACCAGGGCCACTGGCATCCCTAATAGATTCAGTGCCGGCGGGTCTGGGACACAGTTCACTCTCACCGTCAACAGACTGGAGGCTGAAGATTTTGCGGTATATTACTGTCAGCAGTATGGTCGCTCCCCGTACACGTTCGGCCAAGGGACCAAGGTGGAGATCAGAC,GAGGTTCAGCTGGTGGAGTCTGGGGGAGGTCTCATACGGCCGGGGGGGTCCCTGAGACTCTCCTGTAAAGGCTCCGGTTTCATCTTTGAGAATTTTGGCTTCGGCTGGGTCCGCCAAGGTCCAGGGAAGGGGCTGGAGTGGGTGTCTGGCACTAATTGGAATGGAGGTGACTCACGTTATGGAGACTCTGTGAAGGGCCGATTCACAATCTCCAGAGACAACAGCAACAATTTCGTCTACCTGCAAATGAACAGTCTGAGACCCGAGGACACGGCCATATATTATTGTGCGAGAGGGACCGATTACACTATTGACGATCAGGGGATCCGTTATCAAGGTTCGGGGACTTTCTGGTACTTCGATGTCTGGGGCCGCGGCACCCTGGTCACGGTCTCCTCAG,CARGTDYTIDDQGIRYQGSGTFWYFDVW,86.441
nan,,,,,,,Bonsignori2011(21795340) ,SoDA,3-20,3-10,2,24.0,,,11.5,3-20,1,9.0,,,9.4,,,,,,,,,,,,,,,,,
nan,,,,,,,Doria-Rose2014(24590074) ,IMGT/V-QUEST,3-20*01,,,,,,,3-20*01,,,,,,,,,,,,,,,,,,,,,,
CH103,gp120 CD4bs,4JAM(antibody CH103);4JAN(CH103 in complex with HIV-1 gp120),Donor CH505 ,CH103,Liao2013(23552890) ,Antibody-driven selection in donor CH505;CH103 and CH235 evolution;CH103 contacts;hypervariable loop characteristic correlations with bNAb sensitivity;Mutations at the trimer apex that affect sensitivity;Signature Analysis Summary,Liao2013(23552890) ,IMGT/V-QUEST,4-59*01,3-16*01,4*02,15.0,,16.8,,3-1*01,1*01,10.0,,10.6,,L,,Natural monoclonal,human,, ,4.15305,11.0261,1455.0,50.0,2861.0,SETLSLTCTVSGGSMGGTYWSWLRLSPGKGLEWIGYIFHTGETNYSPSLKGRVSISVDTSEDQFSLRLRSVTAADTAVYFCASLPRGQLVNAYFRNWGRGSLVSVTA,PMSLTQPPSVSVSPGQTATITCSGASTNVCWYQVKPGQSPEVVIFENYKRPSGIPDRFSGSKSGSTATLTIRGTQAIDEADYYCQVWDSFSTFVFGSGTQVTVL,CCTATGAGCTTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGACAGACAGCCACCATAACGTGCTCTGGGGCAAGTACAAATGTTTGCTGGTATCAGGTGAAGCCGGGCCAGTCCCCTGAGGTGGTCATCTTTGAGAATTATAAGCGGCCCTCAGGGATCCCTGACCGGTTCTCTGGCTCCAAGTCTGGGAGCACAGCCACTCTGACCATCCGCGGGACCCAGGCTATAGATGAGGCTGATTATTACTGTCAGGTGTGGGACAGCTTCTCCACCTTCGTCTTCGGATCTGGGACCCAGGTCACCGTCCTC,TCGGAGACCCTGTCCCTCACTTGCACTGTCTCTGGTGGCTCCATGGGTGGGACTTATTGGAGTTGGCTGCGCCTGTCCCCCGGGAAGGGACTGGAATGGATTGGCTATATCTTTCATACTGGAGAGACCAATTACAGTCCCTCCCTGAAGGGTCGAGTCTCCATATCAGTGGACACGTCCGAGGACCAGTTCTCCCTGAGACTGAGGTCTGTGACCGCTGCGGACACGGCCGTCTATTTTTGTGCCAGTCTGCCCAGGGGCCAATTAGTCAATGCCTACTTTCGCAATTGGGGCCGCGGATCTCTGGTCTCCGTCACCGCA,,
CH104,gp120 CD4bs,,Donor CH505 ,CH103,Liao2013(23552890) ,,Liao2013(23552890) ,IMGT/V-QUEST,4-59*01,3-16*01,4*02,15.0,,14.9,,3-1*01,1*01,10.0,,10.6,,L,,Natural monoclonal,human,, ,,,8.0,187.0,2862.0,SETLSLTCTVSGGSMGGTYWSWLRLSPGKGLEWIGYIFHTGHTNYNPSLEGRVSISVDTSEDQFSLRLRSVTAADTAVYFCASLPRGQLVNAYFRNWGRGTLVSVTA,SYELTQPPSVSVSPGQTATITCSGDKVASKNVCWYQVKPGQSPEVVMYENYKRASGIPDRFSGSKSGSTATLTIRGTQATDEADYYCQVWDSFSTFVFGSGTQVTVL,TCCTATGAGCTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGACAGACAGCCACCATAACGTGCTCTGGGGATAAAGTGGCAAGTAAAAATGTTTGTTGGTATCAGGTGAAGCCGGGCCAGTCCCCTGAGGTGGTCATGTATGAAAATTATAAGCGGGCCTCAGGGATCCCTGACCGGTTCTCTGGCTCCAAGTCTGGGAGCACAGCCACTCTGACCATCCGCGGGACCCAGGCTACAGATGAGGCTGACTATTACTGTCAGGTGTGGGACAGCTTCTCCACCTTCGTCTTCGGATCTGGGACCCAGGTCACCGTCCTC,TCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATGGGTGGGACTTATTGGAGTTGGCTGCGCCTGTCCCCCGGGAAGGGACTGGAGTGGATTGGCTATATCTTTCACACTGGACACACCAACTACAATCCCTCCCTGGAGGGTCGAGTCTCCATATCAGTGGACACGTCCGAGGACCAGTTCTCCCTGAGACTGAGGTCTGTGACCGCTGCGGACACGGCCGTCTATTTTTGTGCCAGTCTGCCCAGGGGCCAATTAGTCAATGCCTACTTTCGCAATTGGGGCCGCGGAACCCTGGTCTCCGTCACCGCA,,
CH105,gp120 CD4bs,,Donor CH505 ,CH103,Liao2013(23552890) ,,Liao2013(23552890) ,IMGT/V-QUEST,4-59*01,3-16*01,4*02,15.0,,12.7,,3-1*01,1*01,10.0,,10.0,,L,,Natural monoclonal,human,, ,,,8.0,188.0,2863.0,SETLSLTCAVSGGSMGGYYWSWLRHSPVKGLEWIGYVFHTGHTNYNPSLASRVMVSVDTTENQFSLRMRSVTAADTAVYYCASLPRGQLVNAFFDNWGPGTLVTVAS,,,TCGGAGACCCTGTCGCTCACCTGCGCTGTCTCTGGTGGCTCCATGGGTGGGTATTATTGGAGCTGGCTCCGGCATTCCCCCGTGAAGGGACTGGAGTGGATTGGTTATGTCTTTCACACTGGACACACGAACTACAACCCCTCCCTCGCGAGTCGCGTCATGGTCTCAGTGGACACGACCGAGAACCAGTTCTCCCTGAGGATGAGGTCTGTGACCGCTGCGGACACGGCCGTGTATTACTGTGCGAGCCTGCCCAGGGGACAATTAGTCAATGCCTTCTTCGACAACTGGGGCCCGGGAACCCTGGTCACCGTCGCCTCA,CASLPRGQLVNAFFDNW,85.887
CH106,gp120 CD4bs,,Donor CH505 ,CH103,Liao2013(23552890) ,,Liao2013(23552890) ,IMGT/V-QUEST,4-59*01,3-16*01,4*02,15.0,,16.0,,3-1*01,1*01,10.0,,11.2,,L,,Natural monoclonal,human,, ,,,19.0,189.0,2864.0,SETLSLTCSVSGGSMGGTYWSWLRLSPGKGLEWIGYIFHTGHTNYSPSLKGRVSISVDTSEDQFSLRLRSVTAADTAVYFCASLPRGQLVNAYFRNWGXGILVSVTA,SYELTQPPSVSVSPGQTATITCSGDKVASVNVCWYQVKPGQSPDVVMYENYKRPSGIPDRFSGSKSGSTATLTIRGTQATDEAEYYCQVWDSFSTFVFGSGTQVTVL,TCCTATGAGCTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGACAGACAGCCACCATAACGTGCTCTGGGGATAAAGTGGCAAGTGTAAATGTTTGCTGGTATCAGGTGAAGCCGGGCCAGTCCCCTGACGTGGTCATGTATGAAAATTATAAGCGGCCCTCAGGGATCCCTGACCGGTTCTCTGGCTCCAAGTCTGGGAGCACAGCCACTCTGACCATCCGCGGGACCCAGGCTACAGATGAGGCTGAGTATTACTGTCAGGTGTGGGACAGCTTCTCCACCTTCGTCTTCGGATCTGGGACCCAGGTCACCGTCCTC,TCGGAGACCCTGTCCCTCACCTGCTCTGTCTCTGGTGGCTCCATGGGTGGGACTTATTGGAGTTGGCTGCGCCTGTCCCCCGGGAAGGGACTGGAGTGGATTGGCTATATCTTTCATACTGGACACACCAACTACAGTCCCTCCCTGAAGGGTCGAGTCTCCATATCAGTGGACACGTCCGAGGACCAGTTCTCCCTGAGACTGCGGTCTGTGACCGCTGCGGACACGGCCGTTTATTTTTGTGCCAGTCTGCCCAGGGGCCAATTAGTCAATGCCTACTTTCGCAATTGGGGCCRSGGAATCCTGGTCTCCGTCACCGCA,,
CH12,gp41 MPER (membrane proximal external region),,CAP206 ,,Morris2011(21980336) ,,Morris2011(21980336) ,SoDA,1-69*04,,6*03,17.0,,,11.9,3-20*01,,11.0,,,5.2,L,,Natural monoclonal,human,CAP206-CH12," Morris2011 SHM data are entered for AA, but it's unclear if the data are NT or AA.",82.4473,2.16309,446.0,282.0,2854.0,QVQLVQSGAEVKKPGSSVKLSCKASGGTFGSYSVTWVRQAPGQTFEWVGRIVPWVGVPNYAPKFQGRVTITADKSSTVYMELTSLRFEDTAVYYCATAYEASGLSYYYYMDDWGKGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWFRHKPGQAPRLLIYGASYRGTGIPDRISGSGSGTDFTLTISRLEPEDFAVYYCQHYGGSPGMYTFGQGTRLEIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTACCAGCAGCTACTTAGCCTGGTTCCGGCACAAGCCTGGCCAGGCTCCAAGGCTCCTCATATATGGTGCATCATACAGGGGCACTGGCATTCCAGACAGAATCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCACTATGGTGGCTCACCTGGGATGTACACTTTTGGCCAGGGGACCAGGCTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCGGAAGTGAAGAAGCCTGGGTCCTCGGTGAAGCTCTCCTGTAAGGCTTCTGGAGGCACCTTCGGCAGCTATTCTGTCACCTGGGTGCGCCAGGCCCCTGGACAAACGTTTGAGTGGGTGGGCAGGATCGTCCCTTGGGTTGGTGTTCCGAACTACGCACCGAAGTTCCAGGGCAGAGTCACCATTACCGCGGACAAATCGAGCACAGTCTACATGGAATTGACCAGTCTGAGATTTGAGGACACGGCCGTCTATTACTGTGCGACAGCCTATGAGGCGAGTGGGTTGTCATACTACTACTACATGGACGACTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CATAYEASGLSYYYYMDDW,87.797
CH13,gp120 CD4bs,,CH0457 ,CH13,Moody2015(26355218) ,Mutation decreases binding to CD4BS mAbs,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,29.0118,10.8032,37.0,248.0,3236.0,,,,,,
CH14,gp120 V3 // V3 glycan (V3g),,CH0457 ,,Moody2015(26355218) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,48.3679,8.7145,52.0,249.0,3244.0,,,,,,
CH16,gp120 CD4bs,,CH0457 ,CH13,Moody2015(26355218) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,43.7543,7.61358,48.0,250.0,3237.0,,,,,,
CH17,gp120 CD4bs,,CH0457 ,CH13,Moody2015(26355218) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,43.9701,8.29155,48.0,251.0,3238.0,,,,,,
CH18,gp120 CD4bs,,CH0457 ,CH13,Moody2015(26355218) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,46.2777,7.03121,48.0,252.0,3239.0,,,,,,
CH235,gp120 CD4bs,5F9W(CH235 in complex with HIV-1 clade AE 93TH057 gp120);EMD-8082(BG505 SOSIP.664 in complex with CH235 Fab);EMD-8083(B41 SOSIP.664 trimer in complex with CH235 Fab),Donor CH505 ,CH235,Gao2014(25065977) ,Antibody-driven selection in donor CH505;CH103 and CH235 evolution,Bonsignori2016(26949186) ,Cloanalyst,1-46*01,3-10*01,4*02,15.0,CARNVATEGSLLHYDYW,7.9,,3-15*01,1*01,8.0,QYNNWWTF,3.8,,K,,Natural monoclonal,human,, ,58.5985,3.3291,230.0,223.0,3185.0,QVQLVQSGAEVKKPGASVTVSCQASGYTFTNYYVHWVRQAPGQGLQLMGWIDPSWGRTNYAQNFQGRITMTRDTSTSTVYMEMRSLRSEDTAVYYCARNVATEGSLLHYDYWGQGTLVTVSA,EIVLTQSPATLSVSPGERATLSCRASQSVRSNLAWYQQRPGQAPRLLIYGTSTRATGVPARFSGRGSGTEFTLAISSMQSEDFAVYLCLQYNNWWTFGQGTKVEIK,GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGAAGTAACTTAGCCTGGTACCAGCAGAGACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCACCAGGGCCACTGGTGTCCCTGCCAGGTTCAGTGGCCGTGGGTCTGGGACAGAGTTCACTCTCGCCATCAGCAGCATGCAGTCTGAAGATTTTGCAGTTTATCTCTGTCTGCAGTATAATAACTGGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGACGGTTTCCTGCCAGGCATCTGGATACACCTTCACCAACTACTATGTACACTGGGTGCGACAGGCCCCTGGACAGGGGCTTCAATTGATGGGATGGATCGACCCTAGTTGGGGTCGCACAAACTACGCACAGAATTTCCAGGGCAGAATCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGATGAGAAGCCTGAGATCTGAGGACACGGCCGTTTATTATTGTGCGAGAAATGTGGCAACGGAGGGGAGCTTACTCCACTATGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCGCA,CARNVATEGSLLHYDYW,92.177
CH235.12,gp120 CD4bs,5F96(CH235.12 in complex with HIV-1 clade AE 93TH057 gp120);EMD-8078(BG505 SOSIP.664 trimer in complex with CH235.12 Fab);EMD-8079(B41 SOSIP.664 trimer in complex with CH235.12 Fab),Donor CH505 ,CH235,Bonsignori2016(26949186) ,Antibody-driven selection in donor CH505;Electrostatic interactions with D368;hypervariable loop characteristic correlations with bNAb sensitivity;Signature Analysis Summary,Bonsignori2016(26949186) ,Cloanalyst,1-46*01,3-10*01,4*02,15.0,CVRNVGTAGSLLHYDHW,25.7,,3-15*01,1*01,8.0,,12.9,,K,Yes,Natural monoclonal,human,CH557, ,1.00319,6.97703,819.0,225.0,3292.0,QVQLAQYGGGVKRLGATMTLSCVASGYTFNDYYIHWVRQAPGQGFELLGYIDPANGRPDYAGALRERLSFYRDKSMETLYMDLRSLRYDDTAMYYCVRNVGTAGSLLHYDHWGSGSPVIVSS,EIVLTQSPATLSASPGERVTLTCRASRSVRNNVAWYQHKGGQSPRLLIYDASTRAAGVPARFSGSASGTEFTLAISNLESEDFTVYFCLQYNNWWTFGQGTRVDIK,GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCCGCGTCTCCAGGGGAAAGAGTCACCCTAACTTGCAGGGCCAGTCGGAGTGTCCGAAACAACGTGGCCTGGTATCAGCACAAGGGTGGCCAGAGTCCCAGGCTCCTCATTTATGATGCGTCCACGAGGGCCGCTGGTGTCCCAGCCAGGTTCAGCGGCAGTGCATCTGGGACAGAGTTCACTCTCGCCATCAGCAACTTGGAGTCTGAAGATTTTACAGTCTACTTCTGTCTGCAGTATAATAACTGGTGGACCTTCGGCCAAGGGACCAGGGTGGACATCAAA,CAGGTGCAACTAGCCCAATATGGTGGTGGGGTGAAGAGGCTAGGGGCCACAATGACCCTTTCCTGCGTGGCATCTGGATACACCTTCAACGACTACTACATACATTGGGTGCGGCAGGCCCCTGGACAAGGCTTTGAGTTGTTGGGATACATCGACCCCGCTAATGGTCGCCCAGACTACGCAGGGGCGTTGAGGGAGAGACTCTCCTTCTACAGGGACAAGTCCATGGAGACGCTGTACATGGACCTGAGGAGCCTAAGATATGACGACACGGCCATGTATTATTGTGTTAGAAATGTGGGGACCGCTGGCAGCTTGCTGCATTATGACCACTGGGGCTCGGGAAGCCCGGTCATCGTCTCCTCC,CVRNVGTAGSLLHYDHW,74.830
CH235.9,gp120 CD4bs,5F9O(CH235.09 in complex with HIV-1 clade AE 93TH057 gp120);EMD-8080(B41 SOSIP.664 trimer in complex with CH235.9 Fab);EMD-8081(BG505 SOSIP.664 trimer in complex with CH235.9 Fab),Donor CH505 ,CH235,Bonsignori2016(26949186) ,Antibody-driven selection in donor CH505;Electrostatic interactions with D368,Bonsignori2016(26949186) ,Cloanalyst,1-46*01,3-10*01,4*02,15.0,CVRNVGTAGSLLHYDHW,19.6,,3-15*01,1*01,8.0,,2.8,,K,,Natural monoclonal,human,"CH235.09, CH493", ,6.24706,6.05784,199.0,224.0,3291.0,QVRLLQYGGGVKRPGASMTISCVASGYNFNDYYIHWVRQAPGQGLELMGWIDPSGGRTDYAGAFGDRVSMYRDKSMNTLYMDLRSLRSGDTAMYYCVRNVGTAGSLLHYDHWGLGVMVTVSS,,,CAGGTGCGACTACTACAATATGGGGGTGGAGTGAAGAGGCCTGGGGCCTCAATGACGATTTCCTGCGTGGCGTCTGGATACAACTTCAACGACTACTATATACACTGGGTGCGACAGGCCCCTGGACAAGGCCTCGAATTGATGGGATGGATCGACCCTAGTGGTGGTCGCACAGATTACGCAGGGGCGTTTGGGGACAGAGTGTCCATGTACAGGGACAAGTCCATGAACACACTCTACATGGACCTGAGGAGCCTGAGATCTGGCGACACGGCCATGTATTATTGTGTTAGAAATGTGGGAACGGCTGGCAGCTTGCTCCACTATGACCACTGGGGCCTGGGAGTTATGGTCACCGTCTCCTCA,CVRNVGTAGSLLHYDHW,80.612
CH235-L47W(HC),gp120 CD4bs,,Donor CH505 ,CH235,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,68.2638,3.75302,13.0,732.0,4421.0,,,,,,
CH235-Q23K(HC),gp120 CD4bs,,Donor CH505 ,CH235,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,37.0384,5.53909,13.0,734.0,4423.0,,,,,,
CH235-Q46E(HC),gp120 CD4bs,,Donor CH505 ,CH235,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,33.8719,5.91156,13.0,735.0,4424.0,,,,,,
CH235-R57S(HC),gp120 CD4bs,,Donor CH505 ,CH235,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,80.6445,2.10685,13.0,736.0,4425.0,,,,,,
CH235-T19K(HC),gp120 CD4bs,,Donor CH505 ,CH235,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,41.0872,4.97077,16.0,731.0,4420.0,,,,,,
CH235-W55G(HC),gp120 CD4bs,,Donor CH505 ,CH235,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,72.9702,2.97905,13.0,733.0,4422.0,,,,,,
CH27,gp120 CD4bs,,CH0457 ,CH27,Moody2015(26355218) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,32.1877,9.71576,52.0,245.0,3242.0,EVQLVESGGGLVQPGGSLRLSCAASGFSVSYDYMAWVRQAPGKGLEWVSIIYGGGSPYYADSVKGRFAISRDTSRNTLDLQMSSLRRDDSGVYFCARGLASLFDLWGRGTLVTVSSA,EIVLTQSPGTLSLSPGETATLSCRASRRVNVNYLAWYQHRPGQSPRLLMYGPYNRPTGIPGRFWGEWSGPLFTLNIDRLEPVDRAVYYCLHFDSDTSSWAFGRGTKVEVKR,GAAATTGTGTTGACRCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGAGAAACAGCCACCCTCTCCTGCAGGGCCAGTCGGCGTGTTAACGTCAACTACCTAGCCTGGTATCAACACAGACCTGGCCAGAGTCCCAGGCTCCTCATGTACGGTCCTTACAACAGGCCCACTGGCATCCCGGGCAGGTTCTGGGGCGAGTGGTCTGGGCCACTCTTCACTCTCAACATCGACAGACTGGAGCCTGTTGATCGAGCAGTCTATTACTGTCTACACTTTGACTCTGATACTTCTTCGTGGGCGTTCGGCCGAGGGACCAAGGTGGAGGTCAAACGA,GAGGTKCAGCTGGTGGAGTCTGGGGGTGGCTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCTTGTGCAGCCTCTGGATTCAGCGTCAGCTACGACTATATGGCCTGGGTCCGCCAGGCTCCAGGGAAGGGACTGGAGTGGGTCTCTATTATTTATGGTGGTGGTAGTCCATATTACGCAGACTCTGTGAAGGGCCGATTCGCCATCTCCAGAGACACCTCCAGGAATACACTGGATCTTCAAATGAGCAGCCTGAGACGTGACGACAGCGGTGTTTACTTCTGTGCGAGGGGACTCGCCTCGCTCTTCGATCTCTGGGGCCGAGGCACCCTGGTCACTGTCTCGTCAGCA,CARGLASLFDLW,86.897
CH28,gp120 CD4bs,,CH0457 ,CH27,Moody2015(26355218) ,Mutation decreases binding to CD4BS mAbs,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,10.2164,18.223,48.0,246.0,3243.0,EVQLVESGGSCVRLGGSLRLSCAASGFSVRNDQMAWVRQAPGKRLEWVSIINDGASPYYADSVKGRFAMSRDTSKNTVFLQMNSLRRDDTAVYFCARGIASFFDVWGRGTLVAVSSA,EIVLTQSPGTLSLSPGERATLSCRANRRIDMNALAWYQHRSGQAPRLLTHGVYNRATGIPDRFSGYWSGPEFTLVISRLEPEDFAVYYCVHFLYENPAWAFGRGTKIEVKR,GAAATTGTGTTGACRCAGTCTCCAGGCACCCTGTCCTTGTCTCCAGGGGAGAGAGCCACCCTCTCCTGCAGGGCCAATCGGCGGATTGACATGAACGCCTTGGCCTGGTACCAGCACCGATCTGGCCAGGCTCCCAGGCTCCTCACCCATGGTGTCTATAACAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCTATTGGTCTGGGCCAGAGTTCACCCTCGTCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTCTATTACTGTGTACACTTTCTCTACGAAAATCCAGCGTGGGCGTTCGGCCGAGGGACCAAGATAGAGGTCAAGCGA,GAGGTGCAGCTGGTGGAGTCTGGGGGTAGCTGCGTACGTCTCGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAGCGTCAGGAACGACCAGATGGCCTGGGTCCGCCAGGCTCCAGGGAAGCGACTGGAGTGGGTCTCTATTATTAACGATGGTGCTAGTCCATACTACGCAGACTCTGTGAAGGGCCGCTTCGCCATGTCCAGAGACACCTCCAAGAATACAGTGTTTCTTCAGATGAACAGCCTGAGACGTGACGACACAGCTGTTTATTTCTGTGCGAGGGGGATCGCCTCATTCTTCGATGTCTGGGGCCGTGGCACGCTGGTCGCTGTCTCGTCAGCA,CARGIASFFDVW,84.138
CH44,gp120 CD4bs,,CH0457 ,CH27,Moody2015(26355218) ,Signature Analysis Summary,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,12.6426,13.6918,48.0,247.0,3245.0,EVQLVESGGGVVHPGGSLRLSCAASGFSVSHDFMAWIRQAPGKGLEWISIIYNTGSRYYYADSVKGRFALSRDTSNNTLILHMSGLRRDDTAIYFCARGVASFFELWGRGTLVTVSSA,ETTLTQSPAILSVSPGETATLSCRASRRVDMNGLAWYQHRPGQAPRLLMHGVYNRAAGISGRFTGSWSGPVFTLTISRLEPEDFGVYYCQHFYYETSAWAFGRGTRVEGKR,GAAACGACACTCACGCAGTCTCCAGCCATCCTGTCTGTGTCTCCAGGGGAAACCGCCACCCTCTCCTGCAGGGCCAGTCGCCGTGTTGACATGAACGGCCTCGCCTGGTACCAACACAGGCCTGGCCAGGCTCCCAGGCTCCTCATGCATGGTGTTTATAATAGGGCCGCCGGCATCTCAGGCAGGTTCACTGGCAGTTGGTCTGGGCCAGTCTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGGAGTCTATTACTGTCAACACTTTTACTATGAGACTTCAGCGTGGGCGTTCGGCCGAGGGACCAGGGTGGAGGGCAAACGA,GAGGTKCAGCTGGTGGAGTCTGGGGGTGGCGTGGTCCACCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAGCGTCAGTCACGACTTCATGGCCTGGATCCGCCAGGCTCCAGGAAAGGGACTGGAGTGGATCTCTATCATATATAACACTGGTTCTCGATACTACTACGCAGACTCTGTGAAGGGCCGCTTCGCCCTCTCCAGAGATACGTCCAACAACACACTGATTCTTCACATGAGCGGCCTGAGACGTGACGACACGGCTATTTATTTCTGTGCCAGGGGAGTCGCCTCGTTCTTCGAATTGTGGGGCCGTGGCACCCTGGTCACTGTCTCGTCAGCC,CARGVASFFELW,82.594
CH45,gp120 CD4bs,,CH0457 ,CH13,Moody2015(26355218) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,65.2365,3.88002,48.0,253.0,3240.0,,,,,,
CH48,gp120 V3 // V3 glycan (V3g),,CH0457 ,,Moody2015(26355218) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,42.3533,9.47883,52.0,255.0,3246.0,,,,,,
CH58,gp120 V2 // V2 glycan(V2g) // V2 apex,4HPO(RV144-elicited antibody CH58 in complex with V2 peptide);4HQQ(RV144-elicited antibody CH58),347759 ,,Liao2013b(23313589) ,Contacts and binding of CH58 and CH59;Contacts of IGHV5-51 V2 antibodies,Liao2013b(23313589) ,,5-51,3-22,4,19.0,,1.9,,6-57,3,9.0,,1.9,,L,Yes,Natural monoclonal,human,, ,87.5168,1.61731,18.0,622.0,3019.0,EVQLVQSGAEVKKPGESLKISCKGSGYRFTSYWIVWVRQMPGKGLEWMGIIYPGDFDTKYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLGGRYYHDSSGYYYLDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSVASDYVQWYQQRPGSAPTTVVYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDNSSWVFGGGTKLTVL,AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCCGCAGCAGTGGCAGCGTTGCCAGCGACTATGTGCAGTGGTACCAGCAGCGCCCGGGCAGTGCCCCCACCACTGTGGTCTATGAGGATAACCAAAGACCCTCTGGGGTCCCTGATCGATTCTCTGGCTCCATCGACAGCTCCTCCAACTCTGCCTCCCTCACCATCTCTGGACTGAAGACTGAGGACGAGGCTGACTACTACTGTCAGTCTTATGATAACAGCTCTTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTA,GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGGTTTACCAGTTACTGGATCGTCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTTTGATACCAAATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTACAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACTTGGCGGCAGATATTACCATGATAGTAGTGGTTATTACTACCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CARLGGRYYHDSSGYYYLDYW,97.966
CH59,gp120 V2 // V2 glycan(V2g) // V2 apex,4HPY(RV144-elicited antibody CH59 in complex with V2 peptide),347759 ,,Liao2013b(23313589) ,Contacts and binding of CH58 and CH59,Liao2013b(23313589) ,,3-9,1-26,4,13.0,,2.8,,3-10,3,11.0,,0.9,,L,Yes,Natural monoclonal,human,, ,,,10.0,623.0,3020.0,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDGAMHWVRQAPGKGLEWVSGISWNSNIIAYADSVKGRFTISRDNAKNSLYLEMNSLRVEDTALYYCAKDSPRGELPLNYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKNYAYWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNHRVFGGGTKLTVL,TCCTATGAGCTGACACAGCCACCCTCGGTGTCAGTGTCCCCAGGACAAACGGCCAGGATCACCTGCTCTGGAGATGCATTGCCAAAAAACTATGCTTATTGGTACCAGCAGAAGTCAGGCCAGGCCCCTGTGTTGGTCATCTATGAGGACAGCAAACGACCCTCCGGGATCCCTGAGAGATTCTCTGGCTCCAGCTCAGGGACAATGGCCACCTTGACTATCAGTGGGGCCCAGGTTGAGGATGAAGCTGACTACTACTGTTACTCAACAGACAGCAGTGGTAATCATAGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTA,GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATGGTGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAGTTGGAATAGTAATATCATAGCCTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATTTAGAAATGAACAGTCTGAGAGTTGAGGACACGGCCTTGTATTACTGTGCAAAAGATTCTCCGCGGGGGGAGCTACCCTTGAACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CAKDSPRGELPLNYW,96.633
CH98,gp120 CD4bs,,CH5329 ,,Bonsignori2014(24614107) ,Mutation decreases binding to CD4BS mAbs,Bonsignori2014(24614107) ,SoDA,3-20,1-IR1,4,21.0,,25.3,,2-23,3,12.0,,15.8,,L,,Natural monoclonal,human,, ,10.0009,10.7667,42.0,99.0,3052.0,EVQLVESGGGVVEPGKSLTVSCAAFGVNIDTYDFHWVRQAPGKGLEWVACCSNSGEHSFNADIVKGRFSVSRDNMRNKMTLQMTRVMVDDTATYFCVKERGRHRTRDTLEFGRFFDSWGQGARVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSSPFLGSNNWVFGGGTKLTVX,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGATGTTGGGAGTTATAACCTTGTCTCCTGGTACCAACAGCACCCAGGCAAAGCCCCCAAACTCATGATTTATGAGGTCAGTAAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCTGCTCATCCCCTTTTCTTGGTAGTAATAATTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCT,GAGGTTCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCGAACCCGGAAAGTCCCTGACAGTCTCGTGTGCCGCCTTTGGAGTCAACATTGACACGTATGACTTCCACTGGGTCCGCCAGGCTCCAGGCAAGGGTCTGGAGTGGGTGGCCTGTTGTTCAAACAGTGGAGAACACTCTTTCAACGCAGACATTGTCAAGGGCCGCTTTAGCGTCTCCAGGGACAATATGAGGAACAAAATGACTTTGCAGATGACGAGAGTCATGGTTGACGACACGGCTACATACTTCTGTGTGAAGGAGAGGGGAAGACACCGAACACGGGACACACTTGAATTCGGAAGATTTTTTGACTCATGGGGGCAGGGAGCCCGGGTCACCGTCTCGTCA,CVKERGRHRTRDTLEFGRFFDSW,72.297
D5,gp41 five-helix bundle (one CHR of six helix bundle missing);gp41 NHR (N-heptad repeat);gp41 six-helix bundle,2CMR(HIV-1 neutralizing antibody D5 Fab bound to the gp41 inner-core mimetic 5-helix),,,Miller2005(16203977) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,5H/I1-BMV-D5, ,82.7424,1.76199,19.0,864.0,1710.0,QVQLVQSGAEVKKPGSSVTISCKPVGGTFTNFAIHWVRQAPGQGLEWVGGRVPVVGIYKYGKKFHDRLRLYEDDPMKTVFLELRSLTSDDTGVYYCTRWRGCGMCPYDTSSYYNDASDVWGPGTKVIVSA,EIVLTQSPVTLSLSSGETGTLSCRASQNISSSWIAWYQQRRGQVPRLLISAASARAAGIPDRFTGRGSGTDFTLTITRLEPEDLGVYSCQYYGGSFFTFGPGTQVDVK,,,,
D5_AR,gp41 NHR (N-heptad repeat),,,,Rubio2021(33980592) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,D5_H011_L0, ,31.0966,2.70808,21.0,865.0,4657.0,QVQLVQSGAEVRKPGASVKVSCKASGDTFSSYAISWVRQAPGQGLEWMGSIIPLFGTAAYAQKFQGRVTITADESTSTAYMELSSLRSEDTAIYYCARDNPTFGAADSWGKGTLVTVSS,DIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQKPGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQYSNYPLTFGGGTKLEIK,,,,
D7,gp120 CD4bs,,llama#44 ,,Forsman2008(18842738) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,VHH D7, ,45.9572,6.12633,63.0,191.0,1861.0,,,,,,
DF1W-a.01,fusion peptide // near gp41-gp120 interface,"6MPH(DF1W-a.01, elicited by vaccination of Rhesus macaques, in complex with stabilized HIV-1 Env BG505 DS-SOSIP, which was also bound to antibodies VRC03 and PGT122);6MQM(DF1W-a.01 in complex with HIV fusion peptide)",DF1W ,DF1W-a,Kong2019(31348886) ,DF1W-a.01 neutralization-associated sites,Kong2019(31348886) ,IgBlast IMGT/V-QUEST,,,,10.0,CAREGPEDFDVW,13.7,,,,9.0,CGQGVHLPRTF,4.3,,K,,Natural monoclonal,macaque,, ,37.9045,6.84128,417.0,818.0,4508.0,QVQLVESGPGLVRPSETLSLTCAVSGASIRTKAWWSWIRQPPGKGLEWIGYVSGGWDLPNYNPSLKNRVIILKDTSLNQFSLRLTSVTAADTALYYCAREGPEDFDVWGPGFLVTVSS,DVVMTQSPLSLSITPGQPASISCRSSQSLVHSDGKTYLSWYQQKPGQPPRLLIYQVSNWYSGVPDRFSGSGTGTNFTLKISRVEAADVGVYYCGQGVHLPRTFGQGTKVDIK,GATGTTGTGATGACTCAGTCTCCACTCTCCCTGTCCATCACCCCTGGGCAGCCGGCCTCCATCTCCTGCAGGTCCAGTCAAAGCCTTGTACATAGTGATGGAAAAACCTACTTGAGTTGGTATCAGCAGAAGCCAGGCCAACCTCCAAGGCTCCTGATTTATCAGGTTTCTAACTGGTATTCTGGGGTCCCAGACAGATTCAGCGGCAGTGGGACAGGGACAAATTTCACACTGAAAATCAGCAGAGTGGAGGCTGCGGATGTTGGCGTTTATTACTGCGGGCAAGGTGTACACCTTCCTCGGACGTTCGGCCAAGGGACCAAGGTGGATATCAAA,CAGGTGCAGCTGGTGGAGTCGGGCCCCGGACTGGTGAGGCCTTCAGAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGCCTCTATTAGAACTAAGGCTTGGTGGAGCTGGATCCGCCAGCCCCCAGGAAAAGGACTGGAGTGGATTGGCTATGTCAGTGGTGGTTGGGATCTCCCTAATTACAATCCCTCCCTCAAGAATCGAGTCATCATTTTAAAAGACACGTCCTTGAACCAGTTCTCCCTGAGGCTGACCTCTGTGACCGCCGCGGACACGGCCCTATATTACTGTGCAAGAGAGGGTCCGGAGGACTTCGATGTCTGGGGCCCGGGATTCCTGGTCACCGTCTCCTCA,CAREGPEDFDVW,82.609
DF1W-a.02,fusion peptide // near gp41-gp120 interface,,DF1W ,DF1W-a,Kong2019(31348886) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,macaque,, ,46.2556,5.38634,417.0,819.0,4509.0,QVQLQESGPGLVRPSETLFLTCAVSGVSIRTKAWWTWIRQPPGKGLEWIGYVSGGWDSPKSNPSLSTRVAILKDTSNNQFSLKLISVTAADTAVYYCVREGMEDFDVWGPGILVTVSS,DVVMTQSPLSLSITPGQPASISCRSSHSLVHSDGKTYLSWYHQKPGQPPRLLIYQVSNPYSGAPDRFSGSGAGTDFTLNISRVEAEDVGVYFCGQGVHLPRTLGQGTKVDLK,GATGTTGTGATGACTCAGTCTCCACTCTCCCTGTCCATCACCCCTGGACAGCCGGCCTCCATCTCCTGCCGGTCTAGTCACAGCCTTGTGCATAGTGATGGAAAAACCTACTTGAGTTGGTATCACCAGAAGCCAGGCCAACCTCCAAGGCTCCTTATTTATCAGGTTTCTAATCCCTACTCTGGGGCCCCAGACAGATTCAGCGGCAGTGGGGCAGGGACAGATTTCACTCTGAACATCAGCAGAGTGGAGGCTGAAGATGTTGGGGTTTACTTCTGCGGGCAAGGTGTACACCTTCCTCGGACGCTCGGCCAAGGGACCAAGGTGGATCTCAAA,CAGGTGCAGCTGCAGGAGTCGGGCCCCGGGCTGGTGAGGCCTTCAGAGACCCTGTTCCTCACCTGCGCTGTCTCTGGTGTCTCTATCAGAACTAAGGCTTGGTGGACCTGGATCCGACAGCCCCCAGGGAAAGGGCTGGAGTGGATTGGTTATGTCAGTGGTGGTTGGGATAGTCCTAAGTCCAACCCCTCCCTCAGCACTCGAGTCGCCATTTTAAAGGACACGTCCAACAACCAGTTCTCCCTGAAACTGATCTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGTGAGAGAGGGCATGGAGGACTTCGATGTCTGGGGCCCTGGAATCCTGGTCACCGTCTCCTCA,CVREGMEDFDVW,82.943
DFPH-a.01,fusion peptide // near gp41-gp120 interface,,DFPH ,DFPH-a,Kong2019(31348886) ,DFPH-a.01 neutralization-associated sites,Kong2019(31348886) ,IgBlast IMGT/V-QUEST,,,,20.0,CSSRAKIYFAVGYDSGGRIDVW,10.7,,,,9.0,CQQDYSFPLTF,4.9,,K,,Natural monoclonal,macaque,, ,12.9771,7.07928,417.0,823.0,4513.0,QVQLQVSGPGVVKASETLSLTCDVSSASNTRDYFYWSWVRQSPGKGLEWIGGVYSNSDTSNKNPSLESRVTISKDTSKNRFFLRLNSVTAADTAVYYCSSRAKIYFAVGYDSGGRIDVWGPGVLVTVAT,DIQMTQSPSSLSASVGDRVTVTCRASQDIDKDLSWFQQKPGKAPTLLIFTASSLQTGVSSRFSGSGSGTEFTLTISSLQPEDFATYFCQQDYSFPLTFGGGTKVDLK,GACATTCAGATGACCCAGTCTCCTTCCTCCCTGTCTGCATCTGTGGGAGACAGAGTCACCGTCACTTGCCGGGCGAGTCAAGACATTGACAAGGACTTAAGCTGGTTTCAGCAGAAACCAGGGAAAGCCCCTACACTCCTGATCTTTACTGCCTCCAGTTTGCAGACGGGGGTCTCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAACAGGATTACAGTTTCCCACTCACTTTCGGCGGCGGGACCAAGGTGGACCTCAAA,CAGGTGCAGCTGCAGGTGTCGGGCCCAGGAGTGGTGAAGGCTTCGGAGACCCTGTCCCTCACCTGCGATGTCTCCAGTGCCTCTAACACTAGGGATTACTTCTACTGGAGCTGGGTCCGCCAGTCCCCAGGGAAGGGGCTGGAGTGGATTGGGGGTGTCTACAGCAATAGTGACACTTCCAACAAAAACCCCTCCCTCGAGAGTCGAGTCACCATTTCAAAGGACACGTCCAAGAACCGATTCTTCCTGAGGCTGAACTCTGTGACCGCCGCGGACACGGCCGTGTATTATTGTTCGAGCCGAGCCAAAATTTATTTTGCTGTTGGCTATGATTCCGGGGGGCGGATCGATGTCTGGGGCCCGGGAGTCCTGGTCACCGTCGCCACA,,
DFPH-a.03,fusion peptide // near gp41-gp120 interface,,DFPH ,DFPH-a,Kong2019(31348886) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,macaque,, ,23.1555,6.55029,417.0,824.0,4514.0,QVHLQVSGPGMVKPSETLSLTCAVSGDYVRRGYFYWSWVRQPPGKGLEWIGGVYTNNDNTDYNPSLKSRVSISKDTSQNQFSLRLNSVTAADTAVYYCSSRAKIYSGGSSSSSSVGRIDVWGPGVLVTVSS,DIQMTQSPASLSASLGDRVTITCRASQGIDRDLSWFQQKPGKAPTLLIYEASSLQTGVSSRFSGSGSGTEFTLTISSLQPEDLAIYYCQQDYSFPLTFGGGSKVDLK,GACATTCAGATGACCCAATCTCCAGCCTCCCTGTCTGCATCTCTAGGAGACAGAGTCACCATTACTTGCCGGGCGAGTCAGGGCATTGACAGGGACTTAAGCTGGTTTCAACAGAAACCAGGGAAAGCCCCTACACTCCTGATCTATGAAGCCTCCAGTTTGCAGACGGGGGTCTCTTCTCGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATCTTGCGATTTATTACTGTCAACAGGATTATAGTTTCCCGCTCACTTTCGGCGGAGGGTCCAAGGTGGACCTCAAA,CAGGTGCACCTGCAGGTGTCGGGCCCAGGAATGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGCTGTGTCTGGCGACTACGTCAGGAGGGGTTATTTCTACTGGAGTTGGGTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGGGTGTCTACACTAATAATGACAACACCGACTACAACCCCTCCCTCAAGAGTCGAGTCAGCATTTCAAAGGACACGTCCCAAAATCAGTTCTCCCTGAGGCTGAACTCTGTGACCGCCGCGGACACGGCCGTATATTACTGTTCGAGTCGAGCCAAAATTTATTCTGGTGGTAGTTCTTCCTCTTCCTCCGTGGGGCGGATCGATGTCTGGGGCCCGGGAGTCCTGGTCACCGTCTCCTCA,CSSRAKIYSGGSSSSSSVGRIDVW,85.619
DFPH-a.15,fusion peptide // near gp41-gp120 interface,"6MQE(DFPH-a.15 in complex with HIV fusion peptide);6N1W(DFPH-a.15 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122)",DFPH ,DFPH-a,Kong2019(31348886) ,DFPH-a.15 contacts;DFPH-a.15 neutralization-associated sites,,,,,,,,,,,,,,,,K,,Natural monoclonal,macaque,, ,23.7362,6.48896,417.0,825.0,4515.0,QVQLQVSGPGVVRPSETLSLTCEVSSGSTSRDFFYWSWVRQTPGKGLEWIGGMYSNSEETNHNPSLKSRVIISKDTSKNEFSLRLTSVTAADTAVYFCSSRAKIYYSASYSGGRIDVWGPGLLVTVSS,DIQMTQSPSSLSASIGDRVTVTCRASQGIDKDLSWFQQKPGKAPTLLIYTASTLQTGVSSRFSGSGSGTDFSLTINNLQPEDVATYFCQQDFSFPLTFGGGTKVDFK,GACATTCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTATAGGAGACAGAGTCACCGTCACTTGCCGGGCGAGTCAAGGCATTGACAAGGACTTAAGTTGGTTTCAGCAGAAACCAGGGAAAGCCCCTACACTCCTGATCTATACTGCCTCCACTCTGCAGACGGGGGTCTCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGATTTCAGTCTCACCATCAACAACCTGCAGCCTGAAGATGTTGCAACTTATTTCTGTCAACAGGATTTCAGTTTCCCGCTCACTTTCGGCGGAGGGACCAAGGTGGACTTCAAA,CAGGTGCAGCTGCAGGTGTCGGGCCCAGGAGTGGTGAGGCCTTCGGAGACCCTGTCCCTCACCTGCGAAGTCTCTAGTGGCTCCACCAGCAGGGATTTTTTCTATTGGAGTTGGGTCCGGCAGACCCCAGGAAAGGGGCTGGAGTGGATTGGGGGTATGTACAGTAATAGCGAAGAAACGAATCACAACCCCTCCCTCAAGAGTCGAGTCATCATTTCAAAGGACACGTCCAAAAATGAGTTCTCCCTGAGGCTGACCTCTGTGACCGCCGCGGACACGGCCGTGTATTTCTGTTCGAGCCGAGCCAAGATTTACTATAGTGCCTCTTATTCCGGGGGGCGGATCGATGTCTGGGGCCCGGGACTCCTTGTCACCGTCTCCTCA,CSSRAKIYYSASYSGGRIDVW,83.278
DH270.1,gp120 V3 // V3 glycan (V3g),"5U0U(DH270.1 (unliganded, single-chain Fv))",CH848 ,DH270,Bonsignori2017(28298420) ,V3 Signature Analysis Summary,Bonsignori2017(28298420) ,Cloanalyst,1-2*02,3-22*01,4*02,20.0,TTGGWIGLYSDTSGYPNFDY,5.5,14.2,2-23*02,2*01,10.0,CSYAGSSIIF,6.3,10.0,L,,Natural monoclonal,human,DH270, ,10.6907,17.4537,415.0,293.0,3643.0,QVQLVQSGAEMKKPGASVRVSCKASGYTFTDYYIHWVRQAPGQGPEWMGWINPSTGRTNSPQKFQGRVTMTRDTSISTAYMDLNRLTSDDTAMYYCTTGGWIGLYSDTSGYPNFDYWGQGTLVTVSSX,QSALTQPASVSGSPGQSITISCTGTNYDVGSYNLVSWYQQHPGKVPKYIIYEVNKRPSGVSNRFSGSKSGNTASLTISGLQAEDEATYYCCSYAGSSIIFFGGGTKLTVIX,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAATTATGATGTTGGGAGTTATAACCTTGTCTCCTGGTATCAACAGCACCCAGGCAAAGTCCCCAAATACATAATTTATGAGGTCAATAAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCCACTTATTACTGTTGTTCATATGCAGGTAGTAGCATTATATTTTTCGGCGGTGGGACCAAGCTGACCGTCATAG,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGATGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGACTACTATATACACTGGGTGCGACAGGCCCCTGGACAAGGGCCTGAGTGGATGGGATGGATCAACCCTAGCACTGGTCGCACAAACTCTCCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCCTACATGGACCTGAACAGACTGACGTCTGACGACACGGCCATGTATTACTGTACGACCGGGGGGTGGATCGGTCTTTACTCTGATACTAGTGGTTACCCTAACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG,CTTGGWIGLYSDTSGYPNFDYW,94.178
DH270.2,gp120 V3 // V3 glycan (V3g),,CH848 ,DH270,Bonsignori2017(28298420) ,,Bonsignori2017(28298420) ,Cloanalyst,1-2*02,3-22*01,4*02,20.0,AKAGYIALYVDYSGYPNFNS,12.1,21.3,2-23*02,2*01,10.0,CSYAGSSTVI,3.9,6.4,L,,Natural monoclonal,human,DH473, ,1.87215,24.245,38.0,296.0,3649.0,EVQLVESGPELKEPGASVKVSCKASGYTFTDYYIHWVRQAPGQGLEWMAWINPTTGRSSFARGFQGRVTMTRETSVSTAYMELRRLRSDDTAVYYCAKAGYIALYVDYSGYPNFNSWGQGTLVTVSSX,QSALTQPASVSGSPGQSITISCTGTSYDVGSYNLVSWYQQHPGKAPKLIIYEVSQWPSGVSKRFSGSKSGNTASLTISGLQAEDEAHYYCCSYAGSSTVIFGGGTSLTVLX,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGCCAGTCGATCACCATCTCCTGCACTGGAACCAGCTATGATGTTGGGAGTTATAATCTTGTCTCCTGGTACCAACAGCACCCAGGCAAAGCCCCCAAACTCATTATTTATGAGGTCAGTCAGTGGCCCTCAGGGGTTTCTAAGCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTCATTATTACTGTTGCTCATATGCAGGCAGTAGCACTGTAATATTCGGCGGAGGGACCTCGCTGACCGTCCTAG,GAGGTTCAGCTGGTGGAGTCTGGGCCTGAGTTGAAGGAGCCTGGGGCCTCAGTGAAAGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGACTACTACATACACTGGGTGCGACAGGCCCCTGGACAAGGTCTTGAGTGGATGGCATGGATCAACCCTACCACTGGTCGCTCTAGCTTTGCCCGGGGGTTTCAGGGCAGGGTCACCATGACCAGGGAAACGTCCGTCAGCACGGCCTATATGGAACTGAGAAGACTGAGATCTGACGACACGGCCGTCTATTACTGTGCGAAAGCGGGATACATCGCCCTTTACGTTGACTATAGTGGTTACCCTAACTTTAATTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG,CAKAGYIALYVDYSGYPNFNSW,89.153
DH270.3,gp120 V3 // V3 glycan (V3g),5TPL(DH270.3 unliganded);6CBJ(DH270.3 Fab in complex with Man9),CH848 ,DH270,Bonsignori2017(28298420) ,,Bonsignori2017(28298420) ,Cloanalyst,1-2*02,3-22*01,4*02,20.0,ARGGWISLYVDYSYYPNFDS,12.6,21.3,2-23*02,2*01,10.0,SSSTNSATVI,8.2,14.5,L,,Natural monoclonal,human,DH391, ,14.1611,14.7117,27.0,297.0,3650.0,QVQLVQSGAELKKPGASVKVSCKASGYTLSDYYVHWLRQAPGQGLEWVAWINPTSGRTISPRKFQGRVTMTTDTSMNVAYMELRGLRSDDTAVYFCARGGWISLYVDYSYYPNFDSWGQGTLVSVSSX,QPVLTQPASVSGSPGQSITISCTGSSSDVGSYNLVSWYQQHPGKAPKLMIYEVNKWASGVSDRFAGSKSGNTASLTISRLQAEDEANYFCSSSTNSATVIFGGGTKLTVLX,CAGCCTGTGCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAAGCAGCAGTGATGTTGGGAGTTATAACCTTGTGTCCTGGTACCAGCAGCACCCAGGCAAAGCCCCCAAACTGATGATTTATGAGGTCAATAAGTGGGCCTCAGGGGTTTCTGATCGCTTCGCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTAGACTCCAGGCTGAGGACGAGGCTAATTACTTTTGTTCCTCATCTACAAATAGTGCCACTGTCATATTCGGCGGAGGGACCAAGCTGACCGTCCTAG,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAACTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCCTCAGCGACTACTATGTACACTGGCTGCGACAGGCCCCTGGACAGGGGCTTGAGTGGGTGGCTTGGATCAACCCTACCAGTGGTCGCACAATCTCTCCACGGAAGTTTCAGGGCAGGGTCACGATGACTACGGACACGTCCATGAATGTTGCCTACATGGAACTGAGAGGCTTGAGATCTGACGACACGGCCGTCTATTTCTGTGCGAGAGGGGGATGGATCAGTCTCTACGTTGATTACAGTTATTACCCTAACTTTGACTCGTGGGGCCAGGGAACCCTGGTCTCCGTCTCTTCAG,CARGGWISLYVDYSYYPNFDSW,88.475
DH270.4,gp120 V3 // V3 glycan (V3g),,CH848 ,DH270,Bonsignori2017(28298420) ,,Bonsignori2017(28298420) ,Cloanalyst,1-2*02,3-22*01,4*02,20.0,VTGGWISPYYDSSYYPNFDH,11.6,22.0,2-23*02,2*01,10.0,CSFGGSATVV,8.8,14.5,L,,Natural monoclonal,human,DH429, ,0.73671,31.5641,48.0,298.0,3651.0,EVQLVQSGAEMKNPGASVKVSCAASGYGFTDFYIHWVRLAPGHGLQWMGWMNPKTGRTNNAQDFQGRVTLTRDTSIGTAYMELRRLTSDDTAVYYCVTGGWISPYYDSSYYPNFDHWGQGTLITVSSX,QSALTQPASVSGSPGQSITISCTGTSYDVAKFDLVSWFQQHPGKAPKYMIYEVNKWPSGVSHRFSGSKSGNTASLTISGLQAEDEADYYCCSFGGSATVVCGGGTKVTVLX,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGTTATGATGTTGCGAAGTTTGACCTTGTCTCCTGGTTCCAACAGCACCCAGGCAAAGCCCCCAAATACATGATTTATGAAGTCAATAAGTGGCCCTCAGGAGTTTCTCATCGCTTCTCTGGTTCCAAATCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGACTATTATTGCTGCTCATTCGGAGGTAGTGCCACTGTAGTCTGCGGCGGAGGGACCAAGGTGACCGTCCTAG,GAGGTGCAGCTGGTGCAGTCTGGGGCTGAAATGAAGAACCCTGGGGCCTCAGTGAAAGTCTCCTGCGCGGCTTCTGGATATGGTTTCACCGACTTCTACATACACTGGGTGCGACTGGCCCCTGGACACGGGCTCCAGTGGATGGGATGGATGAACCCTAAGACTGGTCGCACAAATAATGCACAAGATTTTCAGGGCAGGGTCACCCTGACCAGGGACACGTCCATCGGCACAGCCTACATGGAGCTGAGGAGGCTGACATCTGACGACACGGCCGTCTATTACTGTGTGACAGGGGGGTGGATCAGTCCTTATTATGATAGTAGTTATTACCCTAATTTTGACCACTGGGGTCAGGGAACCCTGATCACCGTCTCCTCAG,CVTGGWISPYYDSSYYPNFDHW,88.136
DH270.5,gp120 V3 // V3 glycan (V3g),5TPP(DH270.5 (unliganded)),CH848 ,DH270,Bonsignori2017(28298420) ,V3 Signature Analysis Summary,Bonsignori2017(28298420) ,Cloanalyst,1-2*02,3-22*01,4*02,20.0,VTGAWISDYYDSSYYPNFDH,11.8,20.5,2-23*02,2*01,10.0,CSFGGSAAVV,12.4,20.0,L,,Natural monoclonal,human,DH471, ,5.93299,24.2443,415.0,294.0,3652.0,QVQLVQSGAEVKNPGASVKVSCAPSGYTFTDFYIHWVRLAPGQGLEWLGWMNPKTGRTNQGQNFQGRVTMTRDTSIGTAYMELRSLTSDDTAVYYCVTGAWISDYYDSSYYPNFDHWGQGTLVTVSSX,LPVLTQPASVSGSPGQSITISCTGTIYDVGKFDLVSWYQHHPGKAPKYLIYEVKKWPSGVSHRFSGSKSGNTASLTISGLQVEDEADYYCCSFGGSAAVVCGGGTKVTVLX,CTGCCTGTGCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGGCAGTCGATCACCATCTCCTGCACTGGGACCATTTATGATGTTGGGAAGTTTGACCTTGTCTCCTGGTACCAGCACCACCCAGGCAAAGCCCCCAAATATTTGATTTATGAAGTCAAAAAGTGGCCCTCAGGAGTTTCTCATCGCTTCTCTGGCTCCAAATCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGTTGAGGACGAGGCTGACTATTATTGCTGCTCATTCGGAGGTAGTGCCGCTGTGGTCTGCGGCGGAGGGACCAAGGTGACCGTCCTAG,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAAGTGAAGAACCCTGGGGCCTCAGTGAAAGTCTCCTGCGCGCCTTCTGGATATACCTTCACTGACTTCTACATACACTGGGTGCGACTGGCCCCTGGACAAGGGCTTGAGTGGCTGGGGTGGATGAACCCTAAGACTGGTCGCACAAATCAAGGACAAAACTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCGGCACAGCCTACATGGAGTTGAGGAGCCTCACATCTGACGACACGGCCGTCTATTACTGTGTGACAGGGGCCTGGATCAGTGATTATTATGATAGTAGTTATTATCCTAACTTTGACCACTGGGGTCAGGGAACCCTGGTCACCGTCTCCTCAG,CVTGAWISDYYDSSYYPNFDHW,88.475
DH270.6,gp120 V3 // V3 glycan (V3g),5TQA(DH270.6 (unliganded));6CBP(DH270.6 bnAb in complex with the Man9-V3 glycopeptide),CH848 ,DH270,Bonsignori2017(28298420) ,hypervariable loop characteristic correlations with bNAb sensitivity;V3 Signature Analysis Summary,Bonsignori2017(28298420) ,Cloanalyst,1-2*02,3-22*01,4*02,20.0,TTGGWISGYYDSSYYPNFDH,12.3,22.0,2-23*02,2*01,10.0,CSFGGSATVV,11.8,15.5,L,,Natural monoclonal,human,DH542, ,2.71164,35.2194,428.0,295.0,3922.0,QVQLVQSGAQMKNPGASVKVSCAPSGYTFTDFYIHWLRQAPGQGLQWMGWMNPQTGRTNTARNFQGRVTMTRDTSIGTAYMELRSLTSDDTAIYYCTTGGWISLYYDSSYYPNFDHWGQGTLLTVSSX,QSALTQPASVSGSPGQSITISCTGTKYDVGSHDLVSWYQQYPGKVPKYMIYEVNKRPSGVSNRFSGSKSGNTASLTISGLRAEDEADYYCCSFGGSATVVCGGGTKVTVL,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAAGTATGATGTTGGGAGTCATGACCTTGTCTCCTGGTACCAACAGTACCCAGGCAAAGTCCCCAAATACATGATTTATGAAGTCAATAAACGGCCCTCAGGAGTTTCTAATCGCTTCTCTGGCTCCAAATCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCGGGCTGAGGACGAGGCTGACTATTATTGCTGTTCATTTGGAGGGAGTGCCACCGTGGTCTGCGGCGGCGGGACCAAGGTGACCGTCCTA,CAGGTGCAGCTGGTGCAGTCTGGGGCTCAAATGAAGAACCCTGGGGCCTCAGTGAAGGTCTCCTGCGCGCCTTCTGGATATACCTTCACCGACTTTTACATACATTGGTTGCGCCAGGCCCCTGGCCAGGGGCTTCAGTGGATGGGATGGATGAACCCTCAGACTGGTCGCACAAACACTGCACGAAACTTTCAGGGGAGGGTCACCATGACCAGGGACACGTCCATCGGCACAGCCTACATGGAGTTGAGAAGCCTGACATCTGACGACACGGCCATATATTACTGTACGACAGGGGGATGGATCAGTCTTTACTATGATAGTAGTTATTACCCCAACTTTGACCACTGGGGTCAGGGAACCCTGCTCACCGTCTCCTCAG,CTTGGWISLYYDSSYYPNFDHW,86.780
DH270 IA1,gp120 V3 // V3 glycan (V3g),,CH848 ,DH270,Bonsignori2017(28298420) ,,Bonsignori2017(28298420) ,Cloanalyst,1-2*02,3-22*01,4*02,20.0,VTGGWISPYYDSSYYPNFDH,8.7,17.3,2-23*02,2*01,10.0,CSFGGSATVV,7.9,12.7,L,,UCA or intermediate,human,DH270 I1, ,0.79309,34.2106,27.0,299.0,3645.0,,,,,,
DH270 IA2,gp120 V3 // V3 glycan (V3g),,CH848 ,DH270,Bonsignori2017(28298420) ,,Bonsignori2017(28298420) ,Cloanalyst,1-2*02,3-22*01,4*02,20.0,ATGGWIGLYYDSSGYPNFDY,1.8,5.5,2-23*02,2*01,10.0,CSYAGSSTVI,1.8,2.7,L,,UCA or intermediate,human,DH270 I2, ,8.21191,19.2654,38.0,300.0,3646.0,,,,,,
DH270 IA3,gp120 V3 // V3 glycan (V3g),,CH848 ,DH270,Bonsignori2017(28298420) ,,Bonsignori2017(28298420) ,Cloanalyst,1-2*02,3-22*01,4*02,20.0,ARGGWIGLYVDYSGYPNFDS,4.2,8.7,2-23*02,2*01,10.0,CSYAGSSTVI,1.2,1.8,L,,UCA or intermediate,human,DH270 I3, ,19.1294,10.6103,27.0,301.0,3647.0,,,,,,
DH270 IA4,gp120 V3 // V3 glycan (V3g),,CH848 ,DH270,Bonsignori2017(28298420) ,,Bonsignori2017(28298420) ,Cloanalyst,1-2*02,3-22*01,4*02,20.0,ARGGWIGLYYDSSGYPNFDY,1.0,3.1,2-23*02,2*01,10.0,CSYAGSSTVI,0.6,0.9,L,,UCA or intermediate,human,Dh270 I4, ,62.349,3.85642,27.0,302.0,3648.0,,,,,,
DH511.1,gp41 MPER (membrane proximal external region),5U3J(DH511.1 Fab in Complex with HIV-1 gp41 MPER Peptide),CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*04,24.0,TADLGEPVVSRFFEWGSYYYYMDL,15.7,17.7,1-39*01,2*01,11.0,QEAYSSTPTLT,16.3,17.6,K,,Natural monoclonal,human,DH511, ,0.62322,6.66116,73.0,314.0,3847.0,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNTWMSWVRQAPGKGLEWVGRISRNKDGAKTEYAAPVRGRFTISRDDSRDTLYLQMTSLKIEDSGRYFCTADLGEPVVSRFFEWGSYYYYMDLWGKGTTVTVSS,DIQMTQSPSPLSASVGDTVTITCRASQKISDYLNWYQQKPGRAPKILIYAASKLGSGVPSRFSGSGYGRDFTLTITGLQPEDFATYYCQEAYSSTPTLTFGQGTRLDLKX,GACATCCAGATGACCCAGTCTCCATCTCCCCTGTCTGCGTCTGTGGGAGACACAGTCACTATCACTTGTCGGGCCAGCCAGAAGATTAGCGACTATTTGAACTGGTACCAACAGAAGCCGGGGAGAGCCCCCAAAATACTCATTTACGCTGCGTCCAAGTTGGGGAGTGGCGTCCCATCAAGGTTCAGTGGCAGTGGATATGGCAGAGATTTCACTCTCACCATCACCGGTCTGCAGCCTGAAGATTTTGCAACCTATTATTGTCAGGAGGCTTACAGTTCTACTCCCACGTTAACTTTTGGCCAGGGGACCAGGCTGGATCTCAAAC,GAGGTTCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCGGGGGGGTCTCTTAGACTCTCCTGTGCAGCCTCTGGCTTCACTTTCAGCAACACGTGGATGAGTTGGGTCCGTCAGGCGCCAGGGAAGGGACTGGAGTGGGTCGGTCGGATTAGCCGGAACAAAGATGGCGCGAAAACAGAGTACGCCGCACCCGTGAGAGGCAGATTCACCATCTCAAGAGATGACTCCAGAGACACATTGTATCTGCAGATGACCAGCCTGAAAATAGAGGATTCAGGCCGGTATTTTTGCACCGCAGATCTTGGGGAGCCCGTGGTGTCACGATTTTTTGAGTGGGGGTCTTATTATTATTATATGGACCTCTGGGGCAAGGGGACCACGGTCACCGTCTCTTCA,CTADLGEPVVSRFFEWGSYYYYMDLW,84.437
DH511.11P,gp41 MPER (membrane proximal external region),5U3M(DH511.11P Fab in Complex with HIV-1 gp41 MPER Peptide),CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,23.0,TADEGAPILRFFEWGYYNYYMDV,10.6,20.7,1-39*01,2*01,11.0,QESYSSVPMYI,15.5,18.2,K,,Natural monoclonal,human,, Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.,0.64487,5.30457,433.0,319.0,3856.0,QVQLVQSGGGLVKPGGSLTLSCVTSGFTFSNTWMSWVRQTPGKGLEWVARISRVGDGPIIDYAAPVKGRFIISRDDSRNTLFLHMNNLKTEDTAVYYCTADEGAPILRFFEWGYYNYYMDVWGKGTTVIVSS,DIRLTQSPSSLSASVGDRITITCRASQSIKDYLNWYKHRPGEAPKLLIYSASKLRSGVSSRFSGSGYGSAFTLTISSLQPEDFATYYCQESYSSVPMYIFGQGTKVDLKX,GACATCCGGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGGGACAGAATCACCATCACTTGTCGGGCCAGCCAAAGCATTAAAGACTATTTAAATTGGTATAAACACCGGCCAGGGGAAGCCCCCAAACTCCTCATTTATTCTGCATCCAAGTTGAGAAGTGGGGTCTCATCAAGGTTCAGTGGCAGTGGATATGGGTCGGCCTTCACACTGACCATCAGCAGTCTGCAGCCTGAAGATTTTGCGACTTATTATTGTCAGGAGAGTTACAGCAGCGTTCCCATGTACATTTTCGGCCAGGGGACCAAGGTGGACCTCAAAC,CAGGTCCAGCTGGTACAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTACACTCTCCTGTGTCACCTCTGGATTTACTTTCAGCAACACGTGGATGAGTTGGGTCCGCCAGACTCCAGGGAAGGGACTGGAGTGGGTTGCCCGTATTAGTAGGGTCGGGGATGGCCCAATAATAGACTACGCTGCTCCCGTGAAAGGCAGATTCATAATCTCAAGAGATGACTCAAGAAACACACTCTTTCTTCACATGAACAACCTGAAAACCGAGGACACAGCCGTGTATTATTGTACCGCTGATGAGGGGGCCCCAATTTTAAGATTTTTTGAGTGGGGTTATTACAACTACTACATGGACGTCTGGGGCAAGGGGACCACGGTCATCGTCTCCTCG,CTADEGAPILRFFEWGYYNYYMDVW,85.099
DH511.12P,gp41 MPER (membrane proximal external region),5U3N(DH511.12P Fab in Complex with HIV-1 gp41 MPER Peptide),CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,23.0,TADEGAPILRFFEWGYYNYYMDV,11.2,21.8,,,,,,,K,,Natural monoclonal,human,, DH511.12P heavy chain was paired with the DH511.11P light chain.  Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.,0.5949,5.17193,433.0,320.0,3857.0,QVQLVQSGGGLVKPGGSLTPSCVTSGFTFSNTWMSWVRQTPGKGLEWVARISRVGDGPIIDYAAPVKGRFIISRDDSRNTLFLHMNNLKTEDTAVYYCTADEGAPILRFFEWGYYNYYMDVWGKGTTVIVSS,DIRLTQSPSSLSASVGDRITITCRASQSIKDYLNWYKHRPGEAPKLLIYSASKLRSGVSSRFSGSGYGSAFTLTISSLQPEDFATYYCQESYSSVPMYIFGQGTKVDLKX,GACATCCGGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGGGACAGAATCACCATCACTTGTCGGGCCAGCCAAAGCATTAAAGACTATTTAAATTGGTATAAACACCGGCCAGGGGAAGCCCCCAAACTCCTCATTTATTCTGCATCCAAGTTGAGAAGTGGGGTCTCATCAAGGTTCAGTGGCAGTGGATATGGGTCGGCCTTCACACTGACCATCAGCAGTCTGCAGCCTGAAGATTTTGCGACTTATTATTGTCAGGAGAGTTACAGCAGCGTTCCCATGTACATTTTCGGCCAGGGGACCAAGGTGGACCTCAAAC,CAGGTCCAGCTTGTACAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTACACCCTCCTGTGTCACCTCTGGATTTACTTTCAGCAACACGTGGATGAGTTGGGTCCGCCAGACTCCAGGGAAGGGACTGGAGTGGGTTGCCCGTATTAGTAGGGTCGGGGATGGCCCAATAATAGACTACGCTGCTCCCGTGAAAGGCAGATTCATAATCTCAAGAGATGACTCAAGAAACACACTCTTTCTTCACATGAACAACCTGAAAACCGAGGACACAGCCGTGTATTATTGTACCGCTGATGAGGGGGCCCCAATTTTAAGATTTTTTGAGTGGGGTTATTACAACTACTACATGGACGTCTGGGGCAAGGGGACCACGGTCATCGTCTCCTCG,CTADEGAPILRFFEWGYYNYYMDVW,84.437
DH511.2,gp41 MPER (membrane proximal external region),5U3K(DH511.2 Fab in Complex with HIV-1 gp41 MPER 662-683 Peptide);5U3L(DH511.2 Fab in Complex with HIV-1 gp41 MPER 670-683 Peptide),CH0210 ,DH511,Williams2017(28783671) ,DH511.2 and DH511.2_K3 contacts;Signature Analysis Summary,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,4-4*01,6*03,23.0,TMDEGTPVTRFLEWGYFYYYMAV,17.6,27.5,1-39*01,2*03,11.0,QENYNTIPSLS,14.0,20.7,K,,Natural monoclonal,human,"Ab510049, DH512", ,1.01851,6.03869,1742.0,313.0,3656.0,QVQLVQSGGGLVKPGGSLTLSCSASGFFFDNSWMGWVRQAPGKGLEWVGRIRRLKDGATGEYGAAVKDRFTISRDDSRNMLYLHMRTLKTEDSGTYYCTMDEGTPVTRFLEWGYFYYYMAVWGRGTTVIVSS,DIVMTQSPSSVSASVGDRVTITCRASQNIRDYLNWYQHKPGGSPRLLIYAASTLQTGVPSRFSGSGSGNLFTLTITNLQPEDFATYYCQENYNTIPSLSFGQGTKVDIRX,GACATCGTGATGACCCAGTCTCCGTCCTCCGTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAATATTAGAGACTATTTAAATTGGTATCAACATAAACCCGGGGGATCCCCTAGACTCCTAATTTATGCTGCGTCAACTTTGCAAACTGGGGTCCCGTCCAGATTCAGCGGCAGTGGATCTGGGAACCTTTTCACTCTCACCATTACCAATCTGCAACCTGAAGATTTTGCAACTTATTATTGTCAAGAGAATTATAATACTATCCCCTCGCTCAGCTTTGGTCAGGGGACCAAGGTGGACATCAGGC,CAGGTGCAGCTGGTACAGTCTGGGGGAGGTCTGGTGAAGCCGGGGGGGTCCCTCACACTCTCCTGTTCAGCCTCTGGATTCTTTTTCGATAATTCATGGATGGGGTGGGTCCGTCAGGCGCCAGGGAAGGGACTGGAGTGGGTTGGCCGCATTAGAAGGCTCAAAGACGGTGCGACAGGAGAATATGGTGCAGCCGTGAAGGACAGATTCACCATTTCAAGAGATGACAGTAGAAATATGCTGTACCTGCACATGAGGACCCTGAAAACCGAGGACTCAGGCACTTATTATTGTACCATGGATGAGGGGACCCCAGTAACACGCTTCTTAGAATGGGGCTACTTCTATTATTATATGGCCGTTTGGGGCAGAGGGACCACGGTCATCGTCTCTTCA,CTMDEGTPVTRFLEWGYFYYYMAVW,80.201
DH511.2_K3,gp41 MPER (membrane proximal external region),5U3O(DH511.2_K3 Fab in Complex with HIV-1 gp41 MPER Peptide),CH0210 ,DH511,Williams2017(28783671) ,DH511.2 and DH511.2_K3 contacts;Signature Analysis Summary,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,4-4*01,6*03,23.0,TMDEGTPVTRFLEWGYFYYYMAV,,,1-39*01,2*01,11.0,QESYSSTPTHI,,,K,,Engineered monoclonal,human,"DH511.2 K3, DH511 K3",chimeric: heavy chain from DH511.2 + light chain from DH511.8P ,0.34124,5.79184,832.0,321.0,3657.0,,,,,,
DH511.3,gp41 MPER (membrane proximal external region),,CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,24.0,TADLGEAVVSRFFEWGSYYYYMDF,16.0,18.7,1-39*01,2*01,11.0,QEAYSSTPTLT,17.1,19.6,K,,Natural monoclonal,human,DH513, ,1.28786,6.73283,73.0,315.0,3848.0,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNTWMSWVRQAPGKGLEWVGRISRNKDGAKTEYAAPVRGRFTISRDDSRDTLYLQMSSLKIEDSGRYFCTADLGEAVVSRFFEWGSYYYYMDFWGKGTTVTVSS,DIQMTQSPSPLSASVGDTVTITCRASQKISDYLNWYQQRPGRAPKILIYAASKLASDVPSRFSGSGYGRDFTLTITGLQPEDFATYYCQEAYSSTPTLTFGQGTRLDLKX,GACATCCAGATGACCCAGTCTCCATCTCCCCTGTCTGCGTCTGTGGGAGACACAGTCACTATCACTTGCCGGGCCAGCCAGAAGATTAGCGACTATTTGAACTGGTACCAACAGAGGCCGGGGAGAGCCCCCAAGATCCTCATTTACGCTGCGTCCAAGTTGGCAAGCGACGTCCCATCAAGATTTAGTGGCAGTGGATATGGCAGAGATTTCACTCTCACCATAACCGGTCTGCAGCCTGAAGATTTTGCAACCTATTATTGTCAGGAGGCTTACAGTTCTACCCCCACGTTAACTTTTGGCCAGGGGACCAGGCTGGATCTCAAAC,GAGGTTCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCGGGGGGGTCTCTTAGACTCTCCTGTGTAGCCTCTGGCTTCACTTTCAGCAACACGTGGATGAGTTGGGTCCGTCAGGCGCCAGGGAAGGGACTGGAGTGGGTCGGTCGGATTAGCCGGAACAAAGATGGCGCGAAAACAGAGTACGCCGCACCCGTGAGAGGCAGATTCACCATCTCAAGAGATGACTCCAGAGACACATTGTATCTGCAGATGAGCAGCCTGAAAATAGAGGATTCAGGCCGGTATTTTTGCACCGCAGATCTTGGGGAGGCCGTTGTGTCACGATTTTTTGAGTGGGGGTCCTATTATTACTACATGGACTTCTGGGGCAAGGGGACCACGGTCACCGTCTCTTCA,CTADLGEAVVSRFFEWGSYYYYMDFW,84.106
DH511.4,gp41 MPER (membrane proximal external region),5U3P(DH511.4 Fab),CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,23.0,TRDEGAPVTRFLEWGSYYYYMAV,21.4,26.5,1-39*01,2*01,11.0,QEAYNTNPTLS,15.9,21.7,K,,Natural monoclonal,human,DH514, ,1.78849,4.40134,73.0,316.0,3849.0,EVQLVESGGGLIKPGQSLTLFCVGFGFNFANDWMGWVRQAPGKGLEWVGRIRRLKDGAKAEYGSSVKGRFTISRDDSKNTLYLHMSSLKVEDTAVYYCTRDEGAPVTRFLEWGSYYYYMAVWGKGTTVTVSS,DIQLTQSPASLSASVGDTVTITCRASQSIKDYINWYQHKSGSAPRLLIYAASTLQSGISSRFTGSGSGTQFTLTINSLQPEDFATYYCQEAYNTNPTLSFGQGTRVDKKX,GACATCCAGTTGACCCAGTCTCCAGCCTCTCTGTCTGCATCTGTAGGAGACACAGTGACTATCACTTGCCGGGCAAGTCAGAGTATAAAAGATTACATAAATTGGTATCAACACAAATCCGGGAGCGCCCCTAGACTCCTGATTTATGCTGCGTCAACCTTACAAAGTGGAATCTCGTCAAGGTTCACTGGCAGTGGGTCTGGGACACAGTTCACTCTCACCATTAACAGTCTGCAACCTGAAGATTTTGCGACTTATTATTGTCAAGAGGCTTATAACACCAACCCCACACTCTCCTTTGGTCAGGGGACCAGGGTGGACAAGAAGC,GAGGTGCAGCTGGTGGAGTCTGGGGGCGGCTTGATAAAGCCGGGACAGTCACTCACACTATTCTGTGTGGGCTTTGGATTCAACTTCGCTAACGACTGGATGGGCTGGGTCCGCCAGGCTCCAGGGAAGGGACTGGAATGGGTTGGGCGTATAAGGAGACTGAAAGATGGTGCGAAAGCTGAATATGGATCTTCCGTGAAGGGTAGATTCACCATCTCAAGGGATGATTCCAAAAACACCCTATACTTGCACATGAGCAGCCTCAAGGTCGAAGACACAGCCGTCTACTATTGCACCCGAGACGAGGGGGCCCCAGTTACCCGGTTTCTGGAGTGGGGCTCCTATTACTACTACATGGCCGTCTGGGGCAAAGGGACCACGGTCACCGTCTCTTCA,CTRDEGAPVTRFLEWGSYYYYMAVW,78.477
DH511.5,gp41 MPER (membrane proximal external region),,CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,23.0,TRDEGAPVTRFLEWGSYYYYMAV,21.8,29.5,1-39*01,2*01,11.0,QEAYNTYPTLS,17.1,22.7,K,,Natural monoclonal,human,DH515, ,1.52602,5.60216,73.0,317.0,3850.0,EVQLVESGGGLVKPGQSLTLSCVGFGFNFANDWMGWVRQAPGKGLEWVGRIRRLKDGATTEYSSSVKGRFSVSRDDSRNTVYLHMSSLKVQDIGVYYCTRDEGAPVTRFLEWGSYYYYMAVWGRGTTVTVSS,DIQMTQSPTSLSASVGDTVAITCRASQSVKDYVNWYQHKSGSAPRLLIYAASVLHTGVSSRFTGSGSGTQFTLTISSLQPEDFATYYCQEAYNTYPTLSFGQGTRVDRKX,GACATCCAGATGACCCAGTCTCCAACCTCTCTGTCTGCATCTGTAGGAGACACAGTTGCTATCACTTGCCGGGCAAGTCAGAGTGTTAAAGATTATGTGAATTGGTATCAACACAAATCCGGGAGCGCCCCTCGACTCCTGATTTATGCTGCCTCAGTCTTACATACTGGAGTCTCGTCAAGGTTCACTGGCAGTGGGTCTGGGACACAGTTCACTCTCACCATTAGCAGTCTACAACCTGAAGATTTTGCTACTTATTATTGTCAAGAGGCTTATAACACCTATCCCACACTCTCCTTTGGTCAGGGGACCAGGGTGGACAGGAAAC,GAGGTTCAGCTGGTGGAGTCTGGGGGCGGCTTGGTGAAGCCGGGACAGTCACTCACACTTTCCTGTGTGGGCTTTGGATTCAATTTCGCTAACGACTGGATGGGCTGGGTCCGCCAGGCTCCAGGGAAGGGACTGGAATGGGTTGGTCGAATAAGGAGACTAAAAGACGGTGCGACAACAGAATATTCTTCATCCGTGAAGGGGAGATTCAGTGTCTCAAGAGATGATTCAAGGAACACAGTATACTTACACATGAGTAGCCTCAAAGTCCAGGACATTGGCGTCTATTATTGTACTCGAGACGAGGGGGCCCCGGTTACTCGATTTCTGGAGTGGGGCTCCTATTACTACTATATGGCCGTCTGGGGCAGAGGGACCACGGTCACCGTCTCTTCA,CTRDEGAPVTRFLEWGSYYYYMAVW,78.378
DH511.6,gp41 MPER (membrane proximal external region),,CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,24.0,ARGTGVVVGGSWTVPPGMAYYLDV,16.0,17.7,1-39*01,2*03,11.0,QEAYSSTPTLS,17.6,21.7,K,,Natural monoclonal,human,DH516, ,1.34659,8.10451,73.0,318.0,3851.0,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNTWMSWVRQAPGKGLEWVGRISRNKDGAKTDYAAPVRGRFTISRDDSRDTLYLQMSSLKIEDSGRYFCTADLGEAVVSRFFEWGSYYYYMDFWGKGTTVTVSS,DIVMTQSPPPLSASVGDTVTITCRASQKISDYLNWYQQRPGRAPKILIYAASKLGSDVPSRFSGSGYGRDFTLTITGLQPEDFATYYCQEAYSSTPTLSFGQGTRLDLKX,GATATTGTGATGACCCAGTCTCCACCTCCCCTGTCTGCGTCTGTGGGAGACACAGTCACTATCACTTGCCGGGCCAGCCAGAAGATTAGCGACTATTTGAACTGGTACCAACAGAGGCCGGGGAGAGCCCCCAAAATACTCATTTACGCTGCGTCCAAGTTGGGAAGCGACGTCCCATCAAGGTTCAGTGGCAGTGGATATGGCAGAGATTTCACTCTCACCATCACCGGTCTGCAGCCTGAAGATTTTGCAACCTATTATTGTCAGGAGGCTTACAGTTCTACTCCCACGTTAAGTTTTGGCCAGGGGACCAGGCTGGATCTCAAAC,GAGGTTCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCGGGGGGGTCTCTTAGACTCTCCTGTGTAGCCTCTGGCTTCACTTTCAGCAACACGTGGATGAGTTGGGTCCGTCAGGCGCCAGGGAAGGGACTGGAGTGGGTCGGTCGGATTAGCCGGAACAAAGATGGCGCGAAAACAGACTACGCCGCACCCGTGAGAGGCAGATTCACCATCTCCAGAGATGACTCCAGAGACACATTGTATCTGCAGATGAGCAGCCTGAAAATAGAGGATTCAGGCCGGTATTTTTGCACCGCAGATCTTGGGGAGGCCGTGGTGTCACGATTTTTTGAGTGGGGGTCCTATTATTACTACATGGACTTCTGGGGCAAGGGGACCACGGTCACCGTCTCTTCA,CTADLGEAVVSRFFEWGSYYYYMDFW,84.106
DH511_I1,gp41 MPER (membrane proximal external region),,CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,23.0,TRDEGAPVTRFLEWGSYYYYMAV,17.0,23.6,1-39*01,2*01,11.0,QEAYNTNPTLS,14.0,18.6,K,,UCA or intermediate,human,, Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.,,,12.0,573.0,4185.0,EVQLVESGGGLVKPGQSLTLSCVGFGFNFANDWMGWVRQAPGKGLEWVGRIRRLKDGATTEYASSVKGRFTISRDDSRNTLYLHMSSLKVEDTGVYYCTRDEGAPVTRFLEWGSYYYYMAVWGKGTTVTVSS,DIQMTQSPASLSASVGDTVTITCRASQSIKDYINWYQHKSGSAPRLLIYAASTLQSGVSSRFTGSGSGTQFTLTISSLQPEDFATYYCQEAYNTNPTLSFGQGTRVDRKX,GACATCCAGATGACCCAGTCTCCAGCCTCTCTGTCTGCATCTGTAGGAGACACAGTGACTATCACTTGCCGGGCAAGTCAGAGTATTAAAGATTATATAAATTGGTATCAACACAAATCCGGGAGCGCCCCTAGACTCCTGATTTATGCTGCGTCAACCTTACAAAGTGGAGTCTCGTCAAGGTTCACTGGCAGTGGGTCTGGGACACAGTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTGCGACTTATTATTGTCAAGAGGCTTATAACACCAATCCCACACTCTCCTTTGGTCAGGGGACCAGGGTGGACAGGAAAC,GAGGTGCAGCTGGTGGAGTCTGGGGGCGGCTTGGTGAAGCCGGGACAGTCACTCACACTTTCCTGTGTGGGCTTTGGATTCAATTTCGCTAACGACTGGATGGGCTGGGTCCGCCAGGCTCCAGGGAAGGGACTGGAATGGGTTGGTCGTATAAGGAGACTAAAAGATGGTGCGACAACAGAATATGCTTCATCCGTGAAGGGTAGATTCACCATCTCAAGAGATGATTCAAGAAACACACTATACTTGCACATGAGCAGCCTCAAAGTCGAGGACACAGGCGTCTATTATTGTACCCGAGACGAGGGGGCCCCAGTTACCCGATTTCTGGAGTGGGGCTCCTATTACTACTACATGGCCGTCTGGGGCAAAGGGACCACGGTCACCGTCTCTTCA,CTRDEGAPVTRFLEWGSYYYYMAVW,82.781
DH511_I2,gp41 MPER (membrane proximal external region),,CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,23.0,TTDEGAPVTRFLEWGYYYYYMAV,6.1,13.8,1-39*01,2*01,11.0,QETYNTTPTLT,7.2,12.4,K,,UCA or intermediate,human,, Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.,,,12.0,574.0,4186.0,EVQLVESGGGLVKPGGSLTLSCAASGFTFGNAWMGWVRQAPGKGLEWVGRIRRLKDGATTEYAAPVKGRFTISRDDSRNTLYLHMSSLKTEDTGVYYCTTDEGAPVTRFLEWGYYYYYMAVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIRDYLNWYQQKPGRAPRLLIYAASTLQSGVPSRFSGSGSGTHFTLTITSLQPEDFATYYCQETYNTTPTLTFGQGTKVDIKX,GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGTATTAGAGACTATTTAAATTGGTATCAACAGAAACCCGGGAGAGCCCCTAGACTCCTGATTTATGCTGCGTCAACTTTGCAAAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACACATTTCACTCTCACCATTACCAGTCTGCAACCTGAAGATTTTGCAACTTATTATTGTCAAGAGACTTATAATACCACTCCCACGCTCACCTTTGGTCAGGGGACCAAGGTGGACATCAAAC,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCGGGGGGGTCCCTCACACTCTCCTGTGCAGCCTCTGGATTCACTTTCGGTAACGCCTGGATGGGCTGGGTCCGCCAGGCTCCAGGGAAGGGACTGGAGTGGGTTGGCCGTATTAGAAGGCTCAAAGATGGTGCGACAACAGAATATGCTGCACCCGTGAAGGGCAGATTCACCATCTCAAGAGATGATTCAAGAAACACGCTGTACCTGCACATGAGCAGCCTGAAAACCGAGGACACAGGCGTGTATTATTGTACCACAGATGAGGGGGCCCCAGTAACACGATTTTTGGAGTGGGGCTACTACTACTACTACATGGCCGTCTGGGGCAAAGGGACCACGGTCACCGTCTCTTCA,CTTDEGAPVTRFLEWGYYYYYMAVW,92.053
DH511_I3,gp41 MPER (membrane proximal external region),,CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,24.0,TADLGEAVVSRFFEWGSYYYYMDF,15.6,17.7,1-39*01,2*01,11.0,QEAYSSTPTLT,16.7,19.6,K,,UCA or intermediate,human,, bSomatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.,,,12.0,575.0,4187.0,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNTWMSWVRQAPGKGLEWVGRISRNKDGAKTDYAAPVRGRFTISRDDSRDTLYLQMSSLKIEDSGRYFCTADLGEAVVSRFFEWGSYYYYMDFWGKGTTVTVSS,DIQMTQSPSPLSASVGDTVTITCRASQKISDYLNWYQQRPGRAPKILIYAASKLASDVPSRFSGSGYGRDFTLTITGLQPEDFATYYCQEAYSSTPTLTFGQGTRLDLKX,GACATCCAGATGACCCAGTCTCCATCTCCCCTGTCTGCGTCTGTGGGAGACACAGTCACTATCACTTGCCGGGCCAGCCAGAAGATTAGCGACTATTTGAACTGGTACCAACAGAGGCCGGGGAGAGCCCCCAAAATACTCATTTACGCTGCGTCCAAGTTGGCAAGCGACGTCCCATCAAGGTTCAGTGGCAGTGGATATGGCAGAGATTTCACTCTCACCATCACCGGTCTGCAGCCTGAAGATTTTGCAACCTATTATTGTCAGGAGGCTTACAGTTCTACTCCCACGTTAACTTTTGGCCAGGGGACCAGGCTGGATCTCAAAC,GAGGTTCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCGGGGGGGTCTCTTAGACTCTCCTGTGTAGCCTCTGGCTTCACTTTCAGCAACACGTGGATGAGTTGGGTCCGTCAGGCGCCAGGGAAGGGACTGGAGTGGGTCGGTCGGATTAGCCGGAACAAAGATGGCGCGAAAACAGACTACGCCGCACCCGTGAGAGGCAGATTCACCATCTCCAGAGATGACTCCAGAGACACATTGTATCTGCAGATGAGCAGCCTGAAAATAGAGGATTCAGGCCGGTATTTTTGCACCGCAGATCTTGGGGAGGCCGTGGTGTCACGATTTTTTGAGTGGGGGTCCTATTATTACTACATGGACTTCTGGGGCAAGGGGACCACGGTCACCGTCTCTTCA,CTADLGEAVVSRFFEWGSYYYYMDFW,84.106
DH511_I4,gp41 MPER (membrane proximal external region),,CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,24.0,TADLGEAVVSRFFEWGSYYYYMDF,15.6,17.7,1-39*01,2*01,11.0,QEAYSSTPTLT,16.7,19.6,K,,UCA or intermediate,human,, Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.,,,12.0,576.0,4188.0,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNTWMSWVRQAPGKGLEWVGRISRNKDGAKTDYAAPVRGRFTISRDDSRDTLYLQMSSLKIEDSGRYFCTADLGEAVVSRFFEWGSYYYYMDFWGKGTTVTVSS,DIQMTQSPSPLSASVGDTVTITCRASQKISDYLNWYQQRPGRAPKILIYAASKLASDVPSRFSGSGYGRDFTLTITGLQPEDFATYYCQEAYSSTPTLTFGQGTRLDLKX,GACATCCAGATGACCCAGTCTCCATCTCCCCTGTCTGCGTCTGTGGGAGACACAGTCACTATCACTTGCCGGGCCAGCCAGAAGATTAGCGACTATTTGAACTGGTACCAACAGAGGCCGGGGAGAGCCCCCAAGATCCTCATTTACGCTGCGTCCAAGTTGGCAAGCGACGTCCCATCAAGATTTAGTGGCAGTGGATATGGCAGAGATTTCACTCTCACCATAACCGGTCTGCAGCCTGAAGATTTTGCAACCTATTATTGTCAGGAGGCTTACAGTTCTACCCCCACGTTAACTTTTGGCCAGGGGACCAGGCTGGATCTCAAAC,GAGGTTCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCGGGGGGGTCTCTTAGACTCTCCTGTGTAGCCTCTGGCTTCACTTTCAGCAACACGTGGATGAGTTGGGTCCGTCAGGCGCCAGGGAAGGGACTGGAGTGGGTCGGTCGGATTAGCCGGAACAAAGATGGCGCGAAAACAGACTACGCCGCACCCGTGAGAGGCAGATTCACCATCTCCAGAGATGACTCCAGAGACACATTGTATCTGCAGATGAGCAGCCTGAAAATAGAGGATTCAGGCCGGTATTTTTGCACCGCAGATCTTGGGGAGGCCGTGGTGTCACGATTTTTTGAGTGGGGGTCCTATTATTACTACATGGACTTCTGGGGCAAGGGGACCACGGTCACCGTCTCTTCA,CTADLGEAVVSRFFEWGSYYYYMDFW,84.106
DH511_I5,gp41 MPER (membrane proximal external region),,CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,24.0,TADLGEAVVSRFFEWGSYYYYMDF,15.3,16.7,1-39*01,2*01,11.0,QEAYSSTPTLT,15.5,17.6,K,,UCA or intermediate,human,, Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.,,,12.0,577.0,4189.0,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNTWMSWVRQAPGKGLEWVGRISRNKDGAKTDYAAPVRGRFTISRDDSRDTLYLQMSSLKIEDSGRYFCTADLGEAVVSRFFEWGSYYYYMDFWGKGTTVTVSS,DIQMTQSPSPLSASVGDTVTITCRASQKISDYLNWYQQKPGRAPKILIYAASKLGSGVPSRFSGSGYGRDFTLTITGLQPEDFATYYCQEAYSSTPTLTFGQGTRLDLKX,GACATCCAGATGACCCAGTCTCCATCTCCCCTGTCTGCGTCTGTGGGAGACACAGTCACTATCACTTGCCGGGCCAGCCAGAAGATTAGCGACTATTTGAACTGGTACCAACAGAAGCCGGGGAGAGCCCCCAAAATACTCATTTACGCTGCGTCCAAGTTGGGAAGTGGCGTCCCATCAAGGTTCAGTGGCAGTGGATATGGCAGAGATTTCACTCTCACCATCACCGGTCTGCAGCCTGAAGATTTTGCAACCTATTATTGTCAGGAGGCTTACAGTTCTACTCCCACGTTAACTTTTGGCCAGGGGACCAGGCTGGATCTCAAAC,GAGGTTCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCGGGGGGGTCTCTTAGACTCTCCTGTGCAGCCTCTGGCTTCACTTTCAGCAACACGTGGATGAGTTGGGTCCGTCAGGCGCCAGGGAAGGGACTGGAGTGGGTCGGTCGGATTAGCCGGAACAAAGATGGCGCGAAAACAGACTACGCCGCACCCGTGAGAGGCAGATTCACCATCTCAAGAGATGACTCCAGAGACACATTGTATCTGCAGATGAGCAGCCTGAAAATAGAGGATTCAGGCCGGTATTTTTGCACCGCAGATCTTGGGGAGGCCGTGGTGTCACGATTTTTTGAGTGGGGGTCCTATTATTACTACATGGACTTCTGGGGCAAGGGGACCACGGTCACCGTCTCTTCA,CTADLGEAVVSRFFEWGSYYYYMDFW,84.768
DH511_I6,gp41 MPER (membrane proximal external region),,CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,24.0,TTDLEGAPVSRFLEWGYYYYYMDV,12.0,4.1,1-39*01,2*01,11.0,QETYSTTPTFT,3.8,6.2,K,,UCA or intermediate,human,, Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.,,,12.0,578.0,4190.0,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIRRKKDGATTDYAAPVKGRFTISRDDSRNTLYLQMSSLKTEDTGVYYCTTDLEGAPVSRFLEWGYYYYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISDYLNWYQQKPGRAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQETYSTTPTFTFGQGTKLEIKX,GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACAATCACTTGCCGGGCAAGTCAGAGCATTAGCGACTATTTAAATTGGTATCAACAGAAACCAGGGAGAGCCCCTAAACTCCTGATTTATGCTGCGTCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTATTATTGTCAAGAGACTTACAGTACCACTCCCACGTTCACTTTTGGCCAGGGGACCAAGCTGGAGATCAAAC,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGACTGGAGTGGGTTGGCCGTATTAGAAGGAAAAAAGATGGTGCGACAACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAGAAACACGCTGTATCTGCAAATGAGCAGCCTGAAAACCGAGGACACAGGCGTGTATTATTGTACCACAGATCTTGAGGGGGCCCCGGTATCACGATTTTTGGAGTGGGGCTACTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCTTCA,CTTDLEGAPVSRFLEWGYYYYYMDVW,96.026
DH511_UCA,gp41 MPER (membrane proximal external region),,CH0210 ,DH511,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,24.0,TTDLEGAPVLRFLEWGYYYYYMDV,0.0,0.0,1-39*01,2*01,11.0,QQSYSTPPTCT,0.0,,K,,UCA or intermediate,human,, Unmutated Common Ancestor of DH511 lineage.  Other lineage members are compared to this Ab's germline sequence.,,,12.0,572.0,4191.0,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTDLEGAPVLRFLEWGYYYYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTCTFGQGTKLEIKX,GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCTCCCACGTGCACTTTTGGCCAGGGGACCAAGCTGGAGATCAAAC,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTAGACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCGTATTAAAAGCAAAACTGATGGTGGGACAACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAAAAACACGCTGTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTACCACAGATCTTGAGGGGGCCCCGGTATTACGATTTTTGGAGTGGGGCTACTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CTTDLEGAPVLRFLEWGYYYYYMDVW,100.000
DH517,gp41 MPER (membrane proximal external region),,CH0210 ,,Williams2017(28783671) ,,Williams2017(28783671) ,IMGT/V-QUEST,4-34*01,3-16*01,6*01,24.0,ARGTGVVVGGSWTVPPGMAYYLDV,18.1,35.1,3-39*01,2*01,12.0,ASRDRSGDRLGV,13.4,23.0,L,,Natural monoclonal,human,Ab510053, ,17.394,9.28817,64.0,322.0,3665.0,QVQLQESGGGVLKPSQTLSLTCAVHDGSFSDYWWTWIRQSPGKGLEWVAEINESGETNYNGALRSRVSLSLDIMRGHVSLTLRSATAADNGAYFCARGTGVVVGGSWTVPPGMAYYLDVWGTGTTVIVSS,SSELTQDPTVSVALGQTVKIRCQGASLRDCYATWYRQKPGQAPTLLIYDINKRPSGIPDRFSASYSGSTSSLTIIGAQPEDEADYFCASRDRSGDRLGVFGGGTKLTVL,TCTTCTGAGCTGACTCAGGACCCCACTGTGTCTGTGGCCTTGGGCCAGACAGTCAAGATCAGATGCCAAGGAGCCAGCCTCAGAGACTGTTATGCGACCTGGTACCGGCAGAAGCCAGGACAGGCCCCAACACTTCTCATTTATGATATAAATAAGAGGCCCTCAGGTATCCCAGACCGATTCTCTGCCTCCTACTCAGGGAGCACTTCTTCCTTGACCATTATTGGGGCTCAGCCGGAAGATGAGGCTGACTATTTTTGTGCTTCGCGGGACAGGAGTGGTGACCGTCTTGGCGTCTTCGGCGGTGGGACCAAACTGACCGTCCTG,CAGGTGCAGCTGCAGGAGTCGGGCGGAGGAGTGTTGAAGCCTTCACAGACCCTGTCCCTCACCTGTGCTGTGCATGATGGGTCATTCAGTGACTACTGGTGGACGTGGATCCGCCAGTCCCCAGGGAAGGGTCTTGAGTGGGTCGCGGAAATCAATGAAAGTGGAGAGACCAACTACAATGGGGCCCTCAGGAGTCGCGTCTCCTTGTCCCTCGACATCATGAGGGGTCACGTCTCCCTGACACTGCGGTCCGCGACCGCCGCGGATAACGGTGCCTATTTCTGTGCGAGAGGCACGGGGGTTGTTGTGGGCGGAAGTTGGACTGTACCTCCTGGGATGGCGTATTATTTGGACGTCTGGGGGACAGGGACCACAGTCATCGTCTCCTCA,CARGTGVVVGGSWTVPPGMAYYLDVW,77.816
DH563,gp120 V3 // V3 glycan (V3g),,CH765 ,VRC41,Alam2017(28298421) ,Mutation affects neutralization of V3 mAbs,Alam2017(28298421) ,Cloanalyst IMGT/V-QUEST,4-39,3-3,4-1,21.0,,21.0,,3-20,4,9.0,,14.0,,K,,Natural monoclonal,human,CH765-DH563, ,28.4967,3.61814,30.0,310.0,3821.0,QLQLQESGPRLVKPSETMWLICSASGGSFSDHNYYYGWIRQAPGKGLEWVGSVTYNLKAWYHPSLESRITVSADMGRNEMSLKMTSVTVADTAVYFCVRHVVRIRDYWSGPPHYYFDAWGQGLLVTVSA,EIVLTQSPGFLSLSPGDRATLSCRASQTLTRRDLAWYRQRPGQAPTLLIYYASTRAAGIPDRFTGSGSGTDFTLTISRLEPEDFGVYYCQQHDNSPPAFGGGTKVELK,GAAATTGTGTTGACGCAGTCTCCAGGTTTCCTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCAGTCAGACTCTCACTCGGCGTGACTTGGCCTGGTACCGGCAGAGACCTGGCCAGGCTCCCACACTCCTCATCTATTATGCGTCCACCAGGGCCGCTGGCATCCCAGACAGGTTCACTGGCAGTGGGTCTGGTACAGACTTCACTCTCACCATCAGCCGACTGGAGCCTGAGGATTTTGGAGTATATTACTGTCAGCAGCACGATAACTCACCTCCCGCTTTCGGCGGAGGGACGAAGGTGGAGCTCAAA,CAGCTGCAGCTGCAGGAGTCGGGCCCAAGACTGGTGAAGCCGTCGGAGACCATGTGGCTCATCTGCAGTGCCTCGGGCGGCTCTTTCAGTGATCATAATTATTATTATGGCTGGATCCGCCAGGCCCCAGGGAAGGGACTGGAGTGGGTTGGAAGTGTCACTTACAACCTAAAGGCCTGGTATCATCCATCTCTCGAGAGTCGAATCACCGTCTCTGCAGACATGGGCAGGAACGAGATGTCCCTGAAGATGACGTCTGTGACCGTCGCGGACACGGCCGTTTATTTTTGTGTGAGACATGTCGTGCGAATTCGCGATTACTGGAGTGGACCCCCCCATTATTACTTTGACGCGTGGGGACAGGGCTTATTAGTCACCGTCTCCGCA,,
DH576,gp120 CD4bs,5UIX(DH576 CD4bs Fab),3043 ,,Easterhoff2017(28235027) ,,Easterhoff2017(28235027) ,Cloanalyst,3-30,3,6,23.0,ARDRARSTGYFGGIYYYYYGMDV,7.33,,1-33,2,,,3.79,,K,No,Natural monoclonal,human,, ,,,9.0,748.0,3837.0,EVQLVESGGGVVQPGRSLRLSCGVSGFTFSNYAIHWVRQAPGKRLEWVALISYDGKKQYYLDSVKGRFTISRDNSKDMVYLQMNSLKAEDTAIYYCARDRARSTGYFGGIYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIDNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTSFTLTISSLQPEDIGTYYCQKYGSVPFPFGQGTKLEIK,GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGGGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATTGACAACTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTTCTGATCTACGATGCATCCAATTTGGAAACAGGGGTCCCATCAAGATTCAGTGGAAGTGGATCTGGGACATCTTTTACTCTCACCATCAGCAGCCTGCAGCCTGAGGATATTGGAACATATTACTGTCAAAAATATGGCTCTGTCCCGTTCCCTTTTGGCCAGGGGACCAAGCTGGAGATCAAA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGGTGTCTCTGGATTCACTTTCAGTAACTATGCTATCCACTGGGTCCGCCAGGCTCCAGGCAAGAGGCTGGAGTGGGTGGCACTTATATCGTATGATGGAAAGAAGCAATACTACCTAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGGACATGGTGTATCTGCAGATGAACAGCCTGAAAGCTGAGGACACGGCTATTTATTACTGTGCGAGAGATCGGGCGCGTAGTACTGGTTATTTTGGGGGCATTTACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACAACGGTCACCGTCTCCTCA,CARDRARSTGYFGGIYYYYYGMDVW,92.230
DH583,gp120 CD4bs,,3070 ,,Easterhoff2017(28235027) ,,Easterhoff2017(28235027) ,Cloanalyst,5-51,,6,23.0,AVYYCQQYYATPYTFGQGTKVEI,4.68,,4-1,2,,,,,K,Yes,Natural monoclonal,human,, ,,,11.0,749.0,3807.0,DIVMTQSPDSLAVSLGERATINCKSSQSVFYSSNNRNYLAWYQQKPRQPPKLLIYRASTRESGVPGRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYATPYTFGQGTKVEIK,DIVMTQSPDSLAVSLGERATINCKSSQSVFYSSNNRNYLAWYQQKPRQPPKLLIYRASTRESGVPGRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYATPYTFGQGTKVEIK,GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTCTACAGCTCCAACAATAGGAACTACTTAGCTTGGTATCAGCAGAAACCAAGACAACCTCCTAAGTTGCTCATTTATAGGGCATCAACCCGGGAATCTGGGGTCCCTGGCCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATGCTACTCCTTACACTTTTGGCCAGGGGACCAAGGTGGAGATCAAA,GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTCTACAGCTCCAACAATAGGAACTACTTAGCTTGGTATCAGCAGAAACCAAGACAACCTCCTAAGTTGCTCATTTATAGGGCATCAACCCGGGAATCTGGGGTCCCTGGCCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATGCTACTCCTTACACTTTTGGCCAGGGGACCAAGGTGGAGATCAAA,CQQYYATPYTF,96.040
DH650.8,gp120 CD4bs,6XCJ(DH650 Fab from a Rhesus Macaque in Complex with HIV-1 gp120 Core),RM6072 ,,Roark2021(33214287) ,,Roark2021(33214287) ,IMGT/V-QUEST,,,,14.0,CARGQLELTASRFDK,4.9,,,,9.0,CMQGLAFPYSF,4.6,,K,,Natural monoclonal,macaque,,Macaque antibody ,97.4902,1.32261,123.0,816.0,4555.0,QVQLVQSGAEVKKPGASVKLSCKASGYAFTIYSINWVRQAPGQGLEWMGWINPRNGRIGYAQKFQDRVTMTRDTSTNIAYMELGSLRSEDTAVYFCARGQLELTASRFDKWGQGVPVTVSS,DIVMTQSPLSLPVTPGEPAAISCRSSQSLLDRADGNTYLDWYLQKPGQSPQLLIYEVSSRASGVPDRFSGSGSDTDFTLRISRVEAEDVGVYFCMQGLAFPYSFGQGTKVEIK,GATATTGTGATGACCCAGAGTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCGCCATCTCCTGTAGGTCTAGTCAGAGCCTCCTGGATAGAGCCGATGGAAACACCTATTTGGATTGGTACCTGCAGAAGCCAGGCCAGTCTCCACAACTCTTGATTTATGAGGTTTCCAGCCGGGCCTCTGGAGTCCCAGACAGGTTCAGTGGCAGTGGGTCAGACACTGATTTCACACTGAGAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTTTTGCATGCAAGGTCTGGCGTTTCCTTACAGTTTTGGCCAGGGGACCAAAGTGGAGATCAAA,CAGGTCCAGCTGGTGCAATCCGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGCTCTCCTGCAAGGCTTCCGGTTATGCTTTTACCATCTACAGTATAAACTGGGTGAGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGATGGATTAACCCTAGGAATGGTCGTATAGGCTACGCACAGAAGTTCCAGGACAGAGTCACCATGACCAGGGACACGTCCACGAATATAGCCTACATGGAACTGGGCAGCCTCAGATCTGAGGACACGGCCGTATATTTCTGTGCAAGGGGTCAACTAGAACTAACTGCTTCTCGCTTTGACAAGTGGGGCCAGGGAGTCCCGGTCACCGTCTCCTCA,CARGQLELTASRFDKW,85.811
DH651.1,gp120 CD4bs,,NIH45 ,VRC01,Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,670.0,4268.0,QVQLVQSGGQMKKPGESMRISCRTSGYEFIECTLNWIRLAPGRRPEWMGWLKPRGGAVNYARSFQGRVTMTRDVYSDTAFLELRSLTPDDTAVYFCTRGKDCNYNWDFEHWGRGTPVTVSS,EIVLTQSPHPALLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDLGVYYCQQYEFFGQGTKVQVD,GAAATTGTGTTGACGCAGTCTCCACACCCTGCTCTTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCGGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATCTTGGTGTTTATTATTGTCAACAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGAC,CAGGTGCAGCTGGTGCAGTCTGGGGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGCCGGACTTCCGGATATGAATTTATTGAGTGTACACTAAATTGGATTCGTCTGGCCCCCGGAAGAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTTCATTTCAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGTTGCGCTCCTTGACACCAGACGACACGGCCGTCTACTTTTGTACTCGGGGAAAAGACTGTAATTACAATTGGGACTTCGAACACTGGGGCCGGGGTACCCCGGTCACCGTCTCATCA,CTRGKDCNYNWDFEHW,68.056
DH651.2,gp120 CD4bs,,NIH45 ,VRC01,Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,36.0,671.0,4269.0,QVQLVQSGAQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGRRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKTCDYNWDFAHWGQGTPVTVSS,EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPEYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVD,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGACTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGAGTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGAC,CAGGTGCAGCTGGTGCAGTCTGGGGCTCAGATGAAGAAACCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCCGGATATGAATTTATTGATTGTACACTAAATTGGATTCGCCTGGCCCCCGGAAGAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAATTACGCACGTCCACTTCAGGGGAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAACCTGTGATTACAATTGGGACTTCGCACACTGGGGCCAGGGAACCCCGGTCACCGTCTCATCA,CTRGKTCDYNWDFAHW,67.235
DH651.3,gp120 CD4bs,,NIH45 ,VRC01,Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,672.0,4270.0,QVQLVQSGGQVKKPGESMRISCRTSGYEFIDCPINWIRLAPGKRPEWMGWMKPRGGAVSYARPLQGRVTMTRDVYSDTAFLELRSLAVDDTAVYFCTRGKNCDDNWDFEHWGRGTPLTVSS,EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVD,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAATATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGACTCGTCATCTATTCGGGTTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGACTACAATCTCACCATCAGCAACTTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGAC,CAGGTGCAGCTGGTGCAGTCTGGGGGTCAGGTGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGACTTCCGGATATGAATTTATTGATTGTCCAATAAATTGGATTCGTCTGGCTCCCGGAAAGAGGCCTGAGTGGATGGGATGGATGAAGCCTAGGGGGGGGGCCGTCAGTTACGCACGTCCACTTCAGGGCAGAGTGACCATGACTCGAGACGTGTATTCCGACACAGCCTTTTTGGAGCTGCGCTCCTTGGCAGTTGACGACACGGCCGTCTATTTTTGTACTAGGGGAAAAAATTGTGATGACAATTGGGACTTCGAACATTGGGGCCGAGGTACCCCCCTCACCGTCTCATCA,,
DH651.4,gp120 CD4bs,,NIH45 ,VRC01,Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,36.0,673.0,4271.0,QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGRRPEWMGWLKPRGGAVSYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKTCDYNWDFAHWGQGTPVTVSS,EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPEYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVD,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGACTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGAGTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGAC,CAGGTGCAGCTGGTGCAGTCTGGGGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCCGGATATGAATTTATTGATTGTACACTAAATTGGATTCGCCTGGCCCCCGGAAGAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAGTTACGCACGTCCACTTCAGGGGAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTATTTTTGCACTAGGGGGAAAACCTGTGATTACAATTGGGACTTCGCACACTGGGGCCAGGGTACCCCGGTCACCGTCTCATCA,CTRGKTCDYNWDFAHW,67.491
DH651.5,gp120 CD4bs,,NIH45 ,VRC01,Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,674.0,4272.0,QVQLVQSGAQMKKPGESMSLSCRASGYEFLNCPINWIRLAPGRRPEWMGWLKPRGGAVNYARKFHGRMTMTRDVYSDTAFLELRSLTSDDTAVYFCTRGKFCTESDYYNWDFEHWGRGAPVTVSP,EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGADYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVD,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGGCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGAC,CAGGTGCAGCTGGTGCAGTCTGGGGCTCAGATGAAGAAGCCTGGCGAGTCCATGAGTCTTTCTTGTCGGGCTTCCGGATATGAATTTTTGAATTGTCCAATAAATTGGATTCGCCTGGCCCCCGGAAGACGGCCTGAATGGATGGGATGGCTGAAGCCTAGGGGGGGGGCCGTCAATTACGCACGTAAATTTCACGGCAGAATGACCATGACTCGAGACGTGTATTCCGACACTGCCTTTTTGGAGTTGCGCTCCTTGACATCAGACGACACGGCCGTCTATTTTTGTACTAGGGGAAAATTTTGTACTGAGAGCGACTATTATAATTGGGACTTCGAACACTGGGGCCGGGGTGCCCCGGTCACCGTCTCACCA,CTRGKFCTESDYYNWDFEHW,68.259
DH651.6,gp120 CD4bs,,NIH45 ,VRC01,Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,675.0,4273.0,QVQLVQSGAQMKKPGESMRLSCRASGYEFLDCPINWIRLAPGRRPEWMGWLKPRGGAVNYARKFHGRVTMTRDVYSDTAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGRGAPVTVSP,EIVLTQSPGTRSLSPGETAIISCRTSQSGSLAWYQHRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGADYNLSISNLESGDFGVYYCQQYEFFGQGTKVQVD,GAAATTGTGTTGACGCAGTCTCCAGGCACCCGGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTCTGGTTCCTTAGCCTGGTATCAACACAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGGCAGACTACAATCTCAGCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGAC,CAGGTGCAGCTGGTGCAGTCTGGGGCTCAGATGAAGAAGCCTGGCGAGTCGATGAGACTTTCCTGTCGGGCTTCCGGATATGAATTTCTCGATTGTCCAATAAATTGGATTCGCCTGGCCCCCGGAAGACGGCCTGAGTGGATGGGATGGCTGAAGCCTAGGGGGGGGGCCGTCAATTACGCACGTAAATTTCACGGCAGGGTGACCATGACTCGAGACGTGTATTCCGACACAGCCTTTTTGGAGTTGCGCTCCTTGACATCAGACGACACGGCCGTCTATTTTTGTACTAGGGGAAAATATTGTACTGCGCGCGACTATTATAATTGGGACTTCGAACACTGGGGCCGGGGTGCCCCGGTCACCGTCTCACCA,CTRGKYCTARDYYNWDFEHW,70.648
DH651.7,gp120 CD4bs,,NIH45 ,VRC01,Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,676.0,4274.0,QVQLVQSGGQMKKPGESMRLSCRASGYEFLDCPINWIRLAPGRRPEWMGWLKPRGGAVNYARKFHGRVTMTRDVYSDTAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGRGAPVTVSP,EIVLTQSPGTLSLSPGETAIISCRTSQSGSLAWYQHRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGADYNLSISNLESGDFGVYYCQQYEIFGQGTKVQVD,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTCTGGTTCCTTAGCCTGGTATCAACACAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGGCAGACTACAATCTCAGCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAAATTTTTGGCCAGGGGACCAAGGTCCAGGTCGAC,CAGGTGCAGCTGGTGCAGTCTGGGGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGACTTTCCTGTCGGGCTTCCGGATATGAATTTCTCGATTGTCCAATAAATTGGATTCGCCTGGCCCCCGGAAGACGGCCTGAGTGGATGGGATGGCTGAAGCCTAGGGGGGGGGCCGTCAATTACGCACGTAAATTTCACGGCAGGGTGACCATGACTCGAGACGTGTATTCCGACACAGCCTTTTTGGAGTTGCGCTCCTTGACATCAGACGACACGGCCGTCTATTTTTGTACTAGGGGAAAATATTGTACTGCGCGCGACTATTATAATTGGGACTTCGAACACTGGGGCCGGGGTGCCCCGGTCACCGTCTCACCA,CTRGKYCTARDYYNWDFEHW,70.307
DH651.8,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,677.0,4275.0,QVQLVQSGAVVRKPGSSMKISCATSGYNFRDFSIHWVRFNRRYGFEWIGWLKPLWGAVSYARQLQGRVSMSRVFSQDPYYPDRGTAFLEFSGLTSADTADYFCVRRGSSCPHCGDFHFEHWGQGTAVVVSA,EIVLTQSPGTLSLSPGERATLFCRASQGGNSLNWYQKRRGQTPRLLIYDTSRRASDIPEKFVGSGSGTDFSLTITKVGPEDFAVYYCQQFEFFGLGTTLEIN,GAAATTGTGTTGACGCAGTCTCCCGGCACCCTGTCTCTGTCTCCAGGGGAGAGAGCCACCCTCTTTTGTAGGGCCAGTCAGGGTGGCAATTCTTTAAATTGGTATCAGAAGAGACGTGGCCAGACTCCCAGACTCCTCATCTACGACACATCTCGCAGGGCCTCTGACATTCCTGAAAAATTTGTTGGCAGTGGGTCTGGGACAGACTTCTCTCTCACCATCACGAAAGTGGGCCCGGAAGATTTCGCAGTCTATTATTGTCAACAATTTGAATTTTTTGGCCTGGGGACCACGCTGGAAATCAAC,CAGGTGCAGCTGGTGCAGTCTGGGGCTGTCGTCAGGAAGCCTGGGTCCTCGATGAAAATCTCATGCGCGACTTCTGGATACAACTTTCGGGACTTTTCGATTCATTGGGTCCGTTTCAACCGTCGATATGGCTTTGAGTGGATCGGCTGGCTCAAGCCTTTGTGGGGTGCCGTCAGTTATGCCCGGCAACTTCAGGGCCGTGTCTCAATGAGTCGAGTCTTTTCTCAGGACCCATATTACCCGGACAGGGGCACAGCCTTTTTGGAATTCAGTGGGCTGACGTCCGCCGACACGGCCGACTATTTCTGCGTGAGGCGGGGGTCTTCCTGTCCTCATTGCGGAGACTTCCATTTCGAACATTGGGGCCAGGGTACAGCCGTCGTCGTCTCGGCA,,
DH651.9,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,678.0,4276.0,QVQLVQSGAVIKTPGSSVKISCRASGFNFRDYSIHWVRLIPDKGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMELSGLTSADTAEYFCVRRGSCDYCGGFPWQYWGQGTVVVVSS,EIVLTQSPGILSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVH,GAAATTGTGTTGACGCAGTCTCCCGGCATCCTGTCTCTGTCTCCAGGAGAGACAGCCACCCTCTTTTGTAAGGCCAGTCAGGGTGGCAATGCTATGACGTGGTATCAGAAGAGACGTGGCCAGGTTCCCAGACTCCTGATTTACGACACATCTCGCAGGGCCTCTGGCGTTCCTGACAGATTTGTTGGCAGTGGGTCTGGGACAGACTTCTTTCTCACGATCAACAAATTGGACCGGGAAGATTTCGCAGTCTATTACTGTCAACAATTTGAATTTTTTGGCCTGGGGAGCGAGCTGGAAGTCCAT,CAGGTGCAGCTGGTGCAGTCTGGGGCTGTGATTAAGACGCCTGGGTCCTCAGTGAAGATCTCATGTCGGGCTTCTGGATTCAACTTTCGTGATTATTCGATTCATTGGGTCCGCCTCATTCCTGACAAGGGATTTGAGTGGATTGGATGGATAAAACCTCTGTGGGGTGCCGTCAGTTATGCCCGGCAACTTCAGGGCCGAGTCTCTATGACTCGACAATTATCTCAAGACCCAGACGACCCGGACTGGGGCGTTGCCTACATGGAGCTCAGTGGACTGACGTCCGCCGACACGGCCGAATATTTTTGTGTCCGGAGAGGGTCCTGTGATTATTGCGGAGGCTTTCCCTGGCAATACTGGGGTCAGGGCACCGTCGTCGTCGTCTCGTCA,,
DRVIA1,gp120 CD4bs,,DRVI01 ,DRVIA1-6b,Kong2016(27067056) ,,Kong2016(27067056) ,IMGT/V-QUEST,1-18*01,3-22*01,4*02,19.0,,3.8,,1-39*01,4*01,9.0,,3.6,,K,,Natural monoclonal,human,, ,,,8.0,488.0,3492.0,,,,,,
DRVIA3,gp120 CD4bs,,DRVI01 ,DRVIA1-6b,Kong2016(27067056) ,,Kong2016(27067056) ,IMGT/V-QUEST,1-18*01,3-22*01,4*02,19.0,,3.1,,1-39*01,4*01,9.0,,4.0,,K,,Natural monoclonal,human,, ,78.3911,3.21425,24.0,489.0,3493.0,,,,,,
DRVIA4,gp120 CD4bs,,DRVI01 ,DRVIA1-6b,Kong2016(27067056) ,,Kong2016(27067056) ,IMGT/V-QUEST,1-18*01,3-22*01,4*02,19.0,,6.3,,1-39*01,4*01,9.0,,4.8,,K,,Natural monoclonal,human,, ,,,8.0,490.0,3494.0,,,,,,
DRVIA6b,gp120 CD4bs,,DRVI01 ,DRVIA1-6b,Kong2016(27067056) ,,Kong2016(27067056) ,IMGT/V-QUEST,1-18*01,3-22*01,4*02,19.0,,3.8,,1-39*01,4*01,9.0,,3.6,,K,,Natural monoclonal,human,, ,,,8.0,491.0,3495.0,,,,,,
DRVIA7,gp120 CD4bs,5CD3(Immature DRVIA7);5CD5(Immature DRVIA7 bound to clade A/E HIV-1 gp120 core);EMD-6372(JRFL Env SOSIP.664 in complex with DRVIA7);EMD-6373(JRFL Env SOSIP.664 in complex with hybrid antibody DRVIA7/VRC01),DRVI01 ,,Kong2016(27067056) ,DRVIA7 contacts,Kong2016(27067056) ,IMGT/V-QUEST,1-2*02,1-7*01,5*02,11.0,SRTKDYDWDFV,19.0,,1-5*03,1*01,5.0,QQFEE,17.0,,K,,Natural monoclonal,human,A7, ,30.9708,9.14724,85.0,258.0,3489.0,QVQLVESGTQFRRPGASVRLSCEASGYTFISSFIHWIRQGPGQGLEWMGWMNPRHGAVNYPRRFQGKVTMTRDTSIDTAYMELRDLRSDDTAMYFCVTSRTKDYDWDFVWGQGTLVVVSS,DIQMTQSPVTLSASIGDRVTITCRASQRIDNWVAWYQQKPGRAPKLLIYKASILETGVPSRFSGSGSGTEFTLSINSLQPDDVATYYCQQFEEFGRGTKID,,,,
DRVIA7H-VRC01L,gp120 CD4bs,,DRVI01 NIH45 ,,Kong2016(27067056) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,DRVIA7H+ VRC01L, ,4.07941,9.45761,51.0,486.0,4091.0,,,,,,
E51,gp120 CCR5bs;gp120 CD4i,1RZF(Human anti-HIV-1 GP120-reactive antibody E51),AC01 ,,Xiang2003(14592765) ,,,,,,,,,,,,,,,,,L,Yes,Natural monoclonal,human,, ,,,4.0,751.0,1254.0,VQLVQSGAEVNKPGSSVKVSCQASGATLNSHAFSWVRQAPGQGLEWMAGIIPIFGSSHYAQKFQGRVTITADESTRTVYLHLRGLRSDDTAVYYCASNSIAGVAAAGDYADYDGGYYYDMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNDVSWYQQFPGTVPKLVIYENNQRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGSKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC,CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGGAATAATGATGTTTCCTGGTACCAGCAGTTCCCAGGAACAGTCCCCAAACTCGTCATCTATGAAAATAATCAGCGACCCTCAGGGATTCCTGACCGCTTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGCACATGGGATAGCAGCCTGAGTGCTGTGGTCTTCGGCGGAGGGTCCAAGGTGACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACCGTGGCCCCCACCGAGTGC,GTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAACAAGCCTGGGTCCTCGGTGAAGGTCTCCTGTCAGGCTTCTGGAGCCACCTTAAACAGTCATGCTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGCAGGGATCATCCCTATATTTGGTTCATCACACTACGCACAAAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAGTCCACGCGCACAGTGTATTTGCATCTGAGAGGCCTGAGATCTGATGACACGGCCGTTTATTACTGTGCGAGTAATTCTATTGCCGGAGTAGCAGCTGCCGGAGACTACGCTGACTACGATGGGGGCTACTACTACGATATGGATGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACT,CASNSIAGVAAAGDYADYDGGYYYDMDVW,90.690
E70,gp41-gp120 interface,6P62(HIV Env BG505 NFL TD+ in complex with antibody E70 fragment antigen binding);EMD-20259(HIV Env BG505 NFL TD+ in complex with antibody E70 fragment antigen binding);EMD-20273(Negative-stain reconstruction of HIV-1 Env BG505 NFL CC+ trimer in complex with rabbit antibody E70 fragment antigen binding),C3 ,,Dubrovskaya2019(31732167) ,E70 contacts,,,,,,,,,,,,,,,,K,,Natural monoclonal,rabbit,, ,24.9172,13.3709,40.0,765.0,4478.0,QSLEESGGGLVKPGGTLTLTCKASGIDFTSGYDMCWVRQAPGKGLEWVACIYLGDGNTYYASWAKGQFTISKTSSTTVTLQMTSLTAADTATYFCARFAGYRYSVWSYPDLWGPGTLVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLTNGVRTFPSVRQSSGLYSLSSVVSVTSSSQPVTCNVAHPATNTKVDKTVAPSTCSK,DIVMTQTPASVEADVGGTVTIKCQASQRIVNLVAWYQHKPGQPPKLLIIGASDLASGVPSRFSGSGYGTEFTLTISDLECADAATYFCQSAYNGDGDNAFGGGTEVVVKGDPVAPSVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC,,,,
F105,gp120 CD4bs,1U6A(Fab F105);3HI1(gp120 (core with V3) complex with F105),,,Posner1991(1710248) ,mutations affecting F105 binding;mutations affecting F105 binding;Mutations at the trimer apex that affect sensitivity,Gach2013(23991039) ,,4-59*01,,,15.0,GPVPAVFYGDYRLDP,,,3-20*01,,9.0,QQYDNSVCT,,,K,Yes,Natural monoclonal,human,F-105, ,75.1169,3.12222,672.0,74.0,631.0,MKHLWFFLLLVAAPRWVLSQVQLQESGPGLVKPSETLSLTCTVSGGSISSHYWSWIRQSPGKGLQWIGYIYYSGSTNYSPSLKSRVTISVETSKNQFSLKLTSMTAADTAVYYCAR,METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSAGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRVEPEDFAGYYCQQYDNSVCTFGQGTKLEIKR,ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTGCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGGTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGAGTGGAGCCTGAAGATTTTGCAGGTTATTACTGTCAGCAATATGATAACTCCGTTTGCACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGA,ATGAAACATCTGTGGTTCTTCCTTCTCCTGGTGGCAGCTCCCAGATGGGTCCTGTCCCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGAGGCTCCATCAGTAGTCACTACTGGAGCTGGATCCGGCAGTCCCCAGGGAAGGGACTGCAGTGGATTGGATATATCTACTACAGTGGGAGCACCAACTACAGCCCCTCCCTCAAGAGTCGAGTCACCATATCAGTAGAGACGTCCAAGAACCAGTTCTCCCTGAAGCTGACCTCTATGACCGCTGCGGACACGGCCGTGTATTACTGTGCGCGA,,
F2,,,GX2016EU04 ,,Ju2018(30382080) ,,Ju2018(30382080) ,IMGT/V-QUEST,1-69*01,3-22*01,3*01,17.0,TRAYHYDTTIGLGAMDV,18.06,,4-1*01,3*01,9.0,HQYHSTPIS,9.93,,K,,Natural monoclonal,human,, ,39.5362,9.9704,14.0,561.0,4171.0,RVELKQSGPGLVKPSETLSLTCEVSGGLVDQFYWAWIRQFPGKGLEWIGYIYSDGFADYTPSLKSRLTFSLDTPKNRVSLRLTSMTPADAGTYYCARLGPGGLFDRYTGYHGRKWLDAWGQGTLVTVSS,ETVLTQSPAILSVFAGGRATLSCRASQTTDGNYLSWYQQKPGQAPRLLMQGASNRATDIPDRFSGSGSGIEFTLTISRVEPEDSAMYYCQQYGRTFGQGTKLEIT,GAAACTGTCCTGACGCAGTCTCCAGCCATCCTGTCTGTGTTTGCAGGAGGAAGAGCCACCCTCTCTTGCAGGGCCAGTCAGACTACTGATGGCAACTACTTGTCTTGGTATCAGCAAAAACCTGGCCAGGCTCCCAGACTCCTCATGCAGGGCGCAAGTAATAGGGCCACTGACATCCCGGACAGATTCAGTGGCAGTGGGTCGGGCATAGAGTTCACCCTGACTATCAGCAGAGTGGAGCCGGAAGATTCTGCAATGTATTACTGTCAACAATATGGGCGGACCTTCGGCCAAGGGACCAAGTTGGAGATCACA,CGCGTGGAGTTGAAGCAGTCGGGGCCAGGACTGGTGAAGCCTTCGGAGACCCTCTCCCTGACCTGCGAAGTGTCTGGGGGCTTAGTCGATCAGTTCTACTGGGCCTGGATCCGCCAGTTCCCCGGAAAGGGATTAGAGTGGATTGGATACATTTATTCAGATGGCTTTGCCGACTACACTCCCTCCCTCAAGAGTCGACTCACCTTTTCACTCGACACGCCCAAGAATCGGGTCTCCCTCAGACTCACATCTATGACCCCTGCGGACGCGGGAACTTATTACTGCGCGAGACTGGGTCCCGGGGGACTCTTCGATCGTTACACTGGTTACCATGGACGAAAGTGGCTCGACGCCTGGGGCCAGGGCACACTGGTCACCGTCTCCTCA,CARLGPGGLFDRYTGYHGRKWLDAW,75.945
F4,,,GX2016EU04 ,,Ju2018(30382080) ,,Ju2018(30382080) ,IMGT/V-QUEST,1-69*11,3-22*01,3*01,17.0,ARAYYYDSTIGLGAMDV,16.32,,4-1*01,3*01,9.0,HQFHSTPVT,8.87,,K,,Natural monoclonal,human,, ,27.6318,16.9226,14.0,564.0,4174.0,QVQLVQSGGGLVQPGGSLRLSCAAFGFNFSSYVMHWVRQAPGQGLEYLSAISSDGETTYHANSVKGRFTSSRDNSKNTLFLQMGSLRTEDVAVYYCARDRYYETSGSNAFDVWGQGTMVVVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVE,NSVLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQHKPGKAPKLLIYTASNLETGVPSRFSGGGSGTHFSFTITSLQPEDAATYFCQQYDNLGDLSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,,,,
F425 B4e8,gp120 V3 // V3 glycan (V3g),2QSC(Fab F425-B4e8 in complex with a V3-peptide),,,Cavacini2003(12646791) ,Mutations at the trimer apex that affect sensitivity,,,,,,,,,,,,,,,,,,Natural monoclonal,human,"B4e8, F425, F425b, F425-B4e8, F425B4e8", ,,,21.0,548.0,1379.0,,,,,,
F6,gp120,,GX2016EU04 ,,Ju2018(30382080) ,,Ju2018(30382080) ,IMGT/V-QUEST,4-34*01,2-8*01,6*01,18.0,ARWRLMMVDEVTRHGMDV,16.14,,2-28*01,2*02,9.0,LQTRQGAFT,11.83,,K,,Natural monoclonal,human,, ,30.2306,3.85063,37.0,567.0,4177.0,,,,,,
F8,,,GX2016EU04 ,,Ju2018(30382080) ,,Ju2018(30382080) ,IMGT/V-QUEST,1-69*11,3-22*01,3*01,17.0,ARAYYYDTSIGLGAMDV,14.58,,4-1*01,3*01,9.0,HQFHSSPVT,7.8,,K,,Natural monoclonal,human,, ,32.9787,15.9841,14.0,565.0,4175.0,RVELKESGPGLVKPSETLSLTCGVSGGLVDQFYWAWIRQFPGKGLEWIGYIYSDGFADYTPSLKSRLTFSLDTPKNRVSLRLTAMTPADAGSYYCARLGPGGLFDRYTGYHGRKWLDAWGQGTLVIVSS,ETVLTQSPGILSVSAGGRATLSCRASQTTDGNYLSWYQQKPGQAPRLLMQGAYNRATDIPDRFSGSGSGTEFTLTISRVEPEDSAMYYCQQYGRTFGQGTKVEIK,GAAACTGTGCTGACGCAGTCTCCAGGCATCCTGTCTGTGTCTGCAGGAGGAAGAGCCACCCTCTCTTGTAGGGCCAGTCAGACTACTGATGGCAACTATTTGTCTTGGTATCAGCAAAAACCTGGCCAGGCTCCCAGACTCCTCATGCAGGGCGCATACAATAGGGCCACTGACATCCCGGACAGATTCAGTGGCAGTGGGTCGGGCACAGAGTTCACCCTGACTATCAGCAGAGTGGAGCCGGAAGATTCTGCAATGTATTACTGTCAACAATATGGGCGGACCTTCGGCCAAGGGACCAAGGTGGAGATCAAA,CGCGTGGAGTTGAAGGAGTCGGGGCCAGGACTGGTGAAGCCTTCGGAGACCCTCTCCCTGACCTGCGGAGTGTCTGGGGGCTTAGTCGATCAGTTCTACTGGGCCTGGATCCGCCAGTTCCCCGGAAAGGGATTAGAGTGGATTGGATACATTTACTCAGATGGCTTTGCCGACTACACTCCCTCCCTCAAGAGTCGACTCACCTTTTCACTCGACACGCCCAAGAATCGGGTCTCCCTGAGACTCACAGCTATGACCCCTGCGGACGCGGGAAGTTATTACTGCGCGAGACTGGGTCCCGGGGGACTCTTCGATCGTTACACTGGTTACCATGGACGGAAGTGGCTCGACGCCTGGGGCCAGGGCACACTGGTCATCGTCTCCTCA,CARLGPGGLFDRYTGYHGRKWLDAW,75.945
gVRC-H1dC38/VRC01L,gp120 CD4bs,,C38 NIH45 ,,Zhu2013a(24106303) ,,Zhu2013a(24106303) ,IMGT/V-QUEST,1-02*02,2-21*01,5*02,12.0,ARGFGGSDWSFL,,,,,,,,,K,,Engineered monoclonal,human,,chimeric ,1.52584,11.0448,306.0,150.0,3118.0,QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSS,,,CAGGTGCAGCTGGTGCAGTCTGGGGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTTATTGATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTTCAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCCGGTCATCGTCTCATCA,CTRGKNCDYNWDFEHW,68.601
H6,,,GX2016EU04 ,,Ju2018(30382080) ,,Ju2018(30382080) ,IMGT/V-QUEST,1-69*01,3-22*01,3*01,17.0,ARAYYYDTATGLGSMDV,17.01,,4-1*01,3*01,9.0,HQYHSTPIS,11.7,,K,,Natural monoclonal,human,, ,47.919,6.13045,14.0,562.0,4172.0,EVQLVESGGGLVKPGGSLRLPCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLNSINFLYLEMNNLRMEDSGLYFCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTVSS,SYELTQETGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPKLLFYGKNNRPSGIPDRFSGSASGNRASLTISGAQAEDDAEYYCSSRDKSGSRLSVFGGGTKLTVL,TCCTATGAGCTGACACAGGAGACTGGTGTCTCTGTGGCCTTGGGACGGACAGTCACAATCACGTGCCGGGGAGACAGCCTCAGAAGTCATTATGCAAGTTGGTACCAAAAGAAGCCAGGACAGGCCCCTAAACTTCTCTTCTATGGTAAAAATAATCGTCCTTCAGGGATCCCAGACCGATTCTCTGGCTCCGCCTCAGGAAACAGAGCTTCCTTGACCATCTCTGGGGCTCAGGCGGAAGACGACGCGGAATATTATTGTAGTTCTCGAGACAAGAGTGGCAGCCGTCTGTCGGTCTTCGGCGGGGGGACCAAACTGACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCTGGAGGATCCCTTAGACTCCCATGTTCAGCCTCTGGTTTCGACTTCGATAACGCCTGGATGACTTGGGTCCGCCAGCCTCCAGGGAAGGGCCTCGAATGGGTTGGTCGTATTACGGGTCCAGGTGAAGGTTGGTCAGTGGACTATGCTGCACCCGTGGAAGGCAGATTTACCATCTCGAGACTCAATTCAATAAATTTCTTATATTTGGAGATGAACAATTTAAGAATGGAAGACTCAGGCCTTTACTTCTGTGCCCGCACGGGAAAATATTATGATTTTTGGAGTGGCTATCCGCCGGGAGAAGAATACTTCCAAGACTGGGGCCGGGGCACCCTGGTCACCGTCTCCTCA,CARTGKYYDFWSGYPPGEEYFQDW,78.114
HG107,gp120 V2 // V2 glycan(V2g) // V2 apex,,200134 ,,Liao2013b(23313589) ,,Liao2013b(23313589) ,,3-9,2-2,4,14.0,,2.3,,3-10,1,10.0,,0.9,,L,Yes,Natural monoclonal,human,, ,,,2.0,624.0,3021.0,EVQLVESGGDLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWISGISGNSGSRGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCATDGDRSGTTPLDHWGQGTRVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKNYAYWYQQKSGQAPALVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGTPSFGTGTKVTVL,TCCTATGAGCTGACACAGCCACCCTCGGTGTCAGTGTCCCCAGGACAAACGGCCAGGATCACCTGCTCTGGAGATGCATTGCCAAAAAATTATGCTTATTGGTACCAGCAGAAGTCAGGCCAGGCCCCTGCGTTGGTCATCTATGAGGACAGCAAACGACCCTCCGGGATCCCTGAGAGATTCTCTGGCTCCAGCTCAGGGACAATGGCCACCTTGACTATCAGTGGGGCCCAGGTGGAGGATGAAGCTGACTACTACTGTTACTCAACAGACAGCAGTGGTACTCCCTCCTTCGGAACTGGGACCAAGGTCACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGACTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGATCTCAGGTATTAGTGGGAATAGTGGTAGCAGAGGCTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTACTGTGCAACAGATGGAGACAGATCTGGCACTACGCCTCTTGACCATTGGGGCCAGGGAACCCGGGTCACCGTCTCCTCA,CATDGDRSGTTPLDHW,97.980
HG120,gp120 V2 // V2 glycan(V2g) // V2 apex,,302689 ,,Liao2013b(23313589) ,,Liao2013b(23313589) ,,3-23,5-5,4,13.0,,1.6,,3-10,2,10.0,,0.3,,L,Yes,Natural monoclonal,human,, ,,,2.0,625.0,3022.0,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMRWVRQAPGKGLEWVSGISGSGGSTYYADSVKGRFTISRDNSKITLYLQMDSLRVEDTAVYYCATAPLSYDSSTDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNPRFGRGTKLTVL,TCCTATGAGCTGACACAGCCACCCTCGGTGTCAGTGTCCCCAGGACAAACGGCCAGGATCACCTGCTCTGGAGATGCATTGCCAAAAAAATATGCTTATTGGTACCAGCAGAAGTCAGGCCAGGCCCCTGTGCTGGTCATCTATGAGGACAGCAAACGACCCTCCGGGATCCCTGAGAGATTCTCTGGCTCCAGCTCAGGGACAATGGCCACCTTGACTATCAGTGGGGCCCAGGTGGAGGATGAAGCTGACTACTACTGTTACTCAACAGACAGCAGTGGTAATCCCCGATTCGGCAGAGGGACCAAGCTGACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGTTATGCCATGAGGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGGTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGATCACGCTGTATCTGCAAATGGACAGCCTGAGAGTCGAGGACACGGCCGTATATTACTGTGCGACAGCGCCCCTCAGCTATGATTCCTCCACGGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CATAPLSYDSSTDYW,97.627
HGN194,gp120 V3 // V3 glycan (V3g),,VI3265 ,,Corti2010(20098712) ,HGN194 epitope,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,41.2735,8.6293,106.0,89.0,2459.0,EVQLVQSGAEVKKPGESLKISCYGSGYNFNDYWIGWVRQMPGKGLEWMGMIYPDDSDTKYSAAFEGQVTLSADKSISTAYLQWTSLRASDTATYYCARLDGDYADFDSWGQGTLVTVSSX,QSVLTQPPSVSAAPGQKVTISCSGTNSNLGDKFVSWYQQLPGTAPRLLIYDNDKRPSGIPDRFSGSKSGASATLAITGLQTGDEADYYCGTWDNSLSALFGGGTKLTVLX,CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCCGGACAGAAGGTCACCATCTCCTGCTCTGGAACCAACTCCAACCTTGGCGATAAGTTTGTATCCTGGTACCAACAACTCCCAGGAACAGCCCCCAGACTCCTCATTTATGACAATGATAAGCGACCCTCAGGCATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCGCGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGAACATGGGATAACAGCCTGAGTGCCTTATTCGGCGGAGGGACCAAGCTGACCGTCCTAC,GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGAGAGTCTCTGAAGATCTCCTGTTACGGCTCTGGATACAACTTTAACGACTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGTATGATCTATCCTGATGACTCCGATACTAAATACAGTGCGGCCTTCGAAGGCCAGGTCACCCTGTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAATGGACCAGCCTGCGGGCCTCGGACACCGCCACGTATTACTGTGCGAGACTCGACGGTGACTACGCCGATTTTGACTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAC,CARLDGDYADFDSW,91.525
HJ16,gp120 CD4bs,4YE4(Neutralizing Antibody HJ16 in Complex with HIV-1 gp120),VI3208 ,,Corti2010(20098712) ,HJ16 binding requires N276;HJ16 contacts;Mutation decreases binding to CD4BS mAbs;Signature Analysis Summary,Klein2013(23540694) ,IgBlast,3-30,3-3,2,,,,,4-1,4,,,,,K,,Natural monoclonal,human,HJ16_22, Wu2011 %SHM calculated for heavy chain = VH and light chain = VL.,18.844,15.5049,1078.0,88.0,2460.0,QMKLMQSGGVMVRPGESATLSCVASGFDFSRNGFEWLRQGPGKGLQWLATVTFESKTHVTASARGRFTISRDNSRRTVYLQMTNLQPDDTAMYFCVKDQTIFHKNGAVDFFSYFDLWGRGAPVIVSAX,DVVMTQSPEFLAVSLGERATLECKSSHSLLYAPYDKDALVWYQQKPGQPPKLLLDWASSRRSGVSDRFSATSASGRYFTLTISNFRADDVATYYCQQTRWTPPTFGGGTKVDLNX,GACGTCGTGATGACCCAGTCTCCAGAATTCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCCTCGAATGCAAGTCCAGCCACAGTCTTTTATATGCCCCCTACGATAAGGATGCCTTAGTTTGGTATCAGCAAAAACCAGGGCAGCCTCCAAAGTTGCTCCTTGACTGGGCATCAAGTCGTCGCTCCGGGGTCTCTGACCGATTCAGTGCCACCAGCGCATCTGGGAGATACTTTACTCTTACGATTAGCAATTTCCGGGCTGACGACGTGGCGACTTATTATTGTCAACAGACCCGCTGGACTCCCCCTACCTTCGGCGGCGGGACCAAGGTGGATCTCAACC,CAGATGAAGTTGATGCAGTCGGGGGGAGTCATGGTCCGGCCTGGAGAATCGGCGACACTGTCTTGTGTTGCCTCTGGATTCGACTTCAGTCGCAATGGGTTCGAGTGGCTCCGCCAGGGTCCCGGCAAGGGGCTGCAGTGGCTGGCCACAGTCACCTTCGAAAGTAAGACACATGTCACGGCCTCCGCGCGGGGCCGATTCACTATTTCTAGAGACAATTCCAGGAGAACCGTCTATTTGCAAATGACTAATCTGCAGCCTGACGATACGGCAATGTATTTCTGTGTTAAAGACCAGACTATTTTTCACAAAAATGGAGCCGTCGATTTCTTCTCGTACTTCGACCTGTGGGGCCGTGGCGCCCCGGTCATAGTCTCCGCAG,CVKDQTIFHKNGAVDFFSYFDLW,70.946
nan,,,,,,,Wu2011(21835983) ,IgBlast,3-30*18,,,,,,45.9,4-1*01,,,,,30.4,,,,,,,,,,,,,,,,,
nan,,,,,,,Zhu2011(21880764) ,,,,,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,
HK20,gp41 NHR (N-heptad repeat),2XRA(HK20 Fab in complex with a gp41 mimetic 5-Helix),VI3081 ,,Corti2010(20098712) ,HK20 contacts,,,,,,,,,,,,,,,,,Yes,Natural monoclonal,human,, ,94.9494,1.2932,141.0,90.0,2461.0,QVQLVQSGAEVKKPGSSVKVSCKTSGGTFNRLAMSWVRQAPGQGLEWMGGIMPIFDITNYAQKFQGRVTIITDESTSTAYMELRSLTSEDSAVYYCARASYSSSSPYAFDIWGQGTMVTVSSX,DIQMTQSPSSLSPSVGDRVTITCQASQDIRNHLNWYQQKPGKAPKLLIYDASNLATGVPSRFSGSGSGTDFTFTISSLQPEDLATYYCQHYDDLPRITFGQGTRLEIKX,GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTCCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAAGACATTAGGAACCATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTACGATGCATCCAATTTGGCAACAGGGGTCCCATCAAGGTTCAGTGGAAGTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATCTTGCAACATATTACTGTCAACACTATGATGATCTGCCTCGAATCACCTTCGGCCAAGGGACACGACTGGAGATTAAAC,CAGGTCCAGTTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGACCTCTGGAGGCACCTTCAACAGATTAGCTATGAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATGCCTATATTTGATATAACAAACTATGCACAGAAGTTCCAGGGCAGAGTCACGATTATCACGGACGAATCCACGAGCACAGCCTACATGGAACTGAGGAGCCTGACATCTGAGGACTCGGCCGTGTATTATTGTGCGAGAGCATCCTATAGCAGCTCGTCCCCTTATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG,CARASYSSSSPYAFDIW,93.220
IA-Hu5A8,non-HIV: host CD4R,,,,Wu2018(29461979) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,IA-iMab,iMab variant that includes ImmunoAdhesin ,0.08637,7.42203,40.0,618.0,3914.0,,,,,,
IA-PGT128,gp120 V3 // V3 glycan (V3g),,Donor 36 ,PGT128,,,,,,,,,,,,,,,,,,,,Engineered monoclonal,,,Engineered form of PGT128 that includes ImmunoAdhesin ,0.91676,32.6088,40.0,617.0,3913.0,,,,,,
iMab,non-HIV: host CD4R,3O2D(CD4 in complex with a potent antiviral antibody),,,,,,,,,,,,,,,,,,,,,,,humanized mouse,"5A8, Hu5A8, ibalizumab, TMB-355, TNX-335",iMab is an anti-CD4 receptor antibody (not anti-HIV) ,0.094634,9.33202,295.0,376.0,3410.0,QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG,DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,,,,
iMab-CAP256,gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CD4R,,CAP256 ,,Moshoette2019(31703699) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;humanized mouse,,bispecific ,0.0017699,14.8957,20.0,698.0,4293.0,,,,,,
iMab-N6,gp120 CD4bs;non-HIV: host CD4R,,Z258 ,,Moshoette2022(36071449) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;humanized mouse,,bispecific ,0.047116,3.13508,21.0,699.0,4294.0,,,,,,
IOMA,gp120 CD4bs,5T3X(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074);5T3Z(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074);6CHB(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and IOMA),R1 ,,Gristick2016(27617431) ,IOMA contacts,Gristick2016(27617431) ,IgBlast,1-2*02,,,16.0,EMFDSSADWSPWRGMVA,,,2-23*02,,8.0,YSYADGVAF,,,L,,Natural monoclonal,human,IOMA.25, ,12.8509,10.7645,654.0,309.0,3720.0,EVQLVESGAQVKKPGASVTVSCTASGYKFTGYHMHWVRQAPGRGLEWMGWINPFRGAVKYPQNFRGRVSMTRDTSMEIFYMELSRLTSDDTAVYYCAREMFDSSADWSPWRGMVAWGQGTLVTVSSX,QSALTQPASVSGSPGQSITISCAGSSRDVGGFDLVSWYQQHPGKAPKLIIYEVNKRPSGISSRFSASKSGNTASLTISGLQEEDEAHYYCYSYADGVAFGGGTKLTVLX,CAGTCTGCGCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCGCTGGGTCCAGCCGTGATGTTGGGGGTTTTGACCTTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATAATTTATGAGGTCAATAAGCGGCCCTCAGGGATTTCTAGTCGCTTCTCTGCCTCCAAGTCCGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGAAGAGGACGAGGCTCATTATTATTGTTACTCATATGCAGATGGTGTAGCCTTTGGCGGAGGGACCAAGCTGACCGTCCTAG,GAGGTGCAGCTGGTGGAGTCTGGGGCTCAGGTGAAGAAGCCTGGGGCCTCAGTGACGGTCTCCTGCACGGCATCTGGATACAAGTTCACCGGCTACCATATGCACTGGGTGCGACAGGCCCCTGGACGCGGGCTTGAGTGGATGGGATGGATCAACCCTTTCAGGGGTGCCGTAAAGTATCCACAGAATTTTCGGGGCAGGGTCTCCATGACCAGGGACACGTCCATGGAAATATTTTACATGGAGTTGAGCAGACTGACATCTGACGACACGGCCGTCTATTATTGTGCGAGAGAAATGTTCGATAGCAGTGCTGATTGGTCTCCCTGGCGCGGTATGGTGGCCTGGGGCCAGGGGACCCTGGTCACCGTCTCCTCAG,CAREMFDSSADWSPWRGMVAW,88.176
J3,gp120 CD4bs,7LPN(llama J3 VHH antibody in complex with HIV-1 Env BG505 DS-SOSIP.664);7RI1(llama VHH antibody J3 in complex with HIV-1 C1086 gp120),llama#8 ,,McCoy2012(22641382) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,"J3 VHH, L8CJ3",llama antibody ,0.45597,9.69278,574.0,193.0,3216.0,EVQLVESGGGLVQAGGFLRLSCELRGSIFNQNAMAWFRQAPGKEREFVAGMGAVPHYGEFVKGRFTISRDNAKSTVYLQMSSLKPEDTAIYFC,,,,,
JM2,gp120 CD4bs,,,,Matz2013(23152508) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,,llama antibody ,41.385,5.39358,20.0,131.0,3055.0,,,,,,
JM3,gp120-CD4 complex,,,,Matz2013(23152508) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,,llama antibody ,17.5591,5.39603,22.0,132.0,3056.0,,,,,,
JM4,gp120 CD4bs;gp120 CD4i,4LAJ(JM4 in complex with YU2 gp120 and CD4-mimetic miniprotein M48U1),,,Matz2013(23152508) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,"JM4sdAb, JM4SdAb",llama antibody ,15.086,9.38502,67.0,133.0,3053.0,EVQLVESGGGLVQPGGSLRLSCAASGFTLDYYSIGWFRQAPGKEREGVSCISDSDGRTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCATDCTVDPSLLYVMDYYGKGTQVTVSSAAAEQK,EVQLVESGGGLVQPGGSLRLSCAASGFTLDYYSIGWFRQAPGKEREGVSCISDSDGRTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCATDCTVDPSLLYVMDYYGKGTQVTVSSAAAEQK,,,,
JM4-IgG2b,gp120 CD4bs;gp120 CD4i,,,,Acharya2013(23843638) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,,llama antibody ,0.27111,11.9335,195.0,135.0,3105.0,,,,,,
JM4-IgG3,gp120 CD4bs;gp120 CD4i,,,,Acharya2013(23843638) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,,llama antibody ,0.71993,8.96791,30.0,136.0,3106.0,,,,,,
JM5,gp120-CD4 complex,,,,Matz2013(23152508) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,llama,,llama antibody ,44.7172,4.30427,21.0,134.0,3057.0,,,,,,
KD-247,gp120 V3 // V3 glycan (V3g),3NTC(KD-247 Fab),,,Eda2006a(16699036) ,KD-247 epitope,,,,,,,,,,,,,,,,,Yes,Natural monoclonal,humanized mouse,,mouse antibody ,43.4529,7.05055,48.0,198.0,1593.0,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNSWIGWFRQAPGQGLEWIGDIYPGGGYTNYNEIFKGKATMTADTSTNTAYMELSSLRSEDTAVYYCSRGIPGYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC,DIQMTQRPDSLSASVGDRVTMSCKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIYWASTGESGVPDRFSGSGSGTDFTFTISSLQPEDIATYYCQNDYSYPWTFGQGTKVEIKRTVAAPSVFIFPPSDQQLKSGTASVVCLNNNFYPKEAKVQWKVDNALQSGNSQESVTQQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGC,,,,
LM52,non-HIV: host CD4R,,,,Song2013(24097413) ,,,,,,,,,,,,,,,,,,,,humanized mouse,,"LM52 is a variant form of iMab (anti-CD4 receptor antibody, not anti-HIV). ",0.013633,1.82765,236.0,747.0,4472.0,,,,,,
LN01,gp41 MPER (membrane proximal external region),6SNC(LN01 Fab in complex with an HIV-1 gp41 peptide);6SND(LN01 Fab in complex with an HIV-1 gp41 peptide);6SNE(LN01 Fab in complex with an HIV-1 gp41 peptide),SA003 ,,Pinto2019(31653484) ,LN01 contacts,Pinto2019(31653484) ,IMGT/V-QUEST,4-39*07,3-3*01,2*01,20.0,VRMPSHGFWSGYFSYWYFDL,,28.0,1-39*01,1*01,9.0,QQSYSTPWT,,27.0,K,Yes,Natural monoclonal,human,, ,1.36778,7.16531,236.0,497.0,4140.0,EVQLVESGPGLVQPWGTLSLTCRVSGDSVSNDNYYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLRNRVTISLDKSVNVVSLRLGSVSAADTAQYYCVRMPSHGFWSTSFSYWYFDLWGRGHFVAVSWASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVDHKPSNTKVDKKVEPKSCDTTS,DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLNWYQFKTGQAPRILIYGTYTLLSGVSPRFSGAGSGSLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGTHVAANRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGGC,,,,
LSEVh-LS-F,gp120 CD4bs;gp120 CD4i CoRbs (Cluster C),,,,Kong2018(29762173) ,,,,,,,,,,,,,,,,,,Yes,Other,human,, ,,,7.0,850.0,4595.0,,,,,,
M1214_N1,gp120 V2V5 corridor,6VU2(M1214_N1 Fab structure);6VY2(M1214_N1 Fab in complex with CH505 TF chimeric SOSIP.664 Env trimer);EMD-21456(Cryo-EM structure of M1214_N1 Fab in complex with CH505 TF chimeric SOSIP.664 Env trimer),M1214 ,M1214-lin1,Jia2020(32315598) ,M1214_N1 contacts,Jia2020(32315598) ,IMGT/V-QUEST,3-66,,,18.0,ELREAWYGDLRDYSGLDV,35.0,,2-11,,11.0,AVYAGGFTFPR,24.0,,L,,Natural monoclonal,human,, ,3.52279,33.9676,120.0,777.0,4536.0,DRLFQSGGGVSRPGGSLRVNCGASGFTVRTHYMYWLRQSPGKGLEWVAFMNSGGSVSYVDSVRGRFSVSRDNPANAMVLQMDALKIEDTGTYYCARELREAWYGDLRDYSGLDVWGRGTIVSISS,QSALAQPPSVSGSPGQSVTITCTGINDYGAAYKFVSWYQQHPGKEPRLIMKNVKDRWSVTPNRFSGSTSGNTASLTISNLQSDDEAQYFCAVYAGGFTFPRLGGGTKLSVL,CAATCTGCCCTGGCTCAGCCTCCCTCAGTGTCCGGCTCTCCGGGACAGTCCGTCACCATCACCTGCACCGGAATCAACGACTATGGTGCTGCATACAAATTTGTCTCCTGGTATCAACAACACCCGGGCAAAGAACCCAGACTTATAATGAAAAATGTGAAAGATCGGTGGTCAGTTACTCCTAATCGGTTCTCTGGCTCCACGTCTGGCAACACGGCCTCCCTGACTATTTCTAATCTGCAGTCTGACGATGAGGCTCAGTACTTTTGTGCCGTCTATGCCGGCGGATTCACCTTTCCCAGACTTGGTGGGGGGACCAAGTTGTCCGTCCTC,GACAGACTCTTTCAGTCGGGGGGCGGCGTCTCCCGCCCGGGGGGGTCTCTCAGAGTAAATTGTGGAGCCTCTGGTTTTACCGTCCGCACCCATTATATGTATTGGCTTCGTCAGAGTCCGGGGAAGGGACTGGAGTGGGTCGCCTTCATGAATTCTGGCGGCTCAGTATCTTATGTGGACTCCGTGAGGGGCCGCTTTTCCGTCTCCAGGGACAACCCCGCAAATGCAATGGTCCTTCAAATGGATGCCCTGAAGATTGAAGATACAGGTACTTATTATTGTGCGCGAGAATTACGAGAGGCGTGGTACGGAGACCTTCGCGACTATTCCGGCCTAGACGTCTGGGGCCGAGGCACCATAGTCAGCATTTCGTCA,,
M1214_N1.2,gp120 V2V5 corridor,,M1214 ,M1214-lin1,Jia2020(32315598) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,human,, ,5.89386,20.38,120.0,778.0,4537.0,ESVEQSGDASSHPGGSLRVYCWASDFTVRTHYMYWLRQSPGKGLQWVAFMNSGGTTFYTDSVKGRFSVSRDNPQNAMVLEMNDLKVDDTGIYYCARELREAWSGDLRDYTGLDVWGRGTTVTISS,QSALTQPPSVSGSPGQSVTIPCTGINDRGDGKKFISWYQQHPGKEPRLIMKDVKHRWSTIPDRFSGSRSGNTASLIISGLKSEDEALYFCAVYVGGFVFPRLGGGTKLTVL,CAATCTGCCCTGACTCAGCCTCCCTCAGTGTCTGGGTCCCCTGGACAGTCCGTCACCATCCCCTGCACTGGAATCAACGATCGTGGTGATGGGAAAAAATTTATCTCCTGGTATCAGCAACATCCAGGCAAAGAGCCAAGACTTATAATGAAAGATGTCAAACATCGGTGGTCAACTATTCCTGATCGCTTCTCTGGCTCCAGGTCTGGCAACACGGCCTCCCTGATCATCTCTGGACTCAAGTCTGAAGATGAGGCTCTTTATTTTTGTGCCGTTTATGTAGGCGGATTCGTGTTTCCCAGACTCGGCGGGGGGACGAAGTTGACCGTCCTC,GAAAGTGTCGAGCAATCTGGGGACGCCTCCTCTCACCCGGGGGGGTCCCTGAGAGTCTATTGTTGGGCCTCTGATTTCACCGTCCGCACCCATTATATGTACTGGCTGCGCCAGAGTCCAGGGAAGGGACTACAGTGGGTCGCATTCATGAATAGCGGCGGCACTACTTTCTACACAGACTCCGTAAAGGGACGATTTTCCGTCTCCAGGGACAATCCCCAGAACGCGATGGTCCTTGAAATGAATGACTTGAAAGTCGATGACACGGGTATATATTATTGTGCGAGAGAATTGCGGGAGGCTTGGTCCGGAGACCTTCGCGACTATACCGGCCTGGACGTCTGGGGCCGAGGGACGACAGTCACCATTTCATCA,CARELREAWSGDLRDYTGLDVW,72.069
M1214_N2,gp120 V3 // V3 glycan (V3g),,M1214 ,M1214-lin2,Jia2020(32315598) ,,Jia2020(32315598) ,IMGT/V-QUEST,4-34,,,11.0,IVSQVWGTLDL,30.0,,2-24,,9.0,MQGSEFPWT,17.0,,K,,Natural monoclonal,human,, ,19.5062,20.9704,120.0,779.0,4538.0,VRLVQWGSGLVKPSETLKVTCAAYDVTFSDVYWAWVRLSPGRGLEWLGEVGQWGPTQTNPSFKGRLTLSVDKSLGHYSLTLTKVTAADTATYFFARIVSQVWGTLDLWSQGTHVRVSS,AIVLSQAPLSVPVTLGQPASIFCKSDRSLVHSNGNTYLSWLQQRPGQPPRLLISRVSARVSGVPDKFSGSGAGTDFILNISRVDAVDVAVYYCMQGSEFPWTFGQGSKLDIK,GCCATTGTTCTAAGTCAGGCGCCACTCTCTGTTCCTGTCACCCTTGGACAGCCGGCCTCCATCTTCTGCAAGTCCGATCGAAGCCTCGTCCACAGTAATGGGAACACCTACTTGAGTTGGCTTCAGCAGCGGCCAGGCCAGCCTCCGAGACTCCTCATTTCTCGGGTTTCTGCTCGGGTCTCTGGGGTCCCAGACAAGTTCAGTGGCAGTGGGGCAGGGACAGATTTCATACTGAACATCAGCAGAGTTGACGCAGTGGATGTCGCCGTTTATTACTGCATGCAGGGATCGGAATTTCCCTGGACGTTCGGCCAGGGGAGTAAGCTGGACATCAAA,GTGCGATTAGTACAGTGGGGCTCGGGACTGGTAAAGCCTTCCGAGACCCTGAAGGTCACCTGCGCAGCTTACGATGTAACCTTCAGCGATGTCTATTGGGCCTGGGTTCGTCTGTCGCCAGGGAGGGGACTGGAGTGGCTAGGGGAAGTCGGGCAGTGGGGACCCACTCAGACCAATCCGTCGTTCAAGGGTCGCCTCACCCTCTCAGTGGACAAGTCGTTGGGCCATTATTCACTGACCCTGACTAAAGTGACCGCCGCGGACACGGCCACCTATTTCTTTGCGAGGATTGTGTCCCAGGTCTGGGGAACTCTTGATCTTTGGAGTCAAGGAACACACGTCCGCGTCTCTTCA,,
M1214_N2.2,gp120 V3 // V3 glycan (V3g),,M1214 ,M1214-lin2,Jia2020(32315598) ,,Jia2020(32315598) ,IMGT/V-QUEST,4-34,,,11.0,VDPSRGGSFDL,27.0,,2-24,,9.0,MQGSQFPWT,20.0,,K,,Natural monoclonal,human,, ,28.5335,15.8577,120.0,780.0,4539.0,VRLVQWGTGLLKPSETLSITCAVYDMTFGDKYWSWVRLSPERGLEWIGEIGQWGETHYNPSVGSRATLGVDRSLSHFSLRLTSVTPADTAIYFFARVDPSRGGSFDLWSHGTKVLVSS,QIVLTQNPLSLSGTPGQPASISCSSSQSLVHNNGNTYLSWLHQRPGQPPRVLIVGISSRLSGVPDRFRGGGAVTEFTLNITRVEPVDVGMYYCMQGSQFPWTFGQGTRLDIK,CAGATTGTGCTGACCCAAAATCCTCTCTCGTTGTCTGGCACCCCTGGACAGCCGGCCTCCATCTCCTGCTCCTCTAGTCAAAGCCTCGTTCACAACAACGGGAACACATATTTGAGTTGGCTTCACCAGCGGCCAGGCCAGCCTCCTAGAGTCCTCATTGTTGGGATCTCCAGTCGGTTGTCTGGGGTCCCAGACAGATTCAGAGGCGGTGGGGCCGTGACGGAATTCACACTCAATATCACCAGGGTAGAACCTGTGGACGTCGGAATGTATTACTGCATGCAGGGCTCACAATTTCCCTGGACGTTCGGCCAAGGGACCAGGCTGGACATCAAA,GTGCGACTAGTACAGTGGGGCACGGGATTGTTGAAGCCTTCCGAGACCCTGTCCATCACCTGCGCAGTTTATGATATGACCTTCGGTGACAAATATTGGAGCTGGGTCCGACTGTCCCCAGAAAGGGGACTGGAGTGGATTGGAGAAATCGGTCAATGGGGAGAGACCCATTACAATCCGTCCGTCGGGAGCCGAGCCACACTTGGAGTGGACAGGTCTTTAAGTCACTTCTCCTTGCGCCTCACGTCTGTGACCCCCGCAGACACGGCCATATACTTCTTTGCGAGAGTGGACCCAAGCAGGGGGGGCTCCTTTGATCTGTGGAGTCATGGGACGAAAGTCCTCGTGTCTTCA,,
M36/PRO-140,gp120 CD4i;non-HIV: host CCR5,,,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;mouse,m36.4fv-PRO-140fv,bispecific ,0.011253,6.26089,107.0,422.0,3980.0,,,,,,
M4008_N1,gp120 V3 // V3 glycan (V3g),,M4008 ,M4008,Jia2020(32315598) ,M4000_N1 contacts;Mutation affects M4008_N1 neutralization,Jia2020(32315598) ,IMGT/V-QUEST,1-69,,,17.0,LQCAGFSCEMDSGPFDLWGQGTQVTVPS,28.0,,1-5,,9.0,QQYYDSRET,24.0,,K,,Natural monoclonal,human,, ,16.5467,14.4629,120.0,775.0,4527.0,QLVQSGAEMKTSGSSVRVSCKDSGGFFPYAGFRWVRQAPGQGFEWMGGVIPADGTKHYAPKFQARMKMTVVESSRTLYMELRSLTSTDTATYFCARLQCAGFSCEMDSGPFDLWGQGTQVTVPSSGAS,DIQMTQSPSTLAAFVGGNVTLSCRASQGVADRLAWYQQRPGKAPRLLLFRASSRQRGVPSRFSGGGSGTTFTLTIRGLQSDDFATYFCQQYIDTRETFGQGTRVIMENK,GACATCCAGATGACCCAGTCTCCCTCCACCCTGGCTGCCTTTGTCGGAGGCAACGTCACCCTCTCTTGCCGGGCCAGTCAAGGTGTTGCTGATCGATTGGCCTGGTATCAGCAGCGGCCGGGGAAAGCCCCTAGACTACTCCTCTTTCGTGCCTCCAGTCGACAGCGTGGAGTCCCATCACGTTTCAGCGGCGGTGGTTCTGGGACAACCTTCACCCTCACCATCAGAGGCCTGCAGTCCGACGATTTTGCCACTTACTTTTGTCAACAATATATCGATACTCGAGAGACCTTTGGCCAGGGGACCAGAGTCATAATGGAAAACAAA,CAGCTGGTGCAATCTGGGGCTGAGATGAAGACCAGTGGGTCCTCGGTGAGGGTCTCCTGCAAAGACTCAGGAGGCTTTTTCCCTTATGCTGGCTTCCGGTGGGTGCGGCAGGCCCCTGGCCAGGGCTTTGAGTGGATGGGAGGCGTCATTCCTGCGGACGGGACAAAACATTATGCCCCGAAGTTTCAGGCCAGAATGAAAATGACAGTGGTCGAGTCGTCGCGAACCCTTTACATGGAACTGAGGAGTTTGACATCTACAGACACGGCCACTTATTTCTGTGCGAGACTTCAGTGCGCAGGGTTCAGTTGCGAGATGGACTCGGGACCATTTGATCTTTGGGGCCAAGGCACACAAGTCACCGTCCCCTCAAGCGGCGCGTCA,,
M4008_N1.3_dIgA2,gp120 V3 // V3 glycan (V3g),,M4008 ,M4008,Jia2020(32315598) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,32.1582,8.89098,120.0,776.0,4528.0,,,,,,
m66,gp41 MPER (membrane proximal external region),4NRX(m66 in complex with gp41 MPER peptide);4NRY(Antibody m66),SC44 ,,Zhu2011(21880764) ,Mutation decreases binding of m66 and m66.6,Zhu2011(21880764) ,,5-51*01,3-10*01,6*02,21.0,QNHYGSGSYFYRTAYYYAMD,,,1-39*01,3*01,9.0,QQSYNTPFT,,,K,,Natural monoclonal,human,, ,95.5721,1.41734,211.0,92.0,2663.0,QVQLVQSGAEVKKPGESLKISCKVSGYNFASEWIGWVRQMPGKGLEWMGIIYPGDSDTKYSPSFQGQVIISADKSINTAYLQWSSLKASDTAIYYCARQNHYGSGSYFYRTAYYYAMDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSIGSYLNWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQSYSTPFTFGPGTKVDIR,GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTGGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCTTTCACTTTCGGCCCTGGGACCAAAGTGGATATCAGA,CAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGTTTCTGGATACAACTTTGCCAGCGAATGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATTATCTATCCTGGTGACTCTGATACCAAATACAGCCCGTCCTTCCAAGGCCAGGTCATCATCTCAGCCGACAAGTCCATCAACACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATATATTACTGTGCGAGACAGAATCACTATGGTTCGGGGAGTTATTTCTACCGAACGGCCTACTACTATGCTATGGACGTCTGGGGCCAAGGGACAACGGTCACCGTCTCTTCG,CARQNHYGSGSYFYRTAYYYAMDVW,96.284
m66.6,gp41 MPER (membrane proximal external region),4NRZ(Antibody m66.6),SC44 ,,Zhu2011(21880764) ,Mutation decreases binding of m66 and m66.6,Zhu2011(21880764) ,,5-51*01,3-10*01,6*02,21.0,QNHYGSGSYFYRTAYYYAMD,,,1-39*01,3*01,9.0,QQSYSTPFT,,,K,,Natural monoclonal,human,M66.6, ,60.0523,2.79623,335.0,91.0,2664.0,QVQLVQSGAEVKKPGESLKISCKVSGYNFASEWIGWVRQMPGKGLEWMGIIYPGDSDTKYSPSFQGQVIISADKSINTAYLQWSSLKASDTAIYYCARQNHYGSGSYFYRTAYYYAMDVWGQGTTVTVSS,FATVAQAADIQLTQSPSSLSASLGDKVTITCRASQHIKKYLNWYQQKPGKAPKLLIYGALNLQSGVPSRFSGRGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIKR,TTCGCTACCGTGGCCCAGGCGGCCGACATCCAGTTGACCCAGTCTCCATCTTCCCTGTCTGCATCTTTGGGGGACAAAGTCACCATCACTTGCCGGGCAAGTCAGCACATTAAGAAGTATTTAAACTGGTATCAGCAGAAACCTGGGAAAGCCCCTAAACTCCTGATCTATGGTGCACTCAATTTGCAGAGTGGGGTCCCATCAAGGTTCAGTGGCAGAGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAGCAGAGTTACAGTACCCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAACGA,CAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGTTTCTGGATACAACTTTGCCAGCGAATGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATTATCTATCCTGGTGACTCTGATACCAAATACAGCCCGTCCTTCCAAGGCCAGGTCATCATCTCAGCCGACAAGTCCATCAACACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATATATTACTGTGCGAGACAGAATCACTATGGTTCGGGGAGTTATTTCTACCGAACGGCCTACTACTATGCTATGGACGTCTGGGGCCAAGGGACAACGGTCACCGTCTCTTCG,CARQNHYGSGSYFYRTAYYYAMDVW,96.284
m66 G30(LC)K,gp41 MPER (membrane proximal external region),,SC44 ,,Ofek2014(24335316) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"m66-G30K, m66 G30 LCK, m66G30 LCK, m66G30LCK", ,38.1883,3.21715,47.0,152.0,3120.0,,,,,,
m66 S28(LC)H,gp41 MPER (membrane proximal external region),,SC44 ,,Ofek2014(24335316) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"m66-S28H, m66 S28 LCH, m66S28 LCH, m66S28LCH", ,92.8194,1.38582,40.0,151.0,3119.0,,,,,,
m66 S28(LC)H-G30(LC)K,gp41 MPER (membrane proximal external region),,SC44 ,,Ofek2014(24335316) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"m66-S28H-G30K, m66 S28 LCH-G30 LCK, m66S28 LCH-G30 LCK, m66S28LCH-G30LCK", ,33.5914,4.54709,40.0,154.0,3123.0,,,,,,
m66 S28(LC)H-G30(LC)K-S31(LC)K,gp41 MPER (membrane proximal external region),,SC44 ,,Ofek2014(24335316) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"m66-S28H-G30K-S31K, m66 S28 LCH-G30 LCK-S31 LCK, m66S28 LCH-G30 LCK-S31 LCK, m66S28LCH-G30LCK-S31LCK", ,18.3974,4.06931,47.0,155.0,3124.0,,,,,,
m66 S31(LC)K,gp41 MPER (membrane proximal external region),,SC44 ,,Ofek2014(24335316) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"m66-S31K, m66 S31 LCK, m66S31 LCK, m66S31LCK", ,81.7427,1.64876,40.0,153.0,3121.0,,,,,,
m66 Y100e(HC)W,gp41 MPER (membrane proximal external region),,SC44 ,,Ofek2014(24335316) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"m66 Y100e HCW, m66Y100e HCW, m66Y100eHCW, m66-Y100eW", ,50.6663,3.78111,47.0,156.0,3122.0,,,,,,
MEL-1842,gp120 CD4bs,,Cow #1 ,,Heydarchi2022(35584627) ,,,,,,,,,,,,,,,,,L,,Fab or heavy-chain-only,cow,,"The light chain gene of MEL-1842 was not rescued, so it was produced using the MEL-2129 light chain. ",0.34016,108.455,94.0,601.0,4212.0,KVQLQESGPSLVKPSQTLSLTCTASGFSLSDKAVGWVRQAPGQALEWLGSIDTGGNADYNPGLKSRLSITKDNAKSQVSLSVSSVTTEGSATYYCSTVHQKTLRSCPSDYPYICDCEDTGSHCCRATNCPYYCNHGRDRMCTGRTYTYEWHVEAWGQGLLVTVSS,NSQAVLTQPSSVSGSLGQRVSTTCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTVTLTISSLQAEDEADYFCASAEDGSSNAVFGRGTTLTVV,AATTCGCAGGCTGTGCTGACTCAGCCATCATCCGTGTCCGGGTCCCTGGGCCAGAGGGTCTCCACCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGCTGGTACCAACTGATTCCAGGATCGGCCCCCAGAACCCTCATCTATGGTGACACCAGTCGAGCCTCGGGGGTCCCCGACCGATTCTCCGGCTCCAGGTCTGGGAACACAGTCACCCTGACCATCAGCTCGCTCCAGGCTGAGGACGAGGCAGATTATTTCTGCGCATCTGCTGAGGATGGTAGCAGTAATGCTGTTTTCGGCAGAGGGACCACACTGACAGTCGTC,AAGGTGCAGCTGCAGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCGCTCACCTGCACGGCCTCTGGATTCTCATTGAGCGACAAGGCTGTAGGCTGGGTCCGCCAGGCTCCAGGGCAGGCGCTGGAGTGGCTCGGTAGTATAGACACTGGCGGAAACGCAGATTATAACCCAGGCCTGAAATCCCGGCTCAGCATCACCAAGGATAACGCCAAGAGCCAAGTCTCTCTGTCAGTAAGCAGCGTGACAACTGAGGGCTCGGCCACGTATTACTGTTCTACTGTGCACCAGAAGACACTCCGTAGTTGTCCTTCTGATTATCCTTATATTTGTGATTGTGAAGATACTGGTAGTCATTGCTGTCGGGCTACTAATTGTCCTTATTACTGCAATCATGGCCGTGATCGTATGTGTACCGGTCGTACTTACACGTACGAGTGGCACGTCGAAGCCTGGGGCCAGGGACTCCTGGTCACCGTCTCCTCA,CSTVHQKTLRSCPSDYPYICDCEDTGSHCCRATNCPYYCNHGRDRMCTGRTYTYEWHVEAW,68.512
MEL-1872,gp120 CD4bs,,Cow #1 ,,Heydarchi2022(35584627) ,Mutation affects binding or neutralization of MEL-1872,,,,,,,,,,,,,,,,L,,Fab or heavy-chain-only,cow,,"The light chain gene of MEL-1872 was not rescued, so it was produced using the MEL-2129 light chain. ",0.21885,113.074,94.0,600.0,4197.0,KVQLRESGPSLVKPSQTLSLTCTASGFSLSDKAVGWVRQAPGQPLEWLGTIDTTGNAVYNPGLKSRLSITKDNSKSQVSLSLSSVTTEDSATYHCSTVHQKTRRSCPSDYSFICDCEGTGSHCCRASNCPYYCNYGRDRMCTGRSNIHEWHVDAWGQGLLVTVSS,NSQAVLTQPSSVSGSLGQRVSTTCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTVTLTISSLQAEDEADYFCASAEDGSSNAVFGRGTTLTVV,AATTCGCAGGCTGTGCTGACTCAGCCATCATCCGTGTCCGGGTCCCTGGGCCAGAGGGTCTCCACCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGCTGGTACCAACTGATTCCAGGATCGGCCCCCAGAACCCTCATCTATGGTGACACCAGTCGAGCCTCGGGGGTCCCCGACCGATTCTCCGGCTCCAGGTCTGGGAACACAGTCACCCTGACCATCAGCTCGCTCCAGGCTGAGGACGAGGCAGATTATTTCTGCGCATCTGCTGAGGATGGTAGCAGTAATGCTGTTTTCGGCAGAGGGACCACACTGACAGTCGTC,AAGGTGCAGCTGCGGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCGCTCACCTGCACAGCCTCTGGATTCTCATTGAGCGACAAGGCTGTAGGCTGGGTTCGCCAGGCTCCAGGGCAGCCGCTGGAGTGGCTCGGTACTATAGACACTACTGGAAACGCAGTCTATAACCCAGGCCTGAAATCCCGGCTCAGCATCACCAAGGATAACTCCAAGAGCCAGGTCTCTCTGTCACTAAGCAGCGTGACAACTGAGGACTCGGCCACATATCACTGTTCTACTGTGCACCAGAAGACACGTCGCAGTTGTCCTTCTGATTATAGTTTCATTTGTGATTGTGAAGGTACTGGCAGTCATTGCTGTCGGGCTTCTAATTGTCCTTATTACTGCAATTACGGCCGTGATCGTATGTGTACGGGCAGGAGTAACATTCACGAATGGCACGTCGATGCCTGGGGCCAAGGTCTCCTGGTCACCGTCTCCTCA,CSTVHQKTRRSCPSDYSFICDCEGTGSHCCRASNCPYYCNYGRDRMCTGRSNIHEWHVDAW,67.820
MEL-2129,gp120 CD4bs,,Cow #1 ,,Heydarchi2022(35584627) ,,,,,,,,,,,,,,,,,L,,Natural monoclonal,cow,, ,2.89666,54.3181,92.0,602.0,4213.0,KVQLRESGPSLVKPSQTLSLTCTASGFSLSDKAVGWVRQAPGKALEWLGSIDTGGNAGYNPGLKSRLSITKGNSKSQVSLSVSSVTTEDSATYYCSTVHQKTRRSCPVDYYYSCDCEGSGSHCCSASNCPYYCKYGRDRVCTDKHTYSYEWYVDAWGQGLLVTVSS,NSQAVLTQPSSVSGSLGQRVSTTCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTVTLTISSLQAEDEADYFCASAEDGSSNAVFGRGTTLTVV,AATTCGCAGGCTGTGCTGACTCAGCCATCATCCGTGTCCGGGTCCCTGGGCCAGAGGGTCTCCACCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGCTGGTACCAACTGATTCCAGGATCGGCCCCCAGAACCCTCATCTATGGTGACACCAGTCGAGCCTCGGGGGTCCCCGACCGATTCTCCGGCTCCAGGTCTGGGAACACAGTCACCCTGACCATCAGCTCGCTCCAGGCTGAGGACGAGGCAGATTATTTCTGCGCATCTGCTGAGGATGGTAGCAGTAATGCTGTTTTCGGCAGAGGGACCACACTGACAGTCGTC,AAGGTGCAGCTGCGGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCGCTCACCTGCACGGCCTCTGGATTCTCATTAAGCGACAAGGCTGTAGGCTGGGTCCGCCAGGCTCCAGGGAAGGCGCTGGAGTGGCTCGGTAGTATAGACACTGGTGGAAACGCAGGCTATAACCCAGGCCTGAAATCCCGGCTCAGCATCACCAAGGGTAACTCCAAGAGCCAAGTCTCTCTGTCAGTGAGTAGCGTGACGACTGAGGACTCGGCCACATATTACTGTTCTACTGTGCACCAGAAGACACGACGTAGTTGTCCTGTTGATTATTATTATAGTTGCGACTGTGAAGGTAGTGGTAGTCATTGTTGCTCGGCTTCTAATTGTCCTTATTACTGCAAGTATGGCCGTGATAGAGTTTGTACTGACAAACATACTTACAGTTACGAATGGTACGTCGATGCCTGGGGCCAGGGACTCCTGGTCACCGTCTCCTCA,CSTVHQKTRRSCPVDYYYSCDCEGSGSHCCSASNCPYYCKYGRDRVCTDKHTYSYEWYVDAW,68.858
Min12A21,gp120 CD4bs,,Patient 12 ,12A12,Jardine2016a(27560183) ,,Jardine2016a(27560183) ,,1-02*02,,,12.0,GKNCDYNWDFQH,,,1-33*01,,5.0,QQYEF,,,K,,Engineered monoclonal,human,, ,3.99524,22.412,224.0,830.0,4181.0,QVQLVQSGAEVKKPGASVRVSCKASGYTFTNYILHWWRQAPGQGLEWMGWIKPVFGAVNYARQFQGRVTMTRDIYREIAYMELSRLRSDDTAVYYCARDESGDDLKWHLHPWGQGTQVIVSP,DIQMTQSPSSLSASVGDRVTITCQAGQGIGSSLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGFHTTFTFTISSLQPEDIATYYCAVFQWFGPGTKVDIK,,,,
Minimal BF520.1,gp120 V3 // V3 glycan (V3g),,BF520 ,BF520,Simonich2019(31097697) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,Minimal VH Minimal VK, ,,,13.0,710.0,4328.0,,,,,,
MinVRC01,gp120 CD4bs,,NIH45 ,VRC01,Jardine2016a(27560183) ,,Jardine2016a(27560183) ,,1-02*02,,,13.0,DESGDDLKWHLHP,,,3-11*01,,5.0,AVFQW,,,K,,Engineered monoclonal,human,, ,0.75346,20.3587,230.0,829.0,4180.0,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGCTLNWVRQAPGQGLEWMGWIKPRFGAVNYARKFQGRVTMTRDVYSDTAYMELSRLRSDDTAVYYCARGKNCDYNWDFQHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRTSQYGSSYLAWYQQKPGQAPRLLIYDGSNRATGIPARFSGSRWGPDFTLTISSLEPEDFAVYYCQQYEFFGQGTKLEIK,,,,
N49P11,gp120 CD4bs;gp120 CD4i,,N49 ,N49P6,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,35.0,2-11,,5.0,,,30.0,L,,Natural monoclonal,human,, Sajadi2018 %SHM calculated for VH and VL+JL.,1.19929,5.72401,234.0,507.0,4093.0,SAELVQSGAVVKKPGTSVKVSCQAYGYTFTDYLIHWLRQAPGQGLEWMGWMNPVYGQVNYAQNFQGRVSMTRDIYRETAFLEVRDLKTDDTGTYYCVRDTGDGSRRHFDSINWFLDLWGRGTWIRVAPA,QCVLTQPRSVSGSPGQSVTISCTGTHNYVSWCQHHPGNAPKLLLYDFDKRPSGISDRFSGSRSGNTASLTISGLQPEDEADYFCWAFEAFGGGTKVLVLR,CAGTGTGTCTTGACTCAGCCTCGCTCAGTGTCCGGATCTCCTGGACAATCAGTCACCATCTCCTGCACTGGAACTCACAATTATGTCTCCTGGTGTCAACACCACCCAGGCAACGCCCCCAAATTATTACTTTATGATTTCGACAAGCGGCCCTCAGGAATCTCTGATCGCTTCTCTGGCTCTAGGTCTGGCAACACGGCCTCCCTGACCATCTCTGGCCTCCAGCCTGAGGATGAGGCCGATTACTTTTGTTGGGCCTTTGAAGCCTTTGGCGGAGGGACCAAGGTGCTCGTCCTTCGT,TCGGCGGAATTGGTGCAATCTGGGGCTGTGGTGAAGAAGCCTGGGACCTCCGTGAAGGTCTCTTGTCAGGCTTATGGATACACTTTTACCGACTACCTTATTCATTGGCTTCGACAGGCCCCTGGACAAGGACTTGAATGGATGGGATGGATGAATCCTGTTTATGGACAAGTAAATTATGCCCAAAACTTTCAGGGCAGGGTCTCCATGACCAGGGACATTTACAGGGAAACAGCATTTCTAGAGGTGCGCGACCTGAAGACTGACGACACAGGCACTTATTATTGTGTGAGAGACACAGGCGACGGTTCGCGGAGACACTTTGACTCCATCAATTGGTTTCTCGATCTTTGGGGCCGCGGGACATGGATAAGGGTCGCCCCAGCG,,
N49P18.1,gp120 CD4bs;gp120 CD4i,,N49 ,N49P6,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,,2-11,,,,,,L,,Natural monoclonal,human,,Unpublished N49P18.1 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) Unpublished germline gene usage provided by M. Sajadi,14.146,4.03303,234.0,510.0,4115.0,ADLVQSGAVVKKPGDSVRISCEAQGYTFTDYVIHWIRRAPGQGLEWMGWINPGYGQVNIPWNFQGRVSMTRDTSIETAFLDLRGLKSDDTGLYYCVRDRSNGWGKRFESSNWFLDLWGRGTVVTVHSPSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,QSALTQPRSMSASPGQSVTISCTGTHNLVSWCQHHPGRPPKLLIYDFNKRPSGVPDRFSGSGSGGTASLTISGLQDDDDAEYICWAYEAFGGGTKLTVLRQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,CAGTCTGCCCTGACTCAGCCTCGCTCAATGTCCGCATCTCCTGGGCAGTCCGTCACCATTTCCTGCACTGGAACCCACAATTTGGTCTCTTGGTGTCAACATCACCCAGGCAGACCCCCCAAATTATTAATTTATGACTTCAATAAGAGGCCCTCAGGGGTCCCTGATCGCTTCTCTGGCTCCGGGTCTGGCGGCACGGCCTCCCTGACCATCAGTGGACTCCAGGATGACGATGACGCCGAATACATTTGTTGGGCATATGAAGCTTTCGGCGGAGGGACCAAGTTGACCGTACTTCGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCTTGGAAAGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA,GCGGACTTGGTGCAGTCTGGGGCTGTGGTGAAGAAGCCTGGGGACTCAGTGAGAATCTCCTGTGAGGCTCAAGGATACACATTCACTGACTACGTCATTCACTGGATTCGACGGGCCCCTGGACAAGGCCTTGAATGGATGGGGTGGATTAATCCAGGTTATGGACAAGTAAATATTCCATGGAACTTTCAGGGCAGGGTCTCCATGACCCGAGACACGTCCATCGAAACAGCATTTCTGGACTTAAGAGGTCTAAAGTCTGACGACACGGGCCTCTATTATTGCGTGAGAGATCGAAGTAATGGATGGGGAAAGCGATTCGAGTCCTCCAATTGGTTCCTCGATCTGTGGGGCCGCGGCACTGTGGTCACTGTTCACTCACCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,CVRDRSNGWGKRFESSNWFLDLW,75.085
N49P19,gp120 CD4bs;gp120 CD4i,,N49 ,N49P6,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,,2-11,,,,,,L,,Natural monoclonal,human,,Unpublished N49P19 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) Unpublished germline gene usage provided by M. Sajadi,4.97479,10.9474,234.0,511.0,4116.0,ADLVQSGAVVKNAGASVRVSCEAYGYTFVDYFIHWVRQAPGQGFEWMGYMDPLNGRPNIARKFQGRLSLSRDRSSETSFLDLSGLRSDDSAVYYCVRDKSNGSGRRFDSSNWFLDLWGRGTRVSIFSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,QSALTQPRSVSATPGQSVTISCTGTHNYVSWCQQHPGRAPKLLIYDFNKRPSGVPDRFSGSGSGGTASLTITGLQDDDEADYFCWAYDAFGGGTKLTVLRQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,CAGTCTGCCCTGACTCAGCCTCGCTCAGTGTCCGCAACTCCTGGACAGTCAGTCACCATCTCCTGCACTGGAACCCACAATTATGTCTCTTGGTGTCAACAACATCCAGGCAGAGCCCCCAAATTACTAATTTATGACTTCAATAAGAGGCCCTCAGGGGTCCCGGATCGCTTCTCTGGCTCCGGATCTGGCGGCACGGCCTCCCTAACCATCACTGGACTCCAGGATGACGATGAAGCGGACTATTTTTGTTGGGCCTATGATGCTTTTGGCGGAGGGACCAAGTTGACCGTCCTGCGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCTTGGAAAGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA,GCGGACTTGGTGCAGTCTGGGGCTGTGGTGAAAAATGCTGGGGCCTCAGTGAGGGTCTCCTGTGAGGCTTATGGATACACATTCGTGGACTACTTCATTCATTGGGTCCGACAGGCCCCTGGACAAGGCTTTGAATGGATGGGATACATGGATCCCTTGAACGGGCGCCCAAACATTGCGCGAAAATTTCAGGGCAGGCTCTCCCTGAGTCGAGATAGGTCCAGCGAAACTTCATTTCTGGACTTAAGTGGACTGAGGTCTGACGACTCGGCCGTCTATTATTGTGTGAGAGACAAGAGTAATGGATCGGGCAGACGGTTTGACTCGTCTAATTGGTTTCTCGATCTGTGGGGCCGTGGAACCCGGGTCAGTATTTTCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,CVRDKSNGSGRRFDSSNWFLDLW,74.403
N49P22,,,N49 ,,Sajadi2018(29731169) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,,Unpublished N49P22 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) ,10.0963,11.606,234.0,513.0,4119.0,HIQLLQSGPQVKKSGDTVRISCETSGYNFVDSRIHWVRQTPEKRLRWMGWINPLQGGVNYAPEFQGRIRMTRDTFIDTVYVDLSGLTPADTAYYYCARGIDGKSYPFHFWGHGTRVTVFSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,RFALTQPASVSGSPGQTITITCAGGSVSWFHFPPGKTPRLIIYESSKRPSGVSPRFSGSQSGSTASLIISGLQSDDEGTYFCSILEFFGRGTLVTVLSQPKAAPSVTLFPPSSEELQANKATLVCLVSDFYPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEKTVAPAECS,CGATTTGCCCTGACTCAACCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATAACCTGCGCTGGAGGCAGCGTCTCCTGGTTTCATTTCCCTCCAGGCAAAACCCCCAGACTCATTATTTATGAGTCTTCTAAGCGACCCTCTGGGGTCTCTCCTCGATTCTCTGGGTCCCAGTCTGGCAGCACGGCCTCCCTTATAATTTCTGGCCTCCAGTCTGATGACGAAGGGACATACTTCTGTTCTATTCTTGAATTTTTCGGCAGAGGGACTCTTGTCACCGTCCTGAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCACCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCGTAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATGGCAGCCCCGTCAAGGTGGGAGTGGAGACCACCAAACCCTCCAAACAAAGCAACAACAAGTATGCGGCCAGCAGCTACCTGAGCCTGACGCCCGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCGGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTGCAGAATGCTCT,CACATTCAGTTGCTACAGTCGGGGCCTCAAGTTAAGAAGTCTGGGGACACAGTGAGAATCTCCTGTGAGACCTCTGGATATAACTTCGTCGACTCCCGTATCCACTGGGTCCGACAGACCCCGGAAAAACGTCTCAGATGGATGGGCTGGATCAATCCTCTCCAAGGTGGTGTGAATTACGCGCCGGAATTTCAGGGCAGAATCAGGATGACCAGGGACACATTTATAGACACAGTTTACGTGGACCTGAGCGGACTGACACCGGCCGACACGGCCTATTATTACTGCGCGCGAGGGATCGATGGCAAGTCTTACCCCTTTCATTTCTGGGGCCACGGAACCCGGGTCACCGTCTTCTCGGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,CARGIDGKSYPFHFW,71.864
N49P23,,,N49 ,,Sajadi2018(29731169) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,,Unpublished N49P23 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) ,0.89302,40.7691,234.0,512.0,4118.0,QVRLVQSGAGARKTGASMKLSCSTSGYTFTTHHGHFINWVRQARGQGLEWMGWMNPMTGQMNIEGKFQGRVTLTRDIYSDTAYMEMTRLTTGDTGTYYCARGDFGQNYPFHYWGQGSLVIVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,LSALTQPASVSGSPGQSVTISCSGTNRYLVSWYQQHPDKAPKLIIYDDNKRPSGISDRFSASRPDDTASLTISGLQTGDEATYWCASYERFGGGTRLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLVSDFYPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEKTVAPAECS,CTGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGGCAGTCGGTCACCATCTCCTGCTCTGGAACGAACCGTTACCTTGTCTCCTGGTATCAACAACACCCTGACAAAGCCCCCAAACTCATCATTTATGACGACAATAAGCGGCCCTCAGGAATTTCTGATCGCTTCTCAGCCTCCAGGCCTGACGACACGGCCTCCCTGACAATCTCTGGACTCCAGACTGGGGACGAGGCTACTTATTGGTGTGCCTCATATGAACGTTTTGGCGGCGGGACGAGGCTGACCGTCCTTAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCACCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCGTAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATGGCAGCCCCGTCAAGGTGGGAGTGGAGACCACCAAACCCTCCAAACAAAGCAACAACAAGTATGCGGCCAGCAGCTACCTGAGCCTGACGCCCGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCGGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTGCAGAATGCTCT,CAGGTGCGCTTGGTGCAGTCTGGGGCTGGGGCGAGGAAGACTGGGGCCTCAATGAAACTTTCCTGCTCGACCTCTGGATACACCTTCACCACTCATCACGGCCACTTCATAAATTGGGTGCGACAGGCCCGTGGACAAGGGCTTGAGTGGATGGGGTGGATGAATCCCATGACTGGGCAGATGAATATTGAGGGGAAATTTCAGGGCAGAGTCACCCTCACTCGAGACATATACAGTGACACGGCTTACATGGAAATGACCAGACTGACAACTGGCGACACGGGCACTTATTACTGTGCGCGAGGCGATTTCGGACAGAATTATCCCTTTCATTATTGGGGCCAGGGAAGCCTGGTCATCGTCTCCTCGGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,CARGDFGQNYPFHYW,74.013
N49P6,gp120 CD4bs;gp120 CD4i;quaternary structure,6OZ2(N49P6 with HIV-1 strain 93TH057 gp120 core);6OZ4(N49P6 with HIV-1 BG505 SOSIP.664 Env trimer ectodomain),N49 ,N49P6,Sajadi2018(29731169) ,N49P6 contacts,Sajadi2018(29731169) ,SoDA,1-2,,,20.0,DRANGSGRRRFESVNWFLDL,,42.0,2-11,,5.0,WAFEN,,28.0,L,,Natural monoclonal,human,,Structural analysis from Tolbert2021 (PMID 34281393) Sajadi2018 %SHM calculated for VH and VL+JL.,0.5532,8.55265,234.0,504.0,4090.0,AGLMQSGAVMKNSGASVRVSCQADGYDFIDYVIHWFRQRRGEGLEWLGWMNPSGGGTNYPRPFQGKVTMTRDTSTETAYLDVRGLTYDDTAVYYCVRDRANGSGRRRFESVNWFLDLWGRGTQITVVSA,QSALTQPRSVSASPGQSVTISCTGTHNYVSWCQQKPGQAPKLLIYDFNKRPSGVSDRFSGSTSGNTASLTISGLQADDEGHYFCWAFENIGGGTKLTVLG,CAGTCTGCCCTAACTCAGCCTCGCTCAGTGTCCGCATCTCCTGGTCAGTCAGTCACCATCTCCTGCACTGGAACACACAATTATGTGTCCTGGTGTCAACAGAAACCGGGCCAAGCCCCCAAATTATTAATTTACGATTTCAATAAACGGCCCTCAGGGGTCTCTGATCGCTTCTCTGGCTCCACGTCTGGCAACACGGCCTCCCTGACCATCTCTGGACTCCAGGCTGACGATGAGGGTCATTATTTTTGTTGGGCGTTTGAAAATATCGGCGGAGGGACCAAGCTGACCGTCCTGGGT,GCGGGACTGATGCAGTCTGGGGCTGTGATGAAGAATTCGGGGGCCTCAGTGAGGGTCTCTTGTCAGGCTGATGGATACGACTTCATTGACTATGTCATTCACTGGTTTCGACAAAGACGTGGAGAAGGTCTTGAGTGGCTGGGATGGATGAATCCCTCGGGAGGCGGCACAAACTATCCGCGACCATTTCAGGGCAAAGTCACCATGACCAGGGACACGTCCACCGAGACAGCCTATTTAGATGTCAGAGGACTTACATATGACGACACGGCCGTCTATTATTGTGTGAGAGACAGGGCCAACGGTTCGGGAAGAAGACGTTTTGAGTCGGTGAATTGGTTCCTGGATCTGTGGGGCCGCGGCACCCAAATAACAGTCGTCTCGGCG,,
N49P7,gp120 CD4bs;gp120 CD4i,6BCK(N49P7 with HIV-1 strain 93TH057 gp120 core),N49 ,N49P6,Sajadi2018(29731169) ,N49P7 contacts,Sajadi2018(29731169) ,SoDA,1-2,,,19.0,DRSNGSGKRFESSNWFLDL,,38.0,2-11,,5.0,WAYEA,,31.0,L,,Natural monoclonal,human,, Sajadi2018 %SHM calculated for VH and VL+JL.,0.32151,8.64383,889.0,505.0,3951.0,ADLVQSGAVVKKPGDSVRISCEAQGYRFPDYIIHWIRRAPGQGPEWMGWMNPMGGQVNIPWKFQGRVSMTRDTSIETAFLDLRGLKSDDTAVYYCVRDRSNGSGKRFESSNWFLDLWGRGTAVTIQSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,ALTQPRSVSASPGQSVTISCTGTHNLVSWCQHQPGRAPKLLIYDFNKRPSGVPDRFSGSGSGGTASLTITGLQDDDDAEYFCWAYEAFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,GCCCTGACTCAGCCTCGCTCAGTGTCCGCATCTCCTGGGCAGTCCGTCACCATTTCCTGCACTGGAACCCACAATTTGGTCTCTTGGTGTCAACATCAGCCAGGCAGAGCCCCCAAATTATTAATTTATGACTTCAATAAGAGGCCCTCAGGGGTCCCTGATCGCTTCTCTGGCTCCGGGTCTGGCGGCACGGCCTCCCTGACCATCACTGGACTCCAGGATGACGATGACGCCGAATATTTTTGTTGGGCGTATGAAGCTTTTGGCGGAGGGACCAAGTTGACCGTTCTTGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCACCCTCGAGTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCTTGGAAAGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA,GCGGACTTGGTGCAGTCTGGGGCTGTGGTGAAGAAGCCTGGGGACTCAGTGAGGATCTCCTGTGAGGCTCAAGGATATAGATTTCCTGACTACATCATTCACTGGATTCGACGGGCCCCTGGACAAGGCCCTGAATGGATGGGATGGATGAATCCAATGGGCGGACAAGTAAATATTCCATGGAAATTTCAGGGTAGGGTCTCCATGACCCGGGACACGTCCATCGAAACAGCATTTCTGGACTTAAGAGGACTAAAGTCTGACGACACGGCCGTCTATTATTGCGTGAGAGATCGCAGTAATGGATCGGGAAAGCGATTCGAGTCCTCCAATTGGTTCCTCGATCTGTGGGGCCGTGGGACTGCGGTCACAATTCAATCAGCGTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,,
N49P7.1,gp120 CD4bs;gp120 CD4i,,N49 ,N49P6,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,38.0,2-11,,5.0,,,31.0,L,,Natural monoclonal,human,, Sajadi2018 %SHM calculated for VH and VL+JL.,0.20684,5.99105,234.0,506.0,4092.0,ADLVQSGAVVKKPGDSVRISCEAQGYRFPDYIIHWIRRAPGQGPEWMGWMNPMGGQVNIPWKFQGRVSMTRDTSIETAFLDLRGLKSDDTAVYYCVRDRSNGSGKRFESSNWFLDLWGRGTAVTIQSSSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,ALTQPRSVSASPGQSVTISCTGTHNLVSWCQHQPGRAPKLLIYDFNKRPSGVPDRFSGSGSGGTASLTITGLQDDDDAEYFCWAYEAFGGGTKLTVLRQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,GCCCTGACTCAGCCTCGCTCAGTGTCCGCATCTCCTGGGCAGTCCGTCACCATTTCCTGCACTGGAACCCACAATTTGGTCTCTTGGTGTCAACATCAGCCAGGCAGAGCCCCCAAATTATTAATTTATGACTTCAATAAGAGGCCCTCAGGGGTCCCTGATCGCTTCTCTGGCTCCGGGTCTGGCGGCACGGCCTCCCTGACCATCACTGGACTCCAGGATGACGATGACGCCGAATATTTTTGTTGGGCGTATGAAGCTTTTGGCGGAGGGACCAAGTTGACCGTTCTTCGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCACCCTCGAGTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCTTGGAAAGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA,GCGGACTTGGTGCAGTCTGGGGCTGTGGTGAAGAAGCCTGGGGACTCAGTGAGGATCTCCTGTGAGGCTCAAGGATATAGATTTCCTGACTACATCATTCACTGGATTCGACGGGCCCCTGGACAAGGCCCTGAATGGATGGGATGGATGAATCCAATGGGCGGACAAGTAAATATTCCATGGAAATTTCAGGGTAGGGTCTCCATGACCCGGGACACGTCCATCGAAACAGCATTTCTGGACTTAAGAGGACTAAAGTCTGACGACACGGCCGTCTATTATTGCGTGAGAGATCGCAGTAATGGATCGGGAAAGCGATTCGAGTCCTCCAATTGGTTCCTCGATCTGTGGGGCCGTGGGACTGCGGTCACAATTCAATCATCGTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,,
N49P7.2,gp120 CD4bs;gp120 CD4i,,N49 ,N49P6,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,,2-11,,,,,,L,,Natural monoclonal,human,,Unpublished N49P7.2 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) Unpublished germline gene usage provided by M. Sajadi,0.44283,11.4521,234.0,509.0,4112.0,ADLVQSGAVVKKPGDSVRISCEAQGYKFPDYIIHWIRRAPGQGLEWMGWINPMGGQVNIPWQFQGRVSMTRDTSIETAFLDLRGLKSDDTALYYCVRDRSNGSGRRFESSNWFLDLWGRGTAVTVHSPSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,ALTQPRSVSASPGQSVTISCTGTHNLVSWCQHHPGRAPKLLIYDFNKRPSGVPDRFSGSGSGGTASLTISGLQDDDDAEYFCWAYEAFGGGTKLTVLRQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,GCCCTGACTCAGCCTCGCTCAGTGTCCGCATCTCCTGGGCAGTCCGTCACCATTTCCTGCACTGGAACCCACAATTTGGTCTCTTGGTGTCAACATCACCCAGGCAGAGCCCCCAAATTATTAATTTATGACTTCAATAAGAGGCCCTCAGGGGTCCCTGATCGCTTCTCTGGCTCCGGGTCTGGCGGCACGGCCTCCCTGACCATCAGTGGACTCCAGGATGACGATGACGCCGAATATTTTTGTTGGGCGTATGAAGCTTTTGGCGGAGGGACCAAGTTGACCGTACTTCGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCTTGGAAAGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA,GCGGACTTGGTGCAGTCTGGGGCTGTGGTGAAGAAGCCTGGGGACTCAGTGAGGATCTCCTGTGAGGCTCAAGGATACAAATTTCCTGACTACATCATTCACTGGATTCGACGGGCCCCTGGACAAGGCCTTGAGTGGATGGGGTGGATTAATCCAATGGGCGGACAAGTAAACATTCCATGGCAGTTTCAGGGCAGGGTCTCCATGACCCGGGACACGTCCATCGAAACAGCATTTCTGGACTTAAGAGGACTAAAGTCTGACGACACGGCCCTCTATTATTGCGTGAGAGATCGAAGTAATGGATCGGGAAGGCGATTCGAGTCCTCCAATTGGTTCCTCGATCTGTGGGGCCGCGGCACTGCGGTCACTGTTCATTCACCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,,
N49P7.v2,gp120 CD4bs,,N49 ,N49P6,Kwon2021(34328065) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.10327,5.71933,428.0,612.0,4234.0,,,,,,
N49P9,gp120 CD4bs,,N49 ,N49P9,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,38.0,2-23,,5.0,,,42.0,L,,Natural monoclonal,human,, Sajadi2018 %SHM calculated for VH and VL+JL.,0.28921,11.5878,234.0,508.0,4094.0,HVQLVQSGGGVKKIGAAVRISCEVTGYKFMDQLINWVRQAPGQGLEWMGWMNPTYGQVNYSWRFEGRVTMTRDMDTETAFMELRGLRVDDTAVYYCARGPSGENYPFHYWGQGVRVVVSSPSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,LTQPASMSASPGQSVTISCSGTRHIISAWFQQYPGKPPKLIIFDDDKRPSGVPSRFSASRPGDTASLTISNVQPEDEATYICNTYEFFGGGTRLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLVSDFYPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEKTVAPAECS,CTGACTCAGCCTGCCTCCATGTCTGCGTCCCCTGGACAGTCGGTAACCATCTCGTGCTCTGGAACCAGACACATAATCTCTGCTTGGTTCCAACAATATCCAGGCAAACCACCCAAACTCATAATTTTTGACGACGATAAGCGTCCCTCTGGAGTTCCTAGTCGCTTCTCTGCCTCCAGGCCTGGCGACACGGCCTCCCTGACAATCTCTAATGTTCAACCTGAGGACGAGGCGACGTACATTTGCAATACATATGAATTCTTTGGCGGAGGGACCAGATTGACCGTCCTAAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCACCCTCGAGTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCGTAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATGGCAGCCCCGTCAAGGTGGGAGTGGAGACCACCAAACCCTCCAAACAAAGCAACAACAAGTATGCGGCCAGCAGCTACCTGAGCCTGACGCCCGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCGGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTGCAGAATGCTCT,CACGTCCAATTGGTGCAGTCTGGAGGTGGGGTGAAGAAGATTGGGGCCGCTGTGAGGATCTCCTGCGAGGTGACTGGATATAAATTCATGGACCAACTCATAAACTGGGTGCGGCAGGCCCCCGGTCAGGGCCTTGAGTGGATGGGATGGATGAATCCAACATATGGACAAGTAAATTATTCATGGAGATTTGAAGGAAGGGTCACCATGACCAGGGACATGGACACCGAGACGGCCTTCATGGAGTTGAGAGGACTGAGAGTGGACGACACGGCCGTCTATTATTGCGCGAGGGGGCCCTCTGGGGAAAATTATCCTTTTCACTATTGGGGCCAGGGTGTCCGAGTGGTCGTCTCGTCACCCTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,,
N49P9.1,gp120 CD4bs,6OZ3(N49P9.1 with HIV-1 strain 93TH057 gp120 core),N49 ,N49P9,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,,2-23,,,,,,L,,Natural monoclonal,human,,Unpublished N49P9.1 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) Unpublished germline gene usage provided by M. Sajadi,0.42484,12.5522,234.0,514.0,4117.0,HVQLVQSGGGVKKIGAAVRISCEVTGYKFMDQLINWVRQAPGQGLEWMGWMNPTYGQVNYSWRFEGRVTMTRDMDTETAFMELRGLRVDDTAVYYCARGPSGENYPFHYWGQGVRVVVSSPSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK,LTQPASMSASPGQSVTISCSGTRHIISAWFQQYPGKPPKLIIFDDDKRPSGVPSRFSASRPGDTASLTISNVQPEDEATYICNTYEFFGGGTRLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,CTGACTCAGCCTGCCTCCATGTCTGCGTCCCCTGGACAGTCGGTAACCATCTCGTGCTCTGGAACCAGACACATAATCTCTGCTTGGTTCCAACAATATCCAGGCAAACCACCCAAACTCATAATTTTTGACGACGATAAGCGTCCCTCTGGAGTTCCTAGTCGCTTCTCTGCCTCCAGGCCTGGCGACACGGCCTCCCTGACAATCTCTAATGTTCAACCTGAGGACGAGGCGACGTACATTTGCAATACATATGAATTCTTTGGCGGAGGGACCAGATTGACCGTCCTAAGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCACCCTCGAGTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA,CACGTCCAATTGGTGCAGTCTGGAGGTGGGGTGAAGAAGATTGGGGCCGCTGTGAGGATCTCCTGCGAGGTGACTGGATATAAATTCATGGACCAACTCATAAACTGGGTGCGGCAGGCCCCCGGTCAGGGCCTTGAGTGGATGGGATGGATGAATCCAACATATGGACAAGTAAATTATTCATGGAGATTTGAAGGAAGGGTCACCATGACCAGGGACATGGACACCGAGACGGCCTTCATGGAGTTGAGAGGACTGAGAGTGGACGACACGGCCGTCTATTATTGCGCGAGGGGGCCCTCTGGGGAAAATTATCCTTTTCACTATTGGGGCCAGGGTGTCCGAGTGGTCGTCTCGTCACCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA,,
N6,gp120 CD4bs,5TE4(N6 in Complex with HIV-1 Clade G Strain X2088 gp120 Core);5TE5(N6 in Complex with HIV-1 Clade AE Strain 93TH057 gp120 Core);5TE6(N6 in Complex with HIV-1 Clade C Strain DU172.17 gp120 Core),Z258 ,N6,Huang2016a(27851912) ,hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects N6 neutralization;N6 alanine scanning;N6 contacts;Signature Analysis Summary,Huang2016a(27851912) ,IMGT/V-QUEST,1-2*02,2-21*02,6*01,13.0,CARDRSYGDSSWALDAWGQGTTVVVSA,31.0,,1-33*01 or 1D-33*01,5*01,5.0,QVLQF,25.0,,K,,Natural monoclonal,human,, ,0.075722,5.96311,1779.0,280.0,3509.0,QVQLVQSRAEVKKPGASVKVSCEASGYNFVDHYIHWVRQAPGQRPQWVGWMNPRGGGVNYSQRFQGRVTMTRDTSIDTAYMQLNRLTSGDTAVYYCATQVKLDSSAGYPFDIWGQGTMVTVSA,QSALTQPRSVSGSPGQSVNISCTGAYSGLGWYQQHPGRAPKLIIYEVNRRPSGVSDRFSGSKSGNTASLTISGLRTEDEADYFCSAFEYFGEGTKLTVL,CAGTCTGCCCTGACTCAGCCTCGCTCAGTGTCCGGGTCTCCTGGACAGTCAGTCAACATCTCCTGCACTGGAGCCTACAGTGGTCTTGGCTGGTACCAACAACACCCAGGCAGAGCCCCCAAACTCATAATTTATGAAGTCAATAGGCGGCCCTCAGGGGTCTCTGATCGCTTCTCTGGCTCCAAGTCTGGTAACACGGCCTCCCTGACCATCTCTGGGCTCCGGACTGAGGATGAGGCTGATTATTTCTGCTCCGCATTTGAATACTTCGGCGAAGGGACTAAACTGACCGTCCTA,CAGGTGCAGTTGGTGCAGTCTAGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCGAGGCTTCTGGATACAATTTCGTCGACCACTATATACATTGGGTGCGACAGGCCCCTGGACAAAGGCCTCAGTGGGTGGGGTGGATGAACCCTAGGGGAGGTGGCGTAAATTATTCACAGAGATTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCGACACAGCCTACATGCAACTGAACAGACTGACCTCTGGCGACACGGCCGTATACTATTGTGCGACTCAAGTGAAACTGGATTCCTCGGCAGGATATCCTTTTGATATTTGGGGCCAAGGAACAATGGTCACAGTGTCTGCA,CATQVKLDSSAGYPFDIW,86.644
N60P1.1,gp120 CD4bs,5WB9(N60P23 with 93TH057 gp120 core (N60P23 differs from N60P1.1 by 1 AA)),N60 ,N60 lineage 1,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,36.0,1-5,,5.0,,,26.0,K,,Natural monoclonal,human,,Structure 5WB9 is for mAb N60P23 which differs from N60P1.1 by 1 AA Sajadi2018 %SHM calculated for VH and VL+JL.,5.85446,11.1567,73.0,499.0,4095.0,QIELVQSGTEVKRPGASVRISCASSGYRFTNYFIHWVRQAPGRGLEWMGWMNPLHGGVNYSGRFQGRVTMTRDIYTETSFMVLSGLTSDDTAIYFCTRGRDGYDDGFHPWGQGTLVTVSA,YVQSQSPSTLYASVGDKITITCRSSQSGWKAWYQQKPGKAPKLLIYKSSILETGVPSRFSGSDSGTEFTLTISSLQPDDFATYYCQHFETFGQGTRVQVR,TACGTGCAGTCCCAGTCTCCTTCCACCCTGTATGCATCTGTAGGAGACAAAATCACCATCACTTGCCGGTCCAGTCAGAGTGGTTGGAAGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAATCCTCCATTTTGGAAACTGGGGTCCCATCAAGGTTCAGCGGCAGTGATTCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACATTTTGAGACGTTCGGCCAAGGGACCAGGGTGCAAGTCAGA,CAGATCGAGCTGGTGCAGTCTGGGACTGAGGTGAAGAGGCCTGGGGCCTCAGTGAGGATCTCCTGCGCGTCTTCTGGATACAGATTCACCAACTACTTTATCCACTGGGTGCGACAGGCCCCTGGACGAGGGCTTGAGTGGATGGGATGGATGAACCCTCTCCACGGTGGCGTAAACTATTCAGGGAGGTTTCAGGGCAGGGTCACCATGACCAGGGACATCTACACCGAGACATCCTTCATGGTGCTGAGCGGGCTGACATCTGACGACACGGCCATATATTTCTGTACGAGAGGCAGGGACGGTTATGACGACGGGTTCCACCCCTGGGGCCAAGGAACCCTGGTCACCGTCTCCGCA,CTRGRDGYDDGFHPW,84.746
N60P2.1,gp120 CD4bs,,N60 ,N60 lineage 1,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,38.0,1-5,,5.0,,,29.0,K,,Natural monoclonal,human,, Sajadi2018 %SHM calculated for VH and VL+JL.,9.93875,13.3704,73.0,500.0,4097.0,RAQLVQSGPEVKKPGASVRISCAASGYTFVDSFIHWLRQAPGQGLEWIGWINPLRGGVNYSGRFQGRVAMTRNTFTETVYMDINGLTPDDTATYFCVRAPDSYDRGYDAWGQGTRVIVTS,YIQVTQSPSTLSASIGDTVTITCRASEGWLAWYQQKPGKAPKLIIYKTSTLERGVPSRFSGSVSGADFTLTISGLQSDDFATYYCQKFEFFGQGTVVDMK,TACATCCAGGTGACCCAGTCTCCTTCCACCCTGTCTGCATCTATAGGAGACACAGTCACCATCACTTGCCGGGCCAGTGAGGGTTGGTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCATAATTTATAAGACCTCCACTTTGGAAAGAGGGGTCCCATCAAGGTTCAGCGGCAGTGTATCTGGGGCAGACTTCACTCTCACCATCAGCGGCCTGCAGTCTGATGATTTTGCAACTTATTACTGCCAAAAGTTTGAATTTTTTGGCCAGGGGACCGTGGTGGACATGAAA,CGGGCGCAGCTGGTGCAGTCTGGGCCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGGATCTCCTGCGCGGCTTCTGGATACACCTTCGTCGATTCCTTTATCCACTGGCTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATAGGATGGATCAACCCTCTCCGTGGTGGCGTAAACTATTCAGGCAGGTTTCAGGGCAGGGTCGCCATGACCAGGAACACGTTCACCGAGACAGTCTACATGGACATCAACGGGCTGACACCTGACGACACGGCCACGTATTTCTGTGTGAGAGCCCCCGATTCGTACGACAGAGGGTACGACGCCTGGGGCCAAGGAACCCGGGTCATCGTCACCTCA,CVRAPDSYDRGYDAW,84.746
N60P22,gp120 CD4bs,,N60 ,N60 lineage 2,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,4-31,,,,,,9.0,3-20,,9.0,,,11.0,K,,Natural monoclonal,human,, Sajadi2018 %SHM calculated for VH and VL+JL.,88.7001,1.78535,73.0,503.0,4100.0,QVQLQESGPGLVKPSQTVSLTCSVSGGSISSGGYHWSWIRQHPGKGLEWIGYIYHNGNTYYNPSLESRVTISVDTSKNQFSLKLTSVTAADTAVYYCARNSARAGSHLLLGRDKSWFDPWGQGTLVIVSS,ENVLTQSPGTLSLSPGDRATLSCRASQSFSSSNLAWYQQKPGQAPRLLIHGVSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYAYSPATFGQGTKVEIK,GAAAATGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGATAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTTTTAGCAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCCATGGTGTATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTTCTGTCAGCAGTATGCTTACTCACCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCGTGTCCCTCACCTGCAGTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACCACTGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATCACAATGGGAACACCTACTACAACCCGTCCCTCGAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAAGCTGACCTCTGTGACTGCCGCGGACACGGCCGTGTATTACTGTGCGAGAAATAGTGCTAGGGCTGGAAGCCACCTGCTACTCGGAAGGGATAAGTCCTGGTTCGACCCCTGGGGCCAAGGAACCCTGGTCATCGTCTCCTCA,CARNSARAGSHLLLGRDKSWFDPW,97.306
N60P25.1,gp120 CD4bs,,N60 ,N60 lineage 1,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,33.0,1-5,,5.0,,,26.0,K,,Natural monoclonal,human,, Sajadi2018 %SHM calculated for VH and VL+JL.,3.49384,13.6202,72.0,501.0,4098.0,HVQLVQSGTEVKRPGASVRISCASSGYTFSNYFIHWVRQAPGRGLEWMGWMNPLRGAVNYSGKFQGRVTMTRDIYTETSFMVLSGLRSDDTAIYFCARGRDGYEYGFNPWGQGTLVTVSS,YVQTQSPSTLYASVGDRVTITCRSSQSGWKAWYQQKPGKAPKLLIYKSSTLESGVPSRFSGSDSGTEFNLTITSLQPDDFATYFCQHFETFGQGTRVEVR,TACGTGCAGACCCAGTCTCCTTCCACCCTGTATGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGTCCAGTCAGAGTGGCTGGAAGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGTCCTCCACTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGATTCTGGGACAGAATTCAATCTCACCATCACCAGCCTGCAGCCTGATGATTTTGCAACTTATTTCTGCCAACATTTTGAGACGTTCGGCCAAGGGACCAGGGTGGAAGTCAGA,CATGTGCAGCTGGTGCAGTCTGGGACTGAGGTGAAGAGGCCTGGGGCCTCAGTGAGGATCTCCTGCGCGTCTTCTGGATACACCTTCAGCAACTACTTTATTCACTGGGTGCGACAGGCCCCTGGACGAGGGCTTGAGTGGATGGGATGGATGAACCCTCTCAGAGGTGCCGTAAACTATTCAGGGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACATCTACACCGAAACATCCTTCATGGTGCTGAGCGGGCTGAGATCTGACGACACGGCCATCTATTTCTGTGCGAGAGGTAGAGATGGTTATGAGTACGGGTTCAACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CARGRDGYEYGFNPW,87.119
N60P31.1,gp120 CD4bs,,N60 ,N60 lineage 1,Sajadi2018(29731169) ,,Sajadi2018(29731169) ,SoDA,1-2,,,,,,42.0,1-5,,5.0,,,35.0,K,,Natural monoclonal,human,, Sajadi2018 %SHM calculated for VH and VL+JL.,43.0735,7.3424,73.0,502.0,4099.0,RVQLVQSGPEVKKPGASVRISCKASGYKFSDSLIHWLRQSPRDGLQWLGYMNPMGGAVNYAHRLQGRVQMTRDIFSETAYMDIRGLTPDDTATYFCVRDPDAYERGFDAWGQGTRIVVTS,YIQVTQSPSTLSASIGDTVTITCRASEGWLAWYQQKPGKAPKLIIYKTSTLERGVPSRFSGSVSGADFTLTISGLQSDDFATYYCQKFEFFGQGTVVDMK,TACATCCAGGTGACCCAGTCTCCTTCCACCCTGTCTGCATCTATAGGAGACACAGTCACCATCACTTGCCGGGCCAGTGAGGGTTGGTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCATAATTTATAAGACCTCCACTTTGGAAAGAGGGGTCCCATCAAGGTTCAGCGGCAGTGTATCTGGGGCAGACTTCACTCTCACCATCAGCGGCCTGCAGTCTGATGATTTTGCAACTTATTACTGCCAAAAGTTTGAATTTTTTGGCCAGGGGACCGTGGTGGACATGAAA,CGGGTGCAGCTGGTGCAGTCTGGGCCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGGATCTCCTGCAAGGCTTCTGGATACAAGTTCTCCGACTCCCTTATCCACTGGCTGCGACAGTCCCCTCGAGACGGGCTTCAGTGGCTAGGATACATGAACCCTATGGGTGGTGCCGTAAACTATGCACACAGGCTTCAGGGCAGGGTCCAGATGACCAGGGACATCTTCTCCGAGACAGCCTACATGGATATCCGCGGGCTGACACCTGACGACACGGCCACGTATTTCTGTGTGAGAGACCCCGACGCATATGAGCGCGGGTTCGACGCCTGGGGCCAAGGAACCCGGATCGTCGTCACCTCA,CVRDPDAYERGFDAW,81.757
N6/10E8v4-PGDM1400,gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region),,Donor 84 Donor N152 Z258 ,,Xu2017(28931639) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,"trispecific involving N6, PGDM1400, and 10E8 ",0.043305,6.74707,416.0,390.0,3957.0,,,,,,
N6_FR3-03,gp120 CD4bs,6NM6(BG505 SOSIP.664 Prefusion Env Trimer Bound to N6 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv),Z258 ,N6,Liu2019(30760721) ,Mutation affects neutralization by N6_FR3-03,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,N6-FR3 03, ,0.080594,7.24838,416.0,796.0,4572.0,,,,,,
N6-LS,gp120 CD4bs,,Z258 ,N6,Julg2017(28539448) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,0.082206,5.06056,442.0,551.0,4162.0,,,,,,
N6-LS-N72Q-R18D,gp120 CD4bs,,Z258 ,N6,Chuang2020(33121334) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,0.095107,5.33541,416.0,807.0,4575.0,,,,,,
N6/PGDM1400-10E8v4,gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region),,Donor 84 Donor N152 Z258 ,,Xu2017(28931639) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"N6-LS/PGDM1400-10E8v4, N6/PGDM1400x10E8, PGDM1400/N6x10E8v4","trispecific involving N6, PGDM1400, and 10E8 ",0.022389,6.53997,430.0,389.0,3956.0,,,,,,
NC37,quaternary structure,,EB354 ,,Freund2017(28100831) ,,Freund2017(28100831) ,IMGT/V-QUEST,1-2 or 1-46,,,19.0,DNFGTRPVPGRGYYYGMDV,28.8,,3-20,,,,27.9,,K,,Natural monoclonal,human,354NC37, Freund2017 %SHM calculated for VH and VL only.,18.5195,15.2635,237.0,305.0,3621.0,,,,,,
NC-Cow1,gp120 CD4bs,6OO0(bovine Fab NC-Cow1);6OPA(NC-Cow1 Fab in complex with HIV-1 BG505 SOSIP.664 and human Fabs 35022 and PGT128);6PW6(BG505 SOSIP.664 in complex with 3 copies of NC-Cow1 Fab);EMD-20500(BG505 SOSIP.664 in complex with 3 copies of NC-Cow1 Fab),Cow #26 ,,Sok2017(28726771) ,Mutation affects NC-Cow1 binding or neutralization,,,,,,,,,,,,,,,,,,Natural monoclonal,cow,, ,0.52253,44.4645,216.0,586.0,4198.0,MGWSCIILFLVATATGVHSQVQLRESGPSLMKPSQTLSLTCTVSGSSLNDKSVGWVRQAPGKALQWLGSVDTSGNTDYNPGLKSRLSITKDNSKSRISLTVTGMTTEDSATYYCITAHQKTNKKECPEDYTYNPRCPQQYGWSDCDCMGDRFGGYCRQDGCSNYIHRSTYEWYVSAWGQGLLVTVSS,MGWSCIILFLVATATGVHSYELTQPSSVSGSLGQRVSVTCSGSSSNVGNGYVSWYQLIPGSAPRTIIYGDTSRASGVPERFSGSRSGNTATLTISSLQAEDEADFFCASPDDSSSNAVFGSGTTLTVL,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCTATGAGCTGACTCAGCCATCATCCGTGTCCGGGTCCCTGGGCCAGAGGGTCTCCGTCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGTTGGTACCAACTGATCCCAGGATCGGCCCCCAGAACGATCATCTATGGTGACACCAGTCGAGCCTCGGGGGTCCCCGAGCGATTCTCCGGCTCCAGGTCTGGGAACACAGCCACCCTGACCATCAGCTCGCTCCAGGCTGAGGACGAGGCGGATTTCTTCTGTGCATCTCCTGACGATAGTAGCAGTAATGCTGTTTTCGGCAGCGGGACCACACTGACCGTCCTG,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTGCGGGAGTCGGGCCCCAGCCTGATGAAGCCGTCACAGACCCTCTCCCTCACCTGCACGGTCTCTGGATCTTCATTGAACGACAAGTCTGTAGGCTGGGTCCGCCAGGCTCCAGGGAAGGCGCTGCAGTGGCTCGGTAGTGTGGACACTAGTGGAAACACAGACTATAACCCAGGCCTGAAATCCCGGCTCAGCATCACCAAGGACAACTCCAAGAGCCGAATCTCTCTTACAGTGACTGGCATGACAACTGAAGACTCGGCCACATACTACTGCATTACTGCTCACCAAAAAACAAACAAAAAAGAGTGTCCGGAGGATTATACTTATAATCCACGTTGCCCTCAGCAGTATGGTTGGAGTGACTGTGATTGTATGGGCGATAGGTTTGGGGGTTACTGTCGACAGGATGGTTGTAGTAATTATATACATCGTAGTACTTACGAATGGTACGTCAGCGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCA,CITAHQKTNKKECPEDYTYNPRCPQQYGWSDCDCMGDRFGGYCRQDGCSNYIHRSTYEWYVSAW,67.944
NC-Cow10,,,Cow #26 ,,Sok2017(28726771) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,cow,, ,0.46565,53.6086,23.0,595.0,4207.0,MGWSCIILFLVATATGVHSKVQLQESGPSLVKPSQTLSLTCTVSGFSLSDKAVGWVRQAPGKALEWLGTIDTNRNTNYHPGLKSRLSITKDNSKSRVSLSVSTMTTEDSATYYCTTVHQKTNEKDCPEYYSYNPDCPRRYGWSNCDCMADKFGGWCRHDGCSDYADMTTDEWYVDAWGQGLLVTVSS,MGWSCIILFLVATATGVHQDVLTQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLISGSAPRTLIYGDTSRASGIPDRFSGSRSGNTATLTITSLQAEDEADYFCASAEDRRSNAIFGSGTTLTVL,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATCAGGATGTGCTGACTCAGCCATCATCCGTGTCCGGGTCCCTGGGCCAGAGGGTCTCCATCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGTTGGTACCAATTGATCTCAGGATCGGCCCCCAGAACCCTCATCTATGGTGACACCAGTCGAGCCTCGGGAATCCCCGACCGATTCTCCGGCTCCAGGTCTGGGAACACAGCCACCCTGACCATCACCTCGCTCCAGGCTGAGGACGAGGCAGATTATTTCTGTGCATCTGCTGAAGATAGGCGCAGTAATGCTATTTTCGGCAGCGGGACCACACTGACCGTCCTG,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCAAGGTGCAGCTGCAGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCCCTCACCTGCACGGTCTCTGGATTCTCATTGAGCGACAAGGCTGTAGGCTGGGTCCGCCAGGCTCCAGGGAAGGCGCTGGAGTGGCTCGGTACGATAGACACTAATCGAAACACAAACTATCACCCAGGCCTAAAATCCCGGCTCAGCATCACCAAGGACAACTCCAAGAGTCGAGTCTCTCTGTCCGTGAGCACCATGACAACTGAGGACTCGGCCACATACTACTGTACTACTGTACACCAGAAAACAAACGAAAAAGATTGTCCGGAGTATTATAGTTATAACCCCGATTGCCCTAGGCGGTATGGTTGGAGTAACTGTGATTGTATGGCAGATAAATTTGGGGGTTGGTGTCGTCATGATGGTTGTAGTGATTATGCAGATATGACTACTGACGAATGGTACGTCGATGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCA,CTTVHQKTNEKDCPEYYSYNPDCPRRYGWSNCDCMADKFGGWCRHDGCSDYADMTTDEWYVDAW,69.896
NC-Cow2,gp120 CD4bs,,Cow #26 ,,Sok2017(28726771) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,cow,,"NC-Cow2 is an orphan heavy chain, paired with a germline light chain ",0.049206,13.527,23.0,587.0,4199.0,MGWSCIILFLVATATGVHSKVQLRESGPSLVKPSQTLSLTCMVSGSSLSDKAVGWVRQAPGKALEWLGIISAGGNRGYNSGLRSRLTISKDNSKNEVSLRVRSVTTEDSATYFCGTVHQKTQRKPICPDGYSDDSTLRYYSRCSDRDCWRCTGTTYYDTCQCGTYTWIDTHELHVDAWGQGLLVTVSS,MGWSCIILFLVATATGVHQAVLNQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASAEDSSSNAVFGSGTTLTVL,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATCAGGCCGTCCTGAACCAGCCAAGCAGCGTCTCCGGGTCTCTGGGGCAGCGGGTCTCAATCACCTGTAGCGGGTCTTCCTCCAATGTCGGCAACGGCTACGTGTCTTGGTATCAGCTGATCCCTGGCAGTGCCCCACGAACCCTGATCTACGGCGACACATCCAGAGCTTCTGGGGTCCCCGATCGGTTCTCAGGGAGCAGATCCGGAAACACAGCTACTCTGACCATCAGCTCCCTGCAGGCTGAGGACGAAGCAGATTATTTCTGCGCATCTGCCGAGGACTCTAGTTCAAATGCCGTGTTTGGAAGCGGCACCACACTGACAGTCCTG,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCAAGGTGCAGCTGCGGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCTCTCACCTGCATGGTCTCTGGATCTTCATTGAGCGACAAGGCTGTAGGCTGGGTCCGCCAGGCTCCGGGGAAGGCGCTGGAGTGGCTCGGTATTATCAGCGCTGGTGGAAACAGGGGCTATAATTCGGGCCTGAGGTCCCGACTCACTATCTCCAAGGACAACTCCAAGAACGAGGTCTCTCTGAGAGTGAGGAGCGTGACAACTGAGGACTCGGCCACATACTTCTGTGGTACTGTGCACCAGAAGACACAGCGGAAACCAATTTGTCCTGATGGCTATAGTGATGATAGTACTCTTCGTTACTACAGTAGATGTTCTGATCGTGATTGTTGGCGTTGTACCGGGACTACGTATTATGATACTTGTCAATGCGGTACTTATACTTGGATTGATACTCACGAATTACACGTCGATGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCA,CGTVHQKTQRKPICPDGYSDDSTLRYYSRCSDRDCWRCTGTTYYDTCQCGTYTWIDTHELHVDAW,68.966
NC-Cow3,,,Cow #26 ,,Sok2017(28726771) ,,,,,,,,,,,,,,,,,,,Fab or heavy-chain-only,cow,,"NC-Cow3 is an orphan heavy chain, paired with a germline light chain ",69.1312,2.84003,23.0,588.0,4200.0,MGWSCIILFLVATATGVHSQVQLRESGPSLVKPSQTLSLTCMVSGFSLNDKAVGWVRQAPGKALEWLGSIGTGGNKGYNPGLKSRLSISKDSSKNQVSLSMSSVTTEDSATYYCGTVHQRTHRKQNCPGGYSDDNALRYRSRCDDRDCWRCTGTTYYDTCQCASYFYTDTYEFYVDAWGQGLLVTVSS,MGWSCIILFLVATATGVHQAVLNQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASAEDSSSNAVFGSGTTLTVL,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATCAGGCCGTCCTGAACCAGCCAAGCAGCGTCTCCGGGTCTCTGGGGCAGCGGGTCTCAATCACCTGTAGCGGGTCTTCCTCCAATGTCGGCAACGGCTACGTGTCTTGGTATCAGCTGATCCCTGGCAGTGCCCCACGAACCCTGATCTACGGCGACACATCCAGAGCTTCTGGGGTCCCCGATCGGTTCTCAGGGAGCAGATCCGGAAACACAGCTACTCTGACCATCAGCTCCCTGCAGGCTGAGGACGAAGCAGATTATTTCTGCGCATCTGCCGAGGACTCTAGTTCAAATGCCGTGTTTGGAAGCGGCACCACACTGACAGTCCTG,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTGCGGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCCCTCACCTGCATGGTCTCTGGATTCTCATTGAACGACAAGGCTGTAGGCTGGGTCCGCCAGGCTCCAGGGAAGGCGTTGGAGTGGCTCGGTAGTATAGGCACTGGTGGAAACAAAGGCTATAACCCAGGCCTGAAATCCCGGCTCAGCATCTCCAAGGACAGCTCCAAGAACCAAGTCTCTCTGTCAATGAGCAGCGTGACAACTGAGGACTCGGCCACATACTACTGTGGTACTGTGCACCAGAGGACACACCGAAAACAAAATTGTCCTGGAGGGTATAGTGATGATAATGCTCTTCGTTATCGCAGTAGATGTGATGATCGTGATTGTTGGCGTTGTACTGGGACTACGTATTATGATACTTGTCAATGTGCCAGTTATTTTTATACTGATACTTACGAATTCTACGTCGATGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCA,CGTVHQRTHRKQNCPGGYSDDNALRYRSRCDDRDCWRCTGTTYYDTCQCASYFYTDTYEFYVDAW,70.000
NC-Cow4,,,Cow #26 ,,Sok2017(28726771) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,cow,, ,33.0331,11.8105,23.0,589.0,4201.0,MGWSCIILFLVATATGVHSKVQLRESGPSLVKPSQTLSLTCMVSGFSLNDEAVGWVRQAPGKALEWLGSIDAGGSTGYNPGLKSRLSISKDNSKNQVSLSVSSVTTEDSATYYCGTVHQRTQPKQTCPNGYSDDSALRYYSRCSDRDCWRCTGTTYYDTCQCSSYTYIHTYELYVDAWGQGLLVTVSS,MGWSCIILFLVATATGVHQAVLTQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASPEDSSSNAVFGSGTTLTVL,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATCAGGCTGTGCTGACTCAGCCATCATCCGTGTCCGGGTCCCTGGGCCAGAGGGTCTCCATCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGCTGGTACCAACTGATCCCAGGATCGGCCCCCAGAACCCTCATCTATGGTGACACCAGTCGAGCCTCGGGGGTCCCCGACCGATTCTCCGGCTCCAGGTCTGGGAACACAGCCACCCTGACCATCAGCTCGCTCCAGGCTGAAGACGAGGCAGATTATTTCTGTGCATCTCCTGAGGATAGTAGCAGTAATGCTGTTTTCGGCAGCGGGACCACACTGACCGTCCTG,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCAAGGTGCAGCTGCGGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCCCTCACCTGCATGGTCTCTGGATTCTCATTGAACGACGAGGCTGTAGGCTGGGTCCGCCAGGCTCCAGGGAAGGCGCTGGAGTGGCTCGGTAGTATAGACGCTGGTGGAAGCACAGGCTATAACCCAGGCCTGAAATCCCGACTCAGCATCTCCAAGGACAACTCCAAGAACCAAGTTTCTCTGTCAGTGAGCAGCGTGACAACTGAGGACTCGGCCACATACTACTGTGGTACTGTGCACCAGAGGACACAGCCAAAACAAACTTGTCCTAATGGCTATAGTGATGATAGTGCTCTTCGTTATTACAGTAGATGTTCTGATCGTGATTGTTGGCGTTGTACTGGGACTACGTATTATGATACTTGTCAATGTAGTAGTTATACTTATATTCATACTTACGAATTATACGTCGATGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCA,CGTVHQRTQPKQTCPNGYSDDSALRYYSRCSDRDCWRCTGTTYYDTCQCSSYTYIHTYELYVDAW,70.934
NC-Cow5,,,Cow #26 ,,Sok2017(28726771) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,cow,, ,79.3854,2.11641,23.0,590.0,4202.0,MGWSCIILFLVATATGVHSQVQLQESGPSLVKPSQTLSLTCMVSGFSLNDKAVGWVRQAPGKALEWLGSIDAGGSTGYNPGLKSRLSISKDNSKNQVSLSVSSVTTEDSATYYCGTVHQRTQPKQTCPNGYSDDSALRYYSRCSDRDCWRCTGTTYYDTCQCSSYTYIHTYELYVDAWGQGLLVTVSS,MGWSCIILFLVATATGVHQDVLTQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASPEDSSSNAVFGSGTTLTVL,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATCAGGATGTGCTGACTCAGCCATCATCCGTGTCCGGGTCCCTGGGCCAGAGGGTCTCCATCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGCTGGTACCAACTGATCCCAGGATCGGCCCCCAGAACCCTCATCTATGGTGACACCAGTCGAGCCTCGGGGGTCCCCGACCGATTCTCCGGCTCCAGGTCTGGGAACACAGCCACCCTGACCATCAGCTCGCTCCAGGCTGAAGACGAGGCAGATTATTTCTGTGCATCTCCTGAGGATAGTAGCAGTAATGCTGTTTTCGGCAGCGGGACCACACTGACCGTCCTG,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCCCTCACCTGCATGGTCTCTGGATTCTCATTGAACGACAAGGCTGTAGGCTGGGTCCGCCAGGCTCCAGGGAAGGCGCTGGAGTGGCTCGGTAGTATAGACGCTGGTGGAAGCACAGGCTATAACCCAGGCCTGAAATCCCGACTCAGCATCTCCAAGGACAACTCCAAGAACCAAGTCTCTCTGTCAGTGAGCAGCGTGACAACTGAGGACTCGGCCACATACTACTGTGGTACTGTGCACCAGAGGACACAGCCAAAACAAACTTGTCCTAATGGCTATAGTGATGATAGTGCTCTTCGTTATTACAGTAGATGTTCTGATCGTGATTGTTGGCGTTGTACTGGGACTACGTATTATGATACTTGTCAATGTAGTAGTTATACTTATATTCATACTTACGAATTATACGTCGATGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCA,CGTVHQRTQPKQTCPNGYSDDSALRYYSRCSDRDCWRCTGTTYYDTCQCSSYTYIHTYELYVDAW,71.724
NC-Cow6,,,Cow #26 ,,Sok2017(28726771) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,cow,, ,35.7453,9.61165,23.0,591.0,4203.0,MGWSCIILFLVATATGVHSQVQLRESGPSLVKPSQTLSLTCMVSGFSLNDKAVGWVRQAPGKALEWLGSIDAGGSTGYNPGLKSRLSISKDNSKNQVSLSVSSVTTEDSATYYCGTVHQRTQPKQTCPNGYSDDSALRYYSRCSDRDCWRCTGTTYYDTCQCSSYTYIHTYELYVDAWGQGLLVTVSS,MGWSCIILFLVATATGVHQAVLTQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASPEDSSSNAVFGSGTTLTVL,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATCAGGCTGTGCTGACTCAGCCATCATCCGTGTCCGGGTCCCTGGGCCAGAGGGTCTCCATCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGCTGGTACCAACTGATCCCAGGATCGGCCCCCAGAACCCTCATCTATGGTGACACCAGTCGAGCCTCGGGGGTCCCCGACCGATTCTCCGGCTCCAGGTCTGGGAACACAGCCACCCTGACCATCAGCTCGCTCCAGGCTGAAGACGAGGCAGATTATTTCTGTGCATCTCCTGAGGATAGTAGCAGTAATGCTGTTTTCGGCAGCGGGACCACACTGACCGTCCTG,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTGCGGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCCCTCACCTGCATGGTCTCTGGATTCTCATTGAACGACAAGGCTGTAGGCTGGGTCCGCCAGGCTCCAGGGAAGGCGCTGGAGTGGCTCGGTAGTATAGACGCTGGTGGAAGCACAGGCTATAACCCAGGCCTGAAATCCCGACTCAGCATCTCCAAGGACAACTCCAAGAACCAAGTCTCTCTGTCAGTGAGCAGCGTGACAACTGAGGACTCGGCCACATACTACTGTGGTACTGTGCACCAGAGGACACAGCCAAAACAAACTTGTCCTAATGGCTATAGTGATGATAGTGCTCTTCGTTATTACAGTAGATGTTCTGATCGTGATTGCTGGCGTTGTACTGGGACTACGTATTATGATACTTGTCAATGTAGTAGTTATACTTATATTCATACTTACGAATTATACGTCGATGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCA,CGTVHQRTQPKQTCPNGYSDDSALRYYSRCSDRDCWRCTGTTYYDTCQCSSYTYIHTYELYVDAW,71.379
NC-Cow7,,,Cow #26 ,,Sok2017(28726771) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,cow,, ,1.0281,62.7872,23.0,592.0,4204.0,MGWSCIILFLVATATGVHSKVQLRESGPSLVKPFETLSLTCTGSGFSLSDKAAGWVRQAPGKAPEWLGSIDTGGNTGYNPGLKYRLSITKDNSKSQVSLSVSSMTSEDSATYYCTTVHQKAYKKVCPDDYSSNPDCVRLYGWSHCDCMRDSFGGWCRADGCSSTVEIGPYEWYVNAWGQGLLVTVSS,MGWSCIILFLVATATGVHQAVLTQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRSLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASPEDSSSNGVFGSGTTLTVL,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATCAGGCTGTGCTGACTCAGCCATCATCCGTGTCCGGGTCCCTGGGCCAGAGGGTCTCCATCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGTTGGTACCAACTGATCCCAGGATCGGCCCCCAGAAGCCTCATCTATGGTGACACTAGTCGAGCCTCGGGGGTCCCCGACCGATTCTCCGGCTCCAGGTCTGGGAACACAGCCACCCTGACCATCAGCTCGCTCCAGGCTGAGGACGAGGCAGATTATTTCTGTGCATCTCCTGAGGATAGTAGTAGTAATGGTGTTTTCGGCAGCGGGACCACACTGACCGTCCTG,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCAAGGTGCAGCTGCGGGAGTCGGGCCCCAGCCTGGTGAAGCCGTTTGAGACCCTCTCCCTCACCTGCACGGGTTCTGGATTCTCATTGAGCGACAAGGCTGCAGGCTGGGTCCGCCAGGCTCCAGGGAAGGCGCCGGAGTGGCTTGGCAGTATAGACACTGGTGGAAACACAGGCTATAACCCAGGCCTGAAATACCGGCTGAGTATCACCAAGGACAACTCCAAGAGCCAAGTCTCTCTGTCAGTGAGCAGTATGACAAGTGAGGACTCGGCCACATACTACTGTACTACTGTACACCAGAAAGCCTACAAAAAAGTTTGTCCGGATGATTATAGTAGTAATCCCGATTGCGTTCGGTTGTATGGCTGGAGTCACTGTGACTGTATGAGAGACAGTTTTGGGGGTTGGTGTCGTGCTGATGGTTGTAGTAGTACTGTAGAGATTGGGCCTTACGAATGGTACGTCAATGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCA,CTTVHQKAYKKVCPDDYSSNPDCVRLYGWSHCDCMRDSFGGWCRADGCSSTVEIGPYEWYVNAW,68.512
NC-Cow8,,,Cow #26 ,,Sok2017(28726771) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,cow,, ,1.0671,43.4132,23.0,593.0,4205.0,MGWSCIILFLVATATGVHSKVQLQESGPSLVKPSQTLSLTCTVSGFSLSDVAVGWVRQAPGKALEWLGTIYTSGNTNVNPGLKSRLSITKDNAKSQVSLSVTSLTTDDSATYYCTTVYQKTTKKDCPEYYTYNPDCARRYGWSDCECMADKFGGYCRHDGCATNTVRSTYEWHLDAWGQGLLVTVSS,MGWSCIILFLVATATGVHQAVLTQPSSVSGSLGRRVSITCSGSSSNVGNGYVSWYQVIPGSAPRTLIYGDSNRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCGSAEDGSGSGVFGSGTTLTVL,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATCAGGCTGTGCTGACTCAACCATCATCCGTGTCCGGGTCCCTGGGCCGGAGGGTCTCCATCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGTTGGTACCAAGTGATCCCAGGATCGGCCCCCAGAACCCTCATCTATGGTGACAGCAATCGAGCCTCGGGGGTCCCCGACCGATTCTCCGGGTCCAGGTCTGGGAACACAGCCACCCTGACCATCAGCTCGCTCCAGGCTGAGGACGAGGCAGATTATTTCTGTGGCTCTGCTGAGGATGGTAGCGGTAGTGGCGTTTTCGGCAGCGGGACCACACTGACCGTCCTG,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCAAGGTGCAGCTGCAGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCCCTCACCTGCACGGTCTCTGGATTCTCATTGAGCGACGTGGCTGTAGGCTGGGTCCGCCAGGCTCCAGGGAAGGCGCTGGAGTGGCTCGGTACGATATACACTAGTGGAAACACAAACGTTAACCCAGGCCTGAAATCCCGGCTCAGCATCACTAAGGACAACGCCAAGAGCCAAGTCTCTCTATCAGTGACCAGCTTGACAACTGACGACTCGGCCACATACTACTGTACTACTGTATACCAGAAAACAACGAAAAAAGATTGTCCGGAGTATTATACTTATAATCCCGATTGCGCGAGGCGCTATGGTTGGAGTGACTGTGAATGTATGGCAGATAAATTTGGGGGTTATTGTCGTCATGATGGTTGTGCTACTAATACAGTCCGTAGTACTTACGAATGGCACCTCGATGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCA,CTTVYQKTTKKDCPEYYTYNPDCARRYGWSDCECMADKFGGYCRHDGCATNTVRSTYEWHLDAW,70.139
NC-Cow9,,,Cow #26 ,,Sok2017(28726771) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,cow,, ,2.77506,21.5423,23.0,594.0,4206.0,MGWSCIILFLVATATGVHSQVQLQESGPSLVKPSQTLSLTCTVSGFSLSDVAVGWVRQAPGKALEWLGTIYTSGNTNVNPGLKSRLSITKDNAKSQVSLSVTSLTTDDSATYYCTTVYQKTTKKDCPEYYTYNPDCARRYGWSDCECMADKFGGYCRHDGCATNTVRSTYEWHLDAWGQGLLVTVSS,MGWSCIILFLVATATGVHQAVLTQPSSVSGSLGRRVSITCSGSSSNVGNGYVSWYQVIPGSAPRTLIYGDSNRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCGSAEDGSGSGVFGSGTTLTVL,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATCAGGCTGTGCTGACTCAACCATCATCCGTGTCCGGGTCCCTGGGCCGGAGGGTCTCCATCACCTGCTCTGGAAGCAGCAGCAATGTTGGAAATGGATATGTGAGTTGGTACCAAGTGATCCCAGGATCGGCCCCCAGAACCCTCATCTATGGTGACAGCAATCGAGCCTCGGGGGTCCCCGACCGATTCTCCGGGTCCAGGTCTGGGAACACAGCCACCCTGACCATCAGCTCGCTCCAGGCTGAGGACGAGGCAGATTATTTCTGTGGCTCTGCTGAGGATGGTAGCGGTAGTGGCGTTTTCGGCAGCGGGACCACACTGACCGTCCTG,ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAGTCGGGCCCCAGCCTGGTGAAGCCGTCACAGACCCTCTCCCTCACCTGCACGGTCTCTGGATTCTCATTGAGCGACGTGGCTGTAGGCTGGGTCCGCCAGGCTCCAGGGAAGGCGCTGGAGTGGCTCGGTACGATATACACTAGTGGAAACACAAACGTTAACCCAGGCCTGAAATCCCGGCTCAGCATCACTAAGGACAACGCCAAGAGCCAAGTCTCTCTATCAGTGACCAGCTTGACAACTGACGACTCGGCCACATACTACTGTACTACTGTATACCAGAAAACAACGAAAAAAGATTGTCCGGAGTATTATACTTATAATCCCGATTGCGCGAGGCGCTATGGTTGGAGTGACTGTGAATGTATGGCAGATAAATTTGGGGGTTATTGTCGTCATGATGGTTGTGCTACTAATACAGTCCGTAGTACTTACGAATGGCACCTCGATGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCA,CTTVYQKTTKKDCPEYYTYNPDCARRYGWSDCECMADKFGGYCRHDGCATNTVRSTYEWHLDAW,70.486
NIH45-46,gp120 CD4bs,3U7W(Fab NIH45-46);3U7Y(Fab NIH45-46 complexed with gp120);4JDT(chimeric germ-line precursor of NIH45-46 Fab in complex with gp120 (93TH057));4JDV(germ-line precursor of NIH45-46 Fab);5D9Q(BG505 SOSIP gp140 HIV-1 Env trimer in Complex with the Broadly Neutralizing Fab PGT122 and scFv NIH45-46);5IGX(NIH45-46 Fab germline precursor in complex with 426c.TM1deltaV1-3 gp120),NIH45 ,VRC01,Scheid2011(21764753) ,hypervariable loop characteristic correlations with bNAb sensitivity;Mutations allowing binding of germline Abs;NIH45-46 contacts;NIH45-46 signature predictions;Signature Analysis Summary;Signature Analysis Summary,Klein2013(23540694) ,IgBlast,1-2,2-8 or 3-9,1,,,,,3-11,2,,,,,K,Yes,Natural monoclonal,human,"45, 45-46", ,0.31734,15.5088,2300.0,1.0,2580.0,QVRLSQSGGQMKKPGESMRLSCRASGYEFLNCPINWIRLAPGRRPEWMGWLKPRGGAVNYARKFQGRVTMTRDVYSDTAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGRGAPVTVSSASTKGPSX,EIVLTQSPATLSLSPGETAIISCRTSQSGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGADYNLSISNLESGDFGVYYCQQYEFFGQGTKVQVDIKRTVAAP,GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTCTGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGTTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGGCAGACTACAATCTCAGCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATCAAACGTACGGTGGCTGCACCA,CAAGTGCGACTGTCGCAGTCTGGAGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGACTTTCCTGTCGGGCTTCCGGATATGAATTTCTGAATTGTCCAATAAATTGGATTCGCCTGGCCCCCGGAAGACGGCCTGAGTGGATGGGATGGCTGAAGCCTAGGGGAGGGGCCGTCAATTACGCACGTAAATTTCAGGGCAGAGTGACCATGACTCGAGACGTGTATTCCGACACAGCCTTTTTGGAGTTGCGCTCCTTGACATCAGACGACACGGCCGTCTATTTTTGTACTAGGGGAAAATATTGTACTGCGCGCGACTATTATAATTGGGACTTCGAACACTGGGGCCGGGGTGCCCCGGTCACCGTCTCATCAGCGTCGACCAAGGGCCCATCGGT,CTRGKYCTARDYYNWDFEHW,67.577
nan,,,,,,,Zhang2013(24100711) ,IMGT/V-QUEST,1-2*02,1-26,2*01,18.0,,,,3D-15,2,5.0,,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Zhou2013a(23911655) ,IgBlast IMGT/V-QUEST,1-02*02,,,16.0,GKYCTARDYYNWDFEH,,,3-20*01,2*01,5.0,QQYEF,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Scheid2011(21764753) ,,1-2,,,,,,,3-11,,,,,,,,,,,,,,,,,,,,,,
NIH45-46G54F,gp120 CD4bs,,NIH45 ,VRC01,Diskin2011(22033520) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,45-46F, ,0.13264,26.3472,164.0,168.0,3165.0,,,,,,
NIH45-46G54W,gp120 CD4bs,,NIH45 ,VRC01,Diskin2011(22033520) ,NIH45-46G54W mutations causing resistance;NIH45-46(G54W) signature predictions;Signature Analysis Summary,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,"45-46W, NIH45-46 G54W, NIH45-46W", ,0.080624,45.0024,646.0,2.0,2821.0,,,,,,
NIH45-46G54Y,gp120 CD4bs,,NIH45 ,VRC01,Diskin2011(22033520) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,45-46Y, ,0.1378,23.9373,164.0,169.0,3166.0,,,,,,
NIH45-46WPY,gp120 CD4bs,,NIH45 ,VRC01,,Signature Analysis Summary,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,NIH45-46-WPY, ,0.026926,16.037,118.0,439.0,4011.0,,,,,,
NIH45-46WY,gp120 CD4bs,,NIH45 ,VRC01,,Signature Analysis Summary,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,NIH45-46-WY, ,0.028743,15.8862,118.0,440.0,4012.0,,,,,,
PCDN-33A,gp120 V3 // V3 glycan (V3g),,PC76 ,,MacLeod2016(27192579) ,Sites affecting neutralization of PCDN lineage mAbs,,,,,,,,,,,,,,,,,,Natural monoclonal,human,33A, ,6.08665,25.6639,133.0,240.0,3388.0,QVQLQQWGAGLVKPSEPLSLTCAVYGGSFTDYQWSWIRQSPGKGLEWIGEIDYLENVNYNPSLRGRFTISVDTSKNQFSLKFFSATAADTAVYYCARGGRKICYDYWCGYVNNCFDTWGQGTLVTVSS,EIVLTQSPGTLALSPGESASLSCRANQTVTDNCLAWYQRKGGQAPRLLLYGVSNRATGIPDRFSGSGSGTEFTLNISRLGPEDVGVYYCQQCGSSPTFGQGTKVEIKX,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGGCTTTGTCTCCAGGGGAAAGCGCCTCCCTCTCCTGCAGGGCCAATCAAACCGTCACCGACAACTGTTTAGCCTGGTACCAGCGAAAAGGTGGCCAGGCTCCCAGACTCCTCCTATATGGGGTATCCAACAGGGCCACTGGCATTCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCAACATCAGCAGACTGGGGCCTGAAGACGTTGGAGTGTATTACTGTCAGCAGTGTGGTAGCTCACCGACGTTCGGCCAGGGGACCAAGGTGGAGATCAAAC,CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGGTGAAGCCCTCGGAGCCCCTGTCCCTCACCTGCGCTGTCTATGGTGGGTCCTTCACTGACTACCAGTGGAGTTGGATCCGCCAGTCCCCCGGGAAGGGGCTGGAGTGGATTGGCGAAATCGATTATCTTGAAAACGTCAACTACAACCCGTCACTCAGGGGACGATTCACCATATCTGTGGACACGTCCAAGAACCAATTCTCCTTGAAATTTTTCTCCGCGACCGCCGCGGACACGGCTGTCTATTACTGTGCGAGAGGAGGCCGGAAAATTTGTTACGATTATTGGTGTGGCTATGTTAACAACTGCTTCGACACCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CARGGRKICYDYWCGYVNNCFDTW,87.372
PCDN-38A,gp120 V3 // V3 glycan (V3g),,PC76 ,,MacLeod2016(27192579) ,Sites affecting neutralization of PCDN lineage mAbs,Longo2016(27654288) ,IMGT/V-QUEST JoinSolver,4-34*01,,5*01,22.0,ARGGRKICYDYWCGYVNNCFDT,16.0,,3-20*01,1*01,8.0,QQCGSSPT,11.0,,K,,Natural monoclonal,human,"38A, PCDN38A", ,13.1102,20.1397,133.0,241.0,3389.0,QVQLQQWGTGLLKPSESLFLTCAVYNEDLSAFSWSWIRQSPGKGLEWIGEIDHLQNVNYNPSLKGRFTISIDTSKNQFSLRFFSVTAADAAMYYCARGGRKVYHPYWTGYVNNCFDPWGQGTLVTVSS,EIVLTQSPGALSLSPGERASLSCRASQSVSDKNLAWYQQRPGLPPRLLIYGVSLKNTGVPDRFSGSGSGTNFTLTISSLESEDSAVYFCQQYGSSPTFGQGTKVEIKX,GAAATTGTGTTGACGCAGTCTCCAGGCGCCCTGTCTTTGTCTCCGGGGGAGAGAGCCAGCCTCTCCTGCAGGGCCAGCCAGAGTGTCAGCGACAAGAACTTAGCCTGGTACCAGCAGAGACCTGGCCTGCCTCCCAGACTCCTCATATATGGTGTCTCCTTAAAAAACACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAAACTTCACTCTCACCATCAGCAGCCTGGAGTCTGAAGATTCCGCAGTGTATTTCTGTCAGCAGTATGGTAGCTCACCGACCTTCGGCCAAGGGACCAAGGTGGAGATCAAAC,CAGGTGCAGCTACAGCAGTGGGGCACAGGGCTGTTGAAGCCTTCGGAGTCCCTGTTCCTCACCTGCGCTGTCTATAATGAGGACTTGAGTGCTTTCTCCTGGAGTTGGATCCGCCAGTCCCCCGGTAAGGGGCTGGAGTGGATTGGCGAAATCGATCATCTTCAAAACGTCAATTACAATCCGTCCCTCAAGGGTCGGTTCACCATATCAATTGACACGTCCAAGAATCAGTTCTCCCTGAGGTTCTTCTCTGTGACCGCCGCGGACGCGGCTATGTATTACTGTGCGAGGGGAGGCCGCAAAGTTTATCACCCTTATTGGACTGGCTATGTGAACAATTGCTTTGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CARGGRKVYHPYWTGYVNNCFDPW,85.666
PCDN-38B,gp120 V3 // V3 glycan (V3g),,PC76 ,,MacLeod2016(27192579) ,Sites affecting neutralization of PCDN lineage mAbs,,,,,,,,,,,,,,,,,,Natural monoclonal,human,38B, ,7.50007,22.2127,133.0,242.0,3390.0,QVQLQQWGTGLLKPSESLFLTCAVYNESMSAFSWSWIRQSADKGLEWIGEIDHLQHVNYNPSLTGRFTISIDTSKNQFSLRFFSVIAADAAMYYCARGGRKVYHAYWTGYVNNCFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGETASLSCRASQSVSDKNLAWYQQRPGLPPRLLIYGVSLKNTGVPDRFSGSGSGTNFTLTITSLESEDSAVYFCQQYGSSPTFGQGTKVEIKX,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTATCTCCAGGGGAGACAGCCAGCCTCTCCTGCAGGGCCAGCCAGAGTGTCAGCGACAAGAACTTAGCCTGGTACCAGCAGAGACCTGGCCTGCCTCCCAGACTCCTCATATATGGTGTCTCCTTAAAAAACACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAAACTTCACTCTCACCATCACCAGCCTGGAGTCTGAAGATTCCGCAGTGTATTTCTGTCAGCAGTATGGGAGCTCACCGACGTTCGGCCAAGGGACCAAGGTGGAGATCAAAC,CAGGTGCAGCTACAGCAGTGGGGCACAGGGCTGTTGAAGCCTTCGGAGTCCCTGTTCCTCACCTGCGCTGTCTATAATGAGTCCATGAGCGCTTTCTCTTGGAGTTGGATCCGCCAATCTGCCGATAAGGGGCTGGAATGGATTGGCGAAATCGATCATCTTCAACACGTCAACTACAATCCGTCCCTCACGGGTCGATTCACCATATCAATTGACACGTCCAAGAATCAGTTCTCCCTGAGGTTCTTCTCTGTGATTGCCGCGGACGCGGCTATGTATTACTGTGCGAGGGGAGGCCGCAAAGTCTATCACGCTTATTGGACTGGCTATGTGAATAATTGTTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CARGGRKVYHAYWTGYVNNCFDPW,82.935
PCIN66B,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRRDTNWWLDP,9.59,18.42,1-5*03,1*01,5.0,QVLET,12.71,17.71,K,,Natural monoclonal,human,, ,4.65387,12.9274,145.0,831.0,4111.0,QVQLVQSGAEVKKPGASMRVSCKASGYTFTACYIHWFRQAPGQGLEWMGWINPINGARNNPRKFQGRVTMTRDTSIDTAYLELRNLASDDTAMYYCTRDSSRRDTNWWLDPWGQGTLVTVSS,AIRMTQSPATLSASVGERVTITCRASQGIGSDLGWYQQKPGKSPKLLIFKASNLKDGVPPRFSGGGFHTEFTLTISSLQPDDFATYYCQVLETFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGAAAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTGGAAGTGATTTAGGTTGGTATCAGCAGAAACCAGGGAAATCCCCTAAACTTCTTATCTTTAAGGCGTCTAATTTAAAAGATGGCGTCCCGCCGAGGTTCAGCGGCGGTGGATTTCACACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGTTTTGGAAACATTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAATGAGGGTCTCCTGCAAGGCCTCTGGATACACCTTCACCGCCTGCTATATACACTGGTTTCGACAGGCCCCTGGACAAGGCCTTGAGTGGATGGGATGGATCAACCCTATCAATGGTGCCAGAAATAATCCACGCAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATTGATACAGCGTACTTGGAACTGCGCAACCTGGCATCTGACGACACGGCCATGTATTACTGTACGAGAGATTCATCGAGGCGTGATACGAATTGGTGGTTGGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CTRDSSRRDTNWWLDPW,89.189
PCIN71B,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TTHSSSRDFQWSLDP,9.88,16.67,1-5*03,1*01,5.0,QVLET,11.04,16.67,K,,Natural monoclonal,human,, ,81.8744,3.43076,40.0,832.0,4123.0,QVQLVQSGAEVKKPGASVRVSCKASGYTFTAYFIHWVRQAPGQGLEWVGWINPLHGAVNYAHKFQGRVSMTRDTSISTAYMELRSLKSDDTAIYYCTTHSSSRDFQWSLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTITCRASQGIGNKLGWFQQKPGKAPKPLIFKASTLKDGVPSRFSGSGFGTDFTLTISSLQPDDFATYYCQVYESFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCTAGTCAGGGCATTGGAAATAAATTAGGGTGGTTTCAGCAGAAACCAGGGAAAGCCCCTAAGCCCCTGATCTTTAAGGCGTCTACTTTGAAAGATGGGGTCCCATCAAGGTTCAGCGGCAGTGGATTTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGATGACTTTGCAACTTACTATTGTCAAGTCTATGAAAGCTTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGCCTATTTTATACACTGGGTGCGACAGGCCCCTGGACAGGGGCTTGAGTGGGTGGGTTGGATCAACCCTCTCCATGGCGCCGTAAACTATGCACACAAATTTCAAGGCAGGGTCTCCATGACCAGGGACACCTCCATCAGCACAGCCTACATGGAACTTCGCAGCCTGAAATCTGACGACACGGCCATTTATTACTGTACCACACATTCATCGAGCCGTGATTTTCAGTGGTCGTTGGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CTTHSSSRDFQWSLDPW,90.278
PCIN71C,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRRDTNWWLDP,10.76,20.18,1-5*03,1*01,5.0,QVLET,12.37,18.75,K,,Natural monoclonal,human,, ,0.85957,11.6015,40.0,833.0,4124.0,QVQLVQSGAEVKKPGASMRVSCKASGYTFTSCYIHWFRQAPGQGLEWMGWLNPINGARNNPHKFQGRITLTRDTSTDTAYLELRNLRSDDTAVYYCTRDSSRRDTNWWLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTITCRAGQGIGSDLAWYQQKSGQAPKLLIFKASNLKNGVPPRFSGSGFHTDFTLTISGLQPDDFATYYCQVLETFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAGGTCAGGGCATTGGAAGTGATTTAGCCTGGTATCAGCAGAAATCAGGGCAAGCCCCTAAACTTCTTATCTTTAAGGCGTCTAATTTAAAAAATGGAGTCCCGCCAAGATTCAGCGGCAGTGGATTTCACACAGACTTCACTCTCACCATCAGCGGCCTGCAGCCTGATGATTTTGCGACTTATTACTGCCAAGTTTTGGAAACATTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAATGAGGGTCTCCTGCAAGGCCTCTGGATACACCTTCACCTCTTGTTATATACACTGGTTTCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGCTCAACCCTATCAATGGTGCCAGAAATAATCCACACAAGTTTCAGGGCAGGATCACCCTGACCAGGGACACGTCCACTGATACAGCCTACTTGGAACTGCGCAACCTGAGATCTGACGACACGGCCGTATATTATTGTACGAGAGATTCATCGAGGCGTGATACGAATTGGTGGTTGGACCCTTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CTRDSSRRDTNWWLDPW,88.176
PCIN71D2b,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRRDTNWWLDP,10.47,21.05,1-5*03,1*01,5.0,QVLET,12.71,19.79,K,,Natural monoclonal,human,, ,1.56612,12.0412,40.0,834.0,4125.0,QVQLVQSGAEVKKPGASMRVSCKASGYTFTACYIHWFRQAPGQGLEWMGWLNPINGARNNPHKFQGRITLTRDTSTDTAYLELRNLRSDDTAVYYCTRDSSRRDTNWWLDPWGQGALVTVSS,AIRMTQSPATLSASVGDRVTITCRAGQGIGSDLAWYQQKSGQAPKLLIFKASNLKNGVPPRFSGSGFHTDFTLTISGLQSDDFATYYCQVLETFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAGGTCAGGGCATTGGAAGTGATTTAGCCTGGTATCAGCAGAAATCAGGGCAAGCCCCTAAACTTCTTATCTTTAAGGCGTCTAATTTAAAAAATGGAGTCCCGCCAAGATTCAGCGGCAGTGGATTTCACACAGACTTCACTCTCACCATCAGCGGCCTGCAGTCTGATGATTTTGCGACTTATTACTGCCAAGTTTTGGAAACATTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAATGAGGGTCTCCTGCAAGGCCTCTGGATACACTTTCACCGCTTGTTATATACACTGGTTTCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGCTCAACCCTATCAATGGTGCCAGAAATAATCCACACAAGTTTCAGGGCAGGATCACCCTGACCAGGGACACGTCCACTGATACAGCCTACTTGGAACTGCGCAACCTGAGATCTGACGACACGGCCGTGTATTATTGTACGAGAGATTCATCGAGGCGTGATACGAATTGGTGGTTGGACCCTTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCA,CTRDSSRRDTNWWLDPW,88.514
PCIN71F,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRQQRDWWLDP,12.5,21.05,1-5*03,1*01,5.0,QVYES,11.04,18.75,K,,Natural monoclonal,human,, ,68.4587,3.95584,40.0,835.0,4126.0,QVQLVQSGAEVKKPGASVRVSCKASGYSFTDYFVHWVRQAPGQGLEWVGWINPINGAPNYAPNFRGRITLTRDTSIDTLYMDLRSLRVDDTAVYFCTRDSSRQQRDWWLDPWGQGTLVTVSS,AIRMTQSPPTVSASAGDRVTITCRAGQHIGNDLAWYQTKVGMAPKLLIYQASNLKSGVPSRFSGSGSGTEFTLSITSLQPDDFATYYCQVYESFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTCCCACCGTGTCTGCATCTGCGGGAGACAGAGTCACCATCACTTGCCGGGCCGGTCAGCACATTGGTAACGACTTGGCCTGGTATCAGACGAAAGTGGGGATGGCCCCTAAACTCCTCATCTATCAGGCGTCTAATTTAAAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGGTCTGGGACAGAGTTCACTCTTTCCATCACCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGTTTATGAGTCGTTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCCTCTGGATACAGCTTCACCGACTACTTTGTGCACTGGGTGCGACAGGCCCCTGGACAGGGCCTTGAGTGGGTGGGGTGGATAAACCCTATTAATGGAGCCCCTAATTATGCACCGAACTTTCGGGGCAGGATCACCTTGACTAGGGACACATCCATCGACACACTCTATATGGACTTGAGAAGCCTGAGAGTTGACGACACGGCCGTTTACTTCTGTACGAGAGATTCATCGAGGCAACAACGGGACTGGTGGTTAGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CTRDSSRQQRDWWLDPW,85.811
PCIN71G,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDASRDDRAWRLDP,13.08,21.05,1-5*03,1*01,5.0,QVVEW,12.37,15.63,K,,Natural monoclonal,human,, ,1.20328,8.88337,145.0,836.0,4127.0,QVQLVQSGAEVKKPGASVRVSCKASGYTFNSCLIHWWRQAPGQGLQWMAWINPLHGAVNYAHQFQGRITVTRDTSIDTAYMELRGLRSDDTATYYCTRDASRDDRAWRLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTLTCRAGQGIGSDLGWYQQKPGKAPKLLIHKASNLINGVPSRFSGSGFHTEFTLTISSLQPDDFATYYCQVVEWFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCTTGACTTGCCGGGCAGGACAGGGCATTGGAAGTGATTTAGGCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTCATACATAAGGCGTCCAATTTAATAAATGGAGTGCCATCAAGGTTCAGCGGCAGTGGATTTCACACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGTCAAGTTGTTGAATGGTTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCCTCCGGATACACCTTCAACTCCTGCTTAATTCATTGGTGGCGACAGGCCCCTGGACAAGGCCTTCAGTGGATGGCTTGGATCAACCCTCTCCATGGTGCCGTAAATTATGCACACCAGTTTCAGGGGAGGATCACCGTGACCAGGGACACGTCCATCGACACTGCCTACATGGAACTGCGCGGCCTGAGATCTGACGACACGGCCACATATTACTGTACGAGAGATGCATCCAGAGATGATCGCGCGTGGCGCTTGGACCCCTGGGGCCAGGGAACACTGGTCACCGTCTCCTCA,CTRDASRDDRAWRLDPW,86.149
PCIN71H,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,ARDSSREETNWWLDP,13.08,21.93,1-5*03,1*01,5.0,QVLET,13.04,20.83,K,,Natural monoclonal,human,, ,1.25022,14.1086,40.0,837.0,4128.0,QVQLVQSGVAVKKPGASVWVSCKASGYTFTSCYIHWFRQAPGQGLEWMGWLNPINGARNNPYQFQGRISLTRDTSSETAYLELRNLRSDDTAVYYCARDSSREETNWWLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTITCRAGQGIGSDLAWYQQKPGQAPKLLIFKASNLKNGVPTRFTGSGFHTDFTLTINGLQSDDFATYYCQVLETFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAGGTCAGGGCATTGGAAGTGATTTAGCCTGGTATCAGCAGAAACCAGGGCAAGCCCCTAAACTTCTAATCTTTAAGGCGTCTAATTTAAAAAATGGAGTCCCGACAAGATTCACCGGCAGTGGATTTCACACAGACTTCACTCTCACCATCAACGGCCTGCAGTCTGATGATTTTGCGACTTATTACTGCCAAGTTTTGGAGACATTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGTAGCGGTGAAGAAGCCTGGGGCCTCAGTGTGGGTCTCCTGCAAGGCCTCTGGATACACCTTCACCAGTTGCTATATACATTGGTTTCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGCTCAACCCTATCAATGGTGCCAGAAATAATCCATACCAGTTTCAGGGCAGGATCAGCCTGACCAGGGACACGTCCAGTGAAACAGCCTACTTGGAACTGCGTAACCTCAGATCTGACGACACGGCCGTCTATTATTGCGCGAGAGATTCTTCGAGGGAAGAGACGAATTGGTGGCTGGACCCTTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CARDSSREETNWWLDPW,85.811
PCIN71I1a,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDASRDDRAWRLDP,13.66,21.05,1-5*03,1*01,5.0,QVFEW,13.04,17.71,K,,Natural monoclonal,human,PCIN71I, ,0.79599,10.0571,145.0,838.0,4129.0,QVQLVQSGAEVKKPGASVRVSCKASGYTFNSCLIHWWRQAPGQGLQWMAWINPLHGAVNYAHQFQGRITVTRDTSIDTAYMELRGLRSDDTATYYCTRDASRDDRAWRLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTLTCRAGQGIGSDLGWYQQKPGKAPKLLIHKASNLINGVPSRFSGSGFHTEFTLTINSLQPDDFATYYCQVFEWFGPGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCTTGACTTGCCGGGCAGGGCAGGGCATTGGAAGTGATTTAGGCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTCATACACAAGGCGTCTAATTTAATAAATGGGGTGCCATCAAGGTTCAGCGGCAGTGGATTTCACACAGAATTCACACTCACCATCAACAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGTCAAGTTTTTGAGTGGTTCGGCCCAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCCTCCGGATACACCTTCAATTCCTGCTTAATTCATTGGTGGCGACAGGCCCCTGGACAAGGCCTTCAGTGGATGGCTTGGATCAACCCTCTCCATGGTGCCGTAAATTATGCACACCAGTTCCAGGGGAGGATCACCGTGACCAGGGACACGTCCATCGACACTGCCTACATGGAACTGCGCGGCCTGAGATCTGACGACACGGCCACATATTACTGTACGAGAGATGCATCCAGAGATGATCGCGCGTGGCGCTTGGACCCCTGGGGCCAGGGAACACTGGTCACCGTCTCCTCA,CTRDASRDDRAWRLDPW,85.473
PCIN71J2a,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDASRDDRAWRLDP,10.76,20.18,1-5*03,1*01,5.0,QVLET,12.71,18.75,K,,Natural monoclonal,human,, ,0.97592,9.89338,40.0,839.0,4130.0,QVQLVQSGAEVKKPGASMRVSCKASGYTFTACYIHWFRQAPGQGLEWMGWLNPINGARNNPHKFQGRITLTRDTSTDTAYLELRNLRSDDTAVYYCTRDSSRRDTNWWLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTITCRAGQGIGSDLAWYQQKSGQAPKLLIFKASNLKNGVPPRFSGSGFHTDFTLTISGLQPDDFATYYCQVLETFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAGGTCAGGGCATTGGAAGTGATTTAGCCTGGTATCAGCAGAAATCAGGGCAAGCCCCTAAACTTCTAATCTTTAAGGCGTCTAATTTAAAAAATGGAGTCCCGCCAAGATTTAGCGGCAGTGGATTTCACACAGACTTCACTCTCACCATCAGCGGCCTGCAGCCTGATGATTTTGCGACTTATTACTGCCAAGTTTTGGAAACATTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAATGAGGGTCTCTTGCAAGGCCTCTGGATACACTTTCACCGCTTGTTATATACACTGGTTTCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGCTCAACCCTATCAATGGTGCCAGAAATAATCCACACAAGTTTCAGGGCAGGATCACCCTGACCAGGGACACGTCCACTGATACAGCCTACTTGGAACTGCGCAACCTGAGATCTGACGACACGGCCGTGTATTATTGTACGAGAGATTCATCGAGGCGTGATACGAATTGGTGGTTGGACCCTTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CTRDSSRRDTNWWLDPW,88.176
PCIN71K,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRDETNWWLDP,14.24,23.68,1-5*03,1*01,5.0,QVLET,13.04,18.75,K,,Natural monoclonal,human,, ,0.74257,11.9003,40.0,840.0,4131.0,QVQLVQSGAAVKKPGASVWVSCKASGYTFTSCYIHWFRQAPGQGLEWMGWLNPINGARNNPYQFQGRISLTRDTSSETAYLELRNLTPDDTAVYYCTRDSSRDETNWWLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTITCRAGQGIGSDLAWYQQKPGQAPKLLIFKASRLKNGVPTRFTGSGFHTEFTLTISGLQSDDFATYYCQVLETFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAGGTCAGGGCATTGGAAGTGATTTAGCCTGGTATCAGCAGAAACCTGGGCAAGCCCCTAAACTTCTAATCTTTAAGGCGTCTCGTTTAAAAAATGGAGTCCCGACAAGATTCACCGGCAGTGGATTTCACACAGAGTTCACTCTCACCATCAGCGGCCTGCAGTCTGATGATTTTGCGACTTATTACTGCCAAGTTTTGGAAACATTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGCGGTGAAGAAGCCTGGGGCCTCAGTGTGGGTCTCCTGCAAGGCCTCTGGATACACCTTCACCAGTTGTTATATACATTGGTTTCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGCTCAACCCTATCAATGGTGCCAGAAATAATCCATACCAGTTTCAGGGGAGGATCAGCCTGACCAGGGACACGTCCAGTGAAACAGCCTACTTGGAACTGCGTAACCTCACACCAGACGACACGGCCGTCTATTATTGCACGAGAGATTCATCGAGGGATGAGACGAATTGGTGGCTGGACCCTTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CTRDSSRDETNWWLDPW,84.459
PCIN71L,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRDETNWWLDP,14.24,24.56,1-5*03,1*01,5.0,QVLET,13.04,18.75,K,,Natural monoclonal,human,, ,1.04471,15.5751,145.0,841.0,4132.0,QVQLVQSGAAVKKPGASVWVSCKASGYTFTSCYIHWFRQAPGQGLEWMGWLNPINGARNNPYQFQGRISLTRDTSSETAYLELRNLTPDDTAVYYCTRDSSRDETNWWLDPWGQGTLVIVSS,AIRMTQSPATLSASVGDRVTITCRAGQGIGSDLAWYQQKPGQAPKLLIFKASRLKNGVPTRFTGSGFHTEFTLTISGLQSDDFATYYCQVLETFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAGGTCAGGGCATTGGAAGTGATTTAGCCTGGTATCAGCAGAAACCTGGGCAAGCCCCTAAACTTCTAATCTTTAAGGCGTCTCGTTTAAAAAATGGAGTCCCGACAAGATTCACCGGCAGTGGATTTCACACAGAGTTCACTCTCACCATCAGCGGCCTGCAGTCTGATGATTTTGCGACTTATTACTGCCAAGTTTTGGAAACATTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGCGGTGAAGAAGCCTGGGGCCTCAGTGTGGGTCTCCTGCAAGGCCTCTGGATACACCTTCACCAGTTGTTATATACATTGGTTTCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGCTCAACCCTATCAATGGTGCCAGAAATAATCCATACCAGTTTCAGGGGAGGATCAGCCTGACCAGGGACACGTCCAGTGAAACAGCCTACTTGGAACTGCGTAACCTCACACCAGACGACACGGCCGTCTATTATTGCACGAGAGATTCATCGAGGGATGAGACGAATTGGTGGCTGGACCCTTGGGGCCAGGGAACCCTGGTCATCGTCTCTTCA,CTRDSSRDETNWWLDPW,84.459
PCIN71M1a,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,ARDSSRDETNWWLDP,14.53,21.05,1-5*03,1*01,5.0,QVLET,12.37,18.75,K,,Natural monoclonal,human,, ,1.05043,12.8066,40.0,842.0,4133.0,QVQLVQSGAAVKKPGASVWVSCKASGYTFTSCYIHWFRQAPGQGLEWMGWLNPINGARNQAYQFQGRISLTRDTPSETAYLELRDLRSDDTAVYYCARDSSRDETNWWLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTITCRAGQGIGSDLAWYQQKSGQAPKLLIFKASNLKNGVPPRFSGSGFHTDFTLTISGLQPDDFATYYCQVLETFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAGGTCAGGGCATTGGAAGTGATTTAGCCTGGTATCAGCAGAAATCAGGGCAAGCCCCTAAACTTCTTATCTTTAAGGCGTCTAATTTAAAAAATGGAGTCCCGCCAAGATTCAGCGGCAGTGGATTTCACACAGACTTCACTCTCACCATCAGCGGCCTGCAGCCTGATGATTTTGCGACTTATTACTGCCAAGTTTTGGAAACATTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGCGGTGAAGAAGCCTGGGGCCTCAGTGTGGGTCTCCTGCAAGGCCTCTGGATACACCTTTACCAGTTGTTATATACATTGGTTTCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGCTCAACCCTATCAATGGCGCCAGAAATCAGGCGTACCAGTTTCAGGGCAGGATTAGCCTGACCAGGGACACGCCCAGTGAAACAGCCTACTTGGAACTGCGTGACCTCAGATCTGACGACACGGCCGTCTATTATTGCGCGAGAGATTCATCGAGGGATGAGACGAATTGGTGGCTGGACCCTTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CARDSSRDETNWWLDPW,84.122
PCIN71N1a,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRGNTEWRLDP,14.53,21.05,1-5*03,1*01,5.0,QVYQT,12.71,18.75,K,,Natural monoclonal,human,, ,100.0,1.0,40.0,843.0,4134.0,QVQLVQSGAEVKKPGASVRVSCKASGYTFNTCLIHWWRQAPGQGLQWLAWINPLHGAVNYAHNFQGRITVTRDTSIDTAYMELRGLRSDDTATYYCTRDSSRGNTEWRLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDKVTITCRASQGIGNNLGWYQQKPGQAPKLLIFKASNSKDGVPPRFSGSGSHTEFTLTINSLQPDDFATYYCQVYQTFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTAGGAGACAAAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTGGAAATAATTTAGGCTGGTATCAGCAGAAACCAGGGCAGGCCCCTAAACTCCTCATCTTTAAGGCGTCTAATTCAAAAGATGGAGTCCCACCAAGATTCAGCGGTAGTGGATCTCATACAGAGTTCACTCTCACCATCAACAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAGGTTTATCAAACCTTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCTTCCGGATACACTTTCAACACCTGCTTAATTCATTGGTGGCGACAGGCCCCTGGACAAGGCCTTCAGTGGCTGGCTTGGATCAACCCTCTCCATGGTGCCGTTAACTATGCACACAACTTTCAGGGGAGGATCACCGTGACCAGGGACACGTCCATCGACACTGCCTACATGGAACTTCGCGGCCTGAGATCTGACGACACGGCCACATACTACTGCACCAGAGATTCATCGAGAGGTAATACGGAGTGGCGCTTGGACCCCTGGGGCCAGGGAACACTGGTCACCGTCTCCTCA,CTRDSSRGNTEWRLDPW,84.459
PCIN71O,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRDNLEWRLDP,15.99,23.68,1-5*03,1*01,5.0,QVFEW,12.71,15.63,K,,Natural monoclonal,human,, ,0.82024,6.53472,40.0,844.0,4135.0,QVQLVQSGAEVKKPGASVRVSCKASGYTFNTCLIHWWRQAPGQGLQWVAWINPLHGAVNYAHQLQGRITVTRDTSIDTAYMELRGLRADDTATYYCTRDSSRDNLEWRLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTLTCRAGQGIGSDLGWYQQKPGKAPKLLIHKASNLLNGVPSRFSGSGFHTEFTLTISSLQPDDFATYYCQVFEWFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCTTGACTTGCCGGGCAGGGCAGGGCATTGGAAGTGATTTAGGGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTCATACATAAGGCGTCTAATTTACTAAATGGGGTGCCATCAAGGTTCAGCGGCAGTGGATTTCACACGGAATTCACTCTCACCATCAGCAGCCTGCAACCTGATGATTTTGCAACTTATTACTGTCAAGTTTTTGAATGGTTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAAAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCTTCCGGATACACGTTCAACACCTGCTTGATTCATTGGTGGCGACAGGCCCCTGGACAGGGCCTTCAGTGGGTGGCTTGGATCAACCCTCTCCATGGTGCCGTTAATTATGCACACCAATTACAGGGGAGGATCACCGTGACCAGGGACACGTCTATCGACACTGCCTACATGGAACTGCGCGGCCTCAGAGCTGACGACACGGCCACCTACTACTGTACGAGAGATTCATCGAGAGATAATCTGGAGTGGCGCTTGGACCCCTGGGGCCAGGGAACACTGGTCACCGTCTCCTCA,CTRDSSRDNLEWRLDPW,82.770
PCIN71P,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRGDTEWRLDP,15.99,23.68,1-5*03,1*01,5.0,QVFEW,13.04,16.67,K,,Natural monoclonal,human,, ,1.36988,7.71059,40.0,845.0,4136.0,QVQLVQSGAEVKKPGASVRVSCKASGYTFNTCLIHWWRQAPGQGLQWVAWINPLHGAVNYAHQLQGRITVTRDTSIDTAHMELRGLRSDDTATYYCTRDSSRGDTEWRLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTLTCRAGQGIGSDLGWYQQKPGKAPKLLIHKASNLANGVPSRFSGRGFHTEFTLTISSLQPDDFATYYCQVFEWFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCTTGACTTGCCGGGCAGGGCAGGGCATTGGAAGTGATTTAGGGTGGTATCAGCAGAAGCCAGGAAAAGCCCCTAAACTCCTCATACATAAGGCGTCTAATTTAGCAAATGGGGTGCCATCAAGGTTCAGCGGCCGTGGATTTCACACAGAGTTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGTCAAGTTTTTGAATGGTTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAAAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCTTCCGGATACACCTTCAACACCTGCTTAATTCATTGGTGGCGACAGGCCCCTGGACAGGGCCTTCAGTGGGTGGCTTGGATCAACCCTCTCCATGGTGCCGTTAACTATGCACACCAGTTACAGGGGAGGATCACGGTGACCAGGGACACGTCTATCGACACTGCCCACATGGAACTGCGCGGCCTCAGATCTGACGACACGGCCACATACTATTGTACCAGAGATTCATCGAGAGGTGATACGGAGTGGCGCTTGGACCCCTGGGGCCAGGGAACACTGGTCACCGTCTCCTCA,CTRDSSRGDTEWRLDPW,82.770
PCIN77B1b,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRDETNWWLDP,11.34,23.68,1-5*03,1*01,5.0,QVLET,12.71,19.79,K,,Natural monoclonal,human,, ,12.2046,10.3554,40.0,846.0,4137.0,QVQLVQSGAEVKKPGASARVSCKASGYTFTAYFIHWVRQAPGQGLEWVGWINPLHGAVNYAHKFQGRVSMTRDTSISTAYMELRSLKSDDTAIYYCTTHLSSRDFSWSWDPWGQGTLVTVSP,AIRMTQSPATLSASVGDRVTITCRAGQGIGSDLAWYQQKPGQAPKLLIFKASNLKNGVPTRFTGSGFHTDFTLTISGLQSDDFATYYCQVLETFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAGGTCAGGGCATTGGAAGTGATTTAGCCTGGTATCAGCAGAAACCAGGGCAAGCCCCTAAACTTCTAATCTTTAAGGCGTCTAATTTAAAAAATGGAGTCCCGACAAGATTCACCGGCAGTGGATTTCACACAGACTTCACTCTCACCATCAGCGGCCTGCAGTCTGATGATTTTGCGACTTATTACTGCCAAGTTTTGGAAACATTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGCGAGGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGCCTATTTTATACACTGGGTGCGACAAGCCCCTGGACAGGGACTTGAGTGGGTGGGTTGGATCAACCCTCTCCATGGCGCCGTAAATTATGCACACAAATTTCAGGGCAGGGTCTCCATGACCAGAGACACCTCCATCAGCACAGCCTACATGGAACTTCGCAGCCTGAAATCTGACGACACGGCCATTTATTACTGTACCACACATTTGTCGAGTCGTGATTTTTCGTGGTCGTGGGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCCCA,CTTHLSSRDFSWSWDPW,88.889
PCIN77C,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,TRDSSRRDLEWRLDP,11.92,21.05,1-5*03,1*01,5.0,QVLET,13.71,19.79,K,,Natural monoclonal,human,, ,6.24267,16.5622,40.0,847.0,4138.0,QVQLVQSGAEVKKPGASVRVSCKASGYTFTACYIQWFRQAPGQGLEWMGWINPINGARNNNPQTFQGRVTLTRDTSIDTAYLELRNLRDDDTAIYYCTRDSSRRDLEWRLDPWGQGTLVTVSS,AIRMTQSPATLSASVGDRVTITCRAGQGIGSDLAWYQQKPGQAPKLLIFKASNLKKGVPTRFTGSGFHTDFTLTISGLQSDDFATYYCQVLETFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATCTGTGGGAGATAGAGTCACCATCACTTGCCGGGCAGGTCAGGGCATTGGAAGTGATTTAGCCTGGTATCAGCAGAAACCAGGGCAAGCCCCTAAACTTCTAATCTTTAAGGCGTCCAATTTAAAAAAAGGAGTCCCGACAAGATTCACCGGCAGTGGATTTCACACAGACTTCACTCTCACCATCAGCGGCCTGCAGTCTGATGATTTTGCGACTTATTACTGCCAAGTTCTGGAAACATTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAACCCGGGGCCTCAGTGAGGGTCTCCTGCAAGGCCTCTGGATACACCTTCACCGCCTGTTATATACAGTGGTTTCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTATCAATGGTGCCAGAAATAATAATCCACAGACGTTTCAGGGCAGGGTCACCCTGACCAGGGACACGTCCATTGATACCGCCTACTTGGAACTGCGCAACCTGAGAGATGACGACACGGCCATATATTATTGTACGAGAGATTCATCGAGGCGTGATCTGGAGTGGCGGTTGGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CTRDSSRRDLEWRLDPW,86.957
PCIN77D,gp120 CD4bs,,PC063 ,PCIN63,,,Umotoy2019(31315032) ,IMGT/V-QUEST,1-02*02,,5*02,15.0,ARDSSRDETNWWLDP,13.08,20.18,1-5*03,1*01,5.0,QAYES,12.37,19.79,K,,Natural monoclonal,human,, ,39.9006,7.23709,145.0,848.0,4139.0,QVQLVQSGAAVKKPGASVWVSCKASGYTFTSCYIHWFRQAPGQGLEWMGWLNPINGARNHAYQFQGRISLTRDTSSETAYLELRNLRSDDTAVYYCARDSSRDETNWWLDPWGQGTLVTVSS,AIRMTQSPATLSAFVGDRVTITCRASQGIGDDLGWYQQKPGKVPKPLIFKASNLKDGVPSRFSGSGFGTDFTLTINNLQPDDFATYYCQAYESFGQGTKVEIK,GCCATCCGGATGACCCAGTCTCCTGCCACCCTGTCTGCATTTGTAGGAGACAGAGTCACCATCACTTGCCGGGCTAGTCAGGGCATTGGAGATGATTTAGGCTGGTATCAGCAAAAACCAGGGAAAGTCCCTAAGCCCCTGATCTTTAAGGCGTCTAATTTAAAAGATGGGGTCCCATCGAGGTTCAGCGGCAGCGGATTTGGGACAGATTTCACTCTCACCATCAACAACCTGCAGCCTGATGACTTTGCAACTTACTATTGCCAAGCCTATGAAAGCTTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGCGGTGAAGAAGCCTGGGGCCTCAGTGTGGGTCTCCTGCAAGGCCTCTGGATACACCTTCACCAGTTGTTATATACATTGGTTTCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGCTCAACCCTATCAATGGCGCCAGAAATCATGCATACCAGTTTCAGGGCAGGATTAGCCTGACCAGGGACACGTCCAGTGAAACAGCCTACTTGGAACTGCGTAACCTCAGATCTGACGACACGGCCGTCTATTATTGCGCGAGAGATTCATCGAGGGATGAGACGAATTGGTGGCTGGACCCTTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CARDSSRDETNWWLDPW,85.811
PCT64-18B,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVETKDFWGDDYGDYYDHYFIDV,8.62,16.38,3-20*01,3*01,8.0,RQYDTSFT,5.3,11.21,K,,Natural monoclonal,human,PCT64 18B, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,44.1335,8.39332,37.0,339.0,3873.0,EVQLVESGGGLVKPGGSLRLSCVASGFTFSDAWMTWVRQAPGKGLEWVGHMRPIPEGGAIDYAAPVKGRFTISRDDSKKTLYLQMNSLKIEDTALYYCMTGVETKDFWGDDYGDYYDHYFIDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGDRATLSCRASQSVNSNSLAWYQQKPGQAPRLVMYGTSSRPTGIPDRFSGSGSGTDFTLTIGRLEPEDFAVYYCRQYDTSFTFGPGTKVDIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGATAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAACAGCAACTCTTTAGCCTGGTATCAACAGAAACCTGGCCAGGCTCCCAGGCTCGTCATGTATGGTACATCCAGCAGGCCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGGCAGGCTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCGGCAGTATGATACCTCATTCACCTTCGGCCCTGGGACCAAAGTGGATATCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTAAGACTCTCCTGTGTAGCCTCTGGATTCACTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCATCCCTGAAGGTGGGGCAATAGACTACGCTGCACCCGTTAAAGGCAGATTCACCATCTCAAGGGATGATTCAAAAAAGACGCTGTATCTGCAAATGAACAGCCTGAAAATCGAGGACACAGCCCTGTATTACTGTATGACAGGCGTGGAGACAAAGGATTTTTGGGGTGATGATTATGGCGATTACTACGACCACTACTTTATAGACGTCTGGGGCAAAGGGACAACGGTCACCGTCTCCTCA,CMTGVETKDFWGDDYGDYYDHYFIDVW,91.694
PCT64-18C,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVETGDFWSDDYANYYDPYLIDV,9.77,15.52,3-20*01,3*01,8.0,RQYGTSFT,3.12,6.54,K,,Natural monoclonal,human,PCT64 18C, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,77.3056,2.91181,37.0,340.0,3874.0,EVQLVESGGGLVKPGGSLRLSCVGSGFVFSDAWMTWVRQAPGKGLEWVGHMRPTPDGGAKDYAAPVKGRFTISRDDSKNTLYLQMNSLKIEDTAVYYCMTGVETGDFWSDDYANYYDPYLIDVWGKGTTVTVSS,EIVLTQSPGTLSVSPGERATLSCRASQSFSSSYLAWYQHKPGQAPRLLIYGASSRATGIPDRFSGSASGTDFTLTIGRLEPEDFAVYYCRQYGTSFTFGPGTKVDIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACGCTCTCCTGCAGGGCCAGTCAGAGTTTTAGCAGCAGCTACTTAGCCTGGTACCAGCACAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGCGTCTGGGACAGACTTCACTCTCACCATCGGCAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGGCAGTATGGTACGTCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCTTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGCTCTGGATTCGTTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCGGACGGTGGGGCAAAAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAAAAACACCCTATATCTGCAAATGAACAGCCTGAAAATCGAGGACACAGCCGTCTATTACTGTATGACAGGCGTGGAGACAGGGGATTTTTGGAGTGATGATTATGCCAATTACTACGACCCCTACCTCATAGACGTCTGGGGCAAAGGGACAACGGTCACCGTCTCCTCA,CMTGVETGDFWSDDYANYYDPYLIDVW,90.698
PCT64-18D,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVETGDFWSDYYAQYYDPYLIDV,9.77,17.24,3-20*01,3*01,8.0,RQYGTSFT,4.36,8.41,K,,Natural monoclonal,human,PCT64 18D, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,21.5607,17.099,146.0,341.0,3875.0,EVQLVESGGGLVKPGGSLRLSCVGSGFAFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKNTLYLQMNSLKIEDTAVYYCMTGVETGDFWSDYYAQYYDPYLIDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGDRATLSCRATQSVDSNYLAWYQQKPGQAPRLLIYGTSSRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYGTSFTFGPGTKVDIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGAGTGTTGACAGCAACTACTTAGCCTGGTACCAACAAAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCAGCAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGGCAGTATGGTACCTCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCTTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGCTCTGGATTCGCTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGCAAAAGACTACGCTGCACCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAACACCCTATATTTGCAAATGAACAGCCTGAAAATCGAGGACACAGCCGTCTATTACTGTATGACAGGCGTGGAGACAGGGGATTTTTGGAGTGATTATTATGCCCAATACTACGACCCCTACCTCATAGACGTCTGGGGCAAAGGGACAACGGTCACCGTCTCCTCA,CMTGVETGDFWSDYYAQYYDPYLIDVW,90.698
PCT64-18F,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVETGDFWSDYYAQYYDPYLIDV,10.63,17.24,3-20*01,3*01,8.0,RQYGTSFT,4.67,9.35,K,,Natural monoclonal,human,PCT64 18F, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,34.8927,10.6058,37.0,342.0,3876.0,EVQLVESGGGLVKPGGSLRLSCVGSGFAFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKNTLYLQMNSLKIEDTAVYYCMTGVETGDFWSDYYAQYYDPYLIDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGDRATLSCRATQSVDSNSLAWYQQKPGQAPRLLIYGTSSRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYGTSFTFGPGTKVDIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGAGTGTTGACAGCAACTCCTTAGCCTGGTACCAACAAAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCAGCAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGGCAGTATGGTACCTCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGCTCTGGATTCGCTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGCAAAAGACTACGCTGCACCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAGAACACCCTATACTTGCAAATGAACAGCCTGAAAATCGAGGACACAGCCGTCTATTACTGTATGACAGGCGTGGAGACAGGGGATTTTTGGAGTGATTATTATGCCCAATACTACGACCCCTACCTCATAGACGTCTGGGGCAAAGGGACAACGGTCACCGTCTCCTCA,CMTGVETGDFWSDYYAQYYDPYLIDVW,89.701
PCT64-24A,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,NTGVESYDFWSDDYSQYQYKYFWDV,9.48,17.24,3-20*01,3*01,8.0,QQYTSSCT,4.67,9.35,K,,Natural monoclonal,human,PCT64 24A, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,44.5511,7.00016,37.0,343.0,3877.0,EVQLVQSGGGLVEPGGSLRLSCAGSGFTFSDAWMHWVRQAPGKGLEWVGHIKTNADGGAAHYAAPVKGRFIISRDDSKNMLYLQMNGLKTEDTAMYYCNTGVESYDFWSDDYSQYQYKYFWDVWGKGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVNSNYLAWYQQKPGQAPRLLIYGTSNRATGIPDRFSGSGSGTDFTLTINRLEPEDFAMYYCQQYTSSCTFGPGTKVDVK,GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAACAGCAACTACTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCAACAGGGCCACTGGCATCCCAGACAGGTTCAGCGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAACAGACTGGAGCCTGAAGATTTTGCAATGTATTATTGTCAGCAGTATACTAGCTCATGCACTTTCGGCCCTGGGACCAAAGTGGATGTCAAA,GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTAGAGCCTGGGGGGTCCCTTAGACTCTCCTGTGCAGGCTCTGGATTCACTTTCAGTGACGCCTGGATGCACTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTTGGCCATATTAAGACCAATGCCGACGGTGGGGCAGCACACTACGCTGCACCCGTGAAAGGCAGATTCATCATTTCAAGAGATGATTCAAAAAACATGTTGTATCTTCAAATGAACGGCCTGAAAACCGAGGACACCGCCATGTATTACTGCAACACAGGGGTGGAGTCATACGATTTTTGGAGTGATGATTATTCCCAATACCAGTATAAGTATTTCTGGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CNTGVESYDFWSDDYSQYQYKYFWDVW,91.030
PCT64-24B,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,NTGVESYDFWSDDYSQYQYKYFWDV,9.48,17.24,3-20*01,3*01,8.0,QQYTSSCT,4.67,9.35,K,,Natural monoclonal,human,PCT64 24B, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,48.978,6.20823,37.0,344.0,3878.0,EVQLVQSGGGLVEPGGSLRLSCAGSGFTFSDAWMHWVRQAPGKGLEWVGHIKTNADGGAAHYAAPVKGRFIISRDDSKNMLYLQMNGLKTEDTAMYYCNTGVESYDFWSDDYSQYQYKYFWDVWGKGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVNSNYLAWYQQKPGQAPRLLIYGTSNRATGIPDRFSGSGSGTDFTLTINRLEPEDFAMYYCQQYTSSCTFGPGTKVDVK,GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAACAGCAACTACTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCAACAGGGCCACTGGCATCCCAGACAGGTTCAGCGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAACAGACTGGAGCCTGAAGATTTTGCAATGTATTATTGTCAGCAGTATACTAGCTCATGCACTTTCGGCCCTGGGACCAAAGTGGATGTCAAA,GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTAGAGCCTGGGGGGTCCCTTAGACTCTCCTGTGCAGGCTCTGGATTCACTTTCAGTGACGCCTGGATGCACTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTTGGCCATATTAAGACCAATGCCGACGGTGGGGCAGCACACTACGCTGCACCCGTGAAAGGCAGATTCATCATTTCAAGAGATGATTCAAAAAACATGTTGTATCTTCAAATGAACGGCCTGAAAACCGAGGACACCGCCATGTATTACTGCAACACAGGGGTGGAGTCATACGATTTTTGGAGTGATGATTATTCCCAATACCAGTATAAGTATTTCTGGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CNTGVESYDFWSDDYSQYQYKYFWDVW,91.030
PCT64-24E,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,NTGVESYDFWSDDYSQYDYTYLSDV,10.63,18.1,3-20*01,3*01,8.0,QQYSSSCT,4.36,8.41,K,,Natural monoclonal,human,PCT64 24E, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,21.4424,16.4408,145.0,345.0,3879.0,EVQLVQSGGGLVEPGGSLRLSCAGSGFTFSDAWMHWVRQAPGKGLEWVGHIKTNADGGAAHYAAPVKGRFIISRDDSKKMLYLQMNGLKTEDTAMYYCNTGVESYDFWSDDYSQYDYTYLSDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVNSNYLAWYQQKPGQAPRLLIYGTSNRATGIPDRFSGSGSGTDFTLTINRLEPEDFAMYYCQQYSSSCTFGPGTKVDVK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAACAGCAACTACTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCAACAGGGCCACTGGCATCCCAGACAGGTTCAGCGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAACAGACTGGAGCCTGAAGATTTTGCAATGTATTATTGTCAGCAGTATTCTAGCTCATGCACTTTCGGCCCTGGGACCAAAGTGGATGTCAAA,GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTAGAGCCTGGGGGGTCCCTTAGACTCTCCTGTGCAGGCTCTGGATTCACTTTCAGTGACGCCTGGATGCACTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTTGGCCATATTAAGACCAATGCCGACGGTGGGGCAGCACACTACGCTGCACCCGTGAAAGGCAGATTCATCATTTCAAGAGACGATTCAAAAAAGATGTTGTATCTTCAAATGAACGGCCTGAAAACCGAGGACACCGCCATGTATTACTGCAACACAGGGGTGGAGTCATACGATTTTTGGAGTGATGATTATTCCCAATATGACTATACGTATCTCAGTGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CNTGVESYDFWSDDYSQYDYTYLSDVW,90.365
PCT64-24F,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVETGDFWSDEYSQHYDPYLIDV,10.92,17.24,3-20*01,3*01,8.0,RQYDRSFT,6.54,11.21,K,,Natural monoclonal,human,PCT64 24F, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,23.3356,17.7261,143.0,346.0,3880.0,EVQLVESGGGLVKPGGSLRLSCVGSGFTFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGGKDYAAPVKGRFTVSRDDSKNTLYLEMNSLKIEDTAVYYCMTGVETGDFWSDEYSQHYDPYLIDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGDRATLSCRATQSVDSNSLAWYQQKAGQAPRLLIYGTSSRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYDRSFTFGPGTKVDIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGAGTGTTGACAGCAACTCTTTAGCCTGGTACCAACAAAAAGCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCAGCAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGGCAGTATGATAGGTCATTTACTTTCGGCCCTGGGACCAAAGTGGACATCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGCTCTGGATTCACTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGGAAAAGACTACGCTGCACCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAGAACACCCTATACTTGGAAATGAACAGCCTGAAAATCGAGGACACAGCCGTCTATTACTGTATGACAGGCGTGGAGACAGGGGATTTTTGGAGTGACGAATATTCCCAACACTACGACCCCTACCTCATAGACGTCTGGGGCAAAGGGACAACGGTCACCGTCTCCTCA,CMTGVETGDFWSDEYSQHYDPYLIDVW,89.369
PCT64-24G,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVETGDFWSDDYSQHYNSYLIDV,11.21,18.97,3-20*01,3*01,8.0,RQYDTSFT,4.67,11.21,K,,Natural monoclonal,human,PCT64 24G, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,36.6103,9.57143,37.0,347.0,3881.0,EVQLVESGGGLVKPGGSLRLSCVGSEFAFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKRTLYLQMNSLKIEDTAVYYCMTGVETGDFWSDDYSQHYNSYLIDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGDRATLSCRATQSVGSNYLAWYQQRPGQAPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYDTSFTFGPGTKVDIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGAGTGTTGGCAGCAACTACTTAGCCTGGTACCAACAGAGACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCGGCAGTATGATACCTCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGCTCTGAATTCGCTTTCAGTGACGCCTGGATGACCTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGCAAAAGACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGAACCCTATATTTGCAAATGAATAGCCTGAAAATCGAGGACACAGCCGTCTATTATTGTATGACAGGCGTGGAGACAGGGGATTTTTGGAGTGATGATTATTCCCAACACTACAACTCCTACCTCATAGACGTCTGGGGCAAAGGGACAACGGTCACCGTCTCCTCA,CMTGVETGDFWSDDYSQHYNSYLIDVW,88.704
PCT64-24H,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVETGDFWSDDYSQHYNSYLIDV,11.21,18.97,3-20*01,3*01,8.0,RQYDTSFT,5.3,12.15,K,,Natural monoclonal,human,PCT64 24H, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,48.4913,6.57433,37.0,348.0,3882.0,EVQLVESGGGLVKPGGSLRLSCVGSEFAFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKRTLYLQMNSLKIEDTAVYYCMTGVETGDFWSDDYSQHYNSYLIDVWGKGTTVTVSS,EIVMTQSPGTLSLSPGDRATLSCRATQSVGSNYLAWYQQRPGQAPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYDTSFTFGPGTKVDIK,GAAATTGTGATGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGAGTGTTGGCAGCAACTACTTAGCCTGGTACCAACAGAGACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGGCAGTATGATACCTCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGCTCTGAATTCGCTTTCAGTGACGCCTGGATGACCTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGCAAAAGACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGAACCCTATATTTGCAAATGAATAGCCTGAAAATCGAGGACACAGCCGTCTATTATTGTATGACAGGCGTGGAGACAGGGGATTTTTGGAGTGATGATTATTCCCAACACTACAACTCCTACCTCATAGACGTCTGGGGCAAAGGGACAACGGTCACCGTCTCCTCA,CMTGVETGDFWSDDYSQHYNSYLIDVW,88.704
PCT64-35B,gp120 V2 // V2 glycan(V2g) // V2 apex,"5FEH(PCT64_35B, a broadly neutralizing anti-HIV antibody)",PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVEKGDFWSDDYSQHYNTYLIDV,11.49,18.1,3-20*01,3*01,8.0,RQYETSFS,9.35,17.76,K,,Natural monoclonal,human,PCT64 35B, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,22.2694,12.2215,145.0,349.0,3884.0,EVQLVESGGGLVKPGGSLRLSCVGSEFTFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKRTLYLQMNSLKIEDTAVYYCMTGVEKGDFWSDDYSQHYNTYLIDVWGKGTTVTVSS,EIGLTQSPGTLSLSPGDRATLSCRATQRVGSDYLAWYQQRPGQSPRLLVYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYETSFSFGPGTRVDLK,GAAATTGGGTTGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGCGTGTTGGCAGCGACTACTTAGCCTGGTACCAACAAAGACCTGGCCAGTCTCCCAGACTCCTCGTCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACTATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGCCAGTATGAAACCTCATTCAGTTTCGGCCCTGGGACCAGAGTGGATTTGAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGGTCTGAATTCACTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGCAAAGGACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGGACCCTATATCTGCAAATGAATAGCCTGAAAATCGAGGACACAGCCGTCTATTATTGTATGACAGGCGTGGAGAAAGGGGATTTTTGGAGTGATGACTATTCCCAACACTACAACACCTACCTCATAGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CMTGVEKGDFWSDDYSQHYNTYLIDVW,88.372
PCT64-35C,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVEKGDFWSDDYSQHYNTYLIDV,11.49,18.1,3-20*01,3*01,8.0,RQYETSFT,9.35,16.82,K,,Natural monoclonal,human,PCT64 35C, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,28.4326,12.8153,37.0,350.0,3885.0,EVQLVESGGGLVKPGGSLRLSCVGSEFTFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKRTLYLQMNSLKIEDTAVYYCMTGVEKGDFWSDDYSQHYNTYLIDVWGKGTTVTVSS,EIGLTQSPGTLSLSPGDRATLSCRATQRVGSDYLAWYQQRLGQSPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYETSFTFGPGTRVDLK,GAAATTGGGTTGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGCGTGTTGGCAGCGACTACTTAGCCTGGTACCAACAAAGACTTGGCCAGTCTCCCAGACTCCTCATCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACTATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGCCAGTATGAAACGTCATTCACTTTCGGCCCTGGGACCAGAGTGGATTTGAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGGTCTGAATTCACTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGCAAAGGACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGGACCCTATATCTGCAAATGAATAGCCTGAAAATCGAGGACACAGCCGTCTATTATTGTATGACAGGCGTGGAGAAAGGGGATTTTTGGAGTGATGACTATTCCCAACACTACAACACCTACCTCATAGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CMTGVEKGDFWSDDYSQHYNTYLIDVW,88.372
PCT64-35D,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVEKGDFWSDDYSQHYNTYLIDV,11.49,18.1,3-20*01,3*01,8.0,RQYETSFT,9.35,16.82,K,,Natural monoclonal,human,PCT64 35D, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,19.795,12.9663,145.0,351.0,3886.0,EVQLVESGGGLVKPGGSLRLSCVGSEFTFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKRTLYLQMNSLKIEDTAVYYCMTGVEKGDFWSDDYSQHYNTYLIDVWGKGTTVTVSS,EIGLTQSPGTLSLSPGDRATLSCRATQRVGSDYLAWYQQRLGQSPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYETSFTFGPGTRVDLK,GAAATTGGGTTGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGCGTGTTGGCAGCGACTACTTAGCCTGGTACCAACAAAGACTTGGCCAGTCTCCCAGACTCCTCATCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACTATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGCCAGTATGAAACGTCATTCACTTTCGGCCCTGGGACCAGAGTGGATTTGAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGGTCTGAATTCACTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGCAAAGGACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGGACCCTATATCTGCAAATGAATAGCCTGAAAATCGAGGACACAGCCGTCTATTATTGTATGACAGGCGTGGAGAAAGGGGATTTTTGGAGTGATGACTATTCCCAACACTACAACACCTACCTCATAGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CMTGVEKGDFWSDDYSQHYNTYLIDVW,88.372
PCT64-35E,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVEKGDFWSDDYSQHYNTYLIDV,11.49,18.1,3-20*01,3*01,8.0,RQYETSFT,9.35,16.82,K,,Natural monoclonal,human,PCT64 35E, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,27.6653,13.9691,37.0,352.0,3887.0,EVQLVESGGGLVKPGGSLRLSCVGSEFTFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKRTLYLQMNSLKIEDTAVYYCMTGVEKGDFWSDDYSQHYNTYLIDVWGKGTTVTVSS,EIGLTQSPGTLSLSPGDRATLSCRATQRVGSDYLAWYQQRLGQSPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYETSFTFGPGTRVDLK,GAAATTGGGTTGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGCGTGTTGGCAGCGACTACTTAGCCTGGTACCAACAAAGACTTGGCCAGTCTCCCAGACTCCTCATCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACTATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGCCAGTATGAAACGTCATTCACTTTCGGCCCTGGGACCAGAGTGGATTTGAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGGTCTGAATTCACTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGCAAAGGACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGGACCCTATATCTGCAAATGAATAGCCTGAAAATCGAGGACACAGCCGTCTATTATTGTATGACAGGCGTGGAGAAAGGGGATTTTTGGAGTGATGACTATTCCCAACACTACAACACCTACCTCATAGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CMTGVEKGDFWSDDYSQHYNTYLIDVW,88.372
PCT64-35F,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVEKGDFWSDDYSQHYNTYLIDV,11.78,18.97,3-20*01,3*01,8.0,RQYDTSFT,7.48,14.02,K,,Natural monoclonal,human,PCT64 35F, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,34.1535,10.208,37.0,353.0,3888.0,EVQLVESGGGLVKPGGSLRLSCVGSEFTFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYATPVKGRFTVSRDDSKRTLYLQMNSLKIEDTAVYYCMTGVEKGDFWSDDYSQHYNTYLIDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGDRATLSCRATQSVGSNYLAWYQQRPGQTPRLIIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYDTSFTFGPGTKVDMK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGAGACAGAGCCACCCTCTCCTGCCGGGCCACTCAGAGTGTCGGCAGCAACTACTTAGCCTGGTACCAACAAAGACCTGGCCAGACTCCCAGGCTCATCATCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGATTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGCCAGTATGATACCTCATTCACTTTCGGCCCTGGGACCAAAGTGGATATGAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGGTCTGAATTCACTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGCAAAGGACTACGCTACGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGGACCCTATATCTGCAAATGAATAGCCTGAAAATCGAGGACACAGCCGTCTATTATTGTATGACAGGCGTGGAGAAAGGGGATTTTTGGAGTGATGACTATTCCCAACACTACAACACCTACCTCATAGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CMTGVEKGDFWSDDYSQHYNTYLIDVW,88.040
PCT64-35G,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVEKGDFWSDDYSQHYNTYLIDV,11.78,18.97,3-20*01,3*01,8.0,RQYETSFS,8.41,16.82,K,,Natural monoclonal,human,PCT64 35G, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,26.0402,10.2531,145.0,354.0,3889.0,EVQLVESGGGLVKPGGSLRLSCVGSEFTFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKRTLYLQMNSLKIEDTGVYYCMTGVEKGDFWSDDYSQHYNTYLIDVWGKGTTVTVSS,EIGLTQSPGTLSLSPGDRATLSCRATQRVGSDYLAWYQQRPGQSPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYETSFSFGPGTRVDLK,GAAATTGGGTTGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGCGTGTTGGCAGCGACTACTTAGCCTGGTACCAGCAGAGACCTGGCCAGTCTCCCAGACTCCTCATCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACTATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGCCAGTATGAAACCTCATTCAGTTTCGGCCCTGGGACCAGAGTGGATTTGAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGGTCTGAATTCACTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGCAAAGGACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGGACCCTATATCTGCAAATGAATAGCCTGAAAATCGAGGACACAGGCGTCTATTATTGTATGACAGGCGTGGAGAAAGGGGATTTTTGGAGTGATGACTATTCCCAACACTACAACACCTACCTCATAGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CMTGVEKGDFWSDDYSQHYNTYLIDVW,88.040
PCT64-35H,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVERGDFWSDDYSQHYNTYLIDV,12.07,18.97,3-20*01,3*01,8.0,RQYDTSFT,8.41,14.95,K,,Natural monoclonal,human,PCT64 35H, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,41.4128,6.6585,37.0,355.0,3890.0,EVQLVESGGGLVKPGGSLRLSCVGSEFTFSEAWMTWVRQAPGKGLEWVGDMRPTPEGGAKNYAAPVKGRFTVSRDDSKSTLYLQMNSLKIEDTAVYYCMTGVERGDFWSDDYSQHYNTYLIDVWGKGTTVTVSS,EIVLTQSPGILSLSPGDRATLSCRATQSVGSNYLAWYQQRPGQTPRLIIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYDTSFTFGPGTKVDMK,GAAATTGTGTTGACGCAGTCTCCAGGCATTTTGTCTTTGTCTCCAGGAGACAGAGCCACCCTCTCCTGCCGGGCCACTCAGAGTGTCGGCAGCAACTACTTAGCCTGGTACCAACAAAGACCTGGCCAGACTCCCAGGCTCATCATCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGATTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGCCAGTATGATACCTCATTCACTTTCGGCCCTGGGACCAAAGTGGATATGAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTCAGACTCTCCTGTGTAGGCTCTGAATTCACTTTCAGTGAGGCCTGGATGACCTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCGACATGAGACCCACCCCTGAGGGTGGGGCAAAAAACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGCACCCTGTATTTGCAAATGAATAGCCTGAAAATTGAGGACACAGCCGTCTATTACTGTATGACAGGCGTGGAGAGAGGGGATTTTTGGAGTGATGATTATTCGCAACACTACAACACCTACCTCATCGACGTCTGGGGCAAAGGGACAACGGTCACCGTCTCCTCA,CMTGVERGDFWSDDYSQHYNTYLIDVW,88.040
PCT64-35I,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVERGGFWSDEYSQHWDPYLIDV,12.07,19.83,3-20*01,3*01,8.0,RQYDTSFT,9.03,14.95,K,,Natural monoclonal,human,PCT64 35I, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,85.5159,1.92827,37.0,356.0,3891.0,EVQLVESGGGLVKPGGSLRLSCVGSEFTFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGGKEYAAPVKGRFTVSRDDSKNTLYLEMNSLKIEDTAVYYCMTGVERGGFWSDEYSQHWDPYLIDVWGKGTMVTVSS,EIVLTQSPGTLSLSPGDRATLSCRATQRVDSNSLAWYQQRPGQAPRLLIYGTSTRAAGIPDRLSGSGSGTDFTLTIDRLEPEDFAVYYCRQYDTSFTFGPGTKVDSK,GAAATTGTATTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGCGTGTTGACAGCAACTCTTTAGCCTGGTACCAACAAAGACCTGGCCAGGCTCCCAGACTCCTCATCTATGGTACATCCACCAGGGCCGCTGGCATCCCAGACAGACTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGGCAGTATGATACGTCATTTACTTTCGGCCCTGGGACCAAAGTGGACAGCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGCTCTGAATTCACTTTCAGTGACGCCTGGATGACTTGGGTCCGACAGGCCCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCTGAGGGTGGGGGAAAAGAGTACGCTGCACCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAGAACACCCTCTACTTGGAAATGAACAGCCTGAAAATCGAGGACACAGCCGTCTATTACTGTATGACAGGCGTGGAGAGAGGGGGTTTTTGGAGTGACGAATATTCCCAACACTGGGACCCCTACCTCATAGACGTCTGGGGCAAAGGGACAATGGTCACCGTCTCCTCA,CMTGVERGGFWSDEYSQHWDPYLIDVW,88.372
PCT64-35K,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVEAGDFWSDEYSQHYNTYLIDV,12.07,20.69,3-20*01,3*01,8.0,RQYETSFT,9.35,16.82,K,,Natural monoclonal,human,PCT64 35K, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,39.2351,9.58151,37.0,357.0,3892.0,EVQLVESGGGLVEPGGSLRLSCVGSEFAFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKSTLYLQMNSLKIEDTGVYYCMTGVEAGDFWSDEYSQHYNTYLIDVWGKGTTVTVSS,EIGLTQSPGTLSLSPGDRATLSCRATQRVGSDYLAWYQQRLGQSPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYETSFTFGPGTRVDLK,GAAATTGGGTTGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGCGTGTTGGCAGCGACTACTTAGCCTGGTACCAACAAAGACTTGGCCAGTCTCCCAGACTCCTCATCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACTATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGCCAGTATGAAACGTCATTCACTTTCGGCCCTGGGACCAGAGTGGATTTGAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTGGAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGCTCTGAATTCGCTTTCAGTGACGCCTGGATGACCTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCGGAGGGTGGGGCAAAAGACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGCACCCTATATTTGCAAATGAATAGCCTGAAAATCGAGGACACAGGCGTCTATTATTGTATGACAGGCGTGGAGGCAGGGGATTTTTGGAGTGATGAATATTCCCAACACTACAACACCTACCTCATAGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CMTGVEAGDFWSDEYSQHYNTYLIDVW,87.708
PCT64-35M,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,PCT64-35M signature sites,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,NTGVEWYDFWSDEYSQEETKYFKDV,12.36,19.83,3-20*01,3*01,8.0,QQYTRSCT,6.85,10.28,K,,Natural monoclonal,human,PCT64 35M, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,7.43376,29.4003,353.0,358.0,3893.0,EVQLVESGGALVKPGGSVRLSCSASGFKFSDAWMHWVRQAPGKGLEWVAHVRTQADGGTTEYAAPVKGRFIISRDDSKNILYLQMNGLKTEDTAKYYCNTGVEWYDFWSDEYSQEETKYFKDVWGKGTTVIVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSANHLAWYQQKPGQAPRLLIYGTSVRATGIPDRFSGSGSGTDFTLTINRLEPEDFAVYYCQQYTRSCTFGPGTRVDVK,GAAATTGTCTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGTGCCAACCACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCGAGGCTCCTCATCTATGGTACATCCGTCAGGGCCACTGGCATCCCAGACAGGTTCAGCGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCAGCAGTATACCAGGTCATGCACTTTCGGCCCTGGGACCAGAGTGGATGTCAAG,GAGGTGCAGCTGGTGGAGTCTGGGGGAGCCTTGGTCAAGCCTGGGGGGTCCGTTAGACTCTCCTGTTCGGCCTCTGGATTCAAATTCAGTGACGCCTGGATGCACTGGGTCCGCCAGGCTCCAGGGAAGGGCCTGGAGTGGGTTGCCCATGTCAGAACCCAGGCCGACGGTGGGACAACGGAATACGCTGCACCCGTGAAAGGGAGATTCATCATCTCAAGAGATGATTCAAAAAACATATTGTATCTGCAAATGAATGGCCTGAAAACCGAAGACACAGCCAAGTATTACTGTAACACAGGGGTGGAATGGTACGATTTTTGGAGTGATGAATATTCCCAGGAGGAGACCAAGTATTTCAAGGACGTCTGGGGCAAGGGGACCACAGTCATCGTCTCCTCA,CNTGVEWYDFWSDEYSQEETKYFKDVW,88.704
PCT64-35N,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVEAGDFWSDEYSQHYNTYLIDV,12.36,20.69,3-20*01,3*01,8.0,RQYDTSFT,7.48,14.02,K,,Natural monoclonal,human,PCT64 35N, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,45.7088,7.35153,37.0,359.0,3894.0,EVQLVESGGGLVEPGGSLRLSCVGSEFAFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKSTLYLQMNSLKIEDTGVYYCMTGVEAGDFWSDEYSQHYNTYLIDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGDRATLSCRATRSVGSDYLAWYQHRPGQSPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYDTSFTFGPGTKVDIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCGGAGCGTTGGCAGCGACTACTTAGCCTGGTACCAACACAGACCTGGCCAGTCTCCCAGGCTCCTCATTTATGGTACATCTAGAAGGGCCGCTGGCATCCCCGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTACTGTCGGCAGTATGATACCTCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTGGAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGCTCTGAATTCGCTTTCAGTGACGCCTGGATGACCTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCATATGAGACCCACCCCGGAGGGTGGGGCAAAAGACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGCACCCTATATTTGCAAATGAATAGCCTGAAAATCGAGGACACAGGCGTCTATTATTGTATGACAGGCGTGGAGGCAGGGGATTTTTGGAGTGATGAATATTCCCAACACTACAACACCTACCTCATAGACGTCTGGGGCAAAGGGACAACGGTCACCGTCTCCTCA,CMTGVEAGDFWSDEYSQHYNTYLIDVW,87.708
PCT64-35O,gp120 V2 // V2 glycan(V2g) // V2 apex,,PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVEAGDFWSDEYSQHYNTYLIDV,12.36,20.69,3-20*01,3*01,8.0,RQYDTSFT,7.79,13.08,K,,Natural monoclonal,human,PCT64 35O, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,29.9539,10.9467,145.0,360.0,3895.0,EVQLVESGGGLVEPGGSLRLSCVGSEFAFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKSTLYLQMNSLKIEDTGVYYCMTGVEAGDFWSDEYSQHYNTYLIDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGDRATLSCRATQSVGSDYLAWYQHRPGQSPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYDTSFTFGPGTKVDIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGAGCGTTGGCAGCGACTACTTAGCCTGGTATCAACACAGACCTGGCCAGTCTCCCAGGCTCCTCATTTATGGTACATCTAGAAGGGCCGCTGGCATCCCCGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGACTTTGCAGTGTATTATTGTCGGCAGTATGATACCTCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTGGAGCCGGGGGGGTCCCTTAGACTCTCCTGTGTAGGCTCTGAATTCGCTTTCAGTGACGCCTGGATGACCTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTAGGCCATATGAGACCCACCCCGGAGGGTGGGGCAAAAGACTACGCTGCGCCCGTGAAAGGCAGATTCACCGTCTCAAGAGATGATTCAAAAAGCACCCTATATTTGCAAATGAATAGCCTGAAAATCGAGGACACAGGCGTCTATTATTGTATGACAGGCGTGGAGGCAGGGGATTTTTGGAGTGATGAATATTCCCAACACTACAACACCTACCTCATAGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA,CMTGVEAGDFWSDEYSQHYNTYLIDVW,87.375
PCT64-35S,gp120 V2 // V2 glycan(V2g) // V2 apex,"6CA6(Crystal structure of PCT64_35S, a broadly neutralizing anti-HIV antibody.);EMD-7865(PC64M4C054.SOSIP in complex with PCT64-35S Fab)",PC64 ,PCT64,Landais2017(29166592) ,,Landais2017(29166592) ,IMGT/V-QUEST,3-15*01,3-3*01,6*03,25.0,MTGVERGDFWSDDYSQHYNTYLIDV,13.22,20.69,3-20*01,3*01,8.0,RQYETSFT,7.48,14.02,K,,Natural monoclonal,human,PCT64 35S, Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..,19.0401,15.5769,146.0,361.0,3896.0,EVQLVESGGGLVKPGGSLRLACVGSEFTFSEAWMTWVRQAPGKGLEWVGHMRPTTEGGAKDYAAAVRGRFTIARDDSKSTLYLQMNSLKIEDTGVYYCMTGVERGDFWSDDYSQHYNTYLIDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGDRATLSCRATQSVGGDYFAWYQQRPGQSPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYETSFTFGPGTKVDIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGACAGAGCCACCCTCTCCTGCAGGGCCACTCAGAGTGTTGGCGGCGACTACTTCGCCTGGTACCAACAAAGACCTGGCCAGTCTCCCAGGCTCCTCATCTATGGTACATCCAGAAGGGCCGCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCGACAGACTGGAGCCTGAAGACTTTGCAGTATATTACTGTCGGCAGTATGAAACCTCTTTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTCAGACTCGCCTGTGTAGGTTCTGAATTCACTTTCAGTGAGGCCTGGATGACCTGGGTCCGACAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCACATGAGACCCACCACTGAGGGTGGGGCAAAAGACTACGCTGCGGCCGTGAGAGGCAGATTCACCATCGCAAGAGACGATTCAAAAAGTACCCTGTATTTGCAAATGAATAGCCTGAAAATCGAGGACACAGGCGTCTATTATTGTATGACAGGCGTGGAGAGAGGGGATTTTTGGAGTGATGATTATTCCCAACACTACAACACCTACCTCATAGACGTCTGGGGCAAAGGGACAACGGTCACCGTCTCCTCA,CMTGVERGDFWSDDYSQHYNTYLIDVW,86.711
PG16,gp120 V2 // V2 glycan(V2g) // V2 apex,3LRS(Structure of PG16);3MME(Structure and functional dissection of PG16);3MUG(PG16 Fab);4DQO(Fab PG16 complexed with V1V2 region (ZM109)),Donor 24 ,PG9,Walker2009a(19729618) ,Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization;Mutation affects neutralization of PGDM1400 and PG16;Mutation affects PG9-like Ab sensitivity;Mutations at the trimer apex that affect sensitivity;PG16 signature predictions;PG9-like antibodies require N160 for neutralization;PG9-like contacts;V2 Signature Analysis Summary,Klein2013(23540694) ,IgBlast,3-33,3-3,6,,,,,2-14,3,,,,,L,Yes,Natural monoclonal,human,, Wu2011: %SHM calculated for VH gene IGHV3-33*05 and VL gene IGLV2-14*01by IMGT/V-QUEST on nt sequences.,0.68333,39.3136,3506.0,10.0,2125.0,QEQLVESGGGVVQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMRKYHSDSMWGRVTISRDNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSGISNRFSGSKSGNTASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKVTVL,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGATCACCATCTCCTGCAATGGAACCAGCAGTGACGTTGGTGGATTTGACTCTGTCTCCTGGTACCAACAATCCCCAGGGAAAGCCCCCAAAGTCATGGTTTTTGATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAGTCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCGATTATTTCTGCTCTTCACTGACAGACAGAAGCCATCGCATATTCGGCGGCGGGACCAAGGTGACCGTTCTA,CAGGAACAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTTAGCGTCTGGATTCACGTTTCACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGCACTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTCACCATCTCCAGAGACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCTGAAAGTCGAAGACACGGCTATGTTCTTCTGTGCGAGAGAGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGCTACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCGAGC,CAREAGGPIWHDDVKYYDFNDGYYNYHYMDVW,85.473
nan,,,,,,,Pancera2010(20538861) ,IMGT/V-QUEST JoinSolver,3-33*05,3-3*01,6*03,,,,,2-14*01,3*02,,,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Walker2009a(19729618) ,IMGT/V-QUEST,3-33*05,,,,EAGGPIWHDDVKYYDFNDGYYNYHYMDV,,,2-14*01,,,SSLTDRSHRIF,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Wu2011(21835983) ,,,,,,,14.5,21.4,,,,,12.5,21.2,,,,,,,,,,,,,,,,,
PG16/10-1074,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g),,Donor 17 Donor 24 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific ,0.26292,14.491,46.0,267.0,3514.0,,,,,,
PG16-iMab,gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CD4R,,Donor 24 ,,Pace2013a(23878231) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;humanized mouse,PG16-ibalizumab,bispecific ,0.0047604,15.7096,252.0,201.0,3278.0,,,,,,
PG16/PGT121,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g),,Donor 17 Donor 24 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific ,0.30227,19.4428,130.0,265.0,3512.0,,,,,,
PG16/PGT128,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g),,Donor 24 Donor 36 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific ,0.30595,20.1815,131.0,264.0,3513.0,,,,,,
PG9,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,3MUH(PG9 light chain);3U2S(Fab PG9 complexed with V1V2 region (ZM109));3U36(Fab PG9);3U4E(Fab PG9 complexed with V1V2 region (CAP45));5VJ6(BG505 SOSIP.664 in complex with PG9 and 8ANC195),Donor 24 ,PG9,Walker2009a(19729618) ,Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization;Mutation affects neutralization by V1V2 glycan mAbs;Mutation affects PG9-like Ab sensitivity;mutations affecting PG9 binding;Mutations at the trimer apex that affect sensitivity;PG9 contacts;PG9 contacts;PG9 escape mutations;PG9-like antibodies require N160 for neutralization;PG9-like contacts;PG9 residue prediction;PG9 signature predictions;PG9 signature sites;V2 Signature Analysis Summary,Pancera2010(20538861) ,IMGT/V-QUEST JoinSolver,3-33*05,3-3*01,6*03,,,,,2-14*01,3*02,,,,,L,Yes,Natural monoclonal,human,, Wu2100: %SHM calculated for VH gene IGHV3-33*05 and VL gene IGLV2-14*01by IMGT/V-QUEST on nt sequences.,0.83952,23.0883,6586.0,9.0,2124.0,QRLVESGGGVVQPGSSLRLSCAASGFDFSRQGMHWVRQAPGQGLEWVAFIKYDGSEKYHADSVWGRLSISRDNSKDTLYLQMNSLRVEDTATYFCVREAGGPDYRNGYNYYDFYDGYYNYHYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQSITISCNGTSNDVGGYESVSWYQQHPGKAPKVVIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEGDYYCKSLTSTRRRVFGTGTKLTVL,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCAATGGAACCAGCAATGATGTTGGTGGCTATGAATCTGTCTCCTGGTACCAACAACATCCCGGCAAAGCCCCCAAAGTCGTGATTTATGATGTCAGTAAACGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGGTGACTATTACTGCAAGTCTCTGACAAGCACGAGACGTCGGGTTTTCGGCACTGGGACCAAGCTGACCGTTCTA,CAGCGATTAGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGTCGTCCCTGAGACTCTCCTGTGCAGCGTCCGGATTCGACTTCAGTAGACAAGGCATGCACTGGGTCCGCCAGGCTCCAGGCCAGGGGCTGGAGTGGGTGGCATTTATTAAATATGATGGAAGTGAGAAATATCATGCTGACTCCGTATGGGGCCGACTCAGCATCTCCAGAGACAATTCCAAGGATACGCTTTATCTCCAAATGAATAGCCTGAGAGTCGAGGACACGGCTACATATTTTTGTGTGAGAGAGGCTGGTGGGCCCGACTACCGTAATGGGTACAACTATTACGATTTCTATGATGGTTATTATAACTACCACTATATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCGAGC,CVREAGGPDYRNGYNYYDFYDGYYNYHYMDVW,86.007
nan,,,,,,,Zhou2013a(23911655) ,IMGT/V-QUEST,3-33*05,1-1*01,6*03,30.0,,,,2-14,3,10.0,,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Walker2009a(19729618) ,IMGT/V-QUEST,3-33*05,,,,EAGGPDYRNGYNYYDFYDGYYNYHYMDV,,,2-14*01,,,KSLTSTRRRVF,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Wu2011(21835983) ,,,,,,,14.9,18.8,,,,,10.1,14.1,,,,,,,,,,,,,,,,,
PG9/aplaviroc,gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CCR5,,Donor 24 ,,Gavrilyuk2013(23427154) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,PG9-aplaviroc,"Conjugation of PG9 with aplaviroc, a small molecule that blocks CCR5. ",0.33288,7.99799,234.0,549.0,4161.0,,,,,,
PG9-iMab,gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CD4R,,Donor 24 ,,Pace2013a(23878231) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;humanized mouse,PG9-ibalizumab,bispecific ,0.0073056,8.86025,266.0,200.0,3277.0,,,,,,
PG9-PG16-RSH,gp120 V2 // V2 glycan(V2g) // V2 apex,,Donor 24 ,PG9,Pancera2013(23708607) ,,Pancera2010(20538861) ,IMGT/V-QUEST,3-33*05,3-3*01,6*03,,,,,2-14*01,3*02,,,,,L,,Engineered monoclonal,human,"PG9-16, PG916, PG9-16-RSH",chimeric ,0.2509,50.5214,440.0,103.0,3037.0,,,,,,
PGC14,gp120,,Donor 24 ,,Walker2009a(19729618) ,,Walker2009a(19729618) ,IMGT/V-QUEST,1-24*01,,,,GAVGADSGSWFDP,,,3-1*01,,,AWETTTTTFVFF,,,L,,Natural monoclonal,human,, ,76.5847,2.73307,162.0,79.0,2128.0,DGHLVQSGVEVKKTGATVKISCKVSGYSFIDYYLHWVQRAPGKGLEWVGLIDPENGEARYAEKFQGRVTIIADTSIDTGYMEMRSLKSEDTAVYFCAAGAVGADSGSWFDPWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGSKLGDKYVSWYQLRPGQSPILVMYENDRRPSGIPERFSGSNSGDTATLTISGTQALDEADFYCQAWETTTTTFVFFGGGTQLTVL,TCCTATGAACTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGACAGACAGCCAGCATCACCTGTTCTGGATCTAAATTGGGGGATAAATATGTTTCCTGGTATCAACTGAGGCCAGGCCAGTCCCCCATACTGGTCATGTATGAAAATGACAGGCGGCCCTCCGGGATCCCTGAGCGATTCTCCGGTTCCAATTCTGGCGACACTGCCACTCTGACCATCAGCGGGACCCAGGCTTTGGATGAGGCTGACTTCTACTGTCAGGCGTGGGAGACCACCACCACCACTTTTGTTTTCTTCGGCGGAGGGACCCAGCTGACCGTTCTA,GACGGCCACCTGGTTCAGTCTGGGGTTGAGGTGAAGAAGACTGGGGCTACAGTCAAAATCTCCTGCAAGGTTTCTGGATACAGCTTCATCGACTACTACCTTCATTGGGTGCAACGGGCCCCTGGAAAAGGCCTTGAGTGGGTGGGACTTATTGATCCTGAAAATGGTGAGGCTCGATATGCAGAGAAGTTCCAGGGCAGAGTCACCATAATCGCGGACACGTCTATAGATACAGGCTACATGGAAATGAGGAGCCTGAAATCTGAGGACACGGCCGTGTATTTCTGTGCAGCAGGTGCCGTGGGGGCTGATTCCGGGAGCTGGTTCGACCCCTGGGGCCAGGGAACTCTGGTCACCGTCTCGAGC,CAAGAVGADSGSWFDPW,88.814
PGDM11,gp120 V3 // V3 glycan (V3g),,Donor 14 ,,Sok2016(27438765) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,7.71323,21.8645,110.0,261.0,3502.0,EVQLVESGGGVAKPGGSLGLSCTASAFTSSDLSWIRQAPGKGLEWITYMSRSADFSIYSDSVKGRFSVHRDNSRSLFTLQMNNLQIADTAVYYCARVAVGPMDSYYHDTTSAFDIWGHGILVTVSS,DIVMTQTPLSSVVTLGQPASISCTSSQGLVHENGKTYFSWYHQRPGQPPRLLIYLISTRFSGVPDRFSGSGAGTDFTLKISSVEAEDVGTYFCFQGTHYPWTFGQGTKMEIN,GATATTGTGATGACCCAGACTCCACTCTCCTCAGTTGTCACCCTGGGACAGCCGGCCTCCATCTCCTGCACATCTAGTCAAGGCCTCGTCCACGAAAATGGAAAAACTTATTTCAGTTGGTATCATCAGAGGCCGGGCCAGCCTCCGAGACTCTTGATTTATCTCATTTCTACGCGCTTCTCTGGGGTCCCAGACAGATTCAGTGGCAGCGGGGCAGGGACGGATTTCACACTGAAAATCAGTAGCGTGGAGGCTGAGGATGTCGGCACTTATTTCTGCTTCCAAGGGACTCACTATCCGTGGACGTTCGGCCAAGGGACCAAGATGGAGATCAAC,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGGGTGGCCAAGCCGGGGGGGTCACTGGGACTCTCCTGTACAGCCTCTGCATTCACCTCCAGTGACCTGAGTTGGATCCGCCAGGCTCCAGGGAAGGGCCTGGAGTGGATCACATACATGAGTCGCAGCGCTGATTTTTCAATCTACTCAGATTCTGTGAAGGGCCGATTCTCCGTCCACAGAGACAACTCCAGGAGTTTATTCACTTTACAAATGAACAATTTACAAATCGCGGACACGGCCGTCTACTACTGTGCGCGAGTCGCAGTTGGGCCCATGGACTCCTACTATCATGACACTACTTCCGCCTTTGATATTTGGGGCCACGGGATCTTGGTCACCGTCTCTTCA,CARVAVGPMDSYYHDTTSAFDIW,77.966
PGDM12,gp120 V3 // V3 glycan (V3g),,Donor 14 ,,Sok2016(27438765) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,2.84353,33.9304,134.0,262.0,3503.0,QVHVMESGGGVAKPGGSLGLSCTASPFASSDMSWIRQAPGKGLEWISYMSRSADFSIYSDSVKGRFTVHRDNSKSLFYLQMNNLQVADTAVYFCARVAAGPMDQYYFDTTSAFDIWGQGILVTVSS,DIVLNQTSFSSPVTVGQPASISCRSSQGITHENGKTYLSWLHQRPGQAPRLLLYLVSARFSGVPDRFSGSGAGTDFTLKISRVEAEDVGTYYCFQGTHYPWTFGQGTKVEIN,GATATTGTGCTGAATCAGACTTCTTTCTCGTCACCTGTCACCGTTGGACAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAAGGAATCACACACGAGAATGGAAAGACCTACTTGAGTTGGCTTCATCAGAGGCCAGGCCAGGCTCCCAGACTTTTACTTTATTTGGTGTCTGCGCGCTTCTCTGGGGTCCCAGACAGATTCAGTGGCAGCGGGGCAGGGACGGACTTCACACTGAAAATCAGCAGGGTGGAGGCTGAAGATGTCGGCACTTATTACTGCTTCCAGGGGACCCACTATCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAGATCAAC,CAGGTCCACGTGATGGAGTCCGGGGGAGGCGTGGCCAAGCCGGGGGGGTCTCTGGGCCTCTCCTGTACAGCCTCTCCATTCGCCTCCAGTGACATGAGTTGGATTCGCCAGGCTCCAGGGAAGGGGCTCGAGTGGATTTCATATATGAGTCGCAGTGCTGACTTCTCAATTTATTCAGACTCTGTGAAGGGCCGATTCACCGTCCACAGAGACAACTCCAAGAGCTTATTCTATCTACAGATGAACAATCTACAAGTCGCGGACACGGCCGTCTATTTCTGTGCGAGAGTCGCAGCTGGCCCCATGGACCAGTACTATTTCGACACTACTTCCGCCTTTGACATTTGGGGCCAGGGGATATTGGTCACCGTCTCTTCA,CARVAAGPMDQYYFDTTSAFDIW,79.322
PGDM1400,gp120 V2 // V2 glycan(V2g) // V2 apex,4RQQ(Fab PGDM1400),Donor 84 ,PGDM1400,Sok2014(25422458) ,Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization of PGDM1400 and PG16;Mutation causes resistance to V2 bnAbs;PGDM1400 lineage requires N160;PGDM signature sites;V2 Signature Analysis Summary,Sok2014(25422458) ,IMGT/V-QUEST,1-8,,6,34.0,CAKGSKHRLRDYALYDDDGALNWAVDVDYLSNLEFW,,,2-28,1,9.0,CMQGRESPWTF,,,K,,Natural monoclonal,human,, ,0.18886,61.1388,4788.0,174.0,3201.0,QAQLVQSGPEMRKPGASVKVSCKAPGNTLKNHDLHWVRNVPGQGLEWVGWVSHEGDKKVIVEKFKASVTIDWDRSLNTAYLQLRGLRSEDTAVYYCARGSKHRLRDYVMYDDYGALQWAVYVDYLSNLDVWGQGTAVTVSP,DFVLTQSPHSLSVTPGESASISCKSSHSLIHGDRNNYLAWYVQKPGRSPQLLIYLASSRASGVPDRFSGSGSDKDFTLKISRVETEDVGTYYCMQGRESPWTFGQGTKVDIK,GATTTTGTCCTGACTCAGTCTCCACACTCTCTGTCCGTCACCCCTGGAGAGTCGGCCTCCATCTCCTGCAAGTCTAGTCACAGCCTCATTCATGGTGATAGGAACAATTATTTGGCTTGGTACGTACAGAAGCCAGGGCGGTCTCCACAACTCCTGATCTATTTGGCTTCCAGTCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCGGACAAAGATTTTACACTGAAGATCAGCAGAGTGGAGACTGAGGATGTTGGGACGTATTACTGCATGCAAGGTCGAGAAAGTCCCTGGACGTTCGGCCAAGGGACCAAGGTGGACATCAAA,CAGGTGCATCTGACGCAGTCTGGGCCTGAGGTGAGGAAGCCTGGGACCTCCGTAAAGGTCTCCTGCAAGGCCCCTGGAAACACATTGAAGACTTATGATCTACACTGGGTGCGCAGCGTCCCTGGACAAGGCCTTCAGTGGATGGGATGGATAAGCCATGAGGGCGACAAGAAGGTCATTGTGGAAAGATTCAAGGCCAAAGTCACCATTGATTGGGACAGGTCCACCAATACGGCCTATCTCCAACTGAGCGGCCTCACATCTGGCGACACGGCCGTCTATTATTGTGCGAAAGGCTCAAAACACAGGCTGCGAGATTACGCTCTCTACGACGACGACGGCGCATTGAATTGGGCTGTCGATGTTGACTACCTTTCGAACTTGGAATTCTGGGGCCAAGGGACCGCCGTCACCGTCTCTTCA,CAKGSKHRLRDYALYDDDGALNWAVDVDYLSNLEFW,73.986
PGDM1400-LS,gp120 V2 // V2 glycan(V2g) // V2 apex,,Donor 84 ,PGDM1400,,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,0.13842,55.316,416.0,553.0,4164.0,,,,,,
PGDM1400/PRO-140,gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CCR5,,Donor 84 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;mouse,PGDM1400fv-PRO-140fv, ,0.032683,19.2107,107.0,423.0,3979.0,,,,,,
PGDM1401,gp120 V2 // V2 glycan(V2g) // V2 apex,,Donor 84 ,,Sok2014(25422458) ,PGDM1400 lineage requires N160,Sok2014(25422458) ,IMGT/V-QUEST,1-8,,6,34.0,CARGSKHRLRDYVMYDDYGALQWAVYVDYLSNLDVW,,,2-28,1,9.0,CMQGRESPWTF,,,K,,Natural monoclonal,human,, ,0.29088,116.019,108.0,175.0,3203.0,QAQLVQSGPEMRKPGASVKVSCKAPGNTLKNHDLHWVRNVPGQGLEWVGWVSHEGDKKVIVEKFKASVTIDWDRSLNTAYLQLRGLRSEDTAVYYCARGSKHRLRDYVMYDDYGALQWAVYVDYLSNLDVWGQGTAVTVSP,DFVLTQSPHSLSVTPGEPASISCRSSQSLLHGDKNNYLAWYLQKPGHSPQLLIYMASSRPSGVPDRFSGSGSGTHFTLKISRVETEDVGMYYCMQGRESPWTFGQGTKVEIK,GATTTTGTCCTGACTCAGTCTCCACACTCTCTATCCGTCACCCCGGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTTCATGGTGATAAAAACAACTATTTGGCTTGGTATCTCCAGAAGCCAGGGCACTCTCCACAACTGCTGATCTATATGGCTTCTAGTCGGCCCTCAGGGGTCCCTGACAGGTTCAGTGGCAGTGGCTCGGGCACACATTTTACACTGAAAATCAGTAGAGTGGAGACTGAAGATGTTGGGATGTACTACTGCATGCAAGGTCGAGAAAGTCCCTGGACGTTTGGCCAAGGGACCAAGGTGGAAATCAAA,CAGGCGCAACTGGTGCAGTCTGGGCCTGAGATGAGGAAACCTGGGGCCTCCGTAAAGGTCTCCTGCAAGGCCCCTGGAAATACATTGAAGAATCATGATCTACACTGGGTGCGCAACGTCCCTGGACAGGGGCTTGAGTGGGTGGGGTGGGTGAGTCACGAGGGCGACAAAAAGGTCATTGTAGAGAAATTCAAGGCCAGCGTCACCATTGATTGGGACAGGTCCCTGAATACGGCCTATCTTCAACTGCGCGGCCTCAGGTCTGAAGACACGGCCGTCTATTATTGTGCGAGAGGGTCAAAACACAGGCTGCGAGACTACGTTATGTACGACGACTACGGCGCATTGCAGTGGGCTGTCTATGTTGACTATCTTTCGAACTTGGACGTCTGGGGCCAAGGGACCGCCGTCACCGTCTCTCCA,CARGSKHRLRDYVMYDDYGALQWAVYVDYLSNLDVW,73.986
PGDM1402,gp120 V2 // V2 glycan(V2g) // V2 apex,,Donor 84 ,,Sok2014(25422458) ,PGDM1400 lineage requires N160,Sok2014(25422458) ,IMGT/V-QUEST,1-8,,6,34.0,CAKGSKHRLRDYALYDDIGALQWAVDVDYLSTLEFW,,,2-28,1,9.0,CMQGRESPWTF,,,K,,Natural monoclonal,human,, ,10.0606,17.8356,102.0,176.0,3204.0,QVQLAQSGPEVRKPGASVKVSCKAPGNTLKTYDLHWVRDVPGQGLQWMGWVSHEGDKKVIVERFKAKVSIDWDRSTNTAYLQLSGLTSEDTAVYYCAKGSKHRLRDYALYDDIGALQWAVDVDYLSTLEFWGQGTAVTVSS,DFVLTQSPHSLSVTPGEPASISCKSSHSLIHGDKNNYLAWYVQKPGRSPQLLIYLASSRASGVPDRFSGSGSDKDFTLKISRVETEDVGTYYCMQGRESPWTFGQGTKVEIK,GACTTTGTCCTGACTCAGTCTCCACACTCTCTGTCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAAGTCTAGTCACAGCCTCATTCATGGTGATAAGAACAACTATTTGGCTTGGTACGTTCAGAAGCCAGGGCGGTCTCCACAACTCCTGATCTATTTGGCTTCCAGTCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCGGACAAAGATTTTACACTGAAGATCAGCAGAGTGGAGACTGAGGATGTTGGGACCTATTACTGCATGCAAGGTCGAGAAAGTCCCTGGACGTTCGGCCAGGGGACCAAGGTGGAAATCAAA,CAGGTGCAACTGGCGCAGTCTGGGCCTGAGGTGAGGAAGCCTGGGGCCTCCGTAAAGGTCTCCTGCAAGGCCCCTGGAAATACATTGAAGACTTATGATCTACACTGGGTGCGAGACGTCCCTGGACAGGGCCTGCAGTGGATGGGATGGGTGAGCCACGAGGGCGACAAGAAGGTCATTGTGGAGAGATTCAAGGCCAAAGTCAGCATTGATTGGGACAGGTCCACAAATACGGCCTATCTACAACTGAGCGGCCTCACATCTGAAGACACGGCCGTCTATTATTGTGCGAAAGGCTCAAAACACAGGCTGCGAGACTACGCTCTGTACGACGACATCGGCGCATTGCAATGGGCTGTCGATGTTGACTACCTTTCGACCTTGGAATTTTGGGGCCAAGGGACCGCCGTCACCGTCTCTTCA,CAKGSKHRLRDYALYDDIGALQWAVDVDYLSTLEFW,74.662
PGDM1403,gp120 V2 // V2 glycan(V2g) // V2 apex,,Donor 84 ,,Sok2014(25422458) ,PGDM1400 lineage requires N160,Sok2014(25422458) ,IMGT/V-QUEST,1-8,,6,33.0,CVKGSKFRLREWADYNEWGLVSAQHGDYVTQLGIW,,,2-28,1,9.0,CMQGLQSPTTF,,,K,,Natural monoclonal,human,, ,6.3626,43.7463,98.0,177.0,3205.0,EVLLEQSGGEVKQPGASVKISCKASGFNFNNEDVHWVRQAAGQGLEWMAWSKHDDQNVLYAQEFKDRVTVTRDTAANTVYIQMTGLRFEDTALYYCVKGSKFRLREWADYNEWGLVSAQHGDYVTQLGIWGQGTAIYVSS,KIALTQSPLSLAVTPGEPASISCRSSQSLLYKNEHNDAYIEYTFLSWYLQRPGQSPQLLIYLGSKRASGVPGRFSGGGSGTDFTLKISRVEADDVGTYYCMQGLQSPTTFGQGTKLQIK,AAAATTGCGTTGACTCAGTCTCCACTCTCCCTGGCCGTCACCCCTGGAGAGCCGGCCTCCATTTCCTGCAGGTCAAGTCAGAGCCTCCTTTATAAGAATGAACACAATGATGCATATATCGAATATACCTTCTTGAGTTGGTATCTGCAGAGGCCAGGCCAGTCTCCACAACTCCTGATCTATTTGGGTTCTAAGCGGGCCTCCGGGGTCCCTGGCAGGTTCAGTGGCGGTGGATCAGGCACAGATTTCACACTGAAAATCAGCAGAGTGGAGGCTGACGATGTGGGCACATATTACTGCATGCAAGGTCTACAAAGTCCCACGACGTTCGGCCAAGGGACCAAGTTGCAGATCAAA,GAGGTGCTTCTGGAGCAGTCCGGGGGTGAAGTGAAGCAGCCTGGGGCCTCAGTGAAGATCTCCTGCAAAGCCTCTGGATTCAATTTTAACAATGAAGATGTGCACTGGGTGCGACAGGCCGCTGGACAAGGTCTGGAGTGGATGGCATGGTCGAAACATGACGATCAAAATGTTTTGTATGCACAAGAATTTAAGGACAGGGTCACCGTGACGAGGGACACCGCCGCAAATACAGTCTACATTCAGATGACCGGTCTGAGATTTGAAGACACGGCCCTCTATTATTGTGTTAAGGGCTCAAAGTTTAGGCTGAGGGAGTGGGCTGATTACAATGAATGGGGCCTAGTTTCGGCTCAACATGGAGACTACGTGACGCAGTTGGGCATCTGGGGCCAGGGGACCGCGATCTACGTCTCGTCA,,
PGDM1404,gp120 V2 // V2 glycan(V2g) // V2 apex,,Donor 84 ,,Sok2014(25422458) ,PGDM1400 lineage requires N160,Sok2014(25422458) ,IMGT/V-QUEST,1-8,,6,34.0,CVRGAKFRLRHDATYDYWNDLLWADDRDYVTQLDLW,,,2-28,1,9.0,CMQGRHIPLTF,,,K,,Natural monoclonal,human,, ,8.06011,47.5202,89.0,178.0,3206.0,QVFLEQSGGEVRRPGASVKVSCKATGFTFRNDDVHWVRQATGQGPECVAWMKHDDQSTVFPKKFQGRVIVTTDTSATTVYMEMGGLMPEDTAIYYCVRGAKFRLRHDATYDYWNDLLWADDRDYVTQLDLWGPGTAIIVSA,DVVLTQSPLSLSVSPGEPASISCRSSQSLLWSKDDTRYDFLGWYLQKPGQPPRLLIYLGSRRASGVPDRFSASGSGTDFTLRINRVEAADFGTYYCMQGRHIPLTFGQGTRVEIN,GATGTTGTGCTGACTCAATCTCCACTGTCCCTGTCCGTCAGTCCTGGAGAGCCGGCCTCTATCTCCTGCAGGTCCAGTCAGAGTCTCCTGTGGAGTAAGGATGACACAAGATATGACTTTTTGGGATGGTATTTGCAGAAGCCTGGGCAGCCTCCACGACTCCTCATCTATTTGGGTTCTCGTCGGGCCTCCGGGGTCCCTGACAGGTTCAGCGCCAGTGGATCAGGCACAGACTTCACACTGAGAATTAACAGAGTGGAGGCTGCCGATTTCGGAACTTATTACTGCATGCAAGGGCGACACATTCCCTTGACGTTCGGCCAAGGGACCAGGGTGGAAATCAAT,CAGGTGTTTTTGGAACAGTCTGGGGGTGAGGTGAGGAGGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCCACTGGATTCACCTTCCGTAATGATGATGTTCACTGGGTGCGACAGGCCACTGGCCAAGGGCCTGAGTGCGTGGCTTGGATGAAGCATGACGATCAAAGTACAGTCTTTCCAAAGAAGTTCCAGGGCAGAGTCATCGTGACAACGGACACCTCCGCAACAACAGTCTACATGGAGATGGGGGGCCTGATGCCTGAAGACACGGCCATTTATTACTGTGTAAGAGGCGCAAAATTTCGGTTGAGACATGACGCCACTTATGATTACTGGAACGACTTACTTTGGGCTGACGACCGTGACTACGTGACGCAGTTAGACCTTTGGGGCCCAGGGACCGCTATCATTGTCTCCGCA,,
PGDM1405,gp120 V2 // V2 glycan(V2g) // V2 apex,,Donor 84 ,,Sok2014(25422458) ,PGDM1400 lineage requires N160,Sok2014(25422458) ,IMGT/V-QUEST,1-8,,6,34.0,CVRGAKFRLRHDATYDYYNDLLWADDRDYVTQLDLW,,,2-28,1,9.0,CMQGRHIPLTF,,,K,,Natural monoclonal,human,, ,11.3345,50.3411,98.0,179.0,3207.0,QVFLEQSGGEIKRPGASVKVSCKATGFTFHHDDVHWVRQATGQGPECVAWMKHDDQSTVYPQKFQGRVTVTSDTSGTTVYMEMGGLMPEDTAIYYCVRGAKFRLRHDATYDYYNDLLWADDRDYVTQLDLWGQGTAIIVSA,DVVLTQSPLSLSVSPGEPASISCRSSQSLLWTKDHQSYNFLGWYLQKPGQPPRFLISLGSRRANGVPVRFSASGSGTDFTLKISRVQTDDVGIYYCMQGRHIPLTFGQGTKVEIN,GATGTTGTGCTGACTCAATCTCCACTCTCCCTGTCCGTTAGCCCTGGAGAGCCGGCCTCGATCTCCTGCAGGTCCAGTCAGAGTCTCCTGTGGACTAAAGACCATCAAAGTTATAACTTTCTGGGATGGTATTTGCAGAAGCCTGGGCAGCCTCCACGATTCCTAATTTCTTTGGGTTCTCGTCGGGCCAACGGGGTCCCTGTCAGGTTCAGCGCCAGTGGATCAGGCACAGATTTCACACTGAAAATTAGCAGAGTGCAGACTGACGATGTTGGAATTTACTACTGCATGCAAGGTCGACACATTCCCTTGACCTTCGGCCAAGGGACCAAGGTGGAAATCAAT,CAGGTGTTTTTGGAACAATCTGGGGGTGAAATAAAGAGGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCCACTGGATTCACCTTCCATCACGATGATGTTCACTGGGTGCGACAGGCCACTGGCCAAGGGCCTGAGTGCGTGGCTTGGATGAAACATGACGATCAAAGTACAGTCTATCCACAGAAGTTCCAGGGCAGAGTCACCGTGACAAGCGACACCTCCGGTACAACAGTCTATATGGAGATGGGGGGACTGATGCCTGAAGACACGGCCATTTATTACTGTGTCAGAGGCGCAAAGTTCAGGTTGAGACATGACGCAACATATGATTACTACAATGACTTGCTTTGGGCTGACGACCGTGACTACGTGACGCAGTTGGACCTTTGGGGCCAAGGGACCGCGATCATCGTCTCCGCA,CVRGAKFRLRHDATYDYYNDLLWADDRDYVTQLDLW,77.703
PGDM1406,gp120 V2 // V2 glycan(V2g) // V2 apex,,Donor 84 ,,Sok2014(25422458) ,PGDM1400 lineage requires N160,Sok2014(25422458) ,IMGT/V-QUEST,1-8,,1,33.0,CVKGQKFRLTEWADYNEFGLVAAQKGDYVTQLDVW,,,2-28,1,9.0,CMQGLRTPMTF,,,K,,Natural monoclonal,human,, ,53.9685,5.52324,89.0,180.0,3208.0,QVQVDQSGGEVKKPGASVRVSCKASGFSFKSEDMHWVRQAAGRGLEWMAWVKHDSDEILYSEKFKDRVIVTRNTASNTISMDMTGLTSEDTARYYCVKGQKFRLTEWADYNEFGLVAAQKGDYVTQLDVWGQGTDIIVSS,EIVLTQSPLSLGVSPGEAASISCRSNQDLLYKNDHNQVYKEYTFVSWYVQRPGQSPQLLIYLASQRAAGVPDRFSGGGSGTNFTLKINKVEADDVGIYYCMQGLRTPMTFGRGTKVDIR,GAAATCGTGCTGACTCAGTCTCCACTCTCCCTGGGCGTCTCCCCTGGAGAGGCGGCCTCCATCTCCTGCAGGTCTAATCAGGACCTCTTGTATAAGAATGACCACAATCAGGTTTATAAGGAATACACCTTTGTGAGTTGGTACGTGCAGAGGCCGGGCCAGTCTCCACAACTCCTGATCTATTTGGCTTCTCAGCGGGCCGCCGGGGTCCCTGACAGGTTCAGTGGCGGTGGATCAGGCACAAATTTCACTCTAAAGATCAACAAAGTGGAGGCTGACGATGTGGGCATTTACTACTGCATGCAAGGTCTGCGAACTCCCATGACGTTCGGCCGAGGGACCAAGGTGGACATCAGG,CAAGTCCAGGTGGACCAGTCCGGGGGTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCCTCGGGATTCTCTTTTAAGAGTGAAGATATGCACTGGGTGCGACAGGCCGCTGGACGAGGGCTGGAGTGGATGGCATGGGTAAAACATGACAGTGATGAAATATTATATTCAGAAAAGTTTAAGGACAGGGTCATCGTGACCAGGAACACCGCCTCAAACACAATCTCCATGGACATGACCGGTCTGACATCTGAAGACACGGCCCGATATTATTGTGTGAAAGGCCAAAAGTTCAGGCTGACAGAGTGGGCTGACTACAATGAATTCGGCCTAGTGGCGGCTCAAAAAGGAGACTACGTGACACAGCTGGACGTCTGGGGCCAGGGGACCGACATCATCGTCTCGTCA,CVKGQKFRLTEWADYNEFGLVAAQKGDYVTQLDVW,78.041
PGDM21,gp120 V3 // V3 glycan (V3g),EMD-8182(PGDM21 in complex with BG505 SOSIP.664 trimer),Donor 82 ,,Sok2016(27438765) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,4.44153,34.488,134.0,263.0,3506.0,EVQLVEWGARLVKPSETLSLTCGVSGGTLEAYFWTWLRQSPGRELEWLGEVRFFDYGGTTTNVNPSFKSRFSASLDASKGHISLRLTSVTAADTAVYYCARRTFWKSDYTGYYHFHMDVWSNGTSVTVSS,EIVLTQSPVSLSVSPGERATLSCKTSQSLDNKHVAWYQRKPGLAPRLLIYGVSDRATGIPDRFSGSGSGTNFSLTIGRVEPEDLAVYVCQQYSVSLITFGQGTRLDLK,GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTGTGTCGCCAGGGGAAAGAGCCACCCTCTCCTGCAAGACCAGCCAGAGTCTCGACAACAAACACGTAGCCTGGTATCAGCGAAAACCTGGCCTGGCGCCCAGACTCCTCATCTATGGTGTGTCCGACAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAAACTTTTCCCTCACCATCGGTAGAGTGGAGCCTGAAGATCTTGCGGTCTATGTCTGTCAGCAGTACAGTGTCTCTCTTATCACCTTCGGCCAAGGGACACGACTCGACCTGAAA,GAGGTGCAGCTGGTGGAGTGGGGCGCACGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGGTGTCTCTGGCGGGACTCTCGAAGCTTACTTCTGGACGTGGCTCCGCCAGTCACCGGGCAGGGAACTTGAGTGGTTAGGCGAGGTCAGATTTTTTGACTATGGCGGCACCACAACCAATGTCAACCCGTCCTTCAAGAGCCGTTTCAGCGCATCCTTGGACGCGTCCAAGGGCCACATCTCTCTCAGGCTGACGTCTGTGACCGCCGCGGACACGGCTGTCTATTATTGTGCGCGACGCACCTTTTGGAAAAGTGACTACACAGGCTATTATCACTTTCACATGGACGTCTGGAGCAACGGGACCTCGGTCACCGTCTCCTCA,,
PGT121,gp120 V3 // V3 glycan (V3g),4FQ1(PGT121 Fab);4FQC(PGT121 Fab bound to a complex-type sialylated N-glycan);4FQQ(germline antibody PGT121-GL Fab);4JY4(Fab PGT121);5CEZ(BG505 SOSIP gp140 HIV-1 Env trimer in Complex with an early putative precursor of the PGT121 family),Donor 17 ,PGT121,Walker2011(21849977) ,"Disulfide bond introduced in V1V2 affects binding;hypervariable loop characteristic correlations with bNAb sensitivity;Key sites for PGT121-like and 10-1074-like mAbs;Mutation affects neutralization of V3 mAbs;Mutation greatly reduces PGT121 neutralization;mutations affecting neutralization by PGT121;mutations affecting PGT121 binding;mutations affecting PGT121 binding;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 contacts;PGT121 contacts;PGT121 family and N137 glycan;PGT121 resistance;PGT121 signature predictions;V3 Signature Summary",Sok2013(24278016) ,IMGT/V-QUEST,4-59,,6*03,26.0,CARTLHGRRIYGIVAFNEWFTYFYMDVW,18.0,23.0,3-21,3*02,15.0,DYYCHIWDSRVPTKWVF,22.0,28.0,L,Yes,Natural monoclonal,human,PGT-121, ,0.65256,52.7237,7503.0,18.0,2635.0,QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSS,SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVL,TCCGATATATCTGTGGCCCCAGGAGAGACGGCCAGGATTTCCTGTGGGGAAAAGAGCCTTGGAAGTAGAGCTGTACAATGGTATCAACACAGGGCCGGCCAGGCCCCCTCTTTAATCATATATAATAATCAGGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCCCTGACTCCCCTTTTGGGACCACGGCCACCCTGACCATCACCAGTGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCATATATGGGATAGTAGAGTTCCCACCAAATGGGTCTTCGGCGGAGGGACCACGCTGACCGTGTTA,CAGATGCAGTTACAGGAGTCGGGCCCCGGACTGGTGAAGCCTTCGGAAACCCTGTCCCTCACGTGCAGTGTGTCTGGTGCCTCCATAAGTGACAGTTACTGGAGCTGGATCCGGCGGTCCCCAGGGAAGGGACTTGAGTGGATTGGGTATGTCCACAAAAGCGGCGACACAAATTACAGCCCCTCCCTCAAGAGTCGAGTCAACTTGTCGTTAGACACGTCCAAAAATCAGGTGTCCCTGAGCCTTGTGGCCGCGACCGCTGCGGACTCGGGCAAATATTATTGCGCGAGAACACTGCACGGGAGGAGAATTTATGGAATCGTTGCCTTCAATGAGTGGTTCACCTACTTCTACATGGACGTCTGGGGCAATGGGACTCAGGTCACCGTCTCCTCA,CARTLHGRRIYGIVAFNEWFTYFYMDVW,80.756
nan,,,,,,,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-59*01,,6*03,24.0,TLHGRRIYGIVAFNEWFTYFYMDV,17.0,21.0,3-21*02,3*02,12.0,HIWDSRVPTKWV,18.0,30.0,,,,,,,,,,,,,,,,,
PGT121.414.LS,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,1.16397,66.6423,416.0,554.0,4165.0,,,,,,
PGT121GM,gp120 V3 // V3 glycan (V3g),,Donor 17 ,PGT121,Mouquet2012a(23115339) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,41.818,6.17672,26.0,363.0,3898.0,,,,,,
PGT122,gp120 V3 // V3 glycan (V3g),"4JY5(Fab PGT122);4NCO(BG505 in complex with Fab PGT122);4TVP(Env Trimer Ectodomain in Complex with Antibodies PGT122 and 35O22);5D9Q(BG505 SOSIP gp140 HIV-1 Env trimer in Complex with the Broadly Neutralizing Fab PGT122 and scFv NIH45-46);5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5FYL(Clade A BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 and 35O22);5I8H(BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 Fab and VRC34.01 Fab);5U7M(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-378806 in Complex with Human Antibodies PGT122 and 35O22);5U7O(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-626529 in Complex with Human Antibodies PGT122 and 35O22);5UTF(BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, Y177W, N300M, N302M, T320L, I420M in Complex with Human Antibodies PGT122 and 35O22);5UTY(DS-SOSIP.mut4 BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, N300M, N302M, T320L in Complex with Human Antibodies PGT122 and 35O22);6B0N(clade A BG505 isolate in complex with Fabs PGT122 and PGV19);6CUE(vFP7.04 in complex with BG505 DS-SOSIP, and antibodies VRC03 and PGT122)",Donor 17 ,PGT121,Walker2011(21849977) ,"mutations affecting PGT122 binding;mutations affecting PGT122 binding;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 family and N137 glycan;PGT122 glycan contacts;PGT122 neutralization",Sok2013(24278016) ,IMGT/V-QUEST,4-59,,6*03,26.0,CATTKHGRRIYGVVAFKEWFTYFYMDVW,19.0,25.0,3-21,3*02,15.0,DYYCHIWDSRRPTNWVF,18.0,26.0,L,,Natural monoclonal,human,PGT-122, ,1.2886,45.8654,164.0,25.0,2636.0,QVHLQESGPGLVKPSETLSLTCNVSGTLVRDNYWSWIRQPLGKQPEWIGYVHDSGDTNYNPSLKSRVHLSLDKSKNLVSLRLTGVTAADSAIYYCATTKHGRRIYGVVAFKEWFTYFYMDVWGKGTSVTVSS,TFVSVAPGQTARITCGEESLGSRSVIWYQQRPGQAPSLIIYNNNDRPSGIPDRFSGSPGSTFGTTATLTITSVEAGDEADYYCHIWDSRRPTNWVFGEGTTLIVL,ACCTTTGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTACTTGTGGGGAAGAGAGCCTTGGAAGTAGATCTGTTATTTGGTATCAACAGAGGCCAGGCCAGGCCCCTTCATTAATCATCTATAATAATAATGACCGGCCCTCAGGGATTCCTGACCGATTTTCTGGGTCCCCTGGCTCCACTTTTGGGACCACGGCCACCCTGACCATCACCAGTGTCGAAGCCGGGGATGAGGCCGACTATTATTGTCATATCTGGGATAGTAGACGACCAACCAATTGGGTCTTCGGCGAAGGGACCACACTGATCGTGTTA,CAGGTTCATCTGCAGGAGTCGGGCCCCGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACGTGCAATGTGTCTGGGACCCTCGTGCGTGATAACTACTGGAGCTGGATCAGACAACCCCTCGGGAAGCAACCTGAGTGGATTGGCTATGTCCATGACAGCGGGGACACGAATTACAACCCCTCCCTGAAGAGTCGAGTCCACTTATCGTTGGACAAGTCCAAAAACCTGGTGTCCCTGAGGCTGACCGGCGTGACCGCCGCGGACTCGGCCATATATTATTGCGCGACAACAAAACACGGGAGGAGGATTTATGGCGTCGTTGCCTTCAAAGAGTGGTTCACCTATTTCTACATGGACGTCTGGGGCAAAGGGACTTCGGTCACCGTCTCCTCA,CATTKHGRRIYGVVAFKEWFTYFYMDVW,80.277
nan,,,,,,,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-59*01,,6*03,24.0,TKHGRRIYGVVAFKEWFTYFYMDV,18.0,24.0,3-21*02,3*02,12.0,HIWDSRRPTNWV,19.0,26.0,,,,,,,,,,,,,,,,,
PGT123,gp120 V3 // V3 glycan (V3g),4JY6(Fab PGT123),Donor 17 ,PGT121,Walker2011(21849977) ,"Mutation greatly reduces PGT123 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 family and N137 glycan;V3 Signature Analysis Summary",Sok2013(24278016) ,IMGT/V-QUEST,4-59,,6*03,26.0,CARALHGKRIYGIVALGELFTYFYMDVW,20.0,27.0,3-21,3*02,15.0,DYYCHIYDARGGTNWVF,22.0,34.0,L,,Natural monoclonal,human,PGT-123, ,0.99835,65.0371,455.0,26.0,2637.0,QLHLQESGPGLVKPPETLSLTCSVSGASINDAYWSWIRQSPGKRPEWVGYVHHSGDTNYNPSLKRRVTFSLDTAKNEVSLKLVDLTAADSATYFCARALHGKRIYGIVALGELFTYFYMDVWGKGTAVTVSS,SSMSVSPGETAKISCGKESIGSRAVQWYQQKPGQPPSLIIYNNQDRPAGVPERFSASPDFRPGTTATLTITNVDAEDEADYYCHIYDARGGTNWVFDRGTTLTVL,TCCTCTATGTCCGTGTCCCCGGGGGAGACGGCCAAGATCTCCTGTGGAAAAGAGAGCATTGGTAGCAGAGCTGTGCAATGGTATCAGCAGAAGCCAGGCCAGCCCCCCTCATTGATTATCTATAATAATCAGGACCGCCCCGCAGGGGTCCCTGAGCGATTCTCTGCCTCCCCTGACTTCCGTCCTGGGACCACGGCCACCCTGACCATCACCAATGTCGACGCCGAGGATGAGGCCGACTATTACTGTCATATATATGATGCTAGAGGTGGCACCAATTGGGTCTTCGACAGAGGGACCACACTGACCGTCTTA,CAGCTGCACCTGCAGGAGTCGGGCCCAGGGCTGGTGAAGCCTCCGGAGACCCTGTCCCTCACGTGTAGTGTGTCTGGCGCCTCCATCAATGATGCCTATTGGAGTTGGATTCGGCAGTCCCCAGGGAAGCGGCCTGAGTGGGTTGGATATGTCCATCACAGCGGTGACACAAATTATAATCCCTCACTCAAGAGGCGCGTCACGTTTTCATTAGACACGGCCAAGAATGAAGTGTCCCTGAAATTAGTAGACCTGACCGCTGCGGACTCGGCCACATATTTTTGTGCGCGAGCACTTCACGGGAAGAGGATTTATGGGATAGTTGCCCTCGGAGAGTTGTTCACCTACTTCTACATGGACGTCTGGGGCAAGGGGACTGCGGTCACCGTCTCCTCA,CARALHGKRIYGIVALGELFTYFYMDVW,77.397
nan,,,,,,,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-59*01,,6*03,24.0,ALHGKRIYGIVALGELFTYFYMDV,21.0,27.0,3-21*02,3*02,12.0,HIYDARGGTNWV,24.0,38.0,,,,,,,,,,,,,,,,,
PGT124,gp120 V3 // V3 glycan (V3g),4R2G(PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4);5T3S(trimer MD39-10MUTA in complex with Fabs PGT124 and 35022);5UM8(trimer 16055 NFL TD CC (T569G) in complex with Fabs 35022 and PGT124),Donor 17 ,PGT121,Walker2011(21849977) ,PGT121 family and N137 glycan,Sok2013(24278016) ,IMGT/V-QUEST,4-59,,6*03,26.0,CATARRGWRIYGVVSFGEFFYYYYMDVW,15.0,21.0,3-21,3*02,15.0,DYYCHMWDSRSGFSWSF,19.0,35.0,L,,Natural monoclonal,human,PGT-124, ,0.14027,19.4097,86.0,149.0,3115.0,QVQLQESGPGLVRPSETLSVTCIVSGGSISNYYWTWIRQSPGKGLEWIGYISDRETTTYNPSLNSRAVISRDTSKNQLSLQLRSVTTADTAIYFCATARRGQRIYGVVSFGEFFYYYYMDVWGKGTAVTVSS,SYVSPLSVALGETARISCGRQALGSRAVQWYQHKPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTTATLTISGVEVGDEADYYCHMWDSRSGFSWSFGGATRLTVL,TCCTATGTGAGCCCACTGTCAGTGGCCCTGGGGGAGACGGCCAGGATTTCCTGTGGACGACAGGCCCTTGGAAGTAGAGCTGTGCAGTGGTATCAACATAAGCCAGGCCAGGCCCCTATTTTGCTCATCTATAATAATCAAGACCGGCCCTCAGGGATCCCTGAGCGGTTCTCTGGCACCCCTGATATTAATTTTGGGACCACGGCCACCCTGACTATCAGCGGGGTCGAAGTCGGGGATGAAGCCGACTATTACTGTCACATGTGGGACTCTAGAAGTGGTTTCAGTTGGTCTTTCGGCGGGGCGACCAGGCTGACCGTCCTA,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAGACCTTCGGAGACCCTGTCCGTCACCTGCATCGTCTCTGGGGGCTCCATCAGCAATTACTACTGGACTTGGATCCGACAGTCCCCAGGAAAGGGACTGGAGTGGATAGGCTATATTTCTGACAGAGAAACAACGACTTACAATCCCTCCCTCAACAGTCGAGCCGTCATATCACGAGACACGTCGAAAAACCAATTGTCCCTACAATTACGTTCCGTCACCACTGCGGACACGGCCATCTATTTCTGTGCGACAGCGCGCCGAGGACAGAGGATTTATGGAGTGGTTTCATTTGGAGAGTTCTTCTACTACTACTACATGGACGTCTGGGGCAAAGGGACTGCGGTCACCGTCTCCTCA,CATARRGQRIYGVVSFGEFFYYYYMDVW,82.534
PGT125,gp120 V3 // V3 glycan (V3g),,Donor 36 ,PGT128,Walker2011(21849977) ,"Mutation greatly reduces PGT125 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT125 signature sites;V3 Signature Analysis Summary",Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-39*07,,5*02,19.0,FDGEVLVYNHWPKPAWVDL,20.0,27.0,2-8*01,2*01 or 3*01,10.0,GSLVGNWDV,15.0,22.0,L,,Natural monoclonal,human,PGT-125, ,3.1199,60.4455,421.0,27.0,2639.0,QSQLQESGPRLVEASETLSLTCNVSGESTGACTYFWGWVRQAPGKGLEWIGSLSHCQSFWGSGWTFHNPSLKSRLTISLDTPKNQVFLKLTSLTAADTATYYCARFDGEVLVYNHWPKPAWVDLWGRGIPVTVTVSS,QSALTQPPSASGSPGQSITISCNGTATNFVSWYQQFPDKAPKLIIFGVDKRPPGVPDRFSGSRSGTTASLTVSRLQTDDEAVYYCGSLVGNWDVIFGGGTTLTVL,CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAATCACCATCTCCTGCAATGGAACCGCCACTAACTTTGTCTCCTGGTACCAACAATTCCCAGACAAGGCCCCCAAACTCATCATTTTTGGGGTCGATAAGCGCCCCCCCGGTGTCCCCGATCGTTTCTCTGGCTCCCGGTCTGGCACGACGGCCTCCCTTACCGTCTCCCGACTCCAGACTGACGATGAGGCTGTCTATTATTGCGGTTCACTTGTCGGCAACTGGGATGTGATTTTCGGCGGAGGGACCACCTTGACCGTCCTA,CAGTCGCAGCTGCAGGAGTCGGGCCCACGACTGGTGGAGGCCTCGGAGACCCTGTCACTCACGTGCAATGTGTCCGGCGAGTCCACTGGTGCCTGTACTTATTTCTGGGGCTGGGTCCGGCAGGCCCCAGGGAAGGGGCTGGAGTGGATCGGGAGTTTGTCCCATTGTCAGAGTTTCTGGGGTTCCGGTTGGACCTTCCACAACCCGTCTCTCAAGAGTCGACTCACGATTTCACTCGACACGCCCAAGAATCAGGTCTTCCTCAAGCTCACTTCTCTGACTGCCGCGGACACGGCCACTTACTACTGTGCGCGATTCGACGGCGAAGTCTTGGTCTATAATCATTGGCCAAAGCCGGCCTGGGTGGACCTCTGGGGCCGCGGAATACCGGTCACCGTCACCGTCTCCTCA,,
PGT126,gp120 V3 // V3 glycan (V3g),,Donor 36 ,PGT128,Walker2011(21849977) ,"Mutation greatly reduces PGT126 and PGT127 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;V3 Signature Analysis Summary",Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-39*07,,5*02,19.0,FDGEVLVYHDWPKPAWVDL,17.0,23.0,2-8*01,2*01 or 3*01,10.0,SSLVGNWDVI,9.0,13.0,L,Yes,Natural monoclonal,human,PGT-126, ,0.95081,46.7839,604.0,28.0,2640.0,QPQLQESGPGLVEASETLSLTCTVSGDSTAACDYFWGWVRQPPGKGLEWIGGLSHCAGYYNTGWTYHNPSLKSRLTISLDTPKNQVFLKLNSVTAADTAIYYCARFDGEVLVYHDWPKPAWVDLWGRGTLVTVTVSS,QSALTQPPSASGSPGQSISISCTGTSNRFVSWYQQHPGKAPKLVIYGVNKRPSGVPDRFSGSKSGNTASLTVSGLQTDDEAVYYCSSLVGNWDVIFGGGTKLTVL,CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAATCTCCATCTCCTGCACTGGAACCAGCAATAGGTTTGTCTCCTGGTACCAGCAACACCCAGGCAAGGCCCCCAAACTCGTCATTTATGGGGTCAATAAGCGCCCCTCAGGTGTCCCTGATCGTTTTTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCGTCTCTGGGCTCCAGACTGACGATGAGGCTGTCTATTACTGCAGCTCACTTGTAGGCAACTGGGATGTGATTTTCGGCGGAGGGACCAAGTTGACCGTCCTG,CAGCCGCAGCTGCAGGAGTCGGGGCCAGGACTGGTGGAGGCTTCGGAGACCCTGTCCCTCACCTGCACTGTGTCCGGCGACTCCACTGCTGCTTGTGACTATTTCTGGGGCTGGGTCCGGCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGGGGGTTTGTCACATTGTGCAGGTTACTACAATACTGGCTGGACCTACCACAACCCGTCTCTCAAGAGTCGGCTCACGATTTCACTCGACACCCCCAAGAATCAGGTCTTCCTGAAGTTAAATTCTGTGACCGCCGCGGACACGGCCATTTACTACTGTGCGCGATTCGACGGCGAAGTTTTGGTGTACCACGATTGGCCAAAGCCGGCCTGGGTCGACCTCTGGGGCCGGGGAACTTTGGTCACCGTCACCGTCTCCTCA,CARFDGEVLVYHDWPKPAWVDLW,77.460
PGT127,gp120 V3 // V3 glycan (V3g),3TWC(PGT127 complexed with Man(9)),Donor 36 ,PGT128,Walker2011(21849977) ,"Mutation greatly reduces PGT126 and PGT127 neutralization;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT127, PGT128 contacts;V3 Signature Analysis Summary",Zhang2013(24100711) ,IMGT/V-QUEST,4-61*05,3-16*02,5*02,25.0,,,,2-8,3 or 2,10.0,,,,L,,Natural monoclonal,human,PGT-127, ,4.87851,37.5113,420.0,24.0,2641.0,QPQLQESGPGLVEASETLSLTCTVSGDSTGRCNYFWGWVRQPPGKGLEWIGSLSHCRSYYNTDWTYHNPSLKSRLTISLDTPKNQVFLRLTSVTAADTATYYCARFGGEVLVYRDWPKPAWVDLWGRGTLVTVSS,QSALTQPPSASGSPGQSITISCTGTSNNFVSWYQQYPGKAPKLVIYEVNKRPSGVPDRFSGSKSGSTASLTVSGLQADDEGVYYCSSLVGNWDVIFGGGTKLTVL,CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAATCACCATCTCCTGCACTGGAACCAGCAATAACTTTGTCTCCTGGTACCAACAATACCCAGGCAAGGCCCCCAAACTCGTCATTTATGAGGTCAATAAGCGCCCCTCAGGTGTCCCTGATCGTTTCTCTGGCTCCAAGTCTGGCAGCACGGCCTCCCTGACCGTCTCTGGACTCCAGGCTGACGATGAGGGTGTCTATTATTGTAGTTCACTTGTAGGCAACTGGGATGTGATTTTCGGCGGAGGGACCAAGTTGACCGTCCTA,CAGCCGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGGAGGCTTCGGAGACCCTGTCCCTCACGTGCACTGTGTCCGGCGACTCCACTGGTCGTTGTAATTATTTCTGGGGCTGGGTCCGGCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTTTGTCCCACTGTAGAAGTTACTACAATACTGACTGGACCTACCACAACCCGTCTCTCAAGAGTCGACTCACTATTTCACTCGACACGCCCAAGAATCAGGTCTTCCTGAGATTGACCTCTGTGACCGCCGCGGACACGGCCACTTATTACTGTGCGCGATTCGGCGGCGAAGTTCTAGTGTACAGAGATTGGCCAAAGCCGGCCTGGGTCGACCTCTGGGGCCGGGGAACGCTGGTCACCGTCTCGAGC,CARFGGEVLVYRDWPKPAWVDLW,79.683
nan,,,,,,,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-39*07,,5*02,19.0,FGGEVLVYRDWPKPAWVDL,15.0,23.0,2-8*01,2*01 or 3*01,10.0,SSLVGNWDV,9.0,12.0,,,,,,,,,,,,,,,,,
PGT128,gp120 V3 // V3 glycan (V3g),3TV3(PGT128 complexed with Man(9));3TYG(PGT128 complexed with glycosylated gp120);5ACO(PGT128 Fab in complex with BG505 SOSIP.664 Env trimer);5C7K(BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195);5JS9(gp140 trimer with an engineered 8-residue HR1 turn bound to 8ANC195 and PGT128);5JSA(gp140 trimer with an engineered 10-residue HR1 turn bound to 8ANC195 and PGT128);6B3D(PGT128 in complex with a bacterially derived synthetic mimetic of Man9);6OPA(bovine Fab NC-Cow1 in complex with BG505 SOSIP.664 and human Fabs 35022 and PGT128),Donor 36 ,PGT128,Walker2011(21849977) ,"hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects neutralization of V3 mAbs;Mutation greatly reduces PGT128 neutralization;mutations affecting PGT128 binding;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT127, PGT128 contacts;PGT128 contacts;PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO);V3 Signature Analysis Summary",Klein2013(23540694) ,IgBlast,4-39,4-11 or 5-24 or 1-26,5,,,,,2-8,2 or 3,,,,,L,,Natural monoclonal,human,PGT-128, ,0.84897,59.7007,3964.0,23.0,2642.0,QPQLQESGPTLVEASETLSLTCAVSGDSTAACNSFWGWVRQPPGKGLEWVGSLSHCASYWNRGWTYHNPSLKSRLTLALDTPKNLVFLKLNSVTAADTATYYCARFGGEVLRYTDWPKPAWVDLWGRGTLVTVSS,QSALTQPPSASGSPGQSITISCTGTSNNFVSWYQQHAGKAPKLVIYDVNKRPSGVPDRFSGSKSGNTASLTVSGLQTDDEAVYYCGSLVGNWDVIFGGGTKLTVL,CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAATCACCATCTCCTGCACTGGAACCAGCAATAACTTTGTCTCCTGGTACCAGCAACACGCAGGCAAGGCCCCCAAGCTCGTCATTTATGACGTCAATAAGCGCCCCTCAGGTGTCCCTGATCGTTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCGTCTCTGGACTCCAGACTGACGATGAGGCTGTCTATTACTGCGGCTCACTTGTAGGCAACTGGGATGTGATTTTCGGCGGAGGGACCAAGTTGACCGTCCTA,CAGCCGCAGCTGCAGGAGTCGGGCCCAACACTGGTGGAGGCTTCGGAGACTCTGTCCCTCACCTGCGCTGTGTCCGGCGACTCCACTGCTGCATGTAATTCTTTCTGGGGCTGGGTCCGGCAGCCCCCAGGGAAGGGGCTGGAGTGGGTTGGGAGTTTGTCCCATTGTGCAAGCTATTGGAATCGTGGGTGGACCTACCACAACCCGTCTCTCAAGAGTCGGCTCACGCTTGCTCTCGACACACCCAAGAATCTGGTCTTCCTCAAATTAAATTCTGTGACTGCCGCGGACACGGCCACTTACTACTGTGCGCGATTCGGCGGCGAAGTTTTACGCTACACGGATTGGCCAAAGCCGGCCTGGGTCGACCTCTGGGGCCGGGGAACGCTGGTCACCGTCTCGAGC,CARFGGEVLRYTDWPKPAWVDLW,76.582
nan,,,,,,,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-39*07,,5*02,19.0,FGGEVLRYTDWPKPAWVDL,19.0,28.0,2-8*01,2*01 or 3*01,10.0,GSLVGNWDVI,9.0,14.0,,,,,,,,,,,,,,,,,
PGT128-IgG3C-,gp120 V3 // V3 glycan (V3g),,Donor 36 ,PGT128,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,IgG3C hinge variant ,0.84187,53.0508,232.0,271.0,3541.0,,,,,,
PGT130,gp120 V3 // V3 glycan (V3g),,Donor 36 ,PGT128,Walker2011(21849977) ,"Mutation greatly reduces PGT130 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;V3 Signature Analysis Summary",Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-39*07,,5*02,19.0,SGGDILYYYEWQKPHWFSP,22.0,34.0,2-8*01,2*01 or 3*01,10.0,SSLFGRWDVV,12.0,19.0,L,,Natural monoclonal,human,PGT-130, ,3.20269,36.1893,601.0,29.0,2643.0,QVQLQESGPGLVKPAETLSLTCSVSGESINTGHYYWGWVRQVPGKGLEWIGHIHYTTAVLHNPSLKSRLTIKIYTLRNQITLRLSNVTAADTAVYHCVRSGGDILYYYEWQKPHWFSPWGPGIHVTVSS,QSALTQPPSASGSLGQSVTISCNGTSSDIGGWNFVSWYQQFPGRAPRLIIFEVNKRPSGVPGRFSGSKSGNSASLTVSGLQSDDEGQYFCSSLFGRWDVVFGGGTKLTVL,CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCTTGGACAGTCAGTCACCATCTCCTGCAATGGAACCAGCAGTGACATTGGCGGTTGGAATTTTGTCTCCTGGTATCAACAGTTCCCGGGCAGAGCCCCCAGACTCATTATTTTTGAGGTCAATAAGCGGCCCTCAGGGGTCCCTGGTCGCTTCTCTGGCTCCAAGTCGGGCAATTCGGCCTCCCTGACCGTCTCTGGGCTCCAGTCTGACGATGAGGGTCAATATTTCTGCAGTTCACTTTTCGGCAGGTGGGATGTTGTTTTTGGCGGGGGGACCAAGCTGACCGTCCTA,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTGCGGAGACCCTGTCCCTCACCTGCAGTGTCTCTGGAGAATCTATCAATACTGGTCATTACTACTGGGGCTGGGTCCGTCAGGTCCCAGGGAAGGGACTTGAGTGGATAGGTCATATCCATTATACGACGGCTGTCCTGCACAACCCGTCCCTCAAGAGTCGACTCACCATCAAAATTTACACGTTGAGAAACCAGATTACCCTGAGGCTCAGTAATGTGACGGCCGCGGACACGGCCGTCTATCACTGCGTACGATCCGGCGGCGACATCTTATATTATTATGAGTGGCAAAAGCCGCACTGGTTCTCTCCCTGGGGCCCGGGAATCCACGTCACCGTCTCGAGC,CVRSGGDILYYYEWQKPHWFSPW,81.100
PGT131,gp120 V3 // V3 glycan (V3g),,Donor 36 ,PGT128,Walker2011(21849977) ,"PGT121-123, 125-128, 130, 131 sites important for neutralization",Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-39*07,,5*02,19.0,SGGDILYYIEWQKPHWFYP,23.0,33.0,2-8*01,2*01 or 3*01,10.0,SSLSGRWDIV,13.0,23.0,L,,Natural monoclonal,human,PGT-131, ,11.0186,21.2576,162.0,30.0,2644.0,QVQLQESGPGLVKPSETLSLTCTVSGDSINTGHHYWGWVRQVPGKGPEWIAHIHYNTAVLHNPALKSRVTISIFTLKNLITLSLSNVTAADTAVYFCVRSGGDILYYIEWQKPHWFYPWGPGILVTVSS,QSALTQPPSASGSLGQSLTISCSGTGSDIGSWNFVSWYQQFPGRAPNLIIFEVNRRRSGVPDRFSGSKSGNTASLTVSGLRSEDEAEYFCSSLSGRWDIVFGGGTKVTVL,CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCTTGGACAGTCACTCACCATCTCCTGCAGTGGAACCGGCAGTGACATTGGCAGTTGGAATTTTGTCTCCTGGTATCAACAATTCCCAGGCAGAGCCCCCAACCTCATTATTTTTGAGGTCAATAGGCGGCGATCAGGGGTCCCTGATCGCTTCTCTGGTTCCAAGTCGGGCAATACGGCCTCCCTGACCGTCTCTGGGCTCCGGTCTGAGGATGAGGCTGAATATTTTTGCAGTTCCCTTTCAGGCAGGTGGGACATTGTTTTTGGCGGAGGGACCAAGGTGACCGTCCTA,CAGGTGCAACTACAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTTTCCCTCACCTGCACTGTCTCTGGTGACTCCATCAACACTGGTCATCACTACTGGGGCTGGGTCCGTCAGGTCCCAGGGAAGGGACCGGAATGGATTGCTCACATCCACTATAATACGGCTGTCTTACACAATCCGGCCCTCAAGAGTCGAGTCACCATTTCGATTTTCACCCTGAAGAATCTGATTACCCTGAGCCTCAGTAATGTGACCGCCGCGGACACGGCCGTCTATTTCTGCGTTCGATCCGGCGGCGACATTTTATACTATATTGAGTGGCAAAAACCCCACTGGTTCTATCCCTGGGGCCCGGGAATTTTGGTCACCGTCTCGAGC,CVRSGGDILYYIEWQKPHWFYPW,78.966
PGT135,gp120 V3 // V3 glycan (V3g),4JM2(PGT 135 Fab in complex with gp120 core (JR-FL) bound to CD4 and 17b Fab);4JM4(Fab PGT135),Donor 39 ,PGT135,Walker2011(21849977) ,Mutation greatly reduces PGT135 neutralization;Mutations at the trimer apex that affect sensitivity;PGT135 contacts and sites;V3 Signature Analysis Summary,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-39*07,,5*02,18.0,HRHHDVFMLVPIAGWFDV,17.0,29.0,3-15*01,1*01,9.0,QQYEEWPRT,16.0,28.0,K,,Natural monoclonal,human,PGT-135, ,14.8308,19.4218,1285.0,31.0,2645.0,QLQMQESGPGLVKPSETLSLSCTVSGDSIRGGEWGDKDYHWGWVRHSAGKGLEWIGSIHWRGTTHYKESLRRRVSMSIDTSRNWFSLRLASVTAADTAVYFCARHRHHDVFMLVPIAGWFDVWGPGVQVTVSS,EIVMTQSPDTLSVSPGETVTLSCRASQNINKNLAWYQYKPGQSPRLVIFETYSKIAAFPARFVASGSGTEFTLTINNMQSEDVAVYYCQQYEEWPRTFGQGTKVDIK,GAAATTGTGATGACGCAGTCTCCCGACACCCTGTCTGTCTCTCCAGGGGAGACAGTCACACTCTCCTGCAGGGCCAGTCAGAATATTAACAAGAATTTAGCCTGGTACCAATACAAACCTGGCCAGTCTCCCAGGCTCGTAATTTTTGAAACATATAGCAAGATCGCTGCTTTCCCTGCCAGGTTCGTTGCCAGTGGTTCTGGGACAGAGTTCACTCTCACCATCAACAACATGCAGTCTGAAGATGTTGCAGTTTATTACTGTCAACAATATGAAGAGTGGCCTCGGACGTTCGGGCAAGGGACCAAGGTGGATATCAAA,CAGTTGCAGATGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCTCTGAGTTGCACTGTCTCTGGTGACTCCATAAGGGGTGGCGAGTGGGGCGATAAAGATTATCATTGGGGCTGGGTCCGCCACTCAGCAGGAAAGGGCCTGGAGTGGATTGGGAGTATCCATTGGAGGGGGACCACCCACTACAAAGAGTCCCTCAGGAGAAGAGTGAGTATGTCGATCGACACGTCCAGGAATTGGTTCTCCCTGAGGCTGGCCTCTGTGACCGCCGCGGACACGGCCGTCTACTTTTGTGCGAGACACCGACATCATGATGTTTTCATGTTGGTCCCTATTGCGGGCTGGTTCGACGTCTGGGGCCCGGGAGTCCAGGTCACCGTCTCGAGC,CARHRHHDVFMLVPIAGWFDVW,78.846
PGT135-IgG3C-,gp120 V3 // V3 glycan (V3g),,Donor 39 ,PGT135,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,IgG3C hinge variant ,19.8045,16.7842,238.0,277.0,3543.0,,,,,,
PGT136,gp120 V3 // V3 glycan (V3g),,Donor 39 ,PGT135,Walker2011(21849977) ,,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-39*07,,5*02,18.0,HKYHDIFRVVPVAGWFDP,15.0,25.0,3-15*01,1*01,9.0,QQYEEWPRT,12.0,21.0,K,,Natural monoclonal,human,PGT-136, ,54.5814,5.82733,164.0,32.0,2646.0,QLQLQESGPGLVKPSETLSLTCTVSGGSMRGTDWGENDFHYGWIRQSSAKGLEWIGSIHWRGRTTHYKTSFRSRATLSIDTSNNRFSLTFSFVTAADTAVYYCARHKYHDIFRVVPVAGWFDPWGQGLLVTVSS,EIVMTQSPPTLSVSPGETATLSCRASQNVKNNLAWYQLKPGQAPRLLIFDASSRAGGIPDRFSGSGYGTDFTLTVNSVQSEDFGDYFCQQYEEWPRTFGQGTKVDIK,GAAATAGTGATGACGCAGTCTCCACCCACCCTGTCTGTGTCTCCAGGGGAAACAGCCACACTCTCCTGTAGGGCCAGTCAGAATGTTAAGAATAATTTAGCCTGGTACCAGCTGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGATGCGTCCAGCAGGGCCGGTGGTATTCCTGACAGGTTCAGTGGCAGCGGTTATGGGACAGACTTCACTCTCACCGTCAACAGTGTGCAGTCCGAAGATTTTGGAGATTATTTTTGTCAGCAATATGAAGAGTGGCCTCGGACGTTCGGCCAAGGGACCAAGGTGGATATCAAA,CAGCTGCAGTTGCAGGAATCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTGACTTGCACAGTTTCTGGTGGCTCCATGAGGGGCACCGACTGGGGCGAGAATGACTTCCACTACGGCTGGATCCGCCAGTCCTCCGCAAAGGGGCTGGAGTGGATTGGGAGCATCCATTGGAGGGGGAGGACCACCCACTACAAGACGTCCTTCAGGAGTCGGGCCACCTTGTCGATAGACACGTCCAATAATCGCTTCTCCCTGACGTTTAGTTTTGTGACCGCCGCGGACACGGCCGTCTACTATTGTGCGAGACATAAATATCATGATATTTTCAGGGTGGTCCCTGTTGCGGGCTGGTTCGACCCCTGGGGCCAGGGATTACTGGTCACCGTCTCGAGC,CARHKYHDIFRVVPVAGWFDPW,78.730
PGT137,gp120 V3 // V3 glycan (V3g),,Donor 39 ,PGT135,Walker2011(21849977) ,,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,4-39*07,,5*02,18.0,HKYHDIVMVVPIAGWFDP,20.0,29.0,3-15*01,1*01,9.0,QQYEEWPRT,11.0,18.0,K,,Natural monoclonal,human,PGT-137, ,40.3483,8.18728,162.0,33.0,2647.0,EVHLEESGPGLVRPSETLSLTCTASGGSIRGGEWGDSDYHWGWVRHSPEKGLEWIGSIHWRGTTHYNAPFRGRGRLSIDLSRNQFSLRLTSVTAEDTAVYYCVKHKYHDIVMVVPIAGWFDPWGQGLQVTVSS,EIMMTQSPAILSVSPGDRATLSCRASQSVKNNLAWYQKRPGQAPRLLIFDTSSRASGIPARFSGGGSGTEFTLTVNSMQSEDFATYYCQQYEEWPRTFGQGTKVEIK,GAAATAATGATGACGCAGTCTCCAGCCATCCTGTCTGTGTCTCCAGGAGACAGAGCCACACTCTCCTGCAGGGCCAGTCAGAGTGTGAAGAATAATTTAGCCTGGTACCAGAAGAGACCTGGCCAGGCTCCCAGACTCCTCATCTTTGATACATCCAGCAGGGCCTCTGGTATCCCTGCCAGGTTCAGTGGCGGTGGTTCTGGGACAGAGTTCACTCTCACCGTCAACAGCATGCAGTCTGAAGACTTTGCGACTTATTACTGTCAGCAATATGAAGAGTGGCCTCGGACGTTCGGCCAGGGGACCAAGGTGGAAATCAAA,GAGGTGCATCTGGAGGAGTCGGGCCCAGGACTGGTGAGGCCCTCGGAGACCTTGTCCCTGACTTGCACGGCCTCTGGTGGCTCCATAAGGGGGGGCGAGTGGGGCGATAGTGACTACCACTGGGGCTGGGTCCGCCACTCTCCCGAAAAGGGACTGGAATGGATTGGAAGTATTCATTGGCGGGGGACCACCCACTACAACGCGCCCTTCCGGGGGCGAGGCAGATTGTCGATAGACCTCTCCCGGAATCAATTCTCCCTGCGCCTGACGTCTGTGACCGCCGAAGACACTGCCGTCTATTATTGTGTGAAGCACAAATATCATGACATTGTCATGGTGGTCCCCATTGCGGGCTGGTTCGACCCCTGGGGCCAGGGACTCCAGGTCACCGTCTCGAGC,CVKHKYHDIVMVVPIAGWFDPW,73.226
PGT141,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,Donor 84 ,PGT145,Walker2011(21849977) ,Mutation affects PG9-like Ab sensitivity;PG9-like contacts,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,1-8*01,,6*02,32.0,GSKHRLRDYVLYDDYGLINYQEWNDYLEFLDV,12.0,21.0,2-28*01 or 2D-28*01,1*01,9.0,MQGLNRPWT,14.0,21.0,K,,Natural monoclonal,human,PGT-141, ,4.13098,34.5902,196.0,34.0,2648.0,QVQLVQSGPEVKKPGSSVKVSCKASGNTFSKYDVHWVRQATGQGLEWVGWMSHEGDKTESAQRFKGRVTFTRDTSASTAYMELRGLTSDDTAIYYCTRGSKHRLRDYVLYDDYGLINYQEWNDYLEFLDVWGHGTAVTVSS,DTVVTQSPLSLPVTPGEAASMSCSSTQSLRHSNGANYLAWYQHKPGQSPRLLIRLGSQRASGVPDRFSGSGSGTHFTLKISRVEAEDAAIYYCMQGLNRPWTFGKGTKLEIK,GATACTGTCGTGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGGCGGCCTCCATGTCCTGTTCGTCGACTCAGAGCCTCCGGCATAGTAATGGAGCCAACTATTTGGCTTGGTATCAGCACAAACCGGGGCAGTCTCCACGACTCCTAATCCGTTTAGGTTCTCAACGGGCCTCCGGGGTCCCTGACAGATTCAGTGGCAGTGGATCAGGCACTCATTTTACACTGAAAATCAGTAGAGTGGAGGCTGAAGATGCTGCAATTTATTATTGCATGCAAGGTCTGAACCGTCCCTGGACGTTCGGCAAGGGGACCAAGTTGGAAATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGCCGGAGGTGAAGAAGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCCTCTGGAAACACCTTCAGTAAATATGATGTCCACTGGGTACGACAGGCCACTGGACAGGGGCTTGAATGGGTGGGATGGATGAGTCATGAGGGTGATAAGACAGAATCTGCACAGAGATTTAAGGGCCGAGTCACCTTCACGAGGGACACTTCCGCAAGCACAGCCTACATGGAACTGCGCGGCCTGACATCTGACGACACGGCCATCTATTATTGTACGAGAGGCTCAAAACATCGTTTGCGAGACTACGTTCTCTACGATGACTACGGCTTAATTAATTATCAAGAGTGGAATGACTACCTTGAATTTTTGGACGTCTGGGGCCATGGAACCGCGGTCACCGTCTCCTCA,CTRGSKHRLRDYVLYDDYGLINYQEWNDYLEFLDVW,84.122
PGT142,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,Donor 84 ,PGT145,Walker2011(21849977) ,hypervariable loop characteristic correlations with bNAb sensitivity;V2 Signature Analysis Summary;V2 Signature Analysis Summary,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,1-8*01,,6*02,32.0,GSKHRLRDYVLYDDYGLINYQEWNDYLEFLDV,12.0,23.0,2-28*01 or 2D-28*01,1*01,9.0,MQGLNRPWT,14.0,21.0,K,,Natural monoclonal,human,PGT-142, ,1.78526,70.1417,592.0,35.0,2649.0,QVQLVQSGPEVKKPGSSVKVSCKASGNTFSKYDVHWVRQATGQGLEWVGWISHERDKTESAQRFKGRVTFTRDTSATTAYMELRGLTSDDTAIYYCTRGSKHRLRDYVLYDDYGLINYQEWNDYLEFLDVWGHGTAVTVSS,DTVVTQSPLSLPVTPGEAASMSCSSTQSLRHSNGANYLAWYQHKPGQSPRLLIRLGSQRASGVPDRFSGSGSGTHFTLKISRVEAEDAAIYYCMQGLNRPWTFGKGTKLEIK,GATACTGTCGTGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGGCGGCCTCCATGTCCTGTTCGTCGACTCAGAGCCTCCGGCATAGTAATGGAGCCAACTATTTGGCTTGGTATCAGCACAAACCGGGGCAGTCTCCACGACTCCTAATCCGTTTAGGTTCTCAACGGGCCTCCGGGGTCCCTGACAGATTCAGTGGCAGTGGATCAGGCACTCATTTTACACTGAAAATCAGTAGAGTGGAGGCTGAAGATGCTGCAATTTATTATTGCATGCAAGGTCTGAACCGTCCCTGGACGTTCGGCAAGGGGACCAAGTTGGAAATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGCCTGAGGTGAAGAAGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCCTCTGGAAACACCTTCAGTAAATATGATGTCCACTGGGTACGACAGGCCACTGGACAGGGGCTTGAATGGGTGGGATGGATTAGTCATGAGCGTGATAAGACAGAATCTGCACAGAGATTTAAGGGCCGAGTCACCTTCACGAGGGACACTTCCGCAACCACAGCCTACATGGAACTGCGCGGCCTGACATCTGACGACACGGCCATTTATTATTGTACGAGAGGCTCAAAACATCGCTTGCGAGACTACGTTCTCTACGATGACTACGGCTTAATTAATTATCAAGAGTGGAATGACTACCTTGAATTTTTGGACGTCTGGGGCCATGGAACCGCGGTCACCGTCTCCTCA,CTRGSKHRLRDYVLYDDYGLINYQEWNDYLEFLDVW,83.784
PGT143,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,5UXQ(Structure of PGT143),Donor 84 ,PGT145,Walker2011(21849977) ,Mutation causes resistance to V2 bnAbs;Mutation greatly reduces PGT143 neutralization;V2 Signature Analysis Summary,Andrabi2015(26588781) ,IMGT/V-QUEST,1-8*01,4-17*01,6*02,34.0,,16.0,,2-28*01,1*01,9.0,,15.0,,K,,Natural monoclonal,human,PGT-143, ,3.55651,38.5754,611.0,36.0,2650.0,QVQLEQSGAEVKKPGSSVKVSCKASGNTFSKYDVHWVRQATGQGLEWVGWMSHEGDKTESAQRFKGRVTFTRDTSASTAYMELRGLTSDDTAIYYCTRGSKHRLRDYVLYDDYGLINYQEWNDYLEFLDVWGHGTAVTVSS,DTVVTQSPLSLPVTPGEAASMSCTSTQSLRHSNGANYLAWYQHKPGQSPRLLIRLGSQRASGVPDRFSGSGSGTHFTLKISRVEPEDAAIYYCMQGLNRPWTFGKGTKLEIK,GATACTGTCGTGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGGCGGCCTCCATGTCCTGTACGTCGACTCAGAGCCTCCGTCATAGTAATGGAGCCAACTATTTGGCTTGGTACCAGCACAAACCAGGGCAGTCTCCACGACTCCTAATCCGTTTAGGTTCTCAACGGGCCTCCGGGGTCCCTGACAGATTCAGTGGCAGTGGATCAGGCACTCATTTTACACTGAAAATCAGTCGAGTGGAGCCTGAAGATGCTGCAATTTATTATTGCATGCAAGGTCTGAACCGTCCCTGGACGTTCGGCAAGGGGACCAAGTTGGAAATCAAA,CAGGTGCAGCTGGAGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCCTCTGGAAACACCTTCAGTAAATATGATGTCCACTGGGTACGACAGGCCACTGGACAGGGGCTTGAATGGGTGGGATGGATGAGTCATGAGGGTGATAAGACAGAATCTGCACAGAGATTTAAGGGGCGAGTCACCTTCACGAGGGACACTTCCGCAAGCACAGCCTACATGGAACTGCGCGGCCTGACATCTGACGACACGGCCATTTATTATTGTACGAGAGGTTCAAAACATCGCTTGCGAGACTACGTTCTCTACGATGACTACGGCTTAATTAATTATCAAGAGTGGAATGACTACCTTGAATTTTTGGACGTCTGGGGCCATGGAACCGCGGTCACCGTCTCCTCA,CTRGSKHRLRDYVLYDDYGLINYQEWNDYLEFLDVW,84.122
nan,,,,,,,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,1-8*01,,6*02,32.0,GSKHRLRDYVLYDDYGLINYQEWNDYLEFLDV,12.0,21.0,2-28*01 or 2D-28*01,1*01,9.0,MQGLNRPWT,14.0,22.0,,,,,,,,,,,,,,,,,
PGT144,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,5UY3(Structure of human Fab PGT144),Donor 84 ,PGT145,Walker2011(21849977) ,,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,1-8*01,,6*02,32.0,GSKHRLRDYVLYDDYGLINQQEWNDYLEFLDV,14.0,24.0,2-28*01 or 2D-28*01,1*01,9.0,MQGLNRPWT,13.0,23.0,K,,Natural monoclonal,human,PGT-144, ,20.9877,10.5939,162.0,37.0,2652.0,QVQLVQSGAEVKKPGSSVKVSCKASGNTFRKYDVHWVRQATGQGLEWVGWMSHEGDKTESAQRFKGRVSFTRDNSASTAYIELRGLTSDDTAIYYCTGGSKHRLRDYVLYDDYGLINQQEWNDYLEFLDVWGHGTAVTVSS,DTVVTQSPLSLSVTPGEAASMSCTSTQSLRHSNGANYLAWYQHKPGQSPRLLIRLGSQRASGVPDRFSGSGSGTHFTLKISRVEADDAAIYYCMQGLNRPWTFGKGTKLEIK,GATACTGTCGTGACTCAGTCTCCACTCTCCCTGTCCGTCACCCCTGGAGAGGCGGCCTCCATGTCCTGTACGTCGACTCAGAGCCTCCGGCATAGTAATGGAGCCAACTATTTGGCTTGGTACCAGCACAAACCAGGGCAGTCTCCACGACTCCTAATCCGTTTAGGTTCTCAACGGGCCTCCGGGGTCCCTGACAGATTCAGTGGCAGTGGATCAGGCACTCATTTTACACTGAAAATCAGTAGAGTGGAGGCTGACGATGCTGCAATTTATTATTGCATGCAAGGTCTGAACCGTCCCTGGACGTTCGGCAAGGGGACCAAGTTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCCTCTGGAAACACCTTCAGGAAATATGATGTCCACTGGGTACGACAGGCCACTGGACAGGGGCTTGAATGGGTGGGATGGATGAGTCATGAGGGTGATAAGACAGAATCTGCACAGAGATTTAAGGGCCGAGTCTCTTTCACGAGGGACAATTCCGCAAGCACAGCCTACATTGAACTGCGCGGCCTGACATCTGACGACACGGCCATTTATTATTGTACCGGAGGCTCAAAACATCGCTTGCGAGACTACGTTCTCTACGATGATTACGGCCTAATAAATCAGCAAGAGTGGAATGACTACCTTGAATTTTTGGACGTCTGGGGCCATGGAACCGCGGTCACCGTCTCCTCA,CTGGSKHRLRDYVLYDDYGLINQQEWNDYLEFLDVW,82.770
PGT145,gp120 V2 // V2 glycan(V2g) // V2 apex,3U1S(Fab PGT145);5U1F(BG505 DS-SOSIP trimer in complex with CD4 and antibody PGT145);5V8L(BG505 SOSIP.664 trimer in complex with 3BNC117 and PGT145);6NIJ(PGT145 Fab in complex with full length AMC011 Env),Donor 84 ,PGT145,Walker2011(21849977) ,Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization by V1V2 glycan mAbs;Mutation affects PG9-like Ab sensitivity;Mutation causes resistance to V2 bnAbs;Mutation greatly reduces PGT145 neutralization;mutations affecting PGT145 binding;mutations affecting PGT145 binding;mutations affecting PGT145 binding;PG9-like antibodies require N160 for neutralization;PG9-like contacts;PGT145 contacts;PGT145 contacts;PGT145 epitope;PGT145 escape mutations;Signature Analysis Summary;V2 Signature Analysis Summary,Andrabi2015(26588781) ,IMGT/V-QUEST,1-8*01,4-17*01,6*02,33.0,,17.0,,2-28*01,1*01,9.0,,17.0,,K,,Natural monoclonal,human,PGT-145, ,0.9682,39.5196,2646.0,38.0,2651.0,QVQLVQSGAEVKKPGSSVKVSCKASGNSFSNHDVHWVRQATGQGLEWMGWMSHEGDKTGLAQKFQGRVTITRDSGASTVYMELRGLTADDTAIYYCLTGSKHRLRDYFLYNEYGPNYEEWGDYLATLDVWGHGTAVTVSS,EVVITQSPLFLPVTPGEAASLSCKCSHSLQHSTGANYLAWYLQRPGQTPRLLIHLATHRASGVPDRFSGSGSGTDFTLKISRVESDDVGTYYCMQGLHSPWTFGQGTKVEIK,GAGGTTGTCATAACTCAGTCTCCACTCTTCCTGCCCGTCACCCCTGGAGAGGCGGCCTCCTTGTCTTGCAAGTGCAGCCACAGCCTCCAACATTCAACTGGAGCCAACTATTTGGCTTGGTACCTGCAGAGACCAGGGCAAACTCCACGCCTGTTGATCCATTTGGCCACTCATCGGGCCTCCGGGGTCCCTGACAGATTCAGTGGCAGTGGATCAGGCACAGATTTTACACTTAAAATCAGTCGAGTGGAGTCTGACGATGTTGGAACTTATTATTGCATGCAGGGTCTGCACAGTCCCTGGACGTTCGGCCAAGGGACCAAGGTGGAGATCAAA,CAGGTGCAGTTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCCTCTGGAAACAGTTTCAGTAATCATGATGTCCACTGGGTACGACAGGCCACTGGACAGGGGCTTGAATGGATGGGATGGATGAGTCATGAGGGTGATAAGACAGGCTTGGCACAAAAGTTTCAGGGCAGAGTCACCATCACGAGGGACAGTGGCGCAAGTACAGTCTACATGGAGTTGCGCGGCCTGACAGCTGACGACACGGCCATTTATTATTGTTTGACCGGCTCAAAACATCGCCTGCGAGATTATTTTCTGTACAATGAATATGGCCCCAATTATGAAGAGTGGGGTGACTACCTTGCGACTTTGGACGTCTGGGGCCATGGGACCGCGGTCACCGTCTCGAGC,CLTGSKHRLRDYFLYNEYGPNYEEWGDYLATLDVW,83.333
nan,,,,,,,Walker2011(21849977) ,IMGT/V-QUEST SoDA2,1-8*01,,6*02,31.0,GSKHRLRDYFLYNEYGPNYEEWGDYLATLDV,18.0,29.0,2-28*01 or 2D-28*01,1*01,9.0,MQGLHSPWT,16.0,24.0,,,,,,,,,,,,,,,,,
PGT145-scFv-Fc,gp120 V3 // V3 glycan (V3g),,Donor 84 ,,Davis-Gardner2020(31937648) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,,,18.0,774.0,4526.0,,,,,,
PGT151,fusion peptide // near gp41-gp120 interface,4NUG(Antibody PGT151);5FUU(JR-FL EnvdCT trimer in complex with PGT151 Fab);6DCQ(Wild type HIV-1 glycoprotein PC64M18C043 in complex with PGT151 Fab);EMD-0620(Full length HIV-1 Envelope glycoprotein AMC011 in complex with PGT151 Fab and PGZL1 Fab),Donor 31 ,,Falkowska2014(24768347) ,"mutation affecting PGT151 binding;Mutation affects PGT151 neutralization;Mutation affects VRC01, PGT151, and 2G12 binding;mutations affecting PGT151 binding;mutations affecting PGT151 binding;PGT151 contacts;PGT151-PGT158 sites of interaction",Falkowska2014(24768347) ,,3-30*04,,6*02,28.0,ARMFQESGPPRLDRWSGRNYYYYSGMDV,20.0,28.0,2D-29*02,4*01,9.0,MQSKDFPLT,12.0,15.0,K,Yes,Natural monoclonal,human,PGT-151, ,0.25538,75.163,2749.0,123.0,3107.0,RVQLVESGGGVVQPGKSVRLSCVVSDFPFSKYPMYWVRQAPGKGLEWVAAISGDAWHVVYSNSVQGRFLVSRDNVKNTLYLEMNSLKIEDTAVYRCARMFQESGPPRLDRWSGRNYYYYSGMDVWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSESLRQSNGKTSLYWYRQKPGQSPQLLVFEVSNRFSGVSDRFVGSGSGTDFTLRISRVEAEDVGFYYCMQSKDFPLTFGGGTKVDLK,GACATTGTGATGACCCAGACTCCTCTCTCTTTGTCCGTCACCCCTGGACAGCCGGCCTCCATCTCCTGCAAGTCCAGTGAGAGCCTCCGACAAAGTAATGGAAAGACCTCTTTGTATTGGTATCGGCAGAAGCCAGGCCAGTCTCCACAACTCCTAGTGTTTGAAGTTTCTAATCGATTCTCTGGCGTGTCGGATAGGTTTGTTGGCAGCGGGTCAGGGACAGACTTCACACTGAGAATCAGCCGGGTAGAGGCTGAGGATGTTGGATTTTATTACTGCATGCAAAGTAAAGACTTCCCACTTACATTTGGCGGCGGGACCAAGGTGGATCTCAAA,CGGGTGCAGTTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCGTGAGACTTTCCTGTGTAGTCTCCGATTTCCCCTTCAGCAAGTATCCTATGTATTGGGTTCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCCATCTCCGGTGATGCCTGGCATGTGGTCTACTCAAATTCCGTGCAGGGCCGATTTCTCGTCTCCAGGGACAATGTCAAGAACACTCTATATTTAGAAATGAACAGCCTGAAAATTGAGGATACGGCCGTATATCGCTGCGCGAGAATGTTCCAGGAGTCTGGTCCACCACGTTTGGATCGTTGGAGCGGTCGAAATTATTACTATTATTCTGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCGAGC,CARMFQESGPPRLDRWSGRNYYYYSGMDVW,79.592
PGT151/10-1074-IgG3C-,fusion peptide // near gp41-gp120 interface;gp120 V3 // V3 glycan (V3g),,Donor 17 Donor 31 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific; IgG3C hinge variant ,0.12608,23.6649,238.0,275.0,3533.0,,,,,,
PGT151/35O22,fusion peptide // near gp41-gp120 interface;gp41-gp120 interface,,Donor 31 Donor N152 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific ,1.18454,26.2946,120.0,266.0,3518.0,,,,,,
PGT151-IgG3C-,fusion peptide // near gp41-gp120 interface,,Donor 31 ,,Bournazos2016(27315478) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,IgG3C hinge variant ,0.42059,65.6104,238.0,273.0,3542.0,,,,,,
PGT152,fusion peptide // near gp41-gp120 interface,4NUJ(Antibody PGT152),Donor 31 ,,Falkowska2014(24768347) ,PGT151-PGT158 sites of interaction,Falkowska2014(24768347) ,,3-30*04,,6*02,28.0,ARMFQESGPPRFDSWSGRNYYYYSGMDV,19.0,29.0,2D-29*02,4*01,9.0,MQSKDFPLT,12.0,14.0,K,Yes,Natural monoclonal,human,PGT-152, ,0.47199,75.5425,232.0,124.0,3108.0,RVQLVESGGGVVQPGKSVRLSCVVSDFPFSKYPMYWVRQAPGKGLEWVAAISADAWHVVYSGSVQGRFLVSRDNSKNILYLEMNTLKIEDTAVYRCARMFQESGPPRFDSWSGRNYYYYSGMDVWGQGTTVTVSS,DIVMTQTPLSLSVDPGQPASISCKSSQSLRQSNGKTSLYWYQQKPGQSPQLLIFEVSNRFSGVSDRFVGSGSGTDFTLRISRVEAEDVGFYYCMQSKDFPLTFGGGTKVDLN,GACATTGTGATGACCCAGACTCCTCTCTCTTTGTCCGTCGACCCTGGACAGCCGGCCTCCATCTCCTGCAAGTCCAGTCAGAGCCTCCGACAAAGTAATGGAAAGACCTCTTTGTATTGGTATCAGCAGAAGCCAGGCCAGTCTCCACAACTCCTAATATTTGAAGTTTCTAATCGATTCTCTGGCGTGTCGGATAGGTTTGTTGGCAGCGGGTCAGGGACAGACTTCACACTGAGAATCAGCCGGGTAGAGGCTGAGGATGTTGGATTTTATTACTGCATGCAAAGTAAAGACTTCCCACTCACCTTTGGCGGCGGGACCAAGGTGGATCTCAAC,CGGGTGCAGTTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCGTGAGACTTTCCTGTGTAGTCTCTGATTTCCCCTTCAGCAAGTATCCTATGTATTGGGTTCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCCATCTCCGCTGATGCCTGGCATGTGGTCTACTCAGGCTCCGTGCAGGGCCGATTTCTCGTCTCCAGGGACAACTCCAAGAACATTCTGTATTTGGAAATGAACACCCTGAAAATTGAGGACACGGCCGTATATCGCTGCGCGAGAATGTTCCAGGAGTCTGGTCCACCACGTTTCGATTCTTGGAGCGGTCGAAATTACTACTATTACTCTGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCGAGC,CARMFQESGPPRFDSWSGRNYYYYSGMDVW,80.952
PGT153,gp41,,Donor 31 ,,Falkowska2014(24768347) ,PGT151-PGT158 sites of interaction,Falkowska2014(24768347) ,,3-30*04,,6*02,28.0,ARDRDGYGPPQIQTWSGRYLHLYSGIDA,22.0,27.0,2D-29*02,4*01,9.0,MQSKDFPLT,13.0,18.0,K,,Natural monoclonal,human,PGT-153, ,6.87459,34.5845,50.0,125.0,3109.0,QVQLVESGGGVVQPGKSLRLSCVVSNFLFNKRHMHWVRQAPGKGLEWIAVISSDAIHVDYASSVRGRSLISRDNSKNSLYLDMNNLKIEDTATYYCARDRDGYGPPQIQTWSGRYLHLYSGIDAWGLGTTVTVSS,DIVLTQSPLFLSVSPGQPASISCKSSQSLRQSNGKTYLYWYVQKSGQSPQPLIQEVSIRFSGVPGRFAGSGSGTDFTLKISRVEAEDVGVYFCMQSKDFPLTFGGGTKVDLN,GACATTGTGCTGACCCAGAGCCCCCTCTTTCTGTCCGTCAGTCCTGGACAGCCGGCCTCCATCTCCTGTAAGTCTAGTCAGAGCCTCCGACAAAGTAATGGAAAGACATATTTGTATTGGTACGTACAAAAGTCCGGCCAGTCTCCACAACCCCTGATCCAGGAAGTTTCCATTCGCTTCTCTGGAGTGCCAGGTAGATTCGCTGGCAGCGGATCAGGGACAGACTTCACACTGAAAATCAGCCGGGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCATGCAAAGTAAAGACTTTCCACTCACTTTTGGCGGAGGGACCAAGGTGGACCTCAAT,CAGGTGCAGTTGGTGGAGTCGGGCGGAGGCGTGGTCCAGCCTGGGAAGTCCCTGAGACTCTCCTGTGTAGTCTCTAATTTTCTCTTCAATAAACGTCACATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTAGAGTGGATAGCAGTCATTTCCTCTGATGCCATTCACGTAGACTACGCAAGTTCCGTGCGGGGCCGATCCCTCATCTCCAGAGACAATTCCAAAAATAGTTTATATCTAGACATGAATAACCTGAAAATTGAGGACACGGCCACATATTATTGTGCAAGAGATAGAGACGGATATGGTCCACCACAGATCCAGACTTGGAGCGGTCGATACCTCCACCTTTATTCTGGAATAGACGCCTGGGGCCTAGGGACCACGGTCACCGTCTCGAGC,CARDRDGYGPPQIQTWSGRYLHLYSGIDAW,79.392
PGT154,gp41,,Donor 31 ,,Falkowska2014(24768347) ,PGT151-PGT158 sites of interaction,Falkowska2014(24768347) ,,3-30*04,,6*02,28.0,ARNIEEFSVPQFDSWSGRSYYHYFGMDV,18.0,26.0,2D-29*02,4*01,9.0,MQSRDFPIT,17.0,22.0,K,,Natural monoclonal,human,PGT-154, ,4.0906,44.6074,50.0,126.0,3110.0,QVQLVESGGGVVQPGKSLRLSCVVSNFIFNKYPMYWVRQAPGKGLEWVAAISADAWHVDYAASVKDRFLISRDNSKNALYLEMNTLRVEDTGIYYCARNIEEFSVPQFDSWSGRSYYHYFGMDVWGQGTTVTVSS,DIVMTQTPVSLSVSLGQAASISCSSSESLGRGDGRTYLHWYRQKPGQTPQLLMYEVSTRFSGVSDRFAGSGSRTQFTLKISRVEAEDVGVYYCMQSRDFPITFGGGTRVDLK,GACATTGTGATGACTCAGACTCCTGTCTCTCTGTCCGTCAGTCTTGGACAGGCGGCCTCCATCTCCTGCAGCTCCAGTGAGAGTCTCGGACGTGGTGATGGAAGGACCTATTTGCATTGGTACCGACAGAAGCCAGGCCAGACTCCACAATTACTCATGTATGAAGTTTCTACTCGATTCTCTGGAGTGTCCGACAGGTTCGCTGGCAGCGGGTCACGTACACAATTCACATTGAAAATTAGTCGGGTGGAGGCTGAAGATGTTGGCGTTTATTACTGCATGCAAAGTAGAGACTTCCCAATCACTTTTGGCGGAGGGACCAGGGTGGATCTCAAA,CAGGTGCAGCTGGTGGAATCGGGAGGAGGCGTGGTCCAGCCTGGAAAGTCCCTCAGACTCTCATGTGTCGTCTCTAATTTCATCTTTAATAAATATCCTATGTATTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCCATCTCCGCTGATGCCTGGCATGTAGACTACGCAGCCTCCGTGAAGGACCGATTTCTCATCTCCAGAGACAATTCCAAGAATGCTCTATATTTGGAAATGAACACCCTGAGAGTTGAAGACACGGGTATCTACTACTGTGCGAGAAATATAGAGGAGTTTAGTGTTCCACAGTTCGATTCTTGGAGCGGTCGAAGCTACTACCACTATTTTGGGATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCGAGC,CARNIEEFSVPQFDSWSGRSYYHYFGMDVW,81.973
PGT155,gp41,,Donor 31 ,,Falkowska2014(24768347) ,PGT151-PGT158 sites of interaction,Falkowska2014(24768347) ,,3-30*04,,6*02,28.0,AKDGEEHKVPQLHSWSGRNLYHYTGFDV,21.0,30.0,2D-29*02,4*01,9.0,LQTKDFPLT,17.0,20.0,K,,Natural monoclonal,human,PGT-155, ,4.88956,47.1451,50.0,127.0,3111.0,QVHLVESGGGVVQPGKSLRLSCETSGFIFNEYPMYWIRQAPGKGPEWVAAISADAWHVDYAGSVRGRFTVSRDNSKNSLYLDMKSLKVEDTAIYFCAKDGEEHKVPQLHSWSGRNLYHYTGFDVWGPGTTVTVSS,DIVMTQSPVSLSVTLGQPASMSCKSSQSVRQSDGKTFLYWYRQKPGQSPQLLIYEGSSRFSGVSDRISGSGSGTDFTLRISRVEAEDAGVYFCLQTKDFPLTFGGGTRVDLK,GACATTGTGATGACCCAGTCTCCTGTCTCTCTGTCCGTCACCCTCGGACAGCCGGCCTCCATGTCCTGCAAGTCCAGTCAGAGTGTCCGACAGAGTGATGGCAAGACTTTCTTATATTGGTATCGACAGAAGCCAGGCCAGTCTCCACAACTGTTAATATATGAGGGTTCGAGTCGATTCTCTGGAGTGTCAGATAGGATCTCTGGCAGCGGGTCAGGGACAGACTTCACACTGAGGATCAGTCGAGTGGAGGCTGAGGATGCTGGCGTTTACTTCTGCTTGCAAACTAAAGACTTCCCCCTCACTTTTGGCGGAGGGACCAGGGTGGATCTCAAA,CAGGTGCATCTGGTGGAGTCGGGGGGAGGCGTGGTCCAACCTGGGAAGTCCCTAAGACTCTCCTGTGAAACCTCTGGCTTCATCTTCAACGAATATCCCATGTATTGGATCCGCCAGGCTCCAGGCAAGGGACCGGAGTGGGTGGCCGCCATCTCCGCTGACGCCTGGCATGTGGACTACGCAGGCTCCGTGCGGGGCCGATTTACCGTCTCCAGAGACAATTCTAAGAATTCTCTATATTTAGACATGAAGAGTCTGAAAGTTGAAGACACGGCTATATATTTCTGTGCGAAAGATGGGGAGGAACACAAGGTACCACAATTGCATTCCTGGAGCGGACGAAACTTATATCACTACACTGGTTTTGACGTCTGGGGCCCAGGGACCACGGTCACCGTCTCGAGC,CAKDGEEHKVPQLHSWSGRNLYHYTGFDVW,79.392
PGT156,gp41,,Donor 31 ,,Falkowska2014(24768347) ,PGT151-PGT158 sites of interaction,Falkowska2014(24768347) ,,3-30*04,,6*02,28.0,AKDGEEHKVPQLHSWSGRNLYHYTGFDV,21.0,31.0,2D-29*02,4*01,9.0,LQTKDFPLT,17.0,21.0,K,,Natural monoclonal,human,PGT-156, ,3.83441,62.2493,50.0,128.0,3112.0,QVHLVESGGGVVQPGKSLRLSCETSGFIFNQYPMYWVRQAPGKGPEWVAAISADAWHVDYPGSVRGRFTVSRDNSKSSLYLDMKSLKVEDTAIYFCAKDGEEHKVPQLHSWSGRNLYHYTGFDVWGPGTTVTVSS,DIVMTQSPVSLSVTLGQPASMSCKSSQTVRQSDGKTFLYWYRQKAGQSPQLLIYEGSNRFSGVSDRISGSGSGTDFTLRISRVEAEDVGVYFCLQTKDFPLTFGGGTRVDIK,GACATTGTGATGACCCAGTCTCCTGTCTCTCTGTCCGTCACCCTCGGACAGCCGGCCTCCATGTCCTGCAAGTCCAGTCAGACTGTCCGACAGAGTGATGGCAAGACTTTCTTATATTGGTATCGACAGAAGGCAGGCCAGTCTCCACAACTGTTAATATATGAGGGTTCGAATCGATTCTCTGGAGTGTCAGATAGGATCTCTGGCAGCGGGTCGGGGACAGATTTCACACTGAGAATCAGTCGAGTGGAGGCTGAGGATGTTGGCGTTTATTTCTGCCTGCAAACTAAAGACTTCCCCCTCACTTTTGGCGGAGGGACCAGGGTGGATATCAAA,CAGGTGCATCTGGTGGAGTCGGGGGGAGGCGTTGTCCAACCTGGAAAGTCCCTAAGACTCTCCTGTGAAACCTCTGGCTTCATCTTCAATCAATATCCCATGTATTGGGTCCGCCAGGCTCCAGGCAAGGGACCGGAGTGGGTGGCCGCCATCTCCGCTGATGCCTGGCATGTGGACTACCCAGGCTCCGTGCGGGGCCGATTTACCGTCTCCAGAGACAATTCCAAGAGTTCTCTATATTTAGACATGAAGAGTCTGAAAGTTGAAGACACGGCTATATATTTCTGTGCGAAAGATGGGGAGGAACACAAGGTACCACAATTGCATTCCTGGAGCGGACGAAACTTATATCACTACACTGGTTTTGACGTCTGGGGCCCAGGGACCACGGTCACCGTCTCGAGC,CAKDGEEHKVPQLHSWSGRNLYHYTGFDVW,79.392
PGT157,gp41,,Donor 31 ,,Falkowska2014(24768347) ,PGT151-PGT158 sites of interaction,Falkowska2014(24768347) ,,3-30*04,,6*02,28.0,AKDGEEHEVPQLHSWSGRNLYHYTGVDI,20.0,29.0,2D-29*02,4*01,9.0,MQTKDFPLT,14.0,17.0,K,,Natural monoclonal,human,PGT-157, ,9.82692,30.9537,50.0,129.0,3113.0,EVHLVESGGGVVQPGKSLRLSCVTSGFIFKQYPMYWIRQAPGKGLEWVAAISADAWHVDYAGSVRGRFTVSRDNSKNSLYLDMNSLTVEDTAIYFCAKDGEEHEVPQLHSWSGRNLYHYTGVDIWGPGTTVTVSS,DIVMTQTPVSLSVTLGQPASMSCKSSQSLRQSDGKTFLYWYRQKAGQSPQLLISEASNRFSGVSDRFSGSGSGTDFTLKISRVEAEDVGIYFCMQTKDFPLTFGGGTKVDLK,GACATTGTGATGACCCAGACTCCTGTCTCTCTGTCCGTCACCCTCGGACAGCCGGCCTCCATGTCCTGTAAGTCCAGTCAGAGCCTCCGACAAAGTGATGGCAAGACTTTCTTGTATTGGTATCGACAGAAGGCAGGCCAGTCTCCACAACTCCTAATATCTGAGGCTTCGAATCGATTCTCTGGAGTGTCAGATAGGTTCTCTGGCAGCGGTTCAGGGACAGACTTCACACTGAAAATCAGTCGGGTGGAGGCTGAGGATGTTGGCATTTATTTCTGCATGCAAACTAAAGACTTCCCCCTCACTTTTGGCGGAGGGACCAAGGTGGATCTCAAA,GAAGTGCATCTGGTGGAGTCGGGGGGAGGCGTGGTCCAACCTGGAAAGTCCCTCAGACTCTCCTGTGTAACTTCTGGCTTCATCTTCAAACAATATCCTATGTATTGGATCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCCGCCATCTCCGCTGATGCCTGGCATGTGGACTACGCAGGCTCCGTGCGGGGCCGATTTACCGTCTCCAGAGACAACTCCAAGAATTCTCTATATTTAGACATGAACAGTCTGACAGTTGAAGACACGGCTATATATTTCTGTGCGAAAGATGGGGAAGAACACGAAGTACCACAGTTGCACTCCTGGAGCGGACGAAATTTATATCACTACACTGGTGTGGACATCTGGGGCCCAGGGACCACGGTCACCGTCTCGAGC,CAKDGEEHEVPQLHSWSGRNLYHYTGVDIW,80.068
PGT158,gp41,,Donor 31 ,,Falkowska2014(24768347) ,PGT151-PGT158 sites of interaction,Falkowska2014(24768347) ,,3-30*04,,6*02,28.0,AKDGEEHEVPQLHSWSGRNLYHYTGVDV,21.0,31.0,2D-29*02,4*01,9.0,MQTKDFPLT,14.0,19.0,K,,Natural monoclonal,human,PGT-158, ,4.88464,50.9387,50.0,130.0,3114.0,EVRLMESGGGVVQPGKSLRLSCVTSGFIFKKYPMYWIRQAPGKGLEWVAAISADAWHVDYPGSVRGRFTVSRDNSKNSLYLDMNSLTVEDTAIYFCAKDGEEHEVPQLHSWSGRNLYHYTGVDVWGPGTTVTVSS,DIVMTQTPVSVSVTLGQPASMSCKSSQSVRQSDGKTFLYWYRQKAGQSPQLLIYEASKRFSGVSDRFSGSGSGTDFTLKISRVGAEDVGVYFCMQTKDFPLTFGGGTKVDLK,GACATTGTGATGACCCAGACTCCTGTCTCTGTGTCCGTCACCCTCGGACAGCCGGCCTCCATGTCCTGCAAGTCCAGTCAGAGCGTCCGACAAAGTGATGGCAAGACTTTTTTATATTGGTATCGACAGAAGGCAGGCCAGTCTCCACAACTCTTAATATATGAGGCTTCGAAGCGATTCTCTGGAGTGTCAGATAGGTTCTCTGGCAGCGGGTCAGGGACAGACTTCACACTGAAAATCAGTCGGGTGGGGGCTGAGGATGTTGGCGTTTATTTCTGCATGCAAACTAAAGACTTCCCCCTTACTTTTGGCGGAGGGACCAAGGTGGATCTCAAA,GAGGTGCGTCTGATGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCCTCAGACTCTCCTGTGTAACCTCTGGCTTCATCTTCAAAAAATATCCTATGTACTGGATCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCCGCCATCTCCGCTGATGCCTGGCATGTGGACTACCCAGGCTCCGTGCGGGGCCGATTTACCGTCTCAAGAGACAACTCCAAGAATTCTCTATATTTAGACATGAATAGTCTGACAGTAGAAGACACGGCTATATATTTTTGTGCGAAAGATGGGGAGGAACACGAAGTCCCACAACTGCACTCCTGGAGCGGACGAAATTTATATCACTACACTGGTGTAGACGTCTGGGGCCCAGGGACCACGGTCACCGTCTCGAGC,CAKDGEEHEVPQLHSWSGRNLYHYTGVDVW,79.392
PGZL1,gp41 MPER (membrane proximal external region),6O3D(Fab fragment of PGZL1);6O3G(Fab fragment of PGZL1 in complex with its MPER peptide epitope);6O3J(Fab fragment of PGZL1 in complex with its MPER peptide epitope and phosphatidic acid);EMD-0620(Full length HIV-1 Envelope glycoprotein AMC011 in complex with PGT151 Fab and PGZL1 Fab),PG13 ,PGZL1,Zhang2019a(31772165) ,"Mutation affects neutralization by PGZL1, H4K3, or 4E10;PGZL1 contacts",Zhang2019a(31772165) ,IMGT/V-QUEST,1-69*06,3-10*01,3*01,15.0,EGEGWFGKPLRAFEF,20.9,,3-20*01,5*01,9.0,QQYGTSQST,12.6,,K,,Natural monoclonal,human,, ,9.59677,6.16393,260.0,492.0,4120.0,EVQLVQSGGEVKRPGSSVTVSCKATGGTFSTLAFNWVRQAPGQGPEWMGGIVPLFSIVNYGQKFQGRLTIRADKSTTTVFLDLSGLTSADTATYYCAREGEGWFGKPLRAFEFWGQGTVITVSS,DVVMTQSPGTLSLSPGERATLSCRASQSVSGGALAWYQQKPGQAPRLLIYDTSSRPTGVPGRFSGSGSGTDFSLTISRLEPEDFAVYYCQQYGTSQSTFGQGTRLEIK,GATGTTGTGATGACTCAGTCTCCAGGCACTTTGTCTTTGTCTCCCGGAGAAAGGGCCACCCTCTCCTGCCGGGCCAGTCAGAGTGTCAGTGGCGGCGCGTTAGCCTGGTACCAGCAGAAGCCTGGCCAGGCTCCCAGACTCCTCATCTATGACACGTCCAGCAGGCCCACTGGCGTCCCGGGCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAGTCTCACCATCAGTAGGCTGGAGCCTGAAGACTTTGCTGTCTATTACTGTCAGCAATATGGAACCTCACAATCGACCTTCGGCCAGGGGACACGACTGGAGATTAAA,GAGGTGCAGCTGGTGCAGTCTGGCGGTGAGGTGAAGCGGCCTGGGTCCTCGGTGACGGTCTCCTGCAAGGCGACTGGGGGCACATTTAGTACTCTTGCTTTTAACTGGGTGCGCCAGGCCCCTGGACAAGGGCCTGAGTGGATGGGAGGAATTGTCCCTCTTTTCAGCATTGTGAATTATGGACAGAAATTCCAGGGCAGACTTACAATTCGGGCGGACAAATCGACGACCACAGTATTTTTGGATCTGAGTGGCCTCACGTCTGCGGACACGGCCACTTATTATTGTGCGCGAGAGGGAGAGGGGTGGTTCGGGAAGCCCCTCCGTGCTTTTGAATTTTGGGGCCAGGGGACAGTGATCACCGTCTCCTCA,CAREGEGWFGKPLRAFEFW,79.392
PGZL1_gVmDmJ,gp41 MPER (membrane proximal external region),6O41(PGZL1 germline Fab fragment PGZL1_gVmDmJ);6O42(germline PGZL1 (PGZL1_gVmDmJ) Fab in complex with MPER peptide epitope),PG13 ,PGZL1,Zhang2019a(31772165) ,,Zhang2019a(31772165) ,IMGT/V-QUEST,1-69*06,3-10*01,4*03,17.0,CAREGEGWFGKPLRAFEFW,,,3-20*01,5*01,,,,,K,,UCA or intermediate,human,PGZL1 gVmDmJ, ,75.6029,2.38435,260.0,494.0,4122.0,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGEGWFGKPLRAFEFWGQGTVITVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSQSTFGQGTRLETR,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAATATGGTACCTCACAATCGACCTTCGGCCAAGGGACACGACTGGAGACCAGG,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGAGGGAGAGGGGTGGTTCGGGAAGCCCCTCCGTGCTTTTGAATTTTGGGGCCAGGGGACAGTGATCACCGTCTCCTCA,CAREGEGWFGKPLRAFEFW,100.000
PGZL1.H4K3,gp41 MPER (membrane proximal external region),6O3K(Fab fragment of PGZL1.H4K3);6O3L(Fab fragment of PGZL1.H4K3 in complex with its MPER peptide epitope);6O3U(Fab fragment of PGZL1.H4K3 in complex with 06:0 PA),PG13 ,PGZL1,Zhang2019a(31772165) ,"Mutation affects neutralization by PGZL1, H4K3, or 4E10",Zhang2019a(31772165) ,IMGT/V-QUEST,1-69*06,3-10*01,3*01,15.0,EGEGWFGRPLRAFEF,,,3-20*01,5*01,9.0,QQYGTSQST,,,K,,Engineered monoclonal,human,H4K3, ,1.4267,4.66656,260.0,493.0,4121.0,KVQLVQSGAELKKPWSSVRVSCKASGGSFSSYAFNWVRQAPGQRLEWLGGIVPLVSSTNYAQRFRGRVTISADRSTSTVYLEMTGLTSADTAVYFCAREGEGWFGRPLRAFEFWGQGTLVTVST,EIVLTQSPGTFALSPGERATLSCRASQSVSGGALAWYQQKAGQAPRLLIYGTSGRATGVPGRFSGSGSETDFSLTISRLEPEDFAVYYCQQYGTSQSTFGQGTRLETR,GAAATTGTGTTGACGCAGTCTCCAGGCACCTTTGCTTTGTCTCCCGGAGAAAGGGCCACCCTCTCCTGCCGGGCCAGTCAGAGTGTCAGTGGCGGCGCGTTAGCCTGGTACCAGCAGAAGGCTGGCCAGGCTCCCAGACTCCTCATCTATGGTACGTCCGGCAGGGCCACTGGCGTCCCGGGCAGGTTCAGTGGCAGTGGGTCTGAGACAGACTTCAGTCTCACCATCAGCAGGCTGGAGCCTGAAGACTTTGCAGTCTATTACTGTCAGCAATATGGTACCTCACAATCGACCTTCGGCCAAGGGACACGACTGGAGACCAGG,AAGGTACAACTGGTGCAGTCTGGGGCTGAACTGAAGAAGCCTTGGTCCTCGGTGAGGGTCTCCTGCAAGGCATCTGGAGGCAGCTTCAGCAGCTATGCCTTCAACTGGGTGCGACAGGCCCCCGGACAAAGACTTGAGTGGCTGGGAGGCATCGTCCCTCTTGTCAGCAGCACAAACTACGCACAGAGGTTCAGGGGCAGAGTCACAATCAGTGCGGACAGATCAACGAGTACTGTCTACTTGGAGATGACAGGACTGACATCTGCAGACACGGCCGTTTATTTCTGTGCGCGGGAGGGGGAGGGTTGGTTCGGGAGGCCCCTCCGAGCGTTTGAATTCTGGGGCCAAGGAACACTCGTCACCGTTTCTACA,CAREGEGWFGRPLRAFEFW,82.432
polyclonal 391370,gp120 CD4bs,,391370 ,,Barnes2022(35960796) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,90.2876,1.2914,42.0,641.0,4251.0,,,,,,
polyclonal Donor 27845,,,27845 ,,Schoofs2019(31126879) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,84.0426,1.28112,31.0,545.0,4151.0,,,,,,
polyclonal EB179,gp120 CD4bs,,EB179 ,,Freund2015(26516768) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,79.9672,1.54648,14.0,703.0,4288.0,,,,,,
polyclonal IDC561,,,IDC561 ,,Schommers2020(32004464) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,56.2654,1.93335,38.0,629.0,4239.0,,,,,,
polyclonal NIH45,,,NIH45 ,,Wu2010(20616233) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,73.2555,1.74608,278.0,411.0,3967.0,,,,,,
polyclonal Patient 1,,,Patient 1 ,,Scheid2011(21764753) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,79.7209,1.6126,21.0,413.0,3972.0,,,,,,
polyclonal Patient 12,,,Patient 12 ,,Scheid2011(21764753) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,,,6.0,416.0,3975.0,,,,,,
polyclonal Patient 3,,,Patient 3 ,,Scheid2011(21764753) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,65.8404,2.00908,61.0,414.0,3973.0,,,,,,
polyclonal Patient 8,,,Patient 8 ,,Scheid2011(21764753) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,59.3104,2.33271,21.0,415.0,3974.0,,,,,,
polyclonal pt7 IgA,,,pt7 ,,Lorin2022(35230385) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,61.5825,3.41285,24.0,608.0,4222.0,,,,,,
polyclonal pt7 IgG,,,pt7 ,,Lorin2022(35230385) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,59.3504,3.30053,24.0,607.0,4221.0,,,,,,
polyclonal R1,,,R1 ,,Gristick2016(27617431) ,,,,,,,,,,,,,,,,,,,Polyclonal,human,, ,70.0696,1.84216,18.0,724.0,4368.0,,,,,,
PRO-140,non-HIV: host CCR5,,,,Olson1999(10196311) ,,,,,,,,,,,,,,,,,,,,mouse,"P140, PA14, PRO 140, PRO140", ,0.33411,4.05364,106.0,583.0,4157.0,,,,,,
PRO-140/PGDM1400/PGT121,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);non-HIV: host CCR5,,Donor 17 Donor 84 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;humanized mouse,PRO140Fab-PGDM1400fv-PGT121fv,trispecific ,0.054149,16.0618,105.0,424.0,3993.0,,,,,,
QA013.19,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,QA013 ,,Williams2018(29669274) ,,Williams2018(29669274) ,,1-46,4-17,4,20.0,GRSLRLSPNAFTMRTPPPDY,15.0,21.4,2-23,2,10.0,CSYGGASTLI,11.5,19.4,L,,Natural monoclonal,human,, ,37.6701,5.78481,19.0,391.0,3920.0,QVQLIQSGAEVQKPGASVRISCKASGYSFTTYYMHWVRQAPGQGLEWMGIVNPSGGATNYAQSFQGRVTMTSDTSATTVFLHLKNLKFEDTAVYYCGRSLRLSPNAFTMRTPPPDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITIPCIGSRNDIGSHNLVSWFQKHAGKAPKVIIYEVTDRPSGVSHRFSGSKSGNTASLTISGLQPDDEADYYCCSYGGASTLIFGGGTKVTVL,CAGTCTGCCCTGACTCAACCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCCCCTGCATTGGAAGTAGGAATGATATTGGGAGTCATAACCTTGTCTCCTGGTTCCAAAAACACGCTGGGAAAGCCCCCAAAGTCATCATTTATGAGGTCACTGATCGACCCTCAGGGGTTTCTCATCGCTTCTCTGGCTCCAAGTCTGGCAATACGGCCTCCCTGACAATCTCTGGGCTCCAACCTGACGACGAGGCTGATTACTATTGCTGCTCCTATGGAGGTGCCAGCACTTTGATTTTCGGCGGAGGGACCAAGGTGACCGTCCTC,CAGGTGCAGCTAATACAGTCTGGGGCTGAGGTGCAGAAGCCTGGGGCCTCAGTGAGGATTTCCTGCAAGGCATCTGGATACAGCTTCACCACCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGTCTTGAATGGATGGGTATCGTCAATCCTAGCGGTGGAGCCACTAACTACGCACAGAGCTTCCAGGGCAGAGTCACCATGACCAGCGACACGTCCGCGACAACAGTCTTTTTACATCTGAAGAATCTAAAGTTTGAAGACACGGCCGTCTATTATTGTGGCAGATCTCTCCGCCTTAGTCCGAATGCTTTCACTATGCGGACTCCGCCGCCTGATTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CGRSLRLSPNAFTMRTPPPDYW,84.694
QA013.2,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,QA013 ,,Williams2018(29669274) ,,Williams2018(29669274) ,,3-7,6-6,5,21.0,AREAYHLVYDDRIPRGNWFDP,21.2,31.6,1-40,3,11.0,QSYDTTLTASV,11.5,17.2,L,,Natural monoclonal,human,, ,10.861,16.0538,33.0,392.0,3923.0,DIRIAESGGGLVQPGESLRLACEIIELGFRRAWTTWVRQAPGKGLEWVADINEDGSEKKYGPSVTGRFTISRDNGKNLVFLQMNSLRVEDTATYYCAREAYHLVYDDRIPRGNWFDPWGPGTLVTVSS,QSVLTQPPSVSGAPGQRVVISCTGSRSNIGAGYDVHWYQQSPGKVPRIIIYGSNSRSSGVPARFSGSKSGTSASLAITGLQAEDEADYYCQSYDTTLTASVFGGGTKVTVL,CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCGTCATTTCCTGCACTGGGAGCAGGTCCAACATCGGGGCAGGATATGATGTACATTGGTACCAGCAATCTCCGGGAAAAGTCCCCAGAATTATCATCTATGGTAGTAACAGTCGTTCGTCGGGGGTCCCCGCCCGATTTTCTGGCTCTAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGACTCCAGGCTGAGGATGAGGCTGATTATTACTGCCAGTCTTATGACACCACCCTCACTGCTTCGGTGTTCGGCGGGGGGACGAAGGTGACCGTCCTA,GACATACGTATAGCGGAGTCTGGGGGAGGCCTGGTCCAGCCTGGGGAGTCCCTGAGGCTCGCCTGCGAAATAATAGAACTTGGGTTTAGAAGGGCTTGGACGACGTGGGTCCGTCAGGCTCCAGGGAAAGGTCTCGAGTGGGTGGCCGACATAAACGAGGATGGAAGTGAGAAAAAGTATGGGCCCTCTGTGACGGGGCGATTCACCATTTCCAGAGACAACGGCAAGAACTTAGTGTTTTTGCAGATGAATAGCCTGAGAGTCGAGGACACGGCCACTTATTATTGTGCAAGAGAGGCATATCATCTCGTCTATGACGATAGAATACCTCGGGGAAACTGGTTCGACCCCTGGGGCCCGGGAACTCTGGTCACCGTCTCCTCA,CAREAYHLVYDDRIPRGNWFDPW,79.392
QA013.3,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,QA013 ,,Williams2018(29669274) ,,Williams2018(29669274) ,,1-46,6-13,4,10.0,ATYGATGEVY,8.7,15.6,3-25,3,10.0,QSSDSSAIWV,6.1,7.5,L,,Natural monoclonal,human,, ,34.6598,10.6183,19.0,394.0,3925.0,QVQLVQSGAEVKKPGAAVKVSCKASGYNFNSYYMYWVRNAPGRGLEWMGIIDPTGDKTSHAEKFQDRFTMTRDTSTSTIYMELSSLRSEDTAFYYCATYGATGEVYWGQGTLVTVSX,SYELTQPPSVSVSPGQTARITCSGDPLPEQFAYWYQHKPGQAPVLVIYKDNERPSGIPERFSGSSSGTTVTLTISGVQAEDEGDYYCQSSDSSAIWVFGGGTKLTVL,TCCTATGAGCTGACTCAGCCACCCTCGGTGTCAGTGTCCCCAGGACAGACGGCCAGGATCACCTGCTCTGGAGATCCATTGCCAGAGCAATTTGCTTATTGGTACCAACACAAGCCAGGCCAGGCCCCGGTGTTGGTCATCTATAAAGATAATGAGAGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAGCTCAGGGACAACAGTCACGTTGACCATCAGTGGAGTCCAGGCAGAGGACGAGGGTGACTATTACTGTCAATCATCTGACAGTAGTGCTATTTGGGTGTTCGGCGGAGGGACCAAGTTGACCGTCCTA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCGCAGTGAAAGTTTCCTGCAAGGCATCTGGATACAACTTCAACAGCTACTATATGTATTGGGTGCGAAACGCCCCTGGACGGGGGCTTGAGTGGATGGGAATAATCGACCCTACTGGTGATAAAACAAGTCACGCAGAGAAGTTCCAGGACAGATTCACCATGACCAGGGACACGTCCACGAGCACAATTTACATGGAGTTGAGCAGCCTGAGATCTGAGGACACGGCCTTTTATTATTGTGCGACCTACGGCGCAACAGGTGAAGTCTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTC,CATYGATGEVYW,91.438
QA013.32,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,QA013 ,,Williams2018(29669274) ,,Williams2018(29669274) ,,1-46,4-17,4,20.0,GRARRLSPVSSTMRTPPPDS,17.0,28.6,2-23,2,10.0,CSYGGASTLV,9.7,14.3,L,,Natural monoclonal,human,, ,30.6613,8.13293,19.0,393.0,3924.0,QVQLVQSGTSSKRPGASVKISCKASGYSFTTYYIHWVRQAPGQGLEWVAMINPGTGGTNYAQKFQGRVTVTSDTSATTVYLQLTSVTFEDTGFYFCGRARRLSPVSSTMRTPPPDSWGQGTLVTVSS,QSALIQPASVSGSPGQSITISCTGSNSDVGAYNLVSWFQQHPGGAPKVVIYEVTERPSGVSHRFSGSKSGNTASLTISGLQPEDEADYYCCSYGGASTLVFGGGTKVAVL,CAGTCTGCCCTGATTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAAGTAACAGTGATGTTGGGGCTTATAACCTTGTCTCCTGGTTCCAACAACACCCAGGCGGAGCCCCCAAAGTCGTCATTTATGAGGTCACTGAGAGGCCCTCAGGGGTTTCTCATCGCTTCTCTGGCTCTAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGACTCCAACCTGAAGACGAGGCTGATTATTACTGCTGCTCCTACGGAGGTGCCAGCACTTTAGTCTTCGGCGGAGGGACCAAGGTGGCCGTCCTC,CAGGTGCAGCTAGTGCAATCTGGGACTTCGTCGAAGAGGCCTGGGGCCTCAGTGAAGATTTCCTGCAAGGCATCTGGATACAGCTTCACCACCTACTATATCCACTGGGTGCGACAGGCCCCTGGACAGGGTCTTGAGTGGGTGGCAATGATCAACCCTGGGACTGGTGGCACAAACTACGCACAGAAATTCCAGGGCAGAGTCACCGTGACCAGCGACACGTCCGCGACGACTGTCTATCTGCAATTGACTAGCGTCACATTTGAAGACACGGGTTTTTACTTCTGTGGGAGAGCCCGCCGCCTTAGTCCGGTCTCTTCCACAATGCGGACTCCCCCCCCTGACTCGTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CGRARRLSPVSSTMRTPPPDSW,83.390
QA013.4,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,QA013 ,,Williams2018(29669274) ,,Williams2018(29669274) ,,1-18,3-10,6,21.0,ARDGLWAGSQNNLFSYYGMDV,8.7,9.2,3-25,3,10.0,QSADSSGHWV,4.7,7.4,L,,Natural monoclonal,human,, ,31.8265,7.69202,19.0,395.0,3926.0,QVQLVQSGAEVKKPGASVKVSCKASGYTFINYGISWVRQAPGQGLEWMGWISVHNGNANYAQKSQGRVTITTDTSTTTVYMELRSLRSDDTAVYYCARDGLWAGSQNNLFSYYGMDVWGQGTTVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPNHYTYWYQQKPGQAPLLVIFTDSERPSGIPERFSGSSSGTTVTLTISEVQAEDEADYYCQSADSSGHWVFGGGTKLTVL,TCCTATGAGCTGACACAGCCACCCTCGGTGTCAGTGTCCCCAGGACAGACGGCCAGGATCACCTGCTCTGGAGATGCATTGCCAAATCATTATACTTATTGGTACCAGCAGAAGCCAGGCCAGGCCCCTCTGTTGGTGATCTTTACCGACAGTGAGCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAGCTCAGGGACAACAGTCACCTTGACCATCAGTGAAGTCCAAGCAGAAGACGAGGCTGACTATTACTGTCAATCAGCAGACAGCAGTGGTCATTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTA,CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCCTCTGGTTACACTTTTATTAACTATGGTATCAGTTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGATGGATCAGCGTCCACAATGGAAACGCAAATTACGCACAGAAGTCCCAGGGCAGAGTCACCATCACCACAGACACATCCACGACGACAGTCTACATGGAATTGAGGAGCCTCAGATCTGACGACACCGCCGTCTATTACTGTGCGCGAGACGGCCTATGGGCCGGTTCGCAGAATAATCTCTTTTCCTATTACGGTATGGACGTTTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA,CARDGLWAGSQNNLFSYYGMDVW,91.216
QA013.53,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,QA013 ,,Williams2018(29669274) ,,Williams2018(29669274) ,,1-46,6-13,4,10.0,ATYGATGEVY,9.4,16.5,3-25,3,10.0,QSADSSATWV,6.8,10.8,L,,Natural monoclonal,human,, ,29.6894,12.3924,18.0,396.0,3927.0,QVQLLQSGAEVKKPGAAVKLSCKASGYNFNSYYMYWVRNAPGRGLEWMGIIDPTGDKTSHAEKFQGRFTMTRDTSTSTIYMELSSLRSEDTAFYYCATYGATGEVYWGQGTLVTVSS,SYELTQPPSASVSPGQTARITCSGDPLPEQFVYWFQHKPGQAPVLVIYKDNERPSGIPERFSGSSSGTTVTLTIRGVQAEDEGDYYCQSADSSATWVFGGGTKLTVL,TCCTATGAGCTGACACAGCCACCCTCGGCGTCAGTGTCCCCAGGACAGACGGCCAGGATCACCTGCTCTGGAGATCCATTGCCAGAGCAATTTGTTTATTGGTTCCAACACAAGCCAGGCCAGGCCCCGGTGTTGGTCATCTATAAAGATAATGAGAGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAGCTCAGGGACAACAGTCACGTTGACCATCCGTGGAGTCCAGGCAGAGGACGAGGGTGACTATTATTGTCAATCAGCAGACAGTAGTGCTACTTGGGTGTTCGGCGGAGGGACCAAGTTGACCGTCCTA,CAGGTGCAGTTGCTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCGCAGTGAAACTTTCCTGCAAGGCATCTGGATACAACTTCAACAGCTACTATATGTACTGGGTGCGAAACGCCCCTGGACGGGGGCTTGAGTGGATGGGAATAATCGACCCTACTGGTGATAAAACAAGTCACGCAGAGAAGTTCCAGGGCAGATTCACCATGACCAGGGACACGTCCACGAGCACAATTTATATGGAGTTGAGCAGCCTGAGATCTGAGGACACGGCCTTTTATTATTGTGCGACCTACGGCGCAACAGGTGAAGTCTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA,CATYGATGEVYW,90.753
QA255.087,,,QA255 ,,Williams2015(26629541) ,,Williams2015(26629541) ,IMGT/V-QUEST,1-69,4-11,6,28.0,,6.94,,3-20,2,9.0,,5.32,,K,No,Natural monoclonal,human,, Williams2015 %SHM was calculated for V genes only.,,,9.0,705.0,4295.0,,,,,,
QA255.105,gp120 V3 // V3 glycan (V3g),,QA255 ,,Williams2015(26629541) ,QA255.105 epitope,Williams2015(26629541) ,IMGT/V-QUEST,3-15,2-21,6,17.0,,9.18,,3-20,2,9.0,,7.45,,K,Yes,Natural monoclonal,human,, Williams2015 %SHM was calculated for V genes only.,,,9.0,706.0,4296.0,,,,,,
QA255.187,,,QA255 ,,Williams2015(26629541) ,,Williams2015(26629541) ,IMGT/V-QUEST,1-69,2-2,5,18.0,,8.74,,1-39,3,9.0,,9.24,,K,No,Natural monoclonal,human,, Williams2015 %SHM was calculated for V genes only.,,,9.0,708.0,4298.0,,,,,,
RHA1.V2.01,gp120 V2 // V2 glycan(V2g) // V2 apex,6XRT(SHIV-elicited RHA1.V2.01 in complex with HIV-1 Env BG505 DS-SOSIP.664);EMD-22295(SHIV-elicited RHA1.V2.01 in complex with HIV-1 Env BG505 DS-SOSIP.664),RM5695 ,RHA1.V2,Roark2021(33214287) ,RHA1.V2.01 contacts;RHA1.V2.01 signatures,Roark2021(33214287) ,IMGT/V-QUEST,,,,24.0,CARKGEDFYEDDYGQYFTAGWFFDLW,8.5,,,,8.0,CQCYDSSVLF,6.2,,L,,Natural monoclonal,macaque,,Macaque antibody ,6.954,26.1731,232.0,809.0,4544.0,QVQLRESGPGLVKPSETLVLTCAVSGGGDSFGFHYWNWIRQPPGKGLEWIGHIGGSSGSTDFNPSLKSRVTISMDSSRNQFSLRLKSVTAADTAVYFCARKGEDFYEDDYGQYFTAGWFFDLWGPGTPIIISS,QFVLTQPPSVSGAPGQTVTISCTGRSSNFGGHYVQWYQQLPGTAPRLVIFENDRRPSGVSDRFSGSQSGASASLTITGLQSEDEADYYCQCYDSSVLFGRGTRLTVL,CAGTTTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCGCCCGGGCAGACGGTCACCATCTCCTGCACTGGGAGGAGTTCCAATTTTGGCGGTCATTATGTGCAGTGGTACCAGCAGCTTCCAGGAACGGCCCCCAGACTCGTCATCTTTGAAAATGATAGGCGACCCTCAGGGGTTTCTGATCGATTCTCTGGCTCCCAGTCTGGTGCCTCAGCCTCCCTGACCATCACTGGACTCCAGTCTGAGGATGAGGCTGATTATTACTGCCAGTGCTATGACAGTAGCGTATTATTCGGAAGGGGGACCCGGCTGACCGTCCTG,CAGGTGCAGCTGCGGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGGTCCTCACCTGCGCTGTCTCTGGTGGTGGTGACTCCTTCGGTTTTCACTACTGGAACTGGATCCGCCAACCCCCGGGGAAGGGCCTGGAGTGGATTGGACATATCGGTGGCAGTAGTGGGAGTACCGACTTCAACCCCTCCCTCAAGAGTCGAGTCACCATTTCAATGGACTCGTCCAGGAACCAGTTCTCCCTGAGGTTGAAATCTGTGACCGCCGCGGACACGGCCGTGTATTTCTGTGCGAGAAAGGGTGAAGACTTTTACGAGGATGATTACGGTCAATATTTCACCGCAGGCTGGTTCTTCGATCTCTGGGGCCCTGGCACCCCAATCATCATCTCCTCA,CARKGEDFYEDDYGQYFTAGWFFDLW,86.000
RHA1.V2.02,gp120 V2 // V2 glycan(V2g) // V2 apex,,RM5695 ,RHA1.V2,Roark2021(33214287) ,,Roark2021(33214287) ,IMGT/V-QUEST,,,,24.0,CARKGEDFYEDDYGQYFTAGWYFDLW,8.5,,,,8.0,CQCYDTTVLF,6.6,,L,,Natural monoclonal,macaque,,Macaque antibody ,0.55556,14.6803,18.0,810.0,4545.0,QVQLRESGPGLVKPSEALSLTCTVSGGGDSFGFHYWNWIRQPPGKGLEWIGHIGGTSGHTDYNPSLKSRVTISMDSSKNQFSLRLNSVTAADTAVYFCARKGEDFYEDDYGQYFTAGWYFDLWGPGTPIIISS,QFVLTQPPSVSGAPGQRVTISCTGRSSNFGGHYVQWYQQLPGTAPKLVIYENNRRPSGVSERFSGSQSGASASLTITGLQSEDEADYYCQCYDTTVLFGGGTRLTVL,CAGTTTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCGCCCGGACAGAGGGTCACGATCTCCTGCACTGGGAGGAGTTCCAATTTTGGCGGTCATTATGTGCAGTGGTACCAGCAGCTTCCAGGAACGGCCCCCAAACTCGTCATCTATGAAAATAATAGGCGACCCTCAGGGGTTTCTGAGCGATTCTCTGGCTCCCAGTCTGGTGCCTCAGCCTCCCTGACCATCACTGGGCTCCAGTCTGAGGATGAGGCTGATTATTACTGCCAGTGTTATGACACCACCGTGTTATTCGGAGGGGGGACCCGGCTGACCGTCTTG,CAGGTGCAGCTGCGGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGGCCCTGTCCCTCACCTGCACTGTCTCTGGTGGTGGTGACTCCTTCGGTTTTCACTACTGGAATTGGATCCGCCAACCCCCGGGGAAGGGGCTGGAGTGGATTGGGCATATCGGTGGTACTAGTGGACATACCGACTACAACCCCTCCCTCAAGAGTCGAGTCACCATTTCAATGGACTCGTCCAAGAACCAGTTCTCCCTGAGGTTGAACTCTGTGACCGCCGCGGACACGGCCGTGTATTTCTGTGCAAGAAAGGGTGAAGACTTTTACGAGGATGATTACGGTCAATATTTCACCGCAGGCTGGTACTTCGATCTCTGGGGCCCTGGCACCCCAATCATCATCTCCTCA,CARKGEDFYEDDYGQYFTAGWYFDLW,86.333
RHA1.V2.03,gp120 V2 // V2 glycan(V2g) // V2 apex,,RM5695 ,RHA1.V2,Roark2021(33214287) ,,Roark2021(33214287) ,IMGT/V-QUEST,,,,24.0,CARKGEDFYEDDYGQYFTAGWYFDLW,7.5,,,,8.0,CQCYDSNVLF,6.6,,L,,Natural monoclonal,macaque,,Macaque antibody ,1.31063,21.0412,24.0,811.0,4546.0,QVQLRESGPGLVKPSETLSLTCAVSGGGDSFGFHYWNWIRQPPGKGLEWIGHIGGSSGHTDYNPSLKSRVTISMDSSKNQFSLRLNSVTAADTAVYFCARKGEDFYEDDYGQYFTAGWYFDLWGPGTPIIISS,QFVLTQPPSVSGAPGQRVTISCTGRSSNFGGYYVQWYQQLPGTAPKLVIYENNRRPSGVSERFSGSQSGASASLTITGLQSDDEADYYCQCYDSNVLFGGGTRLTVL,CAGTTTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCGCCCGGACAGAGGGTCACCATCTCCTGCACTGGGAGGAGTTCCAATTTTGGCGGTTATTATGTGCAGTGGTACCAGCAACTTCCAGGAACGGCCCCCAAACTCGTCATCTATGAAAATAATAGGCGACCCTCAGGGGTTTCTGAGCGATTCTCTGGCTCCCAGTCTGGTGCCTCAGCCTCCCTGACCATCACTGGACTGCAGTCTGATGATGAGGCTGATTATTACTGCCAGTGTTATGACAGTAACGTGTTATTCGGAGGGGGGACCCGGCTGACCGTCCTG,CAGGTGCAGCTGCGGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGTGCTGTTTCTGGTGGTGGTGACTCCTTCGGTTTTCACTACTGGAACTGGATCCGCCAACCCCCGGGGAAGGGGCTGGAGTGGATTGGGCATATCGGTGGTAGTAGTGGGCATACCGACTACAATCCCTCCCTCAAGAGTCGAGTCACCATTTCAATGGACTCGTCCAAGAACCAGTTCTCCCTGAGGTTGAACTCTGTGACCGCCGCGGACACGGCCGTGTATTTCTGTGCAAGAAAGGGTGAAGACTTTTACGAGGATGATTACGGTCAATATTTCACCGCAGGCTGGTACTTCGATCTCTGGGGCCCTGGCACCCCAATTATCATCTCCTCA,CARKGEDFYEDDYGQYFTAGWYFDLW,85.667
RHA1.V2.04,gp120 V2 // V2 glycan(V2g) // V2 apex,,RM5695 ,RHA1.V2,Roark2021(33214287) ,,Roark2021(33214287) ,IMGT/V-QUEST,,,,24.0,CARKGEDFYEDDYGQYFTAGWFFDLW,7.1,,,,8.0,CQCYDTTVLF,6.2,,L,,Natural monoclonal,macaque,,Macaque antibody ,0.98814,24.8588,24.0,812.0,4547.0,QVQLRESGPGLVKPSETLSLTCAVSGGGDSFGFHFWNWIRQPPGKGLEWIGHIGGSSGSTDYNPSLKSRVTISMDSSKNQFSLRLNSVTAADTAVYFCARKGEDFYEDDYGQYFTAGWFFDLWGPGTPIIISS,QFVLTQPPSVSGAPGQRVTISCTGRSSNFGGHYVQWYQQLPGTAPRLVIYENNRRPSGVSDRFSGSQSGASASLTITGLQSEDEADYYCQCYDTTVLFGGGTRVTVL,CAGTTTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCGCCCGGGCAGAGGGTCACCATCTCCTGCACTGGGAGGAGTTCCAATTTCGGCGGTCATTATGTGCAGTGGTACCAACAGCTTCCAGGAACGGCCCCCAGACTCGTCATCTATGAAAATAATAGGCGACCCTCAGGGGTTTCTGATCGATTCTCTGGCTCCCAGTCTGGTGCCTCAGCCTCCCTGACCATCACTGGACTCCAGTCTGAGGATGAGGCTGATTATTACTGCCAGTGTTATGACACCACCGTGTTATTTGGAGGGGGGACCCGGGTGACCGTCCTG,CAGGTGCAGCTGCGGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGCTGTCTCAGGTGGTGGTGACTCCTTCGGTTTTCACTTCTGGAACTGGATCCGCCAACCCCCGGGGAAGGGGCTGGAGTGGATTGGGCATATCGGTGGTAGTAGTGGTAGTACCGACTACAACCCCTCCCTCAAGAGTCGAGTCACCATTTCAATGGACTCGTCCAAGAACCAGTTCTCCCTGAGGTTGAACTCTGTGACCGCCGCGGACACGGCCGTGTATTTCTGTGCAAGAAAGGGTGAAGACTTTTACGAGGATGACTACGGTCAATATTTCACCGCAGGCTGGTTCTTCGATCTCTGGGGCCCTGGCACCCCAATAATCATCTCCTCA,CARKGEDFYEDDYGQYFTAGWFFDLW,86.333
RoAb13,non-HIV: host CCR5,,,,Ji2007(17166600) ,,,,,,,,,,,,,,,,,,,,mouse,ROAb13, ,0.30728,9.45136,106.0,584.0,4159.0,,,,,,
RoAb13/PGDM1400/PGT121,gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);non-HIV: host CCR5,,Donor 17 Donor 84 ,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human;mouse,RoAb13Fab-PGDM1400fv-PGT121fv, ,0.094815,24.9301,107.0,426.0,3997.0,,,,,,
RoAb13/PRO-140,non-HIV: host CCR5,,,,Khan2018(29976677) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,,RoAb13/PRO 140,bispecific ,0.2401,2.55389,106.0,585.0,4160.0,,,,,,
sCD4,,"1CDJ(glycoprotein CD4);1G9M(gp120 (HXB2) complexed with CD4 and 17b);1G9N(gp120 (YU2) complexed with CD4 and 17b);1GC1(gp120 core complexed with CD4 and 17b);1RZJ(gp120 (HXB2) complexed with CD4 and 17b);1RZK(gp120 (YU2) complexed with CD4 and 17b);2NXY(gp120 (S334A) complexed with CD4 and 17b);2NY0(gp120 (M95W, W96C, T257S, V275C, S334A, S375W, A433M) complexed with CD4 and 17b);2NY5(gp120 (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) complexed with CD4 and 17b)",,,,,,,,,,,,,,,,,,,,,,,,, ,7.27906,5.02791,601.0,39.0,,,,,,,
SF10,gp120 silent face,,27845 ,SF12,Schoofs2019(31126879) ,,Schoofs2019(31126879) ,IgBlast IMGT/V-QUEST,4-59*01,,,23.0,GRVGPGGLFDRWTGYHGHKWVDA,25.3,37.1,3-20*01,,6.0,QQYGRT,19.9,29.0,K,,Natural monoclonal,human,, ,3.33066,43.1113,31.0,544.0,4150.0,HVELKQSGPGQVKPSETLSMTCSVSGGSVRQFYWAWIRQSPGKGLEWMGYIYSDGYADYIPSLKSRLTFTLDEPKNRVSLRLTSVTPADAGIYFCGRVGPGGLFDRWTGYHGHKWVDAWGQGLLVTVSS,ETVLTQSPGTLSVPLGETATLSCMASQNTDFNYFAWYQQKPGQPPRLLMQGASNRANGFPERFTARGSGTHFTLTIDRVEPDDAAVYYCQQYGRTFGQGTKLHIK,GAAACTGTTTTGACGCAGTCTCCAGGCACCCTGTCTGTGCCTCTCGGAGAGACAGCCACCCTCTCTTGTATGGCCAGTCAGAATACTGATTTCAACTACTTTGCCTGGTATCAACAAAAACCTGGCCAGCCTCCCCGGCTCCTCATGCAGGGCGCATCCAACAGGGCCAATGGCTTCCCGGAGAGATTCACTGCCAGGGGGTCGGGGACGCACTTCACCCTCACCATCGACAGAGTGGAGCCCGACGATGCAGCAGTTTATTATTGTCAGCAATATGGGAGGACGTTCGGCCAGGGGACCAAGCTGCACATCAAA,CACGTGGAATTGAAGCAGTCGGGGCCAGGACAGGTGAAGCCTTCGGAGACCCTCTCCATGACCTGCAGTGTTTCTGGTGGATCCGTCCGTCAGTTCTACTGGGCCTGGATCCGCCAGTCCCCGGGAAAGGGACTGGAGTGGATGGGATATATATATTCCGATGGCTACGCCGACTACATTCCGTCACTCAAGAGCCGACTCACTTTCACACTCGACGAGCCCAAGAATCGCGTTTCTTTGAGATTGACATCTGTGACCCCCGCGGACGCGGGAATTTATTTTTGTGGGAGAGTGGGTCCCGGGGGTCTCTTCGATCGGTGGACGGGATATCACGGCCACAAGTGGGTCGACGCCTGGGGCCAGGGACTCCTAGTCACCGTCTCGTCA,CGRVGPGGLFDRWTGYHGHKWVDAW,75.000
SF12,gp120 silent face,6OKP(SOSIP.664 in complex with SF12 and 10-1074);6OKQ(SF12 Fab);EMD-20100(B41 SOSIP.664 in complex with SF12 and 10-1074);EMD-20101(B41 SOSIP.664 trimer in complex with 2 Fab fragments of SF12 and 1 Fab fragment of 10-1074),27845 ,SF12,Schoofs2019(31126879) ,SF12 interaction sites,Schoofs2019(31126879) ,IgBlast IMGT/V-QUEST,4-59*01,,,23.0,ARLGPGGIFDRWTGHYGDKWLDP,17.0,21.4,3-20*01,,6.0,QLSGRR,14.6,20.4,K,,Natural monoclonal,human,, ,2.12886,26.5461,271.0,538.0,4063.0,QVQLQESGPGLVKPSETLSVTCRVSGGSLDLYYWSWIRQPPGKGLQWIGFVYFDGSYGDYDPSLRSRVTISADMSKNQISLRLKSVTPADTAVYYCARLGPGGIFDRWTGHYGDKWLDPWGQGTLVTVSS,QIDLTQSPRTLSLSAGERATLLCRASQSVSNVALAWYQHKPGQAPRLLLHEASTRATGIPDRFIGSGSGRDFTLTITSLEPEDFAVYYCQLSGRRLGQGTKVEIK,CAAATTGACTTGACGCAGTCTCCACGCACCCTGTCTCTGTCTGCAGGGGAAAGAGCCACCCTCCTCTGCAGGGCCAGTCAGAGTGTCAGCAACGTTGCATTAGCCTGGTATCAGCACAAACCTGGCCAGGCTCCCAGGCTCCTCCTTCATGAGGCTTCGACTAGGGCCACTGGCATCCCAGACAGATTCATTGGCAGTGGGTCTGGGCGAGACTTCACTCTCACCATCACTAGTCTGGAACCTGAAGATTTTGCAGTTTACTATTGTCAGCTGTCTGGGAGGCGGCTCGGCCAAGGGACCAAGGTTGAAATCAAG,CAGGTGCAGCTGCAAGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCGTCACCTGTCGGGTCTCTGGTGGCTCACTCGATCTTTACTATTGGAGTTGGATCCGCCAGCCCCCTGGGAAGGGACTGCAGTGGATCGGCTTTGTGTACTTCGATGGGAGTTATGGCGACTATGATCCCTCTCTCAGGAGTCGGGTCACCATTTCAGCGGACATGTCCAAGAACCAGATCTCCCTGAGACTGAAGTCTGTGACCCCTGCGGACACGGCCGTCTATTACTGTGCGAGACTGGGCCCCGGGGGGATTTTCGATCGTTGGACCGGTCATTATGGAGATAAGTGGCTCGACCCCTGGGGCCAGGGGACCCTGGTCACCGTCTCCTCA,CARLGPGGIFDRWTGHYGDKWLDPW,82.993
SF2,gp120 silent face,,27845 ,SF12,Schoofs2019(31126879) ,,Schoofs2019(31126879) ,IgBlast IMGT/V-QUEST,4-59*01,,,23.0,ARLGPGGLFDRYTGYHGRKWLDA,24.4,32.0,3-20*01,,6.0,QQYGRT,18.0,23.9,K,,Natural monoclonal,human,SF02, ,21.2102,16.2415,31.0,539.0,4146.0,RVELKQSGPGLVKPSETLSLTCEVSGGLVDQFYWAWIRQFPGKGLEWIGYIYSDGFADYTPSLKSRLTFSLDTPKNRVSLRLTSMTPADAGTYYCARLGPGGLFDRYTGYHGRKWLDAWGQGTLVTVSS,ETVLTQSPAILSVFAGGRATLSCRASQTTDGNYLSWYQQKPGQAPRLLMQGASNRATDIPDRFSGSGSGIEFTLTISRVEPEDSAMYYCQQYGRTFGQGTKLEIT,GAAACTGTCCTGACGCAGTCTCCAGCCATCCTGTCTGTGTTTGCAGGAGGAAGAGCCACCCTCTCTTGCAGGGCCAGTCAGACTACTGATGGCAACTACTTGTCTTGGTATCAGCAAAAACCTGGCCAGGCTCCCAGACTCCTCATGCAGGGCGCAAGTAATAGGGCCACTGACATCCCGGACAGATTCAGTGGCAGTGGGTCGGGCATAGAGTTCACCCTGACTATCAGCAGAGTGGAGCCGGAAGATTCTGCAATGTATTACTGTCAACAATATGGGCGGACCTTCGGCCAAGGGACCAAGTTGGAGATCACA,CGCGTGGAGTTGAAGCAGTCGGGGCCAGGACTGGTGAAGCCTTCGGAGACCCTCTCCCTGACCTGCGAAGTGTCTGGGGGCTTAGTCGATCAGTTCTACTGGGCCTGGATCCGCCAGTTCCCCGGAAAGGGATTAGAGTGGATTGGATACATTTATTCAGATGGCTTTGCCGACTACACTCCCTCCCTCAAGAGTCGACTCACCTTTTCACTCGACACGCCCAAGAATCGGGTCTCCCTCAGACTCACATCTATGACCCCTGCGGACGCGGGAACTTATTACTGCGCGAGACTGGGTCCCGGGGGACTCTTCGATCGTTACACTGGTTACCATGGACGAAAGTGGCTCGACGCCTGGGGCCAGGGCACACTGGTCACCGTCTCCTCA,CARLGPGGLFDRYTGYHGRKWLDAW,75.945
SF3,gp120 silent face,,27845 ,SF12,Schoofs2019(31126879) ,,Schoofs2019(31126879) ,IgBlast IMGT/V-QUEST,4-59*01,,,23.0,GRVGPGGLFDRWRGYHGHKWVDA,25.3,39.2,3-20*01,,6.0,QQYGRT,21.4,29.0,K,,Natural monoclonal,human,SF03, ,16.7942,20.2421,31.0,540.0,4147.0,HVELKQSGPGQVKPLETLSMTCSVSGGSVRQFYWAWIRQSPGKGLEWMGYIYSDGYADYIPSLKSRLTFTLDEPKNRVSLRLTSMTPADAGIYFCGRVGPGGLFDRWRGYHGHKWVDAWGQGLLVTVSS,ETVLTQSPGSLSVALGETATLSCMASQNTDFNYFAWYQQKPGQAPRLLMQGASNRANGFPERFTARGSGTRFTLTIDRVEPDDAAVYYCQQYGRTFGQGTKLHIK,GAAACTGTTTTGACGCAGTCTCCAGGCTCCCTGTCTGTGGCTCTCGGAGAGACAGCCACCCTCTCTTGTATGGCCAGTCAGAATACTGATTTCAACTACTTTGCCTGGTATCAACAAAAACCTGGCCAGGCTCCCCGACTCCTAATGCAGGGCGCGTCCAACAGGGCCAATGGCTTCCCGGAGAGATTCACTGCCAGGGGGTCGGGGACGCGCTTCACCCTCACCATCGACAGAGTGGAGCCCGACGATGCAGCAGTCTATTATTGTCAGCAATATGGGAGGACGTTCGGCCAGGGGACCAAGCTGCACATCAAA,CACGTGGAATTGAAGCAGTCGGGGCCAGGACAGGTGAAGCCTTTGGAGACCCTCTCCATGACCTGCAGTGTGTCTGGTGGATCCGTCCGTCAATTCTACTGGGCCTGGATCCGCCAGTCCCCAGGAAAGGGACTGGAGTGGATGGGATACATCTATTCCGATGGCTACGCCGACTACATTCCGTCACTCAAGAGTCGACTCACTTTCACACTCGACGAGCCCAAGAATCGCGTTTCTTTGAGATTGACATCTATGACCCCCGCGGACGCGGGAATTTATTTTTGTGGGAGAGTGGGTCCCGGGGGTCTCTTCGATCGGTGGAGGGGATATCACGGCCACAAGTGGGTCGACGCCTGGGGCCAGGGACTCCTAGTCACCGTCTCCTCA,CGRVGPGGLFDRWRGYHGHKWVDAW,75.000
SF5,gp120 silent face,,27845 ,SF12,Schoofs2019(31126879) ,,Schoofs2019(31126879) ,IgBlast IMGT/V-QUEST,4-59*01,,,23.0,ARLGPGGIFDRWTGHYGDKWLDP,19.0,25.5,3-20*01,,6.0,QLSGRR,16.0,21.5,K,,Natural monoclonal,human,SF05, ,3.17704,30.2375,269.0,541.0,4064.0,QVQLQESGPGLVKPSETLSVTCRVSGGSLDRYYWSWIRQPPGEGLQWIGHVYFDGSYGDYDPSLRSRVTITADMSKYQIILRLRSVTPADTAVYYCARLGPGGIFDRWTGHYGDKWLDPWGQGTLVTVSS,QIVLTQSPRTLSLSAGERATLLCRASQSVSNVALAWYQHKPGQAPRLLLHEASIRAAGIPDRFVGSGSGRDFTLTITSLHPEDFAVYYCQLSGRRLGPGTKVEIK,CAAATTGTGTTGACGCAGTCTCCACGCACCCTGTCTTTGTCCGCAGGGGAAAGAGCCACCCTCCTCTGCAGGGCCAGTCAGAGTGTTAGCAACGTTGCTTTGGCCTGGTATCAGCACAAACCTGGCCAGGCTCCCAGGCTCCTCCTTCATGAGGCTTCGATTAGGGCCGCTGGCATCCCAGACAGATTCGTTGGCAGTGGGTCTGGGCGTGACTTCACTCTCACCATCACTAGTCTGCACCCTGAAGATTTTGCTGTTTACTATTGTCAACTGTCTGGGAGGCGGCTCGGCCCAGGGACCAAGGTTGAAATCAAA,CAGGTGCAGTTGCAAGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCGTCACCTGCCGGGTCTCTGGTGGCTCCCTTGATCGTTACTATTGGAGTTGGATCCGTCAGCCCCCTGGGGAGGGTCTGCAGTGGATCGGCCATGTGTACTTCGACGGGAGTTATGGCGACTATGATCCCTCGCTCAGGAGTCGGGTCACCATTACAGCGGACATGTCCAAATACCAGATCATCCTGAGACTGAGGTCTGTGACCCCTGCGGACACGGCCGTCTATTACTGTGCGAGACTGGGCCCCGGGGGCATCTTCGATCGTTGGACCGGTCATTACGGAGATAAGTGGCTCGACCCCTGGGGCCAGGGGACCCTGGTCACCGTCTCCTCA,CARLGPGGIFDRWTGHYGDKWLDPW,80.952
SF7,gp120 silent face,,27845 ,SF12,Schoofs2019(31126879) ,,Schoofs2019(31126879) ,IgBlast IMGT/V-QUEST,4-59*01,,,23.0,GRVGPGGLFDRWRGYHGHKWVDA,25.3,39.2,3-20*01,,6.0,QQYGRT,21.4,29.0,K,,Natural monoclonal,human,SF07, ,16.1502,21.7268,31.0,542.0,4148.0,HVELKQSGPGQVKPLETLSMTCSVSGGSVRQFYWAWIRQSPGKGLEWMGYIYSDGYADYIPSLKSRLTFTLDEPKNRVSLRLTSMTPADAGIYFCGRVGPGGLFDRWRGYHGHKWVDAWGQGLLVTVSS,ETVLTQSPGSLSVALGETATLSCMASQNTDFNYFAWYQQKPGQAPRLLMQGASNRANGFPERFTARGSGTRFTLTIDRVEPDDAAVYYCQQYGRTFGQGTKLHIK,GAAACTGTTTTGACGCAGTCTCCAGGCTCCCTGTCTGTGGCTCTCGGAGAGACAGCCACCCTCTCTTGTATGGCCAGTCAGAATACTGATTTCAACTACTTTGCCTGGTATCAACAAAAACCTGGCCAGGCTCCCCGACTCCTAATGCAGGGCGCGTCCAACAGGGCCAATGGCTTCCCGGAGAGATTCACTGCCAGGGGGTCGGGGACGCGCTTCACCCTCACCATCGACAGAGTGGAGCCCGACGATGCAGCAGTCTATTATTGTCAGCAATATGGGAGGACGTTCGGCCAGGGGACCAAGCTGCACATCAAA,CACGTGGAATTGAAGCAGTCGGGGCCAGGACAGGTGAAGCCTTTGGAGACCCTCTCCATGACCTGCAGTGTGTCTGGTGGATCCGTCCGTCAATTCTACTGGGCCTGGATCCGCCAGTCCCCAGGAAAGGGACTGGAGTGGATGGGATACATCTATTCCGATGGCTACGCCGACTACATTCCGTCACTCAAGAGTCGACTCACTTTCACACTCGACGAGCCCAAGAATCGCGTTTCTTTGAGATTGACATCTATGACCCCCGCGGACGCGGGAATTTATTTTTGTGGGAGAGTGGGTCCCGGGGGTCTCTTCGATCGGTGGAGGGGATATCACGGCCACAAGTGGGTCGACGCCTGGGGCCAGGGACTCCTAGTCACCGTCTCCTCA,CGRVGPGGLFDRWRGYHGHKWVDAW,75.000
SF8,gp120 silent face,,27845 ,SF12,Schoofs2019(31126879) ,,Schoofs2019(31126879) ,IgBlast IMGT/V-QUEST,4-59*01,,,23.0,ARLGPGGLFDRYTGYHGRKWLDA,24.4,32.0,3-20*01,,6.0,QQYGRT,16.5,21.7,K,,Natural monoclonal,human,SF08, ,21.3329,17.876,31.0,543.0,4149.0,RVELKESGPGLVKPSETLSLTCGVSGGLVDQFYWAWIRQFPGKGLEWIGYIYSDGFADYTPSLKSRLTFSLDTPKNRVSLRLTAMTPADAGSYYCARLGPGGLFDRYTGYHGRKWLDAWGQGTLVIVSS,ETVLTQSPGILSVSAGGRATLSCRASQTTDGNYLSWYQQKPGQAPRLLMQGAYNRATDIPDRFSGSGSGTEFTLTISRVEPEDSAMYYCQQYGRTFGQGTKVEIK,GAAACTGTGCTGACGCAGTCTCCAGGCATCCTGTCTGTGTCTGCAGGAGGAAGAGCCACCCTCTCTTGTAGGGCCAGTCAGACTACTGATGGCAACTATTTGTCTTGGTATCAGCAAAAACCTGGCCAGGCTCCCAGACTCCTCATGCAGGGCGCATACAATAGGGCCACTGACATCCCGGACAGATTCAGTGGCAGTGGGTCGGGCACAGAGTTCACCCTGACTATCAGCAGAGTGGAGCCGGAAGATTCTGCAATGTATTACTGTCAACAATATGGGCGGACCTTCGGCCAAGGGACCAAGGTGGAGATCAAA,CGCGTGGAGTTGAAGGAGTCGGGGCCAGGACTGGTGAAGCCTTCGGAGACCCTCTCCCTGACCTGCGGAGTGTCTGGGGGCTTAGTCGATCAGTTCTACTGGGCCTGGATCCGCCAGTTCCCCGGAAAGGGATTAGAGTGGATTGGATACATTTACTCAGATGGCTTTGCCGACTACACTCCCTCCCTCAAGAGTCGACTCACCTTTTCACTCGACACGCCCAAGAATCGGGTCTCCCTGAGACTCACAGCTATGACCCCTGCGGACGCGGGAAGTTATTACTGCGCGAGACTGGGTCCCGGGGGACTCTTCGATCGTTACACTGGTTACCATGGACGGAAGTGGCTCGACGCCTGGGGCCAGGGCACACTGGTCATCGTCTCCTCA,CARLGPGGLFDRYTGYHGRKWLDAW,75.945
T-01 MB,gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region),,,,Rujas2022(35064083) ,,,,,,,,,,,,,,,,,,,Other,human,, ,0.044983,28.5222,261.0,857.0,4653.0,,,,,,
T-01 MB.v2,gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region),,,,Rujas2022(35064083) ,,,,,,,,,,,,,,,,,,,Other,human,, ,0.0022159,18.1969,261.0,859.0,4654.0,,,,,,
T-02 MB,gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region);non-HIV: host CD4R,,,,Rujas2022(35064083) ,,,,,,,,,,,,,,,,,,,Other,human,, ,0.037258,16.9794,14.0,860.0,4655.0,,,,,,
Tri-NAb,gp120 CD4bs;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region),,Donor 17 Donor N152 NIH45 ,,Steinhardt2018(29491415) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,"trispecific involving VRC01, PGT121, and 10E8 ",0.071679,6.29224,416.0,386.0,3959.0,,,,,,
vFP1.01,gp41 fusion domain,5TKJ(vFP1.01 in complex with HIV-1 fusion peptide residue 512-519),1868 ,,Xu2018(29867235) ,Mutation reduces binding/neutralization of fusion peptide mAbs,,,,,,,,,,,,,,,,,,Natural monoclonal,mouse,1868-vFP1.01,mouse Ab ,78.9308,2.30044,436.0,378.0,3937.0,QVQLQQSGTELVWPGTSVTLSCKASGYTFTDYEIHWVKQTPVHGLEWIGAIVPKTGYTAYNQKFRGKAILTADKSSSTAYMDLRRLTSEDSAVYYCTRLRNYWYFDVWGTGTTVTVSP,DFLMAQTPLSLPVSLGDQASISCRSSQSIVYSDGNTYLEWYLQRPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDLGIYYCFQGSHVPYTFGGGTKLEIK,GATTTTTTGATGGCCCAAACTCCACTCTCCCTCCCTGTCAGTCTTGGGGATCAAGCCTCCATCTCTTGCAGATCAAGTCAGAGCATTGTATATAGTGATGGAAACACCTATTTAGAATGGTACCTTCAGAGACCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACTCTCAGGATCAGCAGAGTTGAGGCTGAGGATCTGGGAATTTATTACTGCTTTCAAGGTTCACATGTTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA,CAGGTTCAACTGCAGCAGTCTGGGACTGAGCTGGTGTGGCCTGGGACCTCAGTGACGCTGTCCTGCAAGGCTTCGGGCTACACGTTTACTGACTATGAAATACACTGGGTGAAACAGACACCTGTGCATGGCCTGGAATGGATTGGAGCTATTGTTCCTAAAACTGGTTATACTGCCTACAATCAGAAATTCAGGGGCAAGGCCATACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGGACCTCCGCCGCCTGACATCTGAGGACTCTGCCGTCTATTACTGTACGAGACTACGAAACTACTGGTACTTCGATGTCTGGGGCACAGGGACCACGGTCACCGTCTCACCA,CTRLRNYWYFDVW,72.449
vFP16.02,gp41 fusion domain,"6CDI(antibody vFP16.02 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122);6CDO(vFP16.02 in complex with HIV-1 fusion peptide residue 512-519)",2712 ,,Xu2018(29867235) ,Mutation reduces binding/neutralization of fusion peptide mAbs,,,,,,,,,,,,,,,,,,Natural monoclonal,mouse,2712-vFP16.02,mouse Ab ,37.5988,5.70298,852.0,382.0,3949.0,QVQLLQSGAELVRPGASVTLSCKASGYAFSDYEIHWVKQTPVRGLDWIGAFDPKSGASASNQKVKGRAILTADKSSSTAYMELRSLTSEDSAVYYCTRLRYFGYFDVWGTGTTVTVSS,DVLMTQTPLSLPVSLGGQASISCRSSQSVVYSDGDTYLEWYLQKPGQSPKLLIYKVSRRFSGVPDRFSGSGSGTDFTLKISRVETEDLGVYYCFQGSHVPYTFGGGTKLEIK,GATGTTTTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGCGGTCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCGTTGTATATAGTGATGGAGACACCTATTTAGAGTGGTATCTGCAGAAACCAGGCCAGTCTCCAAAGCTCCTGATCTATAAAGTTTCCAGGCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAAACTGAGGATCTGGGAGTTTATTACTGCTTTCAAGGTTCACATGTTCCTTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA,CAGGTTCAACTGCTGCAGTCTGGGGCTGAACTGGTGAGGCCTGGGGCTTCAGTGACGCTGTCCTGCAAGGCTTCGGGCTACGCATTTAGTGACTATGAAATTCACTGGGTGAAGCAGACACCTGTGCGTGGCCTGGACTGGATTGGAGCTTTTGATCCTAAATCTGGTGCTTCTGCCTCCAATCAGAAGGTCAAGGGCAGGGCCATACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCCGTCTATTACTGTACAAGATTACGTTACTTCGGGTACTTCGATGTCTGGGGCACAGGGACCACGGTCACCGTCTCCTCA,CTRLRYFGYFDVW,72.945
vFP20.01,gp41 fusion domain,6CDP(vFP20.01 in complex with HIV-1 fusion peptide residue 512-519),2716 ,,Xu2018(29867235) ,Mutation reduces binding/neutralization of fusion peptide mAbs,,,,,,,,,,,,,,,,,,Natural monoclonal,mouse,2716-vFP20.01,mouse Ab ,44.3829,4.52989,436.0,383.0,3950.0,QVQLQQSGADLVRPGASVTLSCKASGYTFTDYEMHWMKQTPVHGLEWIGAIVPETGYTAYNQKFKGKAILTADKSSNTVYMQFRSLTSEDSAVYYCSRLKLLGYFDVWGTGTTVTVSS,DVLMTQTPLSLPVSLGDQASISCKSSQSIVYKDGNSYLEWYLQKVGQSPKLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGTHLPYTFGGGTKLEMK,GATGTTTTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAAATCAAGTCAGAGCATTGTCTATAAAGATGGAAATTCTTATTTAGAGTGGTACCTGCAGAAAGTAGGCCAGTCTCCAAAGCTCCTGATTTACAGAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGGTCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTACTGCTTTCAAGGTACACATCTTCCATACACGTTCGGAGGGGGGACCAAGCTGGAAATGAAA,CAGGTTCAACTGCAGCAGTCTGGGGCTGACCTGGTGAGGCCTGGGGCTTCAGTGACGCTGTCCTGCAAGGCTTCGGGCTACACATTTACTGACTATGAGATGCACTGGATGAAACAGACACCTGTGCATGGCCTCGAATGGATTGGAGCTATTGTTCCTGAAACTGGTTATACTGCCTACAATCAGAAGTTCAAGGGCAAGGCCATATTGACTGCAGACAAATCCTCCAACACAGTCTACATGCAGTTCCGCAGCCTGACATCTGAGGACTCTGCCGTCTATTACTGTTCAAGATTGAAATTATTAGGGTATTTCGATGTCTGGGGCACAGGGACCACGGTCACCGTCTCCTCA,CSRLKLLGYFDVW,73.630
vFP5.01,gp41 fusion domain,5TKK(vFP5.01 in complex with HIV-1 fusion peptide residue 512-519),1868 ,,Xu2018(29867235) ,Mutation reduces binding/neutralization of fusion peptide mAbs,,,,,,,,,,,,,,,,,,Natural monoclonal,mouse,1868-vFP5.01,mouse Ab ,98.4733,1.14622,416.0,379.0,3944.0,DVQLQESGPGLVKPSQSLSLTCSVTGYSITRAYYWNWIRQFPGNKLEWMGYILYDGRSDYNPSLKNRVSITRDTSKNQFFLKLNSVTAEDTARYYCTREGNYRAYWGQGTLVTVSA,DIVMTQSQKFMSTSVGDRVSITCKASQNVGSDVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTINNMKSEDLADYFCQQYSSYPLTFGAGTKLELK,GACATTGTGATGACCCAGTCTCAAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGAATGTGGGTTCTGATGTAGCCTGGTATCAACAGAAACCAGGACAGTCTCCTAAACTACTGATTTATTCGGCATCCAATCGGTACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACGGATTTCACTCTCACCATCAACAATATGAAGTCTGAAGACCTGGCAGATTATTTCTGCCAACAATATAGCAGCTATCCTCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA,GATGTACAGCTTCAGGAGTCAGGACCTGGCCTCGTGAAACCTTCTCAGTCTCTGTCTCTCACCTGCTCTGTCACTGGCTACTCCATCACCAGAGCTTATTACTGGAACTGGATCCGGCAGTTTCCAGGAAACAAACTGGAATGGATGGGTTACATACTCTACGATGGTCGCAGTGACTACAACCCATCTCTCAAAAATCGCGTCTCCATCACTCGTGACACTTCTAAGAACCAGTTTTTCCTGAAATTGAATTCTGTGACTGCTGAGGACACAGCCAGATATTACTGTACAAGAGAGGGAAACTATAGAGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA,CTREGNYRAYW,73.913
vFP7.04,gp41 fusion domain,"6CDM(vFP7.04 in complex with HIV-1 fusion peptide residue 512-519);6CUE(vFP7.04 in complex with BG505 DS-SOSIP, and antibodies VRC03 and PGT122)",2586 ,,Xu2018(29867235) ,Mutation reduces binding/neutralization of fusion peptide mAbs,,,,,,,,,,,,,,,,,,Natural monoclonal,mouse,2586-vFP7.04,mouse Ab ,78.8731,2.2905,416.0,380.0,3938.0,QVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGAIVPETGFTAYTQKFKGKAMLTADKSSSTAYMELRSLTSEDSAVYFCSRLRLYWYFDVWGTGTTVTVSS,GVLMTQSPLSLPVRLGDQASISCRSSQSIVYSNGNTYLEWYLQRPGQSPKLLIYKVSNRFSGVPDRVSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,GGTGTTTTGATGACCCAAAGTCCACTCTCCCTGCCTGTCCGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCATTGTATATAGTAATGGAAACACCTATTTAGAATGGTACCTGCAGAGACCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGGTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTACTGCTTTCAAGGTTCACATGTTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA,CAGGTTCAACTGCAGCAGTCTGGGGCTGAGCTGGTGAGGCCTGGGGCTTCAGTGACGCTGTCCTGCAAGGCTTCGGGCTACACATTTACTGACTATGAAATGCACTGGGTGAAGCAGACACCTGTGCATGGCCTGGAATGGATTGGAGCTATTGTTCCTGAAACTGGTTTTACTGCCTACACTCAGAAGTTCAAGGGCAAGGCCATGCTGACTGCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCCGTCTATTTCTGTTCACGATTGCGCCTCTACTGGTACTTCGATGTCTGGGGCACAGGGACCACGGTCACCGTCTCCTCA,CSRLRLYWYFDVW,74.227
vFP7.05,gp41 fusion domain,,2586 ,,Xu2018(29867235) ,Mutation reduces binding/neutralization of fusion peptide mAbs,,,,,,,,,,,,,,,,,,Natural monoclonal,mouse,2586-vFP7.05,mouse Ab ,83.1511,2.09128,416.0,381.0,3939.0,QVQLQQSGAELARPGTSVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGAIVPETGFTAYTQKFKGKAIMTADKSSSTVQMELRSLTSEDAAVYYCSRLRLYWYFDVWGTGTTVTVSS,GVLLTQSPLSLPVSLGDQASISCRSSQSILYRNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRVSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,GGTGTTTTGCTGACCCAAAGTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATTTCTTGCAGATCCAGTCAGAGTATTTTATATAGAAATGGAAACACCTATTTAGAATGGTACCTGCAGAAACCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGGTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTACTGCTTTCAAGGTTCACATGTTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA,CAGGTTCAACTGCAGCAGTCTGGGGCTGAGCTGGCGAGGCCTGGGACTTCAGTGACGCTGTCCTGCAAGGCTTCGGGCTACACATTTACTGACTATGAAATGCACTGGGTGAAGCAGACACCTGTGCATGGCCTGGAATGGATTGGAGCTATTGTTCCTGAAACTGGTTTTACTGCCTACACTCAGAAGTTCAAGGGCAAGGCCATAATGACTGCAGACAAATCCTCCAGCACAGTCCAAATGGAGCTCCGCAGCCTGACATCTGAGGACGCTGCCGTCTATTACTGTTCACGATTGCGCCTCTACTGGTACTTCGATGTCTGGGGCACAGGGACCACGGTCACCGTCTCCTCA,CSRLRLYWYFDVW,73.540
VRC01,gp120 CD4bs,"3NGB(VRC01 complexed with gp120);4JPI(Fab VRC01 germline precursor);4JPK(VRC01 germline precursor Fab complexed with gp120 outer domain);4LSS(VRC01 complexed with gp120 (KER2008));4LST(VRC01 complexed with gp120 (ZM176));5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5KZC(gp120 engineered outer domain with a Man9 glycan at position N276, in complex with VRC01);6MYY(Germline VRC01 antibody recognition of a modified clade C envelope trimer);6NNF(BG505 SOSIP.664 Prefusion Env Trimer Bound to VRC01 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv)",NIH45 ,VRC01,Wu2010(20616233) ,"3BNC117 contacts;Electrostatic interactions with D368;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation abrogates BG24 OR VRC01 neutralization;Mutation affects neutralization;Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;Mutation affects VRC01 neutralization;Mutation affects VRC01, PGT151, and 2G12 binding;Mutation decreases binding to CD4BS mAbs;mutations affecting VRC01 binding;mutations affecting VRC01 binding;Mutations allowing binding of germline Abs;Mutations associated with immunotherapy with BG24 or VRC01;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01;Sequence changes after immunotherapy with VRC01;Signature Analysis Summary;VRC01 contacts;VRC01 contacts;VRC01 residue prediction;VRC01 signature predictions",Klein2013(23540694) ,IgBlast,1-2,3-16 or 5-24,1,,,,,3-11,2,,,,,K,Yes,Natural monoclonal,human,"VRC01 d45, VRC-HIVMAB060-00-AB", Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.,0.86261,9.95782,10750.0,7.0,2163.0,QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSS,EIVLTQSPATLSLSPGERATLSCRTSQYGSSYLAWYQQKPGQAPRLLIYDGSNRATGIPARFSGSRWGPDFTLTISSLEPEDFAVYYCQQYEFFGQGTKLEIK,GAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGCCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAGCGA,CAGGTGCAGCTGGTGCAGTCTGGGGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTTATTGATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTTCAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCCGGTCATCGTCTCATCA,CTRGKNCDYNWDFEHW,68.601
nan,,,,,,,Wu2010(20616233) ,IMGT/V-QUEST JoinSolver,1-02*02,3-16*01 or 3-16*02,1*01 or 2*01,14.0,,32.0,,3-11*01,2*01,5.0,,17.0,,,,,,,,,,,,,,,,,,
nan,,,,,,,Zhang2013(24100711) ,IMGT/V-QUEST,1-02*02,2-21*01,2*01,14.0,,,,3D-15,2,5.0,,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Zhou2013a(23911655) ,IgBlast IMGT/V-QUEST,1-02*02,,,12.0,GKNCDYNWDFEH,,,3-20*01,2*01,5.0,QQYEF,,,,,,,,,,,,,,,,,,,
VRC01-0fH/0fL,gp120 CD4bs,,NIH45 ,VRC01,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,100.0,1.0,21.0,112.0,3071.0,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDCTLNWVRQAPGQGLEWMGWLKPRGGAVNYARPLQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKNCDYNWDFEHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRTSQYGSLAWYQQKPGQAPRLLIYSGSTRAAGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYEFFGPGTKVDIK,,,,
VRC01.23LS,gp120 CD4bs,6VI0(VRC01.23 in complex with HIV-1 Env BG505 DS.SOSIP);EMD-21208(VRC01.23 in complex with HIV-1 Env BG505 DS.SOSIP),NIH45 ,VRC01,Kwon2021(34328065) ,VRC01.23LS primary contacts,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,0.058173,7.34675,428.0,609.0,4223.0,QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRWGAVNYARPLQGRVTMTRQLSQDPDDPDWGTAFLELRSLTVDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK,LTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,,,,
VRC01-30fH/10fL,gp120 CD4bs,,NIH45 ,VRC01,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.116,6.59213,21.0,105.0,3063.0,QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSS,EIVLTQSPATLSLSPGERATISCRTSQYGSLAWYQQKPGQAPRLVIYSGSTRAAGIPARFSGSRSGPDYTLTISSLESGDFGVYYCQQYEFFGPGTKVQVDIK,,,,
VRC01-30fH/19fL,gp120 CD4bs,,NIH45 ,VRC01,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.24418,6.15972,21.0,104.0,3062.0,QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSS,EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,,,,
VRC01-5fH/0fL,gp120 CD4bs,,NIH45 ,VRC01,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,48.8246,6.57282,21.0,111.0,3070.0,QVQLVQSGAEVKKPGASVKVSCKASGYEFIDCTLNWVRQAPGQGLEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSSTAYMELSRLRSDDTAVYYCARGKNCDYNWDFEHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRTSQYGSLAWYQQKPGQAPRLLIYSGSTRAAGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYEFFGPGTKVDIK,,,,
VRC01-5fH/10fL,gp120 CD4bs,,NIH45 ,VRC01,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.47302,7.52701,21.0,109.0,3068.0,QVQLVQSGAEVKKPGASVKVSCKASGYEFIDCTLNWVRQAPGQGLEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSSTAYMELSRLRSDDTAVYYCARGKNCDYNWDFEHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATISCRTSQYGSLAWYQQKPGQAPRLVIYSGSTRAAGIPARFSGSRSGPDYTLTISSLESGDFGVYYCQQYEFFGPGTKVQVDIK,,,,
VRC01-5fH/6fL,gp120 CD4bs,,NIH45 ,VRC01,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.4139,9.21114,21.0,110.0,3069.0,QVQLVQSGAEVKKPGASVKVSCKASGYEFIDCTLNWVRQAPGQGLEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSSTAYMELSRLRSDDTAVYYCARGKNCDYNWDFEHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRTSQYGSLAWYQQKPGQAPRLVIYSGSTRAAGIPARFSGSRSGPDYTLTISSLEPEDFAVYYCQQYEFFGPGTKVQVDIK,,,,
VRC01-8fH/10fL,gp120 CD4bs,,NIH45 ,VRC01,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.48875,8.77056,21.0,107.0,3066.0,QVQLVQSGAEVKKPGASVKVSCKASGYEFIDCTLNWVRQAPGQRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSSTAYMELRRLRSDDTAVYYCARGKNCDYNWDFEHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATISCRTSQYGSLAWYQQKPGQAPRLVIYSGSTRAAGIPARFSGSRSGPDYTLTISSLESGDFGVYYCQQYEFFGPGTKVQVDIK,,,,
VRC01-8fH/19fL,gp120 CD4bs,,NIH45 ,VRC01,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.95145,7.28841,21.0,106.0,3065.0,QVQLVQSGAEVKKPGASVKVSCKASGYEFIDCTLNWVRQAPGQRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSSTAYMELRRLRSDDTAVYYCARGKNCDYNWDFEHWGQGTLVTVSS,EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,,,,
VRC01-8fH/6fL,gp120 CD4bs,,NIH45 ,VRC01,Georgiev2014(24391217) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.86517,7.89262,21.0,108.0,3067.0,QVQLVQSGAEVKKPGASVKVSCKASGYEFIDCTLNWVRQAPGQRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSSTAYMELRRLRSDDTAVYYCARGKNCDYNWDFEHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRTSQYGSLAWYQQKPGQAPRLVIYSGSTRAAGIPARFSGSRSGPDYTLTISSLEPEDFAVYYCQQYEFFGPGTKVQVDIK,,,,
VRC01b,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,642.0,3338.0,QVQLVEFGSQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKNCDYNWDFQHWGGGTTVTVSS,EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,GAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGCCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAGGTGCAGCTGGTGGAGTTTGGAAGTCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTTATTGATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTTCAGGGCAGGGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAAACTGTGATTACAATTGGGACTTCCAACACTGGGGCGGGGGCACCACGGTCACCGTCTCCTCA,CTRGKNCDYNWDFQHW,67.577
VRC01c,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,643.0,3339.0,QVRLSQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGRRPEWMGWLKPRGGAVSYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKTCDYNWDFAHWGQGTPVTVSS,PATLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPEYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,CCAGCCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGACTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGAGTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAGGTGCGTCTGTCGCAGTCTGGAGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCCGGATATGAATTTATTGATTGTACACTAAATTGGATTCGCCTGGCCCCCGGAAGAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAGTTACGCACGTCCACTTCAGGGGAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAACCTGTGATTACAATTGGGACTTCGCACACTGGGGCCAGGGAACCCCGGTCACCGTCTCATCA,CTRGKTCDYNWDFAHW,65.188
VRC01d,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,644.0,3341.0,QVRLSQFGSQLKKPGESMRISCRASGYEFIDCTLNWIRLAPGRRPEWMGWLKPRGGAVNYARSFQGRVTMTRDVYSDTAFLELRSLTPDDTAVYFCTRGKNCDYNWDFEHWGRGTPVTVSS,MTQTPATLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,ATGACCCAGACTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAACAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAGGTGCGTCTGTCGCAGTTTGGAAGTCAATTGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCCGGATATGAATTTATTGATTGTACACTAAATTGGATTCGCCTGGCCCCCGGAAGAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTTCATTTCAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCGTTTTTGGAGCTGCGCTCCTTGACACCAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAGAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGTACCCCGGTCACCGTCTCATCA,CTRGKNCDYNWDFEHW,65.188
VRC01e,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,645.0,3342.0,QVRLSQSGGQMKKPGESMRISCRASGYEFIECTLNWIRLAPGRRPEWMGWLKPRGGAVNYARPFQGRVTMTRDVYSDTAFLELRSLTADDTAVYFCTRGKDCNYNWDFGHWGRGTPVTVSS,PATLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,CCAGCCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCGGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAACAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAGGTGCGTCTGTCGCAGTCTGGAGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGCCGGGCTTCCGGATATGAATTTATTGAGTGTACACTAAATTGGATTCGCCTGGCCCCCGGAAGAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCATTTCAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCCTTGACAGCAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAGACTGTAATTACAATTGGGACTTCGGACACTGGGGCCGGGGTACCCCGGTCACCGTCTCATCA,CTRGKDCNYNWDFGHW,66.894
VRC01-E16A(HC),gp120 CD4bs,,NIH45 ,VRC01,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,,,3.0,738.0,4427.0,,,,,,
VRC01-E28T(HC),gp120 CD4bs,,NIH45 ,VRC01,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,,,3.0,737.0,4426.0,,,,,,
VRC01f,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,646.0,3343.0,QVRLSQSGGQMKKPGESMRISCQASGYEFIDCTLNWVRLAPGRRPEWMGWLKPRGGAVNYARIFQGRVTMTRDVYSDTAFLELRSLTADDTAVYFCTRGKNCDYNWDFEHWGRGTPVTVSP,PATLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPNYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,CCAGCCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAAACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAGGTGCGTCTGTCGCAGTCTGGAGGTCAGATGAAGAAGCCTGGCGAGTCCATGAGAATTTCTTGTCAGGCTTCCGGGTATGAATTTATTGACTGTACACTAAACTGGGTTCGCCTGGCCCCCGGAAGAAGGCCTGAATGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTATATTTCAAGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCCTTGACAGCAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGTACCCCGGTCACCGTCTCACCA,CTRGKNCDYNWDFEHW,67.235
VRC01_FR3-03,gp120 CD4bs,6NNF(BG505 SOSIP.664 Prefusion Env Trimer Bound to VRC01 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22),NIH45 ,VRC01,Liu2019(30760721) ,Mutation affects neutralization by VRC01_FR3-03,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,VRC01 FR3-03, ,0.43466,11.3898,416.0,793.0,4569.0,,,,,,
VRC01g,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,647.0,3344.0,QVHLSQFGSQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSS,PATLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,CCAGCCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAGGTGCATCTGTCGCAGTTTGGAAGTCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTTATTGATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTTCAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCCGGTCATCGTCTCATCA,CTRGKNCDYNWDFEHW,66.553
VRC01h,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,648.0,3345.0,QVRLSQSGGQMKKPGESMRISCQASGYEFIDCTINWVRLAPGRRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTADDTAVYFCTRGKNCDYNWDFEHWGRGTPVTVSS,PATLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPNYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,CCAGCCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAAACTACAATCTCACCATTAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAGGTGCGTCTGTCGCAGTCTGGAGGTCAGATGAAGAAGCCTGGCGAGTCCATGAGAATTTCTTGTCAGGCTTCCGGGTATGAATTTATTGATTGTACAATAAATTGGGTTCGCCTGGCCCCCGGAAGAAGGCCTGAATGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTTCAAGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCCTTGACAGCAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGTACCCCGGTCACCGTCTCATCA,CTRGKNCDYNWDFEHW,66.212
VRC01H-DRVIA7L,gp120 CD4bs,,DRVI01 NIH45 ,,Kong2016(27067056) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,VRC01H+ DRVIA7L, ,92.7804,1.5677,37.0,487.0,4113.0,,,,,,
VRC01i,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,649.0,3346.0,QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGRRPEWMGWLKPRGGAVNYARPLQGRMTMTRDVYSDTAFLELRSLTADDTAVYFCTRGKDCNYNWDFEHWGRGTLVTVSS,EIVLTQSPGTLSLSPGETAIISCRTTQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSWWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKLEIK,GAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCACTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTTGGTGGGGGCCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGCTGGAGATCAAA,CAGGTGCAGCTGGTGCAGTCTGGAGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCCGGATATGAATTTATTGATTGTACACTAAATTGGATTCGCCTGGCCCCCGGAAGAAGGCCTGAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTTCAGGGCAGAATGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCCTTGACAGCAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAGACTGTAATTACAATTGGGACTTCGAACACTGGGGCCGCGGTACCCTGGTCACCGTCTCCTCA,CTRGKDCNYNWDFEHW,67.235
VRC01-I21L(LC),gp120 CD4bs,,NIH45 ,VRC01,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,,,3.0,743.0,4432.0,,,,,,
VRC01-LS,gp120 CD4bs,,NIH45 ,VRC01,Ko2014(25119033) ,,,,,,,,,,,,,,,,,K,Yes,Engineered monoclonal,human,VRC01LS, ,0.46537,9.01353,416.0,571.0,3313.0,,,,,,
VRC01-N73T(LC),gp120 CD4bs,,NIH45 ,VRC01,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,,,3.0,742.0,4431.0,,,,,,
VRC01-P63K(HC),gp120 CD4bs,,NIH45 ,VRC01,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,,,3.0,739.0,4428.0,,,,,,
VRC01/PGDM1400-10E8v4,gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region),,Donor 84 Donor N152 NIH45 ,,Xu2017(28931639) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,"SAR-441236, SAR441236, VRC01-LS/PGDM1400-10E8v4","trispecific involving VRC01, PGDM1400, and 10E8 ",0.039266,9.30439,416.0,388.0,3955.0,,,,,,
VRC01 UCA,gp120 CD4bs,,NIH45 ,VRC01,Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,UCA or intermediate,human,, ,100.0,1.0,14.0,669.0,4267.0,,,,,,
VRC01-W68S(LC),gp120 CD4bs,,NIH45 ,VRC01,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,,,3.0,740.0,4429.0,,,,,,
VRC01-Y28S(LC),gp120 CD4bs,,NIH45 ,VRC01,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,,,3.0,744.0,4433.0,,,,,,
VRC01-Y72F(LC),gp120 CD4bs,,NIH45 ,VRC01,Wiehe2018(29861171) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,,,3.0,741.0,4430.0,,,,,,
VRC02,gp120 CD4bs,,NIH45 ,VRC01,Wu2010(20616233) ,VRC02 signature predictions,Wu2010(20616233) ,IMGT/V-QUEST JoinSolver,1-02*02,3-16*01 or 3-16*02,1*01 or 2*01,14.0,,32.0,,3-11*01,2*01,5.0,,19.0,,K,,Natural monoclonal,human,, Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.,0.52135,8.81276,569.0,45.0,2164.0,QVQLVQSGGQMKKPGESMRISCQASGYEFIDCTLNWVRLAPGRRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTADDTAVYYCTRGKNCDYNWDFEHWGRGTPVTVSS,EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTIRNLESGDFGLYYCQQYEFFGQGTKVQVDIKR,GAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCCGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCAGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGACTACAATCTCACCATCAGGAACCTGGAGTCGGGAGATTTTGGTCTTTATTATTGCCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAGCGA,CAGGTGCAGCTGGTGCAGTCTGGGGGCCAGATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCAGGCTTCCGGATATGAATTTATTGATTGTACACTAAATTGGGTTCGCCTGGCCCCCGGAAGAAGGCCTGAATGGATGGGATGGCTGAAGCCTCGAGGGGGGGCCGTCAACTACGCACGTCCACTTCAAGGCAGAGTGACCATGACTCGAGACGTGTATTCCGACACAGCCTTTTTGGAGCTGCGCTCCTTGACAGCAGACGACACGGCCGTCTACTATTGTACTAGGGGAAAAAATTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGTACCCCGGTCACCGTCTCATCA,CTRGKNCDYNWDFEHW,68.259
VRC03,gp120 CD4bs,"3SE8(VRC03 complexed with gp120);5JOF(VRC03 gHVgLV antigen-binding fragment);5JXA(Ligand-free VRC03 antigen-binding fragment);6CUE(vFP7.04 in complex with BG505 DS-SOSIP, and antibodies VRC03 and PGT122);6E5P(2G12 bound to HIV-1 Env BG505 DS-SOSIP, which was also bound to VRC03);EMD-8981(2G12 bound to HIV-1 Env BG505 DS-SOSIP which was also bound to VRC03)",NIH45 ,VRC01 (VRC03+06 sublineage),Wu2010(20616233) ,Altered glycosylation affects neutralization by CD4BS bnAbs;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary;VRC03 contacts;VRC03 signature predictions;VRC03 signature predictions,Li2012(22875963) ,IMGT/V-QUEST JoinSolver,1-2*02 or 1-2*04,3-22*01,1*01,16.0,,29.0,,3-20*01,2*01,5.0,,20.0,,K,,Natural monoclonal,human,VRC03 d45, Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.,6.45245,21.9965,1787.0,21.0,2165.0,QVQLVQSGAVIKTPGSSVKISCRASGYNFRDYSIHWVRLIPDKGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMEFSGLTPADTAEYFCVRRGSCDYCGDFPWQYWGQGTVVVVSS,EIVLTQSPGILSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVHR,GAAATTGTGTTGACGCAGTCTCCCGGCATCCTGTCTCTGTCTCCAGGAGAGACAGCCACCCTCTTTTGTAAGGCCAGTCAGGGTGGCAATGCTATGACGTGGTATCAGAAGAGACGTGGCCAGGTTCCCAGACTCCTGATCTACGATACATCTCGCAGGGCCTCTGGCGTTCCTGACAGATTTGTTGGCAGTGGGTCTGGGACAGACTTCTTTCTCACGATCAACAAATTGGACCGGGAAGATTTCGCAGTCTATTATTGTCAACAATTTGAATTTTTTGGCCTGGGGAGCGAGCTGGAAGTCCATCGA,CAGGTGCAGCTGGTGCAGTCTGGGGCTGTGATTAAGACGCCTGGGTCCTCAGTGAAGATCTCATGTCGGGCTTCTGGATACAACTTTCGTGATTATTCGATCCATTGGGTCCGCCTCATTCCTGACAAGGGATTTGAGTGGATTGGATGGATTAAACCTCTGTGGGGTGCCGTCAGTTATGCCCGGCAACTTCAGGGCCGAGTCTCTATGACTCGACAATTATCTCAAGACCCAGACGACCCGGACTGGGGCGTTGCCTACATGGAGTTCAGTGGACTGACGCCCGCCGACACGGCCGAATATTTTTGTGTCCGGAGAGGGTCCTGTGATTATTGCGGAGACTTTCCCTGGCAATACTGGGGTCAGGGCACCGTCGTCGTCGTCTCGTCA,,
nan,,,,,,,Wu2010(20616233) ,IMGT/V-QUEST JoinSolver,1-02*02,3,1*01,16.0,,30.0,,3-20*01,2*01,5.0,,20.0,,,,,,,,,,,,,,,,,,
nan,,,,,,,Zhang2013(24100711) ,IMGT/V-QUEST,1-18*01 or 1-2*02 or 1-2*04,2-21*01,2*01,23.0,,,,3-NL5,2,5.0,,,,,,,,,,,,,,,,,,,,
nan,,,,,,,Zhou2013a(23911655) ,IgBlast IMGT/V-QUEST,1-02*02,,,14.0,RGSCDYCGDFPWQY,,,3-20*01,2*01,5.0,QQFEF,,,,,,,,,,,,,,,,,,,
VRC03b,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,VRC03b, ,,,24.0,650.0,3353.0,QVQLVQSGAVIKTPGSSVKISCRASGFNFRDYSIHWVRLIPDKGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMELSGLTSADTAEYFCVRRGSCDYCGGFPWQYWGQGTVVVVSS,EIVLTQSPATLSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVH,GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTCTGTCTCCAGGAGAGACAGCCACCCTCTTTTGTAAGGCCAGTCAGGGTGGCAATGCTATGACGTGGTATCAGAAGAGACGTGGCCAGGTTCCCAGACTCCTGATTTACGATACATCTCGCAGGGCCTCTGGCGTTCCTGACAGATTTGTTGGCAGTGGGTCTGGGACAGACTTCTTTCTCACGATCAACAAATTGGACCGGGAAGATTTCGCAGTCTATTACTGTCAACAATTTGAATTTTTTGGCCTGGGGAGCGAGCTGGAAGTCCAT,CAGGTGCAGCTGGTGCAGTCTGGGGCTGTGATTAAGACGCCTGGGTCCTCAGTGAAGATCTCATGTCGGGCTTCTGGATTCAACTTTCGTGATTATTCGATTCATTGGGTCCGCCTCATTCCTGACAAGGGATTTGAGTGGATTGGATGGATAAAACCTCTGTGGGGTGCCGTCAGTTATGCCCGGCAACTTCAGGGCCGAGTCTCTATGACTCGACAATTATCTCAAGACCCAGACGACCCGGACTGGGGCGTTGCCTACATGGAGCTCAGTGGACTGACGTCCGCCGACACGGCCGAATATTTTTGTGTCCGGAGAGGGTCCTGTGATTATTGCGGAGGCTTTCCCTGGCAATACTGGGGTCAGGGCACCGTCGTCGTCGTCTCGTCA,,
VRC03d,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,VRC03d, ,,,24.0,651.0,3354.0,EVRLVQSGAVMRKPGSSVKISCRASGYNFREYSIHWVRLIPGKGFEWIGWIKPLWGAVSYARQLQGRVAMTRQLSQDPDDPDWGIAYMEFSGLTSADTAEYFCVRRGPCDHCGDFHWQHWGQGTAVVVSA,EIVLTQSPGTLSLSPGERATLFCKASQGGNSLTWYQKRRGQAPRLLIYDTSRRASGVPDRFVGSGSGTDFSLTITKLDREDFAVYYCQQFEFFGLGTALEIH,GAAATTGTGTTGACGCAGTCTCCCGGCACCCTGTCTCTGTCTCCAGGGGAGAGAGCCACCCTCTTTTGTAAGGCCAGTCAGGGTGGCAATTCTTTAACCTGGTATCAGAAGAGACGTGGCCAGGCTCCCAGACTCCTCATCTACGATACATCTCGCAGGGCCTCTGGCGTTCCTGACAGATTTGTTGGCAGTGGGTCTGGGACAGACTTCTCTCTCACGATCACCAAACTGGACCGGGAAGATTTCGCAGTCTATTACTGTCAACAATTTGAATTTTTTGGCCTGGGGACCGCGCTGGAAATCCAT,GAGGTGCGCCTGGTACAATCTGGGGCTGTGATGAGGAAGCCTGGGTCCTCAGTGAAGATCTCATGCCGGGCTTCTGGATACAATTTTCGTGAATATTCGATACATTGGGTCCGACTCATTCCTGGCAAGGGATTTGAGTGGATAGGGTGGATAAAGCCTCTGTGGGGTGCCGTCAGTTATGCCCGGCAGCTTCAGGGCCGGGTCGCTATGACTCGACAATTATCTCAGGACCCAGACGACCCGGACTGGGGCATAGCCTACATGGAGTTCAGTGGACTGACGTCCGCCGACACGGCCGAATATTTTTGTGTGAGGAGAGGACCTTGTGATCATTGCGGAGACTTCCACTGGCAGCATTGGGGTCAGGGCACAGCCGTCGTCGTCTCTGCA,,
VRC03f,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,VRC03f, ,,,24.0,652.0,3356.0,EVRLVQSGAVIKKPGSSVKISCRASGYNFRDYSIHWVRLIPDKGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMEFSGLTSADTAEYFCVRRGSCDYCGDFPWQYWGQGTVVVVSP,PATLSLSPGETATLFCKASQGGSAITWYQKRRGHVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVH,CCAGCCACCCTGTCTCTGTCTCCAGGAGAGACAGCCACCCTGTTTTGTAAGGCCAGTCAGGGTGGCAGTGCTATAACGTGGTATCAGAAGAGACGTGGCCACGTTCCCAGACTCCTGATCTACGATACATCTCGCAGGGCCTCTGGCGTTCCTGACAGATTTGTTGGCAGTGGGTCTGGGACAGACTTCTTTCTCACGATCAACAAATTGGACCGGGAAGATTTCGCAGTCTATTACTGTCAACAATTTGAATTTTTTGGCCTGGGGAGCGAGCTGGAAGTCCAT,GAGGTGCGCCTGGTACAATCTGGGGCTGTGATTAAGAAGCCTGGGTCCTCAGTGAAGATCTCATGTCGGGCTTCTGGATACAACTTTCGTGATTACTCGATTCATTGGGTCCGACTCATTCCTGACAAGGGATTTGAGTGGATAGGATGGATAAAACCTCTATGGGGTGCCGTCAGTTATGCCCGGCAACTGCAGGGCCGAGTCTCTATGACTCGACAATTATCTCAAGACCCAGACGACCCGGACTGGGGCGTTGCCTACATGGAATTTAGTGGACTGACGTCCGCCGACACGGCCGAATATTTTTGTGTCCGGAGAGGGTCCTGTGATTATTGCGGAGACTTTCCCTGGCAATACTGGGGTCAGGGCACCGTCGTCGTCGTCTCGCCA,,
VRC03g,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,VRC03g, ,,,24.0,653.0,3357.0,EVRLVQSGAVIKTPGSSVKISCRASGYNFRDYSIHWVRLIPDRGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMEFSGLTSADTAEYFCVRRGSCDYCGDFPWQYWGQGTVVVVSS,PATLSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVH,CCAGCCACCCTGTCTCTGTCTCCAGGAGAGACAGCCACCCTCTTTTGTAAGGCCAGTCAGGGTGGCAATGCTATGACGTGGTATCAGAAGAGACGTGGCCAGGTTCCCAGACTCCTGATTTACGATACATCTCGCAGGGCCTCTGGCGTTCCTGACAGATTTGTTGGCAGTGGGTCGGGGACAGACTTCTTTCTCACGATCAACAAATTGGACCGGGAAGATTTCGCAGTCTATTACTGTCAACAATTTGAATTTTTTGGCCTGGGGAGCGAGCTGGAAGTCCAT,GAGGTGCGCCTGGTACAATCTGGGGCTGTGATTAAGACGCCTGGGTCCTCAGTGAAGATCTCATGTCGGGCTTCTGGATACAACTTTCGTGATTATTCGATTCATTGGGTCCGCCTCATTCCTGACAGGGGATTTGAGTGGATTGGATGGATAAAACCTCTGTGGGGTGCCGTCAGTTATGCCCGGCAACTTCAGGGCCGAGTCTCTATGACTCGGCAATTATCTCAAGACCCAGACGACCCGGACTGGGGCGTTGCCTACATGGAGTTCAGTGGACTGACGTCCGCCGACACGGCCGAATATTTTTGTGTCCGGAGAGGGTCCTGTGATTATTGCGGAGACTTTCCCTGGCAATACTGGGGTCAGGGCACCGTCGTCGTCGTCTCGTCA,,
VRC03h,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,VRC03h, ,,,24.0,654.0,3358.0,EVRLVQSGAVLKKPGSSVKISCRTSGYDFREISLHWVRLIPARGFEWIGWIKPRWGAVSYARQLQGRVTLTRQLSQDPDDPDWGIGYMELSGLTSADSAEYFCVRRGPCDYCGDFVWQYWGQGTVVVISA,PATLSLSPGESATLFCKVSQSGNALTWIQKRRGQAPRLLIYDSSRRASGVPDRFIGSGSGTDFSLTIKNVIREDFAVYFCQQFEFFGLGTALEIN,CCAGCCACCCTGTCTCTGTCTCCAGGGGAGAGTGCCACCCTCTTTTGTAAGGTCAGTCAAAGTGGCAATGCCTTAACTTGGATTCAAAAGAGACGTGGCCAGGCTCCCAGACTCCTCATCTACGACTCATCTCGCAGGGCCTCTGGTGTTCCGGACCGATTTATTGGCAGTGGCTCTGGGACAGACTTCTCTCTCACAATTAAGAATGTTATCCGGGAAGATTTCGCAGTCTACTTCTGTCAACAATTTGAATTCTTTGGCCTGGGGACCGCGCTGGAAATCAAC,GAGGTGCGCCTGGTACAATCTGGGGCTGTCTTGAAGAAGCCTGGGTCCTCAGTGAAGATTTCATGTCGGACTTCTGGATACGATTTCCGTGAGATCTCGCTACATTGGGTCCGGCTCATTCCTGCCAGGGGCTTTGAGTGGATAGGGTGGATAAAGCCTAGGTGGGGTGCCGTCAGTTATGCCCGACAACTTCAAGGCCGCGTCACTTTGACTCGACAATTATCTCAAGACCCAGACGACCCGGACTGGGGCATCGGCTACATGGAACTCAGTGGACTGACGTCCGCCGATTCGGCCGAATATTTTTGTGTGAGGAGGGGACCTTGTGATTATTGCGGAGACTTCGTCTGGCAGTATTGGGGTCAGGGCACAGTCGTCGTTATCTCGGCA,,
VRC03i,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,VRC03i, ,,,24.0,655.0,3359.0,EVRLVQSGAVVKKPGSSVKISCRASGYDFREISLHWVRLIPARGFEWIGWIKPRWGAVGYARQLQGRVTLTRQLSQDPYDPDWGIAYMELSGLTSADSAEYFCVRRGPCDYCGDFVWQYWGQGTVVVVSA,MTQSPATLSLSPGESATLFCKVSQSGNSLTWIQKRRGQAPRLLIYDSSRRASGVPDRFIGSGSGTDFSLTIKNVIREDFAVYFCQQFEFFGLGTALEIN,ATGACCCAGTCTCCAGCCACCCTGTCTCTGTCTCCAGGGGAGAGTGCCACCCTCTTTTGTAAGGTCAGTCAAAGTGGCAATTCCTTAACTTGGATTCAAAAGAGACGTGGCCAGGCTCCCAGACTCCTCATCTACGACTCATCTCGCAGGGCCTCTGGTGTTCCGGACCGATTTATTGGCAGTGGCTCTGGGACAGACTTCTCTCTCACAATTAAGAATGTTATCCGGGAAGATTTCGCAGTCTACTTCTGTCAACAATTTGAATTCTTTGGCCTGGGGACCGCGCTGGAAATCAAC,GAGGTGCGCCTGGTACAATCTGGGGCTGTGGTGAAGAAGCCTGGGTCCTCAGTGAAGATTTCATGTCGGGCTTCTGGATACGATTTCCGTGAGATTTCCCTACATTGGGTCCGGCTCATTCCTGCCAGGGGCTTTGAGTGGATAGGGTGGATAAAGCCTAGGTGGGGTGCCGTCGGTTATGCCCGACAACTTCAAGGCCGCGTCACTTTGACTCGACAATTATCTCAAGACCCATACGACCCGGACTGGGGCATCGCCTACATGGAACTCAGTGGACTGACGTCCGCCGATTCGGCCGAATATTTTTGTGTGAGGAGGGGACCTTGTGATTATTGCGGAGACTTCGTCTGGCAGTATTGGGGTCAGGGCACAGTCGTCGTCGTCTCGGCA,,
VRC06,gp120 CD4bs,4JB9(VRC06 in complex with HIV-1 gp120 core),NIH45 ,VRC01 (VRC03+06 sublineage),Li2012(22875963) ,,Li2012(22875963) ,IMGT/V-QUEST JoinSolver,1-2*02 or 1-2*04,4-17*01,1*01,17.0,,29.0,,3-20*01,2*01,5.0,,16.0,,K,,Natural monoclonal,human,, ,23.8065,9.61119,807.0,75.0,2660.0,EVQLVESGPVMRKPGSSMKISCATSGYNFRDFSIHWVRFNRRYGFEWIGWIKPMWGAVNYARQLQGRVSMSRLFSQDLYYPDRGTAYLEFSGLTSADTADYFCVRRGSSCPHCGDFHFEHWGQGTAVVVSA,EIVLTQSPATLSLSPGERATLSCRASQGGNSLNWYQKRRGQTPRLLIYDTSRRASDIPEKFVGSGSGTDFSLTITKVGPEDFAVYYCQQFEFFGLGTTLEIN,GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGTAGGGCCAGTCAGGGTGGCAATTCTTTAAATTGGTATCAGAAGAGACGTGGCCAGACTCCCAGACTCCTCATCTACGACACATCTCGCAGGGCCTCTGACATTCCTGAAAAATTTGTTGGCAGTGGGTCTGGGACAGACTTCTCTCTCACCATCACGAAAGTGGGCCCGGAAGATTTCGCAGTCTATTATTGTCAACAATTTGAATTTTTTGGCCTGGGGACCACGCTGGAAATCAAT,GAGGTGCAGCTGGTGGAGTCTGGGCCTGTCATGAGGAAGCCTGGGTCCTCGATGAAGATCTCATGCGCGACTTCTGGATACAACTTTCGTGACTTTTCGATTCATTGGGTCCGTTTCAACCGTCGATATGGCTTTGAGTGGATCGGCTGGATCAAGCCTATGTGGGGTGCCGTCAATTATGCCCGCCAACTTCAGGGCCGCGTCTCAATGAGTCGTCTCTTTTCTCAGGACCTATATTATCCGGACAGGGGCACAGCCTACTTGGAATTCAGTGGACTGACGTCCGCCGACACGGCCGACTATTTCTGTGTGAGGCGGGGGTCTTCCTGTCCTCATTGCGGAGACTTCCATTTCGAACATTGGGGCCAGGGTACAGCCGTCGTCGTCTCGGCA,,
VRC06b,gp120 CD4bs,4XNZ(VRC06B in complex with HIV-1 clade A/E strain 93TH057 gp120),NIH45 ,VRC01 (VRC03+06 sublineage),Li2012(22875963) ,Signature Analysis Summary,Li2012(22875963) ,IMGT/V-QUEST JoinSolver,1-2*02 or 1-2*04,4-17*01,1*01,17.0,,32.0,,3-20*01,2*01,5.0,,18.0,,K,,Natural monoclonal,human,VRC06b, ,9.88935,19.7585,673.0,83.0,2661.0,QVQLVESGSAMRKPGSSVKISCRASGFNFREYSIHWVRLIPGRGLEWMGWIKGMWGAVNYARQLQGRVSMTRQLSQDPDDPDWGVAYLDFSGLTSGDTGEYFCVRKGPSCPHCGDFHWQHWGQGTLVVVST,EIVLTQSPGTLSVSPGERATLFCKASQGGNSLSWYQKRRGQPPRLLIYDTSRRASGIPDRFVGSGSGTDFSLTITKVDRDDFALYFCQQFEFFGLGTALEIN,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTGTGTCTCCAGGGGAGAGAGCCACCCTCTTTTGTAAGGCCAGTCAGGGTGGCAATTCTTTAAGTTGGTATCAGAAGAGACGTGGCCAGCCTCCCAGACTCCTCATCTACGATACATCTCGCAGGGCCTCTGGCATTCCTGACAGATTTGTTGGCAGTGGGTCTGGGACAGATTTCTCTCTCACGATCACCAAAGTGGACCGGGACGATTTCGCACTCTACTTCTGTCAACAATTTGAATTTTTTGGCCTGGGGACCGCGCTGGAAATCAAT,CAGGTGCAGCTGGTGGAGTCTGGGTCTGCGATGAGGAAGCCGGGGTCGTCAGTGAAGATCTCATGTCGGGCTTCTGGATTCAATTTTCGCGAATATTCGATACATTGGGTCCGACTGATTCCTGGCAGGGGACTTGAGTGGATGGGGTGGATAAAGGGTATGTGGGGAGCCGTCAATTATGCCCGGCAACTTCAGGGCCGGGTCTCTATGACTCGACAATTGTCTCAGGACCCAGACGACCCAGACTGGGGCGTCGCCTACCTGGACTTCAGTGGACTGACGTCCGGCGATACAGGCGAATATTTTTGTGTGAGAAAAGGACCCTCCTGTCCTCACTGCGGAGACTTCCACTGGCAACATTGGGGTCAGGGCACACTCGTCGTCGTCTCGACA,,
VRC06c,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,656.0,3360.0,QVRLVQSGPVMRKPGSSMKISCATSGYNFRDFSIHWVRFNRRYGFEWIGWLKPMWGAVSYARQLQGRVSMSRLFSQDPYYPDRGTAYLEFSGLTSADTADYFCVRRGSSCPHCGDFHFEHWGQGTAVVVSA,PATLSLSPGERATLFCRASQGGNSLNWYQKRRGQTPRLLIYDTSRRASDIPDKFVGSGSGTDFSLTITKVGPEDFAVYYCQQFEFFGLGTTLEIN,CCAGCCACCCTGTCTCTGTCTCCAGGGGAGAGAGCCACCCTCTTTTGTAGGGCCAGTCAGGGTGGCAATTCTTTAAATTGGTATCAGAAGAGACGTGGCCAGACTCCCAGACTCCTCATCTACGACACATCTCGCAGGGCCTCTGACATTCCTGATAAATTTGTTGGCAGTGGGTCTGGGACAGACTTCTCTCTCACCATCACGAAAGTGGGCCCGGAAGATTTCGCAGTCTATTATTGTCAACAATTTGAATTTTTTGGCCTGGGGACCACGCTGGAAATCAAC,CAGGTGCGCCTGGTCCAATCTGGGCCTGTCATGAGGAAGCCTGGGTCCTCGATGAAGATCTCATGCGCGACTTCTGGATACAACTTTCGTGACTTTTCGATTCATTGGGTCCGTTTCAATCGTCGATATGGCTTTGAGTGGATCGGCTGGCTCAAGCCTATGTGGGGTGCCGTCAGTTATGCCCGCCAACTTCAGGGCCGCGTCTCAATGAGTCGACTCTTTTCTCAGGACCCATACTACCCGGACAGGGGCACAGCCTACTTGGAATTCAGTGGACTGACGTCCGCCGACACGGCCGACTATTTCTGCGTGAGGCGGGGGTCTTCCTGTCCTCATTGCGGAGACTTCCATTTCGAACATTGGGGCCAGGGTACAGCCGTCGTCGTCTCGGCA,,
VRC06d,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,657.0,3361.0,QVRLVQSGPVMRKPGSSMKISCGTSGYNFRDFSIHWVRFSPQYGFEWIGWIKPMWGAVSYARQLQGRVAMTRQFSQDPYYPDRGTAYLEFSGLTSADTADYFCVRRGPSCPHCGDFHFEHWGQGTAVVVSA,EIVLTQSPGTLSLSPGERATLFCRASQGGNSLNWYQKRRGQTPRLLIYDTSRRASGIPDRFVGSGSGTDFSLTITKLGPEDFAVYYCQQFEFFGLGTALEIN,GAAATTGTGTTGACGCAGTCTCCCGGCACCCTGTCTCTGTCTCCAGGGGAGAGAGCCACCCTCTTTTGTAGGGCCAGTCAGGGTGGCAATTCTTTAAATTGGTATCAGAAGAGACGTGGCCAGACTCCCAGACTCCTCATCTACGACACATCTCGCAGGGCCTCTGGCATTCCTGACAGATTTGTTGGCAGTGGGTCTGGGACAGACTTCTCTCTCACCATCACGAAACTGGGCCCGGAAGATTTCGCAGTCTATTATTGTCAGCAATTTGAGTTTTTTGGCCTGGGGACCGCGCTGGAAATCAAT,CAGGTGCGCCTGGTCCAATCTGGGCCTGTGATGAGGAAGCCTGGGTCCTCAATGAAGATCTCATGCGGGACTTCTGGATATAACTTTCGTGATTTTTCGATTCATTGGGTCCGCTTCAGTCCTCAGTATGGCTTTGAGTGGATCGGGTGGATCAAGCCTATGTGGGGTGCCGTCAGTTATGCCCGGCAACTTCAGGGCCGCGTCGCAATGACTCGGCAATTCTCGCAAGACCCATACTACCCGGACAGGGGCACAGCCTACTTGGAATTCAGTGGACTGACGTCCGCCGACACGGCCGACTATTTTTGCGTGAGGCGGGGGCCTTCTTGTCCTCATTGCGGAGACTTCCACTTCGAGCATTGGGGCCAGGGCACAGCCGTCGTCGTCTCGGCA,,
VRC06e,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,658.0,3362.0,QVRLVQSGPVMRKPGSSMKISCATSGYNFRDFSIHWVRFNRRYGFEWIGWIKPMWGAVSYARQLQGRVSMSRLFSQDPYYPDRGTAFLEFSGLTPADTADYFCVRRGSSCPHCGDFHFEHWGQGTAVVVSA,PATLSLSPGERATLFCRASQGGNSLNWYQKRRGQTPRLLIYDTSRRASDIPEKFVGSGSGTDFSLTITKVDPEDFAVYYCQQFEFFGLGTTLEIN,CCAGCCACCCTGTCTCTGTCTCCAGGGGAGAGAGCCACCCTCTTTTGTAGGGCCAGTCAGGGTGGCAATTCTTTAAATTGGTATCAGAAGAGACGTGGCCAGACTCCCAGACTCCTCATCTACGACACATCTCGCAGGGCCTCTGACATTCCTGAAAAATTTGTTGGCAGTGGGTCTGGGACAGACTTCTCTCTCACCATCACGAAAGTGGACCCGGAAGATTTCGCAGTCTATTATTGTCAACAATTTGAATTTTTTGGCCTGGGGACCACGCTGGAAATCAAT,CAGGTGCGCCTGGTCCAATCTGGGCCTGTCATGAGGAAGCCTGGGTCCTCGATGAAGATCTCATGCGCGACTTCTGGATACAACTTCCGTGACTTTTCGATTCATTGGGTCCGTTTCAACCGTCGATATGGCTTTGAGTGGATCGGCTGGATCAAGCCTATGTGGGGTGCCGTCAGTTATGCCCGCCAACTTCAGGGCCGCGTCTCAATGAGTCGACTCTTTTCTCAGGACCCATACTACCCGGACAGGGGCACAGCCTTCTTGGAATTCAGTGGACTGACGCCCGCCGACACGGCCGACTATTTCTGCGTGAGGCGGGGGTCTTCCTGTCCTCATTGCGGCGACTTCCATTTCGAACATTGGGGCCAGGGTACAGCCGTCGTCGTCTCGGCA,,
VRC06f,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,659.0,3363.0,QVRLVQSGPVMRKPGSSMKISCATSGYNFRDFSIHWVRFNRRYGFEWIGWLKPMWGAVSYARQLQGRVSMSRLFSQDPYYPDRGTAYLEFSGLTSADTADYFCVRRGSSCPHCGDFHFEHWGQGTPVVVSA,MTQTPATLSLSPGERATLFCRASQGGNSLNWYQKRRGQTPRLLIYDTSRRASDIPEKFVGSGSGTDFSLTITKVGPEDFAVYYCQQFEFFGLGTTLEIN,ATGACCCAGACTCCAGCCACCCTGTCTCTGTCTCCAGGGGAGAGAGCCACCCTCTTTTGTAGGGCCAGTCAGGGTGGCAATTCTTTAAATTGGTATCAGAAGAGACGTGGCCAGACTCCCAGACTCCTCATCTACGACACATCTCGCAGGGCCTCTGACATTCCTGAAAAATTTGTTGGTAGTGGGTCTGGGACAGACTTCTCTCTCACCATCACGAAAGTGGGCCCGGAAGATTTCGCAGTCTATTATTGTCAACAATTTGAATTTTTTGGCCTGGGGACCACGCTGGAAATCAAC,CAGGTGCGCCTGGTCCAATCTGGGCCTGTCATGAGGAAGCCTGGGTCCTCGATGAAGATCTCATGCGCGACTTCTGGATACAACTTTCGTGACTTTTCGATTCATTGGGTCCGTTTCAACCGTCGATATGGCTTTGAGTGGATCGGCTGGCTCAAGCCTATGTGGGGTGCCGTCAGTTATGCCCGCCAACTTCAGGGCCGCGTCTCAATGAGTCGACTCTTTTCTCAGGACCCATATTACCCGGACAGGGGCACAGCCTACTTGGAATTCAGTGGACTGACGTCCGCCGACACGGCCGACTATTTCTGCGTGAGGCGGGGGTCTTCCTGTCCTCATTGCGGAGACTTCCATTTCGAACATTGGGGCCAGGGTACACCCGTCGTCGTCTCGGCA,,
VRC06g,gp120 CD4bs,,NIH45 ,VRC01 (VRC03+06 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,660.0,3364.0,QVRLVQSGPVMRKPGSSMKISCATSGYNFRDFSIHWVRFNRRYGFEWIGWLKPMWGAVSYARQLQGRVSMSRVFSQDPYYPDRGTAFLEFTGLTSADTADYFCVRRGSSCPHCGDFHFEYWGQGTAVVVST,MTQTPATLSLSPGERATLFCRASQGGNSLNWYQKRRGQTPRLLIYDTSRRASDIPEKFVGSGSGTDFSLTITKVGPEDFAVYYCQQFEFFGLGTTLEIN,ATGACCCAGACTCCAGCCACCCTGTCTCTGTCTCCAGGGGAGAGAGCCACCCTCTTTTGTAGGGCCAGTCAGGGTGGCAATTCTTTAAATTGGTATCAGAAGAGACGTGGCCAGACTCCCAGACTCCTCATCTACGACACATCTCGCAGGGCCTCTGACATTCCTGAAAAATTTGTTGGCAGTGGGTCTGGGACAGACTTCTCTCTAACCATCACGAAAGTGGGCCCGGAAGATTTCGCAGTCTATTATTGTCAACAATTTGAATTTTTTGGCCTGGGGACCACGCTGGAAATCAAC,CAGGTGCGCCTGGTCCAATCTGGGCCTGTCATGAGGAAGCCTGGGTCCTCGATGAAAATCTCATGCGCGACTTCTGGTTACAACTTTCGTGACTTTTCGATTCATTGGGTCCGTTTCAATCGTCGATATGGCTTTGAGTGGATCGGCTGGCTCAAGCCTATGTGGGGTGCCGTCAGTTACGCCCGCCAACTTCAGGGCCGTGTCTCAATGAGTCGAGTCTTTTCTCAAGACCCATACTACCCGGACAGGGGCACTGCCTTCTTGGAATTCACTGGACTGACGTCCGCCGACACGGCCGACTATTTCTGCGTGAGGCGGGGGTCTTCCTGTCCTCATTGCGGAGACTTCCATTTCGAGTATTGGGGCCAGGGTACAGCCGTCGTCGTCTCGACT,,
VRC07,gp120 CD4bs,"4OLU(VRC07 in complex with 93TH057 gp120);4OLV(VRC07-G54F in complex with 93TH057 gp120);4OLW(VRC07-G54H in complex with 93TH057 gp120);4OLX(VRC07-G54L in complex with 93TH057 gp120);4OLY(VRC07-G54R in complex with 93TH057 gp120);4OLZ(VRC07-G54W in complex with 93TH057 gp120);4OM0(VRC07-G54Y in complex with 93TH057 gp120);4OM1(VRC07-I30Q, G54W, S58N in complex with 93TH057 gp120)",NIH45 ,VRC01,Rudicell2014(25142607) ,hypervariable loop characteristic correlations with bNAb sensitivity;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary,Rudicell2014(25142607) ,IMGT/V-QUEST,1-02*02,,,16.0,CTRGKYCTARDYYNWDFEH,,,3-20*01,,,,,,K,,Natural monoclonal,human,, ,0.28683,10.5764,2152.0,166.0,3059.0,QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRGGAVSYARQLQGRVTMTRDMYSETAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC,EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYTLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCATCCTCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTACCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATGCTGGCTCTACTAGGGCCACTGGCATCCCAGACAGGTTCAGCGGCAGTAGGTGGGGGGCAGAGTACAATCTCACCATCAGCAACCTGGAGTCGGAAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAAGTGCGACTGTCGCAGTCTGGAGGTCAGGTGAAGAAGCCTGGCGACTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGACTTCATTAACTGTCCTATAAATTGGATCCGCCTGGCCCCCGGAAGAAGGCCTGAGTGGATGGGATGGGTGAAGCCTAGGGGGGGGGCCGTGAATTACGCACGCCAATTTCAGGGCAGAGTGACCATGACTCGAGACGTCTACAGCGACACAGCCTTTTTGGAGCTGCGCGCCTTGACATCAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAATACTGTACTGCGCGCGACTATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCTGGTCACCGTCTCTTCA,CTRGKYCTARDYYNWDFEHW,69.625
VRC07-501-LS,gp120 CD4bs,,NIH45 ,VRC01,Rudicell2014(25142607) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,0.058126,10.6101,358.0,170.0,3158.0,,,,,,
VRC07-508-LS,gp120 CD4bs,,NIH45 ,VRC01,Rudicell2014(25142607) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,0.069271,14.2131,358.0,171.0,3159.0,,,,,,
VRC07-523-F54-LS.v3,gp120 CD4bs,,NIH45 ,VRC01,Kwon2021(34328065) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,0.035973,6.70863,416.0,610.0,4236.0,QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRFGAVSYARQLQGRVTMTRQLSQDPDDPDWGTAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK,LTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,,,,
VRC07-523-LS,gp120 CD4bs,,NIH45 ,VRC01,Rudicell2014(25142607) ,hypervariable loop characteristic correlations with bNAb sensitivity;Signature Analysis Summary;Signature Analysis Summary,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,"VRC07-523, VRC07-523LS", ,0.088232,8.53537,2682.0,172.0,3156.0,,,,,,
VRC07-523-LS_FR3-03,gp120 CD4bs,,NIH45 ,VRC01,Liu2019(30760721) ,Mutation affects neutralization by VRC07-523-LS_FR3-03,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,VRC07-523-LS FR3-03, ,0.074689,6.57062,416.0,795.0,4571.0,,,,,,
VRC07-523-LS-N72Q-R24D,gp120 CD4bs,,NIH45 ,VRC01,Chuang2020(33121334) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,0.11916,8.7012,416.0,808.0,4576.0,,,,,,
VRC07-523-W54-LS.v3,gp120 CD4bs,,NIH45 ,VRC01,Kwon2021(34328065) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,0.030373,6.21709,426.0,611.0,4235.0,QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRWGAVSYARQLQGRVTMTRQLSQDPDDPDWGTAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK,LTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,,,,
VRC07-544-LS,gp120 CD4bs,,NIH45 ,VRC01,Rudicell2014(25142607) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,, ,0.074032,10.9016,358.0,173.0,3160.0,,,,,,
VRC07b,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,661.0,3348.0,QVRLSQSGGQVKKPGDSMRISCRASGYDFINCPINWIRLAPGRRPEWMGWVKPRGGAVNYARQFQGRVTMTRDVYSDTAFLELRALTSDDTAVYFCTRGKYCTARDYYNWDFEHWGRGTLVTVSS,EIVLTQSPATLSLSPGERAILSCRTSQYGSLAWYQQRPGQAPRLVIYAGSTRATGIPDRFSGSRWGAEYNLTISNLESEDFGVYYCQQYEFFGQGTKVQVDIK,GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCATCCTCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTACCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATGCTGGCTCTACTAGGGCCACTGGCATCCCAGACAGGTTCAGCGGCAGTAGGTGGGGGGCAGAGTACAATCTCACCATCAGCAACCTGGAGTCGGAAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAAGTGCGACTGTCGCAGTCTGGAGGTCAGGTGAAGAAGCCTGGCGACTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGACTTCATTAACTGTCCTATAAATTGGATCCGCCTGGCCCCCGGAAGAAGGCCTGAGTGGATGGGATGGGTGAAGCCTAGGGGGGGGGCCGTGAATTACGCACGCCAATTTCAGGGCAGAGTGACCATGACTCGAGACGTCTACAGCGACACAGCCTTTTTGGAGCTGCGCGCCTTGACATCAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAATACTGTACTGCGCGCGACTATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCTGGTCACCGTCTCTTCA,CTRGKYCTARDYYNWDFEHW,69.625
VRC07c,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,662.0,3349.0,QVRLSQSGGQVKKPGDSMRISCRASGYDFINCPINWIRLAPGRRPEWMGWVKPRGGAVNYARQFQGRVTMTRDVYSDTAFLELRPLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGRGTLVTVSS,EIVLTQSPATLSLSPGERAILSCRTTQYGSLAWYQQRPGQAPRLVIYAGSTRATGIPDRFSGSRWGADYNLTISNLESEDFGVYYCQQYEFFGQGTKVQVDIK,GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCATCCTCTCTTGTCGGACCACTCAGTATGGTTCCTTAGCCTGGTACCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATGCTGGCTCTACTAGGGCCACTGGCATCCCAGACAGGTTCAGCGGCAGTAGGTGGGGGGCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGAAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAA,CAAGTGCGACTGTCGCAGTCTGGAGGTCAGGTGAAGAAGCCTGGCGACTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGACTTCATTAATTGTCCTATAAATTGGATCCGCCTGGCCCCCGGAAGAAGGCCTGAGTGGATGGGATGGGTGAAGCCTAGGGGGGGGGCCGTTAATTACGCACGCCAATTTCAGGGCAGAGTGACCATGACGCGAGACGTGTATTCCGACACAGCCTTTTTGGAACTGCGCCCCTTGACATCAGACGACACGGCCGTCTATTTTTGCACTAGGGGAAAATACTGTACTGCGCGCGACTATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCTCGTCACCGTCTCATCA,CTRGKYCTARDYYNWDFEHW,69.258
VRC07d,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,663.0,3350.0,QVRLSQFGGQMKKPGESMRLSCRASGYEFLNCPINWIRLAPGRRPEWMGWLKPRGGAVNYARKFQGRVTMTRDVYSDTAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGRGAPVTVSP,EIVLTQSPGTLSLSPGETAIISCRTSQSGSLAWYQQRSGQAPRLVIYSGSTRAAGTPDRFSGSRWGADYNLSISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,GAAATTGTGTTGACACAGTCCCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTCTGGTTCCTTAGCCTGGTATCAACAGAGGTCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCACCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGGCAGACTACAATCTCAGCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAAGTGCGACTGTCGCAGTTTGGAGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGACTTTCCTGCCGGGCTTCCGGATATGAATTTTTGAATTGTCCAATAAATTGGATTCGCCTGGCCCCCGGAAGACGGCCTGAATGGATGGGATGGCTGAAGCCTAGGGGGGGGGCCGTCAATTACGCACGTAAATTTCAGGGCAGAGTGACCATGACTCGAGACGTGTATTCCGACACAGCCTTTTTGGAGTTGCGCTCCTTGACATCAGACGACACGGCCGTCTATTTTTGTACTAGGGGAAAATATTGCACTGCGCGCGACTATTATAATTGGGACTTCGAACACTGGGGCCGGGGTGCCCCGGTCACCGTCTCACCA,CTRGKYCTARDYYNWDFEHW,67.235
VRC07e,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,664.0,3351.0,QVRLSQFGGQMKKPGESMRLSCRASGYEFLNCPINWIRLAPGRRPEWMGWLKPRGGAVNYARKFQGRVTMTRDVYSDTAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEYWGRGAPVTVSP,EIVLTQSPGTLSLSPGETAIISCRTSQSGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGADYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK,GAAATTGTGTTGACACAGTCCCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTCTGGTTCCTTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGGCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAG,CAAGTGCGACTGTCGCAGTTTGGAGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGACTTTCCTGTCGGGCTTCCGGATATGAATTTTTGAATTGTCCAATAAATTGGATTCGCCTGGCCCCCGGAAGACGGCCTGAATGGATGGGATGGCTGAAGCCTAGGGGGGGGGCCGTCAATTACGCACGTAAATTTCAGGGCAGAGTGACCATGACTCGAGACGTGTATTCCGACACAGCCTTTCTGGAGTTGCGCTCCTTGACATCAGACGACACGGCCGTCTATTTTTGTACTAGGGGAAAATATTGTACTGCGCGCGACTATTATAATTGGGACTTCGAATACTGGGGCCGGGGCGCCCCGGTCACCGTCTCACCA,CTRGKYCTARDYYNWDFEYW,66.894
VRC07f,gp120 CD4bs,,NIH45 ,VRC01,Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,665.0,3352.0,QVRLSQFGGQMKKPGESMRLSCRASGYEFLNCPINWIRLAPGRRPEWMGWLKPRGGAVNYARKFQGRVTMTRDVYSDTAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGRGAPVTVSP,EIVLTQSPGTLSLSPGETAIISCRTSQSGSLAWYQQRSGQAPRLVIYSGSTRAAGIPDRFSGSRWGADYNLSISNLESGDFGVYYCQQYEFFGQGTKLEIK,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTCTGGTTCCTTAGCCTGGTATCAACAGAGGTCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGGCAGACTACAATCTCAGCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGTCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGCTGGAGATCAAA,CAAGTGCGACTGTCGCAGTTTGGAGGTCAGATGAAGAAGCCTGGCGAGTCGATGAGACTGTCCTGCCGGGCTTCCGGATATGAATTTTTGAATTGTCCAATAAATTGGATTCGCCTGGCCCCCGGAAGACGGCCTGAATGGATGGGATGGCTGAAGCCTAGGGGGGGGGCCGTCAATTACGCACGTAAATTTCAGGGCAGAGTGACCATGACTCGAGACGTGTATTCCGACACAGCCTTTTTGGAGTTGCGCTCCTTGACATCAGACGACACGGCCGTCTATTTTTGTACTAGGGGAAAATATTGTACTGCGCGCGACTATTATAATTGGGACTTCGAACACTGGGGCCGGGGTGCCCCGGTCACCGTCTCACCA,CTRGKYCTARDYYNWDFEHW,67.235
VRC07_FR3-03,gp120 CD4bs,,NIH45 ,VRC01,Liu2019(30760721) ,Mutation affects neutralization by VRC07_FR3-03,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,VRC07 FR3-03, ,0.1813,9.28102,416.0,794.0,4570.0,,,,,,
VRC07xPG9-16,gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex,,Donor 24 NIH45 ,,Asokan2015(26446600) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,,bispecific ,0.025853,26.973,34.0,235.0,3372.0,,,,,,
VRC08,gp120 CD4bs,4XMP(VRC08 in complex with HIV-1 clade A strain Q842.d12 gp120),NIH45 ,VRC01 (VRC08 sublineage),Wu2015(25865483) ,,Wu2015(25865483) ,IMGT/V-QUEST JoinSolver,1-02*02,,1*01,23.0,CARGRSCCGGRRHCNGADCFNWDFQHW,27.0,,3-20*01,2*01,5.0,QCLEA,22.0,,K,,Natural monoclonal,human,, ,0.25167,11.6464,440.0,613.0,3279.0,QVQLVQSGTQMKEPGASVTISCVTSGYEFVEILINWVRQVPGRGLEWMGWMNPRGGGVNYARQFQGKVTMTRDVYRDTAYLTLSGLTSGDTAKYFCVRGRSCCGGRRHCNGADCFNWDFQHWGQGTLVIVSP,YIGVTQSPAILSVSLGERVTLSCKTSQAITPRHLVWHRQKGGQAPSLVMTGTSERASGIPDRFIGSGSGTDFTLTITRLEAEDFAVYYCQCLEAFGQGTKLEIK,TATATCGGAGTGACGCAGTCTCCAGCCATTTTGTCCGTGTCTTTAGGGGAGAGAGTCACTCTCTCCTGTAAGACCAGTCAGGCTATCACTCCTCGTCACTTAGTCTGGCACCGACAAAAAGGTGGCCAGGCTCCCAGCCTGGTCATGACTGGAACATCTGAGAGGGCCAGTGGCATTCCAGACAGGTTCATTGGCAGTGGGTCTGGGACAGACTTCACACTCACCATCACCAGACTGGAAGCTGAAGATTTTGCTGTCTATTACTGTCAATGTCTTGAGGCTTTTGGCCAGGGGACCAAACTGGAGATCAAG,CAGGTGCAGCTGGTGCAGTCTGGGACTCAGATGAAGGAGCCTGGGGCCTCAGTGACAATCTCCTGCGTGACATCTGGATATGAATTTGTTGAGATTCTTATAAATTGGGTGCGACAGGTCCCCGGTCGGGGACTCGAGTGGATGGGGTGGATGAATCCTCGGGGGGGCGGCGTGAATTATGCTCGTCAATTTCAAGGCAAAGTTACCATGACCAGGGACGTGTATCGGGACACAGCCTACCTGACACTGAGCGGTCTGACATCTGGCGACACGGCCAAGTATTTTTGTGTGAGGGGAAGATCGTGTTGTGGTGGACGGAGACATTGCAATGGGGCCGACTGCTTCAATTGGGACTTCCAACACTGGGGCCAGGGGACCCTAGTCATCGTGTCTCCG,CVRGRSCCGGRRHCNGADCFNWDFQHW,73.038
VRC08c,gp120 CD4bs,,NIH45 ,VRC01 (VRC08 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,666.0,3318.0,QHSQVQSGTQIKTPGASVTLSCGTSGYDFMESLINWVRQEIGKRPEWLGWMNPRGGGVNYAQRFQGKVTMTRDVSSGTAYLTLRGLTSDDTAKYYCVRGKSCCNGRRYCNGADCFNWDFEYWGQGTLVIVSP,YIGLTQSPGTLSVSPGERATLSCRPSQAISKSHLAWYSQKSGQPPRLLLTGTYERASGVPDRFVGSGSGTNYTLTIASVEAEDFAVYFCQCFEGFGQGTKLEIK,TACATCGGACTGACCCAGTCTCCAGGCACCCTGTCAGTGTCTCCAGGGGAAAGAGCCACTCTTTCCTGTCGACCGAGTCAGGCTATAAGTAAGAGTCACTTAGCCTGGTACAGTCAAAAGAGTGGGCAGCCTCCCAGATTGCTCTTGACTGGTACTTATGAGAGGGCCAGTGGCGTCCCAGACAGATTCGTTGGCAGTGGATCTGGAACGAATTACACACTCACCATCGCCAGTGTGGAGGCGGAAGACTTCGCCGTCTATTTCTGTCAATGTTTTGAAGGTTTTGGCCAGGGGACCAAACTGGAGATCAAA,CAGCACTCCCAGGTGCAGTCTGGGACTCAGATAAAAACACCTGGGGCCTCAGTGACACTGTCGTGTGGGACGTCTGGATATGACTTCATGGAGAGTCTCATAAATTGGGTGCGCCAGGAAATCGGCAAGAGACCGGAGTGGCTGGGCTGGATGAATCCTCGGGGGGGCGGTGTGAATTATGCTCAAAGATTTCAAGGGAAAGTCACCATGACGCGAGACGTGTCAAGCGGCACAGCCTACCTGACACTTCGCGGCCTGACATCTGACGACACGGCCAAATACTACTGTGTCAGGGGAAAATCGTGTTGTAATGGACGCAGATATTGCAATGGGGCCGACTGTTTCAATTGGGACTTTGAATACTGGGGTCAGGGGACCCTCGTCATCGTCTCTCCA,CVRGKSCCNGRRYCNGADCFNWDFEYW,67.931
VRC08d,gp120 CD4bs,,NIH45 ,VRC01 (VRC08 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,667.0,3366.0,QHSQVQSGTQIKTPGASVTLSCGTSGYDFMESLINWVRQEIGKGPEWLGWMNPRGGSVNYAHRFQGKITMTRDVSSATAYLTLRGLTSDDTARYYCVRGRSCCDGRRYCNGADCFNWDFENWGQGTLVIVSP,YIGLTQSPGTLSVSPGERATLSCRPSQAISKNHLAWYRQKSGQPPRLLMTGTYERASGVPDRFVGSGSGTNYTLTITKVQAEDFAVYFCQCFEGFGQGTKLEMK,TACATCGGCCTGACCCAGTCTCCAGGCACCTTGTCAGTGTCTCCGGGGGAAAGAGCCACTCTTTCCTGTCGACCGAGTCAGGCTATAAGTAAGAATCATTTAGCCTGGTACCGTCAAAAGAGTGGGCAGCCTCCCAGATTGCTCATGACTGGTACTTATGAGAGGGCCAGTGGCGTCCCAGACAGATTCGTTGGCAGTGGATCTGGAACCAATTACACACTCACCATCACCAAAGTGCAGGCGGAAGACTTTGCCGTCTATTTTTGTCAGTGCTTTGAAGGTTTTGGCCAGGGGACCAAACTGGAGATGAAA,CAGCACTCCCAGGTGCAGTCTGGGACTCAGATAAAAACCCCTGGGGCCTCAGTGACACTGTCGTGTGGGACGTCTGGATATGACTTCATGGAGAGTCTCATAAATTGGGTGCGCCAGGAGATCGGCAAGGGACCAGAGTGGCTGGGCTGGATGAATCCTCGGGGGGGCAGTGTAAATTATGCTCATAGATTTCAAGGTAAAATCACCATGACGCGGGACGTGTCAAGCGCCACAGCCTACCTGACACTTCGCGGCCTGACATCTGACGACACGGCCAGGTATTACTGTGTCAGGGGAAGATCGTGTTGTGATGGACGCAGATACTGTAATGGGGCCGACTGTTTCAACTGGGACTTTGAAAATTGGGGTCAGGGGACCCTCGTCATCGTCTCTCCA,,
VRC08e,gp120 CD4bs,,NIH45 ,VRC01 (VRC08 sublineage),Wu2015(25865483) ,,,,,,,,,,,,,,,,,K,,Natural monoclonal,human,, ,,,24.0,668.0,3367.0,QHSQVQSGTQIKTPGASVTLSCGTSGYDFMESLINWVRQEIGKGPEWLGWMNPRGGGVNYARRFQGKVTMTRDVSSGTAYLTLRGLTSDDTAKYYCVRGKSCCDGRRYCNGADCFNWDFESWGQGTLVIVSP,YIGLTQSPGTLSVSPGERATLSCRPSQAISKSHLAWYSQKSGQPPRLLMTGTYERASGVPDRFVGSGSGTNYTLTITRVEAEDFAVYFCQCFEGFGQGTKLEIK,TACATCGGACTGACCCAGTCTCCAGGCACCCTGTCAGTGTCTCCAGGGGAAAGAGCCACTCTTTCCTGTCGACCGAGTCAGGCTATAAGTAAGAGTCACTTAGCCTGGTATAGTCAAAAGAGTGGGCAGCCTCCCAGATTGCTCATGACTGGGACTTATGAGAGGGCCAGTGGCGTCCCAGACAGATTCGTTGGCAGTGGATCTGGAACGAATTACACACTCACCATCACCAGGGTGGAGGCGGAAGACTTCGCCGTCTATTTCTGTCAATGTTTTGAAGGTTTTGGCCAGGGGACCAAACTGGAGATCAAA,CAGCACTCCCAGGTGCAGTCTGGGACTCAGATAAAAACACCTGGGGCCTCAGTGACACTGTCGTGTGGGACGTCTGGATATGACTTCATGGAGAGTCTCATAAATTGGGTGCGCCAGGAAATCGGCAAGGGACCAGAGTGGCTGGGCTGGATGAATCCTCGGGGGGGCGGTGTGAATTATGCGCGAAGATTTCAAGGGAAAGTCACCATGACGCGAGACGTGTCAAGCGGCACAGCCTACCTGACACTTCGCGGCCTGACATCTGACGACACGGCCAAATACTACTGTGTCAGGGGAAAATCGTGTTGTGATGGACGGAGATATTGTAATGGGGCCGACTGTTTCAATTGGGACTTTGAATCCTGGGGTCAGGGGACCCTCGTCATCGTCTCTCCA,CVRGKSCCDGRRYCNGADCFNWDFESW,66.436
VRC08H/UCAL,gp120 CD4bs,,NIH45 ,VRC01,Bonsignori2018(30552024) ,,,,,,,,,,,,,,,,,K,,Engineered monoclonal,human,VRC08H/UCAL,chimeric: VRC08 HC with VRC01-UCA LC ,9.66349,10.9214,14.0,684.0,4289.0,,,,,,
VRC13,gp120 CD4bs,4YDJ(44-VRC13.01 in complex with HIV-1 clade AE strain 93TH057 gp120),44 ,,Zhou2015(26004070) ,Signature Analysis Summary;VRC13 contacts,Zhou2015(26004070) ,IMGT/V-QUEST,1-69,,,,,,,2-14,,,,,,L,,Natural monoclonal,human,"44-VRC13.01, VRC13.01", ,0.7001,21.6859,1304.0,236.0,3284.0,QVQLVQPGTAMKSLGSSLTITCRVSGDDLGSFHFGTYFMIWVRQAPGQGLEYMGGILPSTKTPTYAHKFRGRVSISAPGVPPVLSLALTNLTYDDTATYFCARERGRHFEPKNRDNLEGKFFDLWGRGTFVRVSP,,,CAGGTGCAGCTGGTGCAGCCCGGGACTGCGATGAAGTCTCTTGGATCATCACTGACGATCACTTGCAGAGTCTCCGGAGACGACCTCGGCTCTTTCCACTTCGGCACTTATTTTATGATCTGGGTGCGTCAAGCCCCTGGACAGGGCCTTGAGTACATGGGAGGCATCCTCCCCTCCACGAAGACACCCACTTACGCGCACAAATTTCGAGGCCGCGTCTCTATTTCCGCTCCCGGGGTTCCGCCCGTGCTGTCCCTCGCGCTGACCAACCTCACATACGACGACACGGCCACCTACTTCTGTGCGCGCGAGAGGGGGCGACATTTTGAGCCAAAGAACAGGGATAATCTGGAAGGCAAATTTTTCGATTTATGGGGTCGTGGCACCTTCGTTCGCGTCTCGCCG,,
VRC16,gp120 CD4bs,4YDK(C38-VRC16.01 in complex with HIV-1 clade AE strain 93TH057 gp120),C38 ,,Zhou2015(26004070) ,Signature Analysis Summary;VRC16 contacts;VRC16 contacts,Zhou2015(26004070) ,IMGT/V-QUEST,3-32,,,,,,,1-39,,,,,,K,,Natural monoclonal,human,"C38-VRC16.01, VRC16.01", ,10.1831,11.4287,704.0,237.0,3286.0,EVQLSESGGGFVKPGGSLRLSCEASGFTFNNYAMGWVRQAPGKGLEWVSVTSAHGGSAYFGEFVKGRFTMSRDHFIDTVYLEMNRLTVEDTAVYYCVRVTFYHEGSGYYYRAGNYFDSWGQGTLVIVSA,,,GAGGTGCAGTTATCAGAGTCGGGGGGAGGCTTCGTAAAGCCGGGGGGGTCCCTGAGACTCTCCTGTGAGGCCTCTGGATTCACCTTCAATAATTATGCCATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCTGTGACGAGTGCTCATGGTGGTAGTGCATACTTTGGAGAATTCGTGAAGGGCCGCTTCACCATGTCCAGAGACCACTTCATAGACACGGTCTACTTGGAAATGAACAGACTGACAGTCGAGGACACGGCCGTCTACTACTGCGTCAGAGTGACATTTTACCATGAGGGCAGTGGCTACTATTATCGTGCCGGGAATTACTTTGATTCCTGGGGCCAGGGAACCCTAGTCATCGTCTCCGCA,CVRVTFYHEGSGYYYRAGNYFDSW,82.578
VRC18,gp120 CD4bs,4YDL(C38-VRC18.02 in complex with HIV-1 clade AE strain 93TH057 gp120),C38 ,,Zhou2015(26004070) ,VRC18 contacts,Zhou2015(26004070) ,IMGT/V-QUEST,1-2,,,,,,,3-20,,,,,,K,,Natural monoclonal,human,"C38-VRC18.02, VRC18.02", ,4.60778,12.1397,175.0,238.0,3287.0,QVRLVQSGNQVRKPGASVRISCEASGYKFIDHFIHWVRQVPGHGLEWLGWINPRGGGVNYSRSFQGKLSMTMTRDNFEETAYLDLSKLNPGDTAVYFCARGFAGYEWSFIWGQGTLVIVSS,,,CAGGTGCGATTGGTCCAATCTGGAAATCAAGTGAGGAAGCCTGGGGCCTCAGTGAGAATCTCCTGCGAGGCTTCCGGGTACAAATTCATCGACCACTTTATCCATTGGGTGCGTCAAGTCCCCGGTCACGGTCTTGAGTGGCTGGGCTGGATCAATCCCCGTGGCGGTGGCGTAAATTATTCACGAAGTTTTCAGGGGAAACTCTCCATGACCATGACAAGGGACAACTTCGAAGAGACAGCCTACCTGGACCTCAGTAAATTGAATCCTGGCGACACGGCCGTGTATTTCTGCGCGAGAGGATTTGCCGGTTATGAGTGGAGTTTCATCTGGGGTCAGGGAACTCTGGTCATTGTCTCCTCT,CARGFAGYEWSFIW,72.757
VRC21.01,gp120 V3 // V3 glycan (V3g),,N170 ,VRC21,Longo2016(27654288) ,,Longo2016(27654288) ,IMGT/V-QUEST JoinSolver,3-30*03,,4*02,12.0,VRGDGENGGTDY,15.0,,6-57*01,3*02,10.0,QSYDSNYYWV,9.0,,L,,Natural monoclonal,human,, ,50.5423,6.41227,28.0,283.0,3559.0,,,,,,
VRC21.02,gp120 V3 // V3 glycan (V3g),,N170 ,VRC21,Longo2016(27654288) ,,Longo2016(27654288) ,IMGT/V-QUEST JoinSolver,3-30*03,,4*02,12.0,VRGDGENGGTDY,17.0,,6-57*01,3*02,10.0,QSYDDTYFWV,10.0,,L,,Natural monoclonal,human,, ,53.3922,5.01602,28.0,284.0,3560.0,,,,,,
VRC22.01,gp120 V3 // V3 glycan (V3g),,N170 ,,Longo2016(27654288) ,,Longo2016(27654288) ,IMGT/V-QUEST JoinSolver,4-34*01,,6*02,19.0,ARAGGMSDWAYPYYYGMDV,7.0,,1-17*01,1*01,9.0,LQYNTFPRT,6.0,,K,,Natural monoclonal,human,, ,79.9232,2.32598,444.0,285.0,3561.0,,,,,,
VRC23,gp120 CD4bs,4J6R(VRC23 in complex with HIV-1 gp120),127/C ,,Georgiev2013(23661761) ,,Georgiev2013(23661761) ,IMGT/V-QUEST JoinSolver,1-2*02,,,,,,,3-15*01,,,,,,K,,Natural monoclonal,human,, ,9.7537,9.06124,637.0,11.0,3012.0,QVQFVQSGAEVKKPGASVRVSCEASGYSFTDYVLQWIRQAPGQRPEWMGWIKPERGAVSYAPQFQGRLTLTRDLYTETAYMHFKNLRSDDTAIYYCARGVRRDASWWLQFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC,EIVMTQSPVTVSVSRGGTATLSCRASQGVGSDVAWYQHKPGQTPRLLIYGASTRASGVPERFSGSGFHVDFTLSISGLQPEDVAIYYCQQYETFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,,,,
VRC23b,gp120 CD4bs,,127/C ,,Georgiev2013(23661761) ,,Georgiev2013(23661761) ,IMGT/V-QUEST JoinSolver,1-2*02,,,,,,,3-15*01,,,,,,K,,Natural monoclonal,human,, ,2.36696,10.0325,50.0,81.0,3014.0,QVQLVQSGAAVRRPGASVRVSCEASGYNFDNYFIQWIRVVPGQGLQWVGWINPQGGAVNYGPNFRGRVRLTRDVSIETAYMDFTYLRSDDTAVYYCARSVRRDKAWWLLFWGQGTPIIVTS,EIVMTQSPATVSVSRGGGATLSCRASQGIGSDLAWYQHRPGHPPRLLIYGASTRASGVPDRFSGSGFHTDFTLSITNLQSEDVAIYYCQVLETFGQGTKVEIKRR,,,,
VRC24,gp120 V3 // V3 glycan (V3g),,N27 ,,Georgiev2013(23661761) ,Mutations at the trimer apex that affect sensitivity,Georgiev2013(23661761) ,IMGT/V-QUEST JoinSolver,4-4*07,,,,,,,1-51*02,,,,,,L,,Natural monoclonal,human,, ,21.1932,14.2941,76.0,82.0,3013.0,QVHLQESGPGLVRPAETLSLTCTVSNATVKDFYWTWIRQPAEKRLEWIGLITNSGHTFRNPSLGSRVSMSLGASSNDVSLTLTSVTAADTAVYYCARLLLGSDFYDFSGYYYINQRMRFDPWGQGTLVTVSS,QSVLTQPPSVSAAPGQSVTISCSGSTSNIGSNFVSWYQQFPGSAPKVIVYEDRRRASGVPDRFTASKSGTSASLAITGLQTGDESIIYCVTWQKDTMLFGRGTSLTVL,,,,
VRC26.01,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,4OCR(Fab CAP256-VRC26.01),CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CAKDVGDYKSDEWGTEYYDISISYPIQDPRAMVGAFDLW,8.3,,51*02,,,,3.9,,L,,Natural monoclonal,human,CAP256-VRC26.01, ,45.7262,6.77853,238.0,137.0,3038.0,EVQVVESGGGVVQPGRSLRLSCTASGFTFSNFAMGWVRQAPGKGLEWVAFISSDGSNKNYGDSVKGRFTISRDNSKNTVFLQMNSLRVEDTALYYCAKDVGDYKSDEWGTEYYDISISYPIQDPRAMVGAFDLWGQGTMVTVSX,QSVLTQPPSVSAAPGQKVTISCSGSSSTIGNNYVSWYRLLPGTAPKLLIYKNDNRPSGIPDRFSGSKSGTSATLGISGLQTGDEADYYCGTWDTSLSGGGVFGTGTKVTVLX,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCACCATTGGGAATAATTATGTCTCCTGGTACCGGCTACTCCCAGGAACAGCCCCCAAACTCCTCATCTATAAAAATGATAACCGACCCTCAGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGGCATCAGCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGAACATGGGATACCAGCCTGAGTGGTGGCGGTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAG,GAAGTGCAGGTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTACAGCCTCTGGATTCACTTTCAGCAACTTTGCCATGGGCTGGGTCCGCCAGGCTCCGGGCAAGGGTCTGGAGTGGGTGGCCTTTATATCATCTGATGGAAGTAATAAAAACTATGGAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGGTGTTCCTGCAAATGAACAGTCTGAGAGTTGAGGACACGGCTTTGTATTACTGTGCGAAAGATGTGGGAGACTACAAAAGTGATGAGTGGGGGACGGAATATTATGATATTTCGATTTCTTACCCTATTCAAGACCCACGGGCCATGGTTGGAGCTTTTGATCTCTGGGGCCAAGGGACAATGGTCACCGTCTCTCC,CAKDVGDYKSDEWGTEYYDISISYPIQDPRAMVGAFDLW,91.892
VRC26.02,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CAKDIREYECEYWTSDYYDFGRPQPCIDSRGVVGTFDVW,8.7,,51*02,,,,4.9,,L,,Natural monoclonal,human,CAP256-VRC26.02, ,24.9844,17.091,102.0,138.0,3039.0,EVQLVESGGGVVQPGRSLRLSCAASQFSFGNYGMHWVRQAPGKGLEWVAAISFAGTKTNYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTALYFCAKDIREYECEYWTSDYYDFGRPQPCIDSRGVVGTFDVWGQGTMVTVSX,QSVLTQPPSVSAAPGQKVTISCSGSNSNIGNKDVSWYQQIPATAPKLLIYENNKRPSGISDRFSGSKSGTSATLAITGLQTGDEADYYCATWDGRVSVIGTGTNVIVLX,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAATTCCAACATTGGGAATAAAGATGTATCCTGGTACCAACAGATCCCAGCAACAGCCCCCAAACTCCTCATCTATGAAAATAACAAGCGACCCTCAGGGATTTCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGCAACATGGGATGGCAGAGTGAGTGTCATCGGAACTGGGACCAATGTCATCGTCCTAG,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTCAATTCAGCTTTGGTAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCAGCCATTTCATTTGCTGGAACTAAGACAAACTATGCAGATTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGGTCTATCTGCAAATGAACAGCCTGCGCGCTGAGGACACGGCTCTATATTTCTGTGCGAAAGATATCCGAGAATACGAATGTGAATATTGGACGTCGGATTATTACGATTTTGGGAGACCGCAACCTTGTATAGACTCACGGGGGGTGGTTGGAACTTTTGATGTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTC,CAKDIREYECEYWTSDYYDFGRPQPCIDSRGVVGTFDVW,91.554
VRC26.03,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,4OD1(Fab CAP256-VRC26.03),CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDGW,8.7,,51*02,,,,7.4,,L,,Natural monoclonal,human,CAP256-VRC26.03, ,5.92568,51.1265,251.0,139.0,3040.0,EVQLVESGGGVVQPGKSLRLSCAASRFSFNRYGMHWVRQAPGKGLEWVAAISYDGTDKYHADKVWGRFTISRDNSKNTLYLQMNSLRAEDTALYYCAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDGWGQGTMVTVSX,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNFVSWYQQRPGTAPKILIYENNKRPSETPDRFSGSKSGTSATLAITGLQTADEAEYYCATWSASLSSARVFGTGTRITVLX,CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGCAATAATTTTGTATCCTGGTACCAGCAGCGCCCAGGAACAGCCCCCAAGATCCTCATTTATGAAAATAACAAGCGACCCTCAGAGACTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGCCTCCAGACTGCGGACGAGGCCGAATATTACTGCGCCACATGGTCTGCCAGCCTGAGCTCCGCGCGTGTCTTCGGAACTGGGACCAGGATCACCGTCCTAG,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCCTGAGACTCTCCTGTGCAGCCTCTCGATTCAGTTTTAATAGATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCCATATCATATGATGGAACTGATAAATATCATGCAGATAAAGTGTGGGGCCGCTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTCTCTATTACTGTGCGAAAGATTTGCGAGAGGACGAATGTGAAGAGTGGTGGTCGGATTATTACGATTTTGGGAAACAGCTCCCTTGCCGAAAGTCACGGGGCGTGGCTGGAATTTTTGATGGCTGGGGCCAAGGGACAATGGTCACCGTCTCTTC,CAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDGW,91.554
VRC26.04,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,4ORG(Fab CAP256-VRC26.04),CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDKW,9.0,,51*02,,,,8.1,,L,,Natural monoclonal,human,CAP256-VRC26.04, ,11.491,30.2338,118.0,140.0,3041.0,EVQLVESGGGVVQPGKSLRLSCAASQFSFNRYGMHWVRQAPGKGLEWVAAISYDGTDKYHADKVWGRFTISRDNSKNTLYLQMNSLRAEDTALYYCAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDKWGQGTMVIVSX,QPVLTQPPSVSAAPGQKVTISCSGSSSNIGNNFVSWYQQRPGTAPSLLIYETNKRPSGIPDRFSGSKSATSATLAITGLQTGDEADYYCATWAASLTSARVFGTGTKVIVSX,CAGCCTGTGCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGCAATAATTTTGTTTCCTGGTACCAGCAGCGGCCAGGAACAGCCCCCAGCCTCCTCATTTATGAAACTAACAAGCGACCCTCAGGAATTCCTGACCGATTCTCTGGCTCCAAGTCTGCCACGTCAGCCACCCTGGCCATCACCGGGCTCCAGACTGGGGACGAGGCCGATTATTACTGCGCCACGTGGGCTGCCAGCCTGACTTCCGCGCGTGTCTTCGGAACTGGGACCAAGGTAATCGTCTCAG,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCCTGAGACTCTCATGTGCAGCCTCTCAATTCAGTTTTAATAGATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCTATATCATATGATGGAACTGATAAATACCACGCTGATAAAGTGTGGGGCCGCTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTCTGTATTACTGTGCGAAAGATTTGCGAGAAGACGAGTGTGAAGAGTGGTGGTCGGATTATTACGATTTTGGGAAACAACTCCCTTGCCGAAAGTCACGGGGCGTGGCTGGAATTTTTGATAAGTGGGGCCAAGGGACAATGGTCATCGTCTCTTC,CAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDKW,91.216
VRC26.05,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CARDQRYYECEEWASDYYDFGREQPCLDPRGVVGIFDLW,10.0,,51*02,,,,5.6,,L,,Natural monoclonal,human,CAP256-VRC26.05, ,14.6264,37.7645,102.0,141.0,3042.0,EVQLVESGGGVVQPGRSLRLSCAASHFSLSSYGMHWVRQAPGKGLEWVTGISFAGTKTYYGDSVRGRFTVSRDISKNTLFLQMNSLRPDDTAMYYCARDQRYYECEEWASDYYDFGREQPCLDPRGVVGIFDLWGQGTMVTVSX,QSALTQPPSVSAAPGQKVTISCSGNIGNNYVSWYQQVPGTAPKLLIYENNKRPSGIPDRFSGSKSGTSATLVITGLQTGDEADFYCGTWGGSLRTGGVLGTGTRVTVLX,CAGTCTGCCCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAACATTGGGAATAATTATGTTTCTTGGTACCAGCAAGTCCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAATAACAAGCGACCCTCAGGCATTCCTGACCGATTCTCTGGCTCTAAGTCTGGCACGTCAGCCACCCTGGTCATCACCGGACTCCAGACTGGGGACGAGGCCGATTTTTACTGCGGAACATGGGGTGGCAGCCTGAGAACTGGCGGTGTCCTCGGAACTGGGACCAGGGTCACCGTCCTAG,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTCACTTCTCCCTTAGTAGTTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGACAGGTATCTCATTTGCTGGAACTAAGACATACTATGGAGATTCCGTGAGGGGCCGTTTCACCGTCTCCAGAGACATTTCCAAGAACACGTTGTTCCTGCAAATGAACAGCCTGCGACCTGACGACACGGCTATGTATTACTGTGCGAGAGATCAGCGATATTACGAGTGTGAAGAGTGGGCGTCGGATTATTACGATTTTGGGAGAGAGCAACCTTGCCTAGACCCACGGGGCGTGGTTGGAATTTTCGATTTGTGGGGCCAAGGGACAATGGTCACCGTCTCTTC,CARDQRYYECEEWASDYYDFGREQPCLDPRGVVGIFDLW,90.203
VRC26.06,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,4OCW(Fab CAP256-VRC26.06),CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,36.0,CARDLRELECEEWTLYNYYDFGSRGPCVDPRGVAGSFDVW,11.0,,51*02,,,,7.4,,L,,Natural monoclonal,human,CAP256-VRC26.06, ,52.2653,6.36854,254.0,142.0,3043.0,EVQLIESGGGVVQPGRSLRLSCGASGFSFNNYGMHWVRQAPGKGLEWVAGISFAGIKKYYGTSVKGRFTISRDNSKNNFYLQMNSLRVEDTALYYCARDLRELECEEWTLYNYYDFGSRGPCVDPRGVAGSFDVWGQGTMVTVSX,QSVLTQPPSVSAAPGQKVTISCSGSTSKIGQNSVSWYQQLPGTAPKLLIYENDRRPSGTPDRFSGSKSGTSATLAITGLQTGDEAEYYCETWDGSGGVFGTGTKVTVLX,CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCACTTCCAAAATTGGGCAAAACTCTGTATCTTGGTACCAGCAACTCCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAATGACCGGCGACCCTCGGGGACTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGAATATTACTGCGAAACATGGGATGGCAGCGGGGGTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAG,GAGGTGCAGCTGATTGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGGAGCGTCTGGATTCAGCTTCAATAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGGTATTTCCTTTGCTGGAATCAAGAAATACTATGGAACTTCCGTGAAGGGCCGATTCACCATCTCCCGAGACAATTCCAAGAACAATTTCTATCTGCAAATGAACAGCCTGCGAGTTGAGGACACGGCTCTCTATTATTGTGCGAGAGATCTGCGAGAATTGGAATGTGAAGAGTGGACACTATATAATTATTATGACTTTGGAAGTCGAGGCCCTTGTGTAGACCCACGGGGCGTGGCTGGATCTTTTGATGTCTGGGGCCAGGGGACAATGGTGACCGTCTCCTC,CARDLRELECEEWTLYNYYDFGSRGPCVDPRGVAGSFDVW,89.865
VRC26.07,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,"4OD3(Fab CAP256-VRC26.07, a potent V1V2-directed HIV-1 neutralizing antibody)",CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CAKDLREDECEEWWSDYYDFGKKLPCRKSRGVAGVFDKW,12.0,,51*02,,,,7.7,,L,,Natural monoclonal,human,CAP256-VRC26.07, ,42.7516,11.2896,102.0,143.0,3044.0,EVQLVESGGGVVQPGRSLRLSCVGSQFSFNRYGMHWVRQAPGKGLEWVAGISFDGTDRYHADNVWGRFTISRDNSKNTLYLQMSSLRAEDTALYYCAKDLREDECEEWWSDYYDFGKKLPCRKSRGVAGVFDKWGQGTMVTVSX,QAVLTQPPSVSAAPGQNVTISCSGSGSNIGNNFVSWYQQRPGTAPKLLIYESNKRPSGIPDRFSGSKSGTSATLAITGLQTGDEAYYYCATWAARLNSARVFGTGTMVTVLX,CAGGCTGTGCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAACGTCACCATCTCCTGCTCTGGAAGCGGCTCCAACATTGGCAATAATTTTGTATCCTGGTACCAGCAACGCCCAGGAACAGCCCCCAAACTCCTCATTTATGAGTCTAACAAGCGACCCTCAGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGGCTCCAGACTGGGGACGAGGCCTATTATTACTGCGCCACATGGGCTGCCAGGCTGAATTCCGCGCGTGTCTTCGGAACTGGGACCATGGTCACCGTCCTAG,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGTAGGCTCTCAATTCAGTTTTAATCGATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCGGGTATATCATTTGATGGAACTGACAGATATCATGCAGACAATGTGTGGGGCCGCTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTACAAATGAGCAGCCTGCGCGCTGAGGACACGGCTCTCTATTATTGTGCGAAAGATTTGCGAGAAGACGAATGTGAAGAGTGGTGGTCGGATTATTACGATTTTGGGAAAAAACTCCCTTGCCGAAAGTCACGGGGCGTGGCTGGAGTTTTTGATAAGTGGGGCCAAGGGACAATGGTCACCGTCTCTTC,CAKDLREDECEEWWSDYYDFGKKLPCRKSRGVAGVFDKW,88.514
VRC26.08,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;hypervariable loop characteristic correlations with bNAb sensitivity;Mutations at the trimer apex that affect sensitivity;V2 Signature Analysis Summary;VRC26.08 signature sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVRDQREDECEEWWSDYYDFGRELPCRKFRGLGLAGIFDIW,12.0,,51*02,,,,9.8,,L,,Natural monoclonal,human,"CAP256.26.08, CAP256-VRC26.08", ,0.67925,146.319,1758.0,144.0,3045.0,EVQLVESGGGVVQPGRSLTLSCAASQFTFSNYGMHWVRQAPGKGLEWVASVSNDGTKKYHGDSVWGRFTISRDNSKNTLFLQMSSLRAEDTAVYFCVRDQREDECEEWWSDYYDFGRELPCRKFRGLGLAGIFDIWGHGTMVTVSX,QSALTQPPSVSAAPGQKVTISCSGNSSNIGNNFVSWYQQVPGTAPKLLLYETYRRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCTVWGVRKGVGAVFGTGTKVTVLX,CAGTCTGCCCTGACTCAGCCGCCCTCAGTGTCCGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCCGGAAACAGCTCCAACATTGGGAATAATTTTGTATCCTGGTACCAGCAAGTCCCAGGAACAGCCCCCAAACTCCTCCTGTATGAAACTTACAGGCGACCCTCAGGTATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGACTACTACTGCACAGTATGGGGTGTCAGGAAGGGTGTCGGCGCTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAG,GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGACACTGTCCTGTGCAGCCTCTCAATTCACTTTTTCGAATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCAAGTGTATCAAATGATGGAACCAAGAAATATCATGGAGATTCCGTGTGGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACACTGTTTCTACAAATGAGCAGCCTGCGAGCTGAGGACACGGCTGTATATTTCTGTGTGAGAGATCAACGAGAAGACGAGTGTGAAGAGTGGTGGTCGGATTATTATGATTTTGGGAGAGAGCTCCCTTGCCGAAAATTCCGGGGCCTGGGCCTGGCTGGAATTTTTGATATCTGGGGCCACGGGACAATGGTCACCGTCTCTTC,CVRDQREDECEEWWSDYYDFGRELPCRKFRGLGLAGIFDIW,88.176
VRC26.09,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;Disulfide bond introduced in V1V2 affects binding and neutralization;mutations affecting VRC26.09 binding;mutations affecting VRC26.09 binding;VRC26.09 escape mutations,Andrabi2015(26588781) ,IMGT/V-QUEST,3-30*18,3-3*01,3*02,39.0,,14.0,,1-51*02,1*01,12.0,,10.0,,L,,Natural monoclonal,human,"CAP256-09, CAP256.09, CAP256-VRC26.09", ,2.13866,98.1991,455.0,145.0,3046.0,EVQLVESGGGVVQPGRSLTLSCAASQFNFANYGMHWVRQAPGKGLEWVASISNDGTKKYHEESVWGRFTISKDNSKSTLFLQMNSLRIEDTALYFCVKDQREDECEEWWSDYYDFGRELPCRKSRGLGLAGIFDMWGHGTMVTVSX,QSALTQPPSVSAAPGQKVTISCSGNSSNIGNNFVSWYQQLPGTAPKLLIYENNRRPSGIPDRFSGSKSGTSATLAISGLQTGDEADYWCAVWGVRRGAGAVFGAGTKVTVLX,CAGTCTGCCCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAATAGTTCCAACATTGGGAATAATTTTGTATCCTGGTACCAGCAACTCCCGGGGACAGCCCCCAAACTCCTCATATATGAAAATAACAGGCGACCCTCAGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCAGCGGACTCCAGACTGGGGACGAGGCCGACTATTGGTGCGCTGTTTGGGGTGTCAGGCGGGGTGCCGGCGCTGTCTTCGGAGCTGGGACCAAGGTCACCGTCCTAG,GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGACACTGTCCTGTGCAGCCTCTCAATTCAATTTTGCGAATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGATTGGAGTGGGTGGCAAGTATATCAAATGATGGAACGAAGAAATATCATGAAGAATCCGTGTGGGGCCGATTCACCATCTCCAAAGACAATTCCAAGAGCACACTATTTCTACAAATGAACAGCCTGCGAATTGAGGACACGGCCCTATATTTCTGTGTGAAAGATCAACGAGAGGACGAATGTGAAGAGTGGTGGTCGGATTATTATGATTTTGGGAGAGAGCTCCCTTGCCGAAAGTCCCGGGGCCTGGGCCTGGCTGGAATCTTTGATATGTGGGGCCACGGGACAATGGTCACCGTCTCTTC,CVKDQREDECEEWWSDYYDFGRELPCRKSRGLGLAGIFDMW,85.811
nan,,,,,,,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVKDQREDECEEWWSDYYDFGRELPCRKSRGLGLAGIFDMW,14.0,,51*02,,,,9.8,,,,,,,,,,,,,,,,,,
VRC26.10,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,4OCS(Fab CAP256-VRC26.10),CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CAKDMREYECEYWTSDYYDFGRPQPCIDRRGVVGIFDMW,12.0,,51*02,,,,3.9,,L,,Natural monoclonal,human,CAP256-VRC26.10, ,19.9435,18.0649,102.0,146.0,3047.0,QAILVESGGGVVQPGRSLRLSCAASQFTFSGHGLHWVRQAPGKGLEWVASISFAGTKMDYADSVKGRFAISRDNSKNTLYLQMNSLRVEDTALYYCAKDMREYECEYWTSDYYDFGRPQPCIDRRGVVGIFDMWGQGTMVTVSX,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGDNYVSWYQHLPGTAPKLLIYENTRRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDVRPNRGAVFGTGTKVTVLX,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGGGATAATTATGTGTCCTGGTACCAGCACCTCCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAATACCAGGCGACCCTCAGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGAACATGGGATGTCAGACCGAATCGTGGCGCTGTCTTCGGAACTGGGACGAAGGTCACCGTCCTAG,CAGGCGATCCTGGTGGAATCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCGCAATTCACATTTAGTGGACATGGCCTGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCCTCTATTTCTTTTGCTGGAACTAAAATGGACTATGCAGATTCCGTGAAGGGCCGATTCGCCATCTCCAGAGACAACTCCAAGAACACGTTGTATCTGCAAATGAACAGCCTGCGAGTTGAGGACACGGCTCTATATTACTGTGCAAAAGATATGCGAGAATATGAATGTGAATATTGGACGTCGGATTATTACGATTTTGGGAGACCTCAACCGTGCATAGACCGACGGGGCGTGGTTGGAATTTTTGATATGTGGGGCCAAGGGACAATGGTCACCGTCTCTAC,CAKDMREYECEYWTSDYYDFGRPQPCIDRRGVVGIFDMW,88.176
VRC26.11,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CVKDMRELECEEWASDYYDFGKPQPCLDRRGVSGISAWW,13.0,,51*02,,,,14.0,,L,,Natural monoclonal,human,CAP256-VRC26.11, ,21.0456,16.7775,102.0,147.0,3048.0,EVQLVESGGGVVPPGKSLTLSCVASRFTFSAFGMHWVRQAPGKGLEWVASISFAGIKKYYADSVKGRFSISRDNSNTLFLQMNGLRGEDTGLYHCVKDMRELECEEWASDYYDFGKPQPCLDRRGVSGISAWWGPGTMVTVSX,QSVLTQPPSVSAAPGQNVTISCSGPPSHIEKNDVSWYQRLPGMAPKMVIYESKRRPLGIPVRFSASRSGSSATLVITGLQTADEADYYCGTWDGRMNFGTGTTVSVLX,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAACGTCACCATCTCCTGCTCTGGACCCCCGTCCCACATTGAGAAGAATGATGTGTCGTGGTACCAACGCCTCCCAGGAATGGCCCCCAAAATGGTCATTTATGAAAGTAAAAGGCGACCTCTCGGGATCCCTGTCCGATTCTCTGCCTCCAGGTCTGGCTCGTCAGCCACCCTGGTCATCACCGGACTCCAGACTGCCGACGAGGCCGATTATTACTGCGGAACATGGGATGGCAGAATGAATTTTGGGACTGGGACCACGGTCTCCGTCCTAA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCCGCCTGGGAAGTCCCTGACACTCTCCTGTGTAGCCTCTCGATTCACCTTTAGTGCCTTTGGGATGCACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCAAGTATATCATTTGCTGGAATTAAGAAATATTATGCAGATTCCGTGAAGGGCCGATTCAGCATCTCCAGAGACAATTCCAACACACTGTTTCTCCAAATGAATGGCCTGCGAGGAGAAGACACGGGTCTATATCACTGTGTCAAAGATATGCGAGAGTTGGAGTGTGAAGAGTGGGCGTCGGATTACTACGATTTTGGGAAGCCTCAGCCTTGTCTGGACCGACGGGGCGTGTCTGGAATCTCTGCTTGGTGGGGTCCTGGGACAATGGTCACCGTCTCTTC,,
VRC26.12,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2014(24590074) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CARDLRESECEEWESDYYDFGKKGPCVKPRGVAGGLDLW,15.0,,51*02,,,,8.4,,L,,Natural monoclonal,human,CAP256-VRC26.12, ,55.1423,6.21408,102.0,148.0,3049.0,EVQLVQSGGGVVQPGRSLRLSCAAPYFEFGRYGFHWVRQAPGKGLEWVASISFAGRDYYHSPSVWGRFTISRDNSKNTLYLQMNSLRIEDTALYFCARDLRESECEEWESDYYDFGKKGPCVKPRGVAGGLDLWGQGTMVIVSX,QSVLTQPPSVSTAPGQTVTVSCSGGTSNTGNNFVSWYQHLPGTAPKLLIYENNKRPLGVPDRFSGAKSGTSATLAITGLQTGDEGDYYCATWSGSLNIGTGTKVSVLX,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTACGGCCCCAGGACAGACGGTCACCGTCTCCTGCTCCGGAGGCACCTCCAACACTGGGAATAATTTTGTCTCCTGGTACCAACACCTCCCAGGAACAGCCCCCAAACTTCTCATCTATGAAAATAACAAGCGACCCTTAGGGGTTCCTGACCGATTCTCTGGCGCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGGCGATTATTACTGCGCAACATGGAGTGGCAGTCTGAACATCGGGACTGGGACCAAAGTCTCCGTCCTAG,GAAGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCCCGTATTTCGAGTTTGGTAGATATGGCTTCCACTGGGTCCGCCAGGCTCCAGGCAAGGGTCTGGAGTGGGTGGCAAGTATATCATTTGCTGGAAGAGATTATTACCACTCACCATCCGTGTGGGGCCGCTTCACCATCTCCAGAGACAATTCCAAGAACACACTATATTTGCAAATGAACAGCCTGCGAATTGAAGACACGGCTCTCTATTTCTGTGCGAGAGATCTGAGAGAAAGCGAATGTGAAGAGTGGGAGTCGGACTATTATGATTTTGGGAAAAAGGGCCCTTGTGTTAAGCCGCGGGGCGTGGCTGGAGGTTTGGATCTCTGGGGCCAAGGGACAATGGTCATCGTCTCATC,CARDLRESECEEWESDYYDFGKKGPCVKPRGVAGGLDLW,85.135
VRC26.13,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CARDLRESECEEWESDYYDFGKKGPCVKPRGVAGGLDLW,15.0,,51*02,,,,9.5,,L,,Natural monoclonal,human,CAP256-VRC26.13, ,57.3671,6.91884,53.0,202.0,3296.0,QSALTQPPSVSTAPGQTVTVSCSGGTSNTGNNFVSWYQHLPGTAPKLLIYENNKRPLGVPDRFSGAKSGTSATLAITGLQTGDEGDYYCATWSGSLNIGTGTKVSVL,QVQLVQSGGGVVQPGRSLRLSCAAPYFEFGRYGFHWVRQAPGKGLEWVASISFAGRDYYHSPSVWGRFTISRDNSKNTLYLQMNSLRIEDTALYFCARDLRESECEEWESDYYDFGKKGPCVKPRGVAGGLDLWGQGTMVIVSS,CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCCCGTATTTCGAGTTTGGTAGATATGGCTTCCACTGGGTCCGCCAGGCTCCAGGCAAGGGTCTGGAGTGGGTGGCAAGTATATCATTTGCTGGAAGAGATTATTACCACTCACCATCCGTGTGGGGCCGCTTCACCATCTCCAGAGACAATTCCAAGAACACACTATATTTGCAAATGAACAGCCTGCGAATTGAAGACACGGCTCTCTATTTCTGTGCGAGAGATCTGAGAGAAAGCGAATGTGAAGAGTGGGAGTCGGACTATTATGATTTTGGGAAAAAGGGCCCTTGTGTTAAGCCGCGGGGCGTGGCTGGAGGTTTGGATCTCTGGGGCCAAGGGACAATGGTCATCGTCTCATCA,CAGTCTGCCCTGACTCAGCCGCCCTCAGTGTCTACGGCCCCAGGACAGACGGTCACCGTCTCCTGCTCCGGAGGCACCTCCAACACTGGGAATAATTTTGTCTCCTGGTACCAACACCTCCCAGGAACAGCCCCCAAACTTCTCATCTATGAAAATAACAAGCGACCCTTAGGGGTTCCTGACCGATTCTCTGGCGCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGGCGATTATTACTGCGCAACATGGAGTGGCAGTCTGAACATCGGGACTGGGACCAAAGTCTCCGTCCTA,,
VRC26.14,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CARDVREMECEEWASDYYDFGRGGPCRDFRGVVGILDIW,10.0,,51*02,,,,7.7,,L,,Natural monoclonal,human,CAP256-VRC26.14, ,21.2703,21.9103,53.0,203.0,3297.0,QVQLMESGGGVVQPGRSLRLSCAASGFNFGGYGMHWVRQAPGKGLEWVAAISFVGLKNYYSNSVRGRFTISRDNSKNILYLQMESLRAEDTALYYCARDVREMECEEWASDYYDFGRGGPCRDFRGVVGILDIWGPGTMVSVSS,QSVLTQPPSVSAAPGQNVTISCSGSASNIGKNFASWYQQLPGTAPKLLIYENNRRPSGTPDRFSGSKSGTSATLAISGLQTGDGADYYCGTWDNSLNSSPLIGPGTKVTVL,CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAACGTCACCATCTCCTGCTCTGGAAGCGCCTCCAACATTGGGAAAAATTTTGCGTCCTGGTATCAACAACTCCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAATAACAGGCGACCCTCAGGGACTCCTGACCGGTTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCTCCGGACTCCAGACTGGCGACGGGGCCGATTATTACTGCGGGACATGGGATAACAGCCTTAATAGTAGTCCTCTCATCGGACCTGGGACCAAGGTCACCGTCCTA,CAGGTGCAGCTGATGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCAACTTTGGTGGTTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCTATTTCATTTGTTGGACTCAAAAATTACTATTCAAATTCCGTGAGGGGCCGATTCACCATCTCCAGAGACAATTCTAAGAACATTCTGTATCTGCAAATGGAAAGCCTGCGAGCTGAGGACACGGCTCTGTATTATTGTGCGAGAGATGTGCGAGAAATGGAATGTGAAGAGTGGGCGTCGGATTATTACGACTTTGGGAGAGGTGGCCCTTGCCGAGACTTCCGGGGCGTCGTTGGAATTCTTGATATCTGGGGCCCAGGGACAATGGTCAGCGTCTCTTCA,CARDVREMECEEWASDYYDFGRGGPCRDFRGVVGILDIW,90.541
VRC26.15,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CARDLREYECELWASDYYDFGKPQPCEDPRGVVGTSDIW,10.0,,51*02,,,,6.7,,L,,Natural monoclonal,human,CAP256-VRC26.15, ,17.7778,18.5014,53.0,204.0,3298.0,EVQLVESGGGVVQPGRSLRLSCAASQFTFSNYGMHWVRQAPGKGLEWVAGISFVGIRKYYADSVKGRFTISRDNSKNTLYLQMNSLRAADTALYFCARDLREYECELWASDYYDFGKPQPCEDPRGVVGTSDIWGQGTMVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGSNYVSWYQHVPGTAPKLLIYENNRRPSGTPDRFSGSKSGTSATLAITGLRTGDEADYYCGTWLNSGGVFGTGTRVNVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGGAGCAATTATGTATCGTGGTACCAGCACGTCCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAATAACAGACGACCCTCAGGGACTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATAACCGGACTCCGGACTGGGGACGAGGCCGATTATTACTGCGGAACATGGCTGAATAGTGGCGGTGTCTTCGGTACTGGGACCAGGGTCAACGTCCTC,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTCAATTCACCTTTAGTAATTATGGCATGCACTGGGTCCGCCAGGCTCCCGGCAAGGGGCTGGAATGGGTGGCAGGCATCTCATTTGTTGGGATCAGGAAATATTATGCAGATTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACTCCAAGAACACCCTGTATCTGCAAATGAACAGCCTGCGAGCTGCGGACACGGCTCTTTACTTCTGTGCGAGAGATCTGCGAGAATACGAATGTGAATTGTGGGCGTCTGACTATTACGATTTTGGGAAACCTCAGCCTTGCGAGGACCCACGGGGCGTGGTTGGAACCTCAGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA,CARDLREYECELWASDYYDFGKPQPCEDPRGVVGTSDIW,90.203
VRC26.16,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CARDVREMECEEWASDYYDFGRGGPCRDFRGVVGILDIW,10.0,,51*02,,,,7.7,,L,,Natural monoclonal,human,CAP256-VRC26.16, ,19.4692,21.7843,53.0,205.0,3299.0,EVQLMESGGGVVQPGRSLRLSCAASGFNFGGYGMHWVRQAPGKGLEWVAAISFVGLKNYYTNSVRGRFTISRDNSKNILYLQMESLRAEDTALYYCARDVREMECEEWASDYYDFGRGGPCRDFRGVVGILDIWGPGTMVTVSS,QSVLTQPPSVSEAPGQKVTISCSGSASNIGKNFVSWYQQFPGTAPKLVIYENNRRPSGTPDRFSGSKSGTSATLAISGLQTGDEADYYCGTWDNSLNSSPVFGTGTKVTVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGAGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCGCCTCCAACATTGGGAAAAATTTTGTGTCCTGGTATCAGCAATTCCCAGGAACAGCCCCCAAACTCGTCATCTATGAAAATAACAGGCGACCCTCAGGGACTCCTGACCGGTTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCTCCGGACTCCAGACTGGCGACGAGGCCGATTATTACTGCGGGACATGGGATAACAGCCTTAATAGTAGTCCTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTA,GAGGTGCAGCTGATGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCAACTTTGGTGGTTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCTATTTCATTTGTTGGACTCAAAAATTACTATACAAATTCCGTGAGGGGCCGATTCACCATCTCCAGAGACAATTCTAAGAACATTCTGTATCTGCAAATGGAAAGCCTGCGAGCTGAGGACACGGCTCTGTATTATTGTGCGAGAGATGTGCGAGAAATGGAATGTGAAGAGTGGGCGTCGGATTATTACGACTTTGGGAGAGGTGGCCCTTGCCGAGACTTCCGGGGCGTCGTTGGAATTCTTGATATCTGGGGCCCAGGGACAATGGTCACCGTCTCTTCA,CARDVREMECEEWASDYYDFGRGGPCRDFRGVVGILDIW,90.203
VRC26.17,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CARDMREMECEEWASDYYDFGRPGPCRDLRGVVGTFDIW,12.0,,51*02,,,,8.1,,L,,Natural monoclonal,human,CAP256-VRC26.17, ,14.2809,29.361,53.0,206.0,3300.0,EVQLEESGGGVVQPGRSLRLSCAASGFSFGRYGMHWVRQAPGKGLEWVAGVSFVGLRKYHANSVRGRFTISRDNSKNILYLQMDSLRGEDTALYYCARDMREMECEEWASDYYDFGRPGPCRDLRGVVGTFDIWGPGTMVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSASNIGKNFVSWYQQLPGTAPKLIIYENNRRPSGTPDRFSGSKSGTSGTLAISGLQTDDEADYYCATWDNTLDSSPLIGPGTKVTVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCGCCTCCAACATTGGGAAAAATTTTGTGTCCTGGTATCAACAACTCCCAGGAACAGCCCCCAAACTCATCATCTATGAAAATAACAGGCGACCCTCAGGGACTCCTGACCGGTTCTCTGGCTCCAAGTCTGGCACGTCAGGCACCCTGGCCATCTCCGGACTCCAGACTGACGACGAGGCCGATTATTACTGCGCGACATGGGATAACACCCTCGATAGTAGTCCTCTCATCGGACCTGGGACCAAGGTCACCGTCCTA,GAGGTGCAGCTGGAGGAGTCGGGGGGAGGCGTGGTCCAGCCCGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCAGTTTTGGTAGATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGGTGTTTCATTTGTTGGACTCAGAAAATACCACGCAAATTCCGTGAGGGGCCGATTCACCATCTCCAGAGACAATTCTAAGAACATTCTGTATCTGCAAATGGACAGCCTGCGAGGTGAGGACACAGCTCTCTATTATTGTGCCAGAGATATGCGAGAAATGGAATGTGAAGAGTGGGCGTCGGATTACTACGACTTTGGGAGACCTGGCCCATGCCGAGACCTACGGGGCGTGGTTGGAACTTTTGATATCTGGGGCCCAGGGACAATGGTCACCGTCTCCTCA,CARDMREMECEEWASDYYDFGRPGPCRDLRGVVGTFDIW,88.851
VRC26.18,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CARDMREMECEEWASDYYDFGRSGPCRDFRGVVGVFDIW,12.0,,51*02,,,,7.4,,L,,Natural monoclonal,human,CAP256-VRC26.18, ,21.2526,18.578,53.0,207.0,3301.0,EVQLEESGGDVVQPGRSLRLSCAASGFSFGNYGMHWVRQAPGKGLEWVAAISFIGLKKYYENSVRGRFTISRDNSKNILYLQMDSLRGEDTALYYCARDMREMECEEWASDYYDFGRSGPCRDFRGVVGVFDIWGPGTMVTVSS,QSVLTQPPSVSAAPGQRVTISCSGSASDIGKNSVSWYQQLPGTAPKLLIYENNRRPSGTPDRFSGSKSGTSATLAISGLQTGDEADYYCGTWDNSLGSSPLIGSGTKVTVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGGCAGAGGGTCACCATCTCCTGCTCTGGAAGCGCCTCCGACATTGGGAAAAATTCTGTGTCCTGGTATCAGCAACTCCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAATAACAGGCGACCCTCAGGGACTCCTGACCGGTTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCTCCGGACTCCAGACTGGCGACGAGGCCGACTATTACTGCGGGACATGGGATAACAGCCTGGGTAGTAGTCCTCTCATCGGAAGTGGGACCAAGGTCACCGTCCTA,GAGGTGCAGCTGGAGGAGTCGGGGGGAGACGTTGTCCAGCCCGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCAGTTTTGGTAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCTATTTCATTCATTGGACTCAAAAAATACTATGAAAATTCCGTGAGGGGCCGATTCACCATCTCCAGAGACAATTCTAAGAACATTCTGTATCTGCAAATGGACAGCCTGCGAGGTGAGGACACGGCTCTGTATTATTGTGCGAGAGATATGCGAGAAATGGAGTGTGAAGAGTGGGCGTCGGATTATTACGACTTTGGGAGAAGTGGCCCTTGCCGAGACTTTCGGGGCGTGGTTGGAGTTTTTGATATCTGGGGCCCAGGGACAATGGTCACCGTCTCTTCA,CARDMREMECEEWASDYYDFGRSGPCRDFRGVVGVFDIW,88.851
VRC26.19,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CARDSREYECELWTSDYYDFGKPQPCIDTRDVGGLFDMW,13.0,,51*02,,,,10.0,,L,,Natural monoclonal,human,CAP256-VRC26.19, ,6.25411,30.6226,53.0,208.0,3302.0,EVQLVESGGGVVQPGRSLRLSCVASQFTFSGHGMHWLRQAPGKGLEWVASTSFAGTKSHYANSVRGRFTISRDNSKNTLYLQMNNLRAEDTALYYCARDSREYECELWTSDYYDFGKPQPCIDTRDVGGLFDMWGQGTMVTVSS,QSVLTQPPSVSATPGQKVTISCSGSNSNIGTKYVSWYQHVPGTAPKLLIFESDRRPTGIPDRFSGSKSATSATLTITGLQTGDEAIYYCGTYGDSRTPGGLFGTGTKLTVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGACCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAACTCCAACATTGGGACCAAGTATGTATCCTGGTATCAACACGTGCCAGGAACAGCCCCCAAACTCCTCATCTTTGAAAGTGACAGGCGACCCACAGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGCCACGTCAGCCACCCTGACCATCACCGGACTCCAGACTGGGGACGAGGCCATTTATTATTGCGGGACATATGGTGACAGCCGGACTCCTGGCGGTCTCTTCGGAACTGGGACCAAGCTCACCGTCCTG,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGAAGGTCCCTCAGACTCTCCTGTGTTGCCTCTCAATTCACCTTTAGTGGCCACGGCATGCACTGGCTCCGCCAGGCTCCAGGCAAGGGGCTGGAATGGGTGGCGTCTACATCCTTTGCCGGAACTAAAAGTCACTATGCAAATTCCGTCAGGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAATACCCTATATCTGCAAATGAACAACCTGCGAGCTGAGGACACGGCTCTCTATTACTGTGCGAGGGATTCACGCGAATACGAATGTGAGCTGTGGACGTCAGACTATTACGATTTTGGAAAACCTCAGCCTTGCATCGACACACGGGACGTCGGAGGACTTTTTGATATGTGGGGCCAGGGCACAATGGTCACCGTCTCTTCA,CARDSREYECELWTSDYYDFGKPQPCIDTRDVGGLFDMW,87.162
VRC26.20,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;Selects for breadth-driven Abs in CAP256 lineages,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVRDQREDECEERWSDYYHFGRVLPCRKYRGLGLAGVFDIW,16.0,,51*02,,,,13.0,,L,,Natural monoclonal,human,CAP256-VRC26.20, ,92.4725,1.71003,64.0,209.0,3315.0,EVQLVESGGGVVQPGKSLTLSCAASQFAFSNYGMHWVRQAPGKGLEWVGSITNDGNKKYHGDSVWDRFTISRDNSKNTLFLQMNSLRVEDTARYFCVRDQREDECEERWSDYYHFGRVLPCRKYRGLGLAGVFDIWGHGTMVIVSS,QSVLTQPPSVSAAPGQKVSISCSGNNSNIGNNFISWFQQFPGTAPKPLIFETYRRHSGISDRFSASKSGTSATLAITGLQPGDEADYYCATWGVRQGVGALFGTGTKVTVL,CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCTCCATCTCCTGCTCAGGAAACAACTCAAACATTGGAAATAACTTTATCTCCTGGTTCCAGCAATTCCCAGGAACAGCCCCCAAGCCCCTCATATTTGAAACTTACAGGCGACACTCAGGTATTTCTGACCGATTCTCTGCCTCCAAATCTGGAACGTCAGCCACCCTGGCCATCACCGGACTCCAGCCTGGGGACGAGGCCGACTATTACTGCGCAACATGGGGTGTCAGGCAGGGTGTCGGCGCTCTCTTCGGAACTGGGACCAAGGTCACCGTCCTG,GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCCTGACACTGTCCTGTGCAGCCTCTCAATTCGCTTTTTCGAATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGGAAGTATAACAAATGATGGGAACAAGAAATATCATGGAGATTCCGTCTGGGACCGATTCACTATCTCCAGAGACAATTCCAAGAATACACTCTTTCTACAAATGAACAGTCTGCGAGTTGAGGACACGGCGCGATATTTCTGTGTGAGAGATCAGCGAGAAGACGAATGTGAAGAGAGGTGGTCAGATTATTATCATTTTGGGAGAGTTCTCCCTTGCCGAAAGTACCGGGGCCTGGGCCTGGCTGGAGTTTTTGATATTTGGGGCCACGGAACAATGGTCATCGTCTCTTCA,CVRDQREDECEERWSDYYHFGRVLPCRKYRGLGLAGVFDIW,83.784
VRC26.21,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVRDRQEDECEEWWSDYYAFGRGGPCRKYHGQGLAGIFDIW,18.0,,51*02,,,,14.0,,L,,Natural monoclonal,human,CAP256-VRC26.21, ,38.5418,15.406,53.0,210.0,3303.0,QMLLVESGGGVVEPGRSLTLSCATSQFTFSHYGMHWVRQTPGRGLEWVASISNEGNKKYHGESVWGRFIISRDNSKNTLFLHMSNLRADDSALYFCVRDRQEDECEEWWSDYYAFGRGGPCRKYHGQGLAGIFDIWGRGTMVTVSS,QSVLTQPPSVSAAPGQKVIISCSGDNSTIGSKFVSWYQQVPGTAPKLLVYETNRRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYFCTVWGVRKGVGALFGTGTKVTVL,CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCCGCGGCCCCAGGACAGAAGGTCATCATCTCCTGCTCCGGAGACAACTCCACCATTGGAAGTAAATTTGTATCGTGGTACCAACAAGTTCCAGGAACAGCCCCCAAACTCCTCGTGTATGAAACCAACAGGCGACCCTCAGGTATTCCTGACCGATTCTCTGGCTCGAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGACTACTTTTGCACAGTATGGGGTGTCAGGAAGGGTGTCGGCGCTCTCTTCGGAACTGGGACCAAGGTCACCGTCCTA,CAGATGCTGTTGGTGGAGTCTGGGGGAGGCGTGGTCGAGCCTGGGAGGTCCCTGACACTGTCCTGTGCAACCTCTCAATTCACTTTTTCGCATTATGGCATGCACTGGGTCCGCCAGACTCCAGGCAGGGGACTGGAGTGGGTGGCTAGTATTTCAAATGAAGGAAACAAGAAATATCATGGAGAGTCCGTGTGGGGCCGATTCATCATCTCCAGAGATAATTCCAAGAACACACTATTCCTACACATGAGCAACCTGCGAGCTGACGACTCGGCTCTCTATTTCTGTGTCAGAGATCGACAAGAAGACGAGTGTGAAGAGTGGTGGTCGGATTATTATGCTTTTGGCAGAGGAGGCCCTTGTCGAAAATACCACGGCCAGGGCCTGGCTGGAATTTTTGACATCTGGGGCCGCGGGACAATGGTCACCGTCTCTTCA,CVRDRQEDECEEWWSDYYAFGRGGPCRKYHGQGLAGIFDIW,82.095
VRC26.22,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW,16.0,,51*02,,,,13.0,,L,,Natural monoclonal,human,CAP256-VRC26.22, ,3.40475,67.4206,53.0,211.0,3304.0,EVQLVESGGGVVQPGTSLTLSCTASQFSFSNYGMHWVRQAPGKGLEWVASISNDGSKRYHGDAVWARFIISRDNSKNTVFLQMTSLRTEDTALYFCVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIWGHGTMVTVSS,QSVLTQPPSVSAAPGQKVIISCSGNNSTIGNNFVSWYQQVPGTAPKLLVYETYRRPSGIPDRFSGSKSGTTATLAISGLQTGDEADYHCTVWGVRKGVAAVFGTGTKVTVL,CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCCGCGGCCCCAGGACAGAAAGTCATCATCTCCTGCTCCGGAAACAACTCCACCATTGGAAATAATTTTGTATCCTGGTATCAACAAGTCCCAGGAACAGCCCCCAAACTCCTCGTGTATGAAACTTACAGGCGACCCTCAGGTATTCCTGACCGATTCTCTGGCTCGAAGTCTGGCACGACAGCCACCCTGGCCATCAGCGGACTGCAGACTGGGGACGAGGCCGACTACCACTGCACAGTATGGGGTGTCAGGAAGGGTGTCGCCGCTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTA,GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGACGTCCCTGACACTGTCCTGTACAGCCTCTCAATTCAGTTTTTCGAATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCAAGTATATCAAATGATGGAAGCAAGAGATATCATGGAGATGCCGTGTGGGCCCGATTCATTATATCCAGGGACAATTCCAAGAACACAGTCTTTCTGCAAATGACAAGCCTGCGAACTGAGGACACGGCTCTATATTTCTGTGTGAGAGATCGGCAAGAAGACGAGTGTGTTGAGTGGTGGTCGGATTATTATAACTTTGGCAGAGAGCTCCCTTGTTCAAAATTTCGGGGCCTGGGCCTGGCTGGAATTTTTGATATCTGGGGCCACGGGACAATGGTCACCGTCTCTTCA,CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW,84.122
VRC26.23,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CAKDLREYECEEWRSDYYDFGRDQPCIDSQGVVGILDIW,9.7,,51*02,,,,6.3,,L,,Natural monoclonal,human,CAP256-VRC26.23, ,56.2467,7.82527,53.0,212.0,3305.0,QVHLVASGGGVVPPGRSLTLSCVASQFTFSSCGLHWVRQAPGKGLEWVAAISFAGTKKHYGNSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCAKDLREYECEEWRSDYYDFGRDQPCIDSQGVVGILDIWGQGTMVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQYLPGTAPKLLIYENGKRPSGIPDRFSASKSGTSATLAITGLQTGDEADYYCGTWMTTGGVFGSGTKVTVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGCAGTTCCAACATTGGGAATAATTATGTATCCTGGTACCAATATCTCCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAATGGCAAGCGACCCTCAGGGATTCCTGACCGATTCTCTGCCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGACTATTACTGCGGAACATGGATGACTACTGGCGGTGTCTTCGGATCTGGGACCAAGGTCACCGTCCTT,CAGGTGCACCTTGTGGCGTCTGGGGGAGGCGTGGTCCCGCCTGGGAGGTCCCTGACACTCTCCTGTGTAGCCTCTCAATTCACCTTTAGTAGTTGTGGCTTGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCGGCTATATCGTTTGCTGGAACTAAAAAACACTATGGAAATTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAAAACACGCTGTATCTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTCTCTACTACTGTGCGAAAGATCTGCGAGAATACGAATGTGAAGAGTGGAGGTCGGATTATTACGATTTTGGGAGAGATCAGCCTTGCATAGATTCACAGGGCGTGGTCGGAATTCTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA,CAKDLREYECEEWRSDYYDFGRDQPCIDSQGVVGILDIW,90.541
VRC26.24,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CAKDLGGIKNDEWGTDYYDISVSYPVQDPRAVAGIFDVW,4.2,,51*02,,,,2.5,,L,,Natural monoclonal,human,CAP256-VRC26.24, ,63.1294,5.52389,48.0,213.0,3306.0,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWVALISYDATNKYYVDSVKGRFTISRDNSKNTLYLQVSSLTAEDTAVYYCAKDLGGIKNDEWGTDYYDISVSYPVQDPRAVAGIFDVWGHGTMVSVSS,QSVLTQPPSVSAAPGQKVTISCSGTSSNIRNNYVSWYQQLPGTAPKLLIYENNKRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDNSLNTGGVFGAGTKVTVL,CAGTCTGTCCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAACCAGCTCCAACATTAGGAATAATTATGTATCCTGGTACCAGCAACTCCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAATAATAAGCGACCCTCAGGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGAACATGGGATAACAGCCTAAATACTGGCGGTGTCTTCGGAGCTGGGACCAAGGTCACCGTCCTA,CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTACCTATGCCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCACTTATATCATATGATGCAACTAATAAATATTATGTAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTCTATCTGCAAGTGAGCAGCCTGACAGCTGAGGACACGGCTGTGTATTATTGTGCGAAAGATCTGGGAGGAATAAAAAATGACGAGTGGGGGACGGATTATTACGATATTTCGGTTTCTTACCCTGTCCAAGACCCACGGGCCGTCGCTGGAATTTTTGATGTCTGGGGCCACGGGACAATGGTCAGCGTCTCTTCA,CAKDLGGIKNDEWGTDYYDISVSYPVQDPRAVAGIFDVW,95.946
VRC26.25,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,5DT1(Fab CAP256-VRC26.25);6VTT(CAP256-VRC26.25 Fab bound to HIV-1 Env trimer CAP256.wk34.c80 SOSIP.RnS2),CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;V2 Signature Analysis Summary;VRC26.25 contacts;VRC26.25 neutralization associated sites;VRC26.25 signature sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,36.0,CAKDLREDECEEWWSDYYDFGKQLPCAKSRGGLVGIADNW,12.0,,51*02,,,,9.8,,L,,Natural monoclonal,human,"CAP256.26.25, CAP256-VRC26.25", ,0.090707,227.384,1970.0,214.0,3285.0,QVQLVESGGGVVQPGTSLRLSCAASQFRFDGYGMHWVRQAPGKGLEWVASISHDGIKKYHAEKVWGRFTISRDNSKNTLYLQMNSLRPEDTALYYCAKDLREDECEEWWSDYYDFGKQLPCAKSRGGLVGIADNWGQGTMVTVSS,QSVLTQPPSVSAAPGQKVTISCSGNTSNIGNNFVSWYQQRPGRAPQLLIYETDKRPSGIPDRFSASKSGTSGTLAITGLQTGDEADYYCATWAASLSSARVFGTGTKVIVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAACACCTCCAACATTGGCAATAATTTTGTGTCCTGGTACCAACAGCGCCCCGGCAGAGCCCCCCAACTCCTCATTTATGAAACTGACAAGCGACCCTCAGGGATTCCTGACCGATTCTCTGCTTCCAAGTCTGGTACGTCAGGCACCCTGGCCATCACCGGGCTGCAGACTGGGGACGAGGCCGATTATTACTGCGCCACATGGGCTGCCAGCCTGAGTTCCGCGCGTGTCTTCGGAACTGGGACCAAGGTCATCGTCCTA,CAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGACGTCCCTGAGACTCTCCTGTGCAGCCTCTCAATTCAGGTTTGATGGTTATGGCATGCACTGGGTCCGCCAGGCCCCAGGCAAGGGGCTGGAGTGGGTGGCATCTATATCACATGATGGAATTAAAAAGTATCACGCAGAAAAAGTGTGGGGCCGCTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTACAAATGAACAGCCTGCGACCTGAGGACACGGCTCTCTACTACTGTGCGAAAGATTTGCGAGAAGACGAATGTGAAGAGTGGTGGTCGGATTATTACGATTTTGGGAAACAACTCCCTTGCGCAAAGTCACGCGGCGGCTTGGTTGGAATTGCTGATAACTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA,CAKDLREDECEEWWSDYYDFGKQLPCAKSRGGLVGIADNW,88.176
VRC26.25 D99E,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Yin2021(34261793) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.028692,48.6146,16.0,712.0,4317.0,,,,,,
VRC26.25 D99E/E100bV,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Yin2021(34261793) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.021264,33.6076,16.0,716.0,4321.0,,,,,,
VRC26.25 D99E/E100bV/K100sR,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Yin2021(34261793) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.016252,29.2692,16.0,719.0,4324.0,,,,,,
VRC26.25 D99E/K100sR,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Yin2021(34261793) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.024566,39.1178,16.0,717.0,4322.0,,,,,,
VRC26.25 E100bV,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Yin2021(34261793) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.020886,38.8285,16.0,713.0,4318.0,,,,,,
VRC26.25 E100bV/K100sR,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Yin2021(34261793) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.015004,28.5054,16.0,718.0,4323.0,,,,,,
VRC26.25 E100bV/K100sR/L:S95bD,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Yin2021(34261793) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.010432,44.5503,16.0,722.0,4327.0,,,,,,
VRC26.25 E100bV/Q100nE/K100sR,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Yin2021(34261793) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.0057805,37.8161,16.0,721.0,4326.0,,,,,,
VRC26.25.K100mA,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Zhang2022(36284200) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,CAP256-VRC26.25.K100mA, ,0.36168,154.443,416.0,552.0,4163.0,,,,,,
VRC26.25 K100sR,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Yin2021(34261793) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.026497,38.644,16.0,714.0,4319.0,,,,,,
VRC26.25 R97G/D99V/E100bV,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,VRC26,Yin2021(34261793) ,,,,,,,,,,,,,,,,,L,,Engineered monoclonal,human,, ,0.019888,39.5049,16.0,715.0,4320.0,,,,,,
VRC26.25-scFv-Fc,gp120 V2 // V2 glycan(V2g) // V2 apex,,CAP256 ,,Davis-Gardner2020(31937648) ,,,,,,,,,,,,,,,,,,,Engineered monoclonal,human,, ,0.10458,58.7531,30.0,773.0,4525.0,,,,,,
VRC26.26,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;hypervariable loop characteristic correlations with bNAb sensitivity;V2 Signature Analysis Summary,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDVW,17.0,,51*02,,,,9.8,,L,,Natural monoclonal,human,CAP256-VRC26.26, ,1.28959,87.6356,722.0,215.0,3289.0,EVQLVESGGGIVQPGRSLTLSCVASQFAFSHYGMHWVRQAPGKGLEWVASISRDETKKYHGDSVWDRFSISRDNSKNTLFLQMNSLRAEDTALYFCVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDVWGHGTMVIVSS,QSALTQPPSVSAAPGQKVSISCSGNNSNIGNNFISWFQQFPGTAPKPLIYETYKRHSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCATWGVRQGVGALFGTGTKVTVL,CAGTCTGCCCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCTCCATCTCCTGCTCTGGAAACAACTCAAACATTGGGAATAACTTTATATCCTGGTTCCAGCAATTCCCAGGAACAGCCCCCAAACCCCTCATATATGAAACTTACAAGCGACACTCAGGTATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGACTATTACTGCGCAACATGGGGTGTCAGGCAGGGTGTCGGCGCTCTCTTCGGAACTGGGACTAAGGTCACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCATAGTCCAGCCTGGGAGGTCCCTGACACTGTCTTGTGTAGCCTCTCAATTCGCTTTTTCGCATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCCAGTATCTCAAGGGATGAGACCAAGAAATATCATGGAGATTCCGTGTGGGACCGATTCAGTATCTCCAGAGACAATTCCAAGAATACCCTGTTTCTACAAATGAACAGCCTGCGAGCTGAGGACACGGCACTATATTTCTGTGTGAGAGATCAGCGAGAAGACGAATGTGAGGAGTGGTGGTCGGACTATTATGATTTTGGGAAAGAACTCCCTTGCCGAAAATTCCGGGGCCTGGGCCTGGCTGGAATTTTTGATGTCTGGGGCCACGGGACAATGGTCATCGTCTCTTCA,CVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDVW,83.108
VRC26.27,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDIW,16.0,,51*02,,,,9.5,,L,,Natural monoclonal,human,CAP256-VRC26.27, ,0.78118,138.474,417.0,216.0,3290.0,QKQLVESGGGVVQPGRSLTLSCAASQFPFSHYGMHWVRQAPGKGLEWVASITNDGTKKYHGESVWDRFRISRDNSKNTLFLQMNSLRAEDTALYFCVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDIWGHGTMVIVSS,QSVLTQPPSVSAAPGQKVSISCSGNNSNIGNNFISWFQQFPGTAPKPLIYETYRRHSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCATWGVRQGVGALFGTGTKVTVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCTCCATCTCCTGCTCTGGAAACAATTCAAACATTGGGAATAACTTTATATCCTGGTTCCAGCAATTCCCAGGAACAGCCCCCAAACCCCTCATATATGAAACTTACAGGCGACACTCAGGTATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGACTATTACTGCGCAACATGGGGTGTCAGGCAGGGTGTCGGCGCTCTCTTCGGAACTGGGACTAAGGTCACCGTCCTA,CAGAAGCAGTTGGTGGAGTCTGGGGGAGGCGTAGTCCAGCCTGGGAGGTCCCTGACACTGTCCTGTGCAGCCTCTCAATTCCCTTTTTCGCATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAAGTATTACAAATGATGGGACCAAGAAATATCATGGAGAGTCCGTGTGGGACCGATTCAGGATCTCCAGAGACAATTCCAAGAATACACTCTTTCTACAAATGAACAGCCTGCGAGCTGAGGACACGGCACTATATTTCTGTGTGAGAGATCAGCGAGAAGACGAATGTGAAGAGTGGTGGTCGGATTATTATGATTTTGGGAAAGAACTCCCTTGCCGAAAATTCCGGGGCCTGGGCCTGGCTGGAATTTTTGATATCTGGGGCCACGGGACAATGGTCATCGTCTCATCA,CVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDIW,84.459
VRC26.28,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW,15.0,,51*02,,,,12.0,,L,,Natural monoclonal,human,CAP256-VRC26.28, ,2.56895,82.5635,53.0,217.0,3307.0,EVQLVESGGGVVQPGTSLTLSCAASQFTFSNYGMHWVRQAPGKGLEWVASISNDGNKKYHGDAVWARFIISRDNSKNTVFLQLTSLRAEDTALYFCVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIWGLGTMVTVSS,QSVLTQPPSVSAAPGQKVIISCSGNNSTIGNNFVSWYQQVPGTAPKLLVYETYRRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCTVWGVRKGVAAVFGTGTKVTVL,CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCCGCGGCCCCAGGACAGAAAGTCATCATCTCCTGCTCCGGAAACAACTCCACCATTGGAAATAATTTTGTATCCTGGTATCAACAAGTCCCAGGAACAGCCCCCAAACTCCTCGTGTATGAAACTTACAGGCGACCCTCAGGTATTCCTGACCGATTCTCTGGCTCGAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTGCAGACTGGGGACGAGGCCGACTACTACTGCACAGTATGGGGTGTCAGGAAGGGTGTCGCCGCTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGACGTCCCTGACACTGTCCTGTGCAGCCTCTCAATTCACTTTTTCGAATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCAAGTATATCAAATGATGGAAACAAGAAATATCATGGAGATGCCGTGTGGGCCCGATTCATCATATCCAGGGACAATTCCAAGAACACAGTCTTTCTACAACTGACAAGCCTGCGAGCTGAGGACACGGCTCTATATTTCTGTGTGAGAGATCGGCAAGAAGACGAGTGTGTTGAGTGGTGGTCGGATTATTATAATTTTGGCAGAGAGCTCCCTTGTTCAAAATTTCGGGGCCTGGGCCTGGCCGGAATCTTTGATATCTGGGGCCTCGGGACAATGGTCACCGTCTCTTCA,CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW,85.135
VRC26.29,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW,15.0,,51*02,,,,13.0,,L,,Natural monoclonal,human,CAP256-VRC26.29, ,2.81206,69.3584,53.0,218.0,3308.0,EVQLVESGGGVVQPGTSLTLSCAASQFSFSNYGMHWVRQAPGKGLEWVASISNDGSKRYHGDAVWARFIISRDNSKNTVFLQMTSLRAEDTALYFCVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIWGHGTMVTVSS,QSVLTQPPSVSAAPGQKVIISCSGNNSTIGNNFVSWYQQVPGTAPKLLVYETYRRPSGIPDRFSGSKSGTTATLAISGLQTGDEADYHCTVWGVRKGVAAVFGTGTKVTVL,CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCCGCGGCCCCAGGACAGAAAGTCATCATCTCCTGCTCCGGAAACAACTCCACCATTGGAAATAATTTTGTATCCTGGTATCAACAAGTCCCAGGAACAGCCCCCAAACTCCTCGTGTATGAAACTTACAGGCGACCCTCAGGTATTCCTGACCGATTCTCTGGCTCGAAGTCTGGCACGACAGCCACCCTGGCCATCAGCGGACTGCAGACTGGGGACGAGGCCGACTACCACTGCACAGTATGGGGTGTCAGGAAGGGTGTCGCCGCTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGACGTCCCTGACACTGTCCTGTGCAGCCTCTCAATTCAGTTTTTCGAATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCAAGTATATCAAATGATGGAAGCAAGAGATATCATGGAGATGCCGTGTGGGCCCGATTCATCATATCCAGGGACAATTCCAAGAACACAGTCTTTCTGCAAATGACAAGCCTGCGAGCTGAGGACACGGCTCTATATTTCTGTGTGAGAGATCGGCAAGAAGACGAGTGTGTTGAGTGGTGGTCGGATTATTATAACTTTGGCAGAGAGCTCCCTTGTTCAAAATTTCGGGGCCTGGGCCTGGCTGGAATTTTTGATATCTGGGGCCACGGGACAATGGTCACCGTCTCTTCA,CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW,85.473
VRC26.30,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVRDRQEDECEEWWSDYYNFGRELPCRKFRGQGLAGIFDIW,16.0,,51*02,,,,13.0,,L,,Natural monoclonal,human,CAP256-VRC26.30, ,10.0708,41.409,53.0,219.0,3309.0,EVQLVESGGGEVQPGTSLTLSCAASQFTFSNYGMHWVRQAPGKGLEWVASISNEGNKKYHGDSVWARFIISRDNSKNTVFLQMTSLRAEDTALYFCVRDRQEDECEEWWSDYYNFGRELPCRKFRGQGLAGIFDIWGHGTMVTVSS,QSVLTQPPSVSAAPGQKVIISCSGNNSTVGNNFVSWYQQVPGTAPKLLVYETYRRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCTVWGVRKGVAAVFGTGTKVTVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCCGCGGCCCCAGGACAGAAGGTCATCATCTCTTGCTCCGGAAACAACTCCACCGTTGGAAATAATTTTGTATCCTGGTATCAGCAAGTCCCAGGAACAGCCCCCAAACTCCTCGTGTATGAAACTTACAGGCGACCCTCAGGTATTCCTGACCGATTCTCTGGCTCGAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTGCAGGCTGGGGACGAGGCCGACTACTATTGCACAGTCTGGGGTGTCAGGAAGGGTGTCGCCGCTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGAGGTCCAGCCTGGGACGTCCCTGACCCTGTCCTGTGCAGCCTCTCAATTCACTTTTTCGAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCAAGTATTTCAAACGAGGGAAATAAGAAATATCACGGAGATTCCGTGTGGGCCCGATTCATCATATCCAGGGACAACTCCAAGAACACAGTCTTTCTACAAATGACCAGCCTGCGAGCTGAAGACACGGCTCTATATTTCTGTGTGAGAGATCGACAAGAAGACGAGTGTGAAGAGTGGTGGTCGGATTATTATAATTTTGGCAGAGAACTCCCCTGTCGCAAATTCCGGGGCCAGGGCCTGGCTGGAATTTTTGATATCTGGGGCCACGGGACAATGGTCACCGTCTCTTCA,CVRDRQEDECEEWWSDYYNFGRELPCRKFRGQGLAGIFDIW,84.122
VRC26.31,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,37.0,CVRDRQEDECEEWWSDYYNFGRELPCRKFRGPGLAGIFDIW,15.0,,51*02,,,,10.0,,L,,Natural monoclonal,human,CAP256-VRC26.31, ,21.3807,27.306,53.0,220.0,3310.0,EVQLVESGGGVVQPGMSLTLSCAASHFTFSNYGMHWVRQAPGKGLEWVASISNEGNKKYHGDSVWGRFIISRDNSKNTLFLHMSSLRVEDTALYFCVRDRQEDECEEWWSDYYNFGRELPCRKFRGPGLAGIFDIWGHGTMVTVSS,QSVLTQPPSVSAAPGQRVTISCSGNNSTIGNNFVSWYQQVPGTAPKLLVYETYRRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCTVWGIRKGVAAVFGTGTKVTVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCCGCGGCCCCAGGACAGAGGGTCACCATCTCCTGCTCCGGAAACAACTCCACCATTGGAAATAATTTTGTATCCTGGTACCAGCAAGTCCCAGGAACAGCCCCCAAACTCCTCGTGTATGAAACTTATAGACGACCCTCAGGTATTCCTGACCGATTCTCTGGCTCGAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGACTACTACTGCACAGTATGGGGTATCAGGAAGGGTGTCGCCGCTGTCTTCGGAACTGGGACCAAAGTCACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGATGTCCCTGACACTGTCCTGTGCAGCCTCTCATTTCACTTTTTCGAATTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGGTGGCAAGTATATCAAATGAAGGGAACAAGAAATATCATGGAGATTCCGTGTGGGGCCGATTTATCATCTCCAGAGACAATTCCAAAAACACACTATTTCTACACATGAGTAGCCTGCGAGTTGAGGACACGGCTCTATATTTCTGTGTGAGAGATCGACAAGAAGACGAATGTGAAGAGTGGTGGTCGGATTATTATAATTTTGGCAGAGAGCTCCCTTGCCGAAAATTCCGGGGCCCGGGCCTGGCTGGAATTTTTGATATTTGGGGCCACGGGACAATGGTCACCGTCTCTTCA,CVRDRQEDECEEWWSDYYNFGRELPCRKFRGPGLAGIFDIW,84.797
VRC26.32,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CVKDLRELECEEWTSDYYDFGRPQPCIDPRGVSGISAMW,11.0,,51*02,,,,15.0,,L,,Natural monoclonal,human,CAP256-VRC26.32, ,24.7511,20.5688,53.0,221.0,3311.0,EVQLVESGGGVVPPGKSLRLSCVASRFTFSAFGMHWVRQAPGKGLEWVAGISFAGIKYYYADSVKGRFTISRDNSKNTLFLQMNGLRGDDTALYYCVKDLRELECEEWTSDYYDFGRPQPCIDPRGVSGISAMWGQGTMVTISS,QSVLTQPPSVSAAPGQNVTISCSGPPSHIEKNDVSWYQRFPGMAPKMLIYESYRRPAGIPARFSASRSGKSATLTITGLQTGDEADYYCGTWNGRMNFGTGTTVTVL,CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAACGTCACCATCTCCTGTTCTGGACCCCCGTCCCACATTGAGAAGAATGATGTGTCCTGGTACCAACGCTTCCCAGGAATGGCCCCCAAAATGCTCATCTACGAAAGTTACAGGCGGCCTGCCGGGATCCCTGCCCGCTTCTCTGCCTCCAGGTCTGGCAAGTCAGCCACCCTGACCATCACCGGACTCCAGACTGGCGACGAGGCCGATTATTACTGCGGAACATGGAATGGCCGTATGAATTTTGGGACTGGGACCACGGTCACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCCGCCTGGGAAGTCCCTGAGACTCTCCTGTGTAGCCTCTCGATTCACCTTTAGTGCCTTTGGGATGCACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCAGGTATCTCATTTGCTGGAATCAAATACTATTATGCAGATTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTTTCTCCAAATGAACGGCCTGCGAGGAGACGACACGGCTCTATATTACTGTGTGAAAGATCTGCGAGAGCTGGAATGTGAAGAGTGGACGTCGGACTATTACGATTTTGGGAGACCTCAGCCTTGCATAGACCCACGGGGCGTGTCTGGAATCTCTGCTATGTGGGGTCAAGGGACAATGGTCACCATCTCTTCA,CVKDLRELECEEWTSDYYDFGRPQPCIDPRGVSGISAMW,89.189
VRC26.33,gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure,,CAP256 ,VRC26,Doria-Rose2016(26468542) ,CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites,Doria-Rose2016(26468542) ,IMGT/V-QUEST,3-30*18,,,35.0,CARDQRYYECEEWASDYYDFGREQPCQDPRGVVGIFDIW,9.4,,51*02,,,,6.5,,L,,Natural monoclonal,human,CAP256-VRC26.33, ,23.192,20.9109,53.0,222.0,3312.0,EVQLVESGGGVVQPGRSLRLSCAASHFSLSSYGMHWVRQAPGKGLEWVAGESFAATNKYYADSVKGRFIVSRDISKNTLYLEVNSLRTEDTALYYCARDQRYYECEEWASDYYDFGREQPCQDPRGVVGIFDIWGQGTMVTVSS,QSALTQPPSVSAAPGQKVTISCSGSIGNNYISWYQQVPGTAPKLLIYENYKRPSGIPDRFSGSKSGTSATLAITGLQTGDEADFYCATWGGSLTTGGVIGTGTKVTVL,CAGTCTGCCCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGTATTGGCAACAATTATATATCCTGGTACCAGCAAGTCCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAATTACAAGCGACCCTCAGGCATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGCCATCACCGGACTCCAGACTGGGGACGAGGCCGATTTTTACTGCGCAACATGGGGTGGCAGCCTGACTACTGGCGGTGTCATCGGAACTGGGACCAAGGTCACCGTCCTA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTCACTTCTCCCTTAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGGTGAATCATTTGCTGCAACTAATAAATACTATGCAGATTCCGTGAAGGGCCGTTTCATCGTCTCCAGAGACATTTCCAAGAACACTCTGTACCTGGAAGTGAACAGCCTGCGAACTGAGGACACGGCTCTCTATTACTGTGCGAGAGATCAGCGATATTACGAGTGTGAAGAGTGGGCGTCGGATTATTACGATTTTGGGAGAGAGCAACCTTGCCAAGACCCACGGGGCGTGGTTGGAATTTTCGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA,CARDQRYYECEEWASDYYDFGREQPCQDPRGVVGIFDIW,90.878
VRC27,gp120 CD4bs,4YDI(Z258-VRC27.01 in complex with HIV-1 gp120 from clade A strain Q23.17),Z258 ,,Zhou2015(26004070) ,VRC27 alanine scanning;VRC27 contacts,Huang2016a(27851912) ,IMGT/V-QUEST,1-2*02,,,13.0,CARDRLYDGSSWRLDPWGQGTRVVVSS,,,1-33*01,,5.0,QVLES,,,K,,Natural monoclonal,human,"VRC27.01, Z258-VRC27.01", ,1.08003,21.5606,365.0,239.0,3288.0,,,,,,
VRC28.01,gp120 V3 // V3 glycan (V3g),,N170 ,,Longo2016(27654288) ,,Longo2016(27654288) ,IMGT/V-QUEST JoinSolver,4-34*03,,4*02,26.0,VRGHLSRDRLGQYAFWSGALIDYLDP,19.0,,2-28*01,1*01,9.0,MQGIDTPRT,18.0,,K,,Natural monoclonal,human,, ,52.3467,6.37489,28.0,286.0,3562.0,,,,,,
VRC29.01,gp120 V3 // V3 glycan (V3g),,N170 ,VRC29,Longo2016(27654288) ,,Longo2016(27654288) ,IMGT/V-QUEST JoinSolver,4-59*08,,3*02,20.0,ARHRYDRWSDSYDIRSPFDI,12.0,,3-20*01,1*01,9.0,HQYDRSPRT,6.0,,K,,Natural monoclonal,human,, ,35.8774,10.0761,28.0,287.0,3563.0,,,,,,
VRC29.02,gp120 V3 // V3 glycan (V3g),,N170 ,VRC29,Longo2016(27654288) ,,Longo2016(27654288) ,IMGT/V-QUEST JoinSolver,4-59*08,,3*02,20.0,ARHRYDVWSKGYDIRSPFDF,16.0,,3-20*01,1*01,9.0,QQFDFSPRT,9.0,,K,,Natural monoclonal,human,, ,23.9047,11.3537,28.0,288.0,3564.0,,,,,,
VRC29.03,gp120 V3 // V3 glycan (V3g),,N170 ,VRC29,Longo2016(27654288) ,,Longo2016(27654288) ,IMGT/V-QUEST JoinSolver,4-59*08,,3*02,20.0,ARHRYDVWSNGYDIRSPYDF,15.0,,3-20*01,1*01,9.0,QQYDFSPRT,9.0,,K,,Natural monoclonal,human,, ,28.0365,9.06713,444.0,289.0,3565.0,,,,,,
VRC29.04,gp120 V3 // V3 glycan (V3g),,N170 ,VRC29,Longo2016(27654288) ,,Longo2016(27654288) ,IMGT/V-QUEST JoinSolver,4-59*08,,3*02,20.0,ARHRYDPWSKGYDIRSPFDF,16.0,,3-20*01,1*01,9.0,EQYDVSPRT,8.0,,K,,Natural monoclonal,human,, ,16.199,14.5892,28.0,290.0,3566.0,,,,,,
VRC34.01,fusion peptide // near gp41-gp120 interface,5I8C(BG505 Fusion Peptide in Complex with VRC34.01 Fab);5I8E(VRC34.01 Fab);5I8H(BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 Fab and VRC34.01 Fab);6NC3(AMC011 v4.2 SOSIP Env trimer in complex with fusion peptide targeting antibody VRC34);EMD-0434(AMC011 v4.2 SOSIP Env trimer in complex with fusion peptide targeting antibody VRC34 fragment antigen binding),N123 ,VRC34,Kong2016a(27174988) ,Mutation affects neutralization by VRC34;Mutation reduces binding/neutralization of fusion peptide mAbs;Mutations affecting binding of VRC34.01 to fusion peptide epitope;mutations affecting VRC34.01 binding;VRC34.01 contacts;VRC34.01 contacts;VRC34.01 mutations affect neutralization,Kong2016a(27174988) ,IMGT/V-QUEST,1-2*02,,6*02,13.0,DKYYGNEAVGMDV,15.0,,1-9*01,4*01,9.0,QHMSSYPLT,10.0,,K,,Natural monoclonal,human,N123-VRC34.01, ,4.89902,22.209,1373.0,259.0,3490.0,QEVLVQSGAEVKKPGASVKVSCRAFGYTFTGNALHWVRQAPGQGLEWLGWINPHSGDTTTSQKFQGRVYMTRDKSINTAFLDVTRLTSDDTGIYYCARDKYYGNEAVGMDVWGQGTSVTVSSX,DIQLTQSPSFLSASVGDKVTITCRASQGVRNELAWYQQKPGKAPNLLIYYASTLQSGVPSRFSATGSGTHFTLTVSSLQPEDFATYFCQHMSSYPLTFGGGTKVEIKX,GACATCCAGTTGACCCAGTCTCCATCCTTCCTTTCTGCCTCTGTAGGAGACAAGGTTACGATCACTTGCCGGGCCAGTCAGGGCGTTCGCAATGAGTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAATCTCCTCATCTATTATGCATCCACTTTGCAAAGTGGGGTCCCGTCAAGATTCAGCGCCACTGGATCTGGGACACACTTCACTCTCACAGTCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAACACATGAGCAGTTACCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC,CAGGAGGTACTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAGGGCTTTTGGATATACCTTTACCGGCAATGCTCTGCACTGGGTTCGGCAGGCCCCTGGGCAAGGTCTTGAGTGGCTGGGGTGGATCAACCCTCACAGTGGTGACACAACCACTTCACAGAAATTTCAGGGCAGGGTCTACATGACCAGGGACAAGTCCATCAACACAGCCTTTTTGGACGTGACCAGGCTAACATCTGACGACACGGGCATATATTATTGTGCGAGAGACAAGTACTATGGTAATGAGGCAGTCGGAATGGACGTCTGGGGCCAGGGGACCTCGGTCACCGTCTCCTCAG,CARDKYYGNEAVGMDVW,85.473
VRC34.02,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Kong2016a(27174988) ,,Kong2016a(27174988) ,IMGT/V-QUEST,1-2*02,,6*02,13.0,DKYYGNEAVGMDV,15.0,,1-9*01,4*01,9.0,QHMSSYPLT,10.0,,K,,Natural monoclonal,human,N123-VRC34.02, ,1.87277,14.5418,22.0,555.0,3496.0,QEVLVQSGAEVKKPGASVKVSCRAFGYTFTGNALHWVRQAPGQGLEWLGWINPHSGDTTTSQKFQGRVYMTRDKAINTAYLDVTRLTSDDTAIYYCARDKYYGNEAVGMDVWGQGTSVTVSSX,DIQLTQSPSFLSASVGDKVTFTCRASQGVRNELAWYQQKPGKAPNLLIYYASTLQSGVPSRFSATGSGTHFSLTVSSLQPEDFATYFCQHMSSYPLTFGGGTKVEIKX,GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCCTCTGTAGGAGACAAGGTTACTTTCACTTGCCGGGCCAGTCAGGGCGTTCGCAATGAGTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAATCTCCTCATCTATTATGCATCCACTTTGCAAAGTGGGGTCCCGTCAAGATTCAGCGCCACTGGATCTGGGACACACTTCAGTCTCACAGTCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAACACATGAGCAGTTATCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC,CAGGAGGTACTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAGGGCTTTTGGATATACCTTTACCGGCAATGCTCTCCACTGGGTTCGACAGGCCCCTGGGCAAGGTCTTGAGTGGCTGGGGTGGATCAACCCTCACAGTGGTGATACAACCACTTCACAGAAATTTCAGGGCAGGGTCTACATGACCAGGGACAAGGCCATCAACACAGCCTATTTGGACGTGACCAGGCTAACATCTGACGACACGGCCATATATTATTGTGCGAGAGACAAGTACTATGGTAATGAGGCAGTCGGAATGGACGTCTGGGGCCAGGGGACCTCGGTCACCGTCTCCTCAG,CARDKYYGNEAVGMDVW,85.473
VRC34.03,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Kong2016a(27174988) ,,Kong2016a(27174988) ,IMGT/V-QUEST,1-2*02,,6*02,13.0,DKYYGDEAVGMDV,14.0,,1-9*01,4*01,9.0,QHMSSYPLT,10.0,,K,,Natural monoclonal,human,N123-VRC34.03, ,14.9115,11.9376,22.0,556.0,3497.0,QEVLVQSGAEVKKPGASVKVSCRAFGYTFTAHALHWVRQAPGQGLEWLGWINPHSGDTTTSQKFQGRVYMTRDKSINTAYLEVTRLTSDDTAIFYCARDKYYGDEAVGMDVWGQGTSVTVSSX,DIQLTQSPSFLSASVGDKVTITCRASHGVRNELAWYQQKPGKAPNLLIYYASTLQSGVPSRFSATGSGTHFTLTVSSLQPEDFATYFCQHMSSYPLTFGGGTKVEIKX,GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCCTCTGTAGGAGACAAGGTTACTATCACTTGCCGGGCCAGTCACGGCGTTCGCAATGAGTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAATCTCCTCATCTATTATGCATCCACTTTGCAAAGTGGGGTCCCGTCAAGATTCAGCGCCACTGGATCTGGGACACACTTCACTCTCACAGTCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAACACATGAGCAGTTATCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC,CAGGAGGTACTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAGGGCTTTTGGATATACCTTTACCGCCCATGCTCTGCACTGGGTTCGACAGGCCCCTGGGCAAGGTCTTGAGTGGCTGGGGTGGATCAACCCTCACAGTGGTGACACAACCACTTCACAGAAATTTCAGGGCAGGGTCTACATGACCAGGGACAAGTCCATCAACACAGCCTATTTGGAGGTGACCAGGCTAACATCTGACGACACGGCCATATTTTATTGTGCGAGAGACAAATACTATGGAGATGAGGCAGTCGGGATGGACGTCTGGGGCCAGGGGACCTCGGTCACCGTCTCCTCAG,CARDKYYGDEAVGMDVW,86.149
VRC34.04,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Kong2016a(27174988) ,,Kong2016a(27174988) ,IMGT/V-QUEST,1-2*02,,6*02,13.0,DMYYSNEAVGMDV,22.0,,1-9*01,4*01,9.0,QQMNSLPLT,14.0,,K,,Natural monoclonal,human,N123-VRC34.04, ,16.5412,14.9627,22.0,557.0,3498.0,SLELVQSGTEVKKPGASVKVSCKLFGDTITSGPIHWVRQAPGQGLEWMGWTNPHSGDTATAPKFQGRVYMTNDKKINTAFLDVTRLASDDTAIYFCARDMYYSNEAVGMDVWGQGTTVSVSSX,DIQLTQSPSFLSASVGDRVSITCRASQGIKHELAWYQQKPGRAPSLLIYYASTLARGVPSRFSASWSGTLFTLTINGLQPEDFATYFCQQMNSLPLTFGGGTKMDVRX,GACATCCAGTTGACCCAGTCTCCGTCCTTCCTGTCTGCCTCTGTTGGAGACAGGGTCAGTATCACTTGTCGGGCCAGTCAGGGCATTAAACATGAGTTAGCCTGGTATCAGCAAAAACCGGGGAGAGCCCCTAGTCTCCTGATCTATTATGCATCCACTTTGGCAAGGGGGGTCCCGTCAAGATTCAGTGCCAGTTGGTCTGGGACACTCTTCACTCTCACTATCAACGGCCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAACAGATGAACTCTCTTCCGCTCACTTTCGGCGGGGGGACCAAGATGGACGTCAGAC,TCCCTGGAACTGGTGCAATCTGGGACTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAACTTTTTGGAGACACGATCACCAGCGGGCCTATACACTGGGTTCGCCAGGCCCCTGGGCAGGGGCTTGAGTGGATGGGATGGACTAACCCTCACAGCGGGGACACAGCCACTGCACCGAAGTTTCAGGGCAGGGTCTACATGACCAACGACAAGAAGATAAATACGGCCTTTTTGGACGTGACAAGGCTGGCATCTGACGACACAGCCATATACTTTTGTGCCAGAGACATGTATTACAGTAATGAGGCAGTCGGCATGGACGTCTGGGGCCAGGGGACCACGGTCAGCGTCTCCTCAG,CARDMYYSNEAVGMDVW,77.703
VRC34.05,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Kong2016a(27174988) ,VRC34.05 contacts,Kong2016a(27174988) ,IMGT/V-QUEST,1-2*02,,6*02,13.0,DKTYSDEATGMDI,23.0,,1-9*01,4*01,9.0,QQLNSFPLT,13.0,,K,,Natural monoclonal,human,N123-VRC34.05, ,98.6298,1.21957,460.0,558.0,3499.0,SQYLAQSGSEVKKPGASVKVSCRLHGDKFGAHYIHWVRQAPGQGLEWLGFFHPGTGDAVSAQKFQGRISLTRDTSISTGYLEVRRLSSDDTAVYYCARDKTYSDEATGMDIWGQGTTVIVSSX,DIKLTQSPAFLSASVGERVTFTCRASQDIRHELVWYQQKPGRGPKLLIYYGSTLEGGVPSRFSGRRSGTEFTVTISSLQPEDVGTYYCQQLNSFPLTFGGGTTVDIRX,GACATCAAGTTGACCCAGTCTCCTGCCTTCCTGTCTGCATCTGTAGGGGAGAGAGTCACCTTCACTTGCCGGGCCAGTCAGGACATTAGACATGAATTAGTCTGGTATCAGCAAAAACCAGGGAGAGGCCCTAAACTTCTTATCTATTATGGGTCCACTTTGGAAGGAGGGGTCCCGTCCAGGTTCAGCGGCCGGCGATCTGGGACAGAGTTCACTGTCACAATCAGCAGCCTGCAGCCTGAAGATGTTGGAACTTATTACTGTCAACAACTTAATAGTTTTCCTCTCACTTTCGGCGGAGGGACGACGGTGGACATCAGGC,TCCCAGTATTTGGCGCAGTCGGGGAGTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGTAGGCTGCATGGGGACAAGTTCGGCGCCCATTATATACATTGGGTGCGGCAGGCCCCTGGGCAAGGTCTTGAGTGGCTGGGATTCTTCCATCCTGGTACCGGTGACGCGGTCTCTGCACAGAAGTTTCAGGGCAGGATCAGTCTGACCAGGGACACGTCCATCAGTACAGGCTATTTGGAAGTGAGAAGGCTGTCATCTGACGACACGGCCGTCTACTATTGTGCACGGGACAAGACTTACAGTGACGAGGCAACCGGCATGGACATCTGGGGCCAGGGGACCACAGTTATCGTCTCCTCAG,CARDKTYSDEATGMDIW,77.241
VRC34.06,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Kong2016a(27174988) ,,Kong2016a(27174988) ,IMGT/V-QUEST,1-2*02,,6*02,13.0,DKTYNDEFTAMDI,22.0,,1-9*01,4*01,9.0,QQLSAFPLT,17.0,,K,,Natural monoclonal,human,N123-VRC34.06, ,77.8393,3.15201,22.0,559.0,3500.0,SQYLAQPGAEVAKPWASVKVSCRVHGDNFRGFYLHWVRQAPGQGLEWIGGINPFSGEAAYGRRFEGRLRLTRDTSINTAYMEVTKLTSDDTAVYFCARDKTYNDEFTAMDIWGQGTTVIVSSX,DIKMTQSPAFLSASVGERVTFTCRASQDISHDVVWFQQKSGSAPKLLMFYGSTLERGVPPRFSGRRSGTEFTVTIDGLQPEDVGTYYCQQLSAFPLTFGGGTTVDIKX,GACATCAAGATGACCCAGTCTCCGGCCTTCCTGTCTGCATCTGTAGGGGAGAGAGTCACCTTCACTTGCCGGGCCAGTCAGGACATTAGCCATGATGTAGTCTGGTTTCAGCAGAAATCAGGGAGCGCCCCTAAACTCCTAATGTTCTATGGATCCACTCTAGAAAGGGGGGTCCCGCCCAGGTTCAGCGGCCGGCGATCTGGGACAGAGTTCACTGTCACAATCGACGGCCTGCAGCCTGAAGATGTTGGAACCTATTACTGTCAACAGCTTAGTGCTTTTCCTCTCACCTTCGGCGGAGGGACCACCGTGGACATCAAAC,TCGCAATATCTGGCGCAGCCGGGGGCTGAGGTGGCGAAGCCATGGGCCTCAGTGAAGGTCTCCTGTAGGGTACATGGAGACAACTTCAGAGGCTTCTATCTACACTGGGTGCGACAGGCCCCTGGACAAGGTCTTGAGTGGATCGGAGGAATCAACCCTTTCAGTGGTGAGGCGGCCTATGGCAGGAGATTTGAGGGCAGGCTCAGGTTGACCAGGGACACGTCCATCAACACAGCCTACATGGAGGTGACGAAATTGACGTCTGACGACACGGCCGTCTATTTTTGTGCGCGGGACAAGACATATAATGATGAGTTTACTGCAATGGACATCTGGGGCCAAGGGACCACCGTCATCGTGTCCTCAG,CARDKTYNDEFTAMDIW,78.378
VRC34.07,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Kong2016a(27174988) ,,Kong2016a(27174988) ,IMGT/V-QUEST,1-2*02,,6*02,13.0,DKTYNDEFTAMDI,23.0,,1-9*01,4*01,9.0,QQLSAFPLT,15.0,,K,,Natural monoclonal,human,N123-VRC34.07, ,100.0,1.0,22.0,560.0,3501.0,SQYLAQPGAEVAKPGASVKVSCKVHGDNFRGHYLHWVRQAPGQGLQWIGGINPFSGEAAYGKRFEGRLRLTRDTSVNTAYMELAKLTPDDTAVYFCARDKTYNDEFTAMDIWGHGTTVIVSSX,DIKLTQSPAFLSASVGERVTFTCRASQDISHDLVWFQQKAGRAPSLLMFYGSTLERGVPPRFSGRRSGTEFTVTIDSLQPEDVGTYYCQQLSAFPLTFGGGTTVDIKX,GACATCAAGTTGACCCAGTCTCCTGCCTTCCTGTCTGCATCTGTAGGGGAGAGAGTCACCTTCACTTGCCGGGCCAGTCAGGACATTAGCCATGATTTAGTCTGGTTTCAGCAGAAAGCAGGGAGAGCCCCTAGCCTCCTGATGTTTTATGGATCCACTTTGGAAAGGGGGGTCCCGCCCAGATTCAGCGGCCGGCGATCTGGGACAGAGTTCACTGTCACAATCGACAGCCTGCAGCCTGAAGATGTTGGAACCTATTACTGTCAACAACTTAGTGCTTTTCCTCTCACCTTCGGCGGAGGGACCACCGTGGACATCAAAC,TCGCAATATCTGGCGCAGCCGGGGGCTGAGGTGGCGAAGCCGGGGGCCTCAGTGAAAGTCTCCTGTAAGGTACATGGAGACAACTTCAGAGGCCACTATCTACACTGGGTGCGACAGGCCCCTGGACAAGGTCTTCAGTGGATCGGAGGAATCAACCCTTTCAGTGGTGAGGCGGCCTATGGCAAGAGATTTGAGGGCAGGCTCAGGTTGACGAGGGACACGTCCGTCAACACAGCCTACATGGAGTTGGCGAAATTGACGCCTGACGACACGGCCGTCTATTTTTGTGCGCGGGACAAGACATATAATGATGAATTCACTGCAATGGACATCTGGGGCCACGGGACCACCGTCATCGTGTCCTCAG,CARDKTYNDEFTAMDIW,77.365
VRC34-pI1,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Shen2020(32130953) ,,Shen2020(32130953) ,,1-02*02,,6*02,13.0,DKYYGNEAVGMDV,1.0,,1-9*01,4*01,9.0,QHLNSYPLT,0.0,,K,,UCA or intermediate,human,VRC34.01-pI1,Unpublished VRC34-pI1 info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953) ,,,22.0,688.0,4254.0,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMEVSRLTSDDTAVYYCARDKYYGNEAVGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHLNSYPLTFGGGTKVEIK,,,,
VRC34-pI2,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Shen2020(32130953) ,,Shen2020(32130953) ,,1-02*02,,6*02,13.0,DKYYGNEAVGMDV,6.1,,1-9*01,4*01,9.0,QHMSSYPLT,2.1,,K,,UCA or intermediate,human,VRC34.01-pI2,Unpublished VRC34-pI2 info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953) ,,,22.0,689.0,4255.0,QEVLVQSGAEVKKPGASVKVSCKASGYTFTGHHMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSINTAYLDVTRLTSDDTAIYYCARDKYYGNEAVGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYFCQHMSSYPLTFGGGTKVEIK,,,,
VRC34-pI2',fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Shen2020(32130953) ,,Shen2020(32130953) ,,1-02*02,,6*02,13.0,DKTYSDEATGMDI,9.4,,1-9*01,4*01,9.0,QQLNSFPLT,10.5,,K,,UCA or intermediate,human,VRC34.01-pI2',Unpublished VRC34-pI2' info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953) ,,,22.0,694.0,4260.0,SQYLAQSGAEVKKPGASVKVSCRVHGDNFSGYYIHWVRQAPGQGLEWMGWINPNSGDAAYAQKFQGRVSLTRDTSISTAYMEVRRLTSDDTAVYYCARDKTYSDEATGMDIWGQGTTVIVSS,DIKLTQSPAFLSASVGERVTFTCRASQDISHDLVWYQQKPGRAPKLLIYYGSTLERGVPSRFSGRRSGTEFTVTISSLQPEDVGTYYCQQLNSFPLTFGGGTTVDIK,,,,
VRC34-pI2 H33P,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Shen2020(32130953) ,,Shen2020(32130953) ,,1-02*02,,6*02,13.0,DKYYGNEAVGMDV,,,1-9*01,4*01,9.0,QHMSSYPLT,,,K,,Engineered monoclonal,human,VRC34.01-pI2 H33P,Unpublished info via personal communication (C. Shen) but related to Shen2020 (PMID 32130953) ,,,22.0,693.0,4259.0,,,,,,
VRC34-pI3,fusion peptide // near gp41-gp120 interface,6UCE(VRC34-pI3 with HIV fusion peptide residues 512-519),N123 ,VRC34,Shen2020(32130953) ,,Shen2020(32130953) ,,1-02*02,,6*02,13.0,DKYYGNEAVGMDV,11.1,,1-9*01,4*01,9.0,QHMSSYPLT,7.3,,K,,UCA or intermediate,human,VRC34.01-pI3, ,3.92824,22.7977,438.0,690.0,4256.0,QEVLVQSGAEVKKPGASVKVSCKAFGYTFTGNPMHWVRQAPGQGLEWMGWINPHSGDTTTAQKFQGRVYMTRDKSINTAYLDVTRLTSDDTAIYYCARDKYYGNEAVGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKGLEVLF,DIQLTQSPSFLSASVGDRVTITCRASQGISNELAWYQQKPGKAPNLLIYYASTLQSGVPSRFSASGSGTHFTLTISSLQPEDFATYFCQHMSSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,,,,
VRC34-pI3',fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Shen2020(32130953) ,,Shen2020(32130953) ,,1-02*02,,6*02,13.0,DKTYNDEFTAMDI,18.9,,1-9*01,4*01,9.0,QQLSAFPLT,14.7,,K,,UCA or intermediate,human,VRC34.01-pI3',Unpublished VRC34-pI3' info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953) ,,,22.0,695.0,4261.0,SQYLAQPGAEVAKPGASVKVSCRVHGDNFRGYYLHWVRQAPGQGLEWIGGINPFSGEAAYGKRFEGRLRLTRDTSINTAYMEVTKLTSDDTAVYFCARDKTYNDEFTAMDIWGQGTTVIVSS,DIKLTQSPAFLSASVGERVTFTCRASQDISHDLVWFQQKAGRAPKLLMFYGSTLERGVPPRFSGRRSGTEFTVTIDSLQPEDVGTYYCQQLSAFPLTFGGGTTVDIK,,,,
VRC34-pI3HCpI2LC,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Shen2020(32130953) ,,Shen2020(32130953) ,,1-02*02,,6*02,13.0,DKYYGNEAVGMDV,11.1,,1-9*01,4*01,9.0,QHMSSYPLT,2.1,,K,,Engineered monoclonal,human,VRC34.01-pI3HCpI2LC,Chimera of pI3 HC and pI2 LC. Unpublished VRC34-pI2 info via personal communication (C. Shen) related to Shen2020 (PMID 32130953) ,,,22.0,692.0,4258.0,QEVLVQSGAEVKKPGASVKVSCKAFGYTFTGNPMHWVRQAPGQGLEWMGWINPHSGDTTTAQKFQGRVYMTRDKSINTAYLDVTRLTSDDTAIYYCARDKYYGNEAVGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKGLEVLF,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYFCQHMSSYPLTFGGGTKVEIK,,,,
VRC34-pI4,fusion peptide // near gp41-gp120 interface,6UCF(VRC34-pI4 with HIV fusion peptide residues 512-519),N123 ,VRC34,Shen2020(32130953) ,,Shen2020(32130953) ,,1-02*02,,6*02,13.0,DKYYGNEAVGMDV,13.2,,1-9*01,4*01,9.0,QHMSSYPLT,8.7,,K,,UCA or intermediate,human,VRC34.01-pI4, ,6.00755,21.0346,438.0,691.0,4257.0,QEVLVQSGAEVKKPGASVKVSCRAFGYTFTGNALHWVRQAPGQGLEWLGWINPHSGDTTTSQKFQGRVYMTRDKSINTAYLDVTRLTSDDTAIYYCARDKYYGNEAVGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH,DIQLTQSPSFLSASVGDRVTITCRASQGVRNELAWYQQKPGKAPNLLIYYASTLQSGVPSRFSASGSGTHFTLTVSSLQPEDFATYFCQHMSSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE,,,,
VRC34-UCA,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Shen2020(32130953) ,,Shen2020(32130953) ,,1-02*02,,6*02,13.0,DKYYGNEAVGMDV,0.0,,1-9*01,4*01,9.0,QQLNSYPLT,0.0,,K,,UCA or intermediate,human,VRC34.01-UCA,Unpublished VRC34-UCA info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953) ,100.0,1.0,436.0,687.0,4253.0,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDKYYGNEAVGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK,,,,
VRC34YD.01,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Wang2018(29309060) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,3.12972,10.735,22.0,441.0,4004.0,,,,,,
VRC34YD.02,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Wang2018(29309060) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,11.6997,9.14855,22.0,442.0,4005.0,,,,,,
VRC34YD.03,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Wang2018(29309060) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,5.57011,13.5579,22.0,443.0,4006.0,,,,,,
VRC34YD.04,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Wang2018(29309060) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,4.45401,11.4055,22.0,444.0,4007.0,,,,,,
VRC34YD.05,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Wang2018(29309060) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,7.22189,12.5243,22.0,445.0,4008.0,,,,,,
VRC34YD.06,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Wang2018(29309060) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,4.8491,15.4402,22.0,446.0,4009.0,,,,,,
VRC34YD.07,fusion peptide // near gp41-gp120 interface,,N123 ,VRC34,Wang2018(29309060) ,,,,,,,,,,,,,,,,,,,Natural monoclonal,human,, ,5.76716,12.7636,22.0,447.0,4010.0,,,,,,
VRC38.01,gp120 V2 // V2 glycan(V2g) // V2 apex,5EWI(Fab VRC38.01);5VGJ(Fab VRC38.01 bound to a scaffolded WITO V1V2 domain),N90 ,VRC38,Cale2017(28514685) ,Mutation affects neutralization by V1V2 glycan mAbs;Mutations at the trimer apex that affect sensitivity;VRC38.01 contacts,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPESGWFYHYYWGLGV,17.5,,2-28*01,4,10.0,MEARQTPRLT,8.5,,K,,Natural monoclonal,human,"N90-VRC38.01, VRC38", ,18.7342,21.8929,775.0,325.0,3775.0,EVQLVESGGKLVQPGGSLRLSCEASGESVGDNDMHWVRQVAGKGLEWVSSIGSSGDTYYIDAVKGRFTVSRDKGRNSVYLQMKTLTVGDTGVYFCVRGPESGWFYHYYWGLGVWGRGTTVTVSS,DLLMTQSPHSLAVTPGEPASISCRSSQSLLLGNGRNYLDWYVQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTYFTLKISRVEAEDVGFYYCMEARQTPRLTFGGGTKLEIR,GATCTTCTGATGACTCAGTCTCCACACTCCCTGGCCGTCACCCCTGGAGAGCCGGCCTCCATTTCCTGCAGGTCTAGTCAGAGCCTCCTCCTTGGTAACGGAAGGAACTATTTGGATTGGTATGTGCAGAAGCCAGGCCAGTCTCCACAACTCTTGATCTACCTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACATATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGCTTTTATTATTGCATGGAAGCTCGACAAACTCCACGGCTCACTTTCGGCGGAGGGACCAAACTAGAGATCAGA,GAAGTGCAGCTGGTGGAGTCTGGGGGAAAGTTGGTTCAGCCGGGGGGGTCCCTGAGACTCTCGTGTGAAGCCTCTGGAGAAAGTGTCGGTGACAACGACATGCACTGGGTCCGCCAAGTCGCAGGAAAAGGTTTGGAGTGGGTCTCATCTATCGGAAGTTCTGGTGACACATATTATATAGACGCCGTTAAGGGCCGATTCACCGTCTCCAGAGACAAAGGCAGGAATTCGGTGTATCTCCAAATGAAGACCCTGACAGTCGGAGACACGGGTGTTTATTTCTGTGTCAGAGGGCCTGAAAGTGGTTGGTTCTATCACTACTACTGGGGTCTGGGCGTCTGGGGCCGAGGGACCACGGTCACCGTCTCCTCA,CVRGPESGWFYHYYWGLGVW,82.192
VRC38.02,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPSSGWHLHYYFGMGL,20.0,,2-28*01,4,10.0,MQSLETPRLS,10.9,,K,,Natural monoclonal,human,N90-VRC38.02, ,41.1956,11.3714,31.0,326.0,3776.0,EDQLVESGGGLVQPGGSVRLSCAASGFDFGDFDMHWIRQGTGKGLEWVASIGGPRDRYYLDSVKDRFTVSRDNGDNKLYLQIKSLKDEDTALYFCARGPSSGWHLHYYFGMGLWGRGTAVIVSS,DVVMTQSPLSLAVTPGEPASISCRSSRSLLQYNGRNYLDWYLHKPGQPPQLLIYLGSLRASGVPDRFTGSGSGTAFTLKISRVEAEDVGIYYCMQSLETPRLSFGEGTKVEIK,GATGTTGTGATGACTCAGTCTCCACTGTCCCTGGCCGTCACCCCTGGAGAGCCCGCCTCCATCTCCTGCAGATCTAGTCGGAGCCTCCTGCAGTACAATGGAAGGAACTATTTGGATTGGTATTTGCACAAGCCAGGGCAGCCTCCACAACTCCTGATCTATTTGGGTTCTCTTCGGGCCTCCGGGGTCCCTGACAGGTTCACTGGCAGTGGATCAGGCACAGCTTTCACACTGAAGATCAGTAGAGTGGAGGCTGAAGATGTTGGAATTTACTACTGCATGCAATCTCTAGAGACTCCGCGGCTCTCTTTCGGCGAAGGGACCAAGGTGGAAATCAAA,GAGGACCAACTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGATCCGTGAGACTCTCCTGTGCAGCCTCTGGGTTCGACTTCGGCGACTTCGACATGCATTGGATCCGCCAAGGGACTGGAAAAGGTCTGGAGTGGGTCGCAAGTATTGGTGGTCCCAGGGACAGGTACTATTTAGATTCCGTGAAGGACCGATTCACCGTCTCGAGAGACAACGGTGACAATAAGTTGTATCTGCAAATCAAGAGCCTGAAAGACGAAGACACGGCTCTCTATTTTTGTGCAAGAGGGCCTAGCAGTGGTTGGCACCTTCACTATTACTTTGGCATGGGCCTCTGGGGCCGAGGGACCGCGGTCATCGTCTCCTCA,CARGPSSGWHLHYYFGMGLW,80.479
VRC38.03,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPASGWWYHDYYGLYV,14.7,,2-28*01,4,10.0,MQARQTPRLS,5.4,,K,,Natural monoclonal,human,N90-VRC38.03, ,46.7849,6.35166,31.0,327.0,3777.0,EVQLVESGGGLVRPGGSLRLSCAASGFTFSDFDFHWVRQVAGKGLQWVAAIGGVRDTYYAESVKGRFTISRNNGGNSLYLQMTGLRDEDTAVYYCVKGPASGWWYHDYYGLYVWGQGTTVTVSS,DIVMTQSPLSLSVTPGEPASISCKSSQSLLESNGYNYLDWYVQKPGRSPQLLIYLGSNRASGVPDRFSGRGSGTDFTLKISRVEAEDVGIYYCMQARQTPRLSFGGGTNLEIR,GATATTGTGATGACTCAGTCTCCACTCTCCCTGTCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCCTGGAGAGTAATGGATATAATTATTTGGATTGGTACGTGCAGAAGCCAGGGCGGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCCGTGGATCAGGCACTGACTTTACACTGAAAATCAGCAGAGTGGAGGCTGAAGATGTTGGAATTTATTACTGCATGCAAGCTCGGCAAACTCCACGGCTCTCTTTCGGCGGGGGGACCAACTTAGAGATCAGA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACGGCCGGGGGGGTCCCTCAGACTCTCCTGTGCAGCCTCTGGGTTCACCTTCAGTGACTTCGACTTTCACTGGGTCCGCCAAGTTGCAGGAAAGGGCCTTCAGTGGGTCGCCGCCATTGGCGGGGTTCGTGACACATATTATGCAGAGTCCGTGAAGGGCCGGTTCACCATCTCCAGAAACAATGGCGGAAACTCCTTATATCTTCAAATGACCGGCCTGAGAGACGAAGACACGGCTGTCTATTACTGTGTTAAAGGGCCAGCGAGTGGCTGGTGGTATCATGACTACTACGGTCTATATGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA,CVKGPASGWWYHDYYGLYVW,85.315
VRC38.04,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPSSGWHLHYYFGMGL,18.9,,2-28*01,4,10.0,MQSLETPRLS,10.2,,K,,Natural monoclonal,human,N90-VRC38.04, ,37.8086,11.7498,31.0,328.0,3778.0,EVQLVESGGGLVQPGGSVRLSCAASGFDFGDFDMHWIRQATGKGLEWVASIGGPRDRYYLDSVKDRFTVSRDNGDNKLYLQIKNLKDEDTALYFCARGPSSGWHLHYYFGMGLWGRGTAVTVSS,DVVMTQSPLSLAVTPGEPASISCRSSRSLLQYNGRNYLDWYLHKPGQPPQLLIYLGSHRASGVPDRFTGSGSGTAFTLKISRVEAEDVGVYYCMQSLETPRLSFGEGTKVEIK,GATGTTGTGATGACTCAGTCTCCACTGTCCCTGGCCGTCACCCCTGGAGAGCCCGCCTCCATCTCCTGCAGATCTAGTCGGAGCCTCCTGCAGTACAATGGAAGGAACTATTTGGATTGGTATTTGCACAAGCCAGGGCAGCCTCCACAACTCCTGATCTATTTGGGGTCTCATCGGGCCTCCGGGGTCCCTGACAGGTTCACTGGCAGTGGATCAGGCACAGCTTTCACACTGAAGATCAGTAGAGTGGAGGCTGAGGATGTTGGAGTTTACTACTGCATGCAATCTCTAGAGACTCCGCGGCTCTCTTTCGGCGAAGGGACCAAGGTTGAGATCAAG,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGATCCGTGAGACTCTCCTGTGCAGCCTCTGGGTTCGACTTCGGCGACTTCGACATGCATTGGATCCGCCAAGCGACTGGAAAAGGTCTGGAGTGGGTCGCAAGTATTGGTGGTCCCAGGGACAGATATTACTTAGATTCCGTGAAGGACCGATTCACCGTCTCCAGAGACAACGGTGACAATAAGTTGTATCTGCAAATCAAGAACCTGAAAGACGAAGACACGGCTCTCTATTTTTGTGCAAGAGGGCCTAGCAGTGGTTGGCACCTTCACTATTACTTTGGCATGGGCCTCTGGGGCCGAGGGACCGCGGTCACCGTCTCCTCA,CARGPSSGWHLHYYFGMGLW,81.507
VRC38.05,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPSSGWHLHYYFGMGL,18.6,,2-28*01,4,10.0,MQSLETPRLS,10.2,,K,,Natural monoclonal,human,N90-VRC38.05, ,79.3197,3.55723,31.0,329.0,3779.0,EVQLVESGGGLVQPGGSVRLSCAASGFDFGDFDMHWIRQATGKGLEWVASIDGPRDRYYLDSVKDRFTVSRDNGDNKLYLQIKSLKDEDTAVYFCARGPSSGWHLHYYFGMGLWGRGTAVTVSS,DVVMTQSPLSLAVTPGEPASISCRSSRSLLQYNGRNYLDWYWHKPGQPPQLLIYLGSHRASGVPDRFTGSGSGTAFTLKISRVEAEDVGVYYCMQSLETPRLSFGEGTKVEIK,GATGTTGTGATGACTCAGTCTCCACTGTCCCTGGCCGTCACCCCTGGAGAGCCCGCCTCCATCTCCTGCAGATCTAGTCGGAGCCTCCTGCAGTACAATGGAAGGAACTATTTGGATTGGTATTGGCACAAGCCAGGGCAGCCTCCACAACTCCTGATCTATTTGGGTTCTCATCGGGCCTCCGGGGTCCCTGACAGGTTCACTGGCAGTGGATCAGGCACAGCTTTCACACTGAAGATCAGTAGAGTGGAGGCTGAGGATGTTGGAGTTTACTACTGCATGCAATCTCTAGAGACTCCGCGGCTCTCTTTCGGCGAAGGGACCAAGGTTGAGATCAAG,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGATCCGTGAGACTCTCCTGTGCAGCCTCTGGGTTCGACTTCGGCGACTTCGACATGCATTGGATCCGCCAAGCGACTGGAAAAGGTCTGGAGTGGGTCGCAAGTATTGATGGTCCCAGGGACAGATACTATTTAGATTCCGTGAAGGACCGATTCACCGTTTCCAGAGACAACGGTGACAATAAGTTGTATCTGCAAATCAAGAGCCTGAAAGACGAAGATACGGCTGTCTATTTTTGTGCAAGAGGGCCTAGCAGTGGTTGGCACCTTCACTATTACTTTGGCATGGGCCTCTGGGGCCGAGGGACCGCGGTCACCGTCTCCTCA,CARGPSSGWHLHYYFGMGLW,81.849
VRC38.06,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPESGWFYHYYFGLGV,17.5,,2-28*01,4,10.0,MQARQTPRLS,11.2,,K,,Natural monoclonal,human,N90-VRC38.06, ,11.7522,28.1813,31.0,330.0,3780.0,EVQLEESGGKLVQPGGSLRLSCSASGFSLEDNDMHWVRQGEGRGLEWVSSIGSSGDTYYADSIKGRFTISRDNGRNSVYLQIKTLNVGDTAVYFCIRGPESGWFYHYYFGLGVWGRGTTVTVSS,MIMLTQSPLSLAVTPGEPASISCRSSQSLLLGNGRNYLDWYVQRPGQSPQLLIYLASHRAPGVPDRFSGSGSGTDFTLKISRVEADDVGFYYCMQARQTPRLSFGEGTKVEIK,ATGATTATGCTGACTCAGTCTCCACTCTCCCTGGCCGTCACCCCCGGAGAGCCGGCCTCCATTTCCTGCAGGTCGAGTCAGAGCCTCCTTCTTGGAAATGGAAGGAACTACTTGGATTGGTACGTACAGAGGCCAGGGCAGTCTCCACAACTCCTGATCTACCTGGCTTCTCATCGGGCCCCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTTACACTGAAAATCAGTAGAGTGGAGGCTGACGATGTTGGGTTTTATTATTGCATGCAAGCTCGACAGACTCCACGGCTCAGTTTCGGCGAAGGGACCAAGGTTGAGATCAAG,GAGGTGCAGTTGGAGGAGTCTGGGGGAAAGTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTCAGCCTCTGGATTCAGCCTCGAGGACAACGACATGCACTGGGTCCGCCAAGGCGAAGGGCGAGGTTTGGAGTGGGTCTCATCAATTGGAAGTTCTGGTGACACATATTACGCAGATTCAATTAAGGGCCGATTTACCATCTCCAGAGACAATGGCAGGAACTCCGTATATCTTCAAATAAAGACCCTGAACGTCGGGGACACGGCTGTGTATTTCTGTATAAGAGGTCCTGAAAGTGGTTGGTTCTATCACTACTACTTCGGTTTGGGCGTCTGGGGCCGCGGGACCACGGTCACCGTCTCCTCA,CIRGPESGWFYHYYFGLGVW,82.192
VRC38.07,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPESGWFYHYYWGLGA,19.6,,2-28*01,4,10.0,MEARQTPRLT,9.2,,K,,Natural monoclonal,human,N90-VRC38.07, ,12.3217,29.2906,31.0,331.0,3781.0,EVQLVESGGKLVQPGGSLRLSCEASGESVADNDMHWVRQVAGKGLEWVSSIGSSGDTYYIDVLKGRFTVSRDKGRNSVYLQMKTLRVEDTGVYFCVRGPESGWFYHYYWGLGAWGRGTTVTVSS,DLVMTQSPHSLAVTPGEPASISCRSSQSLLLNNGRNYLDWYVQKPGQSPQLLIYLGSNRAPGVPDRFSGSGSGTDFTLKISRVEAEDIGFYYCMEARQTPRLTFGGGTKLEIR,GATCTTGTGATGACTCAGTCTCCACACTCCCTGGCCGTCACCCCTGGAGAGCCGGCCTCCATTTCCTGCAGGTCTAGTCAGAGCCTCCTCCTTAATAACGGAAGGAACTATTTGGATTGGTATGTGCAGAAGCCAGGACAGTCTCCACAACTCTTGATCTATCTGGGATCTAATCGGGCCCCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACATTGAAAATCAGCAGAGTGGAGGCTGAGGATATCGGCTTTTATTATTGCATGGAAGCTCGACAAACTCCACGGCTCACTTTCGGCGGAGGGACCAAACTAGAGATCAGA,GAGGTGCAGCTGGTGGAGTCTGGGGGAAAGTTGGTTCAGCCGGGGGGGTCCCTGAGACTCTCGTGTGAAGCCTCTGGAGAAAGTGTCGCTGACAACGACATGCACTGGGTCCGTCAAGTCGCAGGAAAAGGTTTGGAGTGGGTCTCATCTATCGGAAGTTCCGGTGACACATATTATATAGACGTCCTTAAGGGGCGATTCACCGTCTCCAGGGACAAAGGCAGGAATTCGGTGTATCTCCAAATGAAGACCCTGAGAGTCGAAGACACGGGTGTTTATTTCTGTGTCAGAGGGCCTGAAAGTGGTTGGTTCTATCACTACTACTGGGGTCTGGGCGCCTGGGGCCGAGGGACCACGGTCACCGTCTCCTCA,CVRGPESGWFYHYYWGLGAW,80.137
VRC38.08,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPTSGWWYHDYYGLDV,15.4,,2-28*01,4,10.0,MQAVQTPRLS,13.3,,K,,Natural monoclonal,human,N90-VRC38.08, ,25.6964,10.557,30.0,332.0,3782.0,EVQLVESGGALVQPGGSLRLSCAASGFSFRDHDMHWVRQVTGKGLEWISSIGGGGDTYYLDSVKGRFIISRQNGRSSLFLQINSLTVGDTGVYYCVRGPTSGWWYHDYYGLDVWGQGTTVTVSS,LIVMTQSPLSLTVTPGEPASLSCRSSQSLLESNGYNYLDWFVQKPGQSPKLLIYRGSHRASGVPDRFSGSGSGTHFTLRISRVEPEDAGVYFCMQAVQTPRLSFGGGTRVEIK,CTTATTGTTATGACTCAGTCTCCACTCTCCCTGACCGTCACCCCTGGAGAGCCGGCCTCCCTCTCCTGCAGGTCTAGTCAGAGTCTCCTAGAATCTAATGGATACAACTATCTGGATTGGTTCGTACAAAAGCCGGGGCAGTCTCCAAAACTGCTCATTTATAGAGGTTCTCATCGGGCTTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACTCATTTTACACTAAGAATTAGTAGAGTGGAGCCTGAGGATGCTGGGGTCTATTTCTGCATGCAGGCTGTACAAACTCCACGGCTCTCTTTCGGCGGAGGGACCAGGGTGGAGATCAAG,GAAGTGCAGCTGGTGGAGTCGGGGGGAGCGTTGGTGCAGCCGGGGGGGTCCCTGAGACTCTCTTGTGCAGCCTCCGGATTCAGTTTCCGTGATCACGACATGCACTGGGTCCGGCAAGTCACAGGAAAAGGTCTGGAATGGATCTCATCCATTGGTGGTGGTGGTGACACATATTATTTGGACTCCGTGAAGGGCCGATTTATCATCTCCCGACAAAATGGCAGGAGCTCCTTGTTTCTTCAAATAAACAGCCTGACAGTCGGAGACACGGGTGTCTATTATTGTGTAAGAGGGCCCACGAGTGGCTGGTGGTATCATGACTACTATGGTCTGGACGTCTGGGGCCAGGGGACCACGGTCACCGTCTCCTCA,CVRGPTSGWWYHDYYGLDVW,84.589
VRC38.09,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPSSGWWYHYYFGLHL,17.5,,2-28*01,4,10.0,MQARQTPRLS,5.4,,K,,Natural monoclonal,human,N90-VRC38.09, ,18.8304,14.5252,31.0,333.0,3783.0,EVQLVESGGGLVKPGGSLRLSCSASGLTFGDYDFHWVRQVAGKGLEWVAAIGGVRDTYYIESVKGRFIISRDNNRNSLYLQMNNLRDEDTAVYYCVKGPSSGWWYHYYFGLHLWGRGTRVTVSS,DIVMTQSPLSLSVTPGEPASISCRSSQSLLESNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGTGSGTAFTLKISRVEAEDVGIYYCMQARQTPRLSFGEGTKVEIR,GATATTGTGATGACTCAGTCTCCACTCTCCCTGTCCGTCACCCCCGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGGAGAGTAATGGATATAATTATCTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCACTGGATCAGGCACTGCCTTTACACTGAAAATCAGCAGAGTGGAGGCTGAAGATGTTGGAATTTATTACTGCATGCAAGCTCGGCAAACTCCACGGCTCTCTTTTGGCGAAGGGACCAAGGTAGAGATCAGA,GAGGTGCAGCTGGTGGAGTCGGGGGGAGGGTTGGTAAAGCCGGGGGGGTCCCTGAGACTTTCCTGTTCAGCCTCTGGACTCACGTTCGGTGACTACGACTTTCATTGGGTCCGCCAAGTTGCAGGGAAAGGCCTTGAGTGGGTCGCAGCCATTGGCGGCGTCCGTGACACATATTACATAGAGTCCGTGAAGGGCCGATTCATCATTTCCAGAGACAATAACAGAAACTCCCTATATCTGCAAATGAACAACCTGAGAGACGAAGACACGGCTGTCTACTACTGTGTAAAAGGGCCAAGTAGTGGCTGGTGGTATCATTATTACTTTGGTCTACACCTCTGGGGCCGAGGGACCAGGGTCACCGTCTCCTCA,CVKGPSSGWWYHYYFGLHLW,82.192
VRC38.10,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPMSGWWYHDYYGLDV,15.1,,2-28*01,4,10.0,MQAVETPRLS,11.9,,K,,Natural monoclonal,human,N90-VRC38.10, ,34.5202,8.85779,31.0,334.0,3784.0,EVQLVESGGTLVQPGGSLRLSCGASGFTFNDHDMHWVRQVTGKGLEWTSSIGGGGDTYYSDSVKGRFTISRQNGRNSLFLQINSVRDEDTGVYYCVKGPMSGWWYHDYYGLDVWGQGTTVIVST,DVVMTQSPVSLTVTPGESASISCRSSRSLLESNGFNYLDWYVQKPGQSPQLLIYRGSLRAPGVPDRFGGSGSGTHFILKISRVESEDAGIYYCMQAVETPRLSFGGGTRVEIT,GATGTTGTGATGACTCAGTCTCCAGTCTCCCTGACCGTCACCCCTGGAGAGTCGGCCTCCATCTCCTGCAGGTCTAGTCGAAGCCTCCTTGAATCTAATGGATTCAACTATTTGGATTGGTATGTGCAGAAGCCAGGGCAGTCTCCGCAACTCCTGATTTATAGGGGTTCTCTTCGGGCCCCCGGGGTCCCTGACAGGTTCGGAGGCAGTGGATCAGGCACACATTTTATACTGAAGATCAGCAGAGTGGAGTCTGAGGATGCTGGAATTTATTACTGCATGCAGGCTGTGGAAACTCCCCGGCTCAGTTTCGGCGGAGGGACCAGGGTGGAGATCACG,GAGGTGCAGCTGGTGGAGTCTGGGGGAACCTTAGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGGAGCCTCCGGATTCACCTTTAATGATCACGACATGCACTGGGTTCGCCAGGTCACAGGAAAAGGTCTGGAGTGGACCTCATCCATTGGTGGTGGCGGTGACACATATTACTCAGACTCCGTGAAGGGCCGATTCACCATCTCCCGACAAAATGGCAGGAACTCCTTGTTTCTTCAGATAAATAGTGTGAGAGACGAAGACACGGGTGTCTATTATTGTGTGAAGGGGCCTATGAGTGGCTGGTGGTATCATGACTATTACGGTCTGGACGTCTGGGGCCAAGGGACCACGGTCATTGTCTCCACA,CVKGPMSGWWYHDYYGLDVW,84.965
VRC38.11,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPTSGWWYHDYYGLDA,18.6,,2-28*01,4,10.0,MQAVQTPRLS,15.3,,K,,Natural monoclonal,human,N90-VRC38.11, ,23.958,13.3844,31.0,335.0,3785.0,EVQLVESGGALVQPGGSLRLSCVGSGFTFSENDIHWVRQVKGEGLQWISSIGGGGDTYYLDSLKGRLIISRQNARNSVFLQIKSLTDGDTGVYYCVRGPTSGWWYHDYYGLDAWGQGTSVIVSS,LIVMTQSPPSLIVTPGEPASISCRSSQSLLESNGYNYLDWFQQRPGQSPRLLFYRGSHRASGVPDRFTASGSGTDFRLKISRVESEDVGIYYCMQAVQTPRLSFGGGTKLEIK,CTTATTGTGATGACTCAGTCTCCACCCTCCCTAATCGTCACTCCTGGGGAGCCGGCCTCCATCTCCTGTAGGTCTAGTCAGAGCCTCCTAGAGTCTAATGGATATAATTATTTGGATTGGTTTCAACAAAGGCCGGGGCAGTCTCCACGTCTCCTGTTCTATAGGGGTTCTCATCGGGCTTCCGGGGTCCCTGACAGGTTCACTGCCAGTGGATCAGGCACAGATTTTCGACTGAAGATCAGTAGGGTGGAGTCTGAGGACGTTGGCATTTATTATTGCATGCAGGCTGTTCAAACTCCACGGCTCTCTTTCGGCGGAGGGACCAAGCTGGAGATCAAA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGCATTGGTGCAGCCGGGGGGATCTCTGAGACTCTCCTGTGTAGGCTCTGGATTCACATTCAGTGAGAACGACATACATTGGGTCCGCCAAGTCAAAGGAGAAGGTCTGCAGTGGATTTCATCAATCGGCGGTGGTGGTGACACATATTACTTAGACTCTCTGAAGGGCCGACTCATCATTTCCCGACAAAATGCCAGGAACTCCGTGTTTCTCCAAATAAAGAGCCTGACAGACGGCGACACGGGTGTCTATTATTGTGTAAGAGGGCCTACCAGTGGCTGGTGGTACCATGATTATTATGGCCTGGACGCCTGGGGCCAAGGGACCTCGGTCATTGTCTCCTCA,CVRGPTSGWWYHDYYGLDAW,81.507
VRC38.12,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPMSGWWYHDYYGLDA,,,,,,,,,,,Fab or heavy-chain-only,human,N90-VRC38.12,VRC38.12 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01. ,40.5342,8.4795,31.0,336.0,3786.0,EIRLVESGGTLIQPGGSLRLSCGASGFNFNENDMHWVRQVTGKGLEWISSIGGGGDAYYSDSMKGRITISRQNGRNSLFLQIKSVTDGDTGVYYCVRGPMSGWWYHDYYGLDAWGQGTTVIVSA,,,GAAATTCGCCTGGTGGAGTCCGGGGGAACCCTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGGAGCCTCTGGATTTAACTTTAATGAAAACGACATGCACTGGGTTCGCCAGGTCACAGGCAAAGGTCTGGAGTGGATCTCATCCATTGGTGGTGGTGGTGACGCATATTATTCAGACTCCATGAAGGGCCGAATCACCATCTCCCGACAAAATGGCAGGAACTCCTTGTTTCTTCAGATAAAAAGTGTGACAGACGGAGACACGGGTGTCTATTATTGTGTAAGAGGGCCCATGAGTGGCTGGTGGTATCATGACTATTACGGTTTGGACGCCTGGGGCCAAGGGACCACGGTCATTGTCTCCGCA,CVRGPMSGWWYHDYYGLDAW,81.507
VRC38.13,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPESGWFYHYYFGLGV,,,,,,,,,,,Fab or heavy-chain-only,human,N90-VRC38.13,VRC38.13 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01. ,18.4321,20.3122,31.0,337.0,3787.0,EVQLEESGGKLVQPGGSLRLSCSASGFSLEDNDMHWVRQGEGRGLEWVSSIGSSGDTYYADSIKGRFTISRDNGRNSVYLQIKTLNVGDTAVYFCIRGPESGWFYHYYFGLGVWGRGTTVTVSS,,,GAAGTGCAGTTGGAGGAGTCTGGGGGAAAGTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTCAGCCTCTGGATTCAGCCTCGAGGACAACGACATGCACTGGGTCCGCCAAGGCGAAGGGCGAGGTTTGGAGTGGGTCTCATCAATTGGAAGTTCTGGTGACACATATTACGCAGATTCAATTAAGGGCCGATTTACCATCTCCAGAGACAATGGCAGGAACTCCGTATATCTTCAAATAAAGACCCTGAACGTCGGGGACACGGCTGTGTATTTCTGTATAAGAGGTCCTGAAAGTGGTTGGTTCTATCACTACTACTTCGGTTTGGGCGTCTGGGGCCGCGGGACCACGGTCACCGTCTCCTCA,CIRGPESGWFYHYYFGLGVW,81.849
VRC38.14,gp120 V2 // V2 glycan(V2g) // V2 apex,,N90 ,VRC38,Cale2017(28514685) ,,Cale2017(28514685) ,Cloanalyst IMGT/V-QUEST,3-13*01,,6,16.0,GPTSGWWYHQYYGLDV,,,,,,,,,,,Fab or heavy-chain-only,human,N90-VRC38.14,VRC38.14 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01. ,23.4647,14.1259,31.0,338.0,3788.0,EVQLVESGGGLVQPGGSLRLSCVASGFSFNENDMHWVRKVTGKGLEWIASIGGAGDTYYLDSVKGRFTISRQNARNSLFLQINRPTAGDTGVYYCVRGPTSGWWYHQYYGLDVWGQGTTVSVSS,,,GAAGTGCAGCTGGTGGAGTCGGGGGGAGGGTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGTGGCCTCTGGATTCAGTTTCAATGAGAACGACATGCACTGGGTCCGGAAAGTCACAGGAAAAGGTCTGGAGTGGATCGCATCTATTGGCGGTGCTGGCGACACATATTATTTAGACTCCGTGAAGGGCCGATTCACCATCTCCCGACAAAATGCCAGGAACTCCTTGTTCCTTCAAATAAACAGGCCGACAGCCGGGGACACGGGTGTCTATTATTGTGTGAGAGGGCCTACTAGTGGCTGGTGGTATCATCAGTACTACGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCAGTGTCTCCTCA,CVRGPTSGWWYHQYYGLDVW,85.274
VRC41.01,gp120 V3 // V3 glycan (V3g),,CH765 ,VRC41,Alam2017(28298421) ,Mutation affects neutralization of V3 mAbs,Alam2017(28298421) ,Cloanalyst IMGT/V-QUEST,4-39,3-3,4-1,21.0,,21.0,,3-20,4,9.0,,14.0,,K,,Natural monoclonal,human,CH765-VRC41.01, ,4.93196,22.1047,146.0,311.0,3819.0,QLHLQVSGPGLVKPSETLSLTCTISGGPAGDWHYYWAWVRQPPGKGLELIGSVTYNLRTWYSPPLESRVTVSLDTAQNSISLKMTSVTAADTAVYFCARHHVRVRDYWSGPPHYFFDYWSQGSLVTVSS,QVVLTQSPGTLSLSPGERAILSCRASQSLSRGDLAWYQLKPGQPPRLLIYYGSNRAAGIPDRFRGGGVGTVFTLTITRLEPEDFALYYCQQHDNLPPAFGGGTTVDIN,CAAGTTGTATTGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGAGAAAGAGCCATCCTCTCCTGCAGGGCCAGTCAGAGTCTAAGCAGAGGTGACTTAGCCTGGTATCAACTGAAACCTGGCCAGCCTCCCAGACTCCTCATCTATTATGGATCTAACAGGGCCGCTGGCATCCCCGACAGGTTCCGTGGCGGCGGGGTTGGGACAGTCTTCACTCTCACCATCACTAGACTGGAGCCTGAAGATTTTGCACTCTACTATTGTCAGCAGCATGATAACTTACCTCCCGCTTTCGGCGGAGGGACCACCGTGGACATCAAC,CAGCTGCACTTGCAGGTGTCGGGCCCAGGGCTCGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTATCTCTGGCGGGCCCGCCGGCGACTGGCACTATTATTGGGCCTGGGTCCGCCAGCCCCCGGGGAAGGGGCTGGAGTTAATTGGCAGTGTCACTTATAATTTGAGAACCTGGTATAGTCCGCCCCTCGAGAGTCGGGTCACCGTGTCACTGGACACGGCCCAAAATTCTATCTCCCTGAAGATGACTTCTGTGACCGCCGCGGACACGGCCGTCTATTTTTGTGCGAGACATCACGTCCGAGTTCGCGATTATTGGAGTGGCCCCCCCCATTATTTCTTTGACTACTGGAGTCAGGGATCCCTGGTCACCGTCTCCTCA,,
VRC41.02,gp120 V3 // V3 glycan (V3g),,CH765 ,VRC41,Alam2017(28298421) ,Mutation affects neutralization of V3 mAbs,Alam2017(28298421) ,Cloanalyst IMGT/V-QUEST,4-39,3-3,4-1,21.0,,20.0,,3-20,4,9.0,,13.0,,K,,Natural monoclonal,human,CH765-VRC41.02, ,12.5647,7.41578,34.0,312.0,3820.0,QLLLQESGPGLVKPSETLSLTCTVSGGAVGDWQYYWGWVRQTPGKGLEWIGSVTYNLKTYYNPPLESRVTVGLDTAKNSISLKMTSVTAADTAVYFCTRHHVRVRDYWSGPPHYYFDYWSPGSLVTVSS,QVVLTQSPGILSLSPGERATLSCRASQSLSRGDLAWYQLKPGQAPRLLIYYVSNRAAGVPDRFRGGGVGTDFTLTISRLEPEDSAVYYCQQHDNSPPAFGGGTTVEIN,CAGGTTGTGTTGACCCAGTCTCCAGGCATCCTGTCTTTGTCTCCAGGGGAGAGAGCCACCCTCTCCTGCAGGGCCAGTCAAAGTCTAAGTAGAGGTGACTTAGCCTGGTACCAACTGAAACCTGGCCAGGCTCCCAGACTCCTCATTTATTATGTATCCAACAGGGCCGCTGGCGTCCCCGACAGATTCCGTGGCGGCGGGGTTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTCTGCAGTGTACTACTGTCAGCAACATGATAACTCACCTCCCGCTTTCGGCGGAGGGACCACCGTGGAGATCAAC,CAGCTGCTCTTGCAGGAGTCGGGCCCAGGACTCGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGCGGGGCCGTCGGCGACTGGCAATATTATTGGGGCTGGGTCCGCCAGACCCCCGGAAAGGGTCTGGAATGGATTGGAAGTGTCACTTACAATTTGAAAACCTACTACAATCCGCCCCTCGAGAGTCGGGTCACCGTTGGACTGGACACGGCCAAGAATTCTATCTCCCTGAAAATGACCTCTGTGACCGCCGCGGACACGGCCGTCTATTTTTGTACAAGACATCACGTCCGAGTTCGCGATTATTGGAGTGGCCCCCCCCACTACTACTTTGACTACTGGAGTCCTGGATCCCTGGTCACCGTCTCCTCA,,
VRC42.01,gp41 MPER (membrane proximal external region),6MTO(Crystal structure of VRC42.01 Fab in complex with T117-F MPER scaffold),40512 ,VRC42,Krebs2019(30876875) ,Residues important for neutralization or binding by VRC42.01;VRC42.01 contacts,Zhang2019a(31772165) ,IMGT/V-QUEST,1-69*10,3-10*01,4*03,15.0,EGAGWFGKPVGAMGY,10.8,,3-20*01,1*01,9.0,QQYGGSFGT,5.7,,K,,Natural monoclonal,human,RV217-VRC42.01, ,4.43392,4.39672,446.0,496.0,4068.0,QVQLVQSGPEVKKPGSSLKVSCKASGGSFSTYTLSWVRQTPGQGLEWMGGIIPLLGLPNYAPKFQGRVTFSADTSTNTAYMEMSRLRFEDTAVYFCAREGAGWFGKPVGAMGYWGQGTTVTVSS,EIVLTQSPDTLSLSPGERASLSCRASQNVRNSNLAWYQHKPGQPPRLLIYGASSRASGIPGRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSFGTFGQGTKVEFR,GAAATTGTCTTGACGCAGTCTCCAGACACCCTGTCTTTGTCTCCAGGGGAAAGAGCCTCCCTCTCCTGCAGGGCCAGTCAGAATGTTCGCAACAGTAACTTAGCCTGGTACCAACACAAACCTGGCCAGCCTCCCAGGCTCCTCATTTATGGTGCATCCAGCAGGGCCTCCGGCATCCCAGGCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTGGCTCATTTGGGACATTCGGCCAAGGGACCAAGGTGGAGTTCAGA,CAGGTCCAGCTGGTGCAGTCTGGGCCTGAGGTGAAGAAGCCTGGGTCCTCACTGAAGGTCTCCTGCAAGGCTTCTGGAGGCAGCTTCAGCACCTATACTCTCAGTTGGGTGCGACAGACCCCTGGACAAGGACTTGAGTGGATGGGAGGGATCATCCCTCTCCTTGGTCTTCCAAACTACGCACCGAAGTTCCAGGGCAGAGTCACGTTTAGTGCCGACACATCCACAAATACAGCCTACATGGAAATGAGCCGCCTGAGATTTGAAGATACGGCCGTCTATTTTTGTGCGAGAGAGGGGGCTGGATGGTTCGGGAAGCCCGTGGGCGCTATGGGCTACTGGGGCCAAGGGACTACGGTCACCGTCTCCTCA,CAREGAGWFGKPVGAMGYW,89.527
nan,,,,,,,Krebs2019(30876875) ,IMGT/V-QUEST,1-69*10,3-10,6,15.0,EGAGWFGKPVGAMGY,10.5,,3-20*01,,9.0,QQYGGSFGT,6.9,,,,,,,,,,,,,,,,,,
VRC42.02,gp41 MPER (membrane proximal external region),,40512 ,VRC42,Krebs2019(30876875) ,Residues that affect neutralization or binding by VRC42.02,Krebs2019(30876875) ,IMGT/V-QUEST,1-69*10,3-10,6,16.0,EATEGWLAKPVGALGV,12.5,,3-20*01,,9.0,QQFDKSHAT,5.5,,K,,Natural monoclonal,human,RV217-VRC42.02, ,10.4029,6.09119,446.0,783.0,4069.0,QVQLVQSGAEVKRPGSSVKVSCKASGGSFGSFSSYTLSWVRQAPGQGLEWMGSIIPLFNSVNSAQKFQARVTISADKSTNTAFMELRSLRYEDTAVYYCAREATEGWLAKPVGALGVWGQGTTVTVSS,,,CAGGTCCAGTTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCTCCTTCGGCTCTTTCAGCAGCTATACTCTCAGCTGGGTGCGACAGGCCCCTGGACAAGGCCTTGAGTGGATGGGAAGCATCATCCCCCTCTTTAATTCAGTAAACTCTGCACAGAAGTTCCAGGCCAGAGTCACCATTAGCGCGGACAAATCCACCAACACAGCCTTCATGGAACTGCGGAGCCTGAGATATGAGGACACGGCCGTCTATTACTGTGCGAGAGAGGCGACTGAAGGATGGTTGGCGAAGCCCGTGGGCGCTCTGGGCGTCTGGGGCCAGGGGACCACGGTCACCGTCTCCTCA,CAREATEGWLAKPVGALGVW,87.869
VRC42.03,gp41 MPER (membrane proximal external region),,40512 ,VRC42,Krebs2019(30876875) ,Residues important for neutralization or binding by VRC42.03,Krebs2019(30876875) ,IMGT/V-QUEST,1-69*10,3-10,6,16.0,EATEGWLSKPVGALGV,13.1,,3-20*01,,9.0,QQFDKSHST,5.9,,K,,Natural monoclonal,human,RV217-VRC42.03, ,18.7831,4.3654,30.0,784.0,4070.0,QVQLVQSGAEVKRPGSSVKVSCKASGGSFGSFSSYTLTWVRQAPGQGLEWLGSIIPIFNSVNSAQKFQGRVTISADKSTNTAYMELRSLTYGDTAVYYCAREATEGWLSKPVGALGVWGQGTTVTVSA,,,CAGGTCCAGTTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCTCCTTCGGCTCCTTCAGCAGCTATACTCTCACCTGGGTGCGACAGGCCCCTGGACAAGGCCTTGAATGGCTGGGAAGCATCATCCCCATCTTTAATTCAGTAAACTCTGCACAGAAGTTCCAGGGCAGAGTCACCATTAGCGCGGACAAATCTACGAACACAGCCTACATGGAACTGCGGAGCCTGACATATGGGGACACGGCCGTCTATTACTGTGCGAGAGAGGCGACTGAAGGATGGTTGTCGAAGCCCGTGGGCGCTCTGGGCGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCGCA,CAREATEGWLSKPVGALGVW,87.213
VRC42.04,gp41 MPER (membrane proximal external region),6MTP(Crystal structure of VRC42.04 Fab in complex with gp41 peptide),40512 ,VRC42,Krebs2019(30876875) ,Residues important for neutralization or binding by VRC42.04;VRC42.04 contacts,Krebs2019(30876875) ,IMGT/V-QUEST,1-69*10,3-10,6,15.0,EASGWFDKPLGAMGV,10.9,,3-20*01,,9.0,QQYYKPPGT,9.7,,K,,Natural monoclonal,human,RV217-VRC42.04, ,23.6438,4.6235,30.0,785.0,4071.0,RVQLVQSGAEVKKPGSSVRISCKASGGTFSTLTLTWVRQAPGQGLEWMGGIIPLLSLPNYTQKFQGRLTITADTSTSTSYLELSSLRSEDTAVYFCAREASGWFDKPLGAMGVWGQGTMVVVSS,,,CGGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGATCCTCAGTGAGGATTTCCTGCAAGGCTTCTGGAGGCACCTTCAGCACCTTAACTCTCACCTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGAGGCATCATCCCTCTTCTTAGTCTACCTAACTACACACAGAAGTTCCAGGGCAGACTCACCATTACCGCGGACACTTCCACGAGCACATCTTATCTGGAGTTGAGCAGTCTGAGATCTGAGGACACGGCCGTATATTTCTGTGCGAGAGAGGCGTCTGGTTGGTTCGACAAGCCCCTGGGCGCTATGGGCGTCTGGGGCCAGGGGACCATGGTCGTCGTATCTTCA,CAREASGWFDKPLGAMGVW,89.189
VRC42.05,gp41 MPER (membrane proximal external region),,40512 ,VRC42,Krebs2019(30876875) ,,Krebs2019(30876875) ,IMGT/V-QUEST,1-69*10,3-10,6,15.0,EGATYHGKPVGALGV,8.5,,3-20*01,,9.0,QHYSNSAAT,7.2,,K,,Natural monoclonal,human,RV217-VRC42.05, ,100.0,1.0,30.0,786.0,4072.0,EVRLVQSGAEVKKPGSSVKVSCKASGGTFSSYALSWVRQAPGQGLEWMGGIIPILDLRNYARKFQGRVTITADTSTSTAYMELNRLTSDDTGVYYCAREGATYHGKPVGALGVWGQGTTVTVSS,,,GAGGTCCGACTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCTTCCGGAGGCACCTTCAGCAGCTATGCTCTCAGCTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGAGGGATCATTCCCATCCTCGATCTTCGAAACTACGCACGGAAATTCCAGGGCAGAGTCACCATTACCGCGGACACATCCACGAGCACAGCTTACATGGAGCTGAACAGGCTGACATCTGACGACACGGGCGTCTATTACTGTGCGAGAGAGGGGGCTACATATCATGGGAAGCCCGTGGGCGCTCTGGGCGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA,CAREGATYHGKPVGALGVW,91.554
VRC42.I3,gp41 MPER (membrane proximal external region),,40512 ,VRC42,Krebs2019(30876875) ,,Krebs2019(30876875) ,IMGT/V-QUEST,1-69*10,3-10,6,15.0,EGTGWFGKPLGALGV,2.4,,3-20*01,,9.0,QQYGSSPGT,1.7,,K,,UCA or intermediate,human,RV217-VRC42.I3, ,28.0901,4.84146,416.0,792.0,4281.0,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYALSWVRQAPGQGLEWMGGIIPILSLPNYAPKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGTGWFGKPLGALGVWGQGTTVTVSS,,,CAGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTCTCAGCTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGAGGGATCATCCCTATCCTTAGTCTACCAAACTACGCACCGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTATATTACTGTGCGAGAGAGGGGACTGGATGGTTCGGGAAGCCCCTGGGCGCTCTGGGCGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA,CAREGTGWFGKPLGALGVW,97.635
VRC42.N1,gp41 MPER (membrane proximal external region),6MTQ(Crystal structure of VRC42.N1 Fab in complex with T117-F MPER scaffold),40512 ,VRC42,Krebs2019(30876875) ,VRC42.N1 contacts,Krebs2019(30876875) ,IMGT/V-QUEST,1-69*10,3-10,6,18.0,EGAEGWGWFAKPVGALGV,11.2,,3-20*01,,9.0,QQFDKSHVT,6.6,,K,,Engineered monoclonal,human,RV217-VRC42.N1, ,1.34507,5.73287,416.0,791.0,4282.0,QVQLMQSGAEVKRPGSSVKVSCKSSGGSFSDYTLSWVRQAPGQGLQWMGSIVPLLNLVNYAQRFQGRVTITADKSTSTAYMELRTLRPQDTAVYYCAREGAEGWGWFAKPVGALGVWGQGTTVTVSS,,,CAGGTCCAGTTGATGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGTCTTCTGGAGGCTCCTTCAGCGACTATACTCTCAGTTGGGTGCGACAGGCCCCTGGACAAGGGCTTCAGTGGATGGGGAGCATCGTCCCCCTCCTTAATCTAGTAAATTATGCACAGAGATTTCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACATGGAATTGAGGACCCTGAGACCTCAAGACACGGCCGTGTATTACTGTGCGAGAGAGGGGGCTGAAGGATGGGGTTGGTTCGCGAAGCCCGTTGGTGCTCTGGGCGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA,CAREGAEGWGWFAKPVGALGVW,88.851
VRC43.01,gp41 MPER (membrane proximal external region),6MTR(Crystal structure of VRC43.01 Fab),40512 ,VRC43,Krebs2019(30876875) ,Residues important for neutralization or binding by VRC43.01,Krebs2019(30876875) ,IMGT/V-QUEST,4-4,,,19.0,RWDSSGWFSRHSYDYAVDV,11.0,,7-43,,9.0,LVQYSGVWV,9.4,,L,,Natural monoclonal,human,RV217-VRC43.01, ,6.55987,12.0878,446.0,787.0,4073.0,QVQLQESGPGLVKATGTLSLNCAVSGASISSSNWWNWVRQSPGKGLEWIGEIYHSGTVTYNPSLKTRVTISVDKSRNQFSLKLTSVTAADTAKYYCAKRWDSSGWFSRHSYDYAVDVWGRGTTVIVSS,QTVVTQEPSLTVSPGGTVTLTCASSAGAVTSGHCPSWFQQKPGQVPRALIYCTNNRQSWTPARFSGSLRGGKAALTLSGVQPDDEGDYYCLVQYSGVWVFGGGTKLTVL,CAGACTGTGGTGACTCAGGAGCCCTCACTGACTGTGTCCCCAGGAGGGACAGTCACTCTCACCTGTGCTTCCAGCGCTGGGGCAGTCACAAGTGGTCACTGTCCAAGTTGGTTCCAGCAGAAACCTGGGCAAGTTCCCCGGGCTCTGATTTATTGCACAAACAACAGACAGTCCTGGACCCCTGCCCGGTTTTCAGGCTCCCTCCGTGGGGGCAAAGCTGCCCTGACGCTGTCAGGTGTGCAGCCTGACGACGAGGGTGACTATTACTGCCTGGTCCAGTATAGTGGTGTGTGGGTCTTCGGCGGAGGGACCAAGCTGACCGTCCTG,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGATTGGTGAAGGCTACGGGGACCCTGTCCCTCAACTGCGCTGTGTCCGGTGCCTCCATCAGCAGTAGTAACTGGTGGAATTGGGTCCGCCAGTCCCCAGGGAAGGGACTGGAGTGGATTGGCGAAATCTATCACAGTGGGACTGTTACTTACAACCCGTCTCTCAAGACTCGAGTCACCATATCAGTGGACAAGTCCAGGAATCAATTCTCCCTGAAGTTGACCTCTGTGACGGCCGCGGACACGGCCAAATATTATTGTGCGAAGCGATGGGATAGCAGCGGCTGGTTCAGCAGACACTCCTACGACTACGCTGTGGACGTCTGGGGCCGGGGGACCACGGTCATTGTCTCCTCC,CAKRWDSSGWFSRHSYDYAVDVW,89.041
VRC43.02,gp41 MPER (membrane proximal external region),,40512 ,VRC43,Krebs2019(30876875) ,Residues important for neutralization by VRC43.02,Krebs2019(30876875) ,IMGT/V-QUEST,4-4,,,19.0,RWDSSGWITRHTFDYGVDV,12.7,,7-43,,9.0,LVHYRGAWV,8.7,,L,,Natural monoclonal,human,RV217-VRC43.02, ,6.79846,7.72311,30.0,788.0,4074.0,QVQLKLSGPGLVKPSGTLSLTCAVSGAAIGSSNWWNWVRQPPGKGLEWIGEIYHDGTVSRNPSLQSRMTMSVDKSKNQFSLELASVTVADTAVYYCAKRWDSSGWITRHTFDYGVDVWGPGTLVIVSX,QSVVTQEPSLTVSPGGTVTLTCASSSGAVTSDFSPNWFQQKRGQVPRPLIYNTDKRHSWTPARFSGSLLGGKAALTLSGIQPDDEGDYYCLVHYRGAWVFGGGTKLTVL,CAGTCTGTGGTGACTCAGGAGCCCTCACTGACTGTGTCCCCAGGAGGGACAGTCACTCTCACCTGTGCTTCCAGCAGTGGGGCAGTCACCAGTGATTTCTCTCCAAACTGGTTCCAGCAGAAACGTGGACAAGTACCCAGGCCACTGATTTACAATACAGACAAGAGACACTCCTGGACCCCTGCCCGATTCTCAGGCTCCCTCCTTGGGGGCAAAGCTGCCCTGACACTGTCAGGTATACAGCCTGACGACGAGGGTGACTATTATTGCCTGGTCCACTATCGTGGTGCGTGGGTTTTCGGCGGAGGGACCAAACTGACCGTCCTA,CAGGTGCAGCTGAAGCTGTCGGGCCCAGGATTGGTGAAGCCTTCGGGGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGCCGCCATCGGCAGTAGTAATTGGTGGAATTGGGTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATCGGAGAAATTTATCATGATGGGACCGTTAGCCGCAACCCGTCTCTCCAGAGTCGAATGACCATGTCAGTAGACAAGTCCAAGAATCAGTTCTCCTTGGAACTGGCCTCTGTAACTGTCGCGGACACGGCCGTTTATTATTGTGCGAAGCGATGGGATAGTAGTGGTTGGATAACAAGACACACGTTCGACTACGGTGTGGACGTCTGGGGCCCGGGGACGTTGGTCATTGTCTCCTC,CAKRWDSSGWITRHTFDYGVDVW,87.329
VRC43.03,gp41 MPER (membrane proximal external region),6MTS(Crystal structure of VRC43.03 Fab),40512 ,VRC43,Krebs2019(30876875) ,Residues important for neutralization by VRC43.03,Krebs2019(30876875) ,IMGT/V-QUEST,4-4,,,19.0,RWDSSGWITRHTYDYGVDV,9.6,,7-43,,9.0,LVHYRGAWV,8.7,,L,,Natural monoclonal,human,RV217-VRC43.03, ,14.1571,4.54006,30.0,789.0,4075.0,QVQLQESGPGLMKPSGTLFLTCAVSGASISSSNWWNWVRQPPGKGLEWIGEIYHDGSVSRNPFLQSRITMSVDKSKNQFSLKLTSVTAADTAVYYCAKRWDSSGWITRHTYDYGVDVWGRGTSVFVAS,QTVVTQEPSLTVSPGGTVTLTCASSAGAVTSDFSPNWFLQKPGQVPRSLIYNTDKRHSWTPARFSGSLIGGKAALTLSGAQPDDEGDYYCLVHYRGAWVFGGGTRLTVL,CAGACTGTGGTGACTCAGGAGCCCTCACTGACTGTGTCCCCAGGAGGGACAGTCACTCTCACCTGTGCTTCCAGCGCTGGGGCAGTCACCAGTGATTTCTCTCCAAACTGGTTCCTGCAGAAGCCTGGACAAGTTCCCAGGTCACTGATTTATAATACAGACAAAAGACACTCCTGGACCCCTGCCCGGTTCTCAGGCTCCCTCATTGGGGGCAAGGCTGCCCTGACACTGTCAGGTGCGCAGCCTGACGACGAGGGTGACTATTATTGCCTGGTCCACTATCGTGGTGCGTGGGTTTTCGGCGGAGGGACCAGATTGACCGTCCTG,CAGGTGCAGCTGCAGGAGTCGGGCCCAGGATTGATGAAGCCTTCGGGGACCCTGTTCCTCACCTGCGCTGTCTCTGGTGCCTCCATCAGCAGCAGTAATTGGTGGAATTGGGTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGAGAAATTTATCATGATGGGAGTGTTAGCCGCAACCCGTTTCTCCAGAGTCGAATCACCATGTCAGTAGACAAGTCCAAGAATCAGTTCTCCCTGAAATTGACCTCTGTGACCGCCGCGGACACGGCCGTATATTACTGTGCGAAGCGATGGGATAGTAGTGGCTGGATAACGAGACACACGTACGACTACGGTGTGGATGTCTGGGGCCGGGGGACCTCGGTCTTTGTCGCCTCG,CAKRWDSSGWITRHTYDYGVDVW,90.411
VRC46.01,gp41 MPER (membrane proximal external region),6MTT(Crystal structure of VRC46.01 Fab in complex with gp41 peptide),40512 ,VRC46,Krebs2019(30876875) ,Residues important for neutralization or binding by VRC46.01;VRC46.01 contacts,Krebs2019(30876875) ,IMGT/V-QUEST,1-69,,,14.0,HSNSWFSPKWYFDV,8.5,,1-39,,9.0,QQSYSSPYT,4.7,,K,,Natural monoclonal,human,RV217-VRC46.01, ,43.5286,4.81997,446.0,790.0,4076.0,QVQLVQSGSEVKKPGSSVKVSCKASGGTFSTYTFSWVRQAPRHGLEWLGGILPLLNIANYAQKFQGRVKFAADKSTNMAYMELSGLRSDDTAVYYCARHSNSWFSPKWYFDVWGRGTLVTVSS,,,CAGGTCCAGCTGGTGCAGTCTGGGTCTGAGGTGAAGAAGCCTGGGTCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCACATACACTTTCAGCTGGGTGCGACAGGCCCCTCGACACGGGCTTGAGTGGTTGGGAGGGATCCTCCCTCTCCTGAATATAGCGAACTACGCACAGAAGTTCCAGGGCAGGGTCAAGTTTGCCGCGGACAAATCCACGAATATGGCCTACATGGAGCTGAGCGGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGACATAGCAATAGCTGGTTCTCCCCTAAATGGTACTTCGATGTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCG,CARHSNSWFSPKWYFDVW,91.497
VRC-CH30,gp120 CD4bs,,CH0219 ,VRC-CH31,Wu2011(21835983) ,,Wu2011(21835983) ,IMGT/V-QUEST JoinSolver,1-2*02,3-16*01,4*02,15.0,,23.0,,1-33*01,2*01,5.0,,16.0,,K,,Natural monoclonal,human,CH30, Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.,0.43176,18.5182,40.0,46.0,2573.0,QVQLVQSGAAVRKPGASVTVSCKFAEDDDYSPHWVNPAPEHYIHFLRQAPGQQLEWLAWMNPTNGAVNYAWQLHGRLTATRDGSMTTAFLEVRSLRSDDTAVYYCARAQKRGRSEWAYAHWGQGTPVAVSS,DIQMTQSPSSLSASLGDRVTITCQASRGIGKDLNWYQQKPGKAPKLLVSDASILEGGVPSRFSGSGFHQNFSLTISSLQPEDVATYFCQQYETFGQGTKVDIK,GACATCCAGATGACCCAGTCTCCATCGTCCTTGTCTGCATCACTCGGAGACAGAGTCACCATCACTTGTCAGGCGAGTCGGGGCATTGGTAAAGATTTAAATTGGTACCAGCAGAAACCGGGAAAGGCCCCTAAGTTACTGGTCTCTGATGCATCCATTTTGGAAGGGGGGGTCCCATCAAGGTTCAGTGGGAGTGGATTTCACCAAAATTTTAGTCTGACCATCAGCAGCCTGCAGCCTGAGGATGTTGCGACATACTTCTGTCAGCAGTACGAGACTTTTGGCCAGGGGACCAAAGTGGACATCAAA,CAGGTGCAGCTGGTGCAGTCAGGGGCTGCCGTGAGGAAGCCTGGGGCCTCAGTGACTGTCTCCTGCAAATTCGCTGAAGACGACGACTACTCTCCACACTGGGTGAATCCGGCCCCTGAACACTATATTCACTTTCTACGACAGGCCCCTGGACAGCAACTGGAGTGGTTGGCATGGATGAACCCTACGAATGGCGCCGTCAATTATGCATGGCAGCTTCATGGCAGGCTCACGGCGACCAGAGACGGGTCCATGACTACAGCCTTTTTGGAAGTGAGGAGTCTAAGATCTGACGACACGGCCGTCTATTATTGTGCGAGGGCCCAGAAAAGGGGGCGGAGTGAATGGGCCTACGCCCACTGGGGCCAGGGAACCCCGGTCGCCGTCTCCTCA,CARAQKRGRSEWAYAHW,70.938
VRC-CH31,gp120 CD4bs,4LSP(VRC-CH31 complexed with gp120 (93TH057));4LSQ(VRC-CH31 complexed with gp120 (93TH057/3514 chimera));4LSR(VRC-CH31 complexed with gp120 (93TH057/KER2008 chimera));6NNJ(BG505 SOSIP.664 Prefusion Env Trimer Bound to CH31 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv),CH0219 ,VRC-CH31,Wu2011(21835983) ,Signature Analysis Summary;VRC-CH31 signature predictions,Wu2011(21835983) ,IMGT/V-QUEST JoinSolver,1-2*02,3-16*01,4*02,15.0,,24.0,,1-33*01,2*01,5.0,,15.0,,K,,Natural monoclonal,human,"CH31, CHA31, VRC-CH31 d0219, VRC-CHA31", Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.,1.06961,16.5289,1346.0,20.0,2574.0,QVQLVQSGAAVRKPGASVTVSCKFAEDDDYSPYWVNPAPEHFIHFLRQAPGQQLEWLAWMNPTNGAVNYAWYLNGRVTATRDRSMTTAFLEVKSLRSDDTAVYYCARAQKRGRSEWAYAHWGQGTPVVVSS,DIQMTQSPSSLSASLGDRVTITCQASRGIGKDLNWYQQKAGKAPKLLVSDASTLEGGVPSRFSGSGFHQNFSLTISSLQAEDVATYFCQQYETFGQGTKVDIK,GACATCCAGATGACCCAGTCTCCATCGTCCCTGTCTGCATCACTCGGGGACAGAGTCACCATCACTTGCCAGGCGAGTCGGGGCATTGGCAAAGATTTAAATTGGTACCAGCAGAAAGCGGGAAAAGCCCCTAAGTTACTGGTCTCTGATGCATCCACTTTGGAAGGGGGGGTCCCATCAAGGTTCAGTGGGAGTGGATTTCACCAAAATTTTAGTCTGACTATCAGCAGCCTGCAGGCTGAGGATGTTGCAACATACTTCTGTCAACAATACGAGACTTTTGGCCAGGGGACCAAGGTGGACATCAAA,CAGGTGCAGCTGGTGCAGTCAGGGGCTGCCGTGAGGAAGCCTGGGGCCTCAGTGACTGTCTCCTGTAAATTCGCTGAAGACGACGACTACTCTCCATACTGGGTGAATCCGGCCCCTGAACATTTTATTCACTTTTTGCGACAGGCCCCTGGACAACAACTAGAGTGGCTGGCATGGATGAACCCAACGAATGGCGCCGTTAATTATGCATGGTACCTTAATGGCAGGGTCACGGCGACCAGGGACAGGTCCATGACTACAGCCTTTTTGGAAGTGAAGAGTCTAAGATCTGACGACACGGCCGTCTACTATTGTGCGAGGGCCCAGAAAAGGGGGCGGAGTGAGTGGGCCTACGCCCACTGGGGTCAGGGCACTCCGGTCGTCGTCTCGTCA,,
VRC-CH32,gp120 CD4bs,,CH0219 ,VRC-CH31,Wu2011(21835983) ,,Wu2011(21835983) ,IMGT/V-QUEST JoinSolver,1-2*02,3-16*01,4*02,15.0,,23.0,,1-33*01,2*01,5.0,,17.0,,K,,Natural monoclonal,human,CH32, Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.,0.88113,19.1793,40.0,47.0,2575.0,QVQLVQSGAAVRKPGASVTVSCKFAEDDDFSPHWVNPAPEHYIHFLRQAPGQQLEWLAWMKPTNGAVNYAWQLQGRVTVTRDRSQTTAFLEVKNLRSDDTAVYYCARAQKRGRSEWAYAHWGQGTPVVISA,DIQMTQSPSSLSASLGDRVTITCQASRGIGKDLNWYQQKPGRAPKLLVSDASILEGGVPTRFSGSGFHQNFSLTISSLQAEDVATYFCQQYETFGQGTKVDIK,GACATCCAGATGACCCAGTCTCCATCGTCCCTGTCTGCATCACTCGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCGGGGCATTGGCAAAGATTTAAATTGGTACCAACAGAAACCGGGAAGAGCCCCTAAGTTACTAGTCTCTGATGCATCCATTTTGGAAGGGGGGGTCCCAACGAGATTCAGTGGGAGTGGATTTCACCAAAACTTTAGCCTGACCATCAGCAGCCTGCAGGCTGAGGATGTTGCAACATATTTCTGTCAGCAATACGAAACTTTTGGCCAGGGGACCAAGGTGGACATCAAA,CAGGTGCAGCTGGTGCAGTCAGGGGCTGCCGTGAGGAAGCCTGGGGCCTCAGTGACTGTCTCCTGCAAGTTCGCTGAAGACGACGACTTCTCTCCACACTGGGTGAATCCGGCCCCTGAACACTATATTCATTTTCTGCGACAGGCACCTGGACAACAACTAGAGTGGTTGGCATGGATGAAGCCTACGAATGGTGCCGTCAATTATGCATGGCAACTTCAGGGCAGGGTCACGGTGACCAGGGACAGGTCCCAGACTACAGCCTTTTTGGAAGTTAAGAATCTGAGATCTGACGACACGGCCGTCTATTATTGTGCGAGGGCCCAGAAAAGGGGGCGCAGCGAGTGGGCCTATGCCCACTGGGGCCAGGGAACCCCGGTCGTCATCTCCGCA,CARAQKRGRSEWAYAHW,71.250
VRC-CH33,gp120 CD4bs,,CH0219 ,VRC-CH31,Wu2011(21835983) ,,Wu2011(21835983) ,IMGT/V-QUEST JoinSolver,1-2*02,3-16*01,4*02,15.0,,25.0,,1-33*01,2*01,5.0,,17.0,,K,,Natural monoclonal,human,CH33, Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.,0.44584,16.2125,40.0,48.0,2576.0,QVQLVQSGAAVRKPGASISVSCKFADADDYSPHWMNPAPEHYIHFLRQAPGQQLEWLAWMNPTNGAVNYAWYLNGRVTATRDRSMTTAFLEVRSLRSDDTAVYYCARAQKRARSEWAYAHWGQGTPVVVSS,DIQMTQSPSSLSASLGDRVTITCQASRGIGKDLNWYQQKRGRAPRLLVSDASVLEGGVPSRFSGSGFHQNFSLTISTLQPEDVATYFCQQYETFGQGTKVDIK,GACATCCAGATGACCCAGTCTCCATCGTCCTTGTCTGCATCACTCGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCGGGGCATTGGTAAAGATTTAAATTGGTATCAGCAGAAACGGGGAAGAGCCCCTAGGTTACTGGTCTCTGATGCCTCCGTTTTGGAAGGGGGGGTCCCATCAAGGTTCAGTGGCAGTGGATTTCACCAAAACTTTAGCTTGACCATCAGCACCCTGCAGCCTGAGGATGTTGCGACATACTTCTGTCAGCAGTACGAGACTTTTGGCCAGGGGACCAAAGTGGACATCAAA,CAGGTGCAGCTGGTGCAGTCAGGGGCTGCCGTGAGGAAGCCCGGGGCCTCAATTAGTGTCTCCTGCAAATTCGCTGATGCCGACGACTACTCTCCGCACTGGATGAATCCGGCCCCTGAACACTATATTCACTTTCTGCGCCAGGCCCCTGGACAGCAATTAGAGTGGTTGGCGTGGATGAATCCTACGAATGGCGCCGTTAATTATGCCTGGTACCTTAATGGCAGGGTCACGGCGACCAGAGACAGGTCCATGACCACAGCGTTTCTGGAAGTGAGGAGTCTGAGATCTGACGACACGGCCGTCTATTATTGTGCGAGGGCCCAGAAAAGGGCGCGGAGTGAATGGGCCTACGCCCACTGGGGCCAGGGAACCCCGGTCGTCGTCTCCTCA,CARAQKRARSEWAYAHW,69.688
VRC-CH34,gp120 CD4bs,,CH0219 ,VRC-CH31,Wu2011(21835983) ,,Wu2011(21835983) ,IMGT/V-QUEST JoinSolver,1-2*02,3-16*01,4*02,15.0,,23.0,,1-33*01,2*01,5.0,,17.0,,K,,Natural monoclonal,human,CH34, Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.,0.82068,15.5751,40.0,49.0,2577.0,QVQLVQSGAAVRKPGASVTVSCKFAEDDDWSPHWVNPAPEHYIHFLRQAPGQQLEWLAWMNPTNGAVNYAWQLNGRLTATRDTSMTTAFLEVKSLRSDDTAVYYCARAQKRGRSEWAYAHWGQGTPVVVSS,DIQMTQSPSSLSASLGDRVTITCQASRGIGKDLNWYQQKAGKAPKLLVSDASILEGGVPSRFSGSGFHQNFSLTISSLQPEDVATYFCQQYETFGQGTKVDIK,GACATCCAGATGACCCAGTCTCCATCGTCCTTGTCTGCATCACTCGGAGACAGAGTCACCATCACTTGCCAGGCGAGCCGGGGTATTGGTAAAGATTTAAATTGGTACCAACAGAAAGCGGGAAAAGCCCCTAAGTTACTGGTCTCTGATGCATCCATTTTGGAAGGGGGGGTCCCATCAAGGTTCAGCGGGAGTGGATTTCACCAAAATTTTAGTCTGACCATCTCCAGCCTGCAGCCTGAAGATGTTGCGACCTATTTCTGTCAGCAGTACGAGACTTTTGGCCAGGGGACCAAGGTGGACATCAAA,CAGGTGCAGCTGGTGCAGTCGGGGGCTGCCGTGAGGAAGCCTGGGGCCTCAGTAACTGTCTCCTGCAAATTCGCTGAAGACGACGACTGGTCTCCACACTGGGTGAATCCGGCCCCTGAACACTATATTCATTTTCTACGGCAGGCCCCTGGACAGCAATTAGAGTGGTTGGCATGGATGAACCCTACAAATGGTGCCGTCAATTATGCATGGCAGCTTAACGGCAGGCTCACGGCGACCAGAGACACGTCCATGACTACAGCCTTTTTGGAGGTGAAGAGTCTGAGATCTGACGACACGGCCGTCTATTATTGTGCGAGGGCCCAAAAAAGGGGGCGCAGTGAATGGGCCTACGCCCACTGGGGCCAGGGAACCCCGGTCGTCGTCTCCTCA,CARAQKRGRSEWAYAHW,70.625
VRC-PG04,gp120 CD4bs,3J5M(BG505 Env trimer with 3 PGV04 Fabs);3SE9(VRC-PG04 complexed with gp120);4I3R(gp120 complexed with VRC-PG04 space group P3221);4I3S(gp120 complexed with VRC-PG04 space group P21);6CRQ(Glutaraldehyde-treated BG505 SOSIP.664 in complex with PGV04 Fab);7RSN(AMC018 SOSIP.v4.2 in complex with PGV04 Fab);7RSO(AMC016 SOSIP.v4.2 in complex with PGV04 Fab);EMD-7107(PC64M4c054 SOSIP in complex with PGV04 Fab);EMD-8302(SOSIP trimer from patient AMC011 in complex with Fab from IgG PGV04),Donor 74 ,VRC-PG04 ,Wu2011(21835983) ,"Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;Mutation decreases binding to CD4BS mAbs;Signature Analysis Summary;VRC-PG04 alanine scanning;VRC-PG04 contacts;VRC-PG04 signature predictions",Mascola2012() ,IMGT/V-QUEST,1-2*02,2-8*02,2*01,16.0,ARQKFYTGGQGWYFDLWGRGTLIVVSS,,,3-11*01,5*01,5.0,QQLEF,,,K,Yes,Natural monoclonal,human,"PG-04, PG04, PGV04, PV04, VRC04, VRC-PG-04, VRC-PG04 d74", Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.,0.81585,15.4112,2119.0,8.0,2571.0,QVQLVQSGSGVKKPGASVRVSCWTSEDIFERTELIHWVRQAPGQGLEWIGWVKTVTGAVNFGSPDFRQRVSLTRDRDLFTAHMDIRGLTQGDTATYFCARQKFYTGGQGWYFDLWGRGTLIVVSS,EIVLTQSPGTLSLSPGETASLSCTAASYGHMTWYQKKPGQPPKLLIFATSKRASGIPDRFSGSQFGKQYTLTITRMEPEDFARYYCQQLEFFGQGTRLEIRR,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCAGCCTCTCCTGCACGGCGGCCTCATATGGTCACATGACTTGGTATCAGAAAAAACCTGGCCAGCCTCCCAAACTCCTCATTTTTGCAACGTCCAAGAGGGCCAGTGGCATCCCAGACAGGTTCAGTGGCTCCCAGTTTGGTAAACAATATACTCTCACCATCACCAGAATGGAGCCTGAAGATTTTGCGAGATATTACTGTCAGCAACTTGAATTCTTCGGCCAGGGGACACGACTGGAGATTAGACGA,CAGGTGCAGCTGGTGCAGTCTGGGTCTGGAGTGAAGAAGCCTGGGGCTTCGGTGAGAGTCTCCTGTTGGACCTCTGAGGACATCTTCGAAAGAACCGAGTTGATTCATTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATTGGGTGGGTGAAAACCGTCACTGGCGCCGTCAATTTTGGTTCACCAGATTTTCGACAGAGAGTCTCTCTGACCCGCGACAGGGACCTCTTCACAGCCCATATGGACATTCGCGGACTGACACAAGGCGACACGGCCACATATTTTTGCGCGAGACAGAAATTTTATACGGGCGGCCAAGGCTGGTACTTCGATCTCTGGGGCCGTGGAACCCTCATTGTTGTCTCGTCA,CARQKFYTGGQGWYFDLW,70.000
nan,,,,,,,Wu2011(21835983) ,IMGT/V-QUEST JoinSolver,1-2*02,5-12*01,2*01,16.0,,30.0,,3-20*01,5*01,5.0,,19.0,,,,,,,,,,,,,,,,,,
VRC-PG04b,gp120 CD4bs,,Donor 74 ,VRC-PG04 ,Wu2011(21835983) ,VRC-PG04b signature predictions,Wu2011(21835983) ,IMGT/V-QUEST JoinSolver,1-2*02,5-12*01,2*01,16.0,,30.0,,3-20*01,5*01,5.0,,19.0,,K,,Natural monoclonal,human,PG04b, Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.,1.38148,22.7156,355.0,19.0,2572.0,QVQLVQSGSGVKKPGASVRVSCWTSEDIFERTELIHWVRQAPGQGLEWIGWVKTVTGAVNFGSPNFRHRVSLTRDRDLFTAHMDIRGLTQGDTATYFCARQKFERGGQGWYFDLWGRGTLIVVSS,EIVLTQSPGTLSLSPGETASLSCTAASYGHMTWYQKKPGQPPKLLIFATSKRASGIPDRFSGSQFGKQYTLTITRMEPEDFAGYYCQQVEFFGQGTRLEIR,GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGCCAGCCTCTCCTGCACGGCGGCCTCATATGGTCACATGACTTGGTATCAGAAAAAACCTGGCCAGCCTCCCAAACTCCTCATTTTTGCAACGTCCAAGAGGGCCAGTGGCATCCCAGACAGGTTCAGTGGCTCCCAGTTTGGTAAACAATACACTCTCACCATCACCAGAATGGAGCCTGAAGATTTTGCGGGATATTACTGTCAGCAAGTTGAATTCTTCGGCCAGGGGACACGACTGGAGATTAGA,CAGGTGCAGCTGGTGCAGTCTGGGTCTGGAGTGAAGAAGCCTGGGGCTTCGGTGAGAGTCTCCTGTTGGACCTCTGAGGACATCTTCGAAAGAACCGAATTGATTCATTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATTGGGTGGGTGAAAACTGTCACTGGCGCCGTCAATTTTGGTTCACCAAATTTTCGACATAGAGTCTCTCTGACCCGCGACAGGGACCTCTTCACAGCCCATATGGACATTCGCGGACTGACACAAGGCGACACGGCCACATATTTTTGCGCGAGACAGAAATTTGAGAGGGGCGGCCAAGGCTGGTATTTCGATCTCTGGGGCCGTGGAACCCTCATTGTTGTCTCGTCA,CARQKFERGGQGWYFDLW,70.667
VRC-PG05,gp120 silent face,6BF4(HIV-1 Clade AE Strain CNE55 gp120 Core in Complex with VRC-PG05),Donor 74 ,,Zhou2018(29548671) ,Signature Analysis Summary;VRC-PG05 contacts;VRC-PG05 sensitivity and escape,Mascola2012() ,IMGT/V-QUEST,3-7*01,3-3*01,3*02,19.0,ARIRQVSKYLQWYPGVFEMWGQGTMVTVSS,,,4-1*01,2*03,8.0,QQYFFLYS,,,K,,Natural monoclonal,human,"PG-05, PG05, VRC-PG-05", ,22.7512,10.7914,949.0,292.0,3370.0,EVQLVESGGGLVQPGGSLRLSCAASGFPFNRDWMTWVRQAPGKGLEWVANINMDGDKKDYVDSVKGRFTISRDNAKTSLYLQMNSLRAGDTAVYYCARIRQVSKYLQWYPGVFEMWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATIHCKSSQSVLYRPNNRNYVAWYQQKPGQPPRLLIHWASFRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQQYFFLYSFGGGTKLEINR,GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCCACTGCAAGTCTAGTCAGAGTGTTTTGTACAGGCCCAACAATAGGAATTACGTCGCTTGGTACCAGCAGAAACCAGGACAACCTCCGAGGCTGCTCATTCACTGGGCATCTTTCCGGGAATCCGGGGTCCCTGACCGATTCACTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAACAATATTTTTTTTTGTACAGTTTCGGCGGAGGGACCAAACTAGAGATCAATCGA,GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCCCTAAGACTCTCCTGTGCTGCCTCTGGATTCCCCTTTAATAGGGACTGGATGACTTGGGTCCGCCAGGCTCCTGGGAAGGGGCTGGAGTGGGTAGCCAACATAAATATGGATGGAGATAAAAAAGACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGACGTCACTGTATCTGCAGATGAACAGCCTGAGAGCCGGGGACACGGCTGTATATTATTGTGCGAGAATAAGGCAGGTCTCAAAATATCTGCAGTGGTACCCGGGTGTTTTTGAGATGTGGGGCCAAGGGACAATGGTCACCGTCTCCTCA,CARIRQVSKYLQWYPGVFEMW,90.816
nan,,,,,,,Zhou2018(29548671) ,IMGT/V-QUEST,3-7*01,,,17.0,IRQVSKYLQWYPGVFEM,9.0,,4-1*01,,8.0,QYFFLYSF,6.0,,,,,,,,,,,,,,,,,,
VRC-PG19,gp120 V2-CD4bs,6B0N(clade A BG505 isolate in complex with Fabs PGT122 and PGV19),IAVI 23 ,,Zhou2013a(23911655) ,Mutations allowing binding of germline Abs;VRC-PG19 contacts,Zhou2013a(23911655) ,IgBlast IMGT/V-QUEST,1-02*02,,,11.0,MGAAREWDFQY,,,2-14*01,2*01,5.0,NAYEF,,,L,,Natural monoclonal,human,"PG19, PGV19, VRC-PG19 d23", ,1.60753,16.0011,40.0,80.0,3015.0,EVRLVQSGAEVKKPGASVRVSCAASGYTFTDFDIHWLRQAPGRGLEWMGWVRPLGGGVSYARQFQGRVTMTRDFYIDTAFMDFRNLKMDDTALYFCARMGAAREWDFQYWGQGTRVLVSS,QSALTQPASVSGSPGQSITISCTASSDFRGFSSVSWYQQVPGRAPKLLIFSVNRRPSGISHRFSGSKSGNTASLTISGLQIEDEADYHCNAYEFFGGGTKVFVLGQ,CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCGCCTGGACAGTCGATCACCATCTCCTGCACTGCAAGCAGCGACTTTCGTGGTTTTTCCTCTGTCTCCTGGTACCAGCAAGTCCCGGGCCGGGCCCCCAAACTTCTTATTTTTAGTGTCAATAGACGACCCTCGGGGATTTCTCATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGATTGAAGACGAGGCTGATTATCACTGTAATGCATATGAATTTTTCGGCGGCGGGACCAAGGTCTTCGTCCTTGGTCAG,GAGGTGCGTCTGGTGCAATCTGGGGCTGAAGTGAAGAAGCCTGGGGCATCAGTGAGGGTCTCCTGTGCGGCATCTGGATATACGTTCACCGACTTCGACATACACTGGCTGCGCCAGGCCCCCGGAAGAGGGCTTGAGTGGATGGGGTGGGTGAGGCCTCTGGGAGGTGGCGTCAGTTATGCACGCCAGTTTCAGGGCAGGGTCACTATGACCAGGGACTTCTACATCGACACAGCCTTTATGGACTTCAGGAATTTAAAAATGGACGACACGGCCCTCTACTTCTGTGCGAGAATGGGGGCGGCTCGGGAGTGGGACTTCCAGTACTGGGGCCAGGGCACCCGGGTCCTCGTCTCCTCA,CARMGAAREWDFQYW,77.551
VRC-PG20,gp120 CD4bs,4LSU(VRC-PG20 in complex with HIV-1 clade A/E 93TH057 gp120),IAVI 23 ,,Zhou2013a(23911655) ,Altered glycosylation affects neutralization by CD4BS bnAbs;Mutations allowing binding of germline Abs;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs,Zhou2013a(23911655) ,IgBlast IMGT/V-QUEST,1-02*02,,,12.0,RRSQDREWDFQH,,,2-14*01,2*01,5.0,NAYEF,,,L,,Natural monoclonal,human,"PGV20, VRC20, VRC-PG20 d23", ,0.69508,24.9562,578.0,73.0,3017.0,QVHLMQSGTEMKKPGASVRVTCQTSGYTFSDYFIHWLRQVPGRGFEWMGWMNPQWGQVNYARTFQGRVTMTRDVYREVAYLDLRSLTFADTAVYFCARRMRSQDREWDFQHWGQGTRIIVSS,QSALTQPPSVSGSPGQSITLSCTGASTSVAWYQQYADKAPRLIVFDGNKRPSDISSRFSGSQSGGTASLTISGLQSEDEAYYHCNAFEFFGGGTKLTVLSQ,CAGTCTGCCCTGACTCAGCCTCCCTCCGTGTCTGGGTCTCCCGGACAGTCGATCACCCTCTCCTGCACTGGCGCCTCTACCTCTGTCGCCTGGTATCAACAATACGCAGACAAGGCCCCCCGACTCATCGTTTTTGATGGCAATAAGCGGCCCTCAGACATTTCTAGTCGCTTCTCTGGATCCCAGTCTGGCGGCACGGCCTCCCTGACCATTTCTGGACTCCAGAGTGAAGACGAGGCTTATTATCATTGTAATGCATTTGAATTCTTTGGCGGAGGGACCAAGTTGACCGTCCTCAGTCAG,CAAGTGCATTTAATGCAGTCTGGGACTGAAATGAAGAAGCCTGGGGCCTCAGTGAGGGTCACCTGTCAGACTTCTGGATACACCTTCAGCGACTACTTCATCCACTGGTTGCGACAAGTCCCCGGTCGAGGATTTGAGTGGATGGGTTGGATGAACCCTCAATGGGGTCAAGTCAACTATGCACGGACATTTCAGGGAAGAGTCACGATGACAAGAGACGTTTATAGGGAAGTTGCTTACTTGGACCTGAGGAGCCTGACATTTGCCGACACGGCCGTCTATTTCTGTGCGAGAAGAATGAGGTCCCAGGACCGCGAGTGGGACTTCCAGCACTGGGGCCAGGGCACCCGGATCATCGTTTCGTCA,CARRMRSQDREWDFQHW,76.531
X5,gp120 CD4i,1RHH(Fab X5);2B4C(gp120 core protein containing V3 complexed with CD4 and the X5 antibody),FDA2 ,,Moulard2002(11997472) ,,Zhang2013(24100711) ,IMGT/V-QUEST,1-69*01,3-22*01,4*02,24.0,,,,3-20,2,9.0,,,,K,Yes,Fab or heavy-chain-only,human,Fab X5, ,,,21.0,547.0,1121.0,RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVVSA,YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHIK,TACATCCACGTGACCCAGTCTCCGTCCTCCCTGTCTGTGTCTATTGGAGACAGAGTCACCATCAATTGCCAGACGAGTCAGGGTGTTGGCAGTGACCTACATTGGTATCAACACAAACCGGGGAGAGCCCCTAAACTCTTGATCCACCATACCTCTTCTGTGGAAGACGGTGTCCCCTCAAGATTCAGCGGCTCTGGATTTCACACATCTTTTAATCTGACCATCAGCGACCTACAGGCTGACGACATTGCCACATATTACTGTCAAGTTTTACAATTTTTCGGCCGAGGGAGTCGACTCCATATTAAA,CGAGCGCACCTGGTACAATCAGGGACTGCGATGAAGAAACCGGGGGCCTCAGTAAGAGTCTCCTGCCAGACCTCTGGATACACCTTTACCGCCCACATATTATTTTGGTTCCGACAGGCCCCCGGGCGAGGACTTGAGTGGGTGGGGTGGATCAAGCCACAATATGGGGCCGTGAATTTTGGTGGTGGTTTTCGGGACAGGGTCACATTGACTCGAGACGTATATAGAGAGATTGCGTACATGGACATCAGAGGCCTTAAACCTGACGACACGGCCGTCTATTACTGTGCGAGAGACCGTTCCTATGGCGACTCCTCTTGGGCCTTAGATGCCTGGGGACAGGGAACGACGGTCGTCGTCTCCGCG,,
Y498,gp120 CD4bs,,XJ1981 ,,Sun2017(28968970) ,Mutation decreases binding of Y498,Sun2017(28968970) ,IMGT/V-QUEST,1-18*01,3-3*01,3*02,20.0,ARSLLRSLERLMGGTDAFDI,10.76,,1-39*01,1*01,9.0,QQSYSTPRT,1.06,,K,,Natural monoclonal,human,, Sun2017 %SHM calculated for VH and VL only.,50.8973,5.24214,70.0,398.0,3963.0,KVQLVQSGTELKKPGASGKVSCKASGYTFNSNGLNWVRQAPGQGLEWVGWISGHSDETKHAQNFQGRLTLTTDTSTNTAYMELRSLRSDDTAVYYCARSLLRSLERLMGGTDAFDIWGQGTLVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,,,,
Z13e1,gp41 MPER (membrane proximal external region),3FN0(Fab Z13e1 in complex with a 12-residue peptide containing the Z13e1 epitope on gp41);3Q1S(Z13e1 in complex with epitope display protein),FDA2 ,,Nelson2007(17287272) ,Mutation affects Z13e1 binding;Q563R affects binding and neutralization of MPER mAbs;Signature Analysis Summary;Z13e1 contacts,Morris2011(21980336) ,SoDA,4-59*03,,6*03,19.0,,,17.0,3-11*01,,9.0,,,3.5,K,,Engineered monoclonal,human,," Morris2011 SHM data are entered for AA, but it's unclear if the data are NT or AA.",73.133,2.17745,549.0,281.0,1589.0,LLESGPGLLKPSETLSLTCTVSGGSMINYYWSWIRQPPGERPQWLGHIIYGGTTKYNPSLESRITISRDISNSQFSLRLNSVRAADTAIYYCARVAIGVSGFLNYYYYMDVWGSGTAVTVSS,LTQSPATLSLSPGERATLSCRASQSVGRNLGWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQARLLLPQTFGQGTKVEIKRTVAAP,,,,
